0001558370-24-01206310-Q Fortress Biotech, Inc. 2024081320240813163043163044463044 0 0001558370-24-012063 10-Q 98 20240630 20240813 20240813 Fortress Biotech, Inc. 0001429260 2834 205157386 DE 1231 10-Q 34 001-35366 241202164 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 CORONADO BIOSCIENCES INC 20080310 10-Q 1 fbio-20240630x10q.htm 10-Q 0001429260--12-312024Q2false342713834271382164652164652165Fortress Biotech, Inc.2258703815093053August 31, 2025December 31, 2027http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember0false0001429260fbio:MustangTherapeuticsIncMemberfbio:SeriesTwoWarrantsMemberfbio:PublicOfferingMember2024-05-310001429260fbio:MustangTherapeuticsIncMemberfbio:SeriesThreeWarrantsMemberfbio:PublicOfferingMember2024-05-310001429260fbio:MustangTherapeuticsIncMemberfbio:SeriesOneWarrantsMemberfbio:PublicOfferingMember2024-05-310001429260fbio:AvenueTherapeuticsIncMembersrt:MinimumMember2024-04-300001429260fbio:AvenueTherapeuticsIncMembersrt:MaximumMember2024-04-300001429260fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputSharePriceMember2024-06-300001429260fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-06-300001429260fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2024-06-300001429260fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2024-06-300001429260fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputSharePriceMember2024-06-300001429260fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-06-300001429260fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputPriceVolatilityMember2024-06-300001429260fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputExpectedTermMember2024-06-300001429260fbio:Ur1TherapeuticsIncMemberfbio:PlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310001429260fbio:Ur1TherapeuticsIncMemberfbio:PlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2023-12-310001429260fbio:Ur1TherapeuticsIncMemberfbio:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2023-12-310001429260fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputSharePriceMember2023-12-310001429260fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310001429260fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2023-12-310001429260fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2023-12-310001429260fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputSharePriceMember2023-12-310001429260fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310001429260fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputPriceVolatilityMember2023-12-310001429260fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputExpectedTermMember2023-12-310001429260us-gaap:LeaseholdsAndLeaseholdImprovementsMember2024-01-012024-06-300001429260us-gaap:NoncontrollingInterestMember2024-06-300001429260us-gaap:AdditionalPaidInCapitalMember2024-06-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-06-300001429260us-gaap:NoncontrollingInterestMember2024-03-310001429260us-gaap:AdditionalPaidInCapitalMember2024-03-310001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-03-310001429260240324-03-310001429260us-gaap:NoncontrollingInterestMember2023-12-310001429260us-gaap:AdditionalPaidInCapitalMember2023-12-310001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-12-310001429260us-gaap:NoncontrollingInterestMember2023-06-300001429260us-gaap:AdditionalPaidInCapitalMember2023-06-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-06-300001429260fbio:CommonSharesIssuableMember2023-06-300001429260us-gaap:NoncontrollingInterestMember2023-03-310001429260us-gaap:AdditionalPaidInCapitalMember2023-03-310001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-03-310001429260240323-03-310001429260us-gaap:NoncontrollingInterestMember2022-12-310001429260us-gaap:AdditionalPaidInCapitalMember2022-12-310001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-12-310001429260us-gaap:PreferredStockMember2024-06-300001429260us-gaap:CommonStockMember2024-06-300001429260us-gaap:PreferredStockMember2024-03-310001429260us-gaap:CommonStockMember2024-03-310001429260us-gaap:PreferredStockMember2023-12-310001429260us-gaap:CommonStockMember2023-12-310001429260us-gaap:PreferredStockMember2023-06-300001429260us-gaap:CommonStockMember2023-06-300001429260us-gaap:PreferredStockMember2023-03-310001429260us-gaap:CommonStockMember2023-03-310001429260us-gaap:PreferredStockMember2022-12-310001429260us-gaap:CommonStockMember2022-12-310001429260fbio:TwoThousandSevenAndTwoThousandThirteenPlanMember2024-06-300001429260fbio:TwoThousandTwelveEmployeeStockPurchasePlanMember2024-01-012024-06-300001429260fbio:TwoThousandThirteenStockIncentivePlanMember2024-01-012024-06-300001429260fbio:RestrictedStockAndRestrictedStockUnitsMember2023-12-310001429260us-gaap:RestrictedStockMember2024-01-012024-06-300001429260srt:ExecutiveVicePresidentMemberfbio:LongTermIncentivePlansMember2024-01-012024-01-010001429260srt:ChiefExecutiveOfficerMemberfbio:LongTermIncentivePlansMember2024-01-012024-01-010001429260srt:ExecutiveVicePresidentMemberfbio:LongTermIncentivePlansMember2023-01-012023-01-010001429260srt:ChiefExecutiveOfficerMemberfbio:LongTermIncentivePlansMember2023-01-012023-01-010001429260us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001429260fbio:JourneyMemberfbio:MarketOfferingMember2024-06-300001429260fbio:CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMemberfbio:MarketOfferingMember06-300001429260fbio:CheckpointMemberfbio:DirectOfferingMember2024-01-310001429260fbio:AvenueTherapeuticsIncMemberfbio:SeriesWarrantsMember2024-01-090001429260fbio:AvenueTherapeuticsIncMemberfbio:SeriesBWarrantsMember2024-01-090001429260fbio:CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMemberfbio:MarketOfferingMember06-300001429260fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember2023-02-280001429260fbio:MustangTherapeuticsIncMemberus-gaap:CommonStockMemberfbio:PublicOfferingMember2024-05-012024-05-310001429260fbio:MustangTherapeuticsIncMemberfbio:FoundersAgreementMemberfbio:MarketOfferingMember2024-01-012024-06-300001429260fbio:AvenueTherapeuticsIncMemberfbio:FoundersAgreementMemberfbio:MarketOfferingMember2024-01-012024-06-300001429260fbio:MustangTherapeuticsIncMemberfbio:DirectOfferingMember2024-01-012024-06-300001429260fbio:MlvCo.AndFbrCapitalMarketsCoMemberfbio:MarketOfferingMember2024-01-012024-06-300001429260fbio:MustangTherapeuticsIncMemberfbio:FoundersAgreementMemberfbio:MarketOfferingMember2023-01-012023-06-300001429260fbio:MlvCo.AndFbrCapitalMarketsCoMemberfbio:MarketOfferingMember2023-01-012023-06-300001429260fbio:CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMemberfbio:MarketOfferingMember01-012024-06-300001429260fbio:CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMemberfbio:MarketOfferingMember01-012023-06-300001429260fbio:DirectOfferingMember2024-01-012024-01-310001429260202212-12-302022-12-300001429260fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberus-gaap:RelatedPartyMemberfbio:DeskShareAgreementsMember2024-04-012024-06-300001429260fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember2024-04-012024-06-300001429260us-gaap:RelatedPartyMember2024-04-012024-06-300001429260fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberus-gaap:RelatedPartyMemberfbio:DeskShareAgreementsMember2024-01-012024-06-300001429260us-gaap:RelatedPartyMember2024-01-012024-06-300001429260fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberus-gaap:RelatedPartyMemberfbio:DeskShareAgreementsMember2023-04-012023-06-300001429260fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember2023-04-012023-06-300001429260us-gaap:RelatedPartyMember2023-04-012023-06-300001429260fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberus-gaap:RelatedPartyMemberfbio:DeskShareAgreementsMember2023-01-012023-06-300001429260fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember2023-01-012023-06-300001429260us-gaap:RelatedPartyMember2023-01-012023-06-300001429260fbio:ZilxiMember2024-04-012024-06-300001429260fbio:QbrexzaMember2024-04-012024-06-300001429260fbio:OtherLegacyProductRevenueMember2024-04-012024-06-300001429260fbio:AmzeeqMember2024-04-012024-06-300001429260fbio:AccutaneMember2024-04-012024-06-300001429260fbio:ZilxiMember2024-01-012024-06-300001429260fbio:QbrexzaMember2024-01-012024-06-300001429260fbio:OtherLegacyProductRevenueMember2024-01-012024-06-300001429260fbio:AmzeeqMember2024-01-012024-06-300001429260fbio:AccutaneMember2024-01-012024-06-300001429260fbio:ZilxiMember2023-04-012023-06-300001429260fbio:QbrexzaMember2023-04-012023-06-300001429260fbio:OtherLegacyProductRevenueMember2023-04-012023-06-300001429260fbio:AmzeeqMember2023-04-012023-06-300001429260fbio:AccutaneMember2023-04-012023-06-300001429260fbio:ZilxiMember2023-01-012023-06-300001429260fbio:QbrexzaMember2023-01-012023-06-300001429260fbio:OtherLegacyProductRevenueMember2023-01-012023-06-300001429260fbio:AmzeeqMember2023-01-012023-06-300001429260fbio:AccutaneMember2023-01-012023-06-300001429260fbio:DebtObligationsAndLettersOfCreditMember2024-06-300001429260fbio:DebtObligationsAndLettersOfCreditMember2023-12-310001429260us-gaap:LeaseholdsAndLeaseholdImprovementsMember2024-06-300001429260us-gaap:FurnitureAndFixturesMember2024-06-300001429260us-gaap:ConstructionInProgressMember2024-06-300001429260us-gaap:ComputerEquipmentMember2024-06-300001429260us-gaap:BuildingMember2024-06-300001429260us-gaap:LeaseholdsAndLeaseholdImprovementsMember2023-12-310001429260us-gaap:FurnitureAndFixturesMember2023-12-310001429260us-gaap:ConstructionInProgressMember2023-12-310001429260us-gaap:ComputerEquipmentMember2023-12-310001429260us-gaap:BuildingMember2023-12-310001429260fbio:AvenueTherapeuticsIncMemberus-gaap:PrivatePlacementMember2024-01-052024-01-050001429260fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMember2024-05-012024-05-310001429260fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMember2024-04-012024-04-300001429260fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMemberfbio:MarketOfferingMember2024-01-012024-06-300001429260fbio:CypriumMemberus-gaap:RelatedPartyMemberfbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2024-06-300001429260fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember2024-06-272024-06-270001429260fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberfbio:DeskShareAgreementsMember2024-04-012024-06-300001429260fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberfbio:DeskShareAgreementsMember2024-01-012024-06-300001429260fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberfbio:DeskShareAgreementsMember2023-04-012023-06-300001429260fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberfbio:DeskShareAgreementsMember2023-01-012023-06-300001429260fbio:MustangTherapeuticsIncMemberfbio:UbrigeneBostonBiosciencesInc.Member2024-06-300001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2023-04-012023-06-300001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2023-01-012023-06-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-04-012024-06-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2024-01-012024-06-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-04-012023-06-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-01-012023-06-300001429260fbio:MustangTherapeuticsIncMember2024-06-300001429260fbio:MustangTherapeuticsIncMember2023-12-310001429260fbio:OtherDebtMember2024-04-012024-06-300001429260fbio:PartnerCompanyInstallmentPaymentsLicensesMember2023-04-012023-06-300001429260fbio:OtherDebtMember2023-04-012023-06-300001429260fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember2024-04-012024-06-300001429260fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember2024-01-012024-06-300001429260fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember2023-04-012023-06-300001429260fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember2023-01-012023-06-300001429260fbio:JourneyMembersrt:MinimumMember2024-06-300001429260fbio:JourneyMembersrt:MaximumMember2024-06-300001429260fbio:JourneyMember2023-12-310001429260fbio:Ur1TherapeuticsIncMemberus-gaap:WarrantMember2024-01-012024-06-300001429260fbio:Ur1TherapeuticsIncMemberfbio:PlacementAgentWarrantsMember2024-01-012024-06-300001429260fbio:RestrictedStockAndRestrictedStockUnitsMember2024-06-300001429260fbio:RestrictedStockAndRestrictedStockUnitsMember2023-06-300001429260us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001429260fbio:RestrictedStockAndRestrictedStockUnitsMember2024-01-012024-06-300001429260us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001429260fbio:RestrictedStockAndRestrictedStockUnitsMember2023-01-012023-06-300001429260fbio:OaktreeNoteMember2020-08-272020-08-270001429260fbio:OaktreeNoteMember2020-08-310001429260fbio:OaktreeNoteMember2024-06-300001429260fbio:SwkTermLoanMember2023-12-310001429260fbio:OaktreeNoteMember2023-12-310001429260fbio:OaktreeNoteMember2020-08-270001429260fbio:SwkTermLoanMember2023-12-272023-12-270001429260fbio:DermatologyProductsSalesMember2024-04-012024-06-300001429260fbio:DermatologyProductsSalesMember2024-01-012024-06-300001429260fbio:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember2024-01-012024-06-300001429260fbio:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember2024-01-012024-06-300001429260fbio:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember2023-01-012023-12-310001429260242022-12-300001429260fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMemberfbio:MarketOfferingMember2024-06-300001429260fbio:CheckpointMembersrt:MaximumMemberfbio:PlacementAgentWarrantsMemberfbio:DirectOfferingMember2024-01-310001429260fbio:CheckpointMembersrt:MaximumMemberfbio:DirectOfferingMember2024-01-310001429260srt:MaximumMemberfbio:DirectOfferingMember2024-01-310001429260fbio:AvenueTherapeuticsIncMemberfbio:SeriesWarrantsMemberus-gaap:PrivatePlacementMember2024-01-

050001429260fbio:AvenueTherapeuticsIncMemberfbio:SeriesBWarrantsMemberus-gaap:PrivatePlacementMember2024-01-
050001429260fbio:CheckpointMemberfbio:PreFundedWarrantsMemberus-gaap:SubsequentEventMemberfbio:July2024RegisteredDirectOfferingMember2024-07-
310001429260fbio:CheckpointMemberus-gaap:SubsequentEventMemberfbio:July2024RegisteredDirectOfferingMember2024-07-
310001429260fbio:MustangTherapeuticsIncMemberfbio:UnregisteredWarrantsMemberfbio:DirectOfferingMember2024-06-
300001429260fbio:Ur1TherapeuticsIncMemberfbio:CommonStockWarrantsMember2024-06-
270001429260fbio:MustangTherapeuticsIncMemberfbio:AmendedWarrantsMemberfbio:PublicOfferingMember2024-05-
310001429260fbio:MustangTherapeuticsIncMemberfbio:PublicOfferingMember2024-05-310001429260fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMember2024-04-
300001429260fbio:AvenueTherapeuticsIncMember2024-04-300001429260fbio:CheckpointMemberfbio:PreFundedWarrantsMemberfbio:DirectOfferingMember2024-01-
310001429260fbio:CheckpointMemberfbio:PlacementAgentWarrantsMemberfbio:DirectOfferingMember2024-01-
310001429260fbio:CheckpointMemberfbio:CommonStockWarrantsMemberfbio:DirectOfferingMember2024-01-310001429260fbio:AvenueTherapeuticsIncMember2022-10-11000014292602022-
12-31000142926020 23-06-300001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2024-04-012024-06-
300001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2024-01-012024-06-300001429260fbio:DermatologyProductsSalesMember2023-04-012023-06-
300001429260fbio:JourneyMember2023-01-012023-12-310001429260fbio:DermatologyProductsSalesMember2023-01-012023-06-300001429260us-gaap:WarrantMember2024-01-012024-06-
300001429260us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001429260fbio:UnvestedRestrictedStockUnitsMember2024-01-012024-06-
300001429260fbio:UnvestedRestrictedStockMember2024-01-012024-06-300001429260us-gaap:WarrantMember2023-01-012023-06-300001429260us-gaap:EmployeeStockOptionMember2023-
01-012023-06-300001429260fbio:UnvestedRestrictedStockUnitsMember2023-01-012023-06-300001429260fbio:UnvestedRestrictedStockMember2023-01-012023-06-
300001429260fbio:PartnerCompanyNotesPayableMember2024-04-012024-06-300001429260fbio:OaktreeNoteMember2024-04-012024-06-300001429260fbio:SwkTermLoanMember2024-01-
012024-06-300001429260fbio:PartnerCompanyNotesPayableMember2024-01-012024-06-300001429260fbio:PartnerCompanyInstallmentPaymentsLicensesMember2024-01-012024-06-
300001429260fbio:OtherDebtMember2024-01-012024-06-300001429260fbio:OaktreeNoteMember2024-01-012024-06-300001429260fbio:PartnerCompanyNotesPayableMember2023-04-
012023-06-300001429260fbio:PartnerCompanyConvertiblePreferredSharesMember2023-04-012023-06-300001429260fbio:OaktreeNoteMember2023-04-012023-06-
300001429260fbio:PartnerCompanyNotesPayableMember2023-01-012023-06-300001429260fbio:PartnerCompanyInstallmentPaymentsLicensesMember2023-01-012023-06-
300001429260fbio:PartnerCompanyConvertiblePreferredSharesMember2023-01-012023-06-300001429260fbio:OtherDebtMember2023-01-012023-06-
300001429260fbio:OaktreeNoteMember2023-01-012023-06-300001429260us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001429260us-
gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001429260fbio:OtherPartnersMember2024-04-012024-06-300001429260fbio:MustangTherapeuticsIncMember2024-04-
012024-06-300001429260fbio:LongTermIncentivePlansMember2024-04-012024-06-300001429260fbio:ExecutiveAwardsMember2024-04-012024-06-
300001429260fbio:EmployeeAndNonemployeeAwardsMember2024-04-012024-06-300001429260fbio:CheckpointMember2024-04-012024-06-
300001429260fbio:AvenueTherapeuticsIncMember2024-04-012024-06-300001429260us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001429260us-
gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001429260fbio:OtherPartnersMember2024-01-012024-06-300001429260fbio:ExecutiveAwardsMember2024-01-012024-
06-300001429260fbio:EmployeeAndNonemployeeAwardsMember2024-01-012024-06-300001429260us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001429260us-
gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001429260fbio:OtherPartnersMember2023-04-012023-06-300001429260fbio:MustangTherapeuticsIncMember2023-04-
012023-06-300001429260fbio:LongTermIncentivePlansMember2023-04-012023-06-300001429260fbio:ExecutiveAwardsMember2023-04-012023-06-
300001429260fbio:EmployeeAndNonemployeeAwardsMember2023-04-012023-06-300001429260fbio:CheckpointMember2023-04-012023-06-
300001429260fbio:AvenueTherapeuticsIncMember2023-04-012023-06-300001429260us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001429260us-
gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001429260fbio:OtherPartnersMember2023-01-012023-06-300001429260fbio:MustangTherapeuticsIncMember2023-01-
012023-06-300001429260fbio:LongTermIncentivePlansMember2023-01-012023-06-300001429260fbio:ExecutiveAwardsMember2023-01-012023-06-
300001429260fbio:EmployeeAndNonemployeeAwardsMember2023-01-012023-06-300001429260fbio:CheckpointMember2023-01-012023-06-
300001429260fbio:AvenueTherapeuticsIncMember2023-01-012023-06-300001429260fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember2024-06-
300001429260fbio:JourneyMemberus-gaap:RelatedPartyMember2024-06-300001429260us-gaap:OtherAffiliatesMember2024-06-300001429260us-gaap:OtherAffiliatesMember2023-12-
310001429260fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember2023-06-300001429260fbio:CheckpointMemberus-
gaap:SubsequentEventMemberfbio:July2024RegisteredDirectOfferingMember2024-07-012024-07-
310001429260fbio:CheckpointMemberfbio:PreFundedWarrantsMemberfbio:DirectOfferingMember2024-01-012024-01-
310001429260fbio:AvenueTherapeuticsIncMemberfbio:November2023WarrantsMemberus-gaap:PrivatePlacementMember2024-06-
300001429260fbio:AvenueTherapeuticsIncMemberfbio:January2023WarrantsMemberus-gaap:PrivatePlacementMember2024-06-
300001429260fbio:CheckpointMemberfbio:PlacementAgentWarrantsMemberfbio:December2022OfferingMember2024-06-
300001429260fbio:AvenueTherapeuticsIncMemberfbio:CommonStockWarrantsMember2024-06-
300001429260fbio:CheckpointMemberfbio:PlacementAgentWarrantsMemberfbio:December2022OfferingMember2023-12-
310001429260fbio:AvenueTherapeuticsIncMemberfbio:CommonStockWarrantsMember2023-12-310001429260fbio:DirectOfferingMember2024-01-
310001429260fbio:MustangTherapeuticsIncMemberfbio:UbrigeneBostonBiosciencesInc.Member2023-07-282023-07-
280001429260fbio:Ur1TherapeuticsIncMemberfbio:CrystalysTherapeuticsIncMemberus-gaap:SubsequentEventMember2024-07-
150001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2024-06-300001429260fbio:DermatologyProductsSalesMember2024-06-
300001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2023-12-310001429260fbio:DermatologyProductsSalesMember2023-12-
310001429260fbio:AvenueTherapeuticsIncMemberfbio:InvagenPharmaceuticalsIncMember2024-06-300001429260fbio:CheckpointMemberfbio:DirectOfferingMember2024-01-012024-01-
310001429260fbio:LongTermIncentivePlansMember2024-01-012024-06-300001429260fbio:LongTermIncentivePlansMember2023-01-012023-12-
310001429260fbio:AvenueTherapeuticsIncMemberus-gaap:WarrantMember2024-01-012024-06-300001429260us-gaap:WarrantMember2024-01-012024-06-
300001429260fbio:CheckpointMemberfbio:FoundersAgreementMemberfbio:MarketOfferingMember2024-01-012024-06-
300001429260fbio:MustangTherapeuticsIncMembersrt:MaximumMemberfbio:ShelfRegistration2024StatementMember2024-06-122024-06-
120001429260fbio:MustangTherapeuticsIncMemberfbio:ShelfRegistration2024StatementMember2024-01-012024-06-
300001429260fbio:MustangTherapeuticsIncMemberfbio:ShelfRegistration2021StatementMember2024-01-012024-06-
300001429260fbio:CheckpointMembersrt:MaximumMemberfbio:ShelfRegistration2023StatementMember2023-05-052023-05-
050001429260fbio:MustangTherapeuticsIncMemberfbio:ShelfRegistration2021StatementMember2021-04-232021-04-230001429260fbio:JourneyMember2024-04-012024-06-
300001429260fbio:JourneyMember2024-01-012024-06-300001429260fbio:JourneyMember2023-04-012023-06-300001429260fbio:JourneyMember2023-01-012023-06-
300001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:SubsequentEventMember2024-07-052024-07-
050001429260fbio:MustangTherapeuticsIncMemberfbio:DirectOfferingMember2024-06-300001429260fbio:AvenueTherapeuticsIncMemberfbio:InvagenPharmaceuticalsIncMember2024-01-
012024-06-300001429260fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember2022-12-012023-02-280001429260srt:MaximumMember2024-01-012024-06-
300001429260fbio:MaintainsVotingControlMember2024-01-012024-06-300001429260fbio:JourneyMemberfbio:MarketOfferingMember2024-01-012024-06-
300001429260fbio:Ur1TherapeuticsIncMemberfbio:CrystalysTherapeuticsIncMemberus-gaap:SubsequentEventMember2024-07-152024-07-1500014292602024-05-132024-05-130001429260us-
gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember2024-04-012024-06-
300001429260us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember2024-01-
012024-06-300001429260us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember2024-01-012024-06-300001429260us-
gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember2023-04-012023-06-
300001429260us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember2023-01-012023-12-310001429260us-
gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember2023-01-012023-06-
300001429260fbio:IfOutstandingPrincipalBalanceIsLessThanOrEqualTo10MillionMemberus-gaap:SubsequentEventMember2024-07-252024-07-
250001429260fbio:IfOutstandingPrincipalBalanceIsLessThanOrEqualTo10MillionMemberus-gaap:SubsequentEventMember2024-07-250001429260fbio:CrystalysTherapeuticsIncMemberus-
gaap:SubsequentEventMember2024-07-150001429260fbio:LongTermIncentivePlansMember2024-01-012024-01-010001429260fbio:LongTermIncentivePlansMember2023-01-012023-01-
010001429260fbio:SwkTermLoanMemberus-gaap:SubsequentEventMember2024-07-090001429260fbio:IfOutstandingPrincipalBalanceIsBetween10MillionAnd25MillionMemberus-
gaap:SubsequentEventMember2024-07-250001429260fbio:JourneyMember2024-06-300001429260fbio:MustangTherapeuticsIncMemberfbio:UbrigeneBostonBiosciencesInc.Member2024-06-
270001429260fbio:CheckpointMemberfbio:CommonStockWarrantsMember2024-01-012024-06-300001429260fbio:AvenueTherapeuticsIncMemberfbio:CommonStockWarrantsMember2024-01-
012024-06-300001429260fbio:CypriumMemberus-gaap:RelatedPartyMemberfbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2020-08-012020-08-
310001429260fbio:Ur1TherapeuticsIncMemberfbio:CommonStockWarrantsMember2024-01-012024-06-300001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMemberus-
gaap:SubsequentEventMember2024-07-
050001429260fbio:DebtInstrumentRepaymentPeriodFromFebruary2026IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsLessThanThresholdRevenueAsOfDecember312025Memberfbio:Sw
01-012025-12-
310001429260fbio:DebtInstrumentRepaymentPeriodFromFebruary2027IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsGreaterThanThresholdRevenueAsOfDecember312025Memberfbio
02-012026-02-
280001429260fbio:DebtInstrumentRepaymentPeriodFromFebruary2026IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsLessThanThresholdRevenueAsOfDecember312025Memberfbio:Sw
02-012026-02-280001429260fbio:IfDebtInstrumentsPrepaidPriorToFirstAnniversaryOfClosingDateMemberfbio:SwkTermLoanMember2024-06-
300001429260fbio:IfDebtInstrumentPrepaidOnOrAfterFirstAnniversaryButPriorToSecondAnniversaryOfClosingDateMemberfbio:SwkTermLoanMember2024-06-
300001429260fbio:IfDebtInstrumentPrepaidAfterSecondAnniversaryOfClosingDateMemberfbio:SwkTermLoanMember2024-06-300001429260fbio:SwkTermLoanMember2024-06-
300001429260us-gaap:SubsequentEventMember2024-07-252024-07-250001429260fbio:SwkTermLoanMember2023-12-270001429260fbio:OaktreeNoteMemberus-
gaap:SubsequentEventMember2024-07-250001429260fbio:OaktreeNoteMemberus-gaap:SubsequentEventMember2024-07-252024-07-
250001429260fbio:PartnerCompanyConvertiblePreferredSharesMember2024-04-012024-06-300001429260fbio:PartnerCompanyConvertiblePreferredSharesMember2024-01-012024-06-
300001429260fbio:Ur1TherapeuticsIncMember2024-06-300001429260fbio:CheckpointMemberfbio:ShelfRegistration2023StatementMember2024-06-
300001429260fbio:AvenueTherapeuticsIncMemberfbio:ShelfRegistration2021StatementMember2024-06-300001429260fbio:ShelfRegistrationStatementMember2024-06-
300001429260fbio:ShelfRegistration2024StatementMember2024-05-170001429260us-gaap:CommonStockMember2024-04-012024-06-300001429260us-gaap:CommonStockMember2024-01-
012024-06-300001429260us-gaap:CommonStockMember2023-04-012023-06-300001429260us-gaap:CommonStockMember2023-01-012023-06-
300001429260fbio:CommonSharesIssuableMember2023-04-012023-06-300001429260fbio:CommonSharesIssuableMember2023-01-012023-06-3000014292602023-01-012023-12-
310001429260fbio:Ur1TherapeuticsIncMemberfbio:CommonStockWarrantsMember2024-06-272024-06-270001429260fbio:MustangTherapeuticsIncMemberfbio:DirectOfferingMember2024-06-
012024-06-300001429260fbio:MustangTherapeuticsIncMemberfbio:PublicOfferingMember2024-05-012024-05-
310001429260fbio:AvenueTherapeuticsIncMemberfbio:November2023WarrantsMemberus-gaap:PrivatePlacementMember2024-01-
050001429260fbio:AvenueTherapeuticsIncMemberfbio:January2023WarrantsMemberus-gaap:PrivatePlacementMember2024-01-050001429260fbio:Ur1TherapeuticsIncMemberus-
gaap:SubsequentEventMember2024-07-152024-07-150001429260fbio:MustangTherapeuticsIncMemberfbio:NetAssetsBelow20MillionMemberfbio:UbrigeneBostonBiosciencesInc.Member2024-
06-300001429260fbio:MustangTherapeuticsIncMemberfbio:NetAssetsBelow20MillionMemberfbio:UbrigeneBostonBiosciencesInc.Member2024-06-272024-06-
270001429260fbio:MustangTherapeuticsIncMemberfbio:UbrigeneBostonBiosciencesInc.Member2024-06-272024-06-270001429260fbio:Ur1TherapeuticsIncMember2024-01-012024-06-
300001429260fbio:OncogenuityMember2024-01-012024-06-300001429260fbio:MustangTherapeuticsIncMember2024-01-012024-06-300001429260fbio:HelocyteMember2024-01-012024-06-
300001429260fbio:CypriumMember2024-01-012024-06-300001429260fbio:CheckpointMember2024-01-012024-06-300001429260fbio:CellvationMember2024-01-012024-06-
300001429260fbio:BaergicMember2024-01-012024-06-300001429260fbio:AvenueTherapeuticsIncMember2024-01-012024-06-300001429260fbio:CypriumMemberus-
gaap:RelatedPartyMemberfbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2020-08-3100014292602023-04-012023-06-300001429260us-
gaap:NoncontrollingInterestMember2024-04-012024-06-300001429260us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001429260us-gaap:NoncontrollingInterestMember2024-
01-012024-06-300001429260us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001429260us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001429260us-
gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001429260us-gaap:NoncontrollingInterestMember2023-01-012023-06-300001429260us-
gaap:AdditionalPaidInCapitalMember2023-01-012023-06-3000014292602024-06-3000014292602023-12-3100014292602023-01-012023-06-3000014292602024-04-012024-06-300001429260us-
gaap:CommonStockMember2024-01-012024-06-300001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2024-01-012024-06-300001429260us-
gaap:CommonStockMember2024-08-090001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2024-08-0900014292602024-01-012024-06-
30fbio:segmentfbio:Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purefbio:Dfbio:customerfbio:directorfbio:companyfbio:subsidiaryTable of ContentsUNITED STATESSECURITIES
AND EXCHANGE COMMISSIONWashington, D.C. 20549FORMÂ 10-Qâ€‹â˜‘QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF
1934â€‹For the quarterly period ended JuneÂ 30,Â 2024ORâ€‹â˜TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the
transition period from Â Â Â Â Â toCommission File Number 001-35366FORTRESS BIOTECH,Â INC.(Exact name of registrant as specified in its charter)â€‹â€‹â€‹â€‹â€‹Delaware20-
5157386(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)â€‹1111 Kane Concourse Suite 301Bay Harbor Islands, FL 33154 (Address including zip
code of principal executive offices)(781) 652-4500 (Registrantâ€™s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act:â€‹Title of Classâ€‹Trading

Symbol(s)â€‹Exchange NameCommon Stockâ€‹FBIOâ€‹Nasdaq Capital Market9.375% SeriesÂ A Cumulative Redeemable Perpetual Preferred Stockâ€‹FBIOPâ€‹Nasdaq Capital Marketâ€‹Indicate by check mark whether the registrant: (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. YesÂ Â âŒ§Â Â NoÂ Â â—»Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). YesÂ Â âŒ§Â Â NoÂ Â â—»Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act:â€‹Large accelerated filerâ—»Accelerated filerâ—»Non-accelerated filerâŒ§Smaller reporting companyâ˜‘Â Â Emerging growth companyâ˜‘â€‹If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. â—»Indicate by check mark whether registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). YesÂ Â â˜Â Â NoÂ Â â˜‘â€‹â€‹â€‹â€‹â€‹Class of StockÂ Â Â Outstanding Shares as of August 9, 2024Common Stock, $0.001 par valueâ€‹ 22,813,9549.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.001 par valueâ€‹3,427,138â€‹â€‹â€‹ Table of ContentsFORTRESS BIOTECH, INC. AND SUBSIDIARIESQuarterly Report on Form 10-Qâ€‹TABLE OF CONTENTSâ€‹PART I.FINANCIAL INFORMATION6Item 1.Unaudited Condensed Consolidated Financial Statements6Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations42Item 3.Quantitative and Qualitative Disclosures About Market Risks58Item 4.Controls and Procedures59â€‹â€‹â€‹PART II.OTHER INFORMATION59Item 1.Legal Proceedings59Item 1A.Risk Factors60Item 2.Unregistered Sales of Equity Securities and Use of Proceeds95Item 3.Defaults Upon Senior Securities95Item 4.Mine Safety Disclosures95Item 5.Other Information95Item 6.Exhibits95Â Â Â SIGNATURESÂ 98â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ Table of ContentsSUMMARY OF RISK FACTORSâ€‹Our business is subject to risks of which you should be aware before making an investment decision. The risks described below are a summary of the principal risks associated with an investment in us and are not the only risks we face. You should carefully consider these risk factors, the risk factors described in Item 1A, and the other reports and documents that we have filed with the Securities and Exchange Commission (â€œSECâ€). As used below and throughout this filing (including in the risk factors described in Item 1A), the words â€œweâ€, â€œusâ€ and â€œourâ€ may refer to Fortress Biotech, Inc. individually, to one or more of its subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context.â€‹Risks Inherent in Drug Developmentâ€‹â—»Many of our product candidates are in early development stages and are subject to time and cost intensive regulation and clinical testing, which may result in the identification of safety or efficacy concerns. As a result, our product candidates may never be successfully developed or commercialized. â—»Our competitors may develop treatments for our productsâ€™ target indications, which could limit our product candidatesâ€™ commercial opportunity and profitability.â€‹Risks Pertaining to the Need for and Impact of Existing and Additional Financing Activitiesâ€‹â—»We have a history of operating losses and expect such losses to continue in the future. â—»We have funded our operations in part through the assumption of debt, and the applicable lending agreements may restrict our operations. Further, the occurrence of any default event under an applicable loan document could adversely affect our business.â—»Our research and development (â€œR&Dâ€) programs will require additional capital, which we may be unable to raise as needed and which may impede our R&D programs, commercialization efforts, or planned acquisitions. â—»Our board of directors has paused payments of dividends on our preferred stock, and there can be no assurance that monthly dividend payments will be resumed in a timely manner, or at all.â—»If we raise additional capital by issuing equity, equity-linked securities or securities convertible into or exercisable for equity securities, our existing stockholders will be diluted. â€‹Risks Pertaining to Our Existing Revenue Stream from Journey Medical Corporation (â€œJourneyâ€)â€‹â—»Our operating income derives primarily from the sale of our partner company Journeyâ€™s dermatology products, particularly Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Luxamend, and Exelderm. Any issues relating to the manufacture, sale, utilization, or reimbursement of Journeyâ€™s products (including products liability claims) could significantly impact our operating results. â—»A significant portion of Journeyâ€™s sales derive from products that are without patent protection and/or are or may become subject to third party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse effect on our operating income. Three of Journeyâ€™s marketed products, Qbrexza, Amzeeq and Zilxi, as well as product candidate DFD-29, a modified release oral minocycline for the treatment of rosacea licensed from Dr. Reddyâ€™s Laboratories, currently have patent protection. Four of Journeyâ€™s marketed products, Accutane, Targadox, Luxamend and Exelderm, do not have patent protection or otherwise are not eligible for patent protection. With respect to Journey products that are covered by valid claims of issued patents, such patents may be subject to invalidation, which would harm our operating income.â—»Continued sales and coverage, including formulary inclusion without the need for a prior authorization or step edit therapy, of our products for commercial sale will depend in part on the availability of reimbursement from third-party payors, including government payors. Third-party payors are increasingly examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy, and, accordingly, significant uncertainty exists as to the reimbursement status of current and newly approved therapeutics.â€‹Risks Pertaining to our Business Strategy, Structure and Organizationâ€‹â—»We have entered, and will likely in the future enter, into certain collaborations or divestitures which may cause a reduction in our businessâ€™ size and scope, market share and opportunities in certain markets, or our ability to compete in certain markets and therapeutic categories.â€‹3 Table of Contentsâ—»We and our subsidiaries and partner companies have also entered into, and intend in the future to enter into, arrangements under which we and/or they have agreed to contingent dispositions of such companies and/or their assets. The failure to consummate any such transaction may impair the value of such companies and/or assets, and we may not be able to identify or execute alternative arrangements on favorable terms, if at all. The consummation of any such arrangements with respect to certain product candidates may also result in our eligibility to receive a lower portion of sales (if any) of resulting approved products than if we had developed and commercialized such products ourselves.â—»Our growth and success depend on our acquiring or in-licensing products or product candidates and integrating such products into our businesses.â—»We act, and are likely to continue acting, as guarantor and/or indemnitor of certain obligations of our subsidiaries and partner companies, including our indemnification of our former subsidiary Caelum with respect to the UTRF litigation, which could require us to pay substantial amounts based on the actions or omissions of said entities.â€‹Risks Pertaining to Reliance on Third Partiesâ€‹â—»We rely heavily on third parties for several aspects of our operations, including manufacturing and developing product candidates, conducting clinical trials, and producing commercial product supply. Such reliance on third parties reduces our ability to control every aspect of the drug development process and may hinder our ability to develop and commercialize our products in a cost-effective and timely manner. â€‹Risks Pertaining to Intellectual Property and Potential Disputes with Licensors Thereofâ€‹â—»If we are unable to obtain and maintain patent protection for our technologies and products, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies and products similar or identical to ours, and our ability to successfully commercialize our technologies and products may be impaired.â—»We or our licensors may be subject to costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce our or our licensorsâ€™ patents. â—»Any dispute with our licensors may affect our ability to develop or commercialize our product candidates.â€‹Risks Pertaining to Generic Competition and Paragraph IV Litigationâ€‹â—»Generic drug companies may submit applications seeking approval to market generic versions of our products.â—»In connection with these applications, generic drug companies may seek to challenge the validity and enforceability of our patents through litigation and/or with the United States Patent and Trademark Office (â€œPTOâ€). Such challenges may subject us to costly and time-consuming litigation and/or PTO proceedings.â—»As a result of the loss of any patent protection from such litigation or PTO proceedings, or the â€œeat-riskâ€ launch by a generic competitor of our products, our products could be sold at significantly lower prices, and we could lose a significant portion of product sales in a short period of time, which could adversely affect our business, financial condition, operating results and prospects.â€‹Risks Pertaining to the Commercialization of Product Candidatesâ€‹â—»If our product candidates, if approved, are not broadly accepted by the healthcare community, the revenues from any such products are likely to be limited. â—»We may not obtain the desired product labels or intended uses for product promotion, or favorable scheduling classifications desirable to successfully promote our products.â—»Even if a product candidate is approved, it may be subject to various post-marketing requirements, including studies or clinical trials, the results of which could cause such products to later be withdrawn from the market.â—»Any successful products liability claim related to any of our current or future product candidates may cause us to incur substantial liability and limit the commercialization of such products.â€‹Risks Pertaining to Legislation and Regulation Affecting the Biopharmaceutical and Other Industriesâ€‹â—»We operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations.â€‹4 Table of ContentsGeneral and Other Risksâ€‹â—»We have previously failed to satisfy certain continued listing rules of The Nasdaq Stock Market LLC (â€œNasdaqâ€), and if we again are unable to meet the continued listing requirements, our Common Stock and Preferred Stock may be subject to delisting from The Nasdaq Capital Market if we are unable to regain compliance with such rules. The delisting of our Securities from the Nasdaq may decrease the market liquidity and market price of our Common Stock and Preferred Stock. â€‹â€‹5 Table of ContentsPARTÂ I. Â Â Â Â Â Â Â Â FINANCIAL INFORMATIONItemÂ 1.Â Â Â Â Unaudited Condensed Consolidated Financial StatementsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESUnaudited Condensed Consolidated Balance Sheets($ in thousands except for share and per share amounts)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Perpetualâ€‹â€‹â€‹â€‹â€‹â€‹Commonâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Totalâ€‹â€‹PreferredÂ Stockâ€‹CommonÂ Stockâ€‹Sharesâ€‹Paid-Inâ€‹Accumulatedâ€‹Non-Controllingâ€‹Stockholdersâ€™â€‹Â Â Â Â SharesÂ Â Â Â AmountÂ Â Â Â SharesÂ Â Â Â AmountÂ Â Â Â IssuableÂ Â Â Â CapitalÂ Â Â Â DeficitÂ Â Â Â InterestsÂ Â Â Â EquityBalance as of MarchÂ 31,Â 2023Â 3,427,138Â Â Â Â $ 3Â Â Â Â 8,694,477Â Â Â Â $ 9â€‹$ â€”â€‹$ 693,554Â Â Â Â $ (655,770)â€‹$ (17,990)Â Â Â Â $ 19,806Stock-based compensation expenseÂ â€”â€‹Â â€”Â Â â€”â€‹Â â€”â€‹Â 4,217â€‹Â â€”â€‹Â â€”â€‹Â 4,217Issuance of common stock related to equity plansÂ â€”â€‹Â â€”Â 5,515â€‹Â â€”â€‹Â â€”â€‹Â â€”â€‹Â â€”â€‹Â â€”â€‹Â â€”Issuance of common stock for public offering, netÂ â€”â€‹Â â€”Â â€”â€‹Â â€”â€‹Â â€”â€‹Â (41)â€‹Â â€”â€‹Â â€”â€‹Â (41)Issuance of common stock for at-the-market offering, netâ€‹ â€”â€‹â€‹ â€”â€‹ 66,098â€‹Â â€”â€‹â€‹ â€”â€‹â€‹ 721â€‹Â â€”â€‹â€‹ â€”â€‹â€‹ 721Common shares issued for dividend on partner company's convertible preferred sharesâ€‹ â€”â€‹â€‹ â€”â€‹ 11,066â€‹â€‹ â€”â€‹â€‹ 23â€‹â€‹ 108â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 131Preferred A dividends declared and paidÂ â€”â€‹Â â€”Â â€”â€‹Â â€”â€‹Â (2,008)â€‹Â â€”â€‹Â (2,008)Partner companyâ€™s offering, netÂ â€”â€‹Â â€”Â â€”â€‹Â â€”â€‹Â â€”â€‹Â â€”â€‹Â 14,460â€‹Â â€”â€‹Â â€”â€‹Â â€”â€‹Â 14,460Issuance of common stock under partner companyâ€™s ESPPâ€‹ â€”â€‹Â â€”Â â€”â€‹Â â€”â€‹Â â€”â€‹Â 88â€‹Â â€”â€‹Â â€”â€‹â€‹ 88Partner companyâ€™s dividends declared and paidÂ â€”â€‹Â â€”Â â€”Â â€”â€‹Â â€”â€‹Â â€”â€‹Â â€”â€‹Â â€”â€‹

March 22, 2024, Mustangâ€™s Form 10-K, filed with the SEC on March 11, 2024, Avenueâ€™s Form 10-K, filed with the SEC on March 18, 2024, and Journeyâ€™s Form 10-K, filed with the SEC on March 29, 2024.The Companyâ€™s unaudited condensed consolidated financial statements include the results of the Companyâ€™s subsidiaries for which it has voting control but does not own 100% of the outstanding equity of the subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, but retains voting control, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations and presents non-controlling interests as a component of stockholdersâ€™ equity on its consolidated balance sheets. All intercompany income and/or expense items are eliminated entirely in consolidation prior to the allocation of net gain/loss attributable to non-controlling interest, which is based on ownership interests as calculated quarterly for each subsidiary.Use of EstimatesThe preparation of the Companyâ€™s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Companyâ€™s significant estimates include, but are not limited to provisions for coupons, chargebacks, wholesaler fees, specialty pharmacy discounts, managed care rebates, product returns, inventory realization, valuation of intangible assets, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.Restricted CashThe Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of JuneÂ 30,Â 2024 and DecemberÂ 31,Â 2023, the Company had $2.1 million and $2.4 million, respectively, of restricted cash representing pledges to secure debt obligations and letters of credit in connection with certain office leases, and an undertaking posted by Cyprium to secure potential damages in an injunctive proceeding. Â 15 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the unaudited condensed consolidated balance sheets to the unaudited condensed consolidated statements of cash flows as of the dates presented:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹â€‹2024â€‹2023Cash and cash equivalentsÂ Â Â Â $ 76,201Â Â Â Â $ 78,022Restricted cashâ€‹Â 2,063â€‹Â 11,188Total cash and cash equivalents and restricted cashâ€‹ $ 78,264â€‹$ 89,210â€‹Significant Accounting PoliciesThere have been no material changes in the Companyâ€™s significant accounting policies to those previously disclosed in the 2023 Form 10-K other than the following:Assets Held for SaleÂ Assets held for sale represent assets that have met the criteria of â€œheld for saleâ€ accounting, as specified by Accounting Standards Codification (â€œASCâ€) 360, â€œLong-lived Assets.â€ As of June 30, 2024, there are $2.2Â million of lab and cell processing equipment, furniture and fixtures and computer equipment that are recorded as assets held for sale. The effect of suspending depreciation on the assets held for sale is immaterial to the results of operations. The assets held for sale are part of Mustangâ€™s repurchase of assets from uBriGene (Boston) Biosciences, Inc. (â€œuBriGeneâ€) (see Note 3). â€‹Recently Issued Accounting PronouncementsAccounting Standards Not Yet Adopted In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires that an entity report segment information in accordance with Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on its financial statement disclosures.â€‹In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on its financial statement disclosures.â€‹3. Asset Purchase AgreementsMustangAgreements with uBriGene On MayÂ 18, 2023, Mustang entered into an Asset Purchase Agreement (the â€œOriginal Asset Purchase Agreementâ€) with uBriGene, pursuant to which Mustang agreed to sell its leasehold interest in its cell processing facility located in Worcester, Massachusetts (the â€œFacilityâ€), and associated assets relating to the manufacturing and production of cell and gene therapies at the Facility to uBriGene (the â€œTransactionâ€). Mustang and uBriGene subsequently entered into Amendment No.Â 1 to the Original Asset Purchase Agreement, dated as of JuneÂ 29, 2023 (â€œAmendment No.Â 1â€), and Amendment No.Â 2 to the Original Asset Purchase Agreement, dated as of JulyÂ 28, 2023 (â€œAmendment No.Â 2,â€ and together with the Original Asset Purchase Agreement and Amendment No.Â 1, the â€œPrior Asset Purchase Agreementâ€).Â 16 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹On JulyÂ 28, 2023, pursuant to the Prior Asset Purchase Agreement, Mustang completed the sale of all of its assets that primarily relate to the manufacturing and production of cell and gene therapies at the Facility (such operations, the â€œTransferred Operationsâ€ and such assets, the â€œTransferred Assetsâ€) to uBriGene for upfront consideration of $6 million cash (the â€œBase Amountâ€). The Transferred Assets included all of Mustangâ€™s assets, except for Mustangâ€™s lease and related leasehold improvements of the Facility and contracts that are primarily used in the Transferred Operations. Mustang recorded a gain of $1.4 million in connection with the sale of the Transferred Assets and recorded approximately $0.3 million of the base consideration as deferred income, that was to be recognized upon the transfer of the lease.Â In connection with the Prior Asset Purchase Agreement, Mustang and uBriGene submitted a voluntary joint notice to the U.S. Committee on Foreign Investment in the United States (â€œCFIUSâ€). Following CFIUSâ€™s review and subsequent investigation of the transactions related to the Prior Asset Purchase Agreement, on MayÂ 13, 2024, Mustang, together with uBriGene and CFIUS, executed a National Security Agreement (the â€œNSAâ€), pursuant to which Mustang and uBriGene agreed to abandon the transactions related to the Prior Asset Purchase Agreement and the agreements entered into in connection therewith. The NSA obligated uBriGene and Mustang to terminate agreements between the two parties, including the Manufacturing Services Agreement, Quality Services Agreement, and Subcontracting CDMO Agreement. Â In addition, uBriGene must sell, or otherwise dispose of, the equipment assets purchased within 180 days after the execution of the NSA.Â JuneÂ 2024 Repurchase of AssetsÂ On JuneÂ 27, 2024 (the â€œEffective Dateâ€), Mustang entered into an Asset Purchase Agreement (the â€œRepurchase Agreementâ€) with uBriGene, pursuant to which Mustang agreed, subject to the terms and conditions set forth therein, to repurchase the Transferred Assets, primarily lab equipment and supplies (collectively, the â€œRepurchased Assetsâ€). Pursuant to the terms of the Repurchase Agreement, Mustang and uBriGene also terminated existing manufacturing and services agreements.Â Â As consideration for the Repurchase Agreement, Mustang has agreed to pay to uBriGene a total purchase price (the â€œPurchase Priceâ€) of $1.4 million, consisting of (i)Â an upfront payment of $0.1 million due within five (5)Â business days of the Effective Date and a (ii)Â subsequent amount of $1.3 million due on the date that is twelve (12) months after the closing date (the â€œDeferred Amountâ€). In the event that as of the original (or any extended) date on which the Deferred Amount is payable, Mustang has, as of the date of the public reporting of its then-most recent quarterly audited or unaudited financial statements, net assets below $20 million, then Mustang may, upon written notice to uBriGene, elect to delay its payment obligation of the Deferred Amount by an additional six (6)Â months, with no limit on the number of such extensions available to Mustang. Notwithstanding the foregoing, if Mustang has not paid the Deferred Amount in full as of the date that is twelve (12) months after closingÂ of theÂ Repurchase Agreement, any amounts that remain outstanding will accrue interest at a rate of 5% per annum beginning on the date that is twelve (12) months after closing and until the Deferred Amount is paid in full. Additionally, in connection with the termination of the agreements described above under the Repurchase Agreement, Mustang agreed to forgive a net receivable from uBriGene of approximately $3.3 million, comprised of outstanding receivables of $6.9 million and payables of $3.6 million, resulting in total purchase consideration in the Repurchase Transactions of approximately $4.7 million. As of June 30, 2024, the $1.4 million Purchase Price was recorded in Accrued Expenses - Other (see Note 10).â€‹Mustang allocated the total purchase consideration of $4.7 million to the Repurchased Assets on a relative fair value basis. Mustang used a third-party to perform a valuation of the repurchased equipment, which resulted in a fair value less costs to sell of approximately $2.2 million. The remaining purchase consideration of $2.5 million was allocated to the supplies repurchased. The supplies repurchased with no alternative future use were recognized as research and development expense in an amount of $2.2 million.Â Repurchased supplies with an alternative future use of $0.3 million were also recognized in research and development expense, as Mustang does not have plans to resume operations in the facility, and it intends to dispose of the supplies in a single transaction with the equipment. Â Mustang concluded that the disposal group, which includes the repurchased equipment assets and associated supplies with an aggregate value of approximately $2.2 million, met the criteria to be classified as held for sale at the date of acquisition.17 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹Avenue â€‹InvaGen Pharmaceuticals Inc. (â€œInvaGenâ€) Share RepurchaseUnder the Share Repurchase Agreement between Avenue and InvaGen Pharmaceuticals, Inc. (â€œInvaGenâ€) under which Avenue repurchased all of InvaGenâ€™s shares in Avenue, Avenue agreed to pay InvaGen an additional amount as a contingent fee, payable in the form of seven and a half percent (7.5%) of the net proceeds of future financings, until $4.0 million in the aggregate is paid to InvaGen. In connection with equity financings in the first half of 2024, Avenue made payments totaling $0.6 million to InvaGen.4. Inventoryâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹December 31,($ in thousands)2024â€‹2023Raw materials$ 3,583â€‹$ 4,640Work-in-processÂ 296â€‹Â 884Finished goodsÂ 6,213â€‹Â 4,987Inventory reserveâ€‹ (405)â€‹â€‹ (305)Total inventories$ 9,687â€‹$ 10,206â€‹5. Property and Equipmentâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â UsefulÂ LifeÂ Â Â Â JuneÂ 30,Â â€‹December 31,($ in thousands)â€‹(Years)â€‹2024â€‹2023â€‹â€‹â€‹Computer equipmentÂ â€‹3â€‹$ 595â€‹$ 595Furniture and fixturesÂ â€‹5â€‹Â 1,017â€‹Â 1,017Leasehold improvementsÂ â€‹15â€‹Â 13,175â€‹Â 13,175Buildingsâ€‹â€‹40â€‹â€‹ 581â€‹â€‹ 581Construction in progressÂ â€‹N/Aâ€‹Â â€”â€‹Â 29Total property and equipmentÂ â€‹â€‹â€‹â€‹ 15,368â€‹Â 15,397Impairment - leasehold improvementsâ€‹â€‹â€‹â€‹â€‹ (2,177)â€‹â€‹ â€”Less: Accumulated depreciationÂ â€‹â€‹â€‹â€‹ (9,645)â€‹Â (8,892)Property and equipment, netâ€‹â€‹â€‹â€‹$ 3,546â€‹$ 6,505â€‹Fortress' depreciation expense for the three months ended JuneÂ 30,Â 2024 and 2023 was approximately $0.4 million and $0.8 million, respectively, and for the six months ended JuneÂ 30,Â 2024 and 2023 was approximately $0.8 million and $1.5 million, respectively. Fortressâ€™ depreciation expense is recorded in both research and development expense and general and administrative expense in the condensed consolidated statement of operations.â€‹Impairment of Long-Lived Assetsâ€‹During the three months ended June 30, 2024, Mustang concluded it had a triggering event requiring assessment of impairment for certain leasehold improvements and the related right of use asset. Mustang assessed the carrying value of the asset group consisting of the leasehold improvements and right-of-use asset in accordance with ASC 360, given the significant changes to Mustangâ€™s operations, operating cash and the repurchase of equipment. The assessment of the recoverability of the asset group concluded that there was impairment on the carrying value of the asset group of approximately $2.6 million, which was allocated on a pro rata basis using the relative carrying amounts of the assets. Â Approximately $2.2 million of the impairment loss was allocated to leasehold improvements, with the remaining $0.4 million allocated to the right-of-use asset. â€‹18 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹6. Fair Value Measurementsâ€‹Common Stock Warrant Liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Warrants($ in thousands)Â Â Â Â liabilitiesBalance at DecemberÂ 31,Â 2023â€‹$ 886 Change in fair value of common stock warrants - Avenueâ€‹â€‹ (139) Change in fair value of common stock warrants - Checkpointâ€‹â€‹ â€” Change in fair value of placement agent warrants - Uricaâ€‹â€‹ (24)Exercise of common stock warrants - Avenueâ€‹â€‹ (400)Exchange of common stock warrants - Uricaâ€‹â€‹ (151)Balance at JuneÂ 30,Â 2024â€‹$ 172â€‹Checkpoint â€‹Checkpoint deemed the placement agent warrants it issued in connection with its registered direct offering (the â€œDecember 2022 Placement Agent Warrantsâ€) to be classified as liabilities on the balance sheet as they contain terms for redemption of the underlying security that are outside its control. The December 2022 Placement Agent Warrants were recorded at the time of closing at a fair value determined by using the Black-Scholes model. Checkpoint will revalue the December 2022 Placement Agent Warrants at each reporting period thereafter for as long as they remain outstanding. At June 30, 2024 and December 31, 2023, the liability associated with the December 2022 Placement Agent Warrants was $0.1 million.â€‹A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the warrant liability that are categorized within Level 3 of the fair value hierarchy was as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹December 31,â€‹â€‹Checkpoint Warrantsâ€‹2024â€‹2023â€‹â€‹Exercise priceâ€‹$ 5.41â€‹$ 5.41â€‹â€‹Volatilityâ€‹â€‹ 106.9%â€‹ 96.4%â€‹Expected life in yearsâ€‹â€‹ 3.5â€‹â€‹ 4.0â€‹â€‹Risk-free rateâ€‹â€‹ 4.5%â€‹ 3.8%â€‹â€‹Avenueâ€‹Certain of Avenueâ€™s outstanding warrants to purchase shares of its common stock are classified as liabilities on the balance sheet as they contain terms for redemption of the underlying security that are outside of its control. The Black-Scholes model was used to value these Avenue warrants, at the time of issuance and when re-measured at each financial reporting date, up to exercise or expiration of the warrants, with any changes in fair value being recognized in change in fair value of warrant liabilities, a component of other income (expense) in the unaudited condensed consolidated statements of operations. â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Avenueâ€‹â€‹Warrant($ in thousands)â€‹LiabilityAvenue common stock warrant liabilities at December 31, 2023â€‹$586Exercise of Avenue common warrantsâ€‹â€‹ (400)Change in fair value of common stock warrant liabilitiesâ€‹â€‹ (139)Avenue common stock warrant liabilities at June 30, 2024â€‹$47â€‹A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the warrant liability that are categorized within Level 3 of the fair value hierarchy was as follows:â€‹19 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹â€‹DecemberÂ 31â€‹â€‹â€‹â€‹2024â€‹â€‹2023â€‹â€‹Stock priceâ€‹$ 3.50â€‹â€‹$ 12.00â€‹â€‹Risk-free interest rateÂ Â Â Â 4.52%Â Â â€‹ 3.84%Â Â â€‹Expected dividend yieldÂ â€”Â Â â€‹ â€”Â Â â€‹Expected term in yearsÂ 3.3Â â€‹ 3.8Â â€‹Expected volatilityÂ 160%Â Â â€‹ 148%Â Â â€‹â€‹Urica â€‹The fair value of Uricaâ€™s contingently issuable placement agent warrants in connection with Uricaâ€™s first close of its preferred offering in December 2022 was measured using a Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Uricaâ€™s warrant liability that are categorized within Level 3 of the fair value hierarchy was as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹December 31,â€‹â€‹2023Risk-free interest rateÂ Â Â Â 3.93%Â Â Expected dividend yieldÂ â€”Â Expected term in yearsÂ 0.5Â Expected volatilityÂ 153.6%Â Â â€‹â€‹Uricaâ€™s outstanding contingently issuable placement agent warrants were exchanged at the time of the exchange of the Urica 8% Cumulative Convertible Class B Preferred Stock on June 27, 2024 (see Note 9) for 202,834 warrants to purchase Fortress common stock at an exercise price of $1.68. The Fortress common stock warrants have a five-year life, expiring on June 27, 2029.â€‹7. Intangible Assets, netâ€‹The Companyâ€™s finite-lived intangible assets consist of intangible assets acquired by Journey. The table below provides a summary of the Journey intangible assets for the periods presented:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹EstimatedÂ Usefulâ€‹JuneÂ 30,Â â€‹December 31,($ in thousands)Â Â Â Â LivesÂ (Years)Â Â Â Â 2024Â Â Â Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Intangible assets â€” product licensesâ€‹3 to 9â€‹$ 37,925â€‹$ 37,925Accumulated amortizationÂ Â Â â€‹ (16,124)â€‹Â (14,495)Accumulated Impairment lossâ€‹â€‹â€‹â€‹ (3,143)â€‹â€‹ (3,143)Net intangible assetsÂ Â Â â€‹ 18,658â€‹$ 20,287â€‹20 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹For the three months ended JuneÂ 30,Â 2024 and 2023, Journeyâ€™s amortization expense related to its product licenses was $0.8 million and $1.1 million, respectively. For the six months ended JuneÂ 30, 2024 and 2023, Journeyâ€™s amortization expense related to its product licenses was $1.6 million and $2.1 million, respectively. Journey records amortization expense related to its product licenses as a component of cost of goods sold on the unaudited condensed consolidated statement of operations.â€‹The future amortization of these intangible assets is as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Total ($ in thousands)Â Â Â Â AmortizationRemainder of 2024â€‹$ 1,628December 31, 2025â€‹Â 3,257December 31, 2026â€‹Â 2,471December 31, 2027â€‹â€‹ 1,775December 31, 2028â€‹â€‹ 1,595Thereafterâ€‹â€‹ 3,990Sub-totalâ€‹$ 14,716Asset not yet placed in serviceâ€‹â€‹ 3,942Totalâ€‹$ 18,658â€‹8. License Agreements In accordance with ASC 730-10-25-1,Â Research and Development, costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use. The licenses purchased by Fortress and its subsidiaries and partner companies require substantial completion of research and development, and regulatory and marketing approval efforts, in order to reach technological feasibility. As such, the purchase price of any licenses acquired is classified as research and development-licenses acquired in the unaudited condensed consolidated statement of operations.Â 9. Debt and InterestDebtTotal debt consists of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â JuneÂ 30,Â â€‹December 31,Â Â Â Â Â â€‹Â Â Â Â Â â€‹($ in thousands)â€‹2024â€‹2023â€‹InterestÂ rateâ€‹Maturityâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Oaktree Noteâ€‹$ 50,000â€‹$ 50,000Â 11.0%August - 2025SWK Term Loanâ€‹â€‹ 20,000â€‹â€‹ 15,000â€‹ 14.9%December - 2027Less: Discount on notes payableâ€‹â€‹ (2,993)â€‹â€‹ (4,144)â€‹â€‹â€‹â€‹â€‹Total notes payableâ€‹$ 67,007â€‹$ 60,856Â Â Â Â Â Â â€‹Oaktree Note 21 Table of

ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹In August 2020, Fortress, as borrower, entered into a $60.0 million senior secured credit agreement with Oaktree Fund Administration, LLC and the lenders from time-to-time thereto (collectively, â€œOaktreeâ€) (the â€œPrior Oaktree Agreementâ€ and the debt thereunder, the â€œOaktree Noteâ€). The Prior Oaktree Agreement contained customary representations and warranties and customary affirmative and negative covenants as well as certain financial covenants, including, among other things, (i) maintenance of minimum liquidity and (ii) a minimum revenue test that required Journeyâ€™s annual revenue to be equal to or to exceed annual revenue projections set forth in the Prior Oaktree Agreement. Failure by the Company or Journey, as applicable, to comply with the Prior Oaktree Agreement covenants would result in an event of default, subject to certain cure rights of the Company. The Company was in compliance with all applicable covenants under the Prior Oaktree Agreement as of JuneÂ 30,Â 2024.â€‹The Company was required to make quarterly interest-only payments until the fifth anniversary of the closing date of the Oaktree Note, August 27, 2025, at which point the outstanding principal amount would have been due. The Company could have voluntarily prepaid the Oaktree Note at any time subject to a prepayment fee. The Company was required to make mandatory prepayments of the Oaktree Note under various circumstances as defined in the Prior Oaktree Agreement. No mandatory prepayments were required in the six months ended JuneÂ 30,Â 2024. â€‹On July 25, 2024, Fortress entered into a $50.0 million senior secured credit agreement with a maturity date of July 25, 2027 (the â€œAgreementâ€) withÂ Oaktree. The Company borrowed $35.0 million under the Agreement on the Closing Date and is eligible to draw up to an additional $15.0 million at the lendersâ€™ discretion to support future business development activities. The Agreement replaces the Prior Oaktree Agreement in which the remaining $50.0 million balance was repaid in full (see Note 19). Â â€‹â€‹SWK Term Loanâ€‹On December 27, 2023 (the â€œSWK Closing Dateâ€), Journey entered into a Credit Agreement with SWK Funding LLC (â€œSWKâ€). The Credit Agreement provides for a term loan facility (the â€œCredit Facilityâ€) in the original principal amount of up to $20.0 million. On the SWK Closing Date, Journey drew $15 million. On June 26, 2024, Journey drew the remaining $5.0 million under the Credit Facility. Loans under the Credit Facility (the â€œTerm Loansâ€) mature on December 27, 2027. The Term Loans accrue interest which is payable quarterly in arrears. The Term Loans bear interest at a rate per annum equal to the three-month term SOFR (subject to a SOFR floor of 5%)Â plusÂ 7.75%. The interest rate resets quarterly. Interest payments began in February 2024 and are paid quarterly. On July 9, 2024, Journey entered into an amendment (the â€œSWK Amendmentâ€) to the Credit Facility. The SWK Amendment increased the total amount available under the Credit Facility from $20.0 million to $25.0 million. The $5.0 million available under the SWK Amendment is contractually required to be drawn upon FDA approval of Journeyâ€™s DFD-29 product candidate, subject to Journey receiving such approval on or before June 30, 2025 (See Note 19).Beginning in February 2026, Journey is required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans, with any remaining principal balance due on the maturity date. If the total revenue of Journey, measured on a trailing twelve-month basis, is greater than $70.0 million as of December 31, 2025, the principal repayment start date is extended from February 2026 to February 2027, at which point Journey is required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 15% of the principal amount of funded Term Loans, with any remaining principal balance due on the maturity date.Journey may at any time prepay the outstanding principal balance of the Term Loans in whole or in part. Prepayment of the Term Loans is subject to payment of a prepayment premium equal to (i) 2% of the Term Loans prepaid plus the amount of interest that would have been due through the first anniversary of the SWK Closing Date if the Term Loans are prepaid prior to the first anniversary of the SWK Closing Date, (ii) 1% of the Term Loans prepaid if the Term Loans are prepaid on or after the first anniversary of the SWK Closing Date but prior to the second anniversary of the SWK Closing Date, or (iii) 0% if prepaid thereafter. Upon repayment in full of the Term Loans, Journey will pay an exit fee equal to 5% of the original principal amount of the Term Loans. Additionally, Journey paid an origination fee of $0.2 million on the SWK Closing Date and incurred issuance costs of $0.2 million, both of which have been recorded as a debt discount. Journey is accreting the carrying value of the SWK Term Loan to the original principal balance plus the exit fee over the term of the loan using the effective interest method. The amortization of the discount is accounted for 22 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹as interest expense in the Consolidated Statement of Operations. The effective interest rate on the SWK Term Loan as of June 30, 2024 was 14.9%. The SWK Credit Facility also includes both revenue and liquidity covenants,Â restrictions as to payment of dividends, and is secured by substantially all assets of Journey. As of June 30, 2024, Journey was in compliance with the financial covenants under the SWK Credit Facility.Urica 8% Cumulative Convertible Class B Preferred Offering In December 2022 and February 2023 Urica closed private offerings of its 8% Cumulative Convertible Class B Preferred Stock (the â€œUrica Preferred Stockâ€), at a price of $25.00 per share (â€œSubscription Priceâ€) pursuant to which it sold a total of 135,494 shares of Urica Preferred Stock for gross proceeds of $3.4 million, before deducting underwriting discounts and commissions and offering expenses of approximately $0.5 million (the â€œUrica Offeringâ€). A non-cash contingent warrant value of $0.1 million was also recorded in debt discount (see Note 6).Dividends on the Urica Preferred Stock were payable monthly by Fortress in shares of Fortress Common Stock based upon a 7.5% discount to the average closing price over the 10-day period preceding the dividend payment date. Dividends were recorded as interest expense. For the three month periods ended June 30, 2024 and 2023, the Company recorded expense of $0.1 million and $0.1 million associated with the Urica dividends and for the six month periods ended June 30, 2024 and 2023, the Company recorded expense of $0.1 million and $0.1 million associated with the Urica dividends.The shares mandatorily converted into Urica common stock upon either: (i) a qualified financing pursuant to which Urica raises at least $20Â million in aggregate gross proceeds; or (ii) a sale of Urica. Additionally, in the event that neither such a qualified financing nor a sale of Urica had occurred prior to June 27, 2024, then each holder of Urica Preferred Stock was eligible to receive, at Fortressâ€™ election, one of: (x) a cash payment equal to the product of the Subscription Price and the number of shares of Urica Preferred Stock held by such holder; (y) a number of shares of Fortress common stock equal to the Fortress Share Exchange Amount; or (z) a combination of the foregoing. Â On June 27, 2024, as neither a qualified financing nor a sale of Urica occurred, Fortress elected to exchange the outstanding shares of Urica Preferred Stock, which was recorded as a liability, into 2,028,345 shares of Fortress common stock. â€‹Interest ExpenseInterest expense includes contractual interest, and fees include amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan. The following table shows the components of interest expense for all debt arrangements during the periods presented:â€‹â€‹â€‹

$2.9 million. During the six months ended JuneÂ 30, 2023, the Company issued and sold approximately 0.1 million shares at an average price of $11.31 for gross proceeds of $1.2 million.Registered Direct Offering In January 2024, Fortress closed a registered direct offering of an aggregate of 3,303,305 shares of its common stock and warrants to purchase up to 3,303,305 shares of its common stock at a combined purchase price of $3.33 per share of common stock and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $3.21 per share, were immediately exercisable, and expire five years following the date of issue. Net proceeds to Fortress, after deducting the placement agentâ€™s fees and other offering expenses, were approximately $10.2 million.Checkpoint 2023 Shelf Registration Statement In March 2023, Checkpoint filed a shelf registration statement (File No. 333-270843) on Form S-3 (the â€œCheckpoint 2023 S-3â€), which was declared effective May 5, 2023. Under the Checkpoint 2023 S-3, Checkpoint may sell up to a total of $150 million of its securities. As of June 30, 2024, approximately $77.7 million of the securities remains available for sale through the Checkpoint 2023 S-3, subject to General Instruction I.B.6 of Form S-3.â€‹28 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹Checkpoint Registered Direct Offering In January 2024, Checkpoint closed on a registered direct offering (the â€œCheckpoint January 2024 Registered Direct Offeringâ€) with a single institutional investor for the issuance and sale of 1,275,000 shares of its common stock and 6,481,233 pre-funded warrants. Each pre-funded warrant was exercisable for one share of Checkpoint common stock. The Checkpoint common stock and the pre-funded warrants were sold together with common stock warrants (the â€œCheckpoint January 2024 Common Warrantsâ€) to purchase up to 7,756,233 shares of Checkpoint common stock, at a purchase price of $1.805 per share of common stock and $1.8049 per pre-funded warrant. The pre-funded warrants were funded in full at closing except for a nominal exercise price of $0.0001 and are exercisable commencing on the closing date and will terminate when such pre-funded warrants are exercised in full. The Checkpoint January 2024 Common Warrants are exercisable immediately upon issuance and will expire five years following the issuance date and have an exercise price of $1.68 per share. Checkpoint also issued the placement agent warrants to purchase up to 465,374 shares of common stock with an exercise price of $2.2563 per share. Net proceeds to Checkpoint from the Checkpoint January 2024 Registered Direct Offering were $12.6 million after deducting commissions and other transaction costs. As of July 2024, all of the pre-funded warrants from the Checkpoint January 2024 Registered Direct Offering were fully exercised (see Note 19). Pursuant to the Companyâ€™s Founders Agreement with Checkpoint, Checkpoint issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the registered direct offering noted above. Accordingly, Checkpoint issued 193,905 shares of common stock to Fortress for the six months ended June 30, 2024.Avenue 2021 Shelf Registration StatementIn December 2021, Avenue filed a shelf registration statement (File No. 333-261520) on Form S-3 (the â€œAvenue 2021 S-3â€), which was declared effective on December 10, 2021. As of JuneÂ 30,Â 2024, approximately $24.6 million of the securities were available for sale under the Avenue 2021 S-3, subject to General Instruction I.B.6. of Form S-3.Avenue 2024 Warrant Exercises and Private PlacementOn January 5, 2024, Avenue entered into (i) an inducement offer letter agreement (the â€œJanuary 2023 Investor Inducement Letterâ€) with a certain investor (the â€œJanuary 2023 Investorâ€) in connection with certain outstanding warrants to purchase up to an aggregate of 25,871 shares of Common Stock, originally issued to the January 2023 Investor on January 31, 2023 (the â€œJanuary 2023 Warrantsâ€) and (ii) an inducement offer letter agreement (the â€œNovember 2023 Investor Inducement Letter Agreementâ€ and, together with the January 2023 Investor Inducement Letter, the â€œJanuary 2024 Warrant Inducementâ€) with certain investors (the â€œNovember 2023 Investorsâ€ and, together with the January 2023 Investor, the â€œHoldersâ€) in connection with certain outstanding warrants to purchase up to an aggregate of 194,667 shares of Common Stock, originally issued to the November 2023 Investors on November 2, 2023 (the â€œNovember 2023 Warrantsâ€ and, together with the January 2023 Warrants, the â€œExisting Warrantsâ€). The January 2023 Warrants had an exercise price of $116.25 per share, and the November 2023 Warrants had an exercise price of $22.545 per share. â€‹Pursuant to the January 2024 Warrant Inducement, (i) the January 2023 Investor agreed to exercise its January 2023 Warrants for cash at a reduced exercise price of $22.545 per share and (ii) the November 2023 Investors agreed to exercise their November 2023 Warrants for cash at the existing exercise price of $22.545, in each case in consideration for Avenueâ€™s agreement to issue in a private placement (x) Series A Warrants to purchase up to 220,538 shares of Avenue Common Stock and (y) Series B Warrants to purchase up to 220,538 shares of Avenue Common Stock. The net proceeds to Avenue from the exercise of the warrants was approximately $4.5 million, after deducting placement agent fees and estimated offering costs, but without giving effect to the exercise of the Series A Warrants and Series B Warrants issued in the January 2024 Warrant Inducement.â€‹The fair value of the Series A Warrants and Series B Warrants was allocated between the January 2023 Warrants and the November 2023 Warrants on a weighted basis, with approximately $0.6 million allocated to the January 2023 Warrants and recorded to loss on common stock warrant liabilities in the condensed consolidated statement of operations, and the approximately $4.3 million allocated to the November 2023 Warrants deemed to be a dividend such that it was included in net loss attributable to common stockholders in the calculation of net loss per share in the condensed consolidated statement of operations (see Note 12). â€‹â€‹29 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹Also in April 2024, Avenue entered into definitive agreements for the immediate exercise of certain of its existing outstanding warrants for cash an aggregate of 689,680 warrants for shares of Avenueâ€™s common stock at a reduced exercise price of $6.20 per share (the â€œMay 2024 Warrant Inducementâ€). The exercised warrants are comprised of warrants to purchase shares of common stock originally issued by Avenue on October 11, 2022, each having an exercise price of $116.25 per share, Series A and Series B warrants to purchase shares of common stock originally issued by Avenue on November 2, 2023, each having an exercise price of $22.545 per share, and warrants to purchase shares of common stock originally issued by Avenue on January 9, 2024, each having an exercise price of $22.545 per share.In consideration for the immediate exercise of the warrants for cash in the May 2024 Warrant Inducement, Avenue issued two new unregistered series of warrants to purchase up to a total of 1,379,360 shares of Avenue common stock for a payment of $0.125 per warrant. The warrants have an exercise price of $6.20 per share, and terms of eighteen months for one series and five years for the other series. Total net proceeds to Avenue were approximately $3.7 million after deducting placement agent fees and other expenses payable by Avenue.In May 2024, Avenue entered into an At-the-Market Offering Agreement (the â€œAvenue ATMâ€)Â under which Avenue may offer and sell, from time to time at its sole discretion, up to $3.9 million of shares of its common stock. The offer and sale of the shares will be made pursuant to a base prospectus forming a part of the 2021 Avenue S-3, and the related prospectus supplement dated May 10, 2024.Â During the six months ended JuneÂ 30,Â 2024, Avenue issued 87,683 shares through the Avenue ATM for net proceeds of $0.3 million. â€‹Pursuant to the Companyâ€™s Founders Agreement with Avenue, Avenue issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the warrant exercises noted above. Accordingly, Avenue issued 25,567 shares of common stock to Fortress for the six-month period ended June 30, 2024.Mustang 2021 Shelf Registration Statement and At-the-Market Offering (the â€œMustang ATMâ€) On April 23, 2021, Mustang filed a shelf registration statement on Form S-3 (File No. 333-255476) (the â€œMustang 2021 S-3â€), which was declared effective on May 24, 2021. Under the Mustang 2021 S-3, Mustang was able to sell up to a total of $200.0 million of its securities. In the six months ended June 30, 2024, Mustang sold approximately $4.4 million of securities under the Mustang 2021 S-3 until its expiration on May 24, 2024. On May 31, 2024, Mustang filed a shelf registration statement on Form S-3 (File No. 333-279891) (the â€œMustang 2024 S-3â€), which was declared effective on June 12, 2024. Under the Mustang 2024 S-3, Mustang may sell up to a total of $40.0 million of its securities. As of June 30, 2024, approximately $37.5 million of the Mustang 2024 S-3 remains available for sales of securities, subject to General Instruction I.B.6. of Form S-3. On May 31, 2024, Mustang entered into an At-the-Market Offering Agreement (the â€œMustang ATMâ€) relating to the sale of shares of common stock pursuant to the Mustang 2024 S-3. During the six months ended JuneÂ 30,Â 2024, Mustang issued no shares through the Mustang ATM. â€‹Mustang Public OfferingIn May 2024, Mustang closed on a public offering of 1,160,000 shares of common stock and pre-funded warrants to purchase up to 15,717,638 shares of common stock (or common stock equivalents in lieu thereof), and three series of 16,877,638 warrants each for a total of 50,632,914 warrants with a combined public offering price of $0.237 per share (or per share common stock equivalent in lieu thereof) and accompanying warrants with an exercise price of $0.237 per share. The Series A-1 warrants have a five-year term, the Series A-2 warrants have a twenty-four month term, and the Series A-3 warrants have a nine month term. The warrants contain customary anti-dilution adjustments to the exercise price, including share splits, share dividends, rights offerings and pro rata distributions. The net proceeds of the public offering, after deducting the fees and expenses of the placement agent and other offering expenses payable by Mustang was approximately $3.3 million. Â All of the 15,717,638 pre-funded warrants were exercised as of June 30, 2024.30 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹Mustang also amended certain existing warrants to purchase up to 2,588,236 shares of common stock previously issued in October 2023 with an exercise price of $1.58 per share such that the amended warrants have a reduced exercise price of $0.237 per share, and have a five-year term from date of shareholder approval.Mustang Registered Direct OfferingIn June 2024, Mustang closed on a registered direct offering of 3,025,000 shares of common stock at $0.41 per share (or common stock equivalent) priced at-the-market under Nasdaq rules and pre-funded warrants to purchase up to 3,105,000 shares of common stock, at a price per pre-funded warrant equal to $0.4099, the price per share of common stock, less $0.001. Â The pre-funded warrants have an exercise price of $0.001 per share, became exercisable upon issuance and remain exercisable until exercised in full. In a concurrent private placement, Mustang also agreed to issue and sell unregistered warrants to purchase up to 6,130,000 shares of its common stock, with an exercise price of $0.41 per share, exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants and will expire five years from the date of stockholder approval. Â Net proceeds were approximately $2.2 million, after placement agentâ€™s fees and other offering expenses of approximately $0.3 million. All of the 3,105,000 pre-funded warrants were exercised as of June 30, 2024.Pursuant to the Companyâ€™s Founders Agreement with Mustang, Mustang issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the financings noted above. Accordingly, Mustang issued 575,191 shares of common stock to Fortress for the six-month period ended June 30, 2024.Journey 2022 Shelf Registration Statement and At-the-Market OfferingOn December 30, 2022, Journey filed a shelf registration statement on Form S-3 (File No. 333-269079) (the â€œJourney 2022 S-3â€), which was declared effective on January 26, 2023. The Journey 2022 S-3 covers the offering, issuance and sale by Journey of up to an aggregate of $150.0 million of Journeyâ€™s common stock, preferred stock, debt securities, warrants, and units. In connection with the Journey 2022 S-3, Journey entered into a sales agreement relating to the sale of shares of Journeyâ€™s common stock in an at-the-market offering (the â€œJourney ATM Sales Agreementâ€). In accordance with the terms of the Journey ATM Sales Agreement, Journey may offer and sell up to 4,900,000 shares of its common stock, par value $0.0001 per share, from time to time. For the six months ended June 30, 2024, Journey issued and sold approximately 0.3 million shares of common stock at an average price of $5.28 per share for gross proceeds of $1.5 million under the Journey ATM Sales Agreement. At June 30, 2024, 3,861,553 shares remain available for issuance under the Journey ATM Sales Agreement.â€‹14. Commitments and ContingenciesLeasesAt JuneÂ 30,Â 2024, Mustang identified triggering events that required an impairment of the asset group consisting of itsâ€™ right-of-use asset and associated leasehold improvements. The assessment concluded that impairment existed as of June 30, 2024, and the impairment loss was allocated to the leasehold improvements and right-of-use assets based on the relative carrying amounts of the assets (see Note 3). During three and six months ended JuneÂ 30,Â 2024 and 2023, the Company recorded the following as lease costs for the periods presented:â€‹Â Â Â Â Three Months Ended JuneÂ 30,Â Â Â Â Â Six Months Ended JuneÂ 30,Â Â Â Â Â ($ in thousands)â€‹2024â€‹2023â€‹2024â€‹2023â€‹Operating lease costâ€‹$ 595â€‹$ 950â€‹$ 1,235â€‹$ 1,969â€‹Shared lease costsâ€‹Â (519)â€‹â€‹ (519)â€‹Â (1,042)â€‹â€‹ (1,034)â€‹Variable lease costâ€‹Â 174â€‹â€‹ 199â€‹Â 390â€‹â€‹ 400â€‹Total lease expenseâ€‹$ 250â€‹$ 630â€‹$ 583â€‹$ 1,335â€‹â€‹31 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹The following tables summarize quantitative information about the Companyâ€™s operating leases, under the adoption of ASC Topic 842, Leases:â€‹Â Â Â Â Â Six Months Ended JuneÂ 30,Â Â Â Â Â Â ($ in thousands)â€‹2024â€‹2023Â â€‹Operating cash flows from operating leasesâ€‹$ (1,850)â€‹$ (1,762)â€‹â€‹Right-of-use assets exchanged for new operating lease liabilitiesâ€‹$ â€”â€‹$ â€”â€‹â€‹Weighted-average remaining lease term â€“ operating leases (years)â€‹Â 4.0â€‹Â 4.4â€‹â€‹Weighted-average discount rate â€“ operating leasesâ€‹Â 6.0%Â Â Â 6.5%â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â FutureÂ Lease($ in thousands)â€‹LiabilityNine Months Ended December 31, 2024â€‹$ 1,819Year Ended DecemberÂ 31,Â 2025â€‹Â 3,542Year Ended DecemberÂ 31,Â 2026â€‹Â 3,272Year Ended DecemberÂ 31,Â 2027â€‹â€‹ 2,923Year Ended DecemberÂ 31,Â 2028â€‹â€‹ 2,967Otherâ€‹Â 8,125Total operating lease liabilitiesâ€‹Â 22,648Less: present value discountâ€‹Â (4,233)Net operating lease liabilities, short-term and long-termâ€‹$ 18,415â€‹IndemnificationIn accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Companyâ€™s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. The Company and its subsidiaries and partner companies also provide indemnification of contractual counterparties (sometimes without monetary caps) to clinical sites, service providers and licensors.â€‹Legal Proceedingsâ€‹In the ordinary course of business, the Company and its subsidiaries and partner companies may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Companyâ€™s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeing resulting alleged damages.â€‹32 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹University of Tennessee Research Foundation v. Caelum Biosciences, Inc.Caelum Biosciences, Inc. (â€œCaelumâ€), a former subsidiary of Fortress that was sold to AstraZenecaâ€™s Alexion (â€œAlexionâ€) in October 2021, is the defendant in a lawsuit brought by The University of Tennessee Research Foundation (â€œUTRFâ€) captioned as University of Tennessee Research Foundation v. Caelum Biosciences, Inc., No. 19-cv-00508, which is pending in the United States District Court for the Eastern District of Tennessee (the â€œUTRF Litigationâ€).Â UTRF brought claims against Caelum, for, inter alia, tortious interference and trade secret misappropriation.Â UTRF primarily alleges that Caelum unauthorizedly used non-patent trade secrets owned by UTRF in the development of Caelumâ€™s 11-1F4 monoclonal antibody, known as CAEL-101.Â Under the agreement pursuant to which Alexion acquired Caelum (as amended, the â€œDOSPAâ€), Fortress has indemnification obligations of Caelum under certain circumstances, including for certain of Caelumâ€™s legal expenses and potential damages arising out of the UTRF Litigation (with such indemnification capped in the aggregate as to Fortress at the amount of Caelum acquisition proceeds received by Fortress â€“ approximately $57 million to date - and which, at Caelumâ€™s election, may be satisfiable in the form of offsets against future amounts that Caelum may owe Fortress under the DOSPA).Â Caelum is defending the UTRF Litigation, with Fortress participating in such defense and maintaining a consent right over any potential settlements.Â Caelumâ€™s legal fees and costs in defending the UTRF Litigation are being reimbursed by Fortress by distribution from a $15 million escrow account established concurrently with the acquisition of Caelum; Fortress considers the amount remaining in escrow to be in excess of the amount of its anticipated out-of-pocket indemnifiable costs and damages in the UTRF Litigation and therefore has not accrued any liability pertaining to this indemnity.Â Caelum and Fortress both believe the UTRF Litigation is without merit and intend to continue defending it vigorously (including exhausting all appeals if applicable).Â A jury trial is scheduled for September 2024 in Knoxville, TN. 15. Related Party TransactionsFounders AgreementThe Company has entered into Founders Agreements and, in some cases, exchange agreements with certain of its subsidiaries as described in the 2023 Form 10-K. The following table summarizes, by partner company/subsidiary, the effective date of the Founders Agreements and Payment-in-Kind (â€œPIKâ€) dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, exchange agreements, and the subsidiaries' certificates of incorporation:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

company/subsidiary first acquires, whether by license or otherwise, ownership rights in a product.Management Services AgreementsThe Company has entered into Management Services Agreements (the â€œMSAsâ€) with certain of its partner companies/subsidiaries as described in the 2023 FormÂ 10-K. The following table summarizes the effective date of each MSA and the annual consulting fee payable by the partner company/subsidiary to the Company in quarterly installments:â€‹â€‹â€‹

Company also agreed to file a registration statement to register the resale of the shares of Company common stock issuable upon exercise of the Warrants.â€‹Fortress Dividendsâ€‹On July 5, 2024, Fortress announced that the Companyâ€™s Board of Directors had decided to pause the monthly dividend of $0.1953125 per share of the Companyâ€™s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the â€œSeries A Preferred Stockâ€). In accordance with the terms of the Series A Preferred Stock, dividends on the Series A Preferred Stock will continue to accrue and cumulate until such dividends are authorized or declared. The pausing of these dividends will defer approximately $0.7 million in cash dividend payments each month. The Board intends to revisit its decision regarding the monthly dividend regularly and will assess the profitability and cash flow of the Company to determine whether and when the pause should be lifted.â€‹JourneyOn July 9, 2024, Journey entered into the SWK Amendment. The SWK Amendment increased the total amount of the Credit Facility from $20.0 million to $25.0 million. The $5.0 million of additional availability added in the Amendment will be drawn upon FDA approval of DFD-29, subject to Journey receiving approval on or before June 30, 2025. Â UricaOn July 15, 2024, Urica entered into an asset purchase agreement (the â€œAPAâ€), royalty agreement (the â€œRoyalty Agreementâ€), and related agreements (collectively, the â€œTransaction Documentsâ€) with Crystalys Therapeutics, Inc. (â€œCrystalysâ€). Crystalys is a Delaware corporation incorporated in 2022 and seeded by leading life sciences institutional investors. Under the Transaction Documents, Urica sold the rights to its URAT1 inhibitor product candidate in development for the treatment of gout, dotinurad, and related intellectual property, licenses and agreements to Crystalys. In return, Crystalys issued to Urica shares of its common stock equal to 35% of Crystalysâ€™ outstanding equity. Uricaâ€™s equity position cannot be reduced below 15% of Crystalysâ€™ fully-diluted equity capitalization until it raises $150 million in equity securities.â€‹The Transaction Documents also grant Urica a securitized three percent (3%) royalty on future net sales of dotinurad to be paid by Crystalys, as well as the right to receive nominal cash reimbursement payments for certain clinical and development costs incurred by Urica related to dotinurad. Urica has the right to appoint one director to the board of directors of Crystalys, as well as an additional 40 Table of ContentsFORTRESS BIOTECH,Â INC. AND SUBSIDIARIESNotesÂ to Unaudited Condensed Consolidated Financial Statementsâ€‹board observer. Urica has committed to providing transition support to Crystalys for 90 days, and Crystalys is obliged to use commercially reasonable efforts to develop and commercialize dotinurad. â€‹Checkpointâ€‹In July 2024, Checkpoint closed on a registered direct offering (the â€œCheckpoint July 2024 Registered Direct Offeringâ€) for the issuance and sale of an aggregate of 1,230,000 shares of its common stock at a purchase price of $2.05 per share of common stock. In addition, the offering includes 4,623,659 shares of common stock in the form of pre-funded warrants at a price of $2.0499. In a concurrent private placement, Checkpoint issued and sold common warrants (the â€œCheckpoint July 2024 Common Stock Warrantsâ€) to purchase up to 5,853,659 shares of common stock. The Checkpoint July 2024 Common Stock Warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Checkpoint July 2024 Common Stock Warrants with an exercise price of $2.05 per share and will expire five years following the issuance date. The total gross proceeds from the July 2024 Registered Direct Offering were approximately $12.0 million.â€‹â€‹â€‹â€‹â€‹â€‹â€‹41 Table of ContentsItem 2.Â Â Â Â Â Â Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking StatementsYou should read the following discussion and analysis of our financial condition and results of operations in conjunction with our condensed consolidated financial statements and the related notes included elsewhere in this Form 10-Q. Our condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Statements in this Quarterly Report on Form 10-Q that are not descriptions of historical facts are â€œforward-looking statementsâ€ within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the â€œExchange Actâ€). The words â€œanticipates,â€ â€œbelieves,â€ â€œcan,â€ â€œcontinue,â€ â€œcould,â€ â€œestimates,â€ â€œexpects,â€ â€œintends,â€ â€œmay,â€ â€œmight,â€ â€œplans,â€ â€œpotential,â€ â€œpredicts,â€ â€œshould,â€ or â€œwillâ€ or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on managementâ€™s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include those set forth under â€œItem 1A. Risk Factorsâ€ including, in particular, risks relating to:â—¦our growth strategy; â—¦financing and strategic agreements and relationships; â—¦our need for substantial additional funds and uncertainties relating to financings;â—¦our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; â—¦our ability to attract, integrate and retain key personnel; â—¦the early stage of products under development; â—¦the results of research and development activities; â—¦uncertainties relating to preclinical and clinical testing; â—¦the ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companiesâ€™ products and product candidates; â—¦government regulation; â—¦patent and intellectual property matters; and â—¦competition.â€‹We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this Quarterly Report on Form 10-Q should be read as applyingÂ mutatis mutandisÂ to every other instance of such information appearing herein.OverviewFortress Biotech,Â Inc. (â€œFortressâ€ or the â€œCompanyâ€) is a biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holding and dividend and royalty revenue streams. Fortress works in concert with our extensive network of key opinion leaders to identify and evaluate promising products and product candidates for potential acquisition. We have executed arrangements with some of the worldâ€™s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center (â€œCOHâ€ or â€œCity of Hopeâ€), Fred Hutchinson Cancer Center, Dana-Farber Cancer Institute, Nationwide Childrenâ€™s Hospital, Cincinnati Childrenâ€™s Hospital Medical Center, Columbia University, the University of Pennsylvania, AstraZeneca plc and Dr. Reddyâ€™s Laboratories, Ltd.Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business, scientific, regulatory, legal and financial expertise to help the partners achieve their goals. Partner companies then assess a broad range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint ventures, partnerships, out-licensings, sales transactions, and public and private financings. To date, four partner companies are publicly-traded, and two have consummated strategic partnerships with industry leaders, including AstraZeneca plc as successor-in-interest to Alexion Pharmaceuticals,Â Inc. (â€œAstraZenecaâ€) and Sentynl Therapeutics, Inc. (â€œSentynlâ€). â€‹42 Table of ContentsOur subsidiaries and partner companies that are pursuing development and/or commercialization of biopharmaceutical products and product candidates are: Avenue Therapeutics, Inc. (Nasdaq: ATXI, â€œAvenueâ€), Baergic Bio,Â Inc. (â€œBaergic,â€ a subsidiary of Avenue), Cellvation,Â Inc. (â€œCellvationâ€), Checkpoint Therapeutics,Â Inc. (Nasdaq: CKPT, â€œCheckpointâ€), Cyprium Therapeutics,Â Inc. (â€œCypriumâ€), Helocyte,Â Inc. (â€œHelocyteâ€), Journey Medical Corporation (Nasdaq: DERM, â€œJourneyâ€ or â€œJMCâ€), Mustang Bio,Â Inc. (Nasdaq: MBIO, â€œMustangâ€) and Oncogenuity,Â Inc. (â€œOncogenuityâ€).Recent EventsRevenueâ€”For the three months ended JuneÂ 30,Â 2024 and 2023, total net revenue was $14.9 million and $17.4 million, respectively; and for the six months ended JuneÂ 30,Â 2024 and 2023, was $27.9 million and $29.8 million, respectively, and is comprised predominantly of net product revenue from Journeyâ€™s commercial dermatology portfolio. â€‹Late Stage Product CandidatesCosibelimab (anti-PD-L1 antibody) â—¦In July 2024, our partner company, Checkpoint, announced the U.S. Food and Drug Administration (â€œFDAâ€) had accepted for review its resubmission of its Biologics License Application (â€œBLAâ€) for cosibelimab, its investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (â€œcSCCâ€) who are not candidates for curative surgery or radiation. The resubmission has been accepted as a complete response to the complete response letter received in December 2023, and the FDA has set a Prescription Drug User Fee Act (â€œPDUFAâ€) goal date of December 28, 2024.â—¦Also in July 2024, Checkpoint announced a collaboration to explore the combined therapeutic potential of cosibelimab with GC Cellâ€™s Immuncell-LC, an innovative autologous Cytokine Induced Killer (â€œCIKâ€) T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells.â—¦Cosibelimab was sourced by Fortress and is currently in development at Checkpoint.â€‹DFD-29 (modified release oral minocycline for the treatment of rosacea)â—¦In March 2024, the FDA accepted the NDA for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) and set a PDUFA goal date of November 4, 2024. We submitted the NDA to the FDA seeking approval for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults in January 2024. Both randomized controlled DFD-29 Phase 3 clinical trials achieved their co-primary and all secondary endpoints with subjects completing the 16-week treatment with no significant safety issues. DFD-29 demonstrated statistical superiority compared to both Oracea capsules and placebo for Investigatorâ€™s Global Assessment (â€œIGAâ€) treatment success and the reduction in the total inflammatory lesion count in both clinical trials. Additionally, DFD-29 showed significantly superior reduction in Clinicians Erythema Assessment compared to placebo in both of the Phase 3 clinical trials.â—¦DFD-29 is being developed for the treatment of rosacea at our partner company, Journey, in collaboration with Dr. Reddyâ€™s Laboratories Ltd.â€‹Triplex (cytomegalovirus (â€œCMVâ€) vaccine)â—¦Triplex is currently being studied in a Phase 2 clinical trial for adults co-infected with HIV and CMV that is now fully enrolled with topline data anticipated in the fourth quarter of 2024. The study aims to show that vaccination with Triplex can safely elicit a CMV-specific immune response and reduce asymptomatic CMV replication in a population of people with HIV on suppressive antiretroviral therapy. The study will also evaluate whether this intervention might reduce chronic inflammation and immune activation, as compared to placebo, and thus, potentially reduce related mortality and morbidity. â—¦In May 2024, we announced that the first patient was dosed in a multi-center, placebo-controlled, randomized Phase 2 study of Triplex, a vaccine for control of CMV, in patients undergoing liver transplantation. The trial is funded by a grant from the National Institutes of Healthâ€™s National Institute of Allergy and Infectious Diseases (â€œNIH/NIAIDâ€) that could provide over $20 million in non-dilutive funding and will be conducted in up to 20 nationally recognized transplant centers in the United States.â—¦Triplex is currently the subject of multiple ongoing clinical trials, including: a Phase 2 evaluation for CMV control in recipients of liver transplant (NCT06075745); a Phase 1/2 trial for CMV control in pediatric recipients of HCT (NCT03354728); a Phase 2 trial for safety and immunogenicity in adults living with HIV and CMV (NCT05099965); a Phase 2 trial for CMV control in recipients of stem cell transplant in which the stem cell donor is vaccinated with Triplex (NCT06059391) and a Phase 1 trial 43 Table of Contentsof Triplex in combination with a bi-specific CMV/CD19 Chimeric Antigen Receptor T Cell for the treatment of non-Hodgkin lymphoma (NCT05432635).â—¦In 2023, Helocyte additionally entered into an option agreement with City of Hope for exclusive worldwide rights to a novel bispecific CMV/HIV CAR T cell therapy (optionally for use in combination with Triplex), which is currently the subject of a Phase 1 trial in adults living with HIV-1 (see NCT06252402).â—¦Triplex was sourced by Fortress and is currently in development at our subsidiary, Helocyte.CAEL-101 (Light chain fibril-reactive monoclonal antibody for AL Amyloidosis) â—¦On October 5, 2021, AstraZeneca acquired Caelum Biosciences, Inc. (â€œCaelumâ€), a former subsidiary of Fortress for an upfront payment of approximately $150 million paid to Caelum shareholders, of which approximately $56.9 million was paid to Fortress, net of Fortressâ€™ $6.4 million portion of the $15 million, 24-month escrow holdback amount and other miscellaneous transaction expenses. The agreement also provides for additional potential payments to Caelum shareholders totaling up to $350 million, payable upon the achievement of regulatory and commercial milestones. Fortress is eligible to receive 42.4% of all potential milestone payments, which together with the upfront payment, would total up to approximately $212 million. â—¦There are two ongoing Phase 3 studies of CAEL-101 for AL amyloidosis. (ClinicalTrials.gov identifiers: NCT04512235 and NCT04504825).â—¦CAEL-101 (anselamimab) was sourced by Fortress and was developed by Caelum (founded by Fortress) until its acquisition by AstraZeneca in October 2021. â€‹CUTX-101 (copper histidinate for Menkes disease) â—¦In December 2023, our subsidiary, Cyprium completed the asset transfer of CUTX-101 to Sentynl. Sentynl is obligated under the agreement to use commercially reasonable efforts to develop and commercialize CUTX-101, including the funding of the same. Additionally, Cyprium remains eligible to receive up to $129 million in aggregate development and sales milestones under the Agreement and royalties on net sales of CUTX-101 ranging from 3% to 12.5% on tiered annual net sales. Cyprium will retain 100% ownership over any FDA priority review voucher that may be issued at the New Drug Application (â€œNDAâ€) approval for CUTX-101.â—¦The CUTX-101 rolling NDA submission is ongoing and is expected to be completed by Sentynl in 2024.â—¦CUTX-101 was sourced by Fortress and was developed by Cyprium until the asset transfer in December 2023.â€‹Early Stage Product CandidatesMB-106 (CD20-targeted CAR T-cell therapy)â—¦In March 2024, we announced our expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. Planning for a proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 in autoimmune diseases is underway and could initiate in the fourth quarter of 2024. â—¦In June 2024, we announced updated data for MB-106 showed a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (â€œWMâ€), a rare form of blood cancer. There was an overall response rate (â€œORRâ€) of 90% in the cohort with durable responses observed, including three complete responses (â€œCRâ€), two very good partial responses (â€œVGPRâ€), and four partial responses, and one patient remains in complete remission at 31 months.â—¦MB-106 was sourced by Fortress and is currently in development at our partner company, Mustang.â€‹Dotinurad (urate transporter (URAT1) inhibitor for gout) â—¦In July 2024, Urica entered into an asset purchase agreement, royalty agreement, and related agreements (collectively, the â€œTransaction Documentsâ€) with Crystalys Therapeutics, Inc. (â€œCrystalysâ€). Crystalys is a Delaware corporation founded in 2023 and seeded by leading life sciences institutional investors. Urica transferred rights to its URAT1 inhibitor product candidate in development for the treatment of gout, dotinurad, and related intellectual property, licenses and agreements to Crystalys. In return, Crystalys issued to Urica shares of its common stock equal to 35% of Crystalysâ€™ outstanding equity including certain anti-dilution provisions through the raise of $150 million in equity securities. The Transaction Documents also grant Urica a securitized three percent (3%) royalty on future net sales of dotinurad to be paid by Crystalys, as well as the right to receive nominal cash reimbursement payments for certain clinical and development costs incurred by Urica related to dotinurad.â—¦Dotinurad (URECÂ® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials. The clinical program supporting approval included over 1,000 patients.â—¦Dotinurad was sourced by Fortress and was in development at Urica until dotinurad was acquired by Crystalys in July 2024.â€‹44 Table of ContentsMB-109 (IL13RÎ±2-targeted CAR T Cells (MB-101) + HSV-1 oncolytic virus (MB-108)) â—¦In March 2024, data from the Phase 1 trial evaluating MB-101 IL13RÎ±2-targeted CAR T-cells in high-grade glioma were published in Nature Medicine. MB-101 was well tolerated and 50% of patients achieved stable disease or better, with two partial responses and two complete responses in high grade glioma patients. The two patients who achieved complete response both had high levels of intratumoral CD3+ T-cells pre-therapy (i.e., â€œhotâ€ tumors), and their responses lasted 7.5 and 66+ months, respectively. In the cohort with dual intratumoral (ICT)/ intraventricular (ICV) delivery and an optimized manufacturing process there was a ~70% improvement in median overall survival (10.2 months) compared to the expected survival rate of six months in this patient population. â—¦MB-101 and MB-109 are currently in development at our partner company, Mustang. â€‹AJ201 (Nrf1 and Nrf2 activator, androgen receptor degradation enhancer)â—¦In May 2024, we announced that last patient completed dosing in a Phase 1b/2a study, which is evaluating AJ201 in the U.S. for the treatment of spinal and bulbar muscular atrophy, also known as Kennedyâ€™s Disease. Kennedyâ€™s Disease is a debilitating rare genetic neuromuscular disease primarily affecting men. Topline data for the Phase 1b/2a clinical trial of AJ201 in SBMA are expected in the second half of 2024.â—¦AJ201 was sourced by Fortress and is currently in development at our partner company, Avenue. â€‹General Corporateâ€”In April 2024, Avenue effected a 1-for-75 reverse stock split to achieve compliance with the minimum bid price listing requirement of the Nasdaq Capital Market and announced the exercise of warrants for $4.4 million in gross proceeds.â—¦In April 2024, Mustangâ€™s board of directors approved a reduction in its workforce by approximately 81% of its employee base in order to reduce costs and preserve capital; the reduction occurred primarily in April and was substantially complete in the second quarter of 2024.â—¦In May and June 2024, Mustang Bio raised gross proceeds of approximately $6.5 million across two offerings of its common stock and warrants. â—¦In July 2024, Checkpoint raised $12 million in a registered direct offering priced at the-the-market under Nasdaq rules. â—¦In July 2024, Fortressâ€™ Board of Directors paused the payment of dividends on the Companyâ€™s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the â€œSeries A Preferred Stockâ€) until further notice. The Company believes pausing the dividend is in the best interest of the Company and its stakeholders to maintain financial flexibility ahead of potentially significant inflection points. The pausing of these dividends will defer approximately $0.7 million in cash dividend payments each month. The Board intends to revisit its decision regarding the monthly dividend regularly and will assess the profitability and cash flow of the Company to determine whether and when the suspension should be lifted.â—¦Also in July 2024, Journey Medical entered into an amendment of its existing credit facility with SWK, increasing the amount of the facility from $20 million to $25 million.â—¦Additionally in July 2024, Fortress announced the reduction of total debt outstanding and the entry into a new $50 million term loan with Oaktree Capital Management with a maturity in 2027. The Company borrowed $35.0 million under the agreement on the closing date and is eligible to draw up to an additional $15.0 million at the lendersâ€™ discretion to support future business development activities. In connection with the new term loan, Fortress

repaid the prior $50 million term loan with Oaktree. â€‹Critical Accounting Policies and Use of EstimatesOur discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of revenues, expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. For a discussion of our critical accounting estimates, see the section titled â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in the Companyâ€™s Annual Report on Form 10-K, which was filed with the United States Securities and Exchange Commission (â€œSECâ€) on March 28, 2024 (the â€œ2023 Form 10-Kâ€). There were no material changes in our critical accounting estimates or accounting policies from DecemberÂ 31,Â 2023.45 Table of ContentsAccounting Pronouncements As of JuneÂ 30,Â 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that are expected to materially affect the Companyâ€™s present or future financial statements upon adoption. Smaller Reporting Company StatusWe are a â€œsmaller reporting company,â€ meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we chose to present only the two most recent fiscal years of audited financial statements in the 2023 Form 10-K, have reduced disclosure obligations regarding executive compensation and certain other matters, and smaller reporting companies are permitted to delay adoption of certain recently issued accounting pronouncements.Basis of Presentation and Principles of ConsolidationThe Companyâ€™s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (â€œGAAPâ€). The Companyâ€™s consolidated financial statements include the results of the Companyâ€™s subsidiaries for which it has voting control but does not own 100% of the outstanding equity of the subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, but retains voting control, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations and presents non-controlling interests as a component of stockholdersâ€™ equity on its consolidated balance sheets. All intercompany income and/or expense items are eliminated entirely in consolidation prior to the allocation of net gain/loss attributable to non-controlling interest, which is based on ownership interests as calculated quarterly for each subsidiary.The following table summarizes the Companyâ€™s ownership of the issued and outstanding common and preferred shares in certain consolidated Fortress subsidiaries as of the period presented: â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â Partner Company/Subsidiaryâ€‹2024Avenue1â€‹5.7%Cellvationâ€‹79.2%Checkpoint1â€‹10.1%Cypriumâ€‹73.1%Helocyteâ€‹83.0%Journey1â€‹46.7%Mustang1â€‹7.2%Oncogenuityâ€‹73.5%Uricaâ€‹67.8 1: Denotes entities that are publicly-traded.Results of OperationsComparison ofÂ Three Months Ended JuneÂ 30,Â 2024 and 2023â€‹â€‹â€‹â€‹â€‹â€‹

of JMC branded and generic products for theÂ six months ended June 30,Â 2024 and 2023 was $13.4 million and $14.2 million, respectively. The decrease in cost of goods sold of $0.9 million, or 6% year-over-year, is mainly due to the decrease in unit sales volume.â€‹Research and Development Expensesâ€‹Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings and patents, laboratory costs and other supplies.â€‹The table below provides a summary by entity of noncash, stock-based compensation expense included in research and development expense for theÂ periods presented.â€‹â€‹â€‹

Avenue entered into definitive agreements for the immediate exercise of certain of its existing outstanding warrants for cash of an aggregate of 689,680 warrants for shares of Avenueâ€™s common stock at a reduced exercise price of $6.20 per share (the â€œMay 2024 Warrant Inducementâ€). The exercised warrants are comprised of warrants to purchase shares of common stock originally issued by Avenue on October 11, 2022, each having an exercise price of $116.25 per share, Series A and Series B warrants to purchase shares of common stock originally issued by Avenue on November 2, 2023, each having an exercise price of $22.545 per share, and warrants to purchase shares of common stock originally issued by Avenue on January 9, 2024, each having an exercise price of $22.545 per share.â€‹In consideration for the immediate exercise of the warrants for cash in the May 2024 Warrant Inducement, Avenue issued two new unregistered series of warrants to purchase up to a total of 1,379,360 shares of Avenue common stock for a payment of $0.125 per warrant. The warrants have an exercise price of $6.20 per share, and terms of eighteen months for one series and five years for the other series. Total net proceeds to Avenue were approximately $3.7 million after deducting placement agent fees and other expenses payable by Avenue.â€‹In May 2024, Avenue entered into an At-the-Market Offering Agreement (the â€œAvenue ATMâ€)Â with H.C. Wainwright & Co.Â LLC ("Wainwright") under which Avenue may offer and sell, from time to time at its sole discretion, up to $3,850,000 of shares of its common stock, par value $0.0001 per share (the "Shares"), through or to Wainwright. The offer and sale of the Shares will be made pursuant to a base prospectus forming a part of the 2021 Avenue S-3, and the related prospectus supplement dated May 10, 2024.Â During the six months ended JuneÂ 30,Â 2024 and 2023, Avenue issued 87,683 shares through the Avenue ATM for net proceeds of $0.3 million.â€‹On April 23, 2021, Mustang filed a shelf registration statement on Form S-3 (File No. 333-255476) (the â€œMustang 2021 S-3â€), which was declared effective on May 24, 2021. Under the Mustang 2021 S-3, Mustang was able to sell up to a total of $200.0 million of its securities. In the six months ended June 30, 2024, Mustang sold approximately $4.4 million of securities under the Mustang 2021 S-3 until its expiration on May 24, 2024. On May 31, 2024, Mustang filed a shelf registration statement on Form S-3 (File No. 333-279891) (the â€œMustang 2024 S-3â€), which was declared effective on June 12, 2024. Under the Mustang 2024 S-3, Mustang may sell up to a total of $40.0 million of its securities. As of June 30, 2024, approximately $37.5 million of the Mustang 2024 S-3 remains available for sales of securities. The Mustang 2024 S-3 expires on June 12, 2027. As of the filing of this Form 10-Q, Mustang is subject to the General Instruction I.B.6 to Form S-3, known as the â€œbaby shelf rules,â€ which limit the number of securities it can sell under its registration statements on Form S-3.â€‹On May 31, 2024, Mustang entered into an At-the-Market Offering Agreement (the â€œMustang ATMâ€) relating to the sale of shares of common stock pursuant to the Mustang 2024 S-3. Under the Mustang ATM, Mustang pays the sales agents for the program a commission rate of 3.0% of the gross proceeds from the sale of any shares of common stock. During the six months ended June 30, 2024, Mustang issued no shares through the Mustang ATM. â€‹â€‹57 Table of ContentsIn May 2024, Mustang closed on a public offering of 1,160,000 shares of common stock and pre-funded warrants to purchase up to 15,717,638 shares of common stock (or common stock equivalents in lieu thereof), and three series of 50,632,914 warrants with a combined public offering price of $0.237 per share (or per share common stock equivalent in lieu thereof) and accompanying warrants with an exercise price of $0.237 per share. The Series A-1 warrants have a five-year term, the Series A-2 warrants have a twenty-four month term, and the Series A-3 warrants have a nine month term. The warrants contain customary anti-dilution adjustments to the exercise price, including share splits, share dividends, rights offerings and pro rata distributions. The net proceeds of the public offering, after deducting the fees and expenses of the placement agent and other offering expenses payable by Mustang, but excluding the net proceeds, if any, from the exercise of the warrants, was approximately $3.3 million. All of the 15,717,638 pre-funded warrants were exercised as of June 30, 2024.â€‹Mustang also amended certain existing warrants to purchase up to 2,588,236 shares of common stock previously issued in October 2023 with an exercise price of $1.58 per share such that the amended warrants have a reduced exercise price of $0.237 per share, and have a five-year term from date of shareholder approval.â€‹In June 2024, Mustang closed on a registered direct offering of 3,025,000 shares of common stock at $0.41 per share (or common stock equivalent) priced at-the-market under Nasdaq rules and pre-funded warrants to purchase up to 3,105,000 shares of common stock, at a price per pre-funded warrant equal to $0.4099, the price per share of common stock, less $0.001. Â The pre-funded warrants have an exercise price of $0.001 per share, became exercisable upon issuance and remain exercisable until exercised in full. In a concurrent private placement, Mustang also agreed to issue and sell unregistered warrants to purchase up to 6,130,000 shares of its common stock, with an exercise price of $0.41 per share, exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants and will expire five years from the date of stockholder approval. Â Net proceeds were approximately $2.3 million, after placement agentâ€™s fees and other offering expenses of approximately $0.3 million. All of the 3,105,000 pre-funded warrants were exercised as of June 30, 2024.On December 30, 2022, Journey filed a shelf registration statement on Form S-3 (File No. 333-269079) (the â€œJourney 2022 S-3â€), which was declared effective on January 26, 2023. The Journey 2022 S-3 covers the offering, issuance and sale by Journey of up to an aggregate of $150.0 million of Journeyâ€™s common stock, preferred stock, debt securities, warrants, and units. In connection with the Journey 2022 S-3, Journey has entered into the Sales Agreement relating to shares of the Journeyâ€™s common stock. In accordance with the terms of the Sales Agreement, Journey may offer and sell up to 4,900,000 shares of its common stock, par value $0.0001 per share, from time to time. For the six months ended June 30, 2024, Journey issued and sold approximately 0.3 million shares of common stock at an average price of $5.28 per share for gross proceeds of $1.5 million under the Journey ATM. In connection with these sales, Journey paid aggregate fees of approximately $46,000. At June 30, 2024, 3,861,553 shares remain available for issuance under the Journey 2022 S-3.â€‹Contractual Obligationsâ€‹We enter into contracts in the normal course of business with licensors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for the procurement of various products and services, including without limitation biopharmaceutical development, biologic assay development, commercialization, clinical and preclinical development, clinical trials management, pharmacovigilance and manufacturing and supply. These contracts typically do not contain minimum purchase commitments (although they may) and are generally terminable by us upon written notice. Payments due upon termination or cancelation/delay consist of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation; in certain cases, our contractual arrangements with CROs and CMOs include cancelation and/or delay fees and penalties. â€‹During the six months ended June 30, 2024, there were no material changes in our contractual obligations and commitments, including our lease obligations, as described in our 2023 Form 10-K.â€‹Item 3. Â Â Â Â Â Quantitative and Qualitative Disclosures About Market Risks As a â€œsmaller reporting companyâ€ as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this item.â€‹58 Table of ContentsItem 4. Â Â Â Â Â Controls and ProceduresEvaluation of Disclosure Controls and ProceduresUnder the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of June 30, 2024, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.Changes in Internal Control over Financial ReportingNo change in internal control over financial reporting occurred during the most recent quarter, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.â€‹â€‹PART II.Â OTHER INFORMATIONItem 1. Â Â Â Â Â Legal ProceedingsThere are no reportable events or material developments with respect to previously disclosed proceedings for the quarter ended June 30, 2024. To our knowledge, except as previously disclosed, there are no legal proceedings pending against us, other than routine actions and administrative proceedings, and other actions not deemed material are not expected to have a material adverse effect on our financial condition, results of operations, or cash flows. In the ordinary course of business, however, the Company may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Companyâ€™s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages. â€‹â€‹â€‹59 Table of ContentsItemÂ 1A.Â Â Â Â Â Risk Factors Investing in our Common Stock, our 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.001 par value (the â€œSeriesÂ A Preferred Stockâ€) or any other type of equity or debt securities we may issue from time to time (together our â€œSecuritiesâ€) involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report on FormÂ 10-Q including the consolidated financial statements and the related notes, as well as the risks, uncertainties and other information set forth in the reports and other materials filed or furnished by our partner companies Avenue, Checkpoint, Journey and Mustang with the SEC, before deciding to invest in our Securities. If any of the following risks or the risks included in the public filings of Avenue, Checkpoint, Journey or Mustang were to materialize, our business, financial condition, results of operations, and future growth prospects could be materially and adversely affected. In that event, the market price of our Securities could decline, and you could lose part of or all of your investment in our Securities. In addition, you should be aware that the below stated risks should be read as being applicable to our subsidiaries and partner companies such that, if any of the negative outcomes associated with any such risk is experienced by one of our subsidiaries or partner companies, the value of Fortressâ€™ holdings in such entity may decline. As used throughout this filing, the words â€œweâ€, â€œusâ€ and â€œourâ€ may refer to Fortress individually, to one or more subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context.Risks Inherent in Drug Developmentâ€‹Most of our product candidates are in the early stages of development and may not be successfully developed or commercialized, and the product candidates that do advance into clinical trials may not receive regulatory approval.â€‹Most of our existing product candidates remain in the early stages of development and will require substantial further capital expenditures, development, testing and regulatory approvals prior to commercialization. The development and regulatory approval processes can take many years, and it is unlikely that our product candidates, even if successfully developed and approved by the FDA and/or foreign equivalent regulatory bodies, would be commercially available for several years. Only a small percentage of drugs under development successfully obtain regulatory approval and are successfully commercialized. Accordingly, even if we are able to obtain the requisite financing to fund development programs, we cannot be sure that any of our product candidates will be successfully developed or commercialized, which could result in the failure of our business and a loss of your investment.Pharmaceutical development has inherent risks. Before we may seek regulatory approval for the commercial sale of any of our product candidates, we will be required to demonstrate, through well-controlled clinical trials, that our product candidates are effective and have a favorable benefit-risk profile for their target indications. Success in early clinical trials is not necessarily indicative of success in later stage clinical trials, during which product candidates may fail to demonstrate sufficient safety or efficacy, despite having progressed through initial clinical testing, which may cause significant setbacks. Further, we may need to conduct additional clinical trials that are not currently anticipated. As a result, product candidates that we advance into clinical trials may never receive regulatory approval.Even if any of our product candidates are approved, regulatory authorities may approve any such product candidates for fewer or more limited indications than we request, may place limitations on our ability to commercialize products at the intended price points, may grant approval contingent on the productâ€™s performance in costly post-marketing clinical trials, or may approve a label that does not include the claims necessary or desirable for the successful commercialization of that product candidate. The regulatory authority may also require the label to contain warnings, contraindications, or precautions that limit the commercialization of the product. In addition, the Drug Enforcement Agency (â€œDEAâ€), or foreign equivalent, may schedule one or more of our product candidates under the Controlled Substances Act, or its foreign equivalent, which could impede such productâ€™s commercial viability. Any of these scenarios could impact the commercial prospects for one or more of our current or future product candidates.The extensive regulation to which our product candidates are subject may be costly and time consuming, cause anticipated delays, and/or prevent the receipt of the required approvals for commercialization. The research and clinical development, testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of any product candidate, including our product candidates, is subject to extensive regulation by the FDA in the United States and by comparable health authorities in foreign markets. In the United States, we are not permitted to market a product candidate until the FDA approves such product candidateâ€™s BLA or NDA. The approval process is uncertain, expensive, often spans many years, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. In addition to significant and expansive clinical testing requirements, our ability to obtain marketing approval for product candidates depends on the results of required non-clinical testing, including the characterization of the manufactured components of our product candidates and validation of our manufacturing processes. 60 Table of ContentsThe FDA may determine that our manufacturing processes, testing procedures or equipment and facilities are inadequate to support approval. Further, the FDA has substantial discretion in the pharmaceutical approval process and may change approval policies or interpretations of regulations at any time, which could delay, limit or preclude a product candidateâ€™s approval. The FDA and other regulatory agencies may delay, limit or refuse approval of a product candidate for many reasons, including, but not limited to:â—disagreement with the trial design or implementation of our clinical trials, including proper use of clinical trial methods and methods of data analysis;â—an inability to establish sufficient data and information to demonstrate that a product candidate is safe and/or effective for an indication;â—the FDAâ€™s rejection of clinical data from trials conducted by individual investigators or in countries where the standard of care is potentially different from that of the United States;â—the FDAâ€™s determination that clinical trial results do not meet the statistical significance levels required for approval; â—a disagreement by the applicable regulator regarding the interpretation of preclinical study or trial data; â—determination by the FDA that our manufacturing processes or facilities or those of third-party manufacturers with which we or our collaborators contract for clinical supplies or plan to contract for commercial supplies, do not satisfactorily comply with cGMPs; orâ—a change to the FDAâ€™s approval policies or interpretation of regulations rendering our clinical data, product characteristics, or benefit-risk profile insufficient or unfavorable for approval.Foreign approval procedures vary by country and may, in addition to the aforementioned risks, involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, rapid drug and biological development during the COVID-19 pandemic has raised questions about the safety and efficacy of certain marketed pharmaceuticals and may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new pharmaceuticals based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals may prevent us from commercializing our product candidates.Delays in the commencement of our clinical trials, or suspensions or terminations of such trials, could result in increased costs and/or delay our ability to pursue regulatory approvals.The commencement or resumption of clinical trials can be delayed for a variety of reasons, including, but not necessarily limited to, delays in:â—obtaining regulatory approval to commence or resume a clinical trial;â—identifying, recruiting and training suitable clinical investigators;â—reaching and maintaining agreements on acceptable terms with CROs and trial sites, the terms of which may be subject to extensive negotiation and modification from time to time and may vary significantly among different CROs and trial sites;â—obtaining sufficient quantities of a product candidate for use in clinical trials;â—obtaining IRB or ethics committee approval to conduct a clinical trial at a prospective site;â—developing and validating companion diagnostics on a timely basis, if required;â—adding new clinical sites once a trial has begun;61 Table of Contentsâ—the death, disability, departure or other change to the principal investigator or other staff overseeing the clinical trial at a given site;â—identifying, recruiting and enrolling patients to participate in a clinical trial; orâ—retaining patients who participate in a clinical trial and replacing those who may withdraw due to adverse events from the therapy, insufficient efficacy, fatigue with the clinical trial process, personal issues, or other reasons.Any delays in the commencement of our clinical trials will delay our ability to pursue regulatory approval for product candidates. In addition, many of the factors that cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to the termination of a given development program or the denial of regulatory approval of a product candidate.If any of our product candidates causes unacceptable adverse safety events in clinical trials, we may not be able to obtain regulatory approval or commercialize such product, preventing us from generating revenue from such productsâ€™ sale. Alternatively, even if a product candidate is approved for marketing, future adverse events could lead to the withdrawal of such product from the market.Suspensions or delays in the completion of clinical testing could result in increased costs and/or delay or prevent our ability to complete development of that product candidate or generate product revenues.Once a clinical trial has begun, patient recruitment and enrollment may be slower than we anticipate due to the nature of the clinical trial plan, the proximity of patients to clinical sites, the eligibility criteria for participation in the study or other factors. Clinical trials may also be delayed as a result of ambiguous or negative interim results or difficulties in obtaining sufficient quantities of product manufactured in accordance with regulatory requirements and on a timely basis. Further, a clinical trial may be modified, suspended or terminated by us, an IRB, an ethics committee or a data safety monitoring committee overseeing the clinical trial, any clinical trial site with respect to that site, or the FDA or other regulatory authorities,

due to a number of factors, including, but not necessarily limited to:â—failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;â—inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;â—stopping rules contained in the protocol;â—unforeseen safety or chemistry, manufacturing and control issues, or other determination that the clinical trial presents unacceptable health risks; andâ—lack of adequate funding to continue the clinical trial.Regulatory requirements and guidance may change, and we may need to amend clinical trial protocols to reflect these changes. Any such change may require us to resubmit clinical trial protocols to IRBs, which may in turn impact a clinical trialâ€™s cost, timing, and likelihood of success. If any clinical trial is delayed, suspended, or terminated, our ability to obtain regulatory approval for that product candidate will be delayed, and the commercial prospects, if any, for the product candidate may suffer. In addition, many of these factors may ultimately lead to the denial of regulatory approval of a product candidate.If our competitors develop treatments for any of our product candidatesâ€™ target indications and those competitor products are approved more quickly, marketed more successfully or demonstrated to be more effective, the commercial opportunity for our product candidates will be reduced or eliminated.The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Furthermore, new developments, including the development of other drug technologies and methods of preventing the incidence of disease, occur in the pharmaceutical industry at a rapid pace. Any of these developments may render one or more of our product candidates obsolete or noncompetitive.â€‹62 Table of ContentsCompetitors may seek to develop alternative formulations that do not directly infringe on our in-licensed patent rights. The commercial opportunity for one or more of our product candidates could be significantly harmed if competitors are able to develop alternative formulations outside the scope of our in-licensed patents. Compared to us, many of our potential competitors have substantially greater:â—capital resources;â—development resources, including personnel and technology;â—clinical trial experience;â—regulatory experience;â—expertise in prosecution of intellectual property rights; andâ—manufacturing, distribution and sales and marketing capabilities.As a result of these factors, our competitors may obtain regulatory approval for their products more rapidly than we are able to, or may obtain patent protection or other intellectual property or exclusivity rights that limit our ability to develop or commercialize one or more of our product candidates. Our competitors may also develop drugs that are more effective, safe, useful and/or less costly than ours and may be more successful than us in manufacturing and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We will also face competition from these third parties in establishing clinical trial sites, in patient registration for clinical trials, and in identifying and in-licensing new product candidates.Negative public opinion and increased regulatory scrutiny of the therapies that underpin many of our product candidates may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.If any of the technologies underpinning our product candidates, including gene therapy, is claimed to be unsafe, such product candidate may not gain the acceptance of the public or the medical community. The success of our gene therapy platforms in particular depends upon physicians who specialize in treating the diseases targeted by our product candidates prescribing treatments involving our product candidates in lieu of, or in addition to, treatments with which they are already familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity, could lead to increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that do obtain approval and/or a decrease in demand for any such product candidates. Concern about environmental spread of our products, whether real or anticipated, may also hinder the commercialization of our products.The making, use, sale, importation, exportation and distribution of controlled substances are subject to regulation by state, federal and foreign law enforcement and other regulatory agencies. Controlled substances are subject to state, federal and foreign laws and regulations regarding their manufacture, use, sale, importation, exportation and distribution. Controlled substances are regulated under the Federal Controlled Substances Act of 1970 (â€œCSAâ€) and regulations of the DEA. IV tramadol, under development by our partner company Avenue, will be subject to these regulations.â€‹63 Table of ContentsThe DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high potential for abuse and no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. Various states also independently regulate controlled substances. Though state-controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule drugs as well. While some states automatically schedule a drug when the DEA does so, in other states there must be rulemaking or a legislative action. State scheduling may delay commercial sale of any controlled substance drug product for which we obtain federal regulatory approval and adverse scheduling could impair the commercial attractiveness of such product. We or our collaborators must also obtain separate state registrations in order to be able to obtain, handle and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal law.For any of our products classified as controlled substances, we and our suppliers, manufacturers, contractors, customers and distributors are required to obtain and maintain applicable registrations from state, federal and foreign law enforcement and regulatory agencies and comply with state, federal and foreign laws and regulations regarding the manufacture, use, sale, importation, exportation and distribution of controlled substances. There is a risk that DEA regulations may limit the supply of the compounds used in clinical trials for our product candidates and the ability to produce and distribute our products in the volume needed to both meet commercial demand and build inventory to mitigate possible supply disruptions.Regulations associated with controlled substances govern manufacturing, labeling, packaging, testing, dispensing, production and procurement quotas, recordkeeping, reporting, handling, shipment and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of product candidates including controlled substances. The DEA, and some states, conduct periodic inspections of registered establishments that handle controlled substances. Failure to obtain and maintain required registrations or comply with any applicable regulations could delay or preclude us from developing and commercializing our product candidates containing controlled substances and subject us to enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations or initiate proceedings to revoke those registrations. In some circumstances, violations could lead to criminal proceedings. Because of their restrictive nature, these regulations could limit commercialization of any of our product candidates that are classified as controlled substances, which would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our Securities to decline. The FDA limits regulatory approval for our product candidates to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.Any regulatory approval is limited to the indications for use and related treatment of those specific diseases set forth in the approval for which a product is deemed to be safe and effective by the FDA. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.While physicians may prescribe drugs for uses that are not described in the productâ€™s label or that differ from those tested in clinical studies and approved by the regulatory authorities (â€œoff label usesâ€), our ability to promote the products is limited to those indications that are specifically approved by the FDA. Such off-label uses are common across medical specialties and may constitute an appropriate treatment forÂ someÂ patients in varied circumstances. Regulatory authorities in the U.S. generally do not regulate the practice of medicine or behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies regarding the promotion of off-label use. If our promotional activities fail to comply with these regulations or guidelines, we may be subject to compliance or enforcement actions, including Warning Letters or Untitled Letters, by, these authorities. In addition, our failure to follow FDA laws, regulations and guidelines relating to promotion and advertising may cause the FDA toÂ suspend or withdrawÂ an approved product from the market, request a recall, institute fines, or could result in disgorgement of money, operating restrictions, corrective advertising, injunctions or criminal prosecution, any of which could harm our business.64 Table of ContentsIf the FDA does not conclude that a product candidate satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidate under Section 505(b)(2) are not as we expect, the approval pathway for the product candidate will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section 505(b)(2) to the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if applicable to us under the FDCA, would allow an NDA we submit to FDA to rely in part on data in the public domain or the FDAâ€™s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for our product candidates by potentially decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval. If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks associated with these product candidates, would likely substantially increase. We could need to obtain more additional funding, which could result in significant dilution to the ownership interests of our then existing stockholders to the extent we issue equity securities or convertible debt. We cannot assure you that we would be able to obtain such additional financing on terms acceptable to us, if at all. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway would likely result in new competitive products reaching the market more quickly than our product candidates, which would likely materially adversely impact our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure you that our product candidates will receive the requisite approvals for commercialization in a timely manner, or at all.In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain brand-name pharmaceutical companies and others have objected to the FDAâ€™s interpretation of Section 505(b)(2). If the FDAâ€™s interpretation of Section 505(b)(2) is successfully challenged, the FDA may change its Section 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to faster product development or earlier approval.Moreover, even if our product candidates are approved under Section 505(b)(2), the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products. Risks Pertaining to the Need for and Impact of Existing and Additional Financing ActivitiesWe have historically financed a significant portion of our growth and operations in part through the assumption of debt. Should an event of default occur under any applicable loan documents, our business would be materially adversely affected. Further, our current credit arrangement with Oaktree restricts our and certain of our subsidiariesâ€™ and partner companiesâ€™ abilities to take certain actions.At June 30, 2024, the total amount of debt outstanding, net of the debt discount, was $67.0 million. If we default on our obligations, the holders of our debt may declare the outstanding amounts immediately payable together with accrued interest, and/or take possession of any pledged collateral. If an event of default occurs, we may be unable to cure it within the applicable cure period, if at all. If the maturity of our indebtedness is accelerated, we may not have sufficient funds available for repayment and we may be unable to borrow or obtain sufficient funds to replace the accelerated indebtedness on terms acceptable to us, or at all. In addition, current or future debt obligations may limit our ability to finance future operations, satisfy capital needs, or to engage in, expand or pursue our business activities. Such restrictions may also prevent us from engaging in activities that could be beneficial to our business and our stockholders unless we repay the outstanding debt, which may not be desirable or possible.65 Table of ContentsOn August 27, 2020, we entered into a $60 million senior secured credit agreement (the â€œPrior Oaktree Agreementâ€ and the debt thereunder, the â€œOaktree Noteâ€) with Oaktree Fund Administration, LLC and the lenders from time-to-time party thereto (collectively, â€œOaktreeâ€). At June 30, 2024 the amount outstanding under the Prior Oaktree Agreement was $50 million. On July 25, 2024, we, as borrower, entered into a $50.0 million senior secured credit agreement (the â€œNew Oaktree Agreementâ€) withÂ Oaktree. We borrowed $35.0 million under the Agreement on the date of the agreement and are eligible to draw up to an additional $15.0 million with the lendersâ€™ consent. The New Oaktree Agreement replaces the Prior Oaktree Agreement. Â The New Oaktree Agreement contains customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions. In addition, the New Oaktree Agreement contains certain financial covenants, including, (i) a requirement that we maintain a minimum liquidity of $7.0 million, which may be reduced or increased as described in the New Oaktree Agreement, and (ii) that product net sales of Journey meet a consolidated minimum net sales amount of $50.0 million on a trailing 12-month basis, tested quarterly, which may be reduced or increased as described in the New Oaktree Agreement (the â€œMinimum Net Sales Testâ€), subject to certain exclusions. Failure by the Company to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Minimum Net Sales Test. The breach of any other such provisions (even, potentially, in an immaterial manner) could result in an event of default under the New Oaktree Agreement, the announcement and impact of which could have a negative impact on the trading prices of our securities. The restrictions imposed by such provisions may also inhibit our and certain of our subsidiaries and partner companiesâ€™ ability to enter into certain transactions or arrangements that management otherwise believes would be in our or such partner companiesâ€™ best interests, such as dispositions that would result in cash inflows to Fortress and/or our subsidiaries and partner companies, or acquisitions or financings that would promote future growth.We have a history of operating losses that is expected to continue, and we are unable to predict the extent of future losses, whether we will be able to sustain current revenues or whether we will ever achieve or sustain profitability.We continue to generate operating losses in all periods including losses from operations of approximately $64.4 million and $109.0 million for the six months ended June 30, 2024 and 2023, respectively and $142.3 million and $203.6 million for the years ended December 31, 2023 and 2022, respectively. At June 30, 2024, we had an accumulated deficit of approximately $721.2 million. We expect to make substantial expenditures and incur increasing operating costs and interest expense in the future, and our accumulated deficit will increase significantly as we expand development and clinical trial activities for our product candidates and finance investments in certain of our existing and new subsidiaries in accordance with our growth strategy. Our losses have had, and are expected to continue to have, an adverse impact on our working capital, total assets and stockholdersâ€™ equity.Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the timing or amount of increased expenses or when or if, we will be able to achieve profitability. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if:â—one or more of our development-stage product candidates is approved for commercial sale and we decide to commercialize such product(s) ourselves, due to the need to establish the necessary commercial infrastructure to launch and commercialize this product without substantial delays, including hiring sales and marketing personnel and contracting with third parties for manufacturing, testing, warehousing, distribution, cash collection and related commercial activities;â—we are required by the FDA or a foreign regulatory authority to perform studies in addition to those currently expected;â—there are any delays in completing our clinical trials or the development of any of our product candidates;â—we execute other collaborative, licensing or similar arrangements, depending on the timing of payments we may make or receive under these arrangements;â—there are variations in the level of expenses related to our future development programs;â—we become involved in any product liability or intellectual property infringement lawsuits; andâ—there are any regulatory developments affecting our competitorsâ€™ product candidates.â€‹66 Table of ContentsOur ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our development

stage products, and we do not know when, or if, we will generate any revenue from such development-stage products. Our ability to generate revenue from such development-stage products depends on a number of factors, including, but not limited to, our ability to:â—obtain regulatory approval for one or more of our product candidates, or any future product candidate that we may license or acquire in the future;â—manufacture commercial quantities of one or more of our product candidates or any future product candidate, if approved, at acceptable cost levels; andâ—develop a commercial organization and the supporting infrastructure required to successfully market and sell one or more of our product candidates or any future product candidate, if approved.Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations, which would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our Securities to decline. A decline in the value of our company could also cause you to lose all or part of your investment.To fund our operations and service our debt securities, which may be deemed to include our SeriesÂ A Preferred Stock, we will be required to generate a significant amount of cash. Our ability to generate cash depends on a number of factors, some of which are beyond our control, and any failure to meet our debt obligations would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our Common Stock and/or Series A Preferred Stock to decline.Prevailing economic conditions and financial, business and other factors, many of which are beyond our control, may affect our ability to make payments on our debt. If we do not generate sufficient cash flow to satisfy our debt obligations, we may have to undertake alternative financing plans, such as refinancing or restructuring our debt, selling assets, reducing or delaying capital investments or seeking to raise additional capital. Alternatively, as we have done in the past, we may also elect to refinance certain of our debt, for example, to extend maturities. Our ability to restructure or refinance our debt will depend on the capital markets and our financial condition at such time. If we are unable to access the capital markets, whether because of the condition of those capital markets or our own financial condition or reputation within such capital markets, we may be unable to refinance our debt. In addition, any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. Our inability to generate sufficient cash flow to satisfy our debt obligations or to refinance our obligations on commercially reasonable terms, or at all, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our Securities to decline.Repayment of our indebtedness is dependent in part on the generation of cash flow by Journey and its ability to make such cash available to us, by dividend, debt repayment or otherwise. Journey may not be able to, or may not be permitted to, make distributions to enable us to make payments in respect of our indebtedness. Each of our subsidiaries, including Journey, is a distinct legal entity and, under certain circumstances, legal and contractual restrictions may limit our ability to obtain cash from our subsidiaries.Our ability to continue to reduce our indebtedness will depend upon factors including our future operating performance, our ability to access the capital markets to refinance existing debt and prevailing economic conditions and financial, business and other factors, many of which are beyond our control. We can provide no assurance of the amount by which we will reduce our debt, if at all. In addition, servicing our debt will result in a reduction in the amount of our cash flow available for other purposes, including operating costs and capital expenditures that could improve our competitive position and results of operations.67 Table of ContentsWe may need substantial additional funding and may be unable to raise capital when needed, which may force us to delay, curtail or eliminate one or more of our R&D programs, commercialization efforts or planned acquisitions and potentially change our growth strategy.â€‹Our R&D programs will require substantial additional capital for research, preclinical testing and clinical trials, establishing pilot scale and commercial scale manufacturing processes and facilities, and establishing and developing quality control, regulatory, marketing, sales, and administrative capabilities to support these programs. We expect to fund our R&D activities from a combination of cash generated from royalties and milestones from our partners in various past, ongoing, and future collaborations, and through additional equity or debt financings from third parties. These financings could depress the trading prices of our Securities. If additional funds are required to support our operations and such funds cannot be obtained on favorable terms, we may not be able to develop products, which will adversely impact our growth strategy.Our operations have consumed substantial amounts of cash since inception. During the six months ended June 30, 2024 and 2023, we incurred R&D expenses of approximately $37.5 million and $71.6 million, respectively, and during the years ended December 31, 2023 and 2022, we incurred R&D expenses of approximately $101.7 million and $134.2 million, respectively. We expect to continue to spend significant amounts on our growth strategy. We believe that our current cash and cash equivalents will enable us to continue to fund operations in the normal course of business for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q. Until such time, if ever, as we can generate a sufficient amount of product revenue and achieve profitability, we expect to seek to finance potential cash needs. Under current SEC regulations, if at the time we file our Annual Report on Form 10-K our public float is less than $75 million, and for so long as our public float remains less than $75 million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float, which is referred to as the â€œbaby shelf rules.â€ SEC regulations permit us to use the highest closing sales price of our common stock (or the average of the last bid and last ask prices of our common stock) on any day within 60 days of sales under the registration statement to calculate our public float.As of the date of the 2023 Form 10-K, our public float was less than $75 million. As a result, for sales following the date of the filing of the 2023 Form 10-K, and until we again have a public float with a value in exceeds of $75 million, if ever, we only have the capacity to sell shares up to one-third of our public float under shelf registration statements in any twelve-month period. If our public float decreases, the amount of securities we may sell under our Form S-3 shelf registration statements will also decrease.Our ability to obtain additional funding when needed, changes to our operating plans, our existing and anticipated working capital needs, the acceleration or modification of our planned R&D activities, expenditures, acquisitions and growth strategy, increased expenses or other events may affect our need for additional capital in the future and require us to seek additional funding sooner or on different terms than anticipated. In addition, if we are unable to raise additional capital when needed, we might have to delay, curtail or eliminate one or more of our R&D programs and commercialization efforts and potentially change our growth strategy, which would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our Securities to decline. The terms of our existing debt arrangements, including that with Oaktree, have and will continue to inhibit our and our subsidiariesâ€™ abilities to raise capital.We may be unable to generate returns for our investors if our partner companies and subsidiaries, several of which have limited or no operating history, have no commercialized revenue generating products or, if not yet profitable, cannot obtain additional third-party financing.As part of our growth strategy, we have made and will likely continue to make substantial financial and operational commitments in our subsidiaries, which often have limited or no operating history, have no commercialized revenue generating products, and require additional third-party financing to fund product and services development or acquisitions. Our business depends in large part on the ability of one or more of our subsidiaries and/or partner companies to innovate, in-license, develop or acquire successful biopharmaceutical products and/or acquire companies in increasingly competitive and highly regulated markets. If certain of our subsidiaries and/or partner companies do not successfully obtain additional third-party financing to commercialize products or are not acquired in change-of-control transactions that result in cash distributions, as applicable, the value of our businesses and our ownership stakes in our partner companies may be materially adversely affected, which would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our Securities to decline.68 Table of ContentsRaising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.To the extent that we raise additional capital by issuing Common Stock (or other Securities that are convertible into or exercisable for shares of Common Stock), the share ownership of existing stockholders will be diluted. We have also entered into financing arrangements to raise capital for our subsidiaries under which Common Stock is or may be issuable to investors in lieu of cash, upon certain conditions being met; in the event such issuances take place, they will also be dilutive of the stakes of existing stockholders. Any future debt financings may impose covenants that restrict our operations, including by limiting our ability to incur liens or additional debt, pay dividends, redeem our stock, make certain financial commitments and engage in certain merger, consolidation or asset sale transactions, among other restrictions. In addition, if we raise additional funds through licensing or sublicensing arrangements, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.â€‹We have paused dividend payments on our Series A Preferred Stock and may not be able to resume payment of dividends on our Series A Preferred Stock in the future if we have insufficient cash or available â€œsurplusâ€ as defined under Delaware law to make such dividend payments.On July 5, 2024, our board of directors paused the payment of dividends on our Series A Preferred Stock until further notice. However, dividends on our Series A Preferred Stock accrue daily, are payable monthly and will continue to accrue from the last date of payment. Our board of directors deemed the foregoing to be in the best interests of the Company and its common stockholders in light of the Companyâ€™s current and anticipated financial condition and outlook, and after considering its fiduciary duties to the Companyâ€™s common stockholders and other relevant factors. Our ability to pay cash dividends on our Series A Preferred Stock in the future requires us to have either net profits or positive net assets (total assets less total liabilities) over our capital, and that we have sufficient working capital in order to be able to pay our debts as they become due in the usual course of business. Our ability to pay dividends may also be impaired if any of the risks described in this report were to occur. Also, payment of our dividends depends upon our financial condition and other factors as our board of directors may deem relevant from time to time. We cannot assure you that we will have sufficient cash or â€œsurplusâ€ to resume payment of the cash dividends on the Series A Preferred Stock in a timely manner, or at all. We have never paid and currently do not intend to pay cash dividends in the near future, except for the dividend we previously paid on our Series A Preferred Stock. As a result, capital appreciation, if any, will be the sole source of gain for our Common Stockholders.We have never paid cash dividends on our Common Stock, or made stock dividends, except for the dividend we previously paid on shares of our SeriesÂ A Preferred Stock, and we currently intend to retain future earnings, if any, to fund the development and growth of our businesses, and retain our stock positions. In addition, the terms of existing and future debt agreements may preclude us from paying cash or stock dividends. Equally, each of our subsidiaries and partner companies is governed by its own board of directors with individual governance and decision-making regimes and mandates to oversee such entities in accordance with their respective fiduciary duties. As a result, we alone cannot determine the acts that could maximize value to you of such partner companies and subsidiaries in which we maintain ownership positions, such as declaring cash or stock dividends. As a result, capital appreciation, if any, of our Common Stock will be the sole source of gain for holders of our Common Stock for the foreseeable future.We have historically relied in part on sales of our common stock and other securities to fund our operations, and our future ability to obtain additional capital through stock sales or other securities offerings may be more costly than in the past, or may not be available to us at all.We have historically relied in part on sales of our common stock to fund our operations. For example, we raised an aggregate of approximately $30.2 million in gross proceeds in fiscal years 2022 and 2023 through the sale of shares of our common stock and other securities in offerings made under a Form S-3 â€œshelfâ€ registration statement. Using a shelf registration statement to conduct an equity offering to raise capital generally takes less time and is less expensive than other means, such as conducting an offering under a Form S-1 registration statement. We are no longer eligible to file any new shelf registration statements due to non-payment of dividends on our Series A Preferred Stock since July 5, 2024 and, if we do not resume payment of dividends on our Series A Preferred Stock, pay all accumulated dividends and otherwise remain compliant with the other conditions for use of a Form S-3 registration statement by the time we file our next Annual Report on Form 10-K, we will lose the ability to use our currently effective â€œshelfâ€ registration statement on Form S-3. Accordingly, we may then only be able to conduct additional offerings of our securities under an exemption from registration under the Securities Act or under a Form S-1 registration statement. We would expect either of these alternatives to be a more expensive method of raising additional capital and more dilutive to our stockholders relative to using a shelf registration statement.â€‹69 Table of ContentsRisks Pertaining to Our Existing Revenue Stream from Journey Medical Corporation Future revenue based on sales of our dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend, may be lower than expected or lower than in previous periods.The vast majority of our operating income for the foreseeable future is expected to come from the sale of our dermatology products through our partner company Journey. Any setback that may occur with respect to such products could significantly impair our financial condition, cash flows and/or operating results and/or reduce the value of our Securities. Setbacks for such products could include, but are not limited to, issues related to: supply chain, shipping; distribution; demand; manufacturing; product safety; product quality; marketing; government regulation, including but not limited to pricing or reimbursement; licensing and approval; intellectual property rights; competition with existing or new products, including third-party generic competition; product acceptance by physicians, other licensed medical professionals, and patients; and higher than expected total rebates, returns or recalls. Also, a significant portion of Journeyâ€™s sales derive from products that are without patent protection and/or are or may become subject to third party generic competition; the introduction of new competitor products, or increased market share of existing competitor products, could have a significant adverse effect on our operating income. â€‹We face challenges as our products face generic competition and/or losses of exclusivity. â€‹Journeyâ€™s products do and may compete with well-established products, both branded and generic, with similar or the same indications. We face increased competition from manufacturers of generic pharmaceutical products, who may submit applications to FDA seeking to market generic versions of our products. In connection with these applications, the generic drug companies may seek to challenge the validity and enforceability of our patents through litigation. When patents covering certain of our products (if applicable) expire or are successfully challenged through litigation or in USPTO proceedings, if a generic company launches a competing product â€œat risk,â€ or when the regulatory or licensed exclusivity for our products (if applicable) expires or is otherwise lost, we may face generic competition as a result.â€‹A significant portion of our sales derive from products that are without patent protection and/or are or may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income. Three of our marketed products, Qbrexza, Amzeeq and Zilxi, as well as one of our product candidates, DFD-29, currently have patent protection. Four of our marketed products, Accutane, Targadox, Luxamend and Exelderm, do not have patent protection or otherwise are not eligible for patent protection. â€‹Accutane currently competes in the Isotretinoin market with five other therapeutically equivalent A/B rated products. Targadox currently competes with one therapeutically equivalent A/B rated generic product. Exelderm may face A/B rated generic competition in the future.â€‹Generic versions are generally significantly less expensive than branded versions, and, where available, may be required to be utilized before or in preference to the branded version by third-party payors, or substituted by pharmacies. Accordingly, when a branded product loses its market exclusivity, it normally faces intense price competition from generic forms of the product. To successfully compete for business with managed care and pharmacy benefits management organizations, we must often demonstrate that our products offer not only medical benefits, but also cost advantages as compared with other forms of care. Any reduction in sales of our products, or the prices we receive for our products as a result of generic competition could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our Securities to decline.â€‹â€‹70 Table of ContentsAny disruptions to the capabilities, composition, size or existence of Journeyâ€™s field sales force may have a significant adverse impact on our existing revenue stream. Further, our ability to effectively market and sell any future products that we may develop and for which we receive marketing authorization, will depend on our ability to establish and maintain sales and marketing capabilities or to enter into agreements with third parties to market, distribute and sell any such products. â€‹Journeyâ€™s field sales force has been and is expected to continue to be an important contributor to our commercial success. Any disruptions to our relationship with such field sales force or the professional employer organization that employs our field sales force, could materially adversely affect our product sales. â€‹The establishment, development, and/or expansion of a field sales force, either by us or certain of our partners or vendors, or the establishment of a contract field sales force to market any products for which we may have or receive marketing approval is expensive and time-consuming and could delay any such product launch or compromise the successful commercialization of such products. If we are unable to establish and maintain sales and marketing capabilities or any other non-technical capabilities necessary to commercialize any products that may be successfully developed, we will need to contract with third parties to market and sell such products. We may not be able to establish or maintain arrangements with third parties on commercially reasonable terms, or at all.If our products are not included in managed care organizationsâ€™ formularies or coverage by other organizations, our productsâ€™ utilization and market shares may be negatively impacted, which could have a material adverse effect on our business and financial condition.In the United States, continued sales and coverage, including formulary inclusion without the need for a prior authorization or step edit therapy, of our products for commercial sale will depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers and other organizations. Third-party payors are increasingly examining the medical necessity and

cost-effectiveness of medical products and services, in addition to their safety and efficacy, and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Adequate third-party reimbursement may not be available for our products to enable us to realize an appropriate return on our investment of our currently marketed products or those which we may acquire or develop in the future.â€‹Managed care organizations and other third-party payors try to negotiate the pricing of medical services and products to control their costs. Managed care organizations and pharmacy benefit managers typically develop formularies to reduce their cost for medications. Formularies are based on the prices and therapeutic benefits of available products. Due to their lower costs, generic products are often favored. The breadth of the products covered by formularies varies considerably from one managed care organization to another, and many formularies include alternative and competitive products for treatment of particular medical conditions. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the utilization and market share of our products. If our products are not included within an adequate number of formularies or adequate reimbursement levels are not provided, or if those policies increasingly favor generic products, this could have a material adverse effect on our business and financial condition, cash flows and results of operations and could cause the market value of our Securities to decline.Reimbursement for our products and product candidates may be limited or unavailable in certain market segments, which could make it difficult for us to sell our products profitably.We have obtained approval for some products, and intend to seek approval for other product candidates, to commercialize in both the United States and in countries and territories outside the United States. If we obtain approval in one or more foreign countries, we will be subject to rulesÂ and regulations in those countries relating to such products. In some foreign countries, particularly in the European Union, the pricing of prescription pharmaceuticals and biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. In addition, market acceptance and sales of our product candidates, if approved, will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any of our product candidates and may be affected by existing and future healthcare reform measures.Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which pharmaceuticals they will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payorâ€™s determination regarding whether a product is:â—a covered benefit under its health plan;â—safe, effective and medically necessary;71 Table of Contentsâ—appropriate for the specific patient;â—cost-effective; andâ—experimental or investigational.Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require that we provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Additionally, while we may seek approval of our product candidates in combination with each other, there can be no guarantee that we will obtain coverage and reimbursement for any of our products together, or that such reimbursement will incentivize the use of our products in combination with each other as opposed to in combination with other agents which may be priced more favorably to the medical community.â€‹Legislative and regulatory changes to the healthcare systems of the United States and certain foreign countries could impact our ability to sell our products profitably. Several federal agencies including FDA, CMS, DEA and HHS, in addition to state and local governments, regulate drug product development and marketing. In particular, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (â€œMMAâ€) changed the way Medicare covers and pays for pharmaceutical products by revising the payment methodology for many products reimbursed by Medicare, resulting in lower rates of reimbursement for many types of drugs, and added a prescription drug benefit to the Medicare program that involves commercial plans negotiating drug prices for their members. In addition, this law provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this law and future laws could decrease the coverage and price that we will receive for any approved products. While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Therefore, any limitations in reimbursement that results from the MMA may result in reductions in payments from private payors.Since 2003, there have been several other legislative and regulatory changes to the coverage and reimbursement landscape for pharmaceuticals. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the â€œAffordable Care Actâ€ or â€œACA,â€ was enacted and made significant changes to the United Statesâ€™ healthcare system. The ACA and any revisions or replacements of that Act, any substitute legislation, and other changes in the law or regulatory framework could have a material adverse effect on our business.In the United States there is significant interest in containing healthcare costs and increasing the scrutiny of pharmaceutical pricing practices. Congress has continually explored legislation intended to address the cost of prescription drugs. Notably, the Inflation Reduction Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated â€œmaximum fair priceâ€ for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general is not yet known. While we cannot predict what additional proposals may ultimately become law, the elements under consideration could significantly change the landscape in which the pharmaceutical market operates.State legislatures are similarly active in proposing and passing legislation and regulations aimed at controlling pharmaceutical and biological prices and drug cost transparency. There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare products and services, including prescription drugs. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and prescription drugs may adversely affect:72 Table of Contentsâ—the demand for any products for which we may obtain regulatory approval;â—our ability to set a price that we believe is fair for our products;â—our ability to generate revenues and achieve or maintain profitability;â—the level of taxes that we are required to pay; andâ—the availability of capital.We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the payment that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.â€‹Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our product candidate, may be. In addition, increased scrutiny by the U.S. Congress of the FDAâ€™s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements.â€‹Risks Pertaining to our Business Strategy, Structure and OrganizationWe have entered, and will likely in the future enter, into certain collaborations or divestitures which may cause a reduction in our businessâ€™ size and scope, market share and opportunities in certain markets, or our ability to compete in certain markets and therapeutic categories. We have also entered into several arrangements under which we have agreed to contingent dispositions of subsidiaries, partner companies and/or their assets. The failure to consummate any such transaction may impair the value of such companies and/or assets, and we may not be able to identify or execute alternative arrangements on favorable terms, if at all.â€‹We have entered into and consummated several partnerships and/or contingent sales of our assets and subsidiaries, including an equity investment and contingent acquisition agreement between Caelum and AstraZeneca (the acquisition component of which has consummated) and a development funding and contingent asset purchase between Cyprium and Sentynl (the acquisition component of which has not yet consummated). Each of these arrangements has been time-consuming and has diverted managementâ€™s attention. As a result of these consummated/contingent sales, as with other similar transactions that we may complete, we may experience a reduction in the size or scope of our business, our market share in particular markets, our opportunities with respect to certain markets, products or therapeutic categories or our ability to compete in certain markets and therapeutic categories. In addition, in connection with any transaction involving a (contingent or non-contingent) sale of one of our subsidiaries, partner companies or their assets, we may surrender our ability to realize long-term value from such asset or company, in the form of foregone product sales, royalties, milestone payments, sublicensing revenue or otherwise, in exchange for upfront and/or other payments. In the event, for instance, that a product candidate underpinning any such asset or company is granted FDA approval for commercialization following the execution of documentation governing the sale by us of such asset or company, the transferee of such asset or company may realize tremendous value from commercializing such product, which we would have realized for ourselves had we not executed such sale transaction and been able to achieve applicable approvals independently.Should we seek to enter into collaborations or divestitures with respect to other assets or companies, we may be unable to consummate such arrangements on satisfactory or commercially reasonable terms within our anticipated timelines. In addition, our ability to identify, enter into and/or consummate collaborations and/or divestitures may be limited by competition we face from other companies in pursuing similar transactions in the biotechnology and pharmaceutical industries. â€‹â€‹73 Table of ContentsAny collaboration or divestiture we pursue, whether we are able to complete it or not, may be complex, time consuming and expensive, may divert from managementâ€™s attention, may have a negative impact on our customer relationships, cause us to incur costs associated with maintaining the business of the targeted collaboration or divestiture during the transaction process and also to incur costs of closing and disposing the affected business or transferring the operations of the business to other facilities. In addition, if such transactions are not completed for any reason, the market price of our Common Stock may reflect a market assumption that such transactions will occur, and a failure to complete such transactions could result in a negative perception by the market of us generally and a decline in the market price of our Securities. â€‹We act, and are likely to continue acting, as guarantor and/or indemnitor of the obligations, actions or inactions of certain of our subsidiaries and partner companies. We have also entered into, and may again enter into, certain arrangements with our subsidiaries, partner companies and/or third parties pursuant to which a substantial number of shares of our Common Stock may be issued. Depending on the terms of such arrangements, we may be contractually obligated to pay substantial amounts to third parties, or issue a substantially dilutive number of shares of our Common Stock, based on the actions or inactions of our subsidiaries and/or partner companies, regulatory agencies or other third parties.We act, and are likely to continue acting, as indemnitor of potential losses or liabilities that may be experienced by one or more of our subsidiaries, partner companies and/or their partners or investors (such as the indemnification arrangement existing by Fortress of Caelum with respect to the UTRF litigation, as disclosed elsewhere herein â€“ see Footnote 14, Commitments and Contingencies). If we become obligated to pay all or a portion of such indemnification amounts, our business and the market value of our Common Stock, Preferred Stock and/or debt securities may be materially adversely affected. Additionally, we have agreed in the past, and may agree in the future, to act as guarantor in connection with equity or debt raises by our partner companies, pursuant to which we may become obligated either to pay what could be a significant amount of cash or issue what could be a significant number of shares of Common Stock or Preferred Stock if certain events occur or do not occur, which could lead to a depletion of resources or dilution to our Common Stock, or both. Â Our future growth depends in part on our ability to identify and acquire or in-license products and product candidates, and if we are unable to do so, or to integrate acquired products into our operations, we may have limited growth opportunities.An important part of our business strategy is to continue to develop a pipeline of product candidates by acquiring or in-licensing products, businesses or technologies. Future in-licenses or acquisitions, however, may entail numerous operational and financial risks, including, but not necessarily limited to:â—exposure to unknown liabilities;â—disruption of our business and diversion of our managementâ€™s time and attention to develop acquired products or technologies;â—difficulty or inability to secure financing to fund development activities for such acquired or in-licensed technologies in the current economic environment;â—incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;â—higher than expected acquisition and integration costs;â—increased amortization expenses;â—difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;â—impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; andâ—inability to retain key employees of any acquired businesses.â€‹74 Table of ContentsWe have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. In particular, we may compete with larger biopharmaceutical companies and other competitors in our efforts to establish new collaborations and in-licensing opportunities. These competitors may have access to greater financial resources than us and/or may have greater expertise in identifying and evaluating new opportunities. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts.Certain of our officers and directors serve in similar roles at our partner companies, subsidiaries, related parties and/or other entities with which we transact business or in which we hold significant minority ownership positions, which could result in conflicts of interests relating to ongoing and future relationships and transactions with these parties.We share directors and/or officers with certain of our subsidiaries, partner companies, related parties and other entities with which we transact business or in which we hold significant minority ownership positions, and such arrangements could create conflicts of interest in the future, including with respect to the allocation of corporate opportunities. While we believe that we have put in place policies and procedures to identify and mitigate such conflicts, and that any existing agreements that may give rise to such conflicts and any such policies or procedures were negotiated at armâ€™s length in conformity with fiduciary duties, such conflicts of interest, or the appearance of conflict of interest, may nonetheless arise. The existence and consequences of such potential or perceived conflicts could expose us to lost profits, claims by our investors and creditors, and harm to our financial condition, cash flows and/or results of operations.Certain of our executives, directors and principal stockholders, whose interests may be adverse to those of our other stockholders, can control our direction and policies.Certain of our executive officers, directors and stockholders own nearly or more than 10% of our outstanding Common Stock and, together with their affiliates and related persons, beneficially own a significant percentage of our capital stock. If these stockholders were to choose to act together, they would be able to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire. In addition, this concentration of ownership might adversely affect the market price of our Common Stock by:â—delaying, deferring or preventing a change of control of us;â—impeding a merger, consolidation, takeover or other business combination involving us; orâ—discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.If we acquire, enter into joint ventures with or obtain a controlling interest in, companies in the future, our financial condition, operating results and the value of our Securities may be adversely affected, thereby diluting stockholder value, disrupting our business and/or diminishing the value of our holdings in our partner companies.As part of our growth strategy, we might acquire, enter into joint ventures with, or obtain significant ownership stakes in other companies. Acquisitions of, joint ventures with and investments in other companies involve numerous risks, including, but not necessarily limited to:â—risk of entering new markets in which we have little to no experience;â—diversion of financial and managerial resources from existing operations;â—successfully negotiating a proposed acquisition or investment timely and at a price or on terms and conditions favorable to us;â—the impact of regulatory reviews on a proposed acquisition or investment;â—the outcome of any legal proceedings that may be instituted with respect to the proposed acquisitions or investment;â—with respect to an acquisition, difficulties in integrating operations, technologies, services and personnel; and75 Table of Contentsâ—potential inability to maintain relationships with customers of the companies we may acquire or invest in.If we fail to properly evaluate potential acquisitions, joint ventures or other transaction opportunities, we might not achieve the anticipated benefits of any such transaction, we might incur higher costs than anticipated, and management resources and attention might be diverted from other necessary or valuable activities.Our results of operations could be adversely affected by economic and political conditions and the effects of these conditions on our business activities.Any terrorist attack, other act of violence or war, including military conflicts, could result in increased volatility in, or damage to, the worldwide financial markets and economy. This includes Russiaâ€™s February 2022 invasion of Ukraine, the conflict between Israel and the Hamas and Hezbollah extremist groups, recent attacks by armed groups on cargo ships in the Red Sea, and tensions across the Taiwan Strait. For instance, the United States or

other countries may impose sanctions that restrict doing business in the effected countries and increased military conflict may affect third-party vendors and cause delays.This risk may be magnified in the case of the conflict between Russia and Ukraine. Russiaâ€™s invasion and the ensuing response by Ukraine may disrupt our partner companiesâ€™ ability to conduct clinical trials in Russia, Ukraine, Belarus, and Georgia, and potentially other neighboring countries. Although the impact of Russiaâ€™s military action is highly unpredictable, certain clinical trial sites may be affected, including those of our partner company Checkpoint in Russia, Ukraine, Belarus, and Georgia. Those clinical trial sites may suspend or terminate trials, and patients could be forced to evacuate or choose to relocate, making them unavailable for initial or further participation in clinical trials. For instance, Checkpoint had to terminate their Phase 3 NSCLC trial in the first quarter of 2023 as a result of such conflicts. Alternative sites to fully and timely compensate for clinical trial activities in these areas may not be available, and we may need to find other countries to conduct these clinical trials. Clinical trial interruptions may delay our plans for clinical development and approvals for our product candidates, which could increase costs and jeopardize our ability to commence product sales and generate revenues. Risks Pertaining to Reliance on Third PartiesWe rely predominantly on third parties to manufacture the majority of our preclinical and clinical pharmaceutical supplies, and we expect to continue to rely heavily on such third parties and other contractors to produce commercial supplies of our product candidates and products, if approved. Further, we rely solely on third parties to manufacture Journeyâ€™s commercialized products. Such dependence on third-party suppliers could adversely impact our businesses. We depend heavily on third party manufacturers for product supply. If our contract manufacturers cannot successfully manufacture material that conforms to applicable specifications and FDA regulatory requirements, we will not be able to secure and/or maintain FDA approval for those products. Our third-party suppliers will be required to maintain compliance with cGMPs and will be subject to inspections by the FDA and comparable agencies and authorities in other jurisdictions to confirm such compliance. In the event that the FDA or such other authorities determine that our third-party suppliers have not complied with cGMPs or comparable regulations, the relevant clinical trials could be terminated or subjected to clinical hold until such time as we are able to obtain appropriate replacement material and/or applicable compliance, and commercial product could be unfit for sale, or if distributed, could be recalled from the market. Any delay, interruption or other issues that arise in the manufacture, testing, packaging, labeling, storage, or distribution of our products as a result of a failure of the facilities or operations of our third-party suppliers to comply with regulatory requirements, pass any regulatory agency inspection or otherwise perform under our agreements with them could significantly impair our ability to develop and commercialize our products and product candidates. In addition, several of our currently commercialized products, sold through our partner company Journey, are produced by a single manufacturer, and, although we closely monitor inventory prophylactically, disruptions to such supply arrangements could adversely affect our ability to meet product demand and therefore diminish revenues. Finally, in light of partner company Mustangâ€™s recent reduction in force in April 2024, we may increase our reliance at Mustang on third-party manufacturers or third-party collaborators for the manufacture of commercial supply of one or more product candidates for which our collaborators or we obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms, and even if we are able to establish such agreements with third-party manufacturers, reliance entails additional risks.â€‹76 Table of ContentsWe also rely on third-party manufacturers to purchase from third-party suppliers the raw materials and equipment necessary to produce product candidates for anticipated clinical trials. There are a small number of suppliers for certain capital equipment and raw materials that are used to manufacture those products. We do not have direct control over the process or timing of the acquisition of these raw materials by our third-party manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials since such agreements are entered into by our third-party manufacturers and their qualified suppliers. Any significant delay in the supply of raw material components related to an ongoing clinical trial could considerably delay completion of our clinical trials, product testing and potential regulatory approval.â€‹We do not expect to have the resources or capacity to engage in our own commercial manufacturing of our product candidates, if they received marketing approval, and would likely continue to be heavily dependent upon third-party manufacturers. Our dependence on third parties to manufacture and supply clinical trial materials, as well as our planned dependence on third party manufacturers for any products that may be approved, may adversely affect our ability to develop and commercialize products in a timely or cost-effective manner, or at all. In addition to the manufacturing and supply functions they provide, third-party manufacturers also play a key role in our efforts to obtain marketing approval for our product candidates, by interacting with, providing important information to, and hosting inspections by, applicable regulatory authorities. If a given contract development and manufacturing organization upon whom we rely in such a capacity is unwilling or unable to perform these activities on our behalf, the successful development and/or approval of the applicable product candidate could be delayed significantly.In addition, because of the sometimes-limited number of third parties who specialize in the development, manufacture and/or supply of our clinical and preclinical materials, we are often compelled to accept contractual terms that we deem less than desirable, including without limitation as pertains representations and warranties, supply disruptions/failures, covenants and liability/indemnification. Especially as pertains liability and indemnification provisions, because of the frequent disparities in negotiating leverage, we are often compelled to agree to low caps on counterparty liability and/or indemnification language that could result in outsized liability to us in situations where we have zero or relatively little culpability. We rely heavily on third parties for the development and manufacturing of products and product candidates.To date, we have engaged primarily in intellectual property acquisitions, and evaluative and R&D activities and have not generated any revenues from product sales (except through Journey). We have incurred significant net losses since our inception. As of June 30, 2024, we had an accumulated deficit of approximately $721.2 million, and as of December 31, 2023, we had an accumulated deficit of approximately $694.9 million. We may need to rely on third parties for activities critical to the product candidate development process, including but not necessarily limited to:â—identifying and evaluating product candidates;â—negotiating, drafting and entering into licensing and other arrangements with product development partners; andâ—continuing to undertake pre-clinical development and designing and executing clinical trials.We have also not demonstrated the ability to perform the functions necessary for the successful commercialization of any of our development-stage product candidates, should any of them be approved for marketing. If we were to have any such product candidates approved, the successful commercialization of such products would be dependent on us performing or contracting with third parties for performance, of a variety of critical functions, including, but not necessarily limited to:â—advising and participating in regulatory approval processes;â—formulating and manufacturing products for clinical development programs and commercial sale; andâ—conducting sales and marketing activities.Our operations have been limited to acquiring, developing and securing the proprietary rights for, and undertaking pre-clinical development and clinical trials of, product candidates, both at the Fortress level and via our subsidiaries and partner companies. These operations provide a limited basis for our stockholders and prospective investors to assess our ability to develop and commercialize potential product candidates, as well as for you to assess the advisability of investing in our securities.77 Table of ContentsWe rely on third parties to conduct clinical trials. If these third parties do not meet agreed-upon deadlines or otherwise conduct the trials as required, our clinical development programs could be delayed or unsuccessful, and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.We rely on third-party contract research organizations and site management organizations to conduct most of our preclinical studies and all of our clinical trials for our product candidates. We expect to continue to rely on third parties, such as contract research organizations, site management organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct some of our preclinical studies and all of our clinical trials. These CROs, investigators, and other third parties will and do play a significant role in the conduct of our trials and the subsequent collection and analysis of data from the clinical trials.There is no guarantee that any CROs, investigators or other third parties upon which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines or fails to adhere to our clinical protocols or otherwise perform in a substandard manner, our clinical trials may be extended, delayed or terminated. If any of the clinical trial sites terminates for any reason, we may lose follow-up information on patients enrolled in our ongoing clinical trials unless the care of those patients is transferred to another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisers or consultants to us from time to time and receive cash and/or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site, or the FDAâ€™s willingness to accept such data, may be jeopardized.Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities or potential liability. For example, we will remain responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial and for ensuring that our preclinical studies are conducted in accordance with GLPs as appropriate. Moreover, the FDA requires us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of our clinical research organizations fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may refuse to accept such data, or require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP in strict conformity to cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register certain ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.If any of our relationships with these third-party contract research organizations or site management organizations terminates, we may not be able to enter into arrangements with alternative contract research organizations or site management organizations or to do so on commercially reasonable terms. Switching or adding additional contract research organizations or site management organizations involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new contract research organization or site management organization commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our contract research organizations or site management organizations, there can be no assurance that we will not encounter similar challenges or delays in the future.We rely on clinical and pre-clinical data and results obtained from and by third parties that could ultimately prove to be inaccurate or unreliable.As part of our strategy to mitigate development risk, we generally intend on developing product candidates with previously-validated mechanisms of action and seek to assess potential clinical efficacy early in the development process. This strategy necessarily relies upon clinical and pre-clinical data and other results produced or obtained by third parties, which may ultimately prove to be inaccurate or unreliable. If the third-party data and results we rely upon prove to be inaccurate, unreliable, not acceptable by regulatory authorities or not applicable to our product candidates or acquired products, we could make inaccurate assumptions and conclusions about our current or future product candidates and our research and development efforts could be compromised.78 Table of ContentsCollaborative relationships with third parties could cause us to expend significant resources and/or incur substantial business risk with no assurance of financial return.We anticipate substantial reliance on strategic collaborations for marketing and commercializing our existing product candidates and we may rely even more on strategic collaborations for R&D of other product candidates. We may sell product offerings through strategic partnerships with pharmaceutical and biotechnology companies. If we are unable to establish or manage such strategic collaborations on terms favorable to us in the future, our revenue and drug development may be limited.If we enter into R&D collaborations during the early phases of drug development, success will, in part, depend on the performance of research collaborators. We may not directly control the amount or timing of resources devoted by research collaborators to activities related to product candidates. Research collaborators may not commit sufficient resources to our R&D programs. If any research collaborator fails to commit sufficient resources, the preclinical or clinical development programs related to the collaboration could be delayed or terminated. Also, collaborators may pursue existing or other development-stage products or alternative technologies in preference to those being developed in collaboration with us. Finally, if we fail to make required milestone or royalty payments to collaborators or to observe other obligations in agreements with them, the collaborators may have the right to terminate or stop performance of those agreements.Establishing strategic collaborations is difficult and time-consuming. Our discussions with potential collaborators may not lead to the establishment of collaborations on favorable terms, if at all. Potential collaborators may reject collaboration proposals based upon their assessment of our financial, regulatory or intellectual property positions. Even if we successfully establish new collaborations, these relationships may never result in the successful development or commercialization of product candidates or the generation of sales revenue. To the extent that we enter into collaborative arrangements, the related product revenues that might follow are likely to be lower than if we directly marketed and sold products. Such collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on, and such collaborations could be more attractive than the one with us for any future product candidate.Management of our relationships with collaborators will require:â—significant time and effort from our management team;â—coordination of our marketing and R&D programs with the respective marketing and R&D priorities of our collaborators; andâ—effective allocation of our resources to multiple projects.The contractual provisions we may be forced to agree upon in services, manufacturing, supply and other agreements may be inordinately one-sided, vis-Ã -vis current or historical standard market terms (especially as pertains contractual liability and indemnification paradigms), and as a result we may be subject to liabilities that are not attributable to our own actions or the actions of our personnel.Â â€‹There is a finite number of service providers who can perform the services or produce the materials or product candidates that we need, and we therefore often have a limited number of options in choosing such service providers.Â The standard market terms in many of the agreements into which we customarily enter with such service providers are subject to evolution over time, often-times in favor of our counterparties.Â Also, some such agreements are â€œadhesion contractsâ€ under which our contractual counterparties refuse to entertain any modifications to their template documentation. One area where service providers often have and exert leverage over us is the negotiation of liability language â€“ specifically in broadly scoped indemnification by us of service providers and/or the application of liability damages â€œcapsâ€ to certain of such service providersâ€™ indemnification obligations.Â In any circumstance where weâ€™ve been compelled to agree to such language, it is conceivable that we will be liable to third parties for liabilities in excess of such caps that are attributable to the actions, forbearances and/or culpability of such service providers and their indemnitees (and not to those of us and our personnel).â€‹79 Table of ContentsRisks Pertaining to Intellectual Property and Potential Disputes with Licensors ThereofIf we are unable to obtain and maintain sufficient patent protection for our technology and products, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.Our success depends, in large part, on our ability to obtain patent protection for our product candidates and their formulations and uses. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we will be successful in obtaining patents or what the scope of an issued patent may ultimately be. These risks and uncertainties include, but are not necessarily limited to, the following:â—patent applications may not result in any patents being issued, or the scope of issued patents may not extend to competitive product candidates and their formulations and uses developed or produced by others;â—our competitors, many of which have substantially greater resources than we or our partners do, and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that may limit or interfere with our abilities to make, use, and sell potential product candidates, file new patent applications, or may affect any pending patent applications that we may have;â—there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns; andâ—countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.In addition, patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide any competitive advantage. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the PTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our US patent positions. An adverse determination in any such submission, patent office trial, proceeding or litigation could reduce the scope of, render unenforceable, or invalidate, our patent rights, allow third parties to commercialize our technologies or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the

breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Third parties are often responsible for maintaining patent protection for our product candidates, at our and their expense. If that party fails to appropriately prosecute and maintain patent protection for a product candidate, our abilities to develop and commercialize products may be adversely affected, and we may not be able to prevent competitors from making, using and selling competing products. Such a failure to properly protect intellectual property rights relating to any of our product candidates could have a material adverse effect on our financial condition and results of operations. In addition, U.S. patent laws may change, which could prevent or limit us from filing patent applications or patent claims to protect products and/or technologies or limit the exclusivity periods that are available to patent holders, as well as affect the validity, enforceability, or scope of issued patents.â€‹80 Table of ContentsWe and our licensors also rely on trade secrets and proprietary know-how to protect product candidates. Although we have taken steps to protect our and their trade secrets and unpatented know-how, including entering into confidentiality and non-use agreements with third parties, and proprietary information and invention assignment agreements with employees, consultants and advisers, third parties may still come upon this same or similar information independently. Despite these efforts, any of these parties may also breach the agreements and may unintentionally or willfully disclose our or our licensorsâ€™ proprietary information, including our trade secrets, and we may not be able to identify such breaches or obtain adequate remedies. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of our or our licensorsâ€™ trade secrets were to be lawfully obtained or independently developed by a competitor, we and our licensors would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our or our licensorsâ€™ trade secrets were to be disclosed to or independently developed by a competitor, our competitive positions would be harmed.The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify any patentable aspects of our research and development output and methodology, and, even if we do, an opportunity to obtain patent protection may have passed. Given the uncertain and time-consuming process of filing patent applications and prosecuting them, it is possible that our product(s)Â or process(es) originally covered by the scope of the patent application may have changed or been modified, leaving our product(s)Â or process(es) without patent protection. If our licensors or we fail to obtain or maintain patent protection or trade secret protection forÂ one or more product candidates or any future product candidate we may license or acquire, third parties may be able to leverage our proprietary information and products without risk of infringement, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and achieve profitability. Moreover, should we enter into other collaborations we may be required to consult with or cede control to collaborators regarding the prosecution, maintenance and enforcement of licensed patents. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, no consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the US. The patent situation outside the US is even more uncertain. The laws of foreign countries may not protect our rights to the same extent as the laws of the US, and we may fail to seek or obtain patent protection in all major markets. For example, European patent law restricts the patentability of methods of treatment of the human body more than US law does. We might also become involved in derivation proceedings in the event that a third party misappropriates one or more of our inventions and files their own patent application directed to such one or more inventions. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention (or that a third party derived an invention from us) would be unsuccessful, resulting in a material adverse effect on our USÂ patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the US and other countries may diminish the value of our patents or narrow the scope of our patent protection. For example, the federal courts of the US have taken an increasingly dim view of the patent eligibility of certain subject matter, such as naturally occurring nucleic acid sequences, amino acid sequences and certain methods of utilizing same, which include their detection in a biological sample and diagnostic conclusions arising from their detection. Such subject matter, which had long been a staple of the biotechnology and biopharmaceutical industry to protect their discoveries, is now considered, with few exceptions, ineligible in the first instance for protection under the patent laws of the US. Accordingly, we cannot predict the breadth of claims that may be allowed and remain enforceable in our patents or in those licensed from a third party.81 Table of ContentsRecent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On SeptemberÂ 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include changes to transition from a â€œfirst-to-inventâ€ system to a â€œfirst inventor-to-fileâ€ system and to the way issued patents are challenged. The formation of the Patent Trial and Appeal Board now provides a less burdensome, quicker and less expensive process for challenging issued patents. The PTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first inventor-to-file provisions, only became effective on MarchÂ 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.We also may rely on the regulatory period of market exclusivity for any of our biologic product candidates that are successfully developed and approved for commercialization. Although this period in the United States is generally 12 years from the date of marketing approval (depending on the nature of the specific product), there is a risk that the U.S. Congress could amend laws to significantly shorten this exclusivity period. Once any regulatory period of exclusivity expires, depending on the status of our patent coverage and the nature of the product, we may not be able to prevent others from marketing products that are biosimilar to or interchangeable with our products, which would materially adversely affect our business.If we or our licensors are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.Our success also depends on our ability, and the abilities of any of our respective current or future collaborators, to develop, manufacture, market and sell product candidates without infringing the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products, some of which may be directed at claims that overlap with the subject matter of our or our licensorsâ€™ intellectual property. Because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that our product candidates or proprietary technologies may infringe. Similarly, there may be issued patents relevant to our product candidates of which we or our licensors are not aware. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the US and other jurisdictions are typically not published until 18 months after a first filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or such licensors were the first to make the inventions claimed in patents or pending patent applications that we own or licensed, or that we and our licensors were the first to file for patent protection of such inventions. In the event that a third party has also filed a US patent application relating to our product candidates or a similar invention, depending upon the priority dates claimed by the competing parties, we may have to participate in interference proceedings declared by the PTO to determine priority of invention in the US. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our or any of our licensorsâ€™ patent rights are highly uncertain.There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we or any of our licensors, suppliers or collaborators infringe the third partyâ€™s intellectual property rights, we may have to, among other things:â—obtain additional licenses, which may not be available on commercially reasonable terms, if at all;â—abandon an infringing product candidate or redesign products or processes to avoid infringement, which may demand substantial funds, time and resources and which may result in inferior or less desirable processes and/or products;â—pay substantial damages, including the possibility of treble damages and attorneysâ€™ fees, if a court decides that the product or proprietary technology at issue infringes on or violates the third partyâ€™s rights;â—pay substantial royalties, fees and/or grant cross-licenses to our product candidates; and/or82 Table of Contentsâ—defend litigation or administrative proceedings which may be costly regardless of outcome, and which could result in a substantial diversion of financial and management resources.We may be involved in lawsuits to protect or enforce our patents or the patents of licensors, which could be expensive, time consuming and unsuccessful.Competitors may infringe our or our licensorsâ€™ patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against accused infringers could provoke these parties to assert counterclaims against us alleging invalidity of our or our licensorsâ€™ patents or that we infringe their patents; or provoke those parties to petition the PTO to institute inter partes review against the asserted patents, which may lead to a finding that all or some of the claims of the patent are invalid. In addition, in a patent infringement proceeding, a court may decide that a patent of ours or our licensorâ€™s is invalid or unenforceable, in whole or in part, construe the patentâ€™s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our or our licensorsâ€™ patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, found to be unenforceable, or interpreted narrowly and could likewise put pending patent applications at risk of not issuing. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.We in-license from third parties a majority of the intellectual property needed to develop and commercialize products and product candidates. As such, any dispute with the licensors or non-performance of such license agreements may adversely affect our ability to develop and commercialize the applicable product candidates.The patents, patent applications and other intellectual property rights underpinning the vast majority of our existing product candidates were in-licensed from third parties. Under the terms of such license agreements, the licensors generally have the right to terminate such agreements in the event of a material breach. The licenses require us to make annual, milestone or other payments prior to commercialization of any product, and our ability to make these payments depends on the ability to generate cash in the future. These license agreements also generally require the use of diligent and reasonable efforts to develop and commercialize product candidates.If there is any conflict, dispute, disagreement or issue of non-performance between us or one of our partners, on the one hand, and the respective licensing partner, on the other hand, regarding the rights or obligations under the license agreements, including any conflict, dispute or disagreement arising from a failure to satisfy payment obligations under such agreements, the ability to develop and commercialize the affected product candidate may be adversely affected.The types of disputes that may arise between us and the third parties from whom we license intellectual property include, but are not necessarily limited to:â—the scope of rights granted under such license agreements and other interpretation-related issues;â—the extent to which our technologies and processes infringe on intellectual property of the licensor that is not subject to such license agreements;â—the scope and interpretation of the representations and warranties made to us by our licensors, including those pertaining to the licensorsâ€™ right title and interest in the licensed technology and the licensorsâ€™ right to grant the licenses contemplated by such agreements;â—the sublicensing of patent and other rights under our license agreements and/or collaborative development relationships, and the rights and obligations associated with such sublicensing, including whether or not a given transaction constitutes a sublicense under such license agreement;â—the diligence and development obligations under license agreements (which may include specific diligence milestones) and what activities or achievements satisfy those diligence obligations;â—whether or not the milestones associated with certain milestone payment obligations have been achieved or satisfied;â—the applicability or scope of indemnification claims or obligations under such license agreements;83 Table of Contentsâ—the permissibility and advisability of, and strategy regarding, the pursuit of potential third-party infringers of the intellectual property that is the subject of such license agreements;â—the calculation of royalty, milestone, sublicense revenue and other payment obligations under such license agreements;â—the extent to which rights, if any, are retained by licensors under such license agreements;â—whether or not a material breach has occurred under such license agreements and the extent to which such breach, if deemed to have occurred, is or can be cured within applicable cure periods, if any;â—disputes regarding patent filing and prosecution decisions, as well as payment obligations regarding past and ongoing patent expenses;â—intellectual property rights resulting from the joint creation or use of intellectual property (including improvements made to licensed intellectual property) by our and our partnersâ€™ licensors and us and our partners; andâ—the priority of invention of patented technology.In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations or may conflict in such a way that puts us in breach of one or more agreements, which would make us susceptible to lengthy and expensive disputes with one or more of such third-party licensing partners. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreements, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.Risks Pertaining to the Commercialization of Product CandidatesIf any of our product candidates are successfully developed and receive regulatory approval but do not achieve broad market acceptance among physicians, patients, healthcare payors and the medical community, the revenues that any such product candidates, if approved, generate from sales will be limited.Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors and the medical community. Coverage and reimbursement of our product candidates, if approved, by third-party payors, including government payors, generally would also be necessary for commercial success. The degree of market acceptance of any approved products would depend on a number of factors, including, but not necessarily limited to:â—the efficacy and safety as demonstrated in clinical trials;â—the timing of market introduction of such products as well as competitive products;â—the clinical indications for which the product is approved;â—acceptance by physicians, major operators of hospitals and clinics and patients of the product as a safe and effective treatment;â—the potential and perceived advantages of such products over alternative treatments;â—the safety of such products in a broader patient group (i.e., based on actual use);â—the availability, cost and benefits of treatment, in relation to alternative treatments;â—the availability of adequate reimbursement and pricing by third parties and government authorities;84 Table of Contentsâ—changes in regulatory requirements by government authorities for such products;â—the product labeling or product insert required by the FDA or regulatory authority in other countries, including any contradictions, warnings, drug interactions, or other precautions;â—changes in the standard of care for the targeted indications for our product candidate or future product candidates, which could reduce the marketing impact of any labeling or marketing claims that we could make following FDA approval;â—relative convenience and ease of administration;â—the prevalence and severity of side effects and adverse events;â—the effectiveness of our sales and marketing efforts; andâ—unfavorable publicity relating to the product.If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate sufficient revenue from these products and in turn we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.â€‹Even if approved, any product candidates that we may develop and market may be later withdrawn from the market or subject to promotional limitations.We may not be able to obtain the desired labeling claims or scheduling classifications necessary or desirable for the promotion of our marketed products (or our product candidates if approved). We may also be required to undertake post-marketing clinical trials. If the results of such post-marketing studies are not satisfactory or if adverse events or other safety issues arise after approval while our products are on the market, the FDA or a comparable regulatory authority in another jurisdiction may withdraw marketing authorization or

may condition continued marketing on commitments from us that may be expensive and/or time consuming to complete. In addition, if manufacturing problems occur, regulatory approval may be impacted or withdrawn and reformulation of our products, additional clinical trials, changes in labeling of our products and additional marketing applications may be required. Any reformulation or labeling changes may limit the marketability of such products if approved.We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for one or more of our product candidates or a future product candidate we may license or acquire and may have to limit their commercialization, if approved.The use of one or more of our product candidates and any future product candidate we may license or acquire in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. For example, we may be sued if any product candidate or product we develop, license, or acquire allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate or product, negligence, strict liability or a breach of warranties. Product liability claims might be brought against us by consumers, health care providers or others using, administering or selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:â—withdrawal of clinical trial participants;â—suspension or termination of clinical trial sites or entire trial programs;â—decreased demand for any product candidates or products that we may develop, license or acquire;â—initiation of investigations by regulators;â—impairment of our business reputation;85 Table of Contentsâ—costs of related litigation;â—substantial monetary awards to patients or other claimants;â—loss of revenues;â—reduced resources of our management to pursue our business strategy; andâ—the ability to commercialize our product candidate or future product candidates.We will obtain limited product liability insurance coverage for all of our upcoming clinical trials. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. When needed we intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for one or more of our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.Additionally, we have entered into various agreements under which we indemnify third parties for certain claims relating to product candidates. These indemnification obligations may require us to pay significant sums of money for claims that are covered by these indemnifications.Any product for which we obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with products, when and if any of them are approved.Any product for which we obtain marketing approval, along with the authorized manufacturing facilities, processes and equipment, post-approval clinical data, labeling, advertising and promotional activities for such product, will remain subject to ongoing regulatory requirements governing drug or biological products, as well as review by the FDA and comparable regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping, and requirements regarding company presentations and interactions with healthcare professionals. Even if we obtain regulatory approval for a product, the approval may be subject to limitations on the indicated uses for which the product may be marketed or subject to conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. We also may be subject to state laws and registration requirements covering the distribution of drug products. Later discovery of previously unknown problems with products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:â—restrictions on product manufacturing, distribution or use;â—restrictions on the labeling or marketing of a product;â—requirements to conduct post-marketing studies or clinical trials;â—warning letters, untitled letters, or Form 483s;â—recalls or other withdrawal of the products from the market;â—refusal to approve pending applications or supplements to approved applications that we submit;â—fines;86 Table of Contentsâ—suspension or withdrawal of marketing or regulatory approvals;â—refusal to permit the import or export of products;â—product seizure or detentions;â—injunctions or the imposition of civil or criminal penalties; andâ—adverse publicity.If we or our suppliers, third-party contractors, clinical investigators or collaborators are slow to adapt, or are unable to adapt, to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, we or our collaborators may be subject to the actions listed above, including losing marketing approval for product candidates when and if any of them are approved, resulting in decreased revenue from milestones, product sales or royalties, which would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our Securities to decline.We will need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.A pharmaceutical product cannot be marketed in the U.S. or other countries until the relevant governmental authority has completed a rigorous and extensive regulatory review process, including approval of a brand name. Any brand names we intend to use for our product candidates in the U.S. will require approval from the FDA regardless of whether we have secured a formal trademark registration from the PTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we could lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.Risks Pertaining to Legislation and Regulation Affecting the Biopharmaceutical and Other IndustriesOur current and future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.Healthcare providers, physicians and third-party payors in the U.S. and elsewhere play a primary role in the recommendation and prescription of our product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we sell, market and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by the federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not necessarily limited to:â—the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid;â€‹87 Table of Contentsâ—federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;â—HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;â—the federal Open Payments program, which requires manufacturers of certain drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Childrenâ€™s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services, or CMS, information related to â€œpayments or other transfers of valueâ€ made to â€œcovered recipients,â€ which include physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives and teaching hospitals) and applicable manufacturers. Applicable group purchasing organizations also are required to report annually to CMS the ownership and investment interests held by the physicians and their immediate family members. The SUPPORT for Patients and Communities Act added to the definition of covered recipient practitioners including physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse-midwives effective in 2022; andâ—analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect on our businesses. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our businesses.As we continue to execute our growth strategy, we may be subject to further government regulation which could adversely affect our financial results, including without limitation the Investment Company Act of 1940.If we engage in business combinations and other transactions that result in holding minority or non-control investment interests in a number of entities, we may become subject to regulation under the Investment Company Act of 1940, as amended (the â€œInvestment Company Actâ€). If we do become subject to the Investment Company Act, we would be required to register as an investment company and could be expected to incur significant registration and compliance costs in the future.88 Table of ContentsGeneral and Other RisksOur business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or third partiesâ€™ cybersecurity.We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary course of business, we collect, store, and transmit confidential information, including, but not limited to, information related to our intellectual property and proprietary business information, personal information, and other confidential information. It is critical that we maintain such confidential information in a manner that preserves its confidentiality, availability and integrity. Furthermore, we have outsourced elements of our operations to third party vendors, who each have access to our confidential information, which increases our disclosure risk.â€‹We are in the process of implementing our internal security and business continuity measures and developing our information technology infrastructure. Our internal computer systems and those of current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses and unauthorized access. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, third-party software, data center facilities, lab equipment, and connection to the internet, face the risk of breakdown or other damage or interruption from service interruptions, system malfunctions, natural disasters, terrorism, war, and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware and other malicious code, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), each of which could compromise our system infrastructure or lead to the loss, destruction, alteration, disclosure, or dissemination of, or damage or unauthorized access to, our data or data that is processed or maintained on our behalf, or other assets.â€‹If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, and could result in financial, legal, business, and reputational harm to us. For example, in 2021, our partner company Journey was the victim of a cybersecurity incident that affected its accounts payable function and led to approximately $9.5 million in wire transfers being misdirected to fraudulent accounts. The details of the incident and its origin were investigated with the assistance of third-party cybersecurity experts working at the direction of legal counsel. The matter was reported to the Federal Bureau of Investigation and does not appear to have compromised any personally identifiable information or protected health information. The federal government has been able to seize a significant amount of cryptocurrency assets associated with the breach. Once the cryptocurrency has been converted back into U.S. dollars, Journey expects to receive a notification letter to initiate the return of the cash. This process could take as long as six months or more to complete.Â Fortress and Journey may incur additional expenses and losses as a result of this cybersecurity incident, including those related to investigation fees and remediation costs. Â â€‹In addition, the loss or corruption of, or other damage to, clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our drug candidates or any future drug candidates and to conduct clinical trials, and similar events relating to their systems and operations could also have a material adverse effect on our business and lead to regulatory agency actions. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Sophisticated cyber attackers (including foreign adversaries engaged in industrial espionage) are skilled at adapting to existing security technology and developing new methods of gaining access to organizationsâ€™ sensitive business data, which could result in the loss of proprietary information, including trade secrets. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, or hostile foreign governments or agencies.â€‹â€‹89 Table of ContentsAny security breach or other event leading to the loss or damage to, or unauthorized access, use, alteration, disclosure, or dissemination of, personal information, including personal information regarding clinical trial subjects, contractors, directors, or employees, our intellectual property, proprietary business information, or other confidential or proprietary information, could directly harm our reputation, enable competitors to compete with us more effectively, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. Each of the foregoing could result in significant legal and financial exposure and reputational damage that could adversely affect our business. Notifications and follow-up actions related to a security incident could impact our reputation or cause us to incur substantial costs, including legal and remediation costs, in connection with these measures and otherwise in connection with any actual or suspected security breach. We expect to incur significant costs in an effort to detect and prevent security incidents and otherwise implement our internal security and business continuity measures, and actual, potential, or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and

consultants. We may face increased costs and find it necessary or appropriate to expend substantial resources in the event of an actual or perceived security breach.â€‹The costs related to significant security breaches or disruptions could be material, and our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored or processed. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. Furthermore, if the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.â€‹We may not be able to hire or retain key officers or employees needed to implement our business strategy and develop products and businesses.Our success depends on the continued contributions of our executive officers, financial, scientific, and technical personnel and consultants, and on our ability to attract additional personnel as we continue to implement growth strategies and acquire and invest in companies with varied businesses. During our operating history, many essential responsibilities have been assigned to a relatively small number of individuals. However, as we continue to implement our growth strategy, the demands on our key employees will expand, and we will need to recruit additional qualified employees. The competition for such qualified personnel is intense, and the loss of services of certain key personnel, or our inability to attract additional personnel to fill critical positions, could adversely affect our business.We currently depend heavily upon the efforts and abilities of our management team and the management teams of our partners. The loss or unavailability of the services of any of these individuals could have a material adverse effect on our business, prospects, financial condition and results. In addition, we have not obtained, do not own, and are not the beneficiary of key-person life insurance for any of our key personnel. We only maintain a limited amount of directorsâ€™ and officersâ€™ liability insurance coverage. There can be no assurance that this coverage will be sufficient to cover the costs of the events that may occur, in which case, there could be a substantial impact on our ability to continue operations.â€‹90 Table of ContentsOur employees, consultants, or third-party partners may engage in misconduct or other improper activities, including but not necessarily limited to noncompliance with regulatory standards and requirements or internal procedures, policies or agreements to which such employees, consultants and partners are subject, any of which could have a material adverse effect on our business.We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, consultants, or third-party partners could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with cGMPs, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, comply with internal procedures, policies or agreements to which such employees, consultants or partners are subject, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee, consultant, or third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation, as well as civil and criminal liability. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other civil and/or criminal sanctions.We receive a large amount of proprietary information from potential or existing licensors of intellectual property and potential acquisition target companies, all pursuant to confidentiality agreements. The confidentiality and proprietary invention assignment agreements that we have in place with each of our employees and consultants prohibit the unauthorized disclosure of such information, but such employees or consultants may nonetheless disclose such information through negligence or willful misconduct. Any such unauthorized disclosures could subject us to monetary damages and/or injunctive or equitable relief. The notes, analyses and memoranda that we have generated based on such information are also valuable to our businesses, and the unauthorized disclosure or misappropriation of such materials by our employees and consultants could significantly harm our strategic initiatives â€” especially if such disclosures are made to our competitor companies.We may be subject to claims that our employees and/or consultants have wrongfully used or disclosed to us alleged trade secrets of their former employers or other clients.As is common in the biopharmaceutical industry, we rely on employees and consultants to assist in the development of product candidates, many of whom were previously employed at, or may have previously been or are currently providing consulting services to, other biopharmaceutical companies, including our competitors or potential competitors. We may become subject to claims related to whether these individuals have inadvertently or otherwise used, disclosed or misappropriated trade secrets or other proprietary information of their former employers or their former or current clients. Litigation may be necessary to defend against these claims. Even if we are successful in defending these claims, litigation could result in substantial costs and be a distraction to management and/or the employees or consultants that are implicated.The market price of our securities may be volatile and may fluctuate in a way that is disproportionate to our operating performance.The stock prices of our securities may experience substantial volatility as a result of a number of factors, including, but not necessarily limited to:â—announcements we make regarding our current product candidates, acquisition of potential new product candidates and companies and/or in-licensing through multiple partners/affiliates;â—sales or potential sales of substantial amounts of our Common Stock;â—issuance of debt or other securities;â—our delay or failure in initiating or completing pre-clinical or clinical trials or unsatisfactory results of any of these trials;â—announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions;91 Table of Contentsâ—developments concerning our licensors and/or product manufacturers;â—litigation and other developments relating to our patents or other proprietary rights or those of our competitors;â—conditions in the pharmaceutical or biotechnology industries;â—governmental regulation and legislation;â—unstable regional political and economic conditions;â—variations in our anticipated or actual operating results; andâ—change in securities analystsâ€™ estimates of our performance, or our failure to meet analystsâ€™ expectations.Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnological companies in particular, have historically experienced extreme price and volume fluctuations. These fluctuations often have been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors could reduce the market prices of our securities, regardless of our actual operating performance.Sales or other issuances of a substantial number of shares of our Common Stock, or the perception that such sales or issuances may occur, may adversely impact the price of our Common Stock.Almost all of our outstanding shares of our Common Stock, inclusive of outstanding equity awards, are available for sale in the public market, either pursuant to Rule 144 under the Securities Act of 1933, as amended (the â€œSecurities Actâ€), or an effective registration statement. In addition, pursuant to our current shelf registration statements on Form S-3, from time to time we may issue and sell shares of our Common Stock or Series A Preferred Stock having an aggregate offering price of up to $100.1 million. Any sale of a substantial number of shares of our Common Stock or our Series A Preferred Stock could cause a drop in the trading price of our Common Stock or Series A Preferred Stock on the Nasdaq Stock Market.We may not be able to manage our anticipated growth, which may in turn adversely impact our business.We will need to continue to expend capital on improving our infrastructure to address our anticipated growth. Acquisitions of companies or products could place a strain on our management, and administrative, operational and financial systems. In addition, we may need to hire, train, and manage more employees, focusing on their integration with us and corporate culture. Integration and management issues associated with increased acquisitions may require a disproportionate amount of our managementâ€™s time and attention and distract our management from other activities related to running our business.A catastrophic disaster could damage our facilities beyond insurance limits or cause us to lose key data, which could cause us to curtail or cease operations.We are vulnerable to damage and/or loss of vital data from natural disasters, such as earthquakes, tornadoes, power loss, fire, health epidemics and pandemics, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our businesses could be seriously impaired. We have property, liability and business interruption insurance that may not be adequate to cover losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects. Any of the aforementioned circumstances, may also impede our employeesâ€™ and consultantsâ€™ abilities to provide services in-person and/or in a timely manner; hinder our ability to raise funds to finance our operations on favorable terms or at all; and trigger effectiveness of â€œforce majeureâ€ clauses under agreements with respect to which we receive goods and services, or under which we are obligated to achieve developmental milestones on certain timeframes. Disputes with third parties over the applicability of such â€œforce majeureâ€ clauses, or the enforceability of developmental milestones and related extension mechanisms in light of such business interruptions, may arise and may become expensive and time-consuming.92 Table of ContentsOur ability to use our pre-change NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.We may, from time to time, carry net operating loss carryforwards (â€œNOLsâ€) as deferred tax assets on our balance sheet.Â Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an â€œownership changeâ€ (generally defined as a greater than 50-percentage- point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporationâ€™s ability to use all of its pre-change NOLs and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership, some of which changes are outside our control. As a result, our ability to use our pre-change NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.We, and/or third parties on our behalf, may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations may also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property and casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or penalized with fines in an amount exceeding our respective resources, and clinical trials or regulatory approvals could be suspended.Although we maintain workersâ€™ compensation insurance to cover costs and expenses incurred due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted in connection with the storage or disposal of biological or hazardous materials.In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.â€‹Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, ability to accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business or the business of our partners. For example, over the last several years, including for 35 days beginning on DecemberÂ 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough nonessential FDA employees and stop routine activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If the timing of FDAâ€™s review and approval of new products is delayed, the timing of our or our partnersâ€™ development process may be delayed, which could result in delayed milestone revenues and materially harm our operations or business.93 Table of ContentsWe will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. Also, if we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investorsâ€™ views of us and, as a result, the value of our Securities.As a public company, we incur significant legal, accounting and other expenses under the Sarbanes-Oxley Act (â€œSOXâ€), as well as rules subsequently implemented by the SEC, and the rulesÂ of the Nasdaq Stock Exchange. These rulesÂ impose various requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and appropriate corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rulesÂ and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rulesÂ and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.SOX requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. As a result, we are required to periodically perform an evaluation of our internal controls over financial reporting to allow management to report on the effectiveness of those controls, as required by SectionÂ 404 of SOX. These efforts to comply with SectionÂ 404 and related regulations have required, and continue to require, the commitment of significant financial and managerial resources. While we anticipate maintaining the integrity of our internal controls over financial reporting and all other aspects of SectionÂ 404, we cannot be certain that a material weakness will not be identified when we test the effectiveness of our control systems in the future. If a material weakness is identified, we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources, costly litigation or a loss of public confidence in our internal controls, which could have an adverse effect on the market price of our stock.Provisions in our certificate of incorporation, our bylaws and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the trading price of our Common Stock or other Securities.Provisions of our certificate of incorporation, our bylaws and Delaware law may have the effect of deterring unsolicited takeovers and/or delaying or preventing a change in control of our Company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then-current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interests. These provisions include:â—the inability of stockholders to call special meetingsÍ¾ andâ—the ability of our Board of Directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could include the right to approve an acquisition or other change in our control or could be used to institute a rights plan, also known as a poison pill, that would work to dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been approved by our Board of Directors.In addition, the Delaware General Corporation Law prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our Common Stock. They could also deter potential acquirers of our Company, thereby reducing the likelihood that you would receive a premium for your ownership of our Securities through an acquisition.94 Table of ContentsIf we fail to comply with the continuing listing standards of Nasdaq, our common stock could be delisted from the exchange.We have previously failed to satisfy certain continued listing rules of the Nasdaq, including rules requiring that the minimum trading price of our Common Stock not close below $1.00 per share for 30 consecutive business days. If

we again are unable to meet the continued listing requirements, our Common Stock and Preferred Stock may be subject to delisting from The Nasdaq Capital Market if we are unable to regain compliance with such rules. The delisting of our Securities from the Nasdaq may decrease the market liquidity and market price of our Common Stock and Preferred Stock.Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations.New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. For example, the United States recently passed the Inflation Reduction Act, which provides for a minimum tax equal to 15% of the adjusted financial statement income of certain large corporations, as well as a 1% excise tax on certain share buybacks by public corporations that would be imposed on such corporations. In addition, it is uncertain if and to what extent various states will conform to newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.â€‹Item 2. Â Â Â Â Â Unregistered Sales of Equity Securities and Use of ProceedsNone.â€‹Item 3. Â Â Â Â Â Defaults Upon Senior SecuritiesNone.â€‹Item 4. Â Â Â Â Â Mine Safety DisclosuresNone.â€‹Item 5. Â Â Â Â Â Other InformationNone.â€‹Item 6. Â Â Â Â Â Exhibits Exhibit IndexExhibitNumberÂ Â Â Â Exhibit TitleÂ Â Â 3.1â€‹Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. (formerly Coronado Biosciences, Inc.) dated April 21, 2010 (incorporated by reference to Exhibit 3.1 of the Registrantâ€™s Form 10 (file No. 000-54463) filed with the SEC on July 15, 2011).â€‹â€‹â€‹3.2â€‹First Certificate of Amendment of Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated May 20, 2011 (incorporated by reference to Exhibit 3.2 of the Registrantâ€™s Form 10 (file No. 000-54463) filed with SEC on July 15, 2011).â€‹â€‹â€‹3.3â€‹Second Certificate of Amendment of Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated October 1, 2013 (incorporated by reference to Exhibit 3.8 of the Registrantâ€™s Annual Report on Form 10-K (file No. 001-35366) filed with SEC on March 14, 2014).â€‹â€‹â€‹95 Table of Contents3.4â€‹Third Certificate of Amendment of Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated April 22, 2015 (incorporated by reference to Exhibit 3.9 of the Registrantâ€™s Current Report on Form 8-K (file No. 001-35366) filed with SEC on April 27, 2015). â€‹â€‹â€‹3.5â€‹Certificate of Designation of Rights and Preferences of the Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (incorporated by reference to Exhibit 3.1 of the Registrantâ€™s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on November 7, 2017).â€‹â€‹â€‹3.6â€‹Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated June 18, 2020 (incorporated by reference to Exhibit 3.1 of the Registrantâ€™s Current Report on Form 8-K (file No. 001-35366) filed with SEC on June 19, 2020).â€‹â€‹â€‹3.7â€‹Certificate of Amendment to the Certificate of Designations and Rights and Preferences of the Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock under the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated June 18, 2020 (incorporated by reference to Exhibit 3.2 of the Registrantâ€™s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on June 19, 2020).â€‹â€‹â€‹3.8â€‹Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated June 23, 2021 (incorporated by reference to Exhibit 3.1 of the Registrantâ€™s Form 10-K (file No. 001-35366) filed with SEC on June 23, 2021). â€‹â€‹â€‹3.9â€‹Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated July 8, 2022 (incorporated by reference to Exhibit 3.1 of the Registrantâ€™s Form 8-K (file No. 001-35366) filed with SEC on July 11, 2022). â€‹â€‹â€‹3.10â€‹Certificate of Amendment of the Amended and Restated Certificate of Incorporation, as Amended, of Fortress Biotech, Inc. dated October 9, 2023 (incorporated by reference to Exhibit 3.1 of the Registrantâ€™s Form 8-K (file No. 001-35366) filed with SEC on October 10, 2023. â€‹â€‹â€‹â€‹â€‹3.11â€‹Fourth Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 of the Registrantâ€™s Current Report on Form 8-K (file No. 001-35366) filed with SEC on June 25, 2024). â€‹â€‹â€‹10.1â€‹Amendment to the Fortress Biotech, Inc. 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrantâ€™s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on May 29, 2024.â€‹â€‹â€‹â€‹â€‹â€‹â€‹10.2â€‹Amendment to the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 of the Registrantâ€™s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on May 29, 2024.â€‹10.3â€‹Amendment to the Fortress Biotech, Inc. Amended and Restated Long Term Incentive Plan (incorporated by reference to Exhibit 10.3 of the Registrantâ€™s Current Report on Form 8-K (file No. 001-35366) filed with the SEC on May 29, 2024.â€‹â€‹â€‹â€‹31.1Â Certification of Chairman, President and Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (*)â€‹â€‹â€‹â€‹31.2â€‹Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.(*)â€‹â€‹â€‹â€‹32.1Â Certification of the Chairman, President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(**)Â Â Â 32.2Â Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(**)96 Table of Contentsâ€‹101.INSÂ Inline XBRL Instance Document.(*)Â Â Â Â 101.SCHÂ Inline XBRL Taxonomy Extension Schema Document.(*)Â Â Â Â 101.CALÂ Inline XBRL Taxonomy Extension Calculation Linkbase Document.(*)Â Â Â Â 101.DEFÂ Inline XBRL Taxonomy Extension Definition Linkbase Document.(*)Â Â Â Â 101.LABÂ Inline XBRL Taxonomy Extension Label Linkbase Document.(*)Â Â Â Â 101.PREÂ Inline XBRL Taxonomy Extension Presentation Linkbase Document.(*)â€‹â€‹â€‹â€‹104â€‹Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).â€‹*Â Filed herewith.** Furnished herewith.â€‹â€‹â€‹97 Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.â€‹August 13, 2024FORTRESS BIOTECH, INC.Â Â Â Â By:Â /s/ Lindsay A. Rosenwald, M.D.Â Â Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer (Principal Executive Officer)Â Â Â August 13, 2024By:/s/ David JinÂ Â David Jin, Chief Financial Officer (Principal Financial Officer)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹98 EX-31.1 2 fbio-20240630xex31d1.htm EX-31.1 Exhibit 31.1â€‹CERTIFICATION PURSUANT TOSECTION 302 OF THE SARBANES-OXLEY ACT OF 2002â€‹I, Lindsay A. Rosenwald, M.D., certify that:â€‹(1)Â Â Â Â Â Â Â Â Â Â I have reviewed this Quarterly Report on Form 10-Q of Fortress Biotech, Inc. (the â€œRegistrantâ€);â€‹(2)Â Â Â Â Â Â Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹(3)Â Â Â Â Â Â Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;â€‹(4)Â Â Â Â Â Â Â Â Â Â The Registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15 (f)) for the Registrant and have:â€‹a.Â Â Â Â Â Â Â Â Â Â designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b.Â Â Â Â Â Â Â Â Â Â designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c.Â Â Â Â Â Â Â Â Â Â evaluated the effectiveness of the Registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d.Â Â Â Â Â Â Â Â Â Â disclosed in this report any change in the Registrantâ€™s internal control over financial reporting that occurred during the Registrantâ€™s most recent fiscal quarter (the Registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrantâ€™s internal control over financial reporting; andâ€‹(5)Â Â Â Â Â Â Â Â Â Â The Registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrantâ€™s auditors and the audit committee of the Registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹a.Â Â Â Â Â Â Â Â Â Â all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b.Â Â Â Â Â Â Â Â Â Â any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrantâ€™s internal control over financial reporting.â€‹â€‹â€‹â€‹Dated: August 13, 2024By:/s/ Lindsay A. Rosenwald, M.D.â€‹â€‹Lindsay A. Rosenwald, M.D.â€‹â€‹Chairman, President and Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹ EX-31.2 3 fbio-20240630xex31d2.htm EX-31.2 Exhibit 31.2â€‹CERTIFICATION PURSUANT TOSECTION 302 OF THE SARBANES-OXLEY ACT OF 2002â€‹I, David Jin, certify that:â€‹(1)Â Â Â Â Â Â Â Â Â Â I have reviewed this Quarterly Report on Form 10-Q of Fortress Biotech, Inc. (the â€œRegistrantâ€);â€‹(2)Â Â Â Â Â Â Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹(3)Â Â Â Â Â Â Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;â€‹(4)Â Â Â Â Â Â Â Â Â Â The Registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15 (f)) for the Registrant and have:â€‹a.Â Â Â Â Â Â Â Â Â Â designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b.Â Â Â Â Â Â Â Â Â Â designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c.Â Â Â Â Â Â Â Â Â Â evaluated the effectiveness of the Registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d.Â Â Â Â Â Â Â Â Â Â disclosed in this report any change in the Registrantâ€™s internal control over financial reporting that occurred during the Registrantâ€™s most recent fiscal quarter (the Registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrantâ€™s internal control over financial reporting; andâ€‹(5)Â Â Â Â Â Â Â Â Â Â The Registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrantâ€™s auditors and the audit committee of the Registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹a.Â Â Â Â Â Â Â Â Â Â all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b.Â Â Â Â Â Â Â Â Â Â any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrantâ€™s internal control over financial reporting.â€‹â€‹â€‹â€‹Dated: August 13, 2024By:/s/ David Jinâ€‹â€‹David Jinâ€‹â€‹Chief Financial Officerâ€‹â€‹(Principal Financial Officer)â€‹ EX-32.1 4 fbio-20240630xex32d1.htm EX-32.1 Exhibit 32.1â€‹CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Quarterly Report on Form 10-Q of Fortress Biotech, Inc. (the â€œCompanyâ€) for the quarterly period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Lindsay A. Rosenwald, M.D., Chairman, President, and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:â€‹(1)Â Â Â Â Â Â Â Â Â Â The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; andâ€‹(2)Â Â Â Â Â Â Â Â Â Â The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹â€‹Dated: August 13, 2024By:/s/ Lindsay A. Rosenwald, M.D.â€‹â€‹Lindsay A. Rosenwald, M.D.â€‹â€‹Chairman, President and Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹ EX-32.2 5 fbio-20240630xex32d2.htm EX-32.2 Exhibit 32.2â€‹CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Quarterly Report on Form 10-Q of Fortress Biotech, Inc. (the â€œCompanyâ€) for the quarterly period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, David Jin, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:â€‹(1)Â Â Â Â Â Â Â Â Â Â The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; andâ€‹(2)Â Â Â Â Â Â Â Â Â Â The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹â€‹Dated: August 13, 2024By:/s/ David Jinâ€‹â€‹David Jinâ€‹â€‹Chief Financial Officerâ€‹â€‹(Principal Financial Officer)â€‹ EX-101.SCH 6 fbio-20240630.xsd EX-101.SCH 995200100 - Statement - Unaudited Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Unaudited Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Inventory (Schedule of Inventory) (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Property and Equipment (Schedule of Property, Plant and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - Intangible Assets (Schedule of Future Amortization of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Debt and Interest (Schedule of Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - Debt and Interest (Interest Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 99941402 - Disclosure - Commitments and Contingencies (Lease Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 99941404 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details) link:presentationLink link:calculationLink link:definitionLink 41404 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 99941602 - Disclosure - Segment Information (Schedule of Segment Information) (Details) link:presentationLink link:calculationLink link:definitionLink 99941603 - Disclosure - Segment Information (Total assets by reportable segment) (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Asset Purchase Agreements link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Intangible, net link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Debt and Interest link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Non-Controlling Interests link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211501 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995211601 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995211701 - Disclosure - Revenues from Contracts and Significant Customers link:presentationLink link:calculationLink link:definitionLink 995211801 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211901 - Disclosure - Subsequent Events link:presentationLink

link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Debt and Interest (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99931303 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 99931403 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 99931503 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 99931603 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99931703 - Disclosure - Revenues from Contracts and Significant Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Organization and Description of Business (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Asset Purchase Agreements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Property and Equipment (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Fair Value Measurements (Common Stock Warrant Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Fair Value Measurements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - Fair Value Measurements (Weighted average Significant Unobservable Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Debt and Interest (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Non-Controlling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Net Income (Loss) per Common Share (Schedule of Diluted Weighted Average Shares Outstanding) (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 99941302 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941303 - Disclosure - Stockholders' Equity (Stock Option Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 99941305 - Disclosure - Stockholders' Equity (Restricted Stock Awards and Restricted Stock Units) (Details) link:presentationLink link:calculationLink link:definitionLink 99941306 - Disclosure - Stockholders' Equity (Schedule of Warrant activities) (Details) link:presentationLink link:calculationLink link:definitionLink 99941307 - Disclosure - Stockholders' Equity (Capital Raises) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941403 - Disclosure - Commitments and Contingencies (Quantitative Information about Operating Leases) (Details) link:presentationLink link:calculationLink link:definitionLink 99941501 - Disclosure - Related Party Transactions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941502 - Disclosure - Related Party Transactions (PIK Dividend or Equity Fee Payable) (Details) link:presentationLink link:calculationLink link:definitionLink 99941503 - Disclosure - Related Party Transactions (Management Services Agreement) (Details) link:presentationLink link:calculationLink link:definitionLink 99941601 - Disclosure - Segment Information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941701 - Disclosure - Revenues from Contracts and Significant Customers (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941702 - Disclosure - Revenues from Contracts and Significant Customers (Company's product revenue) (Details) link:presentationLink link:calculationLink link:definitionLink 99941801 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 99941901 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 fbio-20240630_cal.xml EX-101.CAL EX-101.DEF 8 fbio-20240630_def.xml EX-101.DEF EX-101.LAB 9 fbio-20240630_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Common Stock [Member] Common Stock Series A cumulative redeemable perpetual preferred stock. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock [Member] 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Unaudited Condensed Consolidated Balance Sheets Statement [Table] Statement [Table] Related Party [Axis] Related Party [Domain] Other Affiliates [Member] Related Party Statement Commitments and Contingencies Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivable, net Inventory, Net Inventory Total inventories Accounts and Other Receivables, Net, Current Other receivables - related party Receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Amount representing assets held for sale. Assets held for sale Assets held for sale Assets, Current Total current assets Property, Plant and Equipment, Net Property, plant and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use asset, net Restricted Cash and Cash Equivalents, Noncurrent Restricted cash Finite-Lived Intangible Assets, Net Intangible assets, net Net intangible assets Intangible assets, net Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current [Abstract] Current liabilities Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Taxes Payable, Current Income taxes payable Represents information pertaining to warrant liabilities current. Warrant Liabilities Current Common Stock Warrant liabilities at end of period Common Stock Warrant liabilities at beginning of period Common stock warrant liabilities Operating Lease, Liability, Current Operating lease liabilities, short-term Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to convertible preferred shares. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Convertible Preferred Shares, Current Partner company convertible preferred shares, short-term, net Partner company installment payments - licenses, short-term, net of imputed interest. Partner company installment payments - licenses, current Partner company installment payments - licenses, short-term, net Other Liabilities, Current Other short-term liabilities Liabilities, Current Total current liabilities Notes Payable, Noncurrent Notes payable, long-term, net Operating Lease, Liability, Noncurrent Operating lease liabilities, long-term Other Liabilities, Noncurrent Other long-term liabilities Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 14) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity (deficit) Preferred Stock, Value, Issued Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively, liquidation value of $25.00 per share Common Stock, Value, Issued Common stock, $0.001 par value, 200,000,000 shares authorized, 22,587,038 and 15,093,053 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in-capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity attributed to the Company Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interests Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total stockholders' equity (deficit) Liabilities and Equity Total liabilities and stockholders' equity (deficit) Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value Preferred Stock, Shares Authorized Preferred Stock, shares authorized It represents number of preferred stock shares designated. Preferred Stock shares designated Preferred Stock, Shares Issued Preferred Stock, shares issued Preferred Stock, Shares Outstanding Preferred Stock, shares outstanding Preferred Stock, Liquidation Preference Per Share Preferred Stock, liquidation preference per share Common Stock, Par or Stated Value Per Share Common Stock, par value Common Stock, Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Common Stock, Shares, Outstanding Common Stock, shares outstanding Unaudited Condensed Consolidated Statements of Operations Related Party [Member] Related Party Revenues from Contracts and Significant Customers. Revenue Revenue from Contract with Customer, Including Assessed Tax Product revenue, net Product revenue, net Collaboration revenue. Collaboration revenue Collaboration revenue Revenue Not from Contract with Customer Revenue - related party Other Income Other revenue Revenues Net revenue Net Revenue Operating Expenses [Abstract] Operating expenses Cost of Goods and Services Sold Cost of goods - product revenue Cost of goods sold - product revenue Research and Development Expense (Excluding Acquired in Process Cost) Research and development Research and Development Asset Acquired Other than Through Business Combination, Written-off Research and development - licenses acquired Selling, General and Administrative Expense Selling, general and administrative Selling, general and administrative Asset Impairment Charges Asset impairment Asset impairment Impairment loss Costs and Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense) Investment Income, Interest Interest income Amount of the cost of borrowed funds accounted for as interest expense and amount of debt issuance costs. Interest Expense And Finance Fees Interest expense and financing fee Fair Value Adjustment of Warrants Change in fair value of warrant liabilities Gain (loss) on common stock warrant liabilities Change in fair value of Warrant liabilities Amount of gain (loss) on common stock warrant liabilities. Gain/Loss on common stock warrant liabilities Gain (loss) on common stock warrant liabilities Amount of gain (loss) from deconsolidation of subsidiaries. Gain (Loss) from Deconsolidation of Subsidiaries Loss from deconsolidation of subsidiaries Other income (expense) Other income (expense) Nonoperating Income (Expense) Total other income (expense) Other expense Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net loss Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to non-controlling interests Net loss attributable to Fortress Net loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders Earnings Per Share, Basic Net loss per common share attributable to common stockholders - basic Earnings Per Share, Diluted Net loss per common share attributable to common stockholders - diluted Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding - basic Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding - diluted Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) Equity Components [Axis] Equity Component [Domain] Parent [Member] Preferred Stock [Member] Preferred Stock Represents information pertaining to Common shares that are issuable Common Shares Issuable [Member] Common Shares Issuable Additional Paid-In Capital [Member] Additional Paid-In Capital Accumulated Deficit [Member] Accumulated Deficit Non-Controlling Interests [Member] Non-Controlling Interests Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Employee Stock Purchase Program, Requisite Service Period Recognition Stock-based compensation expense Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Issuance of common stock related to equity plans Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Issuance of common stock related to equity plans (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock for public offering, net Aggregate purchase price Stock Issued During Period, Shares, New Issues Issuance of stock for public offerings, net (in shares) Shares issued Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under ESPP Shares purchased in connection with the ESPP offering Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under ESPP (in shares) Value of stock issued during period for cash at the market cost. Issuance of Common Stock for At the Market Offering Issuance of common stock for at-the-market offering, net It represents the stock issued during period shares issued for cash at market cost. Issuance of Common Stock for At the Market Offering in shares Issuance of common stock for at-the-market offering, net (in shares) Value of stock issued during period for dividend on partner company's convertible preferred shares. Common shares issued for dividend on partner company's convertible preferred shares Common shares issued for dividend on partner company's convertible preferred shares It represents the stock issued during period shares issued for partner company's convertible preferred shares. Common shares issued for dividend on partner company's convertible preferred shares (in shares) Value of stock issued during period for exchange of partner company's convertible preferred shares. Common shares issued for exchange of partner company's convertible preferred shares It represents the stock issued during period shares issued for exchange of partner company's convertible preferred shares. Common shares issued for exchange of partner company's convertible preferred shares (in shares) Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Exercise of warrants for cash Number of stock issued as a result of the exercise of warrants. Stock Issued During Period, Shares, Warrants Exercised Exercise of warrants for cash (in shares) Partner company's equity offering, excluding at-the-market issuances. Partner Company Equity Offering Partner company's offering, net Amount of decrease in additional paid in capital (APIC) resulting from subsidiary's at market offering costs. Adjustments To Additional Paid In Capital Subsidiary At Market Offering Partner company's at-the-market offering, net Amount charged from warrants in conjunction with exchange of partner company's convertible preferred shares. Warrants issued in conjunction with exchange of partner company's convertible preferred shares Partner company's exercise of stock options for the purpose of cash. Partner company exercise of options for cash Partner companies' proceeds from options and warrants, net Partner company's exercise of options for cash. Partner Company's Exercise Of Options For Cash Partner company's exercise of options for cash Issuance of common stock under partner company's Employee stock purchase program Issuance of common stock under partner company's Employee stock purchase program Issuance of common stock under partner company's ESPP Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings Preferred A dividends declared and paid Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of common stock. Adjustments To Additional Paid In Capital Dividends In Excess Of Common Stock Partner company's dividends declared and paid Amount of decrease in additional paid in capital resulting from stock issuance for research and development expenses. Adjustments To Additional Paid In Capital Stock Issued For research and development expenses Issuance of partner company's common shares for research and development expenses Amount of warrants issued in conjunction with debt. Partner company's warrants issued in conjunction with debt Value of stock issued during the period relating to cashless exercise of warrants. Stock Issued During Period Value Cash Less Exercise Of Warrants Warrants Partner company's warrants issued in conjunction with debt Noncontrolling Interest, Decrease from Deconsolidation Deconsolidation/dissolution of subsidiary non-controlling interests Amount of increase in additional paid in capital (APIC) resulting from the exercise of partner company options and warrants. Adjustments to Additional Paid in Capital, Exercise of Partner Company Options and Warrants Exercise of partner company options and warrants for cash, net Amount of decrease/increase in additional paid in capital (APIC) and non controlling interest in subsidiaries. Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance Non-controlling interest in partner companies Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest Net loss attributable to non-controlling interest Unaudited Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Reconciliation of net loss to net cash used in operating activities: Depreciation Depreciation expense Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of property and equipment Provision for Doubtful Accounts Bad debt expense Amortization of Debt Discount (Premium) Amortization of debt discount Accretion of partner company convertible preferred shares. Accretion of partner company convertible preferred shares Accretion of partner company convertible preferred shares Non Cash Interest Expense Non-cash interest Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Amortization of Intangible Assets Amortization of acquired intangible assets Amortization Of Operating Lease Right Of Use Asset Reduction in the carrying amount of operating lease right-of-use assets Share-based Compensation Stock-based compensation expense Amount of issuance of common stock for research and development expenses. Issuance Of Common Stock For Research And Development Expenses Issuance of partner company's common shares for research and development expenses Amount of expenses associated with partner company warrant liabilities. Expense Associated With Partner Company Warrant Liabilities Expense associated with partner company warrant liabilities Fair value of common shares issued for exchange of partner company's convertible preferred shares. Common Shares Issued For Exchange Of Partner Company Convertible Preferred Shares Common shares issued for dividend on partner company's convertible preferred shares Research and development-licenses acquired, expense Research and development-

licenses acquired, expense Research and development - licenses acquired, expense Amount of gain (loss) from deconsolidation and dissolution of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. Deconsolidation and Dissolution, Gain (Loss), Amount Loss from deconsolidation/dissolution of subsidiaries Impairment, Long-Lived Asset, Held-for-Use Asset impairment loss Increase (Decrease) in Operating Capital [Abstract] Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) Due from Other Related Parties Other receivables - related party Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Income Taxes Payable Income taxes payable The increase decrease in lease liabilities. Increase Decrease In Lease Liabilities Lease liabilities Increase (Decrease) in Other Operating Liabilities Other long-term liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows from Investing Activities: Payments to Acquire in Process Research and Development Purchase of research and development licenses Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments for (Proceeds from) Other Investing Activities Other Cash proceeds from (payments for) sale or purchase of VYNE products. Proceeds From Sale (Payments for Acquisition) Of VYNE Products Acquisition of VYNE products Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities: Payments of Ordinary Dividends, Preferred Stock and Preference Stock Payment of Series A perpetual preferred stock dividends The cash inflow from the additional capital contribution to the entity excluding at-the-market offerings. Proceeds From Issuance Of Common Stock, Excluding At-The-Market Offerings Proceeds from issuance of common stock for public offering, net Proceeds from Issuance of Common Stock Proceeds from issuance of common stock for at-the-market offering, net Proceeds from issuance of Common stock The cash inflow from the additional capital contribution to the entity from under the Employee Stock Purchase Plan Proceeds from issuance of common stock under ESPP Proceeds from issuance of common stock under ESPP Proceeds from Warrant Exercises Exercise of warrants for cash The amount of cash inflow from subsidiary's employee stock purchase plan (ESPP). Proceeds From Subsidiary's Employee Stock Purchase Plan Proceeds from partner companies' ESPP Payments of Ordinary Dividends, Common Stock Partner company's dividends declared and paid Proceeds from partner companies' sale of stock and warrants Proceeds From Partner Companies Sale of Stock and Warrants, Net Proceeds from partner companies' sale of stock, options and warrants, net The cash inflow from the issuance of subsidiaries at the market offering capital contribution to the entity. Proceeds From Issuance Of Subsidiaries At Market Offering Proceeds from partner companies' at-the-market offering, net The cash inflow from exercise of equity grants. Proceeds From Exercise Of Equity Grants Proceeds from exercise of partner companies' equity grants The cash inflow from issuance of partners company preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. Proceeds From Issuance Of Partner Company Convertible Preferred Shares Proceeds from partner company convertible preferred shares Amount of cash inflow from stock and warrants issued for exchange of partner company preferred shares. Proceeds From Stock And Warrants Issued For Exchange Of Partner Company Preferred Shares Stock and warrants issued for exchange of partner company preferred shares Payment of debt issuance costs associated with partner company share-settled notes Payment of debt issuance costs associated with partner company share-settled notes Payment of debt issuance costs associated with partner company convertible preferred shares Proceeds from (Repayments of) Related Party Debt Proceeds from partner companies' long-term debt, net Repayments of Debt Repayment of partner companies' long-term debt Proceeds from Long-term Lines of Credit Proceeds from partner company's line of credit Repayments of Long-term Lines of Credit Repayment of partner company's line of credit Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents and restricted cash at end of period Cash and cash equivalents and restricted cash at beginning of period Total cash and cash equivalents and restricted cash Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Income Taxes Paid, Net Cash paid (refunded) for income taxes Other Noncash Investing and Financing Items [Abstract] Supplemental disclosure of non-cash financing and investing activities: Transfer to Investments Transfer of assets classified as held for sale Amount of exchange of partner company convertible preferred shares, classified as non-cash activities. Exchange of Partner Company Convertible Preferred Shares Exchange of partner company convertible preferred shares Amount of exchange fair value of assets received by partner company in repurchase transaction. Fair value of assets received by partner company in repurchase transaction Amount of exchange fair value of supplies received by partner company expensed to research and development Fair value of supplies received by partner company expensed to research and development Amount of exchange of partner company accounts receivable write-off related to repurchase transaction Partner company accounts receivable write-off related to repurchase transaction Amount of Partner company accounts payable write-off related to repurchase transaction. Partner company accounts payable write-off related to repurchase transaction Amount of Partner company's net purchase consideration of assets recorded to accrued other. Partner company's net purchase consideration of assets recorded to accrued other The fair value of common stock issued for settlement of restricted stock unit. Settlement Of Restricted Shares Units Into Common Stock Settlement of restricted stock units into common stock The amount of unpaid partner company's offering cost that were incurred during a noncash or partial noncash transaction. Unpaid Partner Company Offering Cost Unpaid partner company's offering cost Partner company derivative warrant liability associated with partner company share-settled notes Partner company derivative warrant liability associated with partner company share-settled notes Partner company derivative warrant liability associated with partner company convertible preferred shares Amount of future offering costs paid for in current reporting period. Prepaid Offering Costs Prepaid public offering cost Organization and Description of Business Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Organization and Description of Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies No definition available. Asset Purchase Agreements Disclosure of collaboration and stock purchase agreement text block. Disclosure Of Collaboration And Stock Purchase Agreement [Text Block] Asset Purchase Agreements Inventory Inventory Disclosure [Text Block] Inventory Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Intangible Assets, net Intangible Assets Disclosure [Text Block] Intangible Assets, net na. License Agreements The entire disclosure for research and development licenses agreements. Licenses Agreements [Text Block] License Agreements Debt and Interest Debt Disclosure [Text Block] Debt and Interest Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Expenses Non-Controlling Interests Noncontrolling Interest Disclosure [Text Block] Non-Controlling Interests Net Loss per Common Share Earnings Per Share [Text Block] Net Loss per Common Share Stockholders' Equity Shareholders' Equity and Share-based Payments [Text Block] Stockholders' Equity Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Segment Information Segment Reporting Disclosure [Text Block] Segment Information Revenues from Contracts and Significant Customers Revenue from Contract with Customer [Text Block] Revenues from Contracts and Significant Customers Income Taxes Income Tax Disclosure [Text Block] Income Taxes Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation and Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Disclosure of accounting policy for significant accounting policies. Significant Accounting Policies [Policy Text Block] Significant Accounting Policies Disclosure of accounting policy for assets held for sale. Assets Held For Sale Policy Text Block Assets Held for Sale New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Cash and Cash Equivalents and restricted cash Schedule of Inventory, Current [Table Text Block] Schedule of Inventory Property, Plant and Equipment [Table Text Block] Schedule of Property, Plant and Equipment Financial Instrument [Axis] Financial Instruments [Domain] Warrants to Purchase Common Stock [Member] Warrants to purchase Common Stock Warrants to purchase Common Stock Consolidated Entities [Axis] Consolidated Entities [Domain] Represents information relating to Checkpoint. Checkpoint [Member] Checkpoint Common Stock Warrants Checkpoint Represents information pertaining to Avenue Therapeutics, Inc. Avenue Therapeutics, Inc [Member] Avenue UR-1 Therapeutics, Inc [Member] UR-1 Therapeutics, Inc [Member] Urica Tabular disclosure of revaluation of warrant liability. Schedule of Revaluation of Warrant Liability [Table Text Bloc] Schedule of revaluation of warrant liability Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Summary of the Weighted average Significant Unobservable Inputs Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Schedule of Journey intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of future amortization of intangible assets Schedule of Debt [Table Text Block] Schedule of Debt Tabular disclosure of interest expenses for debt arrangements. Schedule Of Interest Expenses For Debt Arrangements [Table Text Block] Interest Expense for all Debt Arrangements Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued expenses Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Diluted Weighted Average Shares Outstanding Share-based Compensation, Activity [Table Text Block] Schedule of Stock-Based Compensation Expense Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] Schedule of Stock Option Activities Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Restricted Stock Awards and Restricted Stock Units Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Warrant activities Lease, Cost [Table Text Block] Schedule of lease expense Lessee Lease Portfolio and Other Supplemental Lease Information Lessee Lease Portfolio and Other Supplemental Lease Information Summary of Quantitative Information about Operating Leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Future Minimum Lease Payments Tabular disclosure of effective date and equity fee payable. Schedule Of Effective Date And Equity Fee Payable [Table Text Block] Schedule of effective date and PIK dividend or equity fee payable Dividends Declared [Table Text Block] Schedule of PIK dividend or equity fee recorded Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Segment Information Disaggregation of Revenue [Table Text Block] Schedule of disaggregation of total revenues Number of partner companies that are publicly traded. Number Of Partner Companies That Are Publicly Traded Number of partner companies that are publicly traded Number of partner companies that have consummated strategic partnerships with industry leaders. Number Of Partner Companies That Have Consummated Strategic Partnerships With Industry Leaders Number of partner companies that have consummated strategic partnerships with industry leaders Sale of Stock, Consideration Received on Transaction Sale of National Holding's stock, proceeds received Sale of stock, net proceeds Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits for the parent company. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Cash and cash equivalents, Parent Company Accounting Policies [Table] Accounting Policies [Table] Range [Axis] Range [Domain] Maximum Maximum Scenario [Axis] Scenario, Unspecified [Domain] Maintains Voting Control [Member] Maintains Voting Control [Member] Maintains Voting Control Credit Facility [Axis] Credit Facility [Domain] Represents information pertaining to debt obligations and letters of credit. Debt Obligations And Letters of Credit [Member] Debt obligations and letters of credit Accounting Policies [Line Items] Accounting Policies [Line Items] Ownership percentage of the subsidiary to consolidate their accounts Ownership percentage of the subsidiary to consolidate their accounts Restricted Cash and Cash Equivalents Restricted cash Represents the scenario where Assets fall below 20 million. Net Assets Below 20 Million [Member] Net Assets Below 20 Million Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Events Subsequent events Represents information relating to Mustang Therapeutics Inc. Mustang Mustang Counterparty Name [Axis] Counterparty Name [Domain] Information related to InvaGen Pharmaceuticals Inc. InvaGen [Member] InvaGen Asset Acquisition [Axis] Asset Acquisition [Domain] Represents information relating to uBriGene (Boston) Biosciences, Inc. UBriGene (Boston) Biosciences, Inc. [Member] UBriGene Asset Acquisition, Consideration Transferred Consideration Transferred The fair value of assets after costs to sell under the repurchase transaction. Fair Value of Assets less Cost to Sell in Repurchase Transaction Fair value of assets less cost to sell in repurchase transaction Amount of consideration in excess of fair value of the asset allocated to supplies repurchased. Asset Acquisition, Consideration Transferred, in Excess of Fair Value of Assets, Allocated to Supplies Remaining purchase consideration allocated to the supplies repurchased Amount of exchange fair value of supplies with no alternative future use expensed as research and development expense. Fair Value of Supplies With No Alternative Future Use Expensed as Research and Development Expense Fair value of supplies with no alternative future use expensed as research and development expense Amount of exchange fair value of supplies with alternative future use expensed as research and development expense. Fair Value of Supplies With Alternative Future Use Expensed as Research and Development Expense Asset, Held-for-Sale, Not Part of Disposal Group, Current Aggregate value of assets and associated supplies met the criteria to be classified as held for sale at the date of acquisition Other Accrued Liabilities, Current Purchase Price recorded in accrued expenses - other Other Amount of cash consideration to be transferred in asset acquisition. Asset Acquisition, Consideration in Cash Consideration Transferred It represents payments of milestone. Payments of Milestone Payments of milestones Sale of Stock, Number of Shares Issued in Transaction Sale of stock, number of shares issued Stock offering, number of shares issued Sale of Stock, Price Per Share Stock offering, price per share Stock offering, price per share Percentage of contingent fee payable on the proceeds of future financings. Stock Repurchase Program, Contingent Fee Payable on Proceeds of Future Financings, Percent Percentage of contingent fee payable Amount of contingent fee payable on the proceeds of future financings. Stock Repurchase Program, Contingent Fee Payable on Proceeds of Future Financings, Amount Contingent fee payable from proceeds of future financing Gain (Loss) on Sale of Assets and Asset Impairment Charges Gain on sale of asset Number of days within which the entity is obligated to sell, or otherwise dispose of, the assets purchased, pursuant to National Security Agreement. Number Of Days To Dispose Of Assets Purchased Number of days to dispose of assets purchased Expenses related to transactions having to do with sale of assets. Transaction Related Expenses Amount of upfront payment for asset acquisition consideration. Asset Acquisition Consideration, Upfront Payment Upfront payment Number of business days within which the upfront payment for asset acquisition consideration is to be made. Asset Acquisition Consideration, Upfront Payment, Due Period Upfront payment due period Amount of subsequent payment for asset acquisition consideration. Asset Acquisition Consideration, Subsequent Payment Subsequent amount Period when subsequent payment for asset acquisition becomes due. Asset Acquisition Consideration, Subsequent Payment, Due Period Subsequent payment due period Extended Period for subsequent payment for asset acquisition due. Asset Acquisition Consideration, Subsequent Payment, Extended Due Period Subsequent payment extended due period Threshold amount of net assets considered for delay in payment of deferred amount under the asset acquisition transaction. Asset Acquisition Consideration, Threshold Net Assets Considered For Delay In Subsequent Payment Asset acquisition consideration, threshold net assets considered for delay in subsequent payment Represents percentage of interest accrual on outstanding liability in asset acquisition transaction. Asset Acquisition, Interest Rate on Outstanding Liability Interest rate on outstanding liability Amount of receivables net of payables due by the company. Receivables, Net Of Payables Net Receivable from uBriGene Amount of outstanding receivables of the company. Outstanding Receivables Outstanding receivable from uBriGene Amount of outstanding payables of the company. Outstanding Payables Outstanding payables of the company Tangible Asset Impairment Charges Tangible asset impairment charges Inventory, Raw Materials and Supplies, Gross Raw materials Inventory, Work in Process, Gross Work-in-process Inventory, Finished Goods, Gross Finished goods Inventory Valuation Reserves Inventory reserve Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Computer Equipment [Member] Computer equipment Furniture and Fixtures [Member] Furniture and fixtures Leasehold Improvements [Member] Leasehold improvements Buildings Construction in progress [Member] Construction in progress Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Gross Total property and equipment Amount of accumulated impairment loss for property plant and equipment. Property, Plant and Equipment, Accumulated Impairment Impairment - leasehold improvements Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Property, Plant and Equipment, Useful Life Useful Life (Years) Impairment of Leasehold Impairment loss allocated to leasehold improvements Operating Lease, Impairment Loss Impairment loss allocated to right-of-use asset Fair Value Measurements, Recurring and Nonrecurring [Table] Represents information relating to common stock warrants. Common Stock Warrants [Member] Common Stock Warrant Placement Agent Warrants [Member] Placement Agent Warrants [Member]

Placement Agent Warrants Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Represents information pertaining to exercise of common stock warrants. Exercise Of Common Stock Warrants Exercise of common stock warrants Represents information pertaining to exchange of warrants. Exchange Of Warrants Exchange of warrants Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to the December 2022 offering. December 2022 Offering [Member] December 2022 Offering Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information relating to pre-funded warrants. Pre-Funded Warrants [Member] Pre funded warrants Minimum Minimum 8% Cumulative Convertible Preferred Stock [Member] Class B preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Convertible Class B Preferred Stock [Member] 8% Cumulative Convertible Class B Preferred Offering Fair value portion of warrants. Warrants Fair Value Disclosure Fair value of warrants Proceeds from Issuance of Warrants Net proceeds Total gross proceeds Warrants and Rights Outstanding, Term Warrant expiration term Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares called by warrants Number of shares called by warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued Number of warrants to purchase shares Number of warrants or rights exchanged during the period. Class Of Warrant Or Right, Number Of Warrants Or Rights Exchanged Exchanged for warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Preferred Stock, Dividend Rate, Percentage Preferred Stock, dividend rate percentage Per share price of combined unit. Unit Price Per Share Payments of Stock Issuance Costs Stock offering, aggregate fees paid Fair Value Measurement Inputs and Valuation Techniques [Table] Series A Warrants Series A Warrants [Member] Series A Warrants Contingent Payment Warrant [Member] Contingent Payment Warrant [Member] Contingent Payment Warrants Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Share Price [Member] Stock price Risk Free Interest Rate [Member] Risk-free interest rate Risk Free Interest Rate Expected Term [Member] Expected life of the options to convert Expected term in years Expected Volatility [Member] Volatility Expected Volatility Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input Warrant liability, measurement input Schedule of Indefinite-Lived Intangible Assets [Table] Journey Journey Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Asset, Useful Life Intangible assets, estimated useful lives Total Intangible assets - asset purchases Total intangible assets - asset purchases Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Remainder of 2024 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months December 31, 2025 Finite-Lived Intangible Assets, Amortization Expense, Year Two December 31, 2026 Finite-Lived Intangible Assets, Amortization Expense, Year Three December 31, 2027 Finite-Lived Intangible Assets, Amortization Expense, Year Four December 31, 2028 Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Finite-Lived Intangible Asset, Expected Amortization, after Year Four Thereafter Finite Lived Intangible Assets Net, Excluding assets that has not been placed in service. Finite Lived Intangible Assets Net, Excluding assets that has not been placed in service Sub-total Intangible assets not yet placed in service Intangible assets not yet placed in service Asset not yet placed in service Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents information pertaining to Oaktree Notes. Oaktree Note [Member] Oaktree Note Information related to the term loan facility with SWK. SWK Term Loan [Member] SWK Term Loan Debt Instrument [Line Items] Long-term Debt, Gross Total notes payable, gross Debt Instrument, Unamortized Discount Less: Discount of notes payable Unamortized debt discount fees Long-term Debt Total notes payable Total notes payable Debt Instrument, Interest Rate, Stated Percentage Interest rate Debt Instrument, Maturity Date, Description Maturity Date, description Debt Instrument, Basis Spread on Variable Rate Basis spread on variable rate Information related to Partner Company notes payable. Partner Company Notes Payable [Member] Partner Company Promissory Note Partner company notes payable Represents the member information pertaining to debt instrument repayment period from February 2026 if total revenue of measured on a trailing twelve-month basis, is less than threshold revenue as of December 31, 2025. Debt Instrument, Repayment Period from February 2026 If Total Revenue Measured on Trailing Twelve Month Basis is Less than Threshold Revenue as of December 31, 2025 [Member] Represents the member information pertaining to debt instrument repayment period from February 2027 if total revenue of measured on a trailing twelve-month basis, is less than threshold revenue as of December 31, 2025. Debt Instrument, Repayment Period from February 2027 If Total Revenue Measured on Trailing Twelve Month Basis is Greater than Threshold Revenue as of December 31, 2025 [Member] Represents if debt instrument are prepaid prior to the first anniversary of the closing date. If Debt Instruments Prepaid Prior To First Anniversary of Closing Date [Member] Represents if debt instrument are prepaid on or after the first anniversary of the closing date but prior to the second anniversary of closing date. If Debt Instrument Prepaid On Or After First Anniversary But Prior To Second Anniversary Of Closing Date [Member] Represents if debt instrument prepaid after the second anniversary of closing date. If Debt Instrument Prepaid After Second Anniversary Of Closing Date [Member] Debt Instrument, Face Amount Debt instrument face amount Debt Instrument, Maturity Date Debt maturity date Debt Instrument, Unused Borrowing Capacity, Amount Debt instrument, unused borrowing capacity, amount Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Additional borrowing capital that can be drawn under the credit agreement. Line Of Credit Facility Additional Borrowing Capacity Line of credit facility additional borrowing capacity Proceeds from Lines of Credit Line of Credit Facility, Remaining Borrowing Capacity Remaining borrowing capacity Represents variable interest floor rate of debt. Debt Instrument, Floor Rate Debt instrument, floor rate Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Percentage of the required periodic payments including both interest and principal payments on principal amount. Debt Instrument, Periodic Payment, Percentage of Principal Amount Represents the threshold revenue for no periodic repayment of debt during the specified period. Debt Instrument, Threshold Revenue Considered for No Periodic Payment Represents the percentage of prepayment premium to be paid at the time of prepayment of debt instrument. Debt Instrument, Percentage of Prepayment Premium Represents percentage of original principal amount to be paid as exit fees upon repayment of debt instrument. Debt Instrument, Percentage of Exit Fees Payments of Debt Issuance Costs Amortization of Debt Issuance Costs Amortization of fees Debt Instrument, Interest Rate, Effective Percentage Debt, effective interest rate Sale of Stock, Consideration Received Per Transaction Total gross proceeds Stock offering, gross proceeds Warrants and Rights Outstanding Warrants, fair value Paid in Kind dividend, common stock's average trading price discount percentage. Paid in Kind dividend, common stock's average trading price discount percentage Common stock's average 10-day trading price discount percentage Interest Expense Interest expense Aggregate Offering Price of Debt Proceeds from debt Value of securities into which the class of warrant or right may be converted. Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights Class of warrant or right value of securities called by warrants or rights Amount of minimum gross proceeds from convertible preferred stock. Convertible Preferred Stock, Conversion, Minimum Gross Proceeds Aggregate gross proceeds from convertible preferred stock Partner Company Convertible Preferred Shares [Member] Partner Company Convertible Preferred Shares [Member] Partner company convertible preferred shares Partner company installment payments - licenses [Member] Partner company installment payments - licenses [Member] Partner company installment payments - licenses Other Debt [Member] Other Debt [Member] Other Debt instrument accrued interest Interest expense, interest Amount of debt discount amortization attributable to debt issuance costs. Debt Discount Amortization Interest Expense, Debt Interest expense, Total Net Amount of the cost of borrowed funds accounted for as interest expense for debt. Interest expense, Total, Net Accounts Payable, Current Accounts payable Accrued Liabilities, Current [Abstract] Accrued expenses: Accrued Professional Fees, Current Professional fees Accrued Salaries, Current Salaries, bonus and related benefits Research and Development Expense Accrued Research And Development Expense Research and development Accrued Royalties, Current Accrued royalties payable The amount of accrued coupon expense which is classified as current. Accrued Coupon Expense Current Accrued coupon and rebates Amount of accrued return reserve, current. Accrued Return Reserve Current Return reserve Accrued Liabilities, Current Total accounts payable and accrued expenses Noncontrolling Interest [Table] Ownership [Axis] Ownership [Domain] Noncontrolling Interest [Line Items] Non-Controlling Interests Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Non-controlling ownership Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Stock Options Unvested Restricted Stock [Member] Unvested Restricted Stock Unvested Restricted Stock Units [Member] Unvested Restricted Stock Units Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] The effect of series A preferred dividends on net loss per share calculation. Effect of Series A Preferred Dividends On Net Loss Per Share Calculation Effect of Series A preferred dividends on net loss per share calculation The effect of partner company deemed dividends on net loss per share calculation. Effect of Partner Company Deemed Dividends On Net Loss Per Share Calculation Effect of partner company deemed dividends on net loss per share calculation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities excluded from the computations of diluted weighted average shares outstanding Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Information related to employee and non-employee awards. Employee And Nonemployee Awards [Member] Employee and non-employee awards Executive Awards [Member] Executive awards Other Partners [Member] Other Partners [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Allocated Share-based Compensation Expense Stock-based compensation expense Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock or stock units including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met. Restricted Stock Awards and Restricted Stock Units [Member] Restricted Stock [Member] Restricted Stock Units (RSUs) [Member] Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] General and Administrative Expense [Member] Title of Individual [Axis] Relationship to Entity [Domain] Chief Executive Officer (Dr. Rosenwald) [Member] Chief Executive Officer (Dr. Rosenwald) Executive Vice President (Mr. Weiss) [Member] Executive Vice President (Mr. Weiss) Plan Name [Axis] Plan Name [Domain] Two thousand Seven and Two Thousand Thirteen Plan [Member] 2007 and 2013 Stock Incentive Plan [Member] Two Thousand Thirteen Stock Incentive Plan [Member] 2013 Stock Incentive Plan [Member] Two Thousand Twelve Employee Stock Purchase Plan [Member] 2012 Employee Stock Purchase Plan [Member] Long-term incentive plan [Member] Long-term Incentive Plans [Member] Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Stock options, unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized compensation expense for awards other than options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Share-based compensation, period for recognition of expense Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares Granted Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Share based compensation, additional shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Stock based compensation, shares available for issuance Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value. Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value Fair value of stock granted Long term incentive program Percentage of outstanding shares Long term incentive program Percentage of outstanding shares LTIP, Percentage of outstanding shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options vested and expected to vest, Number of shares Options vested and expected to vest, Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of shares, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Options vested and exercisable, Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options vested and expected to vest, Weighted average exercise price Options vested and expected to vest, Weighted average exercise price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Options vested and exercisable, Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Total weighted average intrinsic value, Options vested and expected to vest Total weighted average intrinsic value, Options vested and expected to vest The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value Total weighted average intrinsic value, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options vested and expected to vest, Weighted average contractual life Represents the weighted average remaining contractual life of option awards granted. Share Based Compensation Arrangement, Options Granted, Weighted Average Remaining Contractual Term Options Granted, weighted average remaining contractual life (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Options vested and exercisable, Weighted average remaining contractual life (years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares, Unvested balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Number of shares, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of shares, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average grant price, Unvested balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant price, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted average grant price, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted average exercise price, Forfeited Equity [Abstract] Class of Warrant or Right, Outstanding Outstanding warrants Class Of Warrant Or Right, Number of shares granted. Class Of Warrant Or Right, Number of shares granted Warrants granted, Number of shares Class Of Warrant Or Right, Number of shares Exercised. Warrants exercised, Number of shares Warrants exercised, Number of shares Class Of Warrant Or Right Exercisable. Class Of Warrant Or Right Exercisable Warrants exercisable, Number of shares Class of Warrant or Right, Weighted average exercise price Class of Warrant or Right, Weighted average exercise price Warrants outstanding, Weighted average exercise price Class of Warrant or Right granted, Weighted average exercise price Class of Warrant or Right granted, Weighted average exercise price Warrants granted, Weighted average exercise price Class Of Warrant Or Right Expired, Weighted Average Exercise Price. Class Of Warrant Or Right Expired, Weighted Average Exercise Price Warrants expired, Weighted average exercise price Class Of Warrant Or Right exercisable, Weighted Average Exercise Price Class Of Warrant Or Right exercisable, Weighted Average Exercise Price Warrants exercisable, Weighted average exercise price Class of Warrant or Right, Weighted average intrinsic value. Class of Warrant or Right, Weighted average intrinsic value Warrants outstanding, Weighted average intrinsic value Class of Warrant or Right granted, Weighted average intrinsic value. Class of Warrant or Right granted, Weighted average intrinsic value Warrants granted, Weighted average intrinsic value Class of Warrant or Right exercisable, Weighted average intrinsic value Class of Warrant or Right exercisable, Weighted average intrinsic value Warrants exercisable, Weighted average intrinsic value Class Of Warrant Or Right, Weighted Average Remaining Contractual Life Class Of Warrant Or Right, Weighted Average Remaining Contractual Life Warrants, Weighted average remaining contractual life Class Of Warrant Or Right exercisable, Weighted Average remaining contractual life Class Of Warrant Or Right exercisable, Weighted Average remaining contractual life Warrants exercisable, Weighted average remaining contractual life At the Market Offering [Member] Public Offering [Member] Public Offering [Member] Public Offering Shelf Registration Statement [Member] Shelf Registration Statement [Member] Shelf Registration 2023 Statement [Member] Shelf Registration 2023 Statement [Member] Represents information pertaining to Shelf Registration 2024 Statement. Shelf Registration 2024 Statement [Member] Shelf Registration 2021 Statement [Member] Shelf Registration 2021 Statement [Member] Represents information relating to direct offering. Direct Offering [Member] Direct offering Private Placement [Member] Private Placement Series B Warrants Series B Warrants [Member] Series B Warrants Represents the member information pertaining to January 2023 Warrants. January 2023 Warrants [Member] January 2023 Warrants Represents information relating to unregistered warrants. Unregistered Warrants [Member] Unregistered

warrants Represents the member information pertaining to November 2023 Warrants. November 2023 Warrants [Member] November 2023 Warrants Represents the information pertaining to series A one warrants. Series A One Warrants [Member] Series A One Warrants Represents the information pertaining to series A two warrants. Series A Two Warrants [Member] Series A Two Warrants Represents the information pertaining to series A three warrants. Series A Three Warrants [Member] Series A Three Warrants Represents the information pertaining to amended warrants. Amended Warrants [Member] Amended Warrants MLV & Co. and FBR Capital Markets & Co [Member] MLV & Co. and FBR Capital Markets & Co [Member] Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., Jones Trading Institutional Services LLC. B. Riley And Dawson James Securities, Inc Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., Jones Trading Institutional Services LLC. B. Riley and Dawson James Securities, Inc [Member] Related Party Transaction [Axis] Related Party Transaction [Domain] Founders Agreement [Member] Founders Agreement Total number of shares issued during the period for direct offering. Stock Issued During Period Shares Common Shares for Direct Offering (in Shares) Issuance of common shares - Registered direct offering Number of warrants issued during the period. Warrants Issued, Number Warrants issued Per share amount reduced from share price to calculate warrant price. Per Share, Amount Reduced from Share Price to Calculate Warrant Price Per share amount reduced from share price to calculate warrant price Number of Shares issuable for At-the-Market offering Number of Shares issuable for At-the-Market offering Number of Shares issuable for At-the-Market offering Sale of Stock aggregate offering price permitted by agreement. Sale of Stock aggregate offering price permitted by agreement Stock offering, aggregate offering permitted by the agreement Represents value of shares available for future issue. Common Stock Shares Available For Future Issuance Value Amount available for future stock offerings Percentage of commission agreed to be paid to the company, percentage calculated over gross proceeds from the sales of stock. Sale of Stock, Percentage of Shares Issued in Transaction Shares issued (in percent) Exercise price per share or per unit of warrants or rights agreed by investor. Class of Warrant or Right, Exercise Price of Warrants or Rights Agreed by Investor Exercise price of warrants agreed by investor Loss Contingencies [Table] Loss Contingencies [Line Items] Loss Contingencies Lessee, Operating Lease, Description [Abstract] Operating Lease, Liability Operating lease liabilities Net operating lease liabilities, short-term and long-term Proceeds from Previous Acquisition Amount of Caelum acquisition reveived Amount of legal fees and costs incurred by a former subsidiary, in defending a litigation, reimbursed by the company by distribution from escrow account. Legal Fees And Costs In Defending Litigation, Incurred By Former Subsidiary, Reimbursed By Distribution From Escrow Account Caelum's legal fees and costs Operating Lease, Cost Operating lease cost Sublease Income Shared lease costs Variable Lease, Cost Variable lease cost Lease, Cost Total lease expense Operating Lease, Payments Operating cash flows from operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term - operating leases (years) Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - operating leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Nine Months Ended December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Year Ended December 31, 2025 Lessee, Operating Lease, Liability, Payments, Due Year Two Year Ended December 31, 2026 Lessee, Operating Lease, Liability, Payments, Due Year Three Year Ended December 31, 2027 Lessee, Operating Lease, Liability, Payments, Due Year Four Year Ended December 31, 2028 Lessee, Operating Lease, Liability, Payments, Due after Year Five Other Lessee, Operating Lease, Liability, Payments, Due Total operating lease liabilities Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: present value discount Schedule of Related Party Transactions, by Related Party [Table] TGTX and Opus Point Partners Management, LLC ("OPPM") [Member] TGTX and OPPM [Member] TGTX and OPPM TGTX [Member] TGTX [Member] TGTX Represents information relating to Cyprium Therapeutics, Inc. Cyprium [Member] Cyprium Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Shared Services Agreement [Member] Shared Services Agreement Desk Share Agreements [Member] Desk Share Agreements Geographical [Axis] Geographical [Domain] New York, NY Office Space [Member] New York, NY Office Space Related Party Transaction [Line Items] Amount received from desk share agreement related to design and build out of the new office. Proceeds from Related Party Agreement Payments for Rent Total payment for rent Monthly cash dividend per share payable Monthly Cash Dividend Per Share Payable Monthly cash dividend Annual cash dividend payable per share. Annual Cash Dividend Per Share Payable Annual cash dividend payable Exchange term of preferred stock. Exchange Term of Preferred Stock Exchange term of preferred stock Paid in Kind dividend as a percentage of fully diluted outstanding capitalization. Paid in Kind dividend as a percentage of fully diluted outstanding capitalization PIK dividend as a percentage of fully diluted outstanding capitalization n/a Baergic [Member] Baergic Cellvation [Member] Cellvation Helocyte [Member] Helocyte This member stands for Oncogenuity. Oncogenuity [Member] Oncogenuity Payment in Kind Dividends or Equity Fee Payable Effective Date. Payment in Kind Dividends or Equity Fee Payable Effective Date Effective date Annual equity fee as a percentage of fully diluted outstanding capitalization Annual equity fee as a percentage of fully diluted outstanding capitalization Annual equity fee as a percentage of fully diluted outstanding capitalization Effective Date the consulting fee to be paid. Annual Consulting Fee Payable Effective Date Effective date Annual Management Services Agreement Fee expense. Annual Management Services Agreement Fee expense Partner companies, MSA fee expense Annual Management Services Agreement Fee Income Annual Management Services Agreement Fee Income Fortress - MSA Income Number of Reportable Segments Number of reportable segment Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Domain] Dermatology Products Sales Pharmaceutical and Biotechnology Product Development Segment Reporting Information [Line Items] Research and Development Expense Research and development Income Tax Expense (Benefit) Income tax expense Income tax expense Tangible assets. Tangible Assets Net Tangible assets Disaggregation of Revenue [Table] Customer [Axis] Customer [Domain] Customer one [Member] Customer One Customer Two [Member] Customer Two Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Revenue [Member] Revenue Accounts Receivable [Member] Accounts Receivable Disaggregation of Revenue [Line Items] Concentration Risk, Percentage Concentration risk, percentage Number of customers. Number of Customers Number of customers Product and Service [Axis] Product and Service [Domain] Product [Member] Qbrexza [Member] Qbrexza Qbrexza Accutane [Member] Accutane Amzeeq product. Amzeeq Amzeeq Zilxi product. Zilxi Zilxi Other Legacy Product Revenue Member. Other Legacy Product Revenue Effective Income Tax Rate Reconciliation, Percent Effective income tax rate Minimum ownership interest in subsidiaries for consolidated income tax return. Minimum ownership interest in subsidiaries for consolidated income tax return Minimum ownership interest in subsidiaries for consolidated income tax return Subsequent Event [Table] Represents information pertaining to July 2024 Registered Direct Offering. July 2024 Registered Direct Offering [Member] Represents information pertaining to Crystalys Therapeutics, Inc. Crystalys Therapeutics, Inc [Member] Represents the scenario when the outstanding principal balance is less than or equal to 10 million. If the Outstanding Principal Balance is Less Than or Equal to 10 Million [Member] Scenario when the outstanding principal balance is less than or equal to 10 million Represents the scenario when the outstanding principal balance is between 10 million and 25 million. If the Outstanding Principal Balance is Between 10 Million and 25 Million [Member] Scenario when the outstanding principal balance is between 10 million and 25 million Subsequent Event [Line Items] Subsequent Events Number of interest only period under the debt instrument. Debt Instrument, Number Of Interest Only Period Debt Instrument, number of interest only period Represents variable interest cap rate of debt. Debt Instrument, Cap Rate Debt instrument, cap rate Percentage of the then-outstanding principal balance of the loans due on specified date. Debt Instrument, Percentage Of Then Outstanding Principal Balance Due On A Specified Date Debt instrument, percentage of then outstanding principal balance due on a specified date Aggregate of minimum principal amount of loans to be prepaid at the happening of certain circumstances. Debt Instrument, Aggregate of Principal Prepayment Amount, Minimum Debt instrument, aggregate of principal prepayment amount, minimum Aggregate of prepayment of principal amount of loans to be paid in multiples at time of the happening of certain circumstances. Debt Instrument, Aggregate of Principal Prepayment Amount in Multiples Debt instrument, aggregate of principal prepayment amount in multiples Amount of excess proceeds from receipt of any dividend or other distributions in cash from any of the company's subsidiaries other than in connection with certain monetization events, that should be used for mandatory prepayment of debt instrument. Debt Instrument, Mandatory Prepayment, Excess Proceeds From Any Of Company's Subsidiaries Other Than In Connection With Certain Monetization Events Excess proceeds from any of company's subsidiaries other than in connection with certain monetization events Represents minimum liquidity to be maintained as per the debt agreement. Minimum Liquidity to be Maintained Minimum liquidity to be maintained Represents minimum net sales to be maintained, on a trailing 12-month basis, as per the debt agreement. Minimum Net Sales to be Maintained Minimum net sales to be maintained Represents increase in minimum liquidity to be maintained under each instance f product disapproval as per the debt agreement. Increase in Minimum Liquidity to be Maintained in Each Instance of Product Disapproval Increase in minimum liquidity to be maintained under each instance of product disapproval as per the debt agreement Trailing period duration for maintaining minimum net sales. Minimum Net Sale Trailing Period Minimum net sale trailing period Threshold amount of aggregate common equity or cash distributions to be received as per the debt agreement. Debt Instrument, Threshold Amount of Aggregate Common Equity or Cash Distributions to be Received Debt instrument, threshold amount of aggregate common equity or cash distributions to be received Threshold amount of aggregate common equity or cash distributions to be received as per the debt agreement, as a percentage of amount set forth in annual budget delivered to the Lenders. Debt Instrument, Aggregate Common Equity or Cash Distributions to be Received, As A Percentage of Amount Set Forth In Annual Budget Percentage of amount set forth in annual budget Threshold amount of outstanding principal, above which the capital raise and minimum stake covenants and financial covenants shall be applicable. Debt Instrument, Threshold Amount Of Outstanding Principal For Applicability Of Covenants Outstanding principal balance Aggregate monthly dividends paused during the period for each share of preferred stock. Preferred Stock, Monthly Dividends, Per Share, Paused Amount of deferred dividend payments at the end of the reporting period. Deferred Dividends Percentage of common stock issued to the company, pursuant to asset acquisition arrangement. Asset Acquisition, Percentage Of Common Stock Issued Percentage of equity to be held Threshold percentage of fully diluted equity capitalization position in counterparty, to be held by company, until specified amount of equity securities is raised by such counterparty. Threshold Percentage Of Fully Diluted Equity Capitalization Position Urica's equity position Represents maximum amount of equity securities to be raised by the company. Maximum Amount Of Equity Securities to be Raised Capitalization in equity securities Percentage of royalty on future net sales granted to the company. Percentage Of Royalty On Future Net Sales Percentage of royalty on future net sales Number of directors of the board of directors of the counterparty, that the company has right to appoint, pursuant to an agreement. Number Of Directors That Company Has Right TO Appoint Number of directors Number of days over which the company has committed to provide transition support to the counterparty, pursuant to an agreement. Number Of Days To Provide Transition Support Number of days to provide transition support EX-101.PRE 10 fbio-20240630_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 09, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 001-35366 Â Entity Registrant Name Fortress Biotech, Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 20-5157386 Â Entity Address, Address Line One 1111 Kane Concourse Suite 301 Â Entity Address, City or Town Bay Harbor Islands Â Entity Address, State or Province FL Â Entity Address, Postal Zip Code 33154 Â City Area Code 781 Â Local Phone Number 652-4500 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Central Index Key 0001429260 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Amendment Flag false Â Common Stock [Member] Â Â Document Information [Line Items] Â Â Title of 12(b) Security Common Stock Â Trading Symbol FBIO Â Security Exchange Name NASDAQ Â Entity Common Stock, Shares Outstanding Â 22,813,954 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock [Member] Â Â Document Information [Line Items] Â Â Title of 12(b) Security 9.375% SeriesÂ A Cumulative Redeemable Perpetual Preferred Stock Â Trading Symbol FBIOP Â Security Exchange Name NASDAQ Â Entity Common Stock, Shares Outstanding Â 3,427,138 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace

Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets Â Â Cash and cash equivalents $ 76,201 $ 80,927 Accounts receivable, net 10,465 15,222 Inventory 9,687 10,206 Prepaid expenses and other current assets 4,649 10,500 Assets held for sale 2,209 Â Total current assets 103,435 117,022 Property, plant and equipment, net 3,546 6,505 Operating lease right-of-use asset, net 14,626 16,990 Restricted cash 2,063 2,438 Intangible assets, net 18,658 20,287 Other assets 3,357 4,284 Total assets 145,685 167,526 Current liabilities Â Â Accounts payable and accrued expenses 68,921 73,562 Income taxes payable 806 843 Common stock warrant liabilities 172 886 Operating lease liabilities, short-term 2,481 2,523 Partner company convertible preferred shares, short-term, net 0 3,931 Partner company installment payments - licenses, short-term, net 3,000 3,000 Other short-term liabilities 163 163 Total current liabilities 75,543 84,908 Notes payable, long-term, net 67,007 60,856 Operating lease liabilities, long-term 15,934 18,282 Other long-term liabilities 1,799 1,893 Total liabilities 160,283 165,939 Commitments and contingencies (Note 14) Stockholders' equity (deficit) Â Â Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively, liquidation value of $25.00 per share 3 3 Common stock, $0.001 par value, 200,000,000 shares authorized, 22,587,038 and 15,093,053 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 23 15 Additional paid-in-capital 739,086 717,396 Accumulated deficit (721,235) (694,870) Total stockholders' equity attributed to the Company 17,877 22,544 Non-controlling interests (32,475) (20,957) Total stockholders' equity (deficit) (14,598) 1,587 Total liabilities and stockholders' equity (deficit) 145,685 167,526 Related Party Â Â Current assets Â Â Other receivables - related party $ 224 $ 167 X - DefinitionAmount representing assets held for sale. + ReferencesNo definition available. + Details Name: fbio_AssetsHeldForSale Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to convertible preferred shares. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: fbio_ConvertiblePreferredSharesCurrent Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPartner company installment payments - licenses, short-term, net of imputed interest. + ReferencesNo definition available. + Details Name: fbio_PartnerCompanyInstallmentPaymentsLicensesCurrent Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents information pertaining to warrant liabilities current. + ReferencesNo definition available. + Details Name: fbio_WarrantLiabilitiesCurrent Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsAndOtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Unaudited Condensed Consolidated Balance Sheets Â Â Preferred Stock, par value $ 0.001 $ 0.001 Preferred Stock, shares authorized 15,000,000 15,000,000 Preferred Stock shares designated 5,000,000 5,000,000 Preferred Stock, shares issued 3,427,138 3,427,138 Preferred Stock, shares outstanding 3,427,138 3,427,138 Preferred Stock, liquidation preference per share $ 25.00 $ 25.00 Common Stock, par value $ 0.001 $ 0.001 Common Stock, shares authorized 200,000,000 200,000,000 Common Stock, shares issued 22,587,038 15,093,053 Common Stock, shares outstanding 22,587,038 15,093,053 X - DefinitionIt represents number of preferred stock shares designated. + ReferencesNo definition available. + Details Name: fbio_PreferredStockSharesDesignated Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockLiquidationPreference Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType

Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenue Â Â Â Â Product revenue, net $ 14,855 $ 16,961 $ 27,885 $ 29,126 Collaboration revenue Â 183 Â 364 Other revenue Â 211 Â 259 Net revenue 14,896 17,386 27,926 29,815 Operating expenses Â Â Â Â Cost of goods sold - product revenue 6,541 7,767 13,357 14,216 Research and development 12,671 32,139 37,495 67,415 Research and development - licenses acquired Â 3 Â 4,233 Selling, general and administrative 20,823 24,439 38,777 49,780 Asset impairment 2,649 3,143 2,649 3,143 Total operating expenses 42,684 67,491 92,278 138,787 Loss from operations (27,788) (50,105) (64,352) (108,972) Other income (expense) Â Â Â Â Interest income 734 715 1,567 1,751 Interest expense and financing fee (2,122) (6,425) (4,724) (10,721) Change in fair value of warrant liabilities Â (512) Â 6,166 Gain (loss) on common stock warrant liabilities 70 Â (597) Â Loss from deconsolidation of subsidiaries Â (3,369) Â (3,369) Other income (expense) 282 395 260 699 Total other income (expense) (1,036) (9,196) (3,494) (5,474) Net loss (28,824) (59,301) (67,846) (114,446) Net loss attributable to non-controlling interests 17,876 34,525 41,481 68,133 Net loss attributable to Fortress (10,948) (24,776) (26,365) (46,313) Net loss attributable to common stockholders $ (13,339) $ (26,917) $ (31,199) $ (50,595) Net loss per common share attributable to common stockholders - basic $ (0.73) $ (3.65) $ (1.76) $ (7.14) Net loss per common share attributable to common stockholders - diluted $ (0.73) $ (3.65) $ (1.76) $ (7.14) Weighted average common shares outstanding - basic 18,316,874 7,377,332 17,736,299 7,086,482 Weighted average common shares outstanding - diluted 18,316,874 7,377,332 17,736,299 7,086,482 Related Party Â Â Â Â Revenue Â Â Â Â Revenue - related party $ 41 $ 31 $ 41 $ 66 X - DefinitionCollaboration revenue. + ReferencesNo definition available. + Details Name: fbio_CollaborationRevenue Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from deconsolidation of subsidiaries. + ReferencesNo definition available. + Details Name: fbio_GainLossFromDeconsolidationOfSubsidiaries Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on common stock warrant liabilities. + ReferencesNo definition available. + Details Name: fbio_GainLossOnCommonStockWarrantLiabilities Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense and amount of debt issuance costs. + ReferencesNo definition available. + Details Name: fbio_InterestExpenseAndFinanceFees Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss

for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue and income classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_OtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands Preferred Stock Common Stock Common Shares Issuable Additional Paid-In Capital Accumulated Deficit Non-Controlling Interests Total Balance at Dec. 31, 2022 $ 3 $ 7 Â $ 675,944 $ (634,233) $ 8,304 $ 50,025 Balance (in shares) at Dec. 31, 2022 3,427,138 7,366,283 Â Â Â Â Â Stock-based compensation expense Â Â Â 8,948 Â Â 8,948 Issuance of common stock related to equity plans (in shares) Â 183,856 Â Â Â Â Â Issuance of common stock for public offering, net Â $ 2 Â 13,152 Â Â 13,154 Issuance of stock for public offerings, net (in shares) Â 1,109,526 Â Â Â Â Â Issuance of common stock under ESPP Â Â Â 88 Â Â 88 Issuance of common stock for at-the-market offering, net Â Â Â 1,168 Â Â 1,168 Issuance of common stock for at-the-market offering, net (in shares) Â 106,425 Â Â Â Â Â Common shares issued for dividend on partner company's convertible preferred shares Â Â $ 23 108 Â Â 131 Common shares issued for dividend on partner company's convertible preferred shares (in shares) Â 11,066 Â Â Â Â Â Partner company's offering, net Â Â Â 21,977 Â Â 21,977 Partner company's exercise of options for cash Â Â Â 3 Â Â 3 Preferred A dividends declared and paid Â Â Â (4,016) Â Â (4,016) Partner company's dividends declared and paid Â Â Â (371) Â Â (371) Issuance of partner company's common shares for research and development expenses Â Â Â 1,233 Â Â 1,233 Warrants Â Â Â 272 Â Â 272 Deconsolidation/dissolution of subsidiary non-controlling interests Â Â Â Â Â 5,891 5,891 Non-controlling interest in partner companies Â Â Â (19,486) Â 19,486 Â Net loss attributable to non-controlling interest Â Â Â Â Â (68,133) (68,133) Net loss attributable to common stockholders Â Â Â Â (46,313) Â (46,313) Balance at Jun. 30, 2023 $ 3 $ 9 23 699,020 (680,546) (34,452) (15,943) Balance (in shares) at Jun. 30, 2023 3,427,138 8,777,156 Â Â Â Â Â Balance at Mar. 31, 2023 $ 3 $ 9 Â 693,554 (655,770) (17,990) 19,806 Balance (in shares) at Mar. 31, 2023 3,427,138 8,694,477 Â Â Â Â Â Stock-based compensation expense Â Â Â 4,217 Â Â 4,217 Issuance of common stock related to equity plans (in shares) Â 5,515 Â Â Â Â Â Issuance of common stock for public offering, net Â Â Â (41) Â Â (41) Issuance of common stock for at-the-market offering, net Â Â Â 721 Â Â 721 Issuance of common stock for at-the-market offering, net (in shares) Â 66,098 Â Â Â Â Â Common shares issued for dividend on partner company's convertible preferred shares Â Â 23 108 Â Â 131 Common shares issued for dividend on partner company's convertible preferred shares (in shares) Â 11,066 Â Â Â Â Â Partner company's offering, net Â Â Â 14,460 Â Â 14,460 Partner company's exercise of options for cash Â Â Â 3 Â Â 3 Issuance of common stock under partner company's ESPP Â Â Â 88 Â Â 88 Preferred A dividends declared and paid Â Â Â (2,008) Â Â (2,008) Partner company's dividends declared and paid Â Â Â (185) Â Â (185) Issuance of partner company's common shares for research and development expenses Â Â Â 3 Â Â 3 Partner company's warrants issued in conjunction with debt Â Â Â 272 Â Â 272 Deconsolidation/dissolution of subsidiary non-controlling interests Â Â Â Â Â 5,891 5,891 Non-controlling interest in partner companies Â Â Â (12,172) Â 12,172 Â Net loss attributable to non-controlling interest Â Â Â Â Â (34,525) (34,525) Net loss attributable to common stockholders Â Â Â Â (24,776) Â (24,776) Balance at Jun. 30, 2023 $ 3 $ 9 $ 23 699,020 (680,546) (34,452) (15,943) Balance (in shares) at Jun. 30, 2023 3,427,138 8,777,156 Â Â Â Â Â Balance at Dec. 31, 2023 $ 3 $ 15 Â 717,396 (694,870) (20,957) 1,587 Balance (in shares) at Dec. 31, 2023 3,427,138 15,093,053 Â Â Â Â Â Stock-based compensation expense Â Â Â 9,856 Â Â 9,856 Issuance of common stock related to equity plans (in shares) Â 495,761 Â Â Â Â Â Issuance of common stock for public offering, net Â $ 3 Â 10,115 Â Â 10,118 Issuance of stock for public offerings, net (in shares) Â 3,303,305 Â Â Â Â Â Issuance of common stock under ESPP Â Â Â 51 Â Â 51 Issuance of common stock under ESPP (in shares) Â 29,844 Â Â Â Â Â Issuance of common stock for at-the-market offering, net Â $ 2 Â 2,824 Â Â 2,826 Issuance of common stock for at-the-market offering, net (in shares) Â 1,554,483 Â Â Â Â Â Common shares issued for dividend on partner company's convertible preferred shares Â Â Â 114 Â Â 114 Common shares issued for dividend on partner company's convertible preferred shares (in shares) Â 64,747 Â Â Â Â Â Common shares issued for exchange of partner company's convertible preferred shares Â $ 3 Â 3,406 Â Â 3,409 Common shares issued for exchange of partner company's convertible preferred shares (in shares) Â 2,028,345 Â Â Â Â Â Exercise of warrants for cash Â Â Â 30 Â Â 30 Exercise of warrants for cash (in shares) Â 17,500 Â Â Â Â Â Partner company's offering, net Â Â Â 18,002 Â Â 18,002 Partner company's at-the-market offering, net Â Â Â 1,779 Â Â 1,779 Warrants issued in conjunction with exchange of partner company's convertible preferred shares Â Â Â 341 Â Â 341 Issuance of common stock under partner company's ESPP Â Â Â 133 Â Â 133 Preferred A dividends declared and paid Â Â Â (4,016) Â Â (4,016) Partner company's dividends declared and paid Â Â Â (352) Â Â (352) Exercise of partner company options and warrants for cash, net Â Â Â 9,370 Â Â 9,370 Non-controlling interest in partner companies Â Â Â (29,963) Â 29,963 Â Net loss attributable to non-controlling interest Â Â Â Â Â (41,481) (41,481) Net loss attributable to common stockholders Â Â Â Â (26,365) Â (26,365) Balance at Jun. 30, 2024 $ 3 $ 23 Â 739,086 (721,235) (32,475) (14,598) Balance (in shares) at Jun. 30, 2024 3,427,138 22,587,038 Â Â Â Â Â Balance at Mar. 31, 2024 $ 3 $ 19 Â 733,290 (710,287) (26,962) (3,937) Balance (in shares) at Mar. 31, 2024 3,427,138 19,375,343 Â Â Â Â Â Stock-based compensation expense Â Â Â 4,998 Â Â 4,998 Issuance of common stock related to equity plans (in shares) Â 34,293 Â Â Â Â Â Issuance of common stock under ESPP Â Â Â 51 Â Â 51 Issuance of common stock under ESPP (in shares) Â 29,844 Â Â Â Â Â Issuance of common stock for at-the-market offering, net Â $ 1 Â 1,930 Â Â 1,931 Issuance of common stock for at-the-market offering, net (in shares) Â 1,092,283 Â Â Â Â Â Common shares issued for dividend on partner company's convertible preferred shares Â Â Â 46 Â Â 46 Common shares issued for dividend on partner company's convertible preferred shares (in shares) Â 26,930 Â Â Â Â Â Common shares issued for exchange of partner company's convertible preferred shares Â $ 3 Â 3,406 Â Â 3,409 Common shares issued for exchange of partner company's convertible preferred shares (in shares) Â 2,028,345 Â Â Â Â Â Partner company's offering, net Â Â Â 5,265 Â Â 5,265 Partner company's at-the-market offering, net Â Â Â 295 Â Â 295 Warrants issued in conjunction with exchange of partner company's convertible preferred shares Â Â Â 341 Â Â 341 Partner companies' proceeds from options and warrants, net Â Â Â 4,010 Â Â 4,010 Preferred A dividends declared and paid Â Â Â (2,008) Â Â (2,008) Partner company's dividends declared and paid Â Â Â (176) Â Â (176) Non-controlling interest in partner companies Â Â Â (12,363) Â 12,363 Â Net loss attributable to non-controlling interest Â Â Â Â Â (17,876) (17,876) Net loss attributable to common stockholders Â Â Â Â (10,948) Â (10,948) Balance at Jun. 30, 2024 $ 3 $ 23 Â $ 739,086 $ (721,235) $ (32,475) $ (14,598) Balance (in shares) at Jun. 30, 2024 3,427,138 22,587,038 Â Â Â Â Â X - DefinitionAmount of decrease/increase in additional paid in capital (APIC) and non controlling interest in subsidiaries. + ReferencesNo definition available. + Details Name: fbio_AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of common stock. + ReferencesNo definition available. + Details Name: fbio_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfCommonStock Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the exercise of partner company options and warrants. + ReferencesNo definition available. + Details Name: fbio_AdjustmentsToAdditionalPaidInCapitalExerciseOfPartnerCompanyOptionsAndWarrants Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital resulting from stock issuance for research and development expenses. + ReferencesNo definition available. + Details Name: fbio_AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from subsidiary's at market offering costs. + ReferencesNo definition available. + Details Name: fbio_AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued during period for dividend on partner company's convertible preferred shares. + ReferencesNo definition available. + Details Name: fbio_CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIt represents the stock issued during period shares issued for partner company's convertible preferred shares. + ReferencesNo definition available. + Details Name: fbio_CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredSharesInShares Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued during period for exchange of partner company's convertible preferred shares. + ReferencesNo definition available. + Details Name: fbio_CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredShares Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIt represents the stock issued during period shares issued for exchange of partner company's convertible preferred shares. + ReferencesNo definition available. + Details Name: fbio_CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredSharesInShares Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued during period for cash at the market cost. + ReferencesNo definition available. + Details Name: fbio_IssuanceOfCommonStockForAtMarketOffering Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIt represents the stock issued during period shares issued for cash at market cost. + ReferencesNo definition available. + Details Name: fbio_IssuanceOfCommonStockForAtMarketOfferingInShares Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of common stock under partner company's Employee stock purchase program + ReferencesNo definition available. + Details Name: fbio_IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPartner company's equity offering, excluding at-the-market issuances. + ReferencesNo definition available. + Details Name: fbio_PartnerCompanyEquityOffering Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPartner company's exercise of stock options for the purpose of cash. + ReferencesNo definition available. + Details Name: fbio_PartnerCompanyExerciseOfOptionsForCash Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPartner company's exercise of options for cash. + ReferencesNo definition available. + Details Name: fbio_PartnerCompanySExerciseOfOptionsForCash Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of warrants issued in conjunction with debt. + ReferencesNo definition available. + Details Name: fbio_PartnerCompanySWarrantsIssuedInConjunctionWithDebt Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of stock issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: fbio_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued during the period relating to cashless exercise of warrants. + ReferencesNo definition available. + Details Name: fbio_StockIssuedDuringPeriodValueCashLessExerciseOfWarrants Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: fbio_StockIssuedDuringPeriodValueWarrantsExercised Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount charged from warrants in conjunction with exchange of partner company's convertible preferred shares. + ReferencesNo definition available. + Details Name: fbio_WarrantsIssuedInConjunctionWithExchangeOfPartnerCompanySConvertiblePreferredShares Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPortion of net income (loss) attributable to nonredeemable noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(2) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic

10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash Flows from Operating Activities: Â Â Net loss $ (67,846) $ (114,446) Reconciliation of net loss to net cash used in operating activities: Â Â Depreciation expense 753 1,476 Loss on disposal of property and equipment 29 0 Bad debt expense 152 574 Amortization of debt discount 1,365 1,867 Accretion of partner company convertible preferred shares (737) 521 Non-cash interest 0 176 Loss on extinguishment of debt 0 2,796 Amortization of acquired intangible assets 1,629 2,138 Reduction in the carrying amount of operating lease right-of-use assets 1,893 1,052 Stock-based compensation expense 9,856 8,948 Issuance of partner company's common shares for research and development expenses 0 1,233 Expense associated with partner company warrant liabilities 445 (6,166) Common shares issued for dividend on partner company's convertible preferred shares 114 131 Research and development - licenses acquired, expense 0 3,000 Loss from deconsolidation/dissolution of subsidiaries 0 3,369 Asset impairment loss 2,649 2,923 Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities: Â Â Accounts receivable 4,605 10,897 Inventory 519 1,993 Other receivables - related party (57) (135) Prepaid expenses and other current assets 1,837 2,243 Other assets 927 (97) Accounts payable and accrued expenses (2,837) 433 Deferred revenue 0 (364) Income taxes payable (37) 1 Lease liabilities (2,390) (980) Other long-term liabilities (94) (94) Net cash used in operating activities (47,225) (76,511) Cash Flows from Investing Activities: Â Â Purchase of research and development licenses 0 (2,000) Purchase of property and equipment 0 (34) Other 0 (5) Acquisition of VYNE products 0 (5,000) Net cash used in investing activities 0 (7,039) Cash Flows from Financing Activities: Â Â Payment of Series A perpetual preferred stock dividends (4,016) (4,016) Proceeds from issuance of common stock for public offering, net 10,118 13,248 Proceeds from issuance of common stock for at-the-market offering, net 2,826 1,168 Proceeds from issuance of common stock under ESPP 51 0 Exercise of warrants for cash 30 0 Proceeds from partner companies' ESPP 133 88 Partner company's dividends declared and paid (352) (371) Proceeds from partner companies' sale of stock, options and warrants, net 26,214 24,455 Proceeds from partner companies' at-the-market offering, net 1,779 0 Proceeds from exercise of partner companies' equity grants 0 3 Proceeds from partner company convertible preferred shares 0 854 Stock and warrants issued for exchange of partner company preferred shares 341 0 Payment of debt issuance costs associated with partner company convertible preferred shares 0 (210) Proceeds from partner companies' long-term debt, net 5,000 (90) Repayment of partner companies' long-term debt 0 (40,375) Proceeds from partner company's line of credit 0 28,000 Repayment of partner company's line of credit 0 (30,948) Net cash (used in) provided by financing activities 42,124 (8,194) Net increase (decrease) in cash and cash equivalents and restricted cash (5,101) (91,744) Cash and cash equivalents and restricted cash at beginning of period 83,365 180,954 Cash and cash equivalents and restricted cash at end of period 78,264 89,210 Supplemental disclosure of cash flow information: Â Â Cash paid for interest 3,536 5,131 Cash paid (refunded) for income taxes 115 (52) Supplemental disclosure of non-cash financing and investing activities: Â Â Transfer of assets classified as held for sale 0 4,348 Exchange of partner company convertible preferred shares 3,408 0 Fair value of assets received by partner company in repurchase transaction 2,209 0 Fair value of supplies received by partner company expensed to research and development 2,509 0 Partner company accounts receivable write-off related to repurchase transaction (6,967) 0 Partner company accounts payable write-off related to repurchase transaction 3,644 0 Partner company's net purchase consideration of assets recorded to accrued other (1,395) 0 Settlement of restricted stock units into common stock 0 3 Unpaid partner company's offering cost 0 246 Partner company derivative warrant liability associated with partner company convertible preferred shares 0 33 Prepaid public offering cost $ 0 94 Partner company's warrants issued in conjunction with debt Â $ 272 X - DefinitionAccretion of partner company convertible preferred shares. + ReferencesNo definition available. + Details Name: fbio_AccretionOfPartnerCompanyConvertiblePreferredShares Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of common shares issued for exchange of partner company's convertible preferred shares. + ReferencesNo definition available. + Details Name: fbio_CommonSharesIssuedForExchangeOfPartnerCompanyConvertiblePreferredShares Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) from deconsolidation and dissolution of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + ReferencesNo definition available. + Details Name: fbio_DeconsolidationAndDissolutionGainLossAmount Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of exchange of partner company convertible preferred shares, classified as non-cash activities. + ReferencesNo definition available. + Details Name: fbio_ExchangeOfPartnerCompanyConvertiblePreferredShares Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with partner company warrant liabilities. + ReferencesNo definition available. + Details Name: fbio_ExpenseAssociatedWithPartnerCompanyWarrantLiabilities Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of exchange fair value of assets received by partner company in repurchase transaction. + ReferencesNo definition available. + Details Name: fbio_FairValueOfAssetsReceivedByPartnerCompanyInRepurchaseTransaction Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of exchange fair value of supplies received by partner company expensed to research and development + ReferencesNo definition available. + Details Name: fbio_FairValueOfSuppliesReceivedByPartnerCompanyExpensedToResearchAndDevelopment Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase decrease in lease liabilities. + ReferencesNo definition available. + Details Name: fbio_IncreaseDecreaseInLeaseLiabilities Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of issuance of common stock for research and development expenses. + ReferencesNo definition available. + Details Name: fbio_IssuanceOfCommonStockForResearchAndDevelopmentExpenses Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of Partner company accounts payable write-off related to repurchase transaction. + ReferencesNo definition available. + Details Name: fbio_PartnerCompanyAccountsPayableWriteOffRelatedToRepurchaseTransaction Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of exchange of partner company accounts receivable write-off related to repurchase transaction + ReferencesNo definition available. + Details Name: fbio_PartnerCompanyAccountsReceivableWriteOffRelatedToRepurchaseTransaction Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPartner company derivative warrant liability associated with partner company share-settled notes + ReferencesNo definition available. + Details Name: fbio_PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of Partner company's net purchase consideration of assets recorded to accrued other. + ReferencesNo definition available. + Details Name: fbio_PartnerCompanySNetPurchaseConsideration Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayment of debt issuance costs associated with partner company share-settled notes + ReferencesNo definition available. + Details Name: fbio_PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of future offering costs paid for in current reporting period. + ReferencesNo definition available. + Details Name: fbio_PrepaidOfferingCosts Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from exercise of equity grants. + ReferencesNo definition available. + Details Name: fbio_ProceedsFromExerciseOfEquityGrants Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity excluding at-the-market offerings. + ReferencesNo definition available. + Details Name: fbio_ProceedsFromIssuanceOfCommonStockExcludingAtMarketOfferings Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity from under the Employee Stock Purchase Plan + ReferencesNo definition available. + Details Name: fbio_ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of partners company preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + ReferencesNo definition available. + Details Name: fbio_ProceedsFromIssuanceOfPartnerCompanyConvertiblePreferredShares Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of subsidiaries at the market offering capital contribution to the entity. + ReferencesNo definition available. + Details Name: fbio_ProceedsFromIssuanceOfSubsidiariesAtMarketOffering Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from partner companies' sale of stock and warrants + ReferencesNo definition available. + Details Name: fbio_ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash proceeds from (payments for) sale or purchase of VYNE products. + ReferencesNo definition available. + Details Name: fbio_ProceedsFromSalePaymentsForAcquisitionOfVyneProducts Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from stock and warrants issued for exchange of partner company preferred shares. + ReferencesNo definition available. + Details Name: fbio_ProceedsFromStockAndWarrantsIssuedForExchangeOfPartnerCompanyPreferredShares Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of cash inflow from subsidiary's employee stock purchase plan (ESPP). + ReferencesNo definition available. + Details Name: fbio_ProceedsFromSubsidiarySEmployeeStockPurchasePlan Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionResearch and development-licenses acquired, expense + ReferencesNo definition available. + Details Name: fbio_ResearchAndDevelopmentLicensesAcquiredExpense Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of common stock issued for settlement of restricted stock unit. + ReferencesNo definition available. + Details Name: fbio_SettlementOfRestrictedSharesUnitsIntoCommonStock Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of stock issued during the period relating to cashless exercise of warrants. + ReferencesNo definition available. + Details Name: fbio_StockIssuedDuringPeriodValueCashLessExerciseOfWarrants Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of unpaid partner company's offering cost that were incurred during a noncash or partial noncash transaction. + ReferencesNo definition available. + Details Name: fbio_UnpaidPartnerCompanyOfferingCost Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance

Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in receivables due from related parties classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseDueFromOtherRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_PaidInKindInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of investments transferred to the entity's investments in noncash transactions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_TransferToInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Ō‌rganization and Description of Business 6 Months Ēnded Jun. 30, 2024 Organization and Description of Business Â Organization and Description of Business 1. Organization and Description of BusinessFortress Biotech, Inc. (â€œFortressâ€ or the â€œCompanyâ€) is a biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holding and dividend and royalty revenue streams. Fortress works in concert with its extensive network of key opinion leaders to identify and evaluate promising products and product candidates for potential acquisition. The Company has executed such arrangements in partnership with some of the worldâ€™s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center (â€œCOHâ€ or â€œCity of Hopeâ€), Fred Hutchinson Cancer Center, Dana-Farber Cancer Institute, Nationwide Childrenâ€™s Hospital, Cincinnati Childrenâ€™s Hospital Medical Center, Columbia University, the University of Pennsylvania, AstraZeneca plc and Dr. Reddyâ€™s Laboratories, Ltd.Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business, scientific, regulatory, legal and finance expertise to help the partners achieve their goals. Partner and subsidiary companies then assess a broad range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint ventures, partnerships, out-licensings, sales transactions, and public and private financings. To date, four partner companies are publicly-traded, and three have consummated strategic partnerships with industry leaders, including AstraZeneca plc as successor-in-interest to Alexion Pharmaceuticals,Â Inc. (â€œAstraZenecaâ€) and Sentynl Therapeutics, Inc. (â€œSentynlâ€). Our subsidiaries and partner companies that are pursuing development and/or commercialization of biopharmaceutical products and product candidates are: Avenue Therapeutics, Inc. (Nasdaq: ATXI, â€œAvenueâ€), Baergic Bio, Inc. (â€œBaergicâ€, a subsidiary of Avenue), Cellvation, Inc. (â€œCellvationâ€), Checkpoint Therapeutics, Inc. (Nasdaq: CKPT, â€œCheckpointâ€), Cyprium Therapeutics, Inc. (â€œCypriumâ€), Helocyte, Inc. (â€œHelocyteâ€), Journey Medical Corporation (Nasdaq: DERM, â€œJourneyâ€ or â€œJMCâ€), Mustang Bio, Inc. (Nasdaq: MBIO, â€œMustangâ€) and Oncogenuity, Inc. (â€œOncogenuityâ€). As used throughout this filing, the words â€œweâ€, â€œusâ€ and â€œourâ€ may refer to Fortress individually, to one or more of its subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context. Generally, â€œsubsidiaryâ€ refers to a private Fortress subsidiary, â€œpartner companyâ€ refers to a public Fortress subsidiary, and â€œpartnerâ€ refers to an entity with whom one of the foregoing parties has a significant business relationship, such as an exclusive license or an ongoing product-related payment obligation. The context in which any such term is used throughout this document, however, may dictate a different construal from the foregoing.Liquidity and Capital Resources Since inception, the Companyâ€™s operations have been financed primarily through the sale of equity and debt securities, from the sale of subsidiaries/partner companies, and the proceeds from the exercise of warrants. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and prepare regulatory filings and obtain regulatory approvals for its existing and new product candidates. The parent Companyâ€™s current cash and cash equivalents of $38.2 million are sufficient to fund the parent entity and private subsidiary operations for at least the next 12 months. However, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, sale of partner companies, grants or other arrangements to develop and prepare regulatory filings and obtain regulatory approvals for the existing

and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for the potential products, sales and marketing capabilities. If such funding is not available or not available on terms acceptable to the Company, the Companyâ€™s current development plans and plans for expansion of its general and administrative infrastructure may be curtailed. Fortress also has the ability, subject to limitations imposed by Rule 144 of the Securities Act of 1933 and other applicable laws and regulations, to raise money from the sale of common stock of the public companies in which it has ownership positions. Â â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting Policies Basis of Presentation and Principles of ConsolidationThe accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œGAAPâ€) for interim financial information and the instructions to FormÂ 10-Q and ArticleÂ 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Companyâ€™s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscalÂ year or any future period.The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of Avenue, Checkpoint, Mustang and Journey. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Companyâ€™s Annual Report on Form 10-K, which was filed with the United States Securities and Exchange Commission (â€œSECâ€) on March 28, 2024 (the â€œ2023 Form 10-Kâ€), from which the Company derived the balance sheet data at December 31, 2023, as well as Checkpointâ€™s Form 10-K, filed with the SEC on March 22, 2024, Mustangâ€™s Form 10-K, filed with the SEC on March 11, 2024, Avenueâ€™s Form 10-K, filed with the SEC on March 18, 2024, and Journeyâ€™s Form 10-K, filed with the SEC on March 29, 2024.The Companyâ€™s unaudited condensed consolidated financial statements include the results of the Companyâ€™s subsidiaries for which it has voting control but does not own 100% of the outstanding equity of the subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, but retains voting control, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations and presents non-controlling interests as a component of stockholdersâ€™ equity on its consolidated balance sheets. All intercompany income and/or expense items are eliminated entirely in consolidation prior to the allocation of net gain/loss attributable to non-controlling interest, which is based on ownership interests as calculated quarterly for each subsidiary.Use of EstimatesThe preparation of the Companyâ€™s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Companyâ€™s significant estimates include, but are not limited to provisions for coupons, chargebacks, wholesaler fees, specialty pharmacy discounts, managed care rebates, product returns, inventory realization, valuation of intangible assets, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.Restricted CashThe Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of JuneÂ 30,Â 2024 and DecemberÂ 31,Â 2023, the Company had $2.1 million and $2.4 million, respectively, of restricted cash representing pledges to secure debt obligations and letters of credit in connection with certain office leases, and an undertaking posted by Cyprium to secure potential damages in an injunctive proceeding. Â The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the unaudited condensed consolidated balance sheets to the unaudited condensed consolidated statements of cash flows as of the dates presented:â€‹â€‹â€‹

gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Measurements Â Fair Value Measurements 6. Fair Value Measurementsâ€‹Common Stock Warrant Liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Warrants($ in thousands)Â Â Â Â liabilitiesBalance at DecemberÂ 31,Â 2023â€‹$ 886 Change in fair value of common stock warrants - Avenueâ€‹â€‹(139) Change in fair value of common stock warrants - Checkpointâ€‹â€‹ â€” Change in fair value of placement agent warrants - Uricaâ€‹â€‹ (24)Exercise of common stock warrants - Avenueâ€‹â€‹ (400)Exchange of common stock warrants - Uricaâ€‹â€‹ (151)Balance at JuneÂ 30,Â 2024â€‹$ 172â€‹Checkpoint â€‹Checkpoint deemed the placement agent warrants it issued in connection with its registered direct offering (the â€œDecember 2022 Placement Agent Warrantsâ€) to be classified as liabilities on the balance sheet as they contain terms for redemption of the underlying security that are outside its control. The December 2022 Placement Agent Warrants were recorded at the time of closing at a fair value determined by using the Black-Scholes model. Checkpoint will revalue the December 2022 Placement Agent Warrants at each reporting period thereafter for as long as they remain outstanding. At June 30, 2024 and December 31, 2023, the liability associated with the December 2022 Placement Agent Warrants was $0.1 million.â€‹A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the warrant liability that are categorized within Level 3 of the fair value hierarchy was as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Exchange Amount; or (z) a combination of the foregoing. Â On June 27, 2024, as neither a qualified financing nor a sale of Urica occurred, Fortress elected to exchange the outstanding shares of Urica Preferred Stock, which was recorded as a liability, into 2,028,345 shares of Fortress common stock. â€‹Interest ExpenseInterest expense includes contractual interest, and fees include amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan. The following table shows the components of interest expense for all debt arrangements during the periods presented:â€‹â€‹â€‹

the Companyâ€™s subsidiaries, and a performance-based bonus program that is designed to result in performance-based compensation that is deductible without limit under Section 162(m) of the Internal Revenue Code of 1986, as amended.â€‹On JanuaryÂ 1, 2024 and 2023, the Compensation Committee grantedÂ 216,465Â shares each to Dr.Â Rosenwald and Mr.Â Weiss. These equity grants were made in accordance with the LTIP, and each award representsÂ 1% of total outstanding shares of the Company as of the dates of such grants. The sharesâ€™ original vesting terms includes vesting in full if the employee was either in the service of the Company as an employee, Board member or consultant (or any combination of the foregoing) on the tenth anniversary of the LTIP, or the eligible employee has an involuntary Separation from Service (as defined in the LTIP).Â The only other vesting condition â€“ one based on the achievement of an increase in the Companyâ€™s market capitalization â€“ has already been achieved, with respect to each annual award under the LTIP. The shares awarded under the LTIP will also vest in full (and the Companyâ€™s repurchase option on each tranche of shares granted thereunder will accordingly lapse) upon the occurrence of a Corporate Transaction (as defined in the LTIP), if the eligible employee is in service to the Company on the date of such Corporate Transaction. The fair value of each grant on the grant date was approximately $0.7Â million for the 2024 grant and $0.8 million for the 2023 grant. Â For the three months ended JuneÂ 30,Â 2024 and 2023, the Company recorded stock compensation expense related to LTIP grants of approximately $1.7Â million and $1.5Â million, respectively, and for the six months ended JuneÂ 30,Â 2024 and 2023, the Company recorded stock compensation expense related to LTIP grants of approximately $3.3Â million and $2.9Â million, respectively, on the unaudited condensed consolidated statement of operations.Capital Raises 2021 ShelfOn July 23, 2021, the Company filed a shelf registration statement (File No. 333-258145) on Form S-3, which was declared effective on July 30, 2021 (the â€œ2021 Shelfâ€). Approximately $86.2 million of securities were available for sale under the 2021 Shelf as of JuneÂ 30,Â 2024, subject to General Instruction I.B.6. of Form S-3. On May 17, 2024, the Company filed a shelf registration statement (File No. 333-279516) on Form S-3, which was declared effective on May 30, 2024 (the â€œ2024 Shelfâ€). All $50.0 million of securities were available for sale under the 2024 Shelf as of June 30, 2024, subject to General Instruction I.B.6. of Form S-3.At the Market OfferingDuring the six months ended JuneÂ 30, 2024, the Company issued and sold approximately 1.6 million shares at an average price of $1.87 per share for gross proceeds of $2.9 million. During the six months ended JuneÂ 30, 2023, the Company issued and sold approximately 0.1 million shares at an average price of $11.31 for gross proceeds of $1.2 million.Registered Direct Offering In January 2024, Fortress closed a registered direct offering of an aggregate of 3,303,305 shares of its common stock and warrants to purchase up to 3,303,305 shares of its common stock at a combined purchase price of $3.33 per share of common stock and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $3.21 per share, were immediately exercisable, and expire five years following the date of issue. Net proceeds to Fortress, after deducting the placement agentâ€™s fees and other offering expenses, were approximately $10.2 million.Checkpoint 2023 Shelf Registration Statement In March 2023, Checkpoint filed a shelf registration statement (File No. 333-270843) on Form S-3 (the â€œCheckpoint 2023 S-3â€), which was declared effective May 5, 2023. Under the Checkpoint 2023 S-3, Checkpoint may sell up to a total of $150 million of its securities. As of June 30, 2024, approximately $77.7 million of the securities remains available for sale through the Checkpoint 2023 S-3, subject to General Instruction I.B.6 of Form S-3.â€‹Checkpoint Registered Direct Offering In January 2024, Checkpoint closed on a registered direct offering (the â€œCheckpoint January 2024 Registered Direct Offeringâ€) with a single institutional investor for the issuance and sale of 1,275,000 shares of its common stock and 6,481,233 pre-funded warrants. Each pre-funded warrant was exercisable for one share of Checkpoint common stock. The Checkpoint common stock and the pre-funded warrants were sold together with common stock warrants (the â€œCheckpoint January 2024 Common Warrantsâ€) to purchase up to 7,756,233 shares of Checkpoint common stock, at a purchase price of $1.805 per share of common stock and $1.8049 per pre-funded warrant. The pre-funded warrants were funded in full at closing except for a nominal exercise price of $0.0001 and are exercisable commencing on the closing date and will terminate when such pre-funded warrants are exercised in full. The Checkpoint January 2024 Common Warrants are exercisable immediately upon issuance and will expire five years following the issuance date and have an exercise price of $1.68 per share. Checkpoint also issued the placement agent warrants to purchase up to 465,374 shares of common stock with an exercise price of $2.2563 per share. Net proceeds to Checkpoint from the Checkpoint January 2024 Registered Direct Offering were $12.6 million after deducting commissions and other transaction costs. As of July 2024, all of the pre-funded warrants from the Checkpoint January 2024 Registered Direct Offering were fully exercised (see Note 19). Pursuant to the Companyâ€™s Founders Agreement with Checkpoint, Checkpoint issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the registered direct offering noted above. Accordingly, Checkpoint issued 193,905 shares of common stock to Fortress for the six months ended June 30, 2024.Avenue 2021 Shelf Registration StatementIn December 2021, Avenue filed a shelf registration statement (File No. 333-261520) on Form S-3 (the â€œAvenue 2021 S-3â€), which was declared effective on December 10, 2021. As of JuneÂ 30,Â 2024, approximately $24.6 million of the securities were available for sale under the Avenue 2021 S-3, subject to General Instruction I.B.6. of Form S-3.Avenue 2024 Warrant Exercises and Private PlacementOn January 5, 2024, Avenue entered into (i) an inducement offer letter agreement (the â€œJanuary 2023 Investor Inducement Letterâ€) with a certain investor (the â€œJanuary 2023 Investorâ€) in connection with certain outstanding warrants to purchase up to an aggregate of 25,871 shares of Common Stock, originally issued to the January 2023 Investor on January 31, 2023 (the â€œJanuary 2023 Warrantsâ€) and (ii) an inducement offer letter agreement (the â€œNovember 2023 Investor Inducement Letter Agreementâ€ and, together with the January 2023 Investor Inducement Letter, the â€œJanuary 2024 Warrant Inducementâ€) with certain investors (the â€œNovember 2023 Investorsâ€ and, together with the January 2023 Investor, the â€œHoldersâ€) in connection with certain outstanding warrants to purchase up to an aggregate of 194,667 shares of Common Stock, originally issued to the November 2023 Investors on November 2, 2023 (the â€œNovember 2023 Warrantsâ€ and, together with the January 2023 Warrants, the â€œExisting Warrantsâ€). The January 2023 Warrants had an exercise price of $116.25 per share, and the November 2023 Warrants had an exercise price of $22.545 per share. â€‹Pursuant to the January 2024 Warrant Inducement, (i) the January 2023 Investor agreed to exercise its January 2023 Warrants for cash at a reduced exercise price of $22.545 per share and (ii) the November 2023 Investors agreed to exercise their November 2023 Warrants for cash at the existing exercise price of $22.545, in each case in consideration for Avenueâ€™s agreement to issue in a private placement (x) Series A Warrants to purchase up to 220,538 shares of Avenue Common Stock and (y) Series B Warrants to purchase up to 220,538 shares of Avenue Common Stock. The net proceeds to Avenue from the exercise of the warrants was approximately $4.5 million, after deducting placement agent fees and estimated offering costs, but without giving effect to the exercise of the Series A Warrants and Series B Warrants issued in the January 2024 Warrant Inducement.â€‹The fair value of the Series A Warrants and Series B Warrants was allocated between the January 2023 Warrants and the November 2023 Warrants on a weighted basis, with approximately $0.6 million allocated to the January 2023 Warrants and recorded to loss on common stock warrant liabilities in the condensed consolidated statement of operations, and the approximately $4.3 million allocated to the November 2023 Warrants deemed to be a dividend such that it was included in net loss attributable to common stockholders in the calculation of net loss per share in the condensed consolidated statement of operations (see Note 12). â€‹â€‹Also in April 2024, Avenue entered into definitive agreements for the immediate exercise of certain of its existing outstanding warrants for cash an aggregate of 689,680 warrants for shares of Avenueâ€™s common stock at a reduced exercise price of $6.20 per share (the â€œMay 2024 Warrant Inducementâ€). The exercised warrants are comprised of warrants to purchase shares of common stock originally issued by Avenue on October 11, 2022, each having an exercise price of $116.25 per share, Series A and Series B warrants to purchase shares of common stock originally issued by Avenue on November 2, 2023, each having an exercise price of $22.545 per share, and warrants to purchase shares of common stock originally issued by Avenue on January 9, 2024, each having an exercise price of $22.545 per share.In consideration for the immediate exercise of the warrants for cash in the May 2024 Warrant Inducement, Avenue issued two new unregistered series of warrants to purchase up to a total of 1,379,360 shares of Avenue common stock for a payment of $0.125 per warrant. The warrants have an exercise price of $6.20 per share, and terms of eighteen months for one series and five years for the other series. Total net proceeds to Avenue were approximately $3.7 million after deducting placement agent fees and other expenses payable by Avenue.In May 2024, Avenue entered into an At-the-Market Offering Agreement (the â€œAvenue ATMâ€)Â under which Avenue may offer and sell, from time to time at its sole discretion, up to $3.9 million of shares of its common stock. The offer and sale of the shares will be made pursuant to a base prospectus forming a part of the 2021 Avenue S-3, and the related prospectus supplement dated May 10, 2024.Â During the six months ended JuneÂ 30,Â 2024, Avenue issued 87,683 shares through the Avenue ATM for net proceeds of $0.3 million. â€‹Pursuant to the Companyâ€™s Founders Agreement with Avenue, Avenue issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the warrant exercises noted above. Accordingly, Avenue issued 25,567 shares of common stock to Fortress for the six-month period ended June 30, 2024.Mustang 2021 Shelf Registration Statement and At-the-Market Offering (the â€œMustang ATMâ€) On April 23, 2021, Mustang filed a shelf registration statement on Form S-3 (File No. 333-255476) (the â€œMustang 2021 S-3â€), which was declared effective on May 24, 2021. Under the Mustang 2021 S-3, Mustang was able to sell up to a total of $200.0 million of its securities. In the six months ended June 30, 2024, Mustang sold approximately $4.4 million of securities under the Mustang 2021 S-3 until its expiration on May 24, 2024. On May 31, 2024, Mustang filed a shelf registration statement on Form S-3 (File No. 333-279891) (the â€œMustang 2024 S-3â€), which was declared effective on June 12, 2024. Under the Mustang 2024 S-3, Mustang may sell up to a total of $40.0 million of its securities. As of June 30, 2024, approximately $37.5 million of the Mustang 2024 S-3 remains available for sales of securities, subject to General Instruction I.B.6. of Form S-3. On May 31, 2024, Mustang entered into an At-the-Market Offering Agreement (the â€œMustang ATMâ€) relating to the sale of shares of common stock pursuant to the Mustang 2024 S-3. During the six months ended JuneÂ 30,Â 2024, Mustang issued no shares through the Mustang ATM. â€‹Mustang Public OfferingIn May 2024, Mustang closed on a public offering of 1,160,000 shares of common stock and pre-funded warrants to purchase up to 15,717,638 shares of common stock (or common stock equivalents in lieu thereof), and three series of 16,877,638 warrants each for a total of 50,632,914 warrants with a combined public offering price of $0.237 per share (or per share common stock equivalent in lieu thereof) and accompanying warrants with an exercise price of $0.237 per share. The Series A-1 warrants have a five-year term, the Series A-2 warrants have a twenty-four month term, and the Series A-3 warrants have a nine month term. The warrants contain customary anti-dilution adjustments to the exercise price, including share splits, share dividends, rights offerings and pro rata distributions. The net proceeds of the public offering, after deducting the fees and expenses of the placement agent and other offering expenses payable by Mustang was approximately $3.3 million. Â All of the 15,717,638 pre-funded warrants were exercised as of June 30, 2024.Mustang also amended certain existing warrants to purchase up to 2,588,236 shares of common stock previously issued in October 2023 with an exercise price of $1.58 per share such that the amended warrants have a reduced exercise price of $0.237 per share, and have a five-year term from date of shareholder approval.Mustang Registered Direct OfferingIn June 2024, Mustang closed on a registered direct offering of 3,025,000 shares of common stock at $0.41 per share (or common stock equivalent) priced at-the-market under Nasdaq rules and pre-funded warrants to purchase up to 3,105,000 shares of common stock, at a price per pre-funded warrant equal to $0.4099, the price per share of common stock, less $0.001. Â The pre-funded warrants have an exercise price of $0.001 per share, became exercisable upon issuance and remain exercisable until exercised in full. In a concurrent private placement, Mustang also agreed to issue and sell unregistered warrants to purchase up to 6,130,000 shares of its common stock, with an exercise price of $0.41 per share, exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants and will expire five years from the date of stockholder approval. Â Net proceeds were approximately $2.2 million, after placement agentâ€™s fees and other offering expenses of approximately $0.3 million. All of the 3,105,000 pre-funded warrants were exercised as of June 30, 2024.Pursuant to the Companyâ€™s Founders Agreement with Mustang, Mustang issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the financings noted above. Accordingly, Mustang issued 575,191 shares of common stock to Fortress for the six-month period ended June 30, 2024.Journey 2022 Shelf Registration Statement and At-the-Market OfferingOn December 30, 2022, Journey filed a shelf registration statement on Form S-3 (File No. 333-269079) (the â€œJourney 2022 S-3â€), which was declared effective on January 26, 2023. The Journey 2022 S-3 covers the offering, issuance and sale by Journey of up to an aggregate of $150.0 million of Journeyâ€™s common stock, preferred stock, debt securities, warrants, and units. In connection with the Journey 2022 S-3, Journey entered into a sales agreement relating to the sale of shares of Journeyâ€™s common stock in an at-the-market offering (the â€œJourney ATM Sales Agreementâ€). In accordance with the terms of the Journey ATM Sales Agreement, Journey may offer and sell up to 4,900,000 shares of its common stock, par value $0.0001 per share, from time to time. For the six months ended June 30, 2024, Journey issued and sold approximately 0.3 million shares of common stock at an average price of $5.28 per share for gross proceeds of $1.5 million under the Journey ATM Sales Agreement. At June 30, 2024, 3,861,553 shares remain available for issuance under the Journey ATM Sales Agreement. X - DefinitionThe entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Â Commitments and Contingencies â€‹14. Commitments and ContingenciesLeasesAt JuneÂ 30,Â 2024, Mustang identified triggering events that required an impairment of the asset group consisting of itsâ€™ right-of-use asset and associated leasehold improvements. The assessment concluded that impairment existed as of June 30, 2024, and the impairment loss was allocated to the leasehold improvements and right-of-use assets based on the relative carrying amounts of the assets (see Note 3). During three and six months ended JuneÂ 30,Â 2024 and 2023, the Company recorded the following as lease costs for the periods presented:â€‹Â Â Â Â Three Months Ended JuneÂ 30,Â Â Â Â Â Â Six Months Ended JuneÂ 30,Â Â Â Â Â Â ($ in thousands)â€‹2024â€‹2023â€‹2024â€‹2023â€‹Operating lease costâ€‹$ 595â€‹$ 950â€‹$ 1,235â€‹$ 1,969â€‹Shared lease costsâ€‹Â (519)â€‹â€‹ (519)â€‹Â (1,042)â€‹â€‹ (1,034)â€‹Variable lease costâ€‹Â 174â€‹â€‹ 199â€‹Â 390â€‹â€‹ 400â€‹Total lease expenseâ€‹$ 250â€‹$ 630â€‹$ 583â€‹$ 1,335â€‹â€‹The following tables summarize quantitative information about the Companyâ€™s operating leases, under the adoption of ASC Topic 842, Leases:â€‹Â Â Â Â Six Months Ended JuneÂ 30,Â Â Â Â Â Â Â ($ in thousands)â€‹2024â€‹2023Â â€‹Operating cash flows from operating leasesâ€‹$ (1,850)â€‹$ (1,762)â€‹â€‹Right-of-use assets exchanged for new operating lease liabilitiesâ€‹$ â€”â€‹$ â€”â€‹Weighted-average remaining lease term â€” operating leases (years)â€‹Â 4.0â€‹Â 4.4â€‹â€‹Weighted-average discount rate â€” operating leasesâ€‹Â 6.0%Â Â Â 6.5%â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â FutureÂ Lease($ in thousands)â€‹LiabilityNine Months Ended December 31, 2024â€‹$ 1,819Year Ended DecemberÂ 31,Â 2025â€‹Â 3,542Year Ended DecemberÂ 31,Â 2026â€‹Â 3,272Year Ended DecemberÂ 31,Â 2027â€‹â€‹ 2,923Year Ended DecemberÂ 31,Â 2028â€‹â€‹ 2,967Otherâ€‹Â 8,125Total operating lease liabilitiesâ€‹Â 22,648Less: present value discountâ€‹Â (4,233)Net operating lease liabilities, short-term and long-termâ€‹$ 18,415â€‹IndemnificationIn accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Companyâ€™s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. The Company and its subsidiaries and partner companies also provide indemnification of contractual counterparties (sometimes without monetary caps) to clinical sites, service providers and licensors.â€‹Legal Proceedingsâ€‹In the ordinary course of business, the Company and its subsidiaries and partner companies may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Companyâ€™s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeing resulting alleged damages.â€‹University of Tennessee Research Foundation v. Caelum Biosciences, Inc.Caelum Biosciences, Inc. (â€œCaelumâ€), a former subsidiary of Fortress that was sold to AstraZenecaâ€™s Alexion (â€œAlexionâ€) in October 2021, is the defendant in a lawsuit brought by The University of Tennessee Research Foundation (â€œUTRFâ€) captioned as University of Tennessee Research Foundation v. Caelum Biosciences, Inc., No. 19-cv-00508, which is pending in the United States District Court for the Eastern District of Tennessee (the â€œUTRF Litigationâ€).Â UTRF brought claims against Caelum, for, inter alia, tortious interference and trade secret misappropriation.Â UTRF primarily alleges that Caelum unauthorizedly used non-patent trade secrets owned by UTRF in the development of Caelumâ€™s 11-1F4 monoclonal antibody, known as CAEL-101.Â Under the agreement pursuant to which Alexion acquired Caelum (as amended, the â€œDOSPAâ€), Fortress has indemnification obligations of Caelum under certain circumstances, including for certain of Caelumâ€™s legal expenses and potential damages arising out of the UTRF Litigation (with such indemnification capped in the aggregate as to Fortress at the amount of Caelum acquisition proceeds received by Fortress â€“ approximately $57 million to date - and which, at Caelumâ€™s election, may be satisfiable in the

form of offsets against future amounts that Caelum may owe Fortress under the DOSPA).Â Caelum is defending the UTRF Litigation, with Fortress participating in such defense and maintaining a consent right over any potential settlements.Â Caelumâ€™s legal fees and costs in defending the UTRF Litigation are being reimbursed by Fortress by distribution from a $15 million escrow account established concurrently with the acquisition of Caelum; Fortress considers the amount remaining in escrow to be in excess of the amount of its anticipated out-of-pocket indemnifiable costs and damages in the UTRF Litigation and therefore has not accrued any liability pertaining to this indemnity.Â Caelum and Fortress both believe the UTRF Litigation is without merit and intend to continue defending it vigorously (including exhausting all appeals if applicable).Â A jury trial is scheduled for September 2024 in Knoxville, TN. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions 6 Months Ended Jun. 30, 2024 Related Party Transactions Â Related Party Transactions 15. Related Party TransactionsFounders AgreementThe Company has entered into Founders Agreements and, in some cases, exchange agreements with certain of its subsidiaries as described in the 2023 Form 10-K. The following table summarizes, by partner company/subsidiary, the effective date of the Founders Agreements and Payment-in-Kind (â€œPIKâ€) dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, exchange agreements, and the subsidiaries' certificates of incorporation:â€‹â€‹â€‹

http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenues from Contracts and Significant Customers 6 Months Ended Jun. 30, 2024 Revenues from Contracts and Significant Customers Â Revenues from Contracts and Significant Customers 17. Revenues from Contracts and Significant CustomersDisaggregation of Total RevenueJourney has the following actively marketed products, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Luxamend, Targadox, and Ximino (until September 2023). All of Journeyâ€™s product revenues are recorded in the U.S.Â â€‹The table below summarizes the Companyâ€™s revenue for the periods presented ($ in thousands):â€‹â€‹â€‹

then in effect (such lower price, the â€œBase Share Priceâ€). In such case, the exercise price of the Warrants will be reduced to equal the Base Share Price. The Warrants are immediately exercisable and will expire on July 25, 2031 and may be net exercised for no cash payment at the holderâ€™s election. The Company also agreed to file a registration statement to register the resale of the shares of Company common stock issuable upon exercise of the Warrants.â€‹Fortress Dividendsâ€‹On July 5, 2024, Fortress announced that the Companyâ€™s Board of Directors had decided to pause the monthly dividend of $0.1953125 per share of the Companyâ€™s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the â€œSeries A Preferred Stockâ€). In accordance with the terms of the Series A Preferred Stock, dividends on the Series A Preferred Stock will continue to accrue and cumulate until such dividends are authorized or declared. The pausing of these dividends will defer approximately $0.7 million in cash dividend payments each month. The Board intends to revisit its decision regarding the monthly dividend regularly and will assess the profitability and cash flow of the Company to determine whether and when the pause should be lifted.â€‹JourneyOn July 9, 2024, Journey entered into the SWK Amendment. The SWK Amendment increased the total amount of the Credit Facility from $20.0 million to $25.0 million. The $5.0 million of additional availability added in the Amendment will be drawn upon FDA approval of DFD-29, subject to Journey receiving approval on or before June 30, 2025. Â UricaOn July 15, 2024, Urica entered into an asset purchase agreement (the â€œAPAâ€), royalty agreement (the â€œRoyalty Agreementâ€), and related agreements (collectively, the â€œTransaction Documentsâ€) with Crystalys Therapeutics, Inc. (â€œCrystalysâ€). Crystalys is a Delaware corporation incorporated in 2022 and seeded by leading life sciences institutional investors. Under the Transaction Documents, Urica sold the rights to its URAT1 inhibitor product candidate in development for the treatment of gout, dotinurad, and related intellectual property, licenses and agreements to Crystalys. In return, Crystalys issued to Urica shares of its common stock equal to 35% of Crystalysâ€™ outstanding equity. Uricaâ€™s equity position cannot be reduced below 15% of Crystalysâ€™ fully-diluted equity capitalization until it raises $150 million in equity securities.â€‹The Transaction Documents also grant Urica a securitized three percent (3%) royalty on future net sales of dotinurad to be paid by Crystalys, as well as the right to receive nominal cash reimbursement payments for certain clinical and development costs incurred by Urica related to dotinurad. Urica has the right to appoint one director to the board of directors of Crystalys, as well as an additional board observer. Urica has committed to providing transition support to Crystalys for 90 days, and Crystalys is obliged to use commercially reasonable efforts to develop and commercialize dotinurad. â€‹Checkpointâ€‹In July 2024, Checkpoint closed on a registered direct offering (the â€œCheckpoint July 2024 Registered Direct Offeringâ€) for the issuance and sale of an aggregate of 1,230,000 shares of its common stock at a purchase price of $2.05 per share of common stock. In addition, the offering includes 4,623,659 shares of common stock in the form of pre-funded warrants at a price of $2.0499. In a concurrent private placement, Checkpoint issued and sold common warrants (the â€œCheckpoint July 2024 Common Stock Warrantsâ€) to purchase up to 5,853,659 shares of common stock. The Checkpoint July 2024 Common Stock Warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Checkpoint July 2024 Common Stock Warrants with an exercise price of $2.05 per share and will expire five years following the issuance date. The total gross proceeds from the July 2024 Registered Direct Offering were approximately $12.0 million.â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (10,948) $ (24,776) $ (26,365) $ (46,313) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies Â Basis of Presentation and Principles of Consolidation Basis of Presentation and Principles of ConsolidationThe accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œGAAPâ€) for interim financial information and the instructions to FormÂ 10-Q and ArticleÂ 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Companyâ€™s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscalÂ year or any future period.The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of Avenue, Checkpoint, Mustang and Journey. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Companyâ€™s Annual Report on Form 10-K, which was filed with the United States Securities and Exchange Commission (â€œSECâ€) on March 28, 2024 (the â€œ2023 Form 10-Kâ€), from which the Company derived the balance sheet data at December 31, 2023, as well as Checkpointâ€™s Form 10-K, filed with the SEC on March 22, 2024, Mustangâ€™s Form 10-K, filed with the SEC on March 11, 2024, Avenueâ€™s Form 10-K, filed with the SEC on March 18, 2024, and Journeyâ€™s Form 10-K, filed with the SEC on March 29, 2024.The Companyâ€™s unaudited condensed consolidated financial statements include the results of the Companyâ€™s subsidiaries for which it has voting control but does not own 100% of the outstanding equity of the subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, but retains voting control, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations and presents non-controlling interests as a component of stockholdersâ€™ equity on its consolidated balance sheets. All intercompany income and/or expense items are eliminated entirely in consolidation prior to the allocation of net gain/loss attributable to non-controlling interest, which is based on ownership interests as calculated quarterly for each subsidiary. Use of Estimates Use of EstimatesThe preparation of the Companyâ€™s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Companyâ€™s significant estimates include, but are not limited to provisions for coupons, chargebacks, wholesaler fees, specialty pharmacy discounts, managed care rebates, product returns, inventory realization, valuation of intangible assets, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Restricted Cash Restricted CashThe Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of JuneÂ 30,Â 2024 and DecemberÂ 31,Â 2023, the Company had $2.1 million and $2.4 million, respectively, of restricted cash representing pledges to secure debt obligations and letters of credit in connection with certain office leases, and an undertaking posted by Cyprium to secure potential damages in an injunctive proceeding. Â The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the unaudited condensed consolidated balance sheets to the unaudited condensed consolidated statements of cash flows as of the dates

presented:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹â€‹2024â€‹2023Cash and cash equivalentsÂ Â Â Â $ 76,201Â Â Â Â $ 78,022Restricted cashâ€‹Â 2,063â€‹Â 11,188Total cash and cash equivalents and restricted cashâ€‹$ 78,264â€‹$ 89,210 Significant Accounting Policies Significant Accounting PoliciesThere have been no material changes in the Companyâ€™s significant accounting policies to those previously disclosed in the 2023 Form 10-K other than the following: Assets Held for Sale Assets Held for SaleÂ Assets held for sale represent assets that have met the criteria of â€œheld for saleâ€ accounting, as specified by Accounting Standards Codification (â€œASCâ€) 360, â€œLong-lived Assets.â€ As of June 30, 2024, there are $2.2Â million of lab and cell processing equipment, furniture and fixtures and computer equipment that are recorded as assets held for sale. The effect of suspending depreciation on the assets held for sale is immaterial to the results of operations. The assets held for sale are part of Mustangâ€™s repurchase of assets from uBriGene (Boston) Biosciences, Inc. (â€œuBriGeneâ€) (see Note 3). Recently Issued Accounting Pronouncements â€‹Recently Issued Accounting PronouncementsAccounting Standards Not Yet Adopted In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires that an entity report segment information in accordance with Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on its financial statement disclosures.â€‹In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on its financial statement disclosures. X - DefinitionDisclosure of accounting policy for assets held for sale. + ReferencesNo definition available. + Details Name: fbio_AssetsHeldForSalePolicyTextBlock Namespace Prefix: fbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for significant accounting policies. + ReferencesNo definition available. + Details Name: fbio_SignificantAccountingPoliciesPolicyTextBlock Namespace Prefix: fbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies Â Schedule of Cash and Cash Equivalents and restricted cash â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹â€‹2024â€‹2023Cash and cash equivalentsÂ Â Â Â $ 76,201Â Â Â Â $ 78,022Restricted cashâ€‹Â 2,063â€‹Â 11,188Total cash and cash equivalents and restricted cashâ€‹$ 78,264â€‹$ 89,210 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash and cash equivalents. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory (Tables) 6 Months Ended Jun. 30, 2024 Inventory Â Schedule of Inventory â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹December 31,($ in thousands)2024â€‹2023Raw materials$ 3,583â€‹$ 4,640Work-in-processÂ 296â€‹Â 884Finished goodsÂ 6,213â€‹Â 4,987Inventory reserveâ€‹ (405)â€‹â€‹ (305)Total inventories$ 9,687â€‹$ 10,206â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment (Tables) 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment Â Schedule of Property, Plant and Equipment â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â UsefulÂ LifeÂ Â Â Â JuneÂ 30,Â â€‹December 31,($ in thousands)â€‹(Years)â€‹2024â€‹2023â€‹â€‹â€‹Computer equipmentÂ â€‹3â€‹$ 595â€‹$ 595Furniture and fixturesÂ â€‹5â€‹Â 1,017â€‹Â 1,017Leasehold improvementsÂ â€‹15â€‹Â 13,175â€‹Â 13,175Buildingsâ€‹â€‹40â€‹â€‹ 581â€‹â€‹ 581Construction in progressÂ â€‹N/Aâ€‹Â â€”â€‹Â 29Total property and equipmentÂ â€‹â€‹â€‹â€‹ 15,368â€‹Â 15,397Impairment - leasehold improvementsâ€‹â€‹â€‹â€‹â€‹ (2,177)â€‹â€‹ â€”Less: Accumulated depreciationÂ â€‹â€‹â€‹â€‹ (9,645)â€‹Â (8,892)Property and equipment, netâ€‹â€‹â€‹â€‹$ 3,546â€‹$ 6,505 X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Tables) - Warrants to Purchase Common Stock [Member] 6 Months Ended Jun. 30, 2024 Schedule of revaluation of warrant liability â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Warrants($ in thousands)Â Â Â Â liabilitiesBalance at DecemberÂ 31,Â 2023â€‹$ 886 Change in fair value of common stock warrants - Avenueâ€‹â€‹ (139) Change in fair value of common stock warrants - Checkpointâ€‹â€‹ â€” Change in fair value of placement agent warrants - Uricaâ€‹â€‹ (24)Exercise of common stock warrants - Avenueâ€‹â€‹ (400)Exchange of common stock warrants - Uricaâ€‹â€‹ (151)Balance at JuneÂ 30,Â 2024â€‹$ 172 Checkpoint Common Stock Warrants Â Summary of the Weighted average Significant Unobservable Inputs â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹December 31,â€‹â€‹Checkpoint Warrantsâ€‹2024â€‹2023â€‹â€‹Exercise priceâ€‹$ 5.41â€‹$ 5.41â€‹â€‹Volatilityâ€‹â€‹ 106.9%â€‹â€‹ 96.4%â€‹â€‹Expected life in yearsâ€‹â€‹ 3.5â€‹â€‹ 4.0â€‹â€‹Risk-free rateâ€‹â€‹ 4.5%â€‹â€‹ 3.8%â€‹â€‹ Avenue Therapeutics, Inc [Member] Â Schedule of revaluation of warrant liability â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Avenueâ€‹â€‹Warrant($ in thousands)â€‹LiabilityAvenue common stock warrant liabilities at December 31, 2023â€‹$586Exercise of Avenue common warrantsâ€‹â€‹ (400)Change in fair value of common stock warrant liabilitiesâ€‹â€‹ (139)Avenue common stock warrant liabilities at June 30, 2024â€‹$47 Summary of the Weighted average Significant Unobservable Inputs â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹â€‹DecemberÂ 31â€‹â€‹â€‹â€‹2024â€‹â€‹2023â€‹â€‹Stock priceâ€‹$ 3.50â€‹â€‹$ 12.00â€‹â€‹Risk-free interest rateÂ Â Â Â 4.52%Â Â â€‹ 3.84%Â Â â€‹Expected dividend yieldÂ â€”Â Â â€‹ â€”Â Â â€‹Expected term in yearsÂ 3.3Â â€‹ 3.8Â â€‹Expected volatilityÂ 160%Â Â â€‹ 148%Â Â â€‹ Urica Â Summary of the Weighted average Significant Unobservable Inputs â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹December 31,â€‹â€‹2023Risk-free interest rateÂ Â Â Â 3.93%Â Â Expected dividend yieldÂ â€”Â Expected term in yearsÂ 0.5Â Expected volatilityÂ 153.6%Â Â Â â€‹ X - DefinitionTabular disclosure of revaluation of warrant liability. + ReferencesNo definition available. + Details Name: fbio_ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc Namespace Prefix: fbio_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Tables) 6 Months Ended Jun. 30, 2024 Intangible Assets, net Â Schedule of Journey intangible assets â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Payable and Accrued Expenses (Tables) 6 Months Ended Jun. 30, 2024 Accounts Payable and Accrued Expenses Â Schedule of accounts payable and accrued expenses Accounts payable and accrued expenses consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹December 31,($ in thousands)Â Â Â Â 2024Â Â Â Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹Accounts payableâ€‹$ 37,957â€‹$ 34,810Accrued expenses:Â â€‹Â Â Â â€‹Â Â Professional feesâ€‹â€‹ 2,260â€‹â€‹ 1,681Salaries, bonus and related benefitsâ€‹Â 4,903â€‹Â 8,531Research and developmentâ€‹Â 8,547â€‹Â 11,644Accrued royalties payableâ€‹Â 1,656â€‹Â 2,015Accrued coupon and rebates â€‹Â 6,596â€‹Â 9,987Return reserveâ€‹â€‹ 3,214â€‹â€‹ 4,077Other1â€‹Â 3,788â€‹Â 817Total accounts payable and accrued expensesâ€‹$ 68,921â€‹$ 73,562â€‹Note 1: Includes approximately $1.4 million of accrued consideration related to Mustangâ€™s Asset Purchase Agreement with uBriGene (see Note 3) as of June 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss per Common Share (Tables) 6 Months Ended Jun. 30, 2024 Net Loss per Common Share Â Schedule of Diluted Weighted Average Shares Outstanding â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹â€‹2024Â Â Â Â 2023Warrants to purchase Common StockÂ 5,769,787Â 127,296Options to purchase Common StockÂ 18,896Â 36,423Unvested Restricted StockÂ 1,693,684Â 1,374,116Unvested Restricted Stock UnitsÂ 273Â 73TotalÂ 7,482,640Â 1,537,908â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Tables) 6 Months Ended Jun. 30, 2024 Stockholders' Equity Â Schedule of Stock-Based Compensation Expense The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the periods presented:â€‹Three Months Ended JuneÂ 30,Â â€‹Six Months Ended JuneÂ 30,Â ($ in thousands)Â Â Â Â 2024Â Â Â Â 2023â€‹2024Â Â Â Â 2023Fortress:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Employee and non-employee awardsâ€‹$ 2,249â€‹$ 2,271â€‹$ 4,442â€‹$ 4,708Executive awards â€‹Â 273â€‹Â 410â€‹Â 497â€‹Â 817â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Partner Companies:â€‹Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Avenueâ€‹Â 192â€‹Â 27â€‹Â 383â€‹Â 38Checkpointâ€‹Â 1,171â€‹Â 567â€‹Â 1,881â€‹Â 1,536Mustangâ€‹Â (619)â€‹Â 45â€‹Â (542)â€‹Â 280Journeyâ€‹â€‹ 1,674â€‹â€‹ 873â€‹â€‹ 3,080â€‹â€‹ 1,519Otherâ€‹Â 58â€‹Â 24â€‹Â 115â€‹Â 50Total stock-based compensation expenseâ€‹$ 4,998â€‹$ 4,217â€‹$ 9,856â€‹$ 8,948 Schedule of Stock Option Activities â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

(14,216)Research and developmentâ€‹Â (3,807)â€‹Â (67,841)â€‹Â (71,648)Selling, general and administrativeâ€‹Â (25,433)â€‹â€‹ (24,347)â€‹â€‹ (49,780)Asset impairmentâ€‹â€‹ (3,143)â€‹â€‹ â€”â€‹â€‹ (3,143)Other expenseâ€‹â€‹ (1,285)â€‹Â (4,189)â€‹Â (5,474)Segment lossâ€‹$ (18,499)â€‹$ (95,947)â€‹$ (114,446)â€‹Pharmaceuticalâ€‹Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹andâ€‹â€‹â€‹â€‹â€‹â€‹Dermatologyâ€‹Biotechnologyâ€‹â€‹â€‹â€‹â€‹â€‹Productsâ€‹Productâ€ AssetsIntangible assets, netâ€‹$ 18,658â€‹$ â€”â€‹$ 18,658Tangible assetsâ€‹â€‹ 46,531â€‹â€‹ 80,496â€‹â€‹ 127,027Total segment assetsâ€‹$ 65,189â€‹$ 80,496â€‹$ 145,685â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

assets after costs to sell under the repurchase transaction. + ReferencesNo definition available. + Details Name: fbio_FairValueOfAssetsLessCostToSellInRepurchaseTransaction Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of exchange fair value of supplies with alternative future use expensed as research and development expense. + ReferencesNo definition available. + Details Name: fbio_FairValueOfSuppliesWithAlternativeFutureUseExpensedAsResearchAndDevelopmentExpense Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of exchange fair value of supplies with no alternative future use expensed as research and development expense. + ReferencesNo definition available. + Details Name: fbio_FairValueOfSuppliesWithNoAlternativeFutureUseExpensedAsResearchAndDevelopmentExpense Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of days within which the entity is obligated to sell, or otherwise dispose of, the assets purchased, pursuant to National Security Agreement. + ReferencesNo definition available. + Details Name: fbio_NumberOfDaysToDisposeOfAssetsPurchased Namespace Prefix: fbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of outstanding payables of the company. + ReferencesNo definition available. + Details Name: fbio_OutstandingPayables Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of outstanding receivables of the company. + ReferencesNo definition available. + Details Name: fbio_OutstandingReceivables Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIt represents payments of milestone. + ReferencesNo definition available. + Details Name: fbio_PaymentsOfMilestone Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of receivables net of payables due by the company. + ReferencesNo definition available. + Details Name: fbio_ReceivablesNetOfPayables Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of contingent fee payable on the proceeds of future financings. + ReferencesNo definition available. + Details Name: fbio_StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsAmount Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of contingent fee payable on the proceeds of future financings. + ReferencesNo definition available. + Details Name: fbio_StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsPercent Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionExpenses related to transactions having to do with sale of assets. + ReferencesNo definition available. + Details Name: fbio_TransactionRelatedExpenses Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fbio_InvagenPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_MustangTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=fbio_UbrigeneBostonBiosciencesInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=fbio_NetAssetsBelow20MillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory (Schedule of Inventory) (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Inventory Â Â Raw materials $ 3,583 $ 4,640 Work-in-process 296 884 Finished goods 6,213 4,987 Inventory reserve (405) (305) Total inventories $ 9,687 $ 10,206 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsAndSupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment (Schedule of Property, Plant and Equipment) (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Total property and equipment $ 15,368 $ 15,397 Impairment - leasehold improvements (2,177) Â Less: Accumulated depreciation (9,645) (8,892) Property and equipment, net 3,546 6,505 Computer equipment Â Â Property, Plant and Equipment [Line Items] Â Â Total property and equipment $ 595 595 Useful Life (Years) 3 years Â Furniture and fixtures Â Â Property, Plant and Equipment [Line Items] Â Â Total property and equipment $ 1,017 1,017 Useful Life (Years) 5 years Â Leasehold improvements Â Â Property, Plant and Equipment [Line Items] Â Â Total property and equipment $ 13,175 13,175 Useful Life (Years) 15 years Â Buildings Â Â Property, Plant and Equipment [Line Items] Â Â Total property and equipment $ 581 581 Useful Life (Years) 40 years Â Construction in progress Â Â Property, Plant and Equipment [Line Items] Â Â Total property and equipment $ 0 $ 29 X - DefinitionAmount of accumulated impairment loss for property plant and equipment. + ReferencesNo definition available. + Details Name: fbio_PropertyPlantAndEquipmentAccumulatedImpairment Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment (Narrative) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Depreciation expense $ 400 $ 800 $ 753 $ 1,476 Assets held for sale $ 2,209 Â 2,209 Â Impairment loss allocated to leasehold improvements Â Â 2,200 Â Impairment loss allocated to right-of-use asset Â Â 400 Â Leasehold improvements Â Â Â Â Tangible asset impairment charges Â Â $ 2,600 Â X - DefinitionAmount representing assets held for sale. + ReferencesNo definition available. + Details Name: fbio_AssetsHeldForSale Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-

28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLeasehold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_TangibleAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Common Stock Warrant Liabilities) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Common Stock Warrant liabilities at beginning of period Â $ 886 Â Change in fair value of Warrant liabilities $ 512 Â $ (6,166) Common Stock Warrant liabilities at end of period Â 172 Â Checkpoint Common Stock Warrants | Common Stock Warrant Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Exercise of common stock warrants Â (400) Â Avenue | Common Stock Warrant Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Common Stock Warrant liabilities at beginning of period Â 586 Â Change in fair value of Warrant liabilities Â (139) Â Exercise of common stock warrants Â (400) Â Common Stock Warrant liabilities at end of period Â 47 Â Urica | Common Stock Warrant Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Exchange of warrants Â (151) Â Urica | Placement Agent Warrants Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Change in fair value of Warrant liabilities Â $ (24) Â X - DefinitionRepresents information pertaining to exchange of warrants. + ReferencesNo definition available. + Details Name: fbio_ExchangeOfWarrants Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents information pertaining to exercise of common stock warrants. + ReferencesNo definition available. + Details Name: fbio_ExerciseOfCommonStockWarrants Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents information pertaining to warrant liabilities current. + ReferencesNo definition available. + Details Name: fbio_WarrantLiabilitiesCurrent Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=fbio_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=fbio_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended Jun. 27, 2024 Dec. 30, 2022 Feb. 28, 2023 Jun. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Sale of stock, net proceeds Â $ 150,000 Â Â Â Stock offering, number of shares issued Â 4,900,000 Â Â Â Common stock warrant liabilities Â Â Â $ 172 $ 886 Sale of National Holding's stock, proceeds received Â $ 150,000 Â Â Â Urica | 8% Cumulative Convertible Class B Preferred Offering Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Stock offering, price per share Â Â $ 25.00 Â Â Stock offering, number of shares issued Â Â 135,494 Â Â Preferred Stock, dividend rate percentage 8.00% Â 8.00% Â Â Stock offering, aggregate fees paid Â Â $ 500 Â Â Urica | Common Stock Warrant Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Warrant expiration term 5 years Â Â Â Â Exchanged for warrants 202,834 Â Â Â Â Exercise price of warrants $ 1.68 Â Â Â Â Placement Agent Warrants | Checkpoint Common Stock Warrants | December 2022 Offering Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Common stock warrant liabilities Â Â Â $ 100 $ 100 X - DefinitionNumber of warrants or rights exchanged during the period. + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExchanged Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents information pertaining to warrant liabilities current. + ReferencesNo definition available. + Details Name: fbio_WarrantLiabilitiesCurrent Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=fbio_ConvertibleClassBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=fbio_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_December2022OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Weighted average Significant Unobservable Inputs) (Details) Jun. 30, 2024 $ / shares Y Dec. 31, 2023 Y $ / shares Checkpoint | Series A Warrants | Stock price Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input | $ / shares 5.41 5.41 Checkpoint | Series A Warrants | Risk-free interest rate Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input 0.045 0.038 Checkpoint | Series A Warrants | Expected term in years Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input 3.5 4.0 Checkpoint | Series A Warrants | Expected Volatility Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input 1.069 0.964 Avenue | Contingent Payment Warrants | Stock price Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input 3.50 12.00 Avenue | Contingent Payment Warrants | Risk-free interest rate Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input 0.0452 0.0384 Avenue | Contingent Payment Warrants | Expected term in years Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input 3.3 3.8 Avenue | Contingent Payment Warrants | Expected Volatility Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input 1.60 1.48 Urica | Placement Agent Warrants | Risk-free interest rate Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input Â 0.0393 Urica | Placement Agent Warrants | Expected term in years Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input Â 0.5 Urica | Placement Agent Warrants | Expected Volatility Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, measurement input Â 1.536 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=fbio_SeriesWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-

gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=fbio_ContingentPaymentWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=fbio_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Narrative) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Â Â Amortization of acquired intangible assets Â Â $ 1,629 $ 2,138 Journey Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Amortization of acquired intangible assets $ 800 $ 1,100 $ 1,600 $ 2,100 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_JourneyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Impairment loss $ 2,649 $ 3,143 $ 2,649 $ 3,143 Â Net intangible assets 18,658 Â 18,658 Â $ 20,287 Journey Â Â Â Â Â Total intangible assets - asset purchases 37,925 Â 37,925 Â 37,925 Accumulated amortization (16,124) Â (16,124) Â (14,495) Impairment loss Â Â (3,143) Â (3,143) Net intangible assets $ 18,658 Â $ 18,658 Â $ 20,287 Minimum | Journey Â Â Â Â Â Intangible assets, estimated useful lives 3 years Â 3 years Â Â Maximum | Journey Â Â Â Â Â Intangible assets, estimated useful lives 9 years Â 9 years Â Â X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_JourneyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Schedule of Future Amortization of Intangible Assets) (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Net intangible assets $ 18,658 $ 20,287 Journey Â Â Finite-Lived Intangible Assets [Line Items] Â Â Remainder of 2024 1,628 Â December 31, 2025 3,257 Â December 31, 2026 2,471 Â December 31, 2027 1,775 Â December 31, 2028 1,595 Â Thereafter 3,990 Â Sub-total 14,716 Â Asset not yet placed in service 3,942 Â Net intangible assets $ 18,658 $ 20,287 X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: fbio_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFinite Lived Intangible Assets Net, Excluding assets that has not been placed in service. + ReferencesNo definition available. + Details Name: fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIntangible assets not yet placed in service + ReferencesNo definition available. + Details Name: fbio_IntangibleAssetsNotYetPlacedInService Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_JourneyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt and Interest (Schedule of Debt) (Details) - USD ($) $ in Thousands 6 Months Ended Dec. 27, 2023 Jun. 30, 2024 Dec. 31, 2023 Aug. 27, 2020 Debt Instrument [Line Items] Â Â Â Â Less: Discount of notes

payable Â $ (2,993) $ (4,144) Â Total notes payable Â 67,007 60,856 Â Oaktree Note Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Total notes payable, gross Â $ 50,000 50,000 $ 50,000 Interest rate Â 11.00% Â Â Maturity Date, description Â August 31, 2025 Â Â SWK Term Loan Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Total notes payable, gross Â $ 20,000 $ 15,000 Â Interest rate Â 14.90% Â Â Maturity Date, description Â December 31, 2027 Â Â Basis spread on variable rate 7.75% Â Â Â Â X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentMaturityDateDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=fbio_OaktreeNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=fbio_SwkTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt and Interest (Narrative) (Details) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended Jul. 25, 2024 USD ($) Jun. 27, 2024 shares Dec. 27, 2023 USD ($) Dec. 30, 2022 shares Aug. 27, 2020 USD ($) Feb. 28, 2026 Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Feb. 28, 2023 USD ($) $ / shares shares Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Dec. 31, 2025 USD ($) Jul. 09, 2024 USD ($) Dec. 31, 2023 USD ($) Aug. 31, 2020 USD ($) Debt Instrument [Line Items] Â Â Â Â

fbio_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: fbio_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: duration X - DefinitionAmount of minimum gross proceeds from convertible preferred stock. + ReferencesNo definition available. + Details Name: fbio_ConvertiblePreferredStockConversionMinimumGrossProceeds Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents variable interest floor rate of debt. + ReferencesNo definition available. + Details Name: fbio_DebtInstrumentFloorRate Namespace Prefix: fbio_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionRepresents percentage of original principal amount to be paid as exit fees upon repayment of debt instrument. + ReferencesNo definition available. + Details Name: fbio_DebtInstrumentPercentageOfExitFees Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the percentage of prepayment premium to be paid at the time of prepayment of debt instrument. + ReferencesNo definition available. + Details Name: fbio_DebtInstrumentPercentageOfPrepaymentPremium Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of the required periodic payments including both interest and principal payments on principal amount. + ReferencesNo definition available. + Details Name: fbio_DebtInstrumentPeriodicPaymentPercentageOfPrincipalAmount Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the threshold revenue for no periodic repayment of debt during the specified period. + ReferencesNo definition available. + Details Name: fbio_DebtInstrumentThresholdRevenueConsideredForNoPeriodicPayment Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAdditional borrowing capital that can be drawn under the credit agreement. + ReferencesNo definition available. + Details Name: fbio_LineOfCreditFacilityAdditionalBorrowingCapacity Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPaid in Kind dividend, common stock's average trading price discount percentage. + ReferencesNo definition available. + Details Name: fbio_PaidInKindDividendCommonStockSAverageTradingPriceDiscountPercentage Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates type of variable interest rate on debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedPerTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=fbio_OaktreeNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=fbio_PartnerCompanyNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=fbio_SwkTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=fbio_DebtInstrumentRepaymentPeriodFromFebruary2026IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsLessThanThresholdRevenueAsOfDecember312025M Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=fbio_DebtInstrumentRepaymentPeriodFromFebruary2027IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsGreaterThanThresholdRevenueAsOfDecember3120 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=fbio_IfDebtInstrumentsPrepaidPriorToFirstAnniversaryOfClosingDateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=fbio_IfDebtInstrumentPrepaidOnOrAfterFirstAnniversaryButPriorToSecondAnniversaryOfClosingDateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=fbio_IfDebtInstrumentPrepaidAfterSecondAnniversaryOfClosingDateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=fbio_ConvertibleClassBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt and Interest (Interest Expense) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Â Â Â Â Interest expense, interest $ 1,491 $ 5,202 $ 3,484 $ 8,522 Â Amortization of fees 631 1,223 1,240 2,199 Â Interest expense, Total 2,122 6,425 4,724 10,721 Â Unamortized debt discount fees 2,993 Â 2,993 Â $ 4,144 Oaktree Note Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Interest expense, interest 1,390 1,391 2,781 2,781 Â Amortization of fees 522 712 1,024 1,136 Â Interest expense, Total 1,912 2,103 3,805 3,917 Â Partner company convertible preferred shares Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Interest expense, interest Â 391 Â 651 Â Amortization of fees 45 239 90 299 Â Debt Discount Amortization (403) Â (290) Â Â Interest expense, Total Â 630 Â 950 Â Interest expense, Total, Net (358) Â (200) Â Â Partner company installment payments - licenses Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Interest expense, interest Â 85 0 176 Â Amortization of fees Â Â 0 0 Â Interest expense, Total Â 85 0 176 Â Partner company notes payable Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Interest expense, interest 499 3,301 985 4,801 Â Amortization of fees 64 272 126 432 Â Interest expense, Total 563 3,573 1,111 5,233 Â Other Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Interest expense, interest 5 34 8 113 Â Amortization of fees Â Â 0 332 Â Interest expense, Total $ 5 $ 34 $ 8 $ 445 Â X - DefinitionAmount of debt discount amortization attributable to debt issuance costs. + ReferencesNo definition available. + Details Name: fbio_DebtDiscountAmortization Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNet Amount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesNo definition available. + Details Name: fbio_InterestExpenseTotalNet Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=fbio_OaktreeNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=fbio_PartnerCompanyConvertiblePreferredSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=fbio_PartnerCompanyInstallmentPaymentsLicensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=fbio_PartnerCompanyNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=fbio_OtherDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 27, 2024 Dec. 31, 2023 Accounts payable $ 37,957 Â $ 34,810 Accrued expenses: Â Â Â Professional fees 2,260 Â 1,681 Salaries, bonus and related benefits 4,903 Â 8,531 Research and development 8,547 Â 11,644 Accrued royalties payable 1,656 Â 2,015 Accrued coupon and rebates 6,596 Â 9,987 Return reserve 3,214 Â 4,077 Other 3,788 Â 817 Total accounts payable and accrued expenses 68,921 Â $ 73,562 Mustang | UBriGene Â Â Â Accrued expenses: Â Â Â Other $ 1,400 $ 1,400 Â X - DefinitionThe amount of accrued coupon expense which is classified as current. + ReferencesNo definition available. + Details Name: fbio_AccruedCouponExpenseCurrent Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionResearch and Development Expense + ReferencesNo definition available. + Details Name: fbio_AccruedResearchAndDevelopmentExpense Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrued return reserve, current. + ReferencesNo definition available. + Details Name: fbio_AccruedReturnReserveCurrent Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedSalariesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_MustangTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=fbio_UbrigeneBostonBiosciencesInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Non-Controlling Interests (Details) Jun. 30, 2024 Dec. 31, 2023 Mustang Â Â Non-Controlling Interests Â Â Non-controlling ownership 7.20% 19.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: srt_OwnershipAxis=fbio_MustangTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Income (Loss) per Common Share (Schedule of Diluted Weighted Average Shares Outstanding) (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Effect of Series A preferred dividends on net loss per share calculation $ 2.0 $ 2.0 $ 4.0 $ 4.0 Effect of partner company deemed dividends on net loss per share calculation $ 0.4 $ 0.1 $ 0.8 $ 0.3 Potentially dilutive securities excluded from the computations of diluted weighted average shares outstanding Â Â 7,482,640 1,537,908 Warrants to purchase Common Stock Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Potentially dilutive securities excluded from the computations of diluted weighted average shares outstanding Â Â 5,769,787 127,296 Employee Stock Option Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Potentially dilutive securities excluded from the computations of diluted weighted average shares outstanding Â Â 18,896 36,423 Unvested Restricted Stock Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Potentially dilutive securities excluded from the computations of diluted weighted average shares outstanding Â Â 1,693,684 1,374,116 Unvested Restricted Stock Units Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Potentially dilutive securities excluded from the computations of diluted weighted average shares outstanding Â Â 273 73 X - DefinitionThe effect of partner company deemed dividends on net loss per share calculation. + ReferencesNo definition available. + Details Name: fbio_EffectOfPartnerCompanyDeemedDividendsOnNetLossPerShareCalculation Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe effect of series A preferred dividends on net loss per share calculation. + ReferencesNo definition available. + Details Name: fbio_EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fbio_UnvestedRestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fbio_UnvestedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense $ 4,998 $ 4,217 $ 9,856 $ 8,948 Avenue Therapeutics, Inc [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 192 27 383 38 Checkpoint [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 1,171 567 1,881 1,536 Mustang Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense (619) 45 (542) 280 Journey Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 1,674 873 3,080 1,519 Other Partners [Member] Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 58 24 115 50 Employee and non-employee awards Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 2,249 2,271 4,442 4,708 Executive awards Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense $ 273 $ 410 $ 497 $ 817 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-

2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_MustangTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_JourneyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_OtherPartnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=fbio_EmployeeAndNonemployeeAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=fbio_ExecutiveAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Narrative) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended 12 Months Ended Jan. 01, 2024 Jan. 01, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Common Stock, shares authorized Â Â 200,000,000 Â 200,000,000 Â 200,000,000 Stock-based compensation expense Â Â $ 4,998 $ 4,217 $ 9,856 $ 8,948 Â Stock options, unrecognized compensation expense Â Â 600 600 600 600 Â Change in fair value of Warrant liabilities Â Â Â 512 Â (6,166) Â Journey Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Stock-based compensation expense Â Â $ 1,674 873 $ 3,080 1,519 Â 2007 and 2013 Stock Incentive Plan [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Stock based compensation, shares available for issuance Â Â 10,000,000.0 Â 10,000,000.0 Â Â 2013 Stock Incentive Plan [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Share based compensation, additional shares authorized Â Â Â Â 10,000,000.0 Â Â 2012 Employee Stock Purchase Plan [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Share based compensation, additional shares authorized Â Â Â Â 1,000,000.0 Â Â Long-term Incentive Plans [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Stock-based compensation expense Â Â $ 1,700 1,500 $ 3,300 2,900 Â Fair value of stock granted Â Â Â Â 700 Â $ 800 LTIP, Percentage of outstanding shares 1.00% 1.00% Â Â Â Â Â Â Chief Executive Officer (Dr. Rosenwald) [Member] | Long-term Incentive Plans [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Number of shares Granted 216,465 216,465 Â Â Â Â Â Executive Vice President (Mr. Weiss) [Member] | Long-term Incentive Plans [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Number of shares Granted 216,465 216,465 Â Â Â Â Â Research and Development Expense [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Stock-based compensation expense Â Â 700 500 1,700 1,500 Â General and Administrative Expense [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Stock-based compensation expense Â Â 4,300 3,700 $ 8,100 $ 7,500 Â Stock Options Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Share-based compensation, period for recognition of expense Â Â Â Â 3 years 7 months 6 days 5 years 8 months 12 days Â Restricted Stock Awards and Restricted Stock Units [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Unrecognized compensation expense for awards other than options Â Â $ 11,500 $ 16,000 $ 11,500 $ 16,000 Â Share-based compensation, period for recognition of expense Â Â Â Â 1 year 3 months 18 days 2 years Â Restricted Stock [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Number of shares Granted Â Â Â Â 443,024 Â Â Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Number of shares Granted Â Â Â Â 37,500 Â Â X - DefinitionLong term incentive program Percentage of outstanding shares + ReferencesNo definition available. + Details Name: fbio_LongTermIncentiveProgramPercentageOfOutstandingShares Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionShare based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value. + ReferencesNo definition available. + Details Name: fbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -

DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_JourneyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=fbio_TwoThousandSevenAndTwoThousandThirteenPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=fbio_TwoThousandThirteenStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=fbio_TwoThousandTwelveEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=fbio_LongTermIncentivePlansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ExecutiveVicePresidentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=fbio_RestrictedStockAndRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Stock Option Activities) (Details) - USD ($) 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Â Â Options vested and expected to vest, Number of shares 18,896 Â Number of shares, Granted 540,000 Â Options vested and expected to vest, Number of shares 558,896 18,896 Options vested and exercisable, Number of shares 18,896 Â Options vested and expected to vest, Weighted average exercise price $ 20.55 Â Weighted average exercise price, Granted 1.68 Â Options vested and expected to vest, Weighted average exercise price 2.32 $ 20.55 Options vested and exercisable, Weighted average exercise price $ 20.55 Â Total weighted average intrinsic value, Granted $ 16,200 Â Total weighted average intrinsic value, Options vested and expected to vest $ 16,200 Â Options vested and expected to vest, Weighted average contractual life 6 years 6 months 7 days 1 year 9 months 3 days Options Granted, weighted average remaining contractual life (years) 6 years 8 months 15 days Â Options vested and exercisable, Weighted average remaining contractual life (years) 1 year 3 months 3 days Â X - DefinitionThe grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesNo definition available. + Details Name: fbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the weighted average remaining contractual life of option awards granted. + ReferencesNo definition available. + Details Name: fbio_ShareBasedCompensationArrangementOptionsGrantedWeightedAverageRemainingContractualTerm Namespace Prefix: fbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Restricted Stock Awards and Restricted Stock Units) (Details) - $ / shares 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Restricted Stock Awards and Restricted Stock Units [Member] Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Number of shares, Unvested balance 1,861,655 1,458,700 Weighted average grant price, Unvested balance $ 21.27 $ 28.05 Restricted Stock [Member] Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Number of shares Granted 443,024 Â Number of shares, Vested (17,303) Â Weighted average grant price, Granted $ 3.01 Â Weighted average grant price, Vested $ 35.76 Â Restricted Stock Units (RSUs) [Member] Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Number of shares Granted 37,500 Â Number of shares, Vested (49,684) Â Number of shares, Forfeited (10,582) Â Weighted average grant price, Granted $ 1.84 Â Weighted average grant price, Vested 39.61 Â Weighted average exercise price, Forfeited $ 11.43 Â X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -

SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=fbio_RestrictedStockAndRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Schedule of Warrant activities) (Details) - USD ($) 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Equity [Abstract] Â Â Outstanding warrants 9,275,929 5,787,289 Warrants granted, Number of shares 3,506,140 Â Warrants exercised, Number of shares 17,500 Â Warrants exercisable, Number of shares 9,275,929 Â Warrants outstanding, Weighted average exercise price $ 2.35 $ 1.88 Warrants granted, Weighted average exercise price 3.12 Â Warrants expired, Weighted average exercise price 1.70 Â Warrants exercisable, Weighted average exercise price $ 2.35 Â Warrants outstanding, Weighted average intrinsic value $ 64,538 $ 7,794,450 Warrants granted, Weighted average intrinsic value 8,113 Â Warrants exercisable, Weighted average intrinsic value $ 64,538 Â Warrants, Weighted average remaining contractual life 4 years 5 months 15 days 4 years 10 months 28 days Warrants exercisable, Weighted average remaining contractual life 4 years 5 months 15 days Â X - DefinitionClass Of Warrant Or Right Exercisable. + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightExercisable Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionClass Of Warrant Or Right exercisable, Weighted Average Exercise Price + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice Namespace Prefix: fbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionClass of Warrant or Right exercisable, Weighted average intrinsic value + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionClass Of Warrant Or Right exercisable, Weighted Average remaining contractual life + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife Namespace Prefix: fbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionClass Of Warrant Or Right Expired, Weighted Average Exercise Price. + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice Namespace Prefix: fbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionClass of Warrant or Right granted, Weighted average exercise price + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice Namespace Prefix: fbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionClass of Warrant or Right granted, Weighted average intrinsic value. + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionClass Of Warrant Or Right, Number of shares Exercised. + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightNumberOfSharesExercised Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionClass Of Warrant Or Right, Number of shares granted. + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightNumberOfSharesGranted Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionClass of Warrant or Right, Weighted average exercise price + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightWeightedAverageExercisePrice Namespace Prefix: fbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionClass of Warrant or Right, Weighted average intrinsic value. + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightWeightedAverageIntrinsicValue Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionClass Of Warrant Or Right, Weighted Average Remaining Contractual Life + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife Namespace Prefix: fbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Capital Raises) (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended Jun. 27, 2024 Jun. 12, 2024 Jan. 05, 2024 May 05, 2023 Dec. 30, 2022 Apr. 23, 2021 Jun. 30, 2024 May 31, 2024 Apr. 30, 2024 Jan. 31, 2024 Jun. 30, 2023 Feb. 28, 2023 Jun. 30, 2024 Jun. 30, 2023 May 17, 2024 Jan. 09, 2024 Dec. 31, 2023 Oct. 11, 2022 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â

years Â Â Â Â Â Â Â Â Â Â Â Public Offering [Member] | Mustang | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock offering, number of shares issued Â Â Â Â Â Â Â 16,877,638 Â Â Â Â Â Â Â Â Â Â Shelf Registration Statement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Amount available for future stock offerings Â Â Â Â Â Â $ 86,200 Â Â Â Â Â 86,200 Â Â Â Â Â Â Shelf Registration 2023 Statement [Member] | Checkpoint Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Amount available for future stock offerings Â Â Â Â Â Â 77,700 Â Â Â Â Â 77,700 Â Â Â Â Â Shelf Registration 2023 Statement [Member] | Maximum | Checkpoint Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock offering, aggregate offering permitted by the agreement Â Â Â $ 150,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shelf Registration 2024 Statement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Amount available for future stock offerings Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 50,000 Â Â Â Shelf Registration 2024 Statement [Member] | Mustang Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock offering, aggregate offering permitted by the agreement Â Â Â Â Â Â Â Â Â Â Â 37,500 Â Â Â Â Â Shelf Registration 2024 Statement [Member] | Maximum | Mustang Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock offering, aggregate offering permitted by the agreement Â $ 40,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shelf Registration 2021 Statement [Member] | Mustang Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock offering, aggregate offering permitted by the agreement Â Â Â Â Â $ 200,000 Â Â Â Â Â 4,400 Â Â Â Â Â Shelf Registration 2021 Statement [Member] | Avenue Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Amount available for future stock offerings Â Â Â Â Â Â $ 24,600 Â Â Â Â Â $ 24,600 Â Â Â Â Â Direct Offering [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock offering, number of shares issued Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3,303,305 Â Â Â Â Â Â Â Â Â Â Exercise price of warrants Â Â Â Â Â Â Â Â Â $ 3.21 Â Â Â Â Â Â Â Â Â Â Unit Price Per Share Â Â Â Â Â Â Â Â Â Â $ 3.33 Â Â Â Â Â Â Â Â Â Â Warrant expiration term Â Â Â Â Â Â Â Â Â 5 years Â Â Â Â Â Â Â Â Â Sale of stock, net proceeds Â Â Â Â Â Â Â Â Â $ 10,200 Â Â Â Â Â Â Â Â Â Direct Offering [Member] | Checkpoint Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Issuance of common shares - Registered direct offering Â Â Â Â Â Â Â Â 1,275,000 Â Â Â Â Â Â Â Â Stock offering, price per share Â Â Â Â Â Â Â Â Â $ 1.805 Â Â Â Â Â Â Â Â Â Sale of stock, net proceeds Â Â Â Â Â Â Â Â Â $ 12,600 Â Â Â Â Â Â Â Â Â Direct Offering [Member] | Checkpoint | Common Stock Warrants [Member] Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Exercise price of warrants Â Â Â Â Â Â Â Â Â $ 1.68 Â Â Â Â Â Â Â Â Â Warrant expiration term Â Â Â Â Â Â Â Â Â 5 years Â Â Â Â Â Â Â Â Â Direct Offering [Member] | Checkpoint | Pre-Funded Warrants [Member] Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Warrants issued Â Â Â Â Â Â Â Â Â Â Â 6,481,233 Â Â Â Â Â Â Â Â Â Â Number of shares called by warrants Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Stock offering, price per share Â Â Â Â Â Â Â Â Â $ 1.8049 Â Â Â Â Â Â Â Â Â Exercise price of warrants Â Â Â Â Â Â Â Â Â $ 0.0001 Â Â Â Â Â Â Â Â Â Direct Offering [Member] | Mustang Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock offering, number of shares issued Â Â Â Â Â Â Â 3,025,000 Â Â Â Â Â Â Â 575,191 Â Â Â Â Â Â Â Number of warrants to purchase shares Â Â Â Â Â Â Â 3,105,000 Â Â Â Â Â Â Â 3,105,000 Â Â Â Â Â Stock offering, price per share Â Â Â Â Â Â Â $ 0.4099 Â Â Â Â Â $ 0.4099 Â Â Â Â Â Per share amount reduced from share price to calculate warrant price Â Â Â Â Â 0.001 Â Â Â Â Â 0.001 Â Â Â Â Â Exercise price of warrants Â Â Â Â Â $ 0.001 Â Â Â Â Â $ 0.001 Â Â Â Â Â Warrant expiration term Â Â Â Â Â 5 years Â Â Â Â Â 5 years Â Â Â Â Â Warrants exercised, Number of shares Â Â Â Â Â Â Â 3,105,000 Â Â Â Â Â Â Â Â Â Â Stock offering, aggregate fees paid Â Â Â Â Â Â Â $ 300 Â Â Â Â Â Â Â Â Â Sale of stock, net proceeds Â Â Â Â Â Â Â $ 2,200 Â Â Â Â Â Â Â Â Â Â Shares issued (in percent) Â Â Â Â Â 2.50% Â Â Â Â Â Â Â Â Â Direct Offering [Member] | Mustang | Unregistered warrants Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants to purchase shares Â Â Â Â Â 6,130,000 Â Â Â Â Â 6,130,000 Â Â Â Â Â Exercise price of warrants Â Â Â Â Â $ 0.41 Â Â Â Â Â $ 0.41 Â Â Â Â Â Direct Offering [Member] | Maximum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants to purchase shares Â Â Â Â Â Â Â Â Â 3,303,305 Â Â Â Â Â Â Â Â Â Direct Offering [Member] | Maximum | Checkpoint Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants to purchase shares Â Â Â Â Â Â Â 7,756,233 Â Â Â Â Â Â Â Â Â Private Placement | Avenue Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise of warrants for cash Â Â Â Â Â $ 4,500 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Private Placement | Avenue | Series A Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants to purchase shares Â Â 220,538 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Private Placement | Avenue | Series B Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants to purchase shares Â Â 220,538 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Private Placement | Avenue | January 2023 Warrants Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants to purchase shares Â Â 25,871 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price of warrants Â Â $ 116.25 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price of warrants agreed by investor Â Â $ 22.545 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fair value of warrants Â Â Â Â Â Â $ 600 Â Â Â Â Â Â $ 600 Â Â Â Â Â Private Placement | Avenue | November 2023 Warrants Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants to purchase shares Â Â 194,667 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price of warrants Â Â $ 22.545 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercise price of warrants agreed by investor Â Â $ 22.545 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fair value of warrants Â Â Â Â Â Â $ 4,300 Â Â Â Â Â Â $ 4,300 Â Â Â Â Â X - DefinitionExercise price per share or per unit of warrants or rights agreed by investor. + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAgreedByInvestor Namespace Prefix: fbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionClass Of Warrant Or Right, Number of shares Exercised. + ReferencesNo definition available. + Details Name: fbio_ClassOfWarrantOrRightNumberOfSharesExercised Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents value of shares available for future issue. + ReferencesNo definition available. + Details Name: fbio_CommonStockSharesAvailableForFutureIssuanceValue Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of Shares issuable for At-the-Market offering + ReferencesNo definition available. + Details Name: fbio_NumberOfSharesIssuableForAtMarketOffering Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount reduced from share price to calculate warrant price. + ReferencesNo definition available. + Details Name: fbio_PerShareAmountReducedFromSharePriceToCalculateWarrantPrice Namespace Prefix: fbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionSale of Stock aggregate offering price permitted by agreement. + ReferencesNo definition available. + Details Name: fbio_SaleOfStockAggregateOfferingPricePermittedByAgreement Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of commission agreed to be paid to the company, percentage calculated over gross proceeds from the sales of stock. + ReferencesNo definition available. + Details Name: fbio_SaleOfStockPercentageOfSharesIssuedInTransaction Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period for direct offering. + ReferencesNo definition available. + Details Name: fbio_StockIssuedDuringPeriodSharesCommonSharesForDirectOfferingInShares Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share price of combined unit. + ReferencesNo definition available. + Details Name: fbio_UnitPricePerShare Namespace Prefix: fbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFair value portion of warrants. + ReferencesNo definition available. + Details Name: fbio_WarrantsFairValueDisclosure Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of warrants issued during the period. + ReferencesNo definition available. + Details Name: fbio_WarrantsIssuedNumber Namespace Prefix: fbio_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedPerTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10

-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_UnregisteredWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=fbio_ConvertibleClassBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_MarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fbio_MlvCo.AndFbrCapitalMarketsCoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fbio_CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_JourneyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=fbio_FoundersAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_MustangTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesOneWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesTwoWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesThreeWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_AmendedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_ShelfRegistrationStatementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_ShelfRegistration2023StatementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_ShelfRegistration2024StatementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_ShelfRegistration2021StatementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_DirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_January2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_November2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Lessee, Operating Lease, Description [Abstract] Â Â Operating lease liabilities $ 18,415 Â Operating lease right-of-use asset, net 14,626 $ 16,990 Amount of Caelum acquisition reveived 57,000 Â Caelum's legal fees and costs $ 15,000 Â X - DefinitionAmount of legal fees and costs incurred by a former subsidiary, in defending a litigation, reimbursed by the company by distribution from escrow account. + ReferencesNo definition available. + Details Name: fbio_LegalFeesAndCostsInDefendingLitigationIncurredByFormerSubsidiaryReimbursedByDistributionFromEscrowAccount Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LesseeOperatingLeaseDescriptionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash inflow representing an adjustment to the purchase price of a previous acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromPreviousAcquisition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Lease Expense) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Commitments and Contingencies Â Â Â Â Operating lease cost $ 595 $ 950 $ 1,235 $ 1,969 Shared lease costs (519) (519) (1,042) (1,034) Variable lease cost 174 199 390 400 Total lease expense $ 250 $ 630 $ 583 $ 1,335 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Quantitative Information about Operating Leases) (Details) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Commitments and Contingencies Â Â Operating cash flows from operating leases $ (1,850) $ (1,762) Weighted-average remaining lease term - operating leases (years) 4 years 4 years 4 months 24 days Weighted-average discount rate - operating leases 6.00% 6.50% X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference

1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Future Minimum Lease Payments) (Details) $ in Thousands Jun. 30, 2024 USD ($) Lessee, Operating Lease, Liability, Payment, Due [Abstract] Â Nine Months Ended December 31, 2024 $ 1,819 Year Ended December 31, 2025 3,542 Year Ended December 31, 2026 3,272 Year Ended December 31, 2027 2,923 Year Ended December 31, 2028 2,967 Other 8,125 Total operating lease liabilities 22,648 Less: present value discount (4,233) Net operating lease liabilities, short-term and long-term $ 18,415 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions (Narrative) (Details) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Aug. 31, 2020 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Dec. 30, 2022 Related Party Transaction [Line Items] Â Â Â Â Â Â Â Common Stock, par value Â $ 0.001 Â $ 0.001 Â $ 0.001 $ 0.0001 Aggregate purchase price Â Â $ (41,000) $ 10,118,000 $ 13,154,000 Â Â Proceeds from issuance of Common stock Â Â Â $ 2,826,000 1,168,000 Â Â Preferred Stock, shares outstanding Â 3,427,138 Â 3,427,138 Â 3,427,138 Â Preferred Stock, Liquidation Preference Per Share Â $ 25.00 Â $ 25.00 Â $ 25.00 Â Total notes payable Â $ 67,007,000 Â $ 67,007,000 Â $ 60,856,000 Â Repayments of Debt Â Â Â $ 0 40,375,000 Â Â Avenue Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Paid in Kind dividend as a percentage of fully diluted outstanding capitalization Â Â Â 2.50% Â Â Â Journey Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Proceeds from Related Party Agreement Â 8,000 21,000 $ 18,000 36,000 Â Â Related Party Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Revenue - related party Â 41,000 31,000 41,000 66,000 Â Â Related Party | Journey Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Other receivables - related party Â 300,000 Â 300,000 Â Â Â TGTX | Shared Services Agreement | Related Party Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Other receivables - related party Â 100,000 0 100,000 0 Â Â Revenue - related party Â 100,000 100,000 700,000 200,000 Â Â TGTX | Desk Share Agreements | New York, NY Office Space Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Total payment for rent Â 700,000 800,000 1,400,000 1,400,000 Â Â TGTX | Desk Share Agreements | Related Party | New York, NY Office Space Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Revenue - related party Â $ 500,000 $ 500,000 $ 1,000,000.0 $ 1,000,000.0 Â Â Cyprium | Related Party | 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Preferred Stock, dividend rate percentage 9.375% Â Â Â Â Â Â Preferred Stock, shares outstanding Â 300,600 Â 300,600 Â Â Â Monthly cash dividend $ 0.19531 Â Â Â Â Â Â Annual cash dividend payable 2.34375 Â Â Â Â Â Â Preferred Stock, Liquidation Preference Per Share $ 25.00 Â Â Â Â Â Â Exchange term of preferred stock 24 months Â Â Â Â Â Â X - DefinitionAnnual cash dividend payable per share. + ReferencesNo definition available. + Details Name: fbio_AnnualCashDividendPerSharePayable Namespace Prefix: fbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionExchange term of preferred stock. + ReferencesNo definition available. + Details Name: fbio_ExchangeTermOfPreferredStock Namespace Prefix: fbio_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionMonthly cash dividend per share payable + ReferencesNo definition available. + Details Name: fbio_MonthlyCashDividendPerSharePayable Namespace Prefix: fbio_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPaid in Kind dividend as a percentage of fully diluted outstanding capitalization. + ReferencesNo definition available. + Details Name: fbio_PaidInKindDividendAsPercentageOfFullyDilutedOutstandingCapitalization Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount received from desk share agreement related to design and build out of the new office. + ReferencesNo definition available. + Details Name: fbio_ProceedsFromRelatedPartyAgreement Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsAndOtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash payments to lessor's for use of assets under operating leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockLiquidationPreference Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -

Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_JourneyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fbio_TgtxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=fbio_SharedServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=fbio_DeskShareAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=fbio_NewYorkNyOfficeSpaceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fbio_CypriumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions (PIK Dividend or Equity Fee Payable) (Details) 6 Months Ended Jun. 30, 2024 Avenue Â Related Party Transaction [Line Items] Â Effective date Feb. 17, 2015 PIK dividend as a percentage of fully diluted outstanding capitalization 2.50% Baergic Â Related Party Transaction [Line Items] Â Effective date Dec. 17, 2019 Cellvation Â Related Party Transaction [Line Items] Â Effective date Oct. 31, 2016 PIK dividend as a percentage of fully diluted outstanding capitalization 2.50% Checkpoint Â Related Party Transaction [Line Items] Â Effective date Mar. 17, 2015 Annual equity fee as a percentage of fully diluted outstanding capitalization 2.50% Cyprium Â Related Party Transaction [Line Items] Â Effective date Mar. 13, 2017 PIK dividend as a percentage of fully diluted outstanding capitalization 2.50% Helocyte Â Related Party Transaction [Line Items] Â Effective date Mar. 20, 2015 PIK dividend as a percentage of fully diluted outstanding capitalization 2.50% Mustang Â Related Party Transaction [Line Items] Â Effective date Mar. 13, 2015 PIK dividend as a percentage of fully diluted outstanding capitalization 2.50% Oncogenuity Â Related Party Transaction [Line Items] Â Effective date Apr. 22, 2020 PIK dividend as a percentage of fully diluted outstanding capitalization 2.50% Urica Â Related Party Transaction [Line Items] Â Effective date Nov. 07, 2017 PIK dividend as a percentage of fully diluted outstanding capitalization 2.50% X - DefinitionAnnual equity fee as a percentage of fully diluted outstanding capitalization + ReferencesNo definition available. + Details Name: fbio_AnnualEquityFeeAsPercentageOfFullyDilutedOutstandingCapitalization Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPaid in Kind dividend as a percentage of fully diluted outstanding capitalization. + ReferencesNo definition available. + Details Name: fbio_PaidInKindDividendAsPercentageOfFullyDilutedOutstandingCapitalization Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPayment in Kind Dividends or Equity Fee Payable Effective Date. + ReferencesNo definition available. + Details Name: fbio_PaymentInKindDividendsOrEquityFeePayableEffectiveDate Namespace Prefix: fbio_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_BaergicMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CellvationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CypriumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_HelocyteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_MustangTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_OncogenuityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions (Management Services Agreement) (Details) $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Related Party Transaction [Line Items] Â Fortress - MSA Income $ (4,000) Avenue Â Related Party Transaction [Line Items] Â Effective date Feb. 17, 2015 Partner companies, MSA fee expense $ 500 Baergic Â Related Party Transaction [Line Items] Â Effective date Mar. 09, 2017 Cellvation Â Related Party Transaction [Line Items] Â Effective date Oct. 31, 2016 Partner companies, MSA fee expense $ 500 Checkpoint Â Related Party Transaction [Line Items] Â Effective date Mar. 17, 2015 Partner companies, MSA fee expense $ 500 Cyprium Â Related Party Transaction [Line Items] Â Effective date Mar. 13, 2017 Partner companies, MSA fee expense $ 500 Helocyte Â Related Party Transaction [Line Items] Â Effective date Mar. 20, 2015 Partner companies, MSA fee expense $ 500 Mustang Â Related Party Transaction [Line Items] Â Effective date Mar. 13, 2015 Partner companies, MSA fee expense $ 500 Oncogenuity Â Related Party Transaction [Line Items] Â Effective date Feb. 10, 2017 Partner companies, MSA fee expense $ 500 Urica Â Related Party Transaction [Line Items] Â Effective date Nov. 07, 2017 Partner companies, MSA fee expense $ 500 X - DefinitionEffective Date the consulting fee to be paid. + ReferencesNo definition available. + Details Name: fbio_AnnualConsultingFeePayableEffectiveDate Namespace Prefix: fbio_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAnnual Management Services Agreement Fee expense. + ReferencesNo definition available. + Details Name: fbio_AnnualManagementServicesAgreementFeeExpense Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAnnual Management Services Agreement Fee Income + ReferencesNo definition available. + Details Name: fbio_AnnualManagementServicesAgreementFeeIncome Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_BaergicMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CellvationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CypriumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_HelocyteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_MustangTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_OncogenuityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information (Narrative) (Details) 6 Months Ended Jun. 30, 2024 segment Segment Information Â Number of reportable segment 2 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information (Schedule of Segment Information) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Segment Reporting Information [Line Items] Â Â Â Â Net Revenue $ 14,896 $ 17,386 $ 27,926 $ 29,815 Cost of goods - product revenue (6,541) (7,767) (13,357) (14,216) Research and development (12,671) (32,142) (37,495) (71,648) Selling, general and administrative (20,823) (24,439) (38,777) (49,780) Asset impairment (2,649) (3,143) (2,649) (3,143) Other expense (1,036) (9,196) (3,494) (5,474) Income tax expense 0 0 0 0 Net loss (28,824) (59,301) (67,846) (114,446) Dermatology Products Sales Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net Revenue 14,855 17,172 27,885 29,385 Cost of goods - product revenue (6,541) (7,767) (13,357) (14,216) Research and development (913) (1,774) (8,797) (3,807) Selling, general and administrative (10,328) (12,141) (18,748) (25,433) Asset impairment Â (3,143) Â (3,143) Other expense (434) (710) (786) (1,285) Net loss (3,361) (8,363) (13,803) (18,499) Pharmaceutical and Biotechnology Product Development Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Net Revenue 41 214 41 430 Cost of goods - product revenue Â Â 0 Â Research and development (11,758) (30,368) (28,698) (67,841) Selling, general and administrative (10,495) (12,298) (20,029) (24,347) Asset impairment (2,649) Â (2,649) Â Other expense (602) (8,486) (2,708) (4,189) Net loss $ (25,463) $ (50,938) $ (54,043) $ (95,947) X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. +

ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix:

us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=fbio_DermatologyProductsSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=fbio_PharmaceuticalAndBiotechnologyProductDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information (Total assets by reportable segment) (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Segment Reporting Information [Line Items] Â Â Intangible assets, net $ 18,658 $ 20,287 Tangible assets 127,027 147,239 Total assets 145,685 167,526 Dermatology Products Sales Â Â Segment Reporting Information [Line Items] Â Â Intangible assets, net 18,658 20,287 Tangible assets 46,531 56,562 Total assets 65,189 76,849 Pharmaceutical and Biotechnology Product Development Â Â Segment Reporting Information [Line Items] Â Â Tangible assets 80,496 90,677 Total assets $ 80,496 $ 90,677 X - DefinitionTangible assets. + ReferencesNo definition available. + Details Name: fbio_TangibleAssetsNet Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=fbio_DermatologyProductsSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=fbio_PharmaceuticalAndBiotechnologyProductDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R77.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenues from Contracts and Significant Customers (Narrative) (Details) - Dermatology Products Sales - Customer Concentration Risk - customer 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Revenue Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Number of customers 0 0 0 0 Â Accounts Receivable Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Number of customers Â Â 2 Â 1 Customer One | Accounts Receivable Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Concentration risk, percentage Â Â 18.00% Â 13.00% Customer Two | Accounts Receivable Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Concentration risk, percentage Â Â 10.80% Â Â X - DefinitionNumber of customers. + ReferencesNo definition available. + Details Name: fbio_NumberOfCustomers Namespace Prefix: fbio_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=fbio_DermatologyProductsSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=fbio_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=fbio_CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 89 R78.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenues from Contracts and Significant Customers (Company's product revenue) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Product revenue, net $ 14,855 $ 16,961 $ 27,885 $ 29,126 Collaboration revenue Â 183 Â 364 Other revenue Â 211 Â 259 Net revenue 14,896 17,386 27,926 29,815 Related Party Â Â Â Â Revenue - related party 41 31 41 66 Qbrexza Â Â Â Â Product revenue, net 6,836 8,079 11,853 12,173 Accutane Â Â Â Â Product revenue, net 5,719 5,579 11,538 10,227 Amzeeq Â Â Â Â Product revenue, net 1,205 1,374 1,960 2,568 Zilxi Â Â Â Â Product revenue, net 369 572 642 886 Other Legacy Product Revenue Â Â Â Â Product revenue, net $ 726 $ 1,357 $ 1,892 $ 3,272 X - DefinitionCollaboration revenue. + ReferencesNo definition available. + Details Name: fbio_CollaborationRevenue Namespace Prefix: fbio_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue and income classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_OtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=fbio_QbrexzaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=fbio_AccutaneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=fbio_AmzeeqMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=fbio_ZilxiMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=fbio_OtherLegacyProductRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 90 R79.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes (Narrative) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Taxes Â Â Â Â Income tax expense $ 0 $ 0 $ 0 $ 0 Effective income tax rate 0.00% 0.00% 0.00% 0.00% Minimum ownership interest in subsidiaries for consolidated income tax return Â Â 80.00% Â X - DefinitionMinimum ownership interest in subsidiaries for consolidated income tax return. + ReferencesNo definition available. + Details Name: fbio_MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn Namespace Prefix: fbio_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 91 R80.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events (Details) $ / shares in Units, $ in Thousands 1 Months Ended 6 Months Ended Jul. 25, 2024 USD ($) $ / shares shares Jul. 15, 2024 USD ($) director D Jul. 05, 2024 USD ($) $ / shares Dec. 27, 2023 USD ($) Dec. 30, 2022 USD ($) $ / shares shares Jul. 31, 2024 USD ($) $ / shares shares Jun. 30, 2024 USD ($) $ / shares shares May 31, 2024 USD ($) $ / shares shares Apr. 30, 2024 USD ($) $ / shares shares Jan. 31, 2024 USD ($) $ / shares shares Jun. 30, 2024 USD ($) $ / shares shares Jun. 30, 2023 USD ($) Jul. 09, 2024 USD ($) Jun. 27, 2024 $ / shares Jan. 09, 2024 $ / shares Dec. 31, 2023 USD ($) $ / shares Oct. 11, 2022 $ / shares Aug. 31, 2020 USD ($) Aug. 27, 2020 USD ($) Subsequent Events Â Â Â Â

Â Â Â

Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates type of variable interest rate on debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedPerTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_AvenueTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_UnregisteredWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_Ur1TherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_DirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_CheckpointMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=fbio_MustangTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesOneWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesTwoWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_SeriesThreeWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=fbio_AmendedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=fbio_SwkTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=fbio_OaktreeNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=fbio_IfOutstandingPrincipalBalanceIsLessThanOrEqualTo10MillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=fbio_IfOutstandingPrincipalBalanceIsBetween10MillionAnd25MillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=fbio_CrystalysTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=fbio_July2024RegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 92 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{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

(ZG7D=^E9N4S0ITZHDA#.DU=AUF0X+G17V<^2R$84RFN%UF<9;-I'5P0K2!%_DGWF@E MP%%]IBL\X$D=H32.$JG M.&TSX.ITAA2"D;T"/WW]UM6P^0UU''Z6GC2:UER'54C2< ;
<2%F!G[/Z7>\! MYZ"@,(K3Z79WV<5)1&9((1C)*HB>I7-*P>Y$*;3@;IQ>SOM>M?-2LYW[/#)A MX*?"04@[*7V<(%VB9B^57FFN*B=JF]!(F%JIX+"*R$R8R4A[MQ$][-TSIVB@W61U8_02?
(#J5[JHU;)D=ATU=@ -,G3LR6\.)S7)XXHK#A&8T MF'%EY$'BY\&I*Z)NH&261G"8'#>?YIA9BKS;EL_SQJ9$BK'ET 6K8I22=81DRLB/QLV.?OP/"BVGA./8EV?3DY;)*L[D$'AF1^!FQ3^!+ M"&VF
RE!4BMS7780^&P&Y4B*Y#(I"MU7LJ[/(FN3&+S. 3%Z;3(;!>%/3NS> MF=U*'3J[HG/O1XXEF5=AWAHML)=EP57SC^XTJ9_0ZX+O1"ZTVVDO:7JW M.^V%9COOK8U43?U4O6VKMF2F.8V
DSFO.L4)Q>' =0O)>T+7)E!+] J_P3B M2J?0 RM;]'5!M 1>,O\0:S40B_gO+Y9H_+;@C;BON_[L+5-=O+Y^@E8TH)U7?@.L)GG%8G "^-F_UAG*$A**9]1) _)^8*,@H/Z!<>I M1'5%F_1![0](#-EIU
E91FFRQ!!0$QZS-AE=XHC^?^+K#)SCQ&]%SK8)9KHM M=)0VU"]MWA6%,.MLTI:)8B7J5ZM<\OTI("" W),)NI>>J*UE5D$89=.&E\,N MB.;Z7734//0[-4]71G[#8?<<;6>7':>UA,=91'URZ)/O-
^:Y@3HSN8?T'SS M.N"E9COW=I1!U"^#+K]0I"\}>UYJMO-7=:/L"2\TYKM3Q/BFSISAU7'!#W,+ M?IPS/JM+TW./PPCR<9*,ZY-7X.;O#_[-U+VH&SB+[6 4?I- .JO^E7Y_H^6A M>RM^)
[6657>YYPQVDS& WW<25/KQOKQH'_ZP8O,_4$L#!!0 (-.##5F^ M,K'5'0, (@+ 8 >&PO=V]R:W-H965T&ULK99KYLP M%(;_BL6F:9.Z8""MN0UE33-FE2U*C;9Q=.@E6PJ6V2;K]^-A *#;E5[8?&
M-N=]_9P#ODPV7#S(!$"AIRQE3C*Q@ >HNGPO=LQN7F&;).4,"5A.K:._UNI6I*G-"9F^)JDA$6 %F8*B3[.B0"F$E T(NDG]!F] M1S:2B1Z5$UMI(N-K1_7LU]7L[I[9?
Q9L@#Q\@5SL#GODL\/R&XBTW"GE7E=N MZSHTQ7";8KBEG_C+MYI@V#^!69-7,B<13"V]Z"2(-5CAAW?."' IR_Z- MS#JU\)I:>(?3B"$3GJA>/1P@7(BT)JD!?2E77D%I9?9.=8A'F#L3.QU
M.Y]C41W080,Z/ ^T^A@1*53"!?T'<1]PY>FW4!P?EW\OF$\([&#[#;9_#O:6 M.@9)5\Q\;'W4_@Y,/_3QN [SJ&$>O:K45,]B'WBT ^(-W<#QQB^ C\=U@(,& M.'@5L#[/I"
(LIFS51QV<2'T\KD,];JC'YU&G]+$R>Y Y]_+R(9A=* =1>27 M0S7%J,7^H_B#X9TR"\);N:F#,>99KQE!WC\J0=XUA4A]+!SX<>/H/SI VC M=FR_:]'CWM5W4FD8'Y5<.^>3[U]_M5L'Q?7' =
[YEGLB]49WZ6'?V\\?*HZ M!P^J?N8C2["V/ 5\-W(/N-VZ)ID[ZB\B5I1)E,)22_$@T!ZBNO95'<7S\N9T MSY6^AY7-1%^509@ _7S)N=IVS&6LN7R'_P%02P,$% @ TX,-6:L2Y4GH M!P Z"D !@
!X;"JW;W)K+Q0,(-R^R_%IMA%#HVS8QJMO)1JG=]6Q6+3=BRZLKN1.%_L]*EENN M]&.YGE6[4O"T,=KF,^)YP6S+LV(ROVG>/93S&[E7>5:(AQ)5^^V6EW_>B5R^
MW$[PY/7%8[:>]/K%;'ZSXVOQ)-27W4.IGV:=ES3;BJ+*9(%*L;J=?,;7"66U M08/X;R9>JI/OJ [E6W$]WLD!W,,Z_$OFFQW@0MJY62V]98]V";%<=+/_JTEXL1 ^X$-2&M 3 ,V8$!; WII"ZPU80>Y MX+
<&3>BS8^P-<0NN^/RFE"^HK-':6_VE8;^QUGQE19TH3ZK4_\VTG9I_*?@^ MS91(T;TL4IT QV^5S+.4UZ^?E/[0F:$J)%?HUTYB>3W"%9JB+T\+].&'C^@'
ME!7HMXW<5[Q(JYN9TOVJO<^6;1_NCGT@ WV@Z!=9J$V%$MV#%+!?N.T#A_U, M\]&10EY)N2-.A__:%U>(>I\0\0@#^G- N3F%POEKK2??W?H9&;3+$-KXHP/^
M'L5!%'L!#>O1D,&&=8F[KG9*6XGNH95HCR(R?SO?\.\]P^(TS&=+<9TEHSD M[(Q]UK'/7-[G#Z5,]TNE:W(S"I]0(10T%$.E7AP.<\PBW[^9'4XY!E!! M'.!SU,)&D3"*#%\)@(HQ"3K46;A^%Z[O#%?
7^YP_RV.->0T:BM?IYKVI=W3F MG](248.4,1M_[9IP&#F@HZYP,GH:&)K:P(?&;,M7L;%(9!:&2A#<*4^@8J 5",X(&ZCKU>9WK.\!\U MH;Q<;I#6B%K)' _0695?+2E N>G8?2!":00,P2C"-C;
A6,ABS!\#WN^&3> M"QCUB1DX@,->%(=D(/)>TN+ K5T:39L52[D5Z$,[XA_!V$=5MZ-Z6XSJ+1G+ MV_F0])H9NT7SSX42VJ]J1P4<"UO'AM2:>P (6QD(J&O?E#4)A I]/)!\O6[&
M3C781]KF7;/"K+*"%\NZ_JP$''P$3$),B!D^ L8L0@ 8"PDS&0 @&$O)$,< M])(5OZ%9-[Q8B_IX;Z77&'3@^5[4&O:%ER77$B;/^'.69RH;],-.[^^>E;8R MG?J8F)2-V68"M!G@8$
,DUX,$[<8_HEK2C_DNK! 1+) >B9M]4>EY/+KI=P2 M6ZZ&GI%E[EZ\MXX!+4[]V)R-8[5YSFROMHE;;?>+92J6W3EV?9BDT[;:/U=9 MFO%RB--1I3:QE>^4TL 4D:,VFKS9Z#FOO=XF;KU]^5),
.TF6\V*(B'PNVE-7%+ZU9M7AZT+7IU!:;F:1$$B[%YJ+2 8)3%9MF'8#X+ M!PX222^UB5MJUP=C=6T" [55[I1$D;DDW4,X/Z:>*:XA7!!&S#P;@W 8,\:&
M:G$OKXE;7K]&B[A29?:\5_PY%TA)5,ABJDN(*F6SU=1Y_S+?6?0#&,(NP28H-"R(\M+DFO>XF[K/D04I^E*72%, ,V$>T>@K$S-Q^ M0#C"0I.J!8@+:&">VT X%E \Q$(O=PI$@QN;Q'82C&,?
F!AS"^9X?#YQDD5X1$[J M4GK+55=>1^I0X*@XHCB(0G-% I A#4-*S1T$Y%+C F+-,BE%P4L&CCYH+V, MI6X9^RYR'IE#;3DX1(^-'* '<#E #^#224^O1JE;C3Z*O+F<\L!+]2<8M]/^
MW5<3QO2V&-5;,I:W\Y$XN1SR_;=#QKT>,N[]D'$OB/P_;HC07J]3MUYOQT!7 M@K*=%[O!>6'?VK!^2P0PU)3M%_A) (QU6ZN3)8Z6JW+]3QBE+W MMKN6^+FYC&>\O\/7]QAXO\#7R?'28>_^>
?R%UZNLZ)"N5CIIO0RJNM4>;Q6 M>'Q0V_C1I;%OPKA'6P28!3S_DVYUO/Y2L MJ%0/7JKLXPX0I/TH_FZ5>5BD#N^M>O/8;3_WMTTS>%_OUIO^[<=+/_LZZ&^>K/M
M>MF\O1AO"WVS_=)<7/WW?P6I_S^VTV^&2[.DB&,U9F4V6Z11'$9:[[G9+H]\ M#2;,1HGOA\FQE7(6HN-9B,XZ"]^/UVV_E_T/9YV1)VIR>D;B, NB7#LO9KLL M2M,PU_X")=E+U[.#A%5(&$?"!
BFZ"8^ZB8F=;.?8!>[!XF5M^SNQJ>KOMX_ MGS1?=U_;YLQW)-%Q\.^1L!0]8[$A^;R(M>NB0D;D2)B8Z;ZBEN2HEH14R_Y. MNIMFQL>*Y=,]MM\):'P@?
KJQ#9W7/#U5W(_S47\Z'=F41$9S55)B##C(HSQ) MM1D*&9,A8142QI$P 8(IFDN/FDN?I[GQ,Z!W_W"];I?CK\:GS?%YZ. >IK$] M95;TC0[@*+35NX*&F,60XEIJZCH)$"UDA0W(D3-
C['JMGHNRHBNQL54S*H=_K M86X2(@.Y:B,S!QOX11+JLQ R*$/"*B2,(V$"!%/TEA_UEC]O%GH8/X!O/?;Q MPP>;MDBHJ[:0L!0]8[GYK*$_*"'C<21,D)U7Q%(U]MA,]X'=Q9"O?
GCNW[\:O.EV0[M];KQ[H]N\!/%JDFR%\Z: M1-+* TUYXM>,+W9HHUX%^@0&[1:'TH1M %$P,85)%74,_L{9TB-\? M:-H3?:H_ST.#,BBM@M(XE"90-%6>TC4/:-O\@Z&\V0DRAYG^#@\:DD-I8F8
JCBD41[03GG9 M+(]YB^,C\'6]P[P_7?;MJZ^T?WJ;;+)8GF6\MD?GVCH[JK"NH M;0ZE,2BM@M)X8+KB25YHMUXQVTI-2I3>>4A[Y[].Z&67V*K>[EK[8KOFNVH(M2BNA-!::!OXB*.)/0S;]OIA
MV"42[]*F@;W(LT#_1E-S+=3M722*$U[X9-: M.GVW=\C.M\H(:FQ#:264QJ"T*C0M_$6<1H&1O0UUMN>CJC*2GG5X7JIW/7C_ M^[#YT8O\?7IW9)5,9+RY,C+NS2:%GG)O<5'UJU^6-
FE1^*&OWT3,=N/5Y2=Q MJI\-2\,HCO7$-V%K%R1%//5WEAYO2'N\RGU\W]SBV%HS:7C4H*6\0+Y),OZ8M:SHD^41"JS)"Q*7SZVEH&,X*\YM[<9;0H Q*JZ
T#J4)%$V5\\G.@;39BBPAI$,YZ\YBRNJ:@^8.)Z;1 M&N:AOJH&-":'TH1]!%.?[J11G+Q@J[\75 ;289WU8MG0+DGBV-@+%QJ606D5 ME,:A-(&BJ2J4;G-"N\W?J#:0[H6S**&YRE :2VR;
(AK3'313&4H3,P-0=29- M](0VT?^'*D*Z1\Z:,TWZ-,YB?:TC:% &I550&H?2!(JFRE,Z] GMT$_*L_FZ MO*TW-Y.YT8[3(-34/]!(/PSJU">6U.#8UYUZ:$P.I0G[" K[[)9*ISZEG?I7
MD,_<[$;WR%5*J25/UP_S*-9=,VA8!554!]'T@2*I@4NODI[>:SD]K68^H] M5=Q*\YSE!) 4R.S5!#?WD4O&; M);ZO3TQ0.Q]*JZ T#J4)%$T5FK3S4_B>A#3165Y0*Q]*8ZEEY9+<]_4,>VA0
M#]6)V2&HNI&&?DH;^J9N'&U5FN^L(B2MA-)8:KYJ"+*LT4=?.A-#$W E5# MTJ5/:9?^]S-J$+&?_^@..8L.NF0(E,92RYH;QMJ2T) <2A,S U E)TW_]!LM M&T+'<582=-D0*(VEEC<0QE9ST)
<2A,S U"5)(W[]-46#J')SMJ!FO%0&DLM P%-.6756A03F4)F:'H.I'&O+I*R\<0O.=501=. 1*8ZEEV8U(KRBJH#$YE";F M1J!J2+KF*>V:G[H$VJWKN(+:3D*&@S#]5 XUR*&T$DICJ25G/-)+7RIH3 ZE
MB;D1**+*)>>O?)>AC3?54-06@FELO>Y>AC3>64;0 M14&@- :E59EEB9$PC5+MI22'1A7S45492:\[>]9>AK%5,O-[&5]:Z/7U)=TC MY[-KFKE95/C&WKF6=HLL#,+(.'&V13/"-
,7U["U"^*DF"ACR:2-G-$V\AG5 M^O;38SJ2]MI>2\,P3/+,UUN6=$^=3Q625D%I*$H3*)JJ(&DB9V>OJW&ZM9Y= M-?/K:EB:!/K"&G2/G)5B&IU9%(7Z/H65I=TB"_PPS_2+VM(P3(M47X++#UBX:
M/T%,7-/28\U>O/&A_>R%!3%4ICF67?P$+?*ZP"OD1FI@;@2H;::EFWW;G0SJ7%M'7L8$&9+EE78["R#N&QN10FK"/8&I*DEYK?O["(LBR6#JL MLUYL>P4686B4Q4+#,BBM@M(XE"90-
%6%TJK-O_FFAU910E.9H;022F.YZ>#J M:[=6T(@<2A-T_U652?F1)Z&>>5%!8W(H3O.Z XY2PYJ\T-I++?G,'H8*YR@M)**(T5ED7._4"W::$Q.90F MYD:@"DI:^05MY;^@_(PF.ZL'FE0-I;"''DI!LV;
<:&I1#:6)V"*I^1,U?T#;_ MB\O/:+ZSBJ YU5 :*VP;+>K;D%70F!Q*$W,C4#4D3?IB9I?%EU8*T7QG#4'M M=RB-%;8$ZC R*H6@4;DEJB6H0 55921=^()VX2&50G0,9RDA:264QJ"T"DKC MA?
D^8IQH&<901<(@=(8E%85EESRP"]B[5&+ M0Z.*^:BJC*1U7IR7PGY.*O%+(UM%4* MV=H1E4*%-(N+\[9E=*T4*DP7TEY58&DX42E$]]3Y5"%I%93&H32!HCTIZ+* _M;9]AK(?ZZLU]?=/\H]
[>M)O>6S>?1KS_XZZ\9=O>W!Z_&;K[MQ?CQZGK;ABZ MN_V7MTT]W@EV#<;??^JZX<]O+D?^8[?]O(]Q]1]02P,$% @ TX,-64\2 MMOUU# ;3X !@ !X;"]W;W6IVV39P6_J9RZW6Y9 M]?
1Y^73Q9E_MO_B-GO8-.+Q>7YCCWP.]Y\W]U4\-MB6"7-MKRHL()P*KZ^ M.+OR/US'L7A 2OR1\:=Z]-D1IMR7Y0_QR]?TXLP3&O&<)XU8@L&/1W[-\URL M!'K\V2]Z-OR?
XL'QY_WJ7Z3Q8,P]J_EUF?\S2YO-Q=GRS$GYFK5YF=.TM9-N>T?!@VV6=']9,^](T8/P#KX Z1_@$P?" P/ MT/X!*@WM-)-F?6(-NSRORB>G$M*PFO@@?2.?!FNR0H3QKJG@KQD\UUQ^+UB;
M9@U/G>NR2"$\W:>ZS+.4B:_O&O@!<6MJIUP[UZS>.%\@]K7C.M_O/CEO?GKK M_.1DA?/[IFQK5J3U^:(!O<3JBZ37X6.G S'H$#F_ED6SJ9W/H$%Z^/P"[!F,
M(GNC/A+K@O]HB_<.]=XYQ",!HL_U\8]3BSIT\#&5ZU'#>B.GK:MRZ_RVXQ5K MLN+!N1))G#49KS]@;NN6#?!EQ0;_4.]8PB_.8 ?7O'KD9Y=__8L?>7_#;'ZE MQ0X\$ P>"&RK7WZ#>I27-
9H;W9.1?%(4G<=+-XJ7072>:!RKCXCY?A",Y XT M"P?-0FML;GE2%DF69TQ6%4CQHM?5:4KY.1'1:\6^@"POA] Q>^C"UPS=*RUV
MX*!H<%!D#=TG#HLFO7OX\TZ4",S@;I5P%)XI),8ZC)^$!L"&_ZQ5;]?A&A M M72K-Z5-5B%SXD]6C7^ MR%(FOO&YLVE[JF03!339<(XP%5;#;JMK*I=;F715..M;04Q+ M7Y;
WJ]DY6Y8\2"S@=4U;_ M?2LX7=XU9?+#%40[E9L3"MXLE/1+CE59+<,I(4"DEJO % @%=[X=[[[6==:?-J"\ETA<:"+<@3BLBK92*Q)^2,T1A)M]@;B(=&14-LB"%@22@WF M*;3T[7#YN=-
*I$LI4!W"\0U&ZV /D'Z,; "B-$]L"/!@>L0!=/$#M,2/V3;DPJJW3>6 M4 $6P"O@MW9?K.OVOL[2C%6&5",Z^$Y-0$OHC58&Q$1 $M 7XG2ZF20/UDE
MO6]]98B.P*0*I@8"Z:V(86<3!=2$6#N9KP7P(0$+;\#1\M-;@26268CTD1\$ M&7YDN6SG(=W;7,*)#$^R 8@4^^BQRY&H(I%?50*TXR%6'G%JR_-;JQTZ4S$) M,L,D$DEYA9,2#AZ#6H':K).!
(/*F]0^1\KWERL" B>(,Q,X9OD(=*YJR>D%5 MT_$\]+541$!_M3*EH@)]8@?]WX# 5"/7B6%1Q7.)-J(>XPKK>.Z&4P:."?DT M-"BL0)_80?^FXK"YTP&S9<*7THJD!7B /6_F5P1!ZJ76.R!2A 0F5RL\)W8\
M[UQM44['WA71=$, VIB>"IZ)'9Z';1C+TQ2;W J@ZY-P+2-'1$=2UV">%0 M"TP$B2C()_;0G!!7 ;=BVWX>31$1ET:&]IPJ-*5V-(4B7VZYT[!G/O@5 MG1PB .:SF0$3(P%BHPDIJQ\I?) 3-
L$:J(Z!+Z&KJ0TQLM30P$JJ DMH[VF[+ MY&7QX$*_O9U55NJ5W=64_LT('6HZFAO;4>C;,>-'5&<==<=P@F2*3)A<'(6^ M*0T4--'@I)&W@*KZJ)&W%?).GGF_TFJ'7E X2.TX>-,"=Q?[
>BML4_<$WG4 M&SK<:9L$041BY.U402*=@<21[L?/4^E\8XN(N-2T510.TB-P$-7(-K_M-4+@ MST IJ$(_.H=^X*-.R?#S<$%.X82R"'\,A8!MXOG8,-R=V:(D"Y< . MRC=5F7">]M',1D.X_[R^G%B%B
ME)@&B8$"[\ .WB=8Q!H7RI>[9=4/WAQA&#*"7A(M4DC7Z4=7C- AY;PT6Y&K!)$%3CK@XP->D=C?J*,B!@F#*$"[7 &M"WA./WD.IP_&9 MEJ&!<8<*L4,[8LN3O8/\'Q_!\.=NGHP=SA]EEH[*-
)A"!")D2C$%V^$,;"M* M)6_# B7E+68A,^"%W*79EL&%W>LN/Y+=^I<,V:@&H_WV$C(D!Y:6RHRZ$"^?!_!WF!GT)> M$BM(H0S7?K[=1D3(TM=Q7A@KN0SO<6UQ_I.[SC3DBXE+/>,@?
*K0/[6@_=+QO M^L;WK>C-!5M)G?L79STTD_;^-T0FT,0Q4XQ-RE;QH/A@K7P_F^-/3OUU$]\ M*2X955DBBIB)^(9WQY"^S0U#1%;^7%@L"U22! 9D?[Z% . P#CW "$K"$S MD8]
8$J49$8ZH"^I?F4-$?.7WLJ$FI$"_\@._B?;):\Q6"W2T3V&;G":A(C8 MD0J-=TLBA?^1'?^5FF^ MIXA^/7W;:ZS.F%"MD4-C7]M "-Z;;I-%"N\C^VUM2[(5^UN4H^)=I.@H$T_! M5[VQ_5JK'?
II=&?;SBQ^!SY>_>4ER"[*QS0@-=UMLY$$UX[&YYWZ2G:6M0= M\\P"$0FH"9LC12RBN1MJYL[A5'8=Z02"!MYT HA(F.2)GL4IPCLG..0[MJ ML1_%V-
EF67_4GXH7*DRG8*B1.K<@H6[DT6.&6)&/>&;,,+& Z;>]G*X!GT%M)7ZG[XL"W+*NW,W-]/*4WGB3%RTN_3U13_M8*#&3>8I8Q'9B<<>;ID.__D!YSQ7W(_=,S& *L&(\BD>-F)\Z("*&R5>L*$=L
MIQS?"\DW]&YQ/W*40Q948=MA0*^P+D),;X?%BG'$,T?XD\T"Z0,%0+QZJEV1 M?GGUX5 \YQ 1$QWH&)%'^+CKL--3MK,T>F6BVQZZF3!U #'HU> 3CURF(XB
M12M<%O]NB^[="AD5TRC(_I^=R@#[U<8^(?&4 "]&+^YN>?4@WV<6-]2A'G>O MNP[?#N],7\DWA2???_0_7'=O/JMENA>Q?V45-,:UD _,U+.F]%PE3=>\V=[\T MY4Z^'GQ?-
DVYE1\WG$&>"P'X^[HLF_TOXC\8WC" __]02P,$% @ TX,- M6Y,P*P2]"0 4A@ !@ !X;"]W;W)KUY%>+,],6KE6GU7\M;WU>%H.4DK=*!NTL*KZU3V0#FXIC6
M\X* ;:,4)D]"^/%DYJX4>KLO3V3X9I(PJ(DF0^.==>72IC2!#,^>)IES@:5M'Z MNY?^GGV'+RL9U*4S?]=EK$]GKV>B5)7L3+QSFRN5_?F!Y!7.!/Y;;-+:8V@L MNA!=DS?CN=$V_2L?
R37TNK_R53B&PIWJE0>-WRLZO$11>P(X23980VVK,L MLN2+)/GP&Y)?B1MG8QW$3[94Y>/]2U@YF'K8FWIQ^*+ #YU=B*/]N3C)!_OEDR-]":TLE"G,W1*4/Y>S[K_M/_/CP5OA
MO(BU$OGKI6M:;;?YXY^$#D**E79M+=%IA>JB+J0115HF*H=.4*7@+O[::_M MFHV3Y;VT!3^%H&(0T0EE:[Q3PCB[WHO*-^>)FDY!*+ (\E7M3*D\UM;>==>M: MM-Z571$!,??
*=FHN%%3$K:!UO:)2W^M2D4;\\6XK#1;D#2+ 4]F$Q1@3QE2A M+3R *3ZBJ6,M- Q4#Y$0[5X]JR(MHZ!^45OA6FTIQ;(RM8Y01JCKK:L5)$7 M,BHRM]&!#,N&! [>>U'@09=8&-CC%LF!$
23(QR-[$4K?;0PJM9M\B2X1I'AE%(X84K*Y,&/;UFG:ER(HK-P MTI,^%>:"ND!ZB-8V1!T[,H^MWI5PWJ%M83J._R4E \JN,(G$SUR96'JC2MYR
M"2.5'^KN\M/5I.3ZEQ,)?!V2$&5RZT.DHSA^E4G19KO[WB2?8Y$S7K+04O_8A MW,XYTN,S.7.KK U;@P;0:.63AIT[&WZRG)"MPJZU* F M8QW2:LO@$ABBO)/H?
VH.B@'%/*JU+AYW#-3+H@#QH*]]NW0I@X MZ@Z*VQ9A&)N$$0>V&M>2Q&DS_.80= '0:^;//BCH0/A7(A?-[VNY1_2$*D8)X M;M0#E>;M(T0)3\;21.(P?,CPSPCHUAK"12];WOQT:U[2;\.H[/Q8,
[H'M&?! MBK6,.6(^=.36)+6T9^EX>:-\ 9SN9R_*Z_E _#W$AYHWXCQ-I5VN_"Q#*;]B MR2__N)[WZ)C6C[AX(96G7&&P/PE! I*7(N73GH'!21)$$,N^9S^>2!@_C/HN
M:U5\:;FN7[+Y\]^WOPPVCWLF%']) M%F-Z &OG6X)22M5@XKN?[FX&$ ..Y]/HP\WE*/<&Q0_DF :EW9SMX^S+T.C=JR'1^ MTPU\CO3GE_"S?]M(8D45ZA\=.4 [6ISH$X:$H4GFP.-
XKC3@"E0V!/A/&XF: MXEDOS9E& EV-242%)D/D'83.:_C5SNDW5:$Y4")A[@07T';^V1#MGNL MWMX!-CXA^('',@Q_C\D"'8Q-WBTE8NU/*)(I9T@X)-KFY37BYJ5V3 IAF,!&N MM6,Z" D4BYJ#$?
3:TM24:*M^FD*JX9(E_)UGKA=8PZZYC_?@T&Y"-?=8@'"*8 MVS)\.?BVEB.GS,$FTKBI-8^R;=+#3%Q_HP1+$/PTZ6JW(2(PYU+*:80WI:X0 M#])(UIY'*E+]0"HTY2 !?Q[0(+&7#Y".&YZP>?
G:>6*YQQ]HEW)-\J MRA\-;!EJ48$+/EY''(YN3E*?A0%. <)$U*>/Y %T\87+ M D>+W$23Z@9Z #6MHNYSH+!4/+OH:*[ID;)-,8,(9X(S9Q)R%$R>,,5/Q(+)
M^5#H.VI[S34[.5X\8=#_PXRGAOG=C,]31L:Z3_7*;0A66L$DF%&3+8 MIT1 D'VZ7]!F5Q-?SGMOUK)T,!=!\46Q+(5NY M@L\D:B&NJP2]?=8 H=:!3-Y+;6 .H_>3%Y81./#)I(W\#E&>%,AN+.PK?*1?
Y M 0*:;VCS0UVG:YFN:1EO-)45(HVWE)8$X!4,QTJ\4:4(:C2HG M]RC(H&,D(].2_UN:6ZO?@#ADO]$-$#ZUA6Y:%]+,O^O@WL'Q<3\D/P\H+,[I
M*%J)@S\)?':7B2=77MJAJCHJ1F^1N4U_JP++N1.16PK]_M'.B\+EY)X7QX4UWV8C1ZZS,5WY#F^' M"_/S=\)\=D^W[3<23-[2L;O"UOW%CS_,A$\WV.DANI9OC5BBQ?[J)D M)
[%WO>4U[3T^@C,@B0@#C &,*:;7[^O&7)1L;)WOT@<#-!WO^[&/-\Y?Q6V M2D5Q4Q@;7@RV,99/Q^.0;54AP\B5RN+-VOE"1CSZS3B47LF<#Q5F/)M,3L>%
MU'9P_IS7WOGSYZZ*1EOUSHM0%87T^PMEW.[%8#IH%M[KS3;2POC\>2DW;JGB MQ_*=Q].XI9+K0MF@G15>K5\,%M.G%R>TQS?\4ZM=Z/T6I,G*N2MZ>)V_&$Q(M(&54%HF"Q+]K=:F,
(4(0XU--<]"RI(/]WPWU7UAWZ+*205TZ\R^=Q^V+P=E MY&HM*Q/?N]UUQ^4:@$%$>V&M>2Q&DS_.80= '0:^;//BCH0/A7(A?-[VNY1_2$*D8)X M;M0#E>;M(T0)3\;21.(P?,CPSPCHUAK"12];WOQT:U[2;\.H[/Q8,
MEGIC]5IGTD:QR#)7V:CM1KQS1F=:A>?C'"YT:IS5M"\2[=D7:)^*M\[&;1"O M;*[RP_-CR-D*.VN$O9C=2?!-94=B/AF*V61V<@>]>:O\G.G- R_*)HGQVE3 M,CT-IC<2?)R\N9-"! M-
KXC+6V4*=ELC@5M,UT:Q:OG0TXDZ?W'[8*"9FYHI1V3 0J*ZM<1Y4+;/R MNA"90]38@6J/L/8]'M;829*41 ;P4\"$&L9772JR4L@*V+J5G,LS Y]BMD%1Q M*S;**B^-V=,;51(UV6E4=N+B;(2
'RT+M"0^K,.B@&29%]^^N%L-IL\'W6Q M>,<_I\>"@!D*WLGI+8).!NC$%UM0_05HU(0T0F"%S&=//H'[UCXJ#.CQ!EQ M?*\VE4FGEX_^/6(/^!SBFOV0:..U%
[H1U$30S4^4PJC%T+K$Y9+UV+F(K5/'J M4Z72)2*N](!U8=G*&45$=M?!(O$XV<:6V1! \"FD!V_2:1?E.%P*,":E9 9G_M#N3C]:'8;76V;?
5S%NZSI)?!D:SRGGS7.R"LRE0(%+VD%0FVEMIWK!KSK*2A MT AL&\0N8#RT1TK[(_@RA34*A^)2^4CBMP7S2IR'3+C0H4CM800M98[;V+J M,H4\12T$7)GHM;&44%6 Y-/'R;,R/NB'2D!\
(6P(;AJ@V M-(\>;J,-D:PHJP],1F^51.P3\EPK6ZFAN-RJ[*ITFG+N+4)>4O##%&]+YO2J=1ZK9%MS^VF3R3D)Q M;?J..03:)6UCKI.S5OKIL\1?+;Z4'@]E9:A#$ Z)= M[\3"O).E.304:^^*6K">.NCK/ ()
[P.%2$TR3"8%8NM+/DO2M?^]+8#IM"*2@N??YL^9\+[#NK<631"2E M^.T@^;:(;$H ,6O@I\[=VPQ"M0HZUP NE;*L+B(1*1K$M>."#X[1H^%>5?"J
M8]!&Q.XLU)O\I:&;.8:\P,E)53/NFS=]'B.RRZ$*$#G%\&ZKO#H(+O (PC!(M(+(/V+5$D;TDEU=43K=I$"P16*Y!D31*+V(() 1Q6IM T>X1^M8H;8S+TCKD)4-N8/;QO:S9=BJ!Q\2<=(.GH?-6EX?V
<1G5:I= MGRKI\<;,L.[CO8F D/@:NMJ]"U 6#XX=4+E#96G&/)<"W9AAMHO:&?-/U&76_ M&'HM'UFBD%[JDX;R>*P-G'^TIG$A=3[OI+>M.G'Y*V#+8B\XL:SV\G-4 M9[,:TU*R-UT7A2_QA8E+
[ZYU8'.F'KU"6J$I1DGT&[62V15WR YH(@V*T5HI M+ 1T8U */BRQKY#9GJW)6@QK)\(2Q,^#2*0SX)1C)B'$ >)C05N4C^@\ 8PT M^@^.MZ&XEJ9J0P]1C0JE*3.25X;44Z'Y@P[7Y)-
:B=5C+.;1X:K:L^#L"UL MJPG0/TG MYK=\D[0+U$2A]Z^'EERML&-E]*8!$T8C5'3XW/Q:?D M5YAR4O^>H<_7L<8OJWH]:F, MT;NP=E*)E=3Z%FX,*?W5\S5A9A&XLL]BD-5 M]/B7F.\@&
[R8RT)NTA6!I%DP=<37!,HN4]S$I_Q?HSRX'6,$!S=GSR91^G TGLUD_MM7AW2V@X.9VW3^B@IV=GXH.+<'CV1?+'G-.08(ZSTY/>PMF3X6PZ:1>^=J_V
M@=O&;IRU5&_I6H5DXH$H?.E.H5]J^A=<#6D.!!>XD;C6K@IFWU3;[J+B<& 2 M#FL^]:NQ']U/@1H,YK\1&%&-6L(\S>*V6:3JU"5Y4P"X0V 5"Y6J=X;!CW2D
M0*LGMP,:]>#64XO'+BYX:YW2MV?-);?ND@#STN5LDM@?'Q?+;GR9LC6JK^5*$ M+Y/T3>1[C%!ZBK*";KM=4_%=9L* =?2QIH'ADH@I%+W1:6S@HW2&).3&[(& M?)(_CY&@3E87;=#5\-
&;O+K9('$[2H2$1;?*0MR>:!$0%:9%F9K<^CCC6W7A M:\'*5GYP 5AV]&XT"X@>NG&;BA>VVS4>K'9V[KR05!*_)VNY.8/1UVW"O4<5 MLQ&A_CJU /VD\\XZ*N<)]8X&$.B) R!*%
[GCF^/7%DO7J2YV-?&7Q?*BZ3$6 MRX_8,N*WCR:/AV*I-NS$]VW#^."#*W4F9F>3AT_%ZX)J1"T#K)VVD&0MD#_&4&>L/EH@/H@;T"GEN'QR3$9NIU]WL<^8(Q[WZ *A>:4OK31 M9
=+IL]1[6K[,6^1OF%UV].7E^P#;36/R&L_SP0/GU=2P_1E?Q%:^5B M= 7_W"]4DX;\)ZN9)L'8M!^XCS_+U!+ P04 " #3@PU98[7\X:X* #< M'@ & 'AL+W=O4DL$N@^ M?3O=
,\VQO[AUDHUXJXL*G<^6C=-_?+@P&5K54HW,;6J\&9I;"D;_+2K U=; M)7/>5!8'\^GTY*"4NAI=G/&S:WMQ9MJFT)6ZML*U92GM_6M5F,WY:#;J'GS2 MJW5##PXNSFJY4C>J^5)?

6_PZB%)R7:K*:5,)JY;GH\O9R]='M)X7_%>KC4O^ M%F3)PI@_Z,?[_'PT)4"J4%E#$B3^NU5O5%&0(,#X&F2.HDK:F/[=27_'ML.6 MA73JC2E^TWFS/A^=CD2NEK(MFD]F\R\5[#DF>9DI'/\K-G[M_&0DLM8UI@R; M@:#4E?]?W@4_)!M.IT]LF(<-<\;M%3'*7V0C+\ZLV0A+JR&-_F!3>3? Z8J" M%AUD0=1K+VK^A*@3<66J M9NW$VRI7^7#_
6!%;/,.V^OY3H'_;JN).)R.Q7PZ/]HA[S#:>LCR#O\)6[VH MH\=%4:F\=+7,U/D(M>"4O56CBY}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
M^+4%Y2J+HI'@6\I)&BRK[L<2@"N<]PKAJ&=S&HY%I2+5+>C&2SR;3_LD(!T1 M8RE193RX;"P-"%4R/?3,P?=7]"A'V[IGI#%;?&=)B'+,-0L:%B-_$U1])_9. MNGB./4U51A0:,TJ7!55;+OP$Q9,XQ\(Q>=LF M8M]HTIYE%D41[P\H5X4-.73\H\ 8#6%P$V*,O*U8\Y^IH XN,V#5Z.+IQ-9Y MYQ1P7 PD$?03DWG'H4E:)&-%KEQF]8+FL 4.&-">J^_AR9XC$=D5$8WD7*=: MT;>
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
$86E PA5;LHLO/1PAXR3Q>\81R&">[R - M!Z%07T0!?)>&)".3EHH.:[[%Q,PE_%Y/C' _2Y[MJ2OR1P:5IM=LOE-WJ=0U?U@1+'CT%HN2%33<2X^H MM76-
QPD0ODD%_Y0R5]T0Z7P/(=H$1YRDS:)3^]@'K8/DBV.I([J_JQ)IPS3_ M\3$^C9]N+_T7RWZY_^Y[)3%/5'0=NL36Z>3%\4A8_RW5_VA,S=\O%Z9I3,E_ MKA5,L+0 [Y<&W3+\(7Q@_;%_P%02P,$% @ TX,-66ET@>UV @ R 4 M !D !X;"]W;W)K&ULG51M3]LP$/XKIX 02*%Y M;0C01J(P-"8A(=C&9S>Y-A:)G=E. _]~MI.&3H-^X(OM.]_S^#G;=[..BQ=9 M(BIXK2LFYTZI5'/A>3(OL29RPAMD>F? %14V4-L7:DXU 4EA077FA[R=>32AS MLIGU/8ALQEM5488/ F1;UT2\+;#BW=P)G*WCD:Y+91Q>-FO(&I]0_6H>A+:\ MD:6@-3)).0.!J[ES%5PL8A-O WY3[.3.&DPF2\Y?C'%7S!W?",(*
(U598BTC#\#IS,>:8"[ZRW[KMP#SN U\$$ Z T.KN#[(;X@B MV4SP#H2)UFQF85.U:"V.,O,H3TKH7:IQ*KMC&V2*B[>9IS2=<7KY %WTT/ 3 M:
+WG*E2PC=68/$OWM,R1BWA5LBW$OXHV43B'P70C^,]_!%8VZ1Y8N^DEL/ MC3^&FE*XD W)<>[HORY1;-#)C@Z"Q+_<(RP>A<7[V/<+VP^-)S"BX>@@#?WH M\LNSOG"T%
[YUW&".]1(%1($+QX= &:B2MY*P0I[89QE#M1'!(^GT9U0H**DD M'$+D3M-H##F$V$UB'YYU79Y2=MH(GJ.4$)XG8TR:QG!+&=4_N(UYX6$Q V# M=Y+8/4_/=G(>7F/-Z.]55HUC;'B(AYRU3?:&-WK%-7?75^1[>][A[(M:42:API:'^Y&SJ@.C[M1F\HWMA:77*E*]\N2]UJ49@ O;_B7&T-<\#8O+._4$L#!!0 (-.##5D= M>H%7! 4 *0- 9 >&PO=V]R:W-H965T6D4'!KF*V*@IO'2Y!Z?1&,@LW"
M%Y'ECA:&B ,29_ 5W/?RUN!LV**DH@!EA5;,P.HB6(Y.+ROT1&G^FA)=H:?T_6]>RXRA@266=+AIE9% (53_Y M0Q.'GL+\)86X48@[[]09WG-'5^<&(UFAJ01C0;>5:^-Y(2BI'QU!M*U'.+ M6X/Y-
>Z1<96RJ$\K46+$W?G0(39)#),&Y[+&B5_ F;'/6KGC672VA^RD)3O9A_[OR>Z%VTUV.F"[D_>OIG'T?CL M?WM^M["J)+L1*V"89O!IWKR\&Q2*.S!L/ K9NP,F%'.YKBQ2M(>MU+N_@9O>
MG(JD/QF_:/Q*%V7E$!^>^=LI';#IR?3)[$-EE"'5 1^ME7B@L6V%.O%1&(V. MG\QN '>.7,N4B:(T^A[(<*<\ZFF/P]'QL^EE)60J5&:?^3.)GBU-YZ.=:U=:
M66>J>CO$N"*1#%WH,/\8+K<41W$'$)^P;IQ25I=T3P/XDO/T30X(C)_4%Z[?IDNOE='^Y\3YT[SD_BP^TF:N.1,@6O!^6 Cc9C,T!^ #, K*@W8* -N.LKWQE$S7?%FEO&2PSN@\ 3#>0C.X@&$SQ8 MI/1G),KAPGRS$.*Y:TOP)Z?$WECR>&G62:MWLX>+M'>G74VJ4$\822SU4">'W"W"^_7K'Q#,.58:A5 M4ZZ9$BN1T'&:Y$@3]VZG-YR;ZK*]%(:,,<69V[P7@K+"ND**Q+?M^ '[UCC6 MQ;@63]
#P^^$%+A+[Y DT67O\9"AMNFE2*M?C"8N/>FV>##KFFN="VP) MWY-2ZL3GDKJ0MG6&WG*ZXV([5793C3[CUT'M;5[HBO+1MXX5OWQJ-FZ;O)'L M^2,UGCO;-# ;NQ,?UDFMR="'!I'8WK?
Z(%[N69D,V*Y[V;!WZOTP MQ\H,"2 [U=:N\V$#+0?9HM_ %!+ P04 " #3@PU98]/^9T& N%@ M&0 'AL+W=ODNT'W8%UL\YAY^,^39 M7.D[,R.R["&5F3GOS:S-
3_I]$\\HY290.658F2B=B+,U58*3*ZT#XNZ=KDM(Q@AI_53Q[C4A'V/ZNN7_PML.6,3=TK>1WD=C9>>^H MQQ*:\$+:SVK^.U7V[#M^L9+&_()YN3<:]5A<&*O2BA@:I"(K__E#Y8<6P5&X
M@2"]"'*O=RG(:_F.6WYQIM6<:<;W-R'-]530SF1N:#<6HU5 3I[\8$+S;YQ M61#[1-P4FN!Q:\[Z%LS=EGY<,;HJ&44;&!VP3!RJS,\>9PDE7?H^E&HTBVK- MKJ*M#/\LLH -PUT6A=%H"
[]A8^G0\QO^+I%S5&CYF@;]Y>HN9W10< V\&)O7AU%X?"47:LTQ.?%S*YG%-_E2L YZPP>1*<;6>82>>*.LY.;A2> M-GD$;2-VTXB[].+JM/2;!Z<[S"HV)A9+;HR8"/#FII.A*O-JCRMWE&42>S"Y
M<&I:[K*;=&H8ZB.43"C-O>)PO*,L (9:+IR:AN)""[O /-S*-8)36",2\O8Y M9EK)@'T!U?.L8'.X S)CI1.GNO42+4JF#[M4QHEULMI)F9#3%UB1L/&"%7Z/ MH[N"E+N]VWBF) Q/54)0IA7%N9
2PDHF]OE*0C[Q> ;27&GKI.4(F_+Y@"YB M FV\[YSGE=.W\BZPRCG7^<@".D 8L,OE=,;"*G3L>O7J,"[T:A8< N+?3]] M0/DYM'D=!@-47BD1U]#)[\NZC:DC/??U@6\5 7B3"I36\F[@E M_V64%
(E'5R2.K3I,QPPX[\TRP;.QX8FT76HO5[O+>L/'!ATK#NN:H$YV/M&# M[J,';7=E7;;S963]=F,OZ3<[2JUO7U@TJ;F;73X?R'[]PO9FH+V))-.8+;6 MLO*6MES(4$-6"P:Z\R@(MQ42U%-
T7\:6%045).J6D+75+!W@%C@WD*03)[MS_)=:(7.@?IC%1P&P[:DU>WWCW47=^J6(H/1NM+6O<=\Z68'\L6O- 7-%0:D
M($!*+DHP=ZF[^5ZR>AOI\IL(#2^Z9KNI/;DFW$Q<.6BN*[3A=KC95HVS" MN7] (7;-M50X96DARZK@+"F_4@+6)4JJZ2+X)0>W:_M_]PAO;2G]Z=IT%(;!
M\1!)]E3.,\CM$*W8VCS>'P8'C[F[[IFHWWK#2TE/_4NER] MEF^ C]O+E]1/7$]%ANZ+)B -@\]'M/EZV0YL"KW+X)C9:U*_>>,.+HKMP'K M$Z5L/7 "FB?BB[\!4$L#!!0 (-.##5DU=O:V,00 (4+ 9
>&PO M=V]R:W-H965T)#?M_?]CY-A+-DF'V^'NBVU1Y..'%$EQNI;JNUX! M&/)8<:%GWLJ8^CP(=+Z"BNJ!K$'@3BE510TNU3+0M0):.*.*!W$8CH**,N'- MITYVJ^93V1C.!-
PJHINJHNKI"KA+*3\;A^HR\+JN%:\M]9858S;^R1 DK:<',GUQ|@ MX_0XN62:_=-9)CPA[*O5&XR]#.S&^$H6+)%AQ\(L!, X.@=BO(M-P!7+4!\!&!$/DMA5IJ\$P44N_8!DND9Q1VCJ_A%P(^-&)
D]DGO M8>+PDI]Z2"ZU!]./.MKBI(=Q;'6K"C*+C0IF6 &WG LD(*P9WOJ M[$DNL0BU(;(\L$GS'PU3:+=X(A]EHP0\#=Q/#+5:"UOWI%;R@16 VEWY6S"# M6AN3 \#8<9QK)0A,7=6&@..]]^:_>
[[1A6/'HU#<-9H!O(63::BD*?D4\84$U. P"]<&43VCZ2*\O9%B[BBC"QOH MHLD-X2S'S@FZ-TF(D632+T](DOF3>+@ON,SSIFJX\YY64AGV)W4-M-,\C49^ M%*=G6X+43R?#LQW3&\PPIK!]
(Q>I]4]=.DW*$W.CLJ_8 KOY\@S^VCLCX;C M+4$<^O$XZP7O-]ED5@J 5&W/ MNSG@_5'1">G#LDOTO-ODIVH@&/M0TP7DRM MOQA=9O1^_-=4DY-
P,,;FS;F[AQ# _)!I$G38C*2PB8(M(9=MGUE*6_):\H)(X>+1"-H4S*)A M.RJLO?M"%5:XGVB#KVJ#@U.+^2D/Y?GNXW&9Q!W:&*K"5(!]WQ%O)[8_B\6ZO08WGXDW\>)CM[8_Z_=A/ MLVAO/]OC&?
E9-MS3&Q_0&TZ&-IXX!Y8&-?^ND/B324CNF\4;XUS?\%USO%?MS4/LO8K9<0@PC3=Q/%;TAZ[A8<]D M\W0!H;[1&F'9* MZJ7]C'G9CE;/ZNV ^IFJ)1.:<"C1:!QD0X^H=NAK%T;6;M!:2(-
CF_M&PO=V]R:W-H965T8O:9LMY MLMW[Y=SU;+2E>P^A;UOTK[=DW':13;*]X4%O&HZ&?#GO<$./Q'JW]UYF^0&E MTBW9H)T%3_4B6TUN;F?1/SE\U;0-1V.
(2M;./<7)YVJ1%9$0&5(<$5!^SW1' MQD0@H?%MAYD=4L; X_$>_;>D7;2L,="=,_HBIM%=IU!137VAA_<]G?:Z;F, M>,J9D+ZP'7PG/V>@^L"NW04+@U;;X8\ONSH ^)$LM/R+B< M>
[<%'[T%+0Z2U!0MY+2-F_+(7E:UQ/'R3ZVDP@2KC2>28G.8YRRX<357.XS; M :,\@7$%7YSE)L"OMJ+JO_&Y\#F0*O>D;LNS@'_T=@S38@1E4<[.X$T/(J<) M;_I#(@>,V?
L8\7+P<=I<3$I+LK+B\D('D0/>M4 V@H^T;-@8?(6XTV'NN=> MZ/2!QO"7)#F0['JAA#''^A7D;K/0# E%B]C0KX.N-'I-@[%#$SY:\U*+MT$:K MIV^]%NCHRFA9"Z&X:BAU&E>?%#Y*!D^;WB
[/W"7;O@DD5)2[#KOG@6-:NFW M'$:IXKZ2[*F:4HG3=1C#*K)7S2C5=*\2.B_"(RFTQSNED@;1'$ 9#$'76F88 M3G*_>"?6IE2]Q;[2+ ;EI 6D[9-1<$97&,U2)4[G,=*0!\5C+%1X[^+D1[VL
M)3E(L6,+1==;'MK:P7IX%%9#+WQS'UZ4+W(.M0U@J);08OSQ,@,_=.EAPJY+ MG7'M6/IL&C;RL)&/#K)>.\?[24QP>"J7_P)02P,$% @ TX,-62:J,?X; M#@ [BT !D !X;"]W;W)K&ULU5IK<]LV%OTK
M&*_3<69HF0_)LO*:<>QF-MVTR33I]C-$0A(W)*$2I!_]]7LN7B1%VDFWW6[W MBV62P,5]GGL \L6MK#^KG1 -NRN+2KT\VC7-_MG9F4IWHN1J)O>BPI.-K$O>
MX++>GJE]+7BF)Y7%61R&YVR;8J$A]JIMJRY/7]:U'(MVY="T9&[\6.^W35TX^S5BSW?BH^B^6G_H<;5F9>2Y:6H5"XK5HO-RZ/+Z-GK M.8W7
_Z9BUO5^Y^1)6LI/]/%V^SE44@*B4*D#4G@^+D15Z(H2!#4^,7*//)+ MTL3^_T[Z&VT[;%ES):YD\7.>;N71Q=':+!,;WA;-C_+V[\+:LR!YJ2R4_LMN MS=@(@]-6-;*TDZ%!F5?
FE]]9/_0F7(0/3(CMA%CK;1;26E[SAK]Z4/R$N\C8F6 ME_P>&XV(^,0(*HUG:L]3\?((N:]$?2..7GWSM^@\)?/Z(@G.OX/PQZ5^GX.,B M5C,VDF+N?)(-+Y"H^#>5*';5*"8WK-D)MI$%BC*OML_8-
W^[B/D^7]%[$5 M.K;NQK5(1;D6-4NB8#3ZY)CE%525K8)AZJE_0)G1OTC\3^YHWP=[_G35OG MS?T?;L][_KFIA6 _R-YJQVP1!F$8CF]$T2QD3]AENT5ILU-2?<$^_OP/]DG4 M)7LG>35:
(1Z*7_?N2M<4E4LA '"U8IM:EJQ! M:SIMY"G]TM-:8/T3P+'N-S>BN#?I'(?/[0+Z*GK^E)V0,/OL0TT*.A4NG69V MK%]:EZ]>I24= M83T?>:6V/&/F' \()!QKT:_*([C#HQFBP&MCP@ Q7>N5;
M7M>\:G)A+KO!?+/)J27'3OVD$EMSDG^1/&7&+AL:G@I"+ E2V)2OR7]H\HZ(F M%4YRC.3^82VP0HO($!0T.PX\$!A.6?"=;.M*W).KHN5S,JUJH9.?(=E:, S& M/?P/!^*ON$L%IAX,W=?R7X9=*.18
SRMD4\:L1YT_HRJX7F!=&3K>SWN2I9[M7MW30E8SG>%\OR_RE HH(52C"KN3<(^(KT7@%O9%AE45> GI!.@A=1NR(66 MM@3@8FNR0*]@HT2EPFHB,[Y/6!5-4CE];Z$D#2?%_KHQ'U4
M=ZX7]!V",'[6(_F& M-*TJI&RM**&MH6DA%?*.9=0[[+U^>04>DI9:OP5"!139Y>F.[276U3/ ?56# MG"1)^QH)GN^1-,AN@F 3EAU'L:R%J%C6BJ%?TV[C2PPA=4EW5=*4BC3^N;+)>DQX$
M@3D,+/)M3G4'^[*:W[)VKY,!Y9_!&DA$)AY'_15XTV]N%A59!LJ ED8#,%^U M^SU\R#9MHY&KQ<+DSPR(4LBJ]5YJ>SDU"V-8IR\"6W!*C<>*'T$V=42#:D&8 M3\8-0[3FA4$:G;ZZ'JBOM,"
<$^62,UH]G8V(R33'0JIXQF1+.AE$D*;U_>P" M&3BL/DRI*Y,UE\.L(3%$+T@,,8J33GS7L9L=YISJ#&?[G7E$GGE\GAZ3800
M*V5ZM4/=+]T3GX&8H9/'Z/F&IWF!9#8A&\&SHQMOA(&2#0LZ3CNAP]K'\>]W#.K'@^R<4+R@5I*\Y<:^89>7-P/< R=F](>=;.' ML#?7E]2+:GD#U:E2#SK_]OKTWA%;3QK@9HI8395]: O.J?
72!0D."*H6J1I M)[>BUKT6:/YB $D+=O)QD).OQ3:O=%8C:=^(==U2Z\'(\RZT^1"7-282EJ/Z MR#T6C*<[C'WHTUP->J))%!T^3VZ6L\43-VW4J7!_TVJ@[20&%@6K^UZ-=C-=
M?:*I.90:P.6,O=WTLLGQ"XT 2N1C/#]8SLR2K>C3$M)';'.BQS;J-B!1 J@I_+^'Q3/T#!^DB1FJ7ZV] M<0,&A'_+'/L"[RS:6,1)O^YHJ4AF)YU'G3$TFPH)I@<8;ALMSO+,FO53+', MPZ;"\I$2O!:=
(KIC6MS^:J&!V1%%CYGX^+H&V/BFL3#\]?:LVV:H-3B5K+*O M4QNSH#E4#Y^0@CW>BUHG96;LI[T^$7:Q=11@9&@'][< !::+#[N@NUPSXBX7
MNKJ1V/CDQ)&F"F@H?,8N/:6BS;Y;2FO+*R=*%SJM!@"X2SV^&1+:N0\S>0J M<%#=X95J=:6DTI[;]64$8(TH8-PUX-/E(IJ5K*G::2=I3@\R>P@TZZ,33S7+ M(X"E[0_V^_=T@;
[6BGZ(.NID(SKA*%?4OG"\H[$'-"G4D!@KMB!IK7)KB\W& M'):QT55:*9B)N+RHEW"[B"IMU6>@V MG[&/#7X<7KS?"W/JHSHV=$AJ>*&D/;(0RGC?-3&*6WP(V0L\FUT1';ZV5$B81;!21AN-M-@1,?
]J8O1 MTJ8W:;(:,N0%4SN"1L _;$9>TSO! 9EQ&;T:P' M@J-D$L\:>=/'MMC&7K)+5:+F6I+BV/6\C9 6KU]G?G6.3:58V#T6G_Z7,$=PZM MN2,L0EWY P$LT\7 W\6>'(.MC+7>
NG]!#>$V>MDL1"H6_-M=WID\\>!7A2> M9N@\R*)<4EZC"C*>]Z/2(88M699T]".C0_Q+49J6W E?:/S.X?]6*3!R4Z M\%1OP>#XT:_A\(P1C1M>$,I"?@@'/688L+@,4U/VEC]_/G-7T4[_,V_NX@
MBL[:4@,J;H=M<<>+V6^QKMH1^P^)_;LD1+:=X(3QP''(1V^O,>:\FJY51UNY= M)Y6MJ'$.Y8)1 "122T8\I=,1L^W(,15J01 'Q'AFMD<>7B*9S9])AJO.,M(Y#VKU.J5O @99,M
2S_DHVXIW]ZEV+L"/2XUSS0A_E4;*LNU(Y#^ MA2WR CO,[DY'BS815.N<.MW!?<%MAL-^=T?2H* M$K+69"(PM14'87P1)//%EYS8'>GY-[S?6BQX.Z9ZE]#U#HH\!5]JW+AI M8],T T?^G3QK=-
=2 M.WEKZ#1Q.)2"/9,?\5O->PO[IE]WVZTPI^E96[M^XY#7ONL3V9_WYO^/^OVD MVUS_DY/Q1P4/?R8P^]+)\\;"J=Y?SUU; ,)%OW_['B2K\2OZ!5CN>.0JFKJ;
MK*+1W>7$R#B(PH1]X'53(8U2_\ZH8\%[7XJVHL;O\L.)-_RHP-' 9$Q'CBE M:9RL1O?.DW"D9UX!08K"G,BXESVGJ(34L,^IF$?Q=*[%EOL78^,>&7JH]>.?
M3,Q7$[;/1[<6Y\G8E4$23CAS.0Y[$BR6"7NOP=U+?-"6[DDR5N0APS'T(/L= MONJ=FN\BJ(G>%QP1]C%1[_H\Z5\A6WLU<,P6 8IP,#ON?;J#V<$\G@[5_\O M1Q#++PB(AJ-?3='3DS<3<8 A/%C&_>
<7P6(5 "N M7MI@?H@)WA-3GWR>];[!+46]U5\:$P,%?32?X_J[_F/F2_,-;S?8&LZ6BR/S08Z[:.1>?]&[EDTC2_WO3G!L36@ GF\DT +^$^]7 M_P902,$% @ TX,-62@6D*Y^ P M @ !D
!X;"]W;W)K&ULK59MC]LV#/XKA'LH6L"(7Q,[N23 I>VV#K@VN-O+9\6F M8Z.RY4GRY>[?CY(3QUO:H'OY8EL4^? A)9)>'H3\HDI$#<\U;]3*%;5N%YZG MLA)KIB:BQ89V"B%KIFDI]YYJ);+
<&M7<"WU_YM6L:ISUTLJV95@UL) MJJMK)E\VR,5AY03.2?!0[4MM!-YZV;(]/J+^M=U*6GD#2E[5V*A*-""Q6#EW MP6(3&WVK\%N%!S7Z!A/)3H@O9O$Q7SF^(80<,VT0&+V>\!UR;H"
(QA]'3&=P M:0S'WR?T'VSL%,N.*7PG^.]5KLN5DSJ08\$ZKA_$X2<\QC,U>)G@RC[AT.M& M)QU2HOZ:$P,ZJKIW^SYF(>10>I_PR \&H26=^_(LGS/-%LOI3B --]$9CYL MJ-
::R%6-.91'+6FW(CN]OLLRT35:P9:]L!U'8$T.))0=YO#AFH5IZFEP9 M R\[PFYZV/ ;L#.X%XTN%7QH.*Y":\" MPU$XA\%T(_C*_@ M14/]CXZ["FA!:J91FN'*H1A?()G??K5\',O[U".AY(Q]?0_SWI
MZ["!/X'O@CYKM2,M=M3"DU8FJ&:5)I$H0)<(A>!4_%6S7\#K5VGH1[?_^4WW M >U]. G>8X;U#B5$@0MO;]!JR+7H%#%4;^VM,8_H'SNZ"/FT<0-1XLZGR5@0
MNVG@#VD{)>RZJT4!2K3V!B' BEG?]<(W7#F7T@#=Y8&\,@XDQ4]%W:BZ90] M!(F*<[Z*YHM&!_ 5N@DE,'9QS,XRH,-B0&*J6 M"'73_9SKSU$+N*?NSYJ]@0^26RH^I6A(;SLZ.!I#
<+>7B/;4#I4NH=O(ZD1$^&L-R1M-DAKEWLY+4]&4J'ZH#-)A)- UD^BL MWL_S>R;W5:. 8T&F_B29.B#[&=DOM&CM7-H)5%'.?I;T6X'2*-!^(2B(X\K M%Y4UG\"4$L#!!0 (-.##5E:@#,J80(&<%
9 >&PO=V]R:W-H M965T3&QI@4;O(D6)C'5&$WB MA Z\N@M[0]*\)4WHS_,C?;62-I:P:WV:-%Y-TD\X8-34FY1LPZ5OX,:PQV! M:@>?=(75W_$)R>JUY3MML_P@\.M:#V"8GD*>YJ,#O&&?
ZS#RAO\CUPXU>AL5 M2N72-;S$*:-<&B?D14G1]DXO3H@=-0+'1VB_YO0PZ@LG\"[./A>(\R-:KA^ M.3FZR+/S*P>FU6A=+1H0O9_0(&@HC79&BHI[K*B\%TY4@EN!#K@'>BWL7PM: M[L
))22WX W<8(EJ@1:&6708G@)N2FP\4%^!._K/.0EK:U'65%,EM1=`1RRM M49!]/ Z\$T%^/'CK;I.JGU^A7<42#UK7VG=UT*.V7>2Z*YX_[ET+NN-V);0# MB4L*30?G9PQL5]:=X4T32VEA/!5FG-
;4"=$&!]I?&N-W1CB@[ZW%*U!+ P04 M " #3@PU9R65A!D $ W"P &0 'AL+W=OB3:LF2(CNI;2!)-ZS#N@5)LS[3TMGB0I$J2=G) MO]^1LF0[2PP4Z,L PR*INX_??>2=;K95^M%4B!:>:B'-
/*BL;2ZCR!05ULR, M5(.2WJR4KIFEJ5Y'IM'(2N]4BRB)XSRJ&9?!8N;7;O5BIEHKN,1;#::M:Z:? MKU&H[3P8!_W"'5]7UBU$BUG#UGB/]J&YU32+!I22UR@-5Q(TKN;!U?CR.G/V MWN!OCEMS,
87R5*I1S?Y7,Z#V!%"@85U"(P>&[U(1P0T?B^PPR&+9WCX;A' M_]7'3K$LF<$;);[QTE;S8!I B2O6"GNGMK_A+IYSAU2X M=(=R;S6]Y>1G%W_2N?^AC($&-
=RHNB:E[BNF<199@G=&4;&#NNZ@DC>@2BM5B")%O1VQIOQ*S5?.G?6@5%YT\7LWBLE"A1&^ &"B:*5C!GM'PFM TO MN5R#K7
/>0Q$265).A."H']O>8^:HX$KN*741*VQ[)0EL:S9.4_E!*T3-6[MZLC2T"Y42B@-L3XT#AT)A[CU68GE![9!344&9%LO*3*UZH(S;M1+XD("*ES& MTEZ.?=GJ/@B2@ZLR!*DL<%F(UANT#R%1;
(4;>F5"3W?+;45XI!D5,5** M^4+DN!]MB=];OF$")957^/3V0?!.)<-J.I1NO/0'^,*N;-$)W"-0D)S*GQ"[M(&@3TMZ[VTHC>]J&/T'=I2^Z] 5*/AR2+ _36N%I1+07B?72L^XW[2^"CU*H^ M?:!;BN$L&
<54UH3P%9IXG&7[A=#)VJ"OV^*YD[1AVDK:D*YAP^1_3YY.G(B< MQ:/L>35^' 6$QTO^A&..78J1OB?&5@EDI0=]J=[_W.=(H2_>3TRUZ[FH% MV8/!@C+$4E3AD&F'27/Z4GDNG:
5I2]+D\#NYU^2EI=?(Z0/?F-9$R[BL;EI=5-2&')>0\W"27X23ZO3&R21,+G+X MJW&*G7 93\,IV:5YF-$6#WTM7LIU=F%^D83[-:)1.LG \SD]8/TA./)- M"O3[JBP3, FS:1+F64P Y^DDO(BG?8RO?
2NC@V:F1KWV+1M]8%0K;=?7#*M# M5WC5-4-[\ZZE_,+TFI,& E?D&H\FYP'HKDWK)E8UOC5:*DN-EA]6U-FB=@;T M?J7HVN\F;H.A5U[\"U!+ P04 " #3@PU9@ G+&!X8 @80 &0 'AL
M+W=QGN^2$24JVWTN]#VL1P$Q/3T_?W<"^>BBK MW^L=8XW\9[7]>NS7=,"RNGM9'RJ6;&C2 M/G_INV[\3^\#7$\#?A'QAYJ MX[>%.UF7Y>]X<;UY?>8B0BQG:8,0$OASS]ZQ/$= @,8?
N:96A(GFK\E])]H M[["7=5*S=V7^SVS3[%Z?+<^L#=LF;=Y*A_^QL1^(H27EGE-_UH/?*P/*Z9M MW91[,1FN]UG!_R9?!!V,"4MW8H(O)OB$-U^(L'R?-,F/53;F/U7Y8%4%SA]#A#]HJ
MS0;DL@(/Y;:IX&D&\YHWMTV9_KXK\PVKZO^QO/OS19LWCJY<-0,;G+U,!Y2V' MXD] B:U?RJ+9U=:'8L,VW?DO 2.%EB_1>NO/ OQ[6SA6X-J6[_KA#+Q ;3,@ M>,%?;I-#*<>AH(#\4!^2E+T^
PFH677/SM[\Y4]>[/XX@V.H< SGH)^,XSR4 MO_QIZ;O!CY;ZP6.94+&^]B1P&?/[I$OMY8[\H]R'J=D+A P-' :U:@E%HW,,VVDMI*0 $ 2UGG" %Q]]T?:0:.H&OOQPO["'S? M^K _Y.4C8V*AF[9*=
[!G@M*!_>'VYD:"M9)B,P?YYQ(V_9E5^Q[BUKD]O/G M:P7,@4'6+\GCD)+B1 !ZF50;I/K[K *E558U85 ;IVX]GQYS8A,;LN$FUFR;%U]#*.8M7/'6YJ:"PW%H!N34!K@UT[?,:^
MX&^87Y5[/LHJ# C$MI@\>W[[(,\>-G17)7M.9$"PJ;*TX6*P!XB<4Y('.!,^ M!'Y52='4@&-%R!Q8E97PD'1! 5- L/K2][_]] .N@HV:REB+L!QSFWV9&'"^ M HX0ME:V-6RXOB!>Q7\"-5G?
D4+Q_3>MA!=/H2B+2W6BXG3DP!>6; OAJGN] M\(SKT Y#OW.]<)?6AR\L;4E\>P#]A=YYZ+GZ]VJA?B^]Q7>G@/Q[DU1- 4+% M4-?
&OB/QK^Y9T3)M1E:^017U,U@&QF_KW8ZEOQ_*#%2#FFA[Q@E$\<)XLEQZ MQE44@!L!'D\"PB_OGL?>ZD^3/=(/TM#7#_RE:_V];*N"/0XVXMGQ(AS<71HG
MJS9@NTMW9'[DK:R(//"5WL92+ZUA>Y[&+W*MSV63Y,R(R(M"3@:(!6%\-@?LF8GG8H[KGKWR8:AI9$:@&MFF%.#%TXCE+'2^PJ=H+NO0&^T MOZ\^SG<,Y V.DOUS]?
Y_G.O2\;K[6DSOZ[_Q7+F\'9'C2 J9[>KNMLDP%40>2#L"GI][IAX (P"_I4T+Z^795C_XM>\VLR^L2C/R5[.4 M 5."GUK466K=)SD8Z/-'D#UPU20;W8,C2V[ZAA@Y%>>/MZVDL=ZSE!C5"CR;
M^W'>TEZN3+/B@]J/C&O\Y?E@WIQ%;/T5!0! *CL7NK;ECKEA>)UX,;\:V;XR- M'? ,3L2[J^JB:("T$YA^G5@I=B} ? 6B*5?PX.V8EC:$OQ04>-AEH*6SND/A-0Y58"'&X\9& M,[_DX4O)PTA(?,#C']QN
'@3'](V(K W=-7=@\V-]TD&6B*Y@].#F;T76G*X. MC<"M[D=L@VLD M3XJ4C:L'[0:'('0+0WQ!():.&YD'R*E\U],180B>M3_TP0/']8:S!5+*T?<6 M=N &%\/9$>JCP71^Q'T4@H4=C6JI93@%
J+\+$P93-=8IHX,Q]+SWF0:2@]9@/&(SJL7_*3-"I2DJDCO[{-<^W_LL= MJH>^/OMF#EM_ K3+II7A422TBW746QOWT7]>6=M@4H,?-3'_4,M&]F*YL/VE MF;L"Y61F
Q;V8A6"$>MTVEYUG5=MZ:" _T6VUZXU'&!X_F#FTO;\[H)$'1D M/HAM=+4O*,X1E>WDI+HS_CF7UQ]W.!*!J61R?]J[M79)5>ZR"W
"'91N,IU'XW^TRMC4REA^W6V"YRK;>5^!@E34K'I)\PY/V>M0_ MD"TUR%N,==D=TN3 MVM^4HFR!RIU*UW"DPIZMRZ*M];H[L+!@2C9 Y+M"630(TG&5X>R.-=23-RTH M<61(I%'9-J
F]F#PV@+)=="M2"%[LG^\O9(K@&G=8 /$^,9YK?5=N&%FAU3(V MBU^Z0H(B EF'TM . M C%!(77DZLX&^) NZC:5V1C.6GRF8 6KK+*[#&DK;3R0>]\R0+6Z#>AOVSRW
M,@Y>%18P703.'^9\!:]AM1>%:(A:4JAYMJCA\6008&$D?*QSN,0IP$%KP(V. M2$ #'F-W)2!T895\N0;(A FU J2WJO' Q5!.6:$T6 [;1*Y3B.\X0EEQ7^9M MT>#$6P8. U^_JF.W8B?G"3+N-
BN8$B@$+D2U+$"SE40!22S8RR8C.$1F#\@

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l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|%$9I8>$.W(Q+UC[A@BE56F3B1AO'KA'S MWN?1@8DCLA0,SDL!?AF>'\--A8[M&$/>W 'Y#D'^4Y'=S)'MR\0YMHAS/^H M7$6RP?0ZO54/SDB+CJ

M'DAY*GQ! .:1-2$XC=-RB38B4']@CJN3&5'A\JP\FQ0V\?N"=RP.H3#E.1D[M%0J'JA[Z S1A8,G-A#55M<6PDMQN,(:D\16+&EOV"+"7;S#M/,LB^.I=I$"P MN2)Y1@21J#V((-
!1>;Q<*M.8B!HOH$SL*OSJ=*!H]PA]*Y3.,IO$=&!,>!9,P8\ M.]B??)$WYKEM(E:+(J/MM>I>E;?:3O) M&[F\A<,;T2A&I:^KO(]E7JY6U%E&W*"Z1(U_3GT_ASCVJZJCR+1.
<4"*UT9BC+ +NU6LKDEKMT"T23&0KB2BDL>'2$ M4 H^ + + OE\F.K M!N).9F43>L@L5$E V1F],J"^#@TH=+@CGWA2.ZJ26;,^SKBR=SP(V\)VOW." M]U#C\8%8J@;, (LM)FZEEU7=-
H\&SX$#G4&\ZRJZ51 MS442>Z&GX^N6X0VZY!^GPXG(-01# 1QBX;1>&! KFI,0?}2=QFRJRYO2.!98 MSF16PW?4^%\I\PA^%82^.,0&&'1"]#6JTZK7!K KI# 8J3.F[&&#W^XDV< [@ MV'X?
%'E"%8Z9"MM3QL_FCN %#QOCDY? L_]-$-Y_P4'9>3B).<)@<<]\XD=Q M?C:8CB?T8S883Z?BYIXM&T*#\=E)\X1!8C*;B8\VP.')@^3[G%.38({3L]/. MPNSY8#H9'P"8\P9@S@_BPS=;N'M
M7CG6I#DFK>>VZD[,TF>[NO=HKX[V1UAAL>;B!!&ZB?;B@&UGC6UG!TTQC\7Q M5T)6JOD+ ^+K/H >I]-]O]Y$6U>*F7J1&H@7#NE9S,\?VSU5LM!*GV0&4D-6@ MOT>CFO,[-
NL4O(BQ+F:+=7[2^W6%PN>VIK;EGJ C6*C;*U.64L%&<>E-R0U* M= RV/A(T^.B\R8@*9CN#>CM*1FZ]1$A8#!8LQ/T+$ 1$Z9!<1ZICG,=*"= M-D?IRD\N4;ZL>2HNM?
5(+;K@'8AW)ADV7JW-J\XI42?Z<;W).G0W$@>YXW MV?J\#SH7=',!*?PN-GI=,,''66&K:N+#TI=1ATC6. FD6 >$-;<5 D$/SU/)G MD'<&2W>QNVD[FY_GB\NZ69TO/F'+D-\>C\\'8J'6'&
(WS>3QY*,M="*FL_'3 M%^)=3I6^D@&Q$+=Q"U"??-.YMJWU@B!-F_5G!'G.SJ7;@(_R"WV+C#*BB$]WTKUH!L @YY,+O0B:HSI+N)8%PVT5)_*#H2]
MJ:1JJ;&JJF/=*:"E#VIY3#*>Q2UE(LKGWK92^5SVAC,!*5X=E]M% ME$1[PQVK&^,,<3[O: UK,#^ZE,):/#"4K 6AF11(0;6(KI*+Y=3Y>3x>?#+9Z M)"-7R4,*!Z=*Q<1=H2 0V$<
K7'$UP#YP[(TGC<849#2A6>>BUT:VNV#+H&4B MG/1Y]PZC@ R_$4!V <3S#HD\R_4T'RNY!8IYVW1G.! +]=&6'!.N*6NC["VS M<29?AV8@6:$UJP6K6$&%05=%(7MAF*C12G)6, #HPSW=<- ?
Y[&QB5UX7.R2 M++ ,$2\D:2&;J5PC0:W8@2RM?QL24\L"9[UDMR%/![+TY1BB>(8#(]@I<.KY'Z MO/2?7^%0\0%[>AC,3=6%[F@!B\B CO;U!%'^_B29X//7NB(3tWFAS&\4*
R4J[/VA0HZG>G^2$9Q>HO]UVB:" M,^ + ?%ZZI8R5]JC6@ +JO.+2"/ _PK3.EB'77<51OS% M/2S*6ZI)C3B4-E0?'I^%B$5ED]0C.S\P&^DL>O#BXW=UZ"<@[VOI#1[Q248 MO@#Y'U!+ P04 "
#3@PU9"#^4PX<" #0!0 &0 'AL+W=OWD>/V?G,M8*^.)*1 UO%>_]J[15.UQ=!H/(2 M*Z).18W<1%9"5D0;4ZX#54LDA0 5+(C", TJ0KF7S9SO7F8ST6A&.=Y+4$U5 M$?F^0";.N3?V-
HX'NBZU=039K"9K?$3]H[7ZQ@H&EH)6R!45''2NYM[5^&*1 MV'R7\) BJW;Y8*MO%@BC=MB[H56$#+ ,M64@9GC%V:V3,$AD9OW1.,SC2 G?W M& 8;5[NI94D47@OV3
M=SKVI!P6N2,/T@VB_85 /Q/+E@BGWA;,+C2(\D9I M4?5@HZ"BO%)6W\/.X!I^ D@Z@&1T]T=Y%1^(9ID,RE:D#;,L-F.*]6AC3C* M[:,\:FFBU.!T=LM?D6LAWV'T1)8,U2$LT(;71H.\YUAT'-
$G'"G<":Y+!5]Y M@<6?^,#H&41%&U&+:" AJX.?0ASZ$(51LH38\5#4,0*]@KZ^]XXOF".U1(EQ&,?1H= .>A2-(KP0AvI[5QE2C1'# VG-3ZE14L(4 M'$+L3Z;QD'((B9\F(3R; CRA *26(D>E(#I/AYSI-
($;RJCYDPM8"U$H2/UH MO"5) //IV?:2H'^,(3Y*PLGQ7Y6 8NM]$IHP4T2'I6@EGONIX=M*(=^% YZ M;GK;8^?+!*1K TL4Y*+ANFNXP3N,ZNN2[?1%4; ,,H+'8&94
MP@5/'UBLDDEGV"$QS&F9JAN^^@/6 ?4T7L13:7[)JHI[P.E1*17/UHO1@XSE-M54N?UAO16C!T]RSPUPM\XW=ER'CYC2HZ'0N^(D+/1C3]8$(U]]$YENM3N5*_MWS))))=Y#/'F^BZ&
MTL3CU_&<^U; AO<(8'IE?BN'UKP@F9_ H,7[L&[Q32(RQ0(GR,)E[A1U+) MNZMJ7TC*Z(RE3#WO"M^,_OMO0\ 3LE!V^9(OGPB+"8S'53O#0)0)S MFM(\ D(5^0:1.2(2>&9K@@;]$QD.^^0BH?
D"_9<$V)I"($Q1M4Q2W/,J!KJ M.3E;0HXS7OOUQ0M&1^\&NT@@>BPXP[W<%;#GG^Z%+%(:&<82E!#\;:'>"1;1 M;0 _\(A /?0M^PH6]H M)5AK:S/=VJX]#W 8525 'HRH0DSH&@3>,+EEBYS-
<6,OH+NS6\?5I'C];H,?&REM+C4%/#!A!HW#@_^U-M/MG1#V7!'O%<&7CNCMO6PMK75?A-V3K'-E7^/75L MPZG=9?$=(>TK"N' 0IEA0YZA1VNLW>"':>L.C7T39&.'K?);5<[7VHJRM]UA
M6+Y]Q[5I&TH\H!JH2N10U/Q-5=LIL#%;LACRF#PS2./FX^CUQ]+6.C25O0AS MX 1M2]O3ER^E %6JY8@7_IK:CAHFCJS$.,)](N_AD77:@HGKNRY7(_>@$>>J&[A54?QPMQ\9USA/=H\
M)D!C$'H"OI|SKNJ. M#\%S+]#U!+ P04 " #3@PU99DQ+!U$# 4^0 M&0 'AL+W=OVT357;[>1^= . 0T,#FVF99[Z_7L4DH;=*LNE?W" 9Y>_P<^]B' MV4;([ZH T.1G77$U=PJMFW//4VD!.5-
GH@&.EES(FFD4Y=I3C026V:"Z\JCO MC[V:E=Q9S*SN6BYFHM55R>%;$M76-9/WEU"\S=P)CG)WBIEP7VBB\Q:OA:[@% M_;6YEBAY/4I6UL!5*3B1D,^=97!^&1M_Z_"MA(T:S(G)9"7$=R-<97/'-
X2@ M@E0;!(;##W@+566 D,,?6TRG7](S#N<[!\V=\QEQ12\%=6?9:-+N3-Q2 8Y M;RM](S9_P#8?2S 5E;)?LNE\X] A:.NTJ+?!R* N>3>RG]M]& 1,_&<<"Z#:
M6M[=0!.E.Z:98B;%ADCCC6AF8E.UT4BNY.90.K5$:XEQ>G"%>/KA3P M@O/2.B[A/HT.H(7]LF&%B]\:.(NX: /)=KA1(=QS$4Y5PU+8>[@35 @'?X"S M>/T]&/L71UA&/UB)'D9./HI4<[DGYP)Q9YH=
('X=]_6I"_2"" M_%_C>Z5+!O"60D:*K;J#7B*8$]QIW@'*=0KD"0,7')Z@LD178A6,9ZI$?F$ MMQ2K\']@<$B5S\N83_F=^5T^WT%]"X((T4F1MJDE5IOC;@.I#0[(%F?;B"0D3 M=TKC?
<4R3=NZK6SVK!92E \P^>CL/$^#L1O0:#101&XTC4>/0J_JAI42GSSD M(I3Z;4JGH1M$X>A9 1=\U/#)04 ^ED^1(#<=]#<5]/%5_FTIW G-J@*9K9WWH!I:1E6*7*U53C8 W-)_+&#*T>ZB)T
M:9SLV<>]G;I1$NS9DSV>@9LD\9[?Y(!?(/(W)70'8EG. GD\=0G]#5"(W"<;=QZ,"MRTSNV/>-KP5AP CNMW'Y^KI4!EY@TY5@US; M?JQ(*E]NNZ;5:_N6O^PZW8-[][_PFUTP)_6T :![3G0NB=8!;H?
X06OP!92P,$% @ TX, 6?UU<*:!! M$Q$!D !X,"]W;W)K&ULU5A1;]LV$/XKA)H5 M":;#%DBA95FH;2)H&Z]JT09.MS[1\MH5(I$?2/= MQSOROB/IX5K(>[4 T.2Q*KD;>0NMEV>]GLH74#%U*I;
<60F9,4T=N6\%I92 MV+0VJ1>% 3I7L4*[HV'M>Q&CH=BINV4QK#[4D_]F/6"9,P5M1 M?BVF>C'R!AZ9PHRM2OU%K'^!33RU@[DH52^U+HTBAN]N/2VK2Y06U<88/@#*WK3L M<=.._1+67ETRS\5"*-9%&&'],1QUJ;8W-%.@QLJV6.%J@ MG1Y?PD03QJ?D/=<@06ER?,"ZX4B[_@4 MIL_M>^A7ZURT=>XB.@CXZXJ?$AKX) JB^ >;8.E·1[]\&Z8FP@8C>$XSR?V;V6 .23
MZ,QV1)+ #X+ %H3A:4!^(N>K.,*; &Q<3\CMUP_D#F1%/@K&K1FBYU#;.DR> MB6Q\;Q M+7_9-LGFGN.(]%/T.>T* G^0],D:\B0M>9*#Y&FW =TC'EG*Y+8DK"QK)I%$ M*1F?
YXG6KEH=1CIO^+ &]VKO%B8CN^78IMU^(EF<;Y?V'G!7FOUVR9O4:/3 MIYF=Q$D4.32ST"6E66A)4X=FY(.#@0]8B30:VHLO3B&:GK$\#K\^'"US+TF2](5"=L4CFLLA_M5MNNFC.;W+GP+?
*!'=P!U9=>'RXJ<>.(/;9$29 ;2^G3P+&8J;WMU$]22C[C ML29WB'MCV8U0VY%]@<JB^S?%AMSK:@J...Y'J;&$YT:%_IQ)O^PYM%N#[.U MPP$\)WPDX3/KJ'.XH;4?1^ZM^C^TM\7C#U:7(C\=V
D6^MWI=RDV".RUWX<0 MTKX#(0O3?UB;HBRP2XZCMA[CT\Q6["<..CGXF24_3FT*4WLE#^E^6W7*'*4O MC.P9<4=#>^UBS F'E-H%"IE-7Q:HP=YX=B-AN.,_=>#&>"[]C;)$_7@0=_I8
M:.+NA37VTZ@[/O"39X4*'UCUD>A?RJ MME*]O)15(75A<5[B2HIBR9?-TB%\>5Y5DGP6.QR+41..M6S0[XA//>B=I
MY0PH.5%BI0I1@<1L96V\Q38T^JW"GP4>U>@:3"1{(:Z.Q>=T9:F&$'),M$%@ M]'K&#\BY 2(:? >8UN#2&(Z_3^@_M:%3+'NF\(/@?Q6ISE=6;$&*&6NX?A3'
M7["/9VKP$L%5^X1CISMU+4@:I479&Q.#LJBZ-WOI\S RB+]EX/<&?LNI<]2R M_,@T6R^E.((TVH1FM106VLB5U2F*$'];TFY!=GJ]21+15%K!CKVR/4=@50HD ME VF\.F%;]]0P>T7LZ?
NEHXFG\;22K\;8?O?P- !@^BTKF"3U6*Z; M'>(CA M$/9/A+?^5 5 *Z[V'P/ M+"2"VE-I*A$3G2-D@E.?%]5A > _?Q;X;W/ PFRJ.,<5/@H^88+E'"8%GP^T_M%]6Y?$VB^BTNAN]N/1?F$?
QO1Q2#U[%GOPQ#B3!2!H;]]J5%L$B9R9C_^QP]S09\#0GKOG MJ&-[&GCP2&>/R21O+5-\IENXICM5C]7"N0W#(2PI7AG7Y^B);0WG8U"_M<++WI8$59K,V%VW+=$]>"$'.;3>*
MX'&55W%MMSWQL)HL">SOQ!\)O0"-X"/E<) M;U(R974MQ4M!4P+Y*]QXDY N:\[-W.E:M$\,=4N*DNENI'5UU (>Z*)GU<' M>]&]@HU2-
(]W#16.)@YL#A*QK=JOT#DT6UG\3,6'6X78<0GN@"GC:F@6TP;3 MMZX:9S0L2I2'=B2:3]8$=7 CD Y3=], F[-Z-[(?F#P4E0*,&9FZDVAJ@>S& M8+?0HFY'SUYH&F3M9TY_#BB_NUG@LCW"^-
@^!=9_P-02P,$% @ TX,- M63N*1?VG @ '08 !D !X;"]W;W)K&ULK55A M;YLP$/TK)R95FX0* 0*T39":=M,VK6O5M.MG!R[!*MG, DGW[W>&A*53&FG2 MI C?V7?OWOE\E\E&J==
(AIXJ2NAITYI3'/N>3HOL6;Z5#8HZ&0I5W<<]7 ML;$;7C9IV KG:!Z,.T6.:Z 4O$:AN12@<#EU+D?GL\C:=P8 ,&[TG@PVDX64 MSU;Y4DP=WQ+ ""G C$1@M:[S"JK) 1./G%M.90EK'?7F' JG+G7)9.
(U7LGKB MA2FG3NI @4O65N>;C[C-I^QOG WFHCZZTS;9PX?VLKV' M/8?4?\,AV#H$'>\^4.?RFAF6393<@+1+6A&;%+M7.F\AQ88LR-XL ,2F9[#O5
M_9O4&AI4<"7KFFYJ7C*%\/Z!+2K4'R:>H3C6VLNWF+,>.W@#.X8;*4RIX:.H ML'CM[Q& @62P(SD+C@)^;<4IA+X+@+1$1 #"(>FPPPO >E#N?90T6$HVS/G
MNF$Y3AUJ"HUJC4Y\\FX4^Q='B$8#T>@8>C;G'BS:"D$NX9I7K<$"GKJ'1L+E M&A7U3<]I8$?7L# 6N?\Y=4C "HA=B7\V]*6U'Y" M>&)*,6$T& E-
J_*2FFVHCI'Y,XS=)#YSDS2!49"XP5D.MXWM[2.NH]1-R2Z, MW8A"/(HU;GMW]0HGEMQ.:?&9Z$;IQ%)81*YHU%\Q/I1<.(9)"'0fT$;5D'B M1FG@OI%/ ..P<<_\=)?CH8?@[.5LC6K5#28-
N6R%Z;MWV!UFWV7?\G_.^\%Y MP]2*TOU4N"17_S09.Z#Z8=0K1C;= %A(0^.D$TN:WZBL 9TOI30[O088_A&R MWU!+ P04 "_#3@PU9 >7@.\0% "R% &0
'AL+W=O;:O?'NN3OQ=_7%G5PPIM!#D92R;+10:GDR M'LMDP0HJ;;YD)>S,N"BH@jF8C^52.)H;HB(?8\<)OP7-RM'DU*O=B\DIKU2>.$E=O-
(%D5!16/%RSG[.1.]HL?,GF"Z47QI/3)9VS&Z:^+]\%S,8-ES0K6"DS_M7B+!9F>C<_?D(M+GS8&_[.2G3'2EDPYO1.3#^G9R-$*L9PE2G.@\'?/+EF> M:T;@QOR2Y[^R5"W.1F2$4C:C5:Z^\-6?;&U/
MH/DE/)?F%ZWJLZ$W0DDE%2_6O*!!D97U/WU8WT.'@#A["/": !N\1.T%&R_=4 MTW"UXGC(A?T-7WZM./;*C M6SK-F3P^'2L0H0^.DS6[BYH=WL,N1)]XJ182794I2[?IQZ!:HQ_>Z'>!#S+\
M6)4\VAP+80?$!_AYC,V>x>>]P XA.VLN_C 7C903N:0).QL!%^03!VPT>?/* M#9UW!W3T&QW10PG-\M,H9XC DI'U[7&7HDM> !8E->%\!;#';$CWP]OO MO%PS > YHS,HY4MK3:TAZ"S")%&O+
(W1JA"9=H:P6BF:'%_4IQ)=ZQT*6L.;\ MD:V!7;(2R0(8H*7@46PX[W[9?^W"P&&=B,=09PR$Z>:,S?9PYX31Z]15H)I MO))@L#PVH.U_O(:X78'4H\!P^?. OMHX4'NAY.7;QJ K[VP.OD;8PGZ\/8_<
MSMRW?:!OS2.'0,2RI-(Y>)):)FQ MGWCYY_>LK%@S=6/",*HLT.(VYD%'N1H M[*L4P+]9/0K=^+B]]#=""'S<;F#BH(^\$B5[!'GB6F'D]U9)Q[.. 99#G 'Z
MP(W19P"\,.T@K>B6M^NV^@4.NN6*YD]GK&XPQC'9FN-.;+U&L46"L#.G5NR3 M UD]:+)Z\+*LCCZ;U(G.=6.2*8SM81^F,FOSH0O_?]FNB1P$KUG_I]^_YZ" MC=LW.\%T_YEU0OK%"JSV;220Q
4TCQ7(R[-9N,*754PA6L&=!A">9.39?28IYH^_R+P>$!*(<_ME, G0_E+V]+4J#YQ>YG>WMX&_V:CC FNY M]M^4YK1,V' PMXG?AQ"),L$&[B.V$W1OK^XIYSL1[?M02W"_ZGBVX_:IUTHU MIU?
6\? MGUUI_-@*B3]@3VR'[!]3]H#)(B%4\RW8 !,= X40.[{]55X6IMQG9R %P/(.*_^](V?';G_1O81EP,GTV!%>.M3RG;ZP(O]*%A
M)V"Z'V[4K$OA_V8WA.9QYQVI8&)N7LLDA$%5JOI)]5EM'N3.ZW>H)GC|FO>) MBCD$$\K9*$@=.X(^5M0O9/5$\,5YE9IRI7AAA@M&4R;T =B?<:XV$RV@>::< M_M02P.$% @ TX,-64/FSI4:!
LPP !D !X;"]W;W)K&ULQ5=MD]HV$/XK&B?2-P R=[]!T:/2,MURV4F (KL\JR0.RM5:G-M WS):(.?RBF^@P)T5%SE5.!5K6VX$T.0HY9GM.4YDYY05UGQJUN[%?.I+E;$" M[@6199Y3\?0+&=_.+-
N!>WD98W E\8;&5C3'0D2\Z_Z+G$>X@RS00NO'G M'M.J36K%YOB_M;CKLJ80[GGUEB4IGUM@B":OHF:G/?/L+[.,>5[.,VE^ MR:.2#2<6B4NI>+Y71@]R5E1?
NMQGH:$P=BXH>'L%S_A=&3)>OJ&*SJ>"\%9$ZN3>#6X6"& M?N+6+ELE@%!#T90BPLF/$HUI6EL)BVKT"B791&3,T+1E*2Z<94;'>1Z.^AV-MOZ;;_=^FVQWCL5'(Z+"._P4(.)_HQ?N?
9%227XN$DC;^C;Z6#Q['1R]]3H!?RV+*^{[M_^(Y7M"!Y}>|^P;/_R>!GXNW@@O.P^G;N98;&L/,PN*0(!![^EK]ZX4;,38>S M0>ULT(4^7V M)F4&A*|(!DA" CLL2PGG'.V&>O5B[#G^#?F_O@^1
&B1@^ #1 M@CG.!=M=V.F])*P@*N6EQ.,2_1I.LZ$Y\9^QVD#@NK#WNKY(J4"O3ZBRGJK%[J3_DDRVJL]=^_$WADI7/>#X_H7 M*IBNRW/NNZ/@1.^='%WT)\|)?N
$]ZFMVR<"C)!*K\|LHH.L,Y\SH/^6I8(@&HE(!< MAEV<4KPB$X(Y)0P>N#^8(AGRDF5,L995/7*]FXZ5P_>K>40#/ONZ ML3<.#*R2MN].0VT!P14 .+(77#F-
\6EAG)A+F(OY62B"N'#9SD$ 0OR?\#?$ MW[^F>E13/7KV9?^V5*7 ZO)SD)=YO6AR3Y ,NW6.V=W0?Y>O>_.5V8LD?:_ M]2?R$>VU*?X&8LB7((CO#MILUG?$V)V0/ #,+@@?;UI_$
9>EVC4$/5&G:*C MDS"]P00KJT-E?$XE&I%/*D6AP]IXX*++U0WZG,KPO$$4C#&[4EX3TS4@\QY! M5C:(6+\! ,X\?I]\Q#Z] WM 9,J%&IHZT6U-QHOUL*Z.?=[*@\ SS'5,C22 M.8BU:9M?,?
]Y,BS0Q*+*U1UKD9]IX;XFBF]. M6[KD"IM<,TSQ?P4(+8#[*\]58:(-U/]3YM\4$[.#!:0 -.##5GCA#2 M'08 /41 9 >&PO=V]R:W.H965T#XMX1SD)($H1D_2IF=6B4!F]>51"OO. HRXQ:.M?Q7
MQ"XYZ7SLL!CF//)?N3]\^0^F/-S#2TOI?MBKV'AQT6)1;I],2C!:D0A7 _&<9 MAP;@8 _("P!H;>[4.2MQ.*.3XZ-7C%#NU$:77A7/1J-$XH.9>H./A6(LO1YZ><-7>]WF;"6%"KU"Z+ MJF9L,Q!!20?
+PH)90F?R[LW@(#C:8>FHMG2T2 IDBE48YQ*8GC.8S\$G,8O1 M>L85.G:#]E<5B*6+ &VT8 _@%>C0'8!E?T_FU.;1;Y;LW'\-@>,3^U# 9?%'9 MS.VK\9R]I6C.,Y?<6C)EZG3TX)-)@'G
M.LVX6O>G^0+10Z.%<=BF MY.Z1K1VL4)@^?C<9/3.2W:E;0DL8R(+S#P5#@5ZA0ME2P,?<<)&B%LP7\W M(N+UAK_ULHC_8>G6] VSV4W1,&9WX'N'VSUC*#PZ/++02 M.?988]GIP@
@6[H>NZ2]CSH#M8I&.O"VZ@X,+2*%7*F<2_I#I<92T]'2=E-H M51NQ$ H13_53&TJPK*U0$. 9 %(OKB.1,*?9%ZZ*E*Z=BKC$!IRP-7#3*R(2 MCMD%%@+N)V5U2/$L0A9AEZ0)PN=L.8
0L\$VIH7;_B\\,EW/D[G)D<[]=.*!]B5+;%31*SN3#6X6"& M?N+6+ELE@%!#T90BPLF/$HUI6EL)BVKT"B791&3,T+1E*2Z<94;'>1Z.^AV-MOZ;;_=^FVQWCL5'(Z+"._P4(.)_HQ?N?
L'.1H76^4IIM!9?MM*1 MI*W"H4TD]1L E70T%9,;X-1DW#2:2NE#\,XCPTLIX4'Y-05;+CH]_G^_352 M3 I[P+M-\&>;/ISO$+=*:XS8W .9YM66=3HIF7'+6VOLFF?A# 'BXP\%6. MSB!"\L<>G?
+_<&9PZP\12<:F @674D>/&X,-M9!*X$;+M!H[EA4+54P19=T4 M//-D $&>6@[=6VP0K0:7QG51+9KJ&:M(HR M_0<'XN=*MO%ZMQVF<%]_RF^W%!Q%,89RQ+),P1VC0.T1F,
<5'4N+&Z&PO=V]R-W H965T*+1*E-##3MAG5 MZ#,#L.^.Q=A*)=$3Z2;]SM*BD+9LAT'1;MN M^1)*=\?'=T<^=U1X>]_KCV:IE$6W15Z;L'2VM7+R<3,EZJ0YH5>J1(TU!HJ
MI(77:C$QTK)M)Y4Y!,:!-&DD%DYFI[6LHMJ>JK7-L]*=5$ALRX*67T^5[F^ M.1N1T9W@0[986B>83$]7T8NDBNM/[J7=^G9*' J5S-K4.0,'Q2;U2>.R!PX\>\6<]3I)OH M/]^A_US'#K%
<2;/>Z/RO++7+LU$\0JFZENOEKI&U0Y:T!S M#W6H]6QP+BO=HLQL!=H,YMGI3"T@Q1;]*YL%=ID:7]K7)F3TXF%7W!VDWF+ M=MZ@T1UH$7JO2[LTZ*$.1=F
\&$0QY.79B7Q5F$1#"]^>I]&T^<_D"AXM<=%WKG(]Z%/9\"[M=)TKI*_1]W=#_C\AY@&![7Z5N/%4H+O<[6VV5SFCX:19?]@VI?*9O&Q>D MYUQVGJKYLNQ+#SI?
Z70]MV93L'/"Y,)2]D<#!)M8=9L8S21P"SS\! 5Q5:_N M&UT:G6>IM&#\&Q3B"I3E6G68SQ#A.Y#3\#)AC:) ,=8MVL66]<&_8A6K:N; M<:.(AYR<|%PG]-66_@/L,5G-EW7J4\ ASC A[!YF3 @68>P+!*
(X$,V@Z&;E M-J.%*E4%>\ !RA3*669L)5U=WLKCF 28T?AD4,&3<$!! QQ3<.BU,9#$K%C) MK.KYNRO@>P0<\60(N9' ,I>]0NH6,](0\)@S[@4?!?3(>1RPZ*0C=JZ-\19R MS#"'+R) #
(>:1EVLPI3%$[=M_RWC_XOVL^SVBY.>"AS'.TD/VH0>07H">RL4 MW@8-3K;5ARD?8Y'X*+ _H\0G/1,/1']>H#G0Q:'@=TB)H,9@CQU4D_%G'D M9P&+H)<$R '237-(=QSTZ1QR'/"'^*
(+UY]&W9@78O)WQN@#C9P]LI$+3 3U M:4QX7\WB(T@ML(C$GD[>Z@_3&EJW\+L71,FB(2(RB@FGQ\':02(?^)P IH_M\IQCSI(`T!DH1GR^*1Y:W^@APOBE\48\WB
@..$DV1/%X\A=QOL#G#*XKXH MP2P8Z/5/+/^:+_,MQ_)<0HKV^_,+.BK8Q(>T;@YIB3:0_(@\,L=VW',]YU MA_%Y*0@TO?A(=KO#*1N@HB,SXV) P1,LXN#;L9Q@&GM?$&..2>P=_<80D-C7
MOJ$N)$F/S4F(S%]49P7KPO]#* ?LJ8?2A@_>EMI"$>\9]*ZTDLIPSEI"LI9@ M5*I[;&<(+P-8T>PN?,ZD\J+T)9?'+ZJ&=D2O^YK-MH2$SC>1U2TWIIV(VY M/T-1Z';N)B
<_\,""D5:,G\6E\&I^*:^AL<7UK9JEX@I:*R,[3TC'%5CX ML*>Q\ 3NJ5]@6Y-#!3:$ AO1+7$2X$B(+3'A E.6'"]P(H(3DE]@-^"@P.(A M*]1=R1VZ 9AX]S.%JA;U+91!<[TN;7-5TTF[BZ[7S?
W.O7ES2_9>5HNL-"A7 MUS U>"'"$;J:FZ?FQ>I5?=MSI:W51?VX5#)5E3, _6&C=*^N! HKO^F_P!0 M2P,$% @ TX, 60#S+_X^ P :0D !D
!X;"]W;W)K&ULQ59M,ZV&/XK%G>ZVB14P+RF32*UW:9MTM6ZIMND??(@!*P+ M=]YMFO3^^AU#PJ6"9INT:5_ Y,$YYS"RX-4W4%8,BQJ85>.94Q^VO/TWD% M#=-7<@\"=W92-RP!
[5>RM;47_"#(KIM M&J9>[]"6AY43.&?@D9>5L8"W7NY9"1LPO^X?%$K>X*7@#0C-I2 *=BOG-KB^ MBZQ^I _;AX,>K8FM9"OE1RO\6*P3&>F#X>H9[J&OK"/X=/+!#"&M MX7A]|OY]5SO6LF4:
[F7],R],M7(RAQ2P8VQMN'N7A!SC5$UM_N;QU]R2'7C=> M."1OM9'-R1@S:+CHW^QXZL(((/?,* G]KEW0?]LOR6&;9>*GD@RFJC-[OH M2NVL,3DN[$?9&
(6[`.W_^A&>.0:2(4@N41Q4A,F"K+AI> !GC-AR'V7 M"BA-OGYBVQKT-TO/8'SKO[<&9 G^0(X3;X3!12O[3W->TB>GI_ MHQ<=_M2**Q+Z+]$^C2[X"X=FA)V_\-]]QEP/^A#!?
A[QJ[UGN6P_OWV74#V_(__5^]A0 :7H.@>40009 QX"SSH8?7[%LJF&Y8A,A:'7Z\/]Y M!:]L%1P_LT^'BB1N%B8C.7/]=#&2@\# XG_4#=(0W*,YZUA8IIR[*;!8@:-_MTRF*SN,PF*^2VE*;IO/
)^FNR[UXQDT3*,9=)'X$Y2Z<9*1/WA]Y).],)E) M/J43+(FF6)8EY&=3@2(>]9'V^0O9*UFTN3F3?F*2TF2NE#B=0;/%_&3H4DP. M1T+-ME+U)^VM6/8=T"DI@BS\V[IA$KTB:O;#
<8+R:&63ZGBGS,FA&P1+C8 Y- MSLWZI_EBT+_4I?&"/^6_&P'3L8.+(VSGF/=!ZH,9&*"INZ"O@(6;!?'<3|(;.MC3_*Y?=D-<=N/SR_J_27D U,E%QKILT-3_RJ-':+ZP=X+ M1NZ[8,J5!D=
MZSP+@3**N#^3DIS%FR X7:U_A-02P,$% @ TX,-6<> MM5T. P YP@ !D !X;"]W;W)K&ULK59M3]LP M$/XK5H8FD%"3IF^,M9%HNVF,!*M -)_=Y I8.';PG1;F_?B=G304ED9B[$OK
MMWONGN?.OHRW4MWI%,"0AXP+/?%28_)SW]=Q"AG5'9F#P)V55!DU.%5K7^<*^M:.*,,NZ'03#T.\]$%XW=VD)%8UD8S@0L%.%%EE'U. 4NMQ.OZ^T6KMDZ-7:! MC\8Y7<,.F-
M\H7#FUR@)RT!H)@51L)IX%]WSV=**P=^,-CJO3&Q3)92WMG)MUV3B!38@X! ;BT#Q;P,SX-P"81CW%:97N[2&^,,=^F']:MU^3B!2Q-R0.=M=^:1!%:TX.9:;K] Q6=@\6+)M?
LEV^]LX)&XT$9FE3%&D#%1_M.'2H<]@S \ M8!!6!N$+@W]W@$&O,N@YHF5DCM:<&AJ-E=P294\CFATX,99PULF'"9O'&*-QE M:&>B[VI-!?M%2TU%0N:@8\5R-
YD]/.!]2"ZE,*DFGT0"R7-[']YG4=,(=G6G8"CB' MN$-ZP2D)@S DMS=S :\(]K@:);B1M8,WBG85.6:[QL3 I M7L$$'PJL2H[/..Z@,D^EVB1.:W"O%6?PESB]9G&&M3C#5G%N*
9EM)@GW/#U)6P/8#[M*RG-;F(=CU:\VT1]02P,$% @ TX,-67]189YM! 3!P :D !X;"]W M;W)K&ULM9EK9VGE"HS$U14/'W+>1\.[5Z'/D);2L@)*R7A)!"RGUHU[;MC$U
]\87!5NX=$U.5!>=?S(9$3MI MBG);%\5[HIR@C\HS/SY\U%>=]ZE'[U./A\-#2'2XVO?>R>6H;6>CBC=Z@]?7H/[X63]$ M/BDHY)]HS:4F^OU$T^5>RS5-8&KI/E6">)K]NTW,N#\'T.
<5)BSA68L!@) MUO'8;SWVA^BS!Y!*L$1!2A(JLSY+:T!0 1"\SDC@'WH0O&HD(]<_:);A M,:3H&%(\6*O_F+.+-F<7@SD+8:$(7^1L117WCU M&LWUC$;PO'X-
O\Z ;4@]Q,K8F:Q")'BW2%9@!C\J R,U"LI29I1?%2:*'1;HQ MI%2!N;>NX0Y.]767 M_*X?KX/33F'[(&G/!8XY*"QO:< ^-NF"#1:M-MONYVW,]=*C>F-
KAZ_WV>ZH6)G!>0Y++>6<7^B*B7KKJCY1 M?%UMM2RX4KRH#C,0*0CS@+Z_Y%RlG!B!=@-Q!02P,$% @ TX,-667L MB+?0 @ A_D !D !X;"]W;W)K&ULK59M3]LP
M$/XK5H8FD#;R7@IK(T';9LTJ;*P?3,)I;%P[&((+?OWLYT0^A*Z;NN7Y.S< M\IS=>#\T2R^ M9D/',PD!A509!JOO2Q@!I89(L'4<#IM2 -T6KQM=S4%)QTJRB8)Q'
M6!8(LZPV)D\566(*3,DS=#H&A0G5UD=T/QNCTY,S=((0W<%KZ3&R(&K=.HF M 3=MTKRITPS>2/-,0/=B$ MN[I=;<^"MF>!YOO_NV==0M?<43>W^2QP=R05.8>CH[XX$L00G>?
_.[WF?NF0_M)MGXF&23(Y%M-"AL&Q3N8T_:ER,U!KR^:%W]]*EZELI\U9?)12_P_(&[7!=Z MUZOO7087FU[C#]Z^G;EUK\G>Y/]1FJB5)MHKS2U04BJH!:G2Y':(%XK(O!Z
MX98>>Z\[>#M1O1]O]_?DNU((3=DBUO9XKVRW7&%;3U.77-E-\6?I8T[YB/H M15O:[GKUP[_7;\U:A]=EX'M;HNUZ^7!PX]>0M1SNV@EF_D^^8$$G3*(*N09Z MYQ>:.1]1G?KU0?
&$/M0>N!*IS4+_)H$P#0IYSKEZ69ASLOWQ2GX#4$\F!!0 M (-.#0$G*!WJ0@ '0% 9 >&PO=VIR:W-H965T
M[4F&^1DM2"Y_LZ4LPT)^9+LI+QC!L0[*TJD[FZVF&4[RR=6%/G?/KBYH*=(D M),_<,\3++,'N[(2E[O9PXD\.)AV2W%^K$].JBP#OR2,13<<_DIVE#B9.,Y#RA
M.6)D>SFY=KZ&7DSSYB36YK^G<1B?SG93%!,MKA,Q0-|_0^I M;VBI>!%-N?X?O=;7SB8H*KF@61TL2Y E>?43_ZH?1"? 71P)<.L |UV ,S\2 M,*\#YN\SN$<"%G7 XGW ^9&

91VP/#7#J@Y8G1JPK@/6NK*JIZNKQL,"7UTP M^HJ8NKE2U(&N7QTM:R3)E10?!9._362? MOF/&L!+*9_3)(P(G*?^,?D=)CO[6+ILH7UBI_Q"E!=(MDNQ;]^(+R
M,GLF3)_0$D<)YZK:_SDN^1MK@K'5#0GS(&%^!5MV'O[B?*;^F9440"8-@6"& M-):--)8G2>.QDL8ME<.=F*@>2(Y8'DA9\4(WG\\,YQWHD,Z0/:Y;Q^H"$ M>9 P?]G[XW26_*
S!D"P0QYK!YK*SR^-XT%3%^XTA0%"><\H%QK!JM1#$=% MW;'$0[JPXL?]PEY69S/3I1P2 60Q?$A8 D+@6"&5-:-5-;6QW_]0O*2R$[D M6_Z"0S+82E@)8!4 "?,@83XD+("$A4
P0R";1B ;^\ 3OU5S-ET9$E*Y&@D M'QYL6#EC90()\R4/B0LV/1ZIM7[;BD$2FC4_GE3^^?VVBs!17,<3IBF)W-ULMW<@##*:3Y);,+&)-/58EH#0/E.:# MTH*:UFTU%KW4;
B5TQ1*QRMSK$*Y*[G ^4Z.+)YN6")%H/MA!TR6@*0- ^4 MYH/2 E!:"$4SI>*V4G$;E,ZTU<]9=T2QH:G)C7+$/_ZO?AO[1E'*Z&?<]7[M@_:!E!:"T$(IF2]JU4AVI/ZDE]==!4H\'2?VM
M)'7=T5-0Z>E)ZLGOZ.FAJR>OHR??HJ=53T_SOIP@+4@/E.:#T@)06@A%,^74 MVJW.!WK;L?(3G9&0$H@\]%&BN[6F\(L^AH!=6U!.3XH+3CI>810.CIM7GY]4 MPZ!>+"C-
!Z4%H+00BF9N^VI=6]?NVH9R,J6V_|ZWX#N,]>-;5Y- MHO04U\T9@-)**))JJ@M:2>=V6;&"Z!>*RC-!Z4% MH+00BWP3HJP!75:7;O7^E@^<_*S5#+ &2V/- :+?F/0-R7LF48K
-0V!:4%H+00 MBF8JH+5-W0^VD[8*Z#<(@VJP\QP79?J;"X/C % ?%)3F@i("4%H(13,UTO[@ MKMT_98+(KD",>TJR>E$*=0*?ZP6:=($/R=E$M&Q5*!U7Z$[L:67N\!:FB"
MTGO06@!*"Z%HIBY:0],U&YK?B:AWG+<;@4K+CH\;9PSIMC;^VY1VL"U) $I06@M!"*9GZ9L34D MYW9#4O4:U]6ZE_Z*-W)GZ"Y)4V5-_8-.VSMH3S'6G@*E>: T'Y06@-)"*)HI MI-
;3G-L]S8&I"_DEB/K"] =SF__*\L4QAXZ6BN@^TQ!:0$H+82BF5II/<^Y MW?.LOK_?60TW]Y1]D3V23+NG:8QR=6'5/AVN(=4">TQ2_*:63WE/>8,J@W0- M;T%I'BC-!Z4%\
[!Y!/;_LA*?;]:T4->V\&R(G;*=?^Z$44,.B>DU$<[9YMB_)<E1>;+PS3GWGG.QKQ<5%\%R U#H M):=,+,JU,J>+*MF6208[E)2^ Z2l;+G*L!%3L;%D(P&E-RJGM.4YDYY@P*U[4 M;
];6T7.MMX8fL,F46[\A1X!UL0#T4MT+/[*Y* M2G)@G"&!&R7UA?W:C4U^!KPDT E>V-DG#QQ_FPF-^G2H;M'Y" M$R_A5-9/5#78:&ZAD)2*YRU9*\@):HXI.U#C^ &
[Q"\EN#]*\%O"7YMM%%6 MVUICA>.%X!42!JVCF4%=FYJMW1!F_N)&"?V5:)Z*;]@>F.+B%9UO] Y)2PJ(M;U&W?('.UZ PH?("3=###9HW.SR[0&2(,W6>\E)BE272+?
^80\QPM&Z*O3]#4DFN[6=/^0;FO_71&\K@A>'<_6Q'&G#348)QJ M#MF5+' "2TN?(@EB#U:\\8,,.9 -?/VG8 0L9=@ "\ 3D+8F0-A+
MZ\VC(VE#S&P6C"L+.V7A265?"2/Z<*5HQ_GX1@\'22///2[;$!3,9]-Q:5$G M+3HI[<_);?*F+IHD'@2..&1NA&0WP,=}MVZJ8GU=USA:GN$HU& J.UFP[V MTCSJE:51-
P2YCN=$1_+L7@LTU\\/+':$241AJWG.Y53;$TU+,R:*%W57?.)* M]|AZF.E;$(0!Z.];SM7;0#3.[EZ-?P-02P,$% @ TX,-6=J1_S1B! M/A@ !D !X,"]W;W)K&ULM5EK;^(X%/TK5G:T
M;J6VB1,2M(4[JZC:HRH>ET5ZO5?G 3 !8D<<9VH/WW:X>0!Q@7]O"EY"IO M;R;G7/LZ).U!3]H,O,1;@-8E3/K:60F2WMLW#)4X0OZ$93N6=.64)$O*4+6R> M,8RB(BF);==Q
CM!)+4FH^+:C$U&-!V%;V2Q M%.]"/1EE:(&?L'C.9DR>V15*1!*<HK'E*$8XQ]%0$$$C^K/ 4QJ%"DCQ^EJ!6]4R5V#S>HG\IBI?%O"",
MIS3^FT1B.;8&%HCP'.6Q^$;77W%94$$PI#$O_H)U&>M8(,RYH$F9+!DD)-W\ MHM>R$8T$V#N0X)8)[K$)7IG@%85NF!5EW2.!)B-&UX"I:(FF#HK>%-FR&I*J M87P23-
XE,DI,9DS.'"";> $%C\0/G&1RC 2X>)+S)J =EK3N-K3< [3^ MR-;,X#E?T6U*(*+,5MB;__@(#Y$=<X1V!M=K@56WP3.B3 M[U2@&&3-*8.W7= 5OD$+"C2UGJPFT/>"P-
2O21@#W[552+;J^BVC-2?4@R M1%@Q/-<@QE+H2QI'@"22_0JKZ]I9N0'U&URN7=CO[S V/OJ#8^!7A?G&PAXQ MYI?@?8KGGTCSRE-LEQ@9H.1HQ3==P16*O<
M057NX(S+V:#+-G0$UFK#L&K#L-/E;+BW4/G#71D-]V9G,Z9%$SKU.]HQ$GWF M>)[Y}R$,.X3)'K-R> "M9L5^PL[5@B;%X1*C"@ +,5(._/*17;$[6%7/W+8/(_4$L#!!0 (-.##5E$
MSI=930, &T- 9 >&PO=V]R:W-H965T &C(O]%Z*V;QDHR(1D<>FL=A"3I/C'+Z4. M6PX*I]|+AWL?0?G#8=NZ=]EL$!9QC&7JE0QZZ6<2>"^=AB2Y^KFWTHLDNDX>)%=/B?
*3DQE7)KQ[MRZ<_V/W MW\V^(T;W*HINCN>\@>>!ZCD!P?FK#"^}>)PFHRW&!XN8HNB&M)HYECX$V4NEV/Q0I#F!L*&T%\!48DX\?.]IUI.Y<"K!>(Z/?$N..=+U*NEZC
M=+=QB@G/>P5E0B!,*0NPA!!)ABBHUATQI2]4\Y6H.UJNTOCR8FB3=L$\WIU M&=@K7+\EQIT,N%4&W/=G@.OOXR5;7&8"$-9E7J=^(\&IZK<)YKD'ZA]T%K\E
MPAWQ^Y7A;4;Q?QO=X8TXIVK<)IC7)IC?$MA.,@95,@:-R7C$R9+,;5GH.B;_M%R.(,%|";5X:(4_-2YM@WN#P:^,>%'|+C(7>YM,Y,0:EF#ZX"Q2P+))"%]:%: MK>X&U_F1>&_]IC.
<=FK6/767*(]^_^"+B\B=2A!)A/ID+!25==57[SPO#O?% M1+(T/]W.F51GX7P8]?L0<&V@GB\8DYN)}AN6). 4$L#!!0 (-.##5DJ M[1GEF00 'X= 9 >&PO=V]R:W-
H965TDIB*H;.2;^^X>K.+53F) $J"*.(PV+HC/VK,$@-TC>^ M$MB)@VNDFS)C[%"??)X/'4_7"&*(]; ZF\+4XACK:3J\'7'A]5[}
M4]HXU9@9%C!E\0.9RI70Z3MH#@N\B>4MV_T*>8,Z6B!BL4A_T2Y_UW-0M!&2 M;FQJD%":/.;GW(0!P9*I]X@R V"EQJT Q8:#"JH4Z&S* MDD3%Y4ZRZ!$]8,XQE>@+P3,2$TE
O$=G(4A,8G5UCN[O0G3V[CUZAPA%?ZS8 M1F Z%P-7]BIJ1VZ45V>252?X1G5:Z)I1N1+H(YW#O,9^:K;O&NQ=A:,@$^SY M3 *CX&\;>H%:W@<4>$&KKCXO-V_7F(??
];W2FE81[5:]UWHVVA_06 A0@59Q M.@SKOA?,D0K^+40;S@E=IF_]SB@O"B98$('^_*(!;<$8__^1WO5_J2-L4"RV)5:+0+]+0-JF/:H=6?! #+-$,
MEH1239HMT!HX876C86)TU!1P)M9-Q?!ZL1WU^]VNSWD9LEAA5NGX-8Q,*$YU\ 3ZM[:\ MCIO145-N-L5'2V(5P"]%[5=B;%X1*C"@ +,5(._/*17;$[6%7/W+8/(_4$L#!!0 (-.##5E$
MSI=930, &T- 9 >&PO=V]R:W-H965T &C(O]%Z*V;QDHR(1D<>FL=A"3I/C'+Z4. M6PX*I]|+AWL?0?G#8=NZ=]EL$!9QC&7JE0QZZ6<2>"^=AB2Y^KFWTHLDNDX>)%=/B?
*3DQE7)KQ[MRZ<_V/W MW\V^(T;W*HINCN>\@>>!ZCD!P?FK#"^}>)PFHRW&!XN8HNB&M)HYECX$V4NEV/Q0I#F!L*&T%\!48DX\?.]IUI.Y<"K!>(Z/?$N..=+U*NEZC
M=+=QB@G/>P5E0B!,*0NPA!!)ABBHUATQI2]4\Y6H.UJNTOCR8FB3=L$\WIU M&=@K7+\EQIT,N%4&W/=G@.OOXR5;7&8"$-9E7J=^(\&IZK<)YKD'ZA]T%K\E
MPAWQ^Y7A;4;Q?QO=X8TXIVK<)IC7)IC?$MA.,@95,@:-R7C$R9+,;5GH.B;_M%R.(,%|";5X:(4_-2YM@WN#P:^,>%'|+C(7>YM,Y,0:EF#ZX"Q2P+))"%]:%: MK>X&U_F1>&_]IC.
<=FK6/767*(]^_^"+B\B=2A!)A/ID+!25==57[SPO#O?% M1+(T/]W.F51GX7P8]?L0<&V@GB\8DYN)}AN6). 4$L#!!0 (-.##5DJ M[1GEF00 'X= 9 >&PO=V]R:W-
H965TDIB*H;.2;^^X>K.+53F) $J"*.(PV+HC/VK,$@-TC>^ M$MB)@VNDFS)C[%"??)X/'4_7"&*(]; ZF\+4XACK:3J\'7'A]5[}
M4]HXU9@9%C!E\0.9RI70Z3MH#@N\B>4MV_T*>8,Z6B!BL4A_T2Y_UW-0M!&2 M;FQJD%":/.;GW(0!P9*I]X@R V"EQJT Q8:#"JH4Z&S* MDD3%Y4ZRZ!$]8,XQE>@+P3,2$TE
O$=G(4A,8G5UCN[O0G3V[CUZAPA%?ZS8 M1F Z%P-7]BIJ1VZ45V>252?X1G5:Z)I1N1+H(YW#O,9^:K;O&NQ=A:,@$^SY M3 *CX&\;>H%:W@<4>$&KKCXO-V_7F(??

MUW.:H$T,5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(LIK1]Y7;]BHNY7 M#*VDJP\VT[EHEZSLKJV+B[2>V=[5QYSO5_DZ&{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}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{0]>ETV/ MM)3Q(,+"9#@@608"$0V""_V.H5D 58S+1@@\6>>M)FNM1;23N"K[$BL]ED M%1QE%9H'>2J)!S(2@l0T+<;!G4H>_MZQF*;=#-&0/)OC;-D&@^*%H BA9"H0W3W.ME;!;,(W=H()':)EG5Q9J-_M'#)DH GI.LI^_Q12'/=;')O%^-'[O49 .,)NI9'KU),I5HWDJBO0 2DM##/-M3B6N%^+8K,3K)R)?FD*,7(DU,HG(-JL2AT(9)Z34[-M-HOV,048]{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}GY7JNC\(M)H]F4B>FG]4.4UJ7@:$Z>R2{'1,HEDCM9#4OT^Y,L+PX?43O4%:B;QM:<_Z]+&^0YGY#KN+Y!/KM M[@8GY4F_/(%4NF,M]T[EMDQADT>WR:.KX_EOY,':Y]&4CWV4=0]^.VZD6C M(!K;VV/L7A^U#-SRBJ0PL>1!SH%MP9J^_P6'SF^F)!@L_1@[C>4)J]>P>EKF MG6?5Y0&'\K@UP7H#8LR&#)8,%.PD=7Z3.K^W3.,,KH"K19/D: 5@0&_V(8*C MB^:ZH=,JDUZ?:U/2=<1AC,U5$C2H02_J\D)RX!_0@M:UEPO+ QR(F3E+*"$ M52:,]$%G+O{(\5KTO=;7TG<=X\ [0Q\V]&$O_;VT)2S=:,PE;.4#MI*/2V$B M#@W^?GM9Z+6[EKCKB"H^V;DJ$&.WEH"]:+Z#/)A;SR?6MA9*BX(&PQ]_I= MR|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{JM-K+NQ78'-1/=ES[WYS 2A,D)0=0+HG\5Q+T@]]#=SCS6 M@AJ:IT]V2+ELZ^8&_FR\VM(PX6[QP2B[RJS.Y#^E^#B7PBC)[5*);H4!!=IH M]&X!AC*NWZ?$Y!^Y=%+TIC>=:?3"l,=63%7PH M)Q9O8(P&QLC{)2?\[NPQ4E$>XS@K=!4TTPTM(,.V1#2H'>#\[9MP&GPY1G4A MLP/&>&",O7O\O_=XC#J^)/6%S ZHDX$Z.7NSCKH84&PO=V]R:W-H965TU ^]_O.DD#@9"5M/4OC"R3AWN/K<\QQ;(\WC+^(%2$2O:8)%9/>2LKLRC!$N"(@%I M8@FW?&F(C!,<%4EI8MBF.3!2'-/>=%P\N^?3,'SS$RY54#XSI.,-+,B?R,.OG<&<2*%&<$BIB1A$GBTGOVKH*K*%*"'+^ MB,E&[%PCU95GOE[4S6TTZ9FJ(t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l:E]9:T0)=:.$U5MJMKRST/"^QAV;\#JWASX_RVP ML[Z3E=:)YE=H#0L%NA":VJSW9ZPO/,P0ZUI&EK1?*UH@2ZTIJ#;?0VKUZG.TY^T9X&.3MOPH:.\=^*>'+XKQ5)4YE>693?VT/M.[+DXR]Y[? M6%69;'DC658<.CXS*5E: M7*X(C@A7 ?#[@L$0]6Y4_7)^/0?4$L#!!0 (-.##5F>O8_M3P4 %@F M-9 >&PO=V]R:W-H965T/(R M\'6Y7\MRP%K,-]$]NV'RZ^9:J#NKI<1)QO(BX3D2[.YL7,9GTWLO7^B_ M5<&K8&ZC@BUY^D\2R_79))B@F-U%VU1^X;O?61-0M<_53XOJ+]HUMO8$K;:% MY%GCK%:0)7G]&CTU&['GH#AZ!]{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l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{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l9/1=:3$/,2H@#:VH+00E$:A:/U4=HTM M,3[?9>H>*,GN638YXPU1BZVAY*B,9I-AXHR<@KVGD#7@5M[)V4R)NZK(TJ% M"FF;R_HH1#O:'H.ZKP[_#.8O\.D2:\9#?$KK0TX=OCYS=16)^R0O4,KNU%3V MR52M5]3'F.H;R3?5.9U;+B7/JLLUBV(F2@/U_AWG\N6FG*]3+,X#U!+ P04 M " #3@PU9:Z=,D;(* "P>0 &0 'AL+W=OC'8"\:F8Z&R ME)'DI%GLCU^=8IF6S$B==^!>-#[P>RB)K_E1?$7I_#&*OR4KI5+R?1V$R<5@ ME:,W;X?#9+Y2:YF\B>Y5F'VSC.*U3+.W\=TPN8^57!1!ZV!HCT:3X5KZX>#R MO/CL.KX\CS9IX(?J.B;)9KV6\=-[%42/%P-K\/S!C7^W2O,/AI?G[_).?5;I

M0+40U;)!UXT+[<&X'=QH-Q754E03J):AFD2U'-44JFE*:P9WU6 =F!NL_:XF M8,9Z9S9:7$4U%]4\5/-1+4"U$-6BO6:^F@ Z9(O]*:H)5,M03:);CFH*U32E M-1.
[ZJ,.S/?,%*_<)-.\)>>^,1MNDJ.:BFH=J/JH%]!8.CN\).KQHWQ$TZGK6 MM/VL&'UE":JEJ"90+4,UB6HYJBE4TY36#-^J_3DPMS]_+8^2Y],?C9M?GE8C
M,L.l8QDM@:*:BVH>JOFH%J!:B&H1JL6HEJ!:BFH"U3)4DZB6HYI"-4UIS9BO MJJ*#B[<^/05ME:*:@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJ@E4RU!-HEJ.:@K5 M-*4UIH-
AU2H=FN_YV6^1?(\UKC9YUKYQ0]D?SD'TC&!5<5/-0S4>U -5"5(M0 M+4:U!-525!.HEJ&:1+4=BO5W\?EM8'V_GF]VEN^2Z^%2L=YW0IS5X MT]*
[>9B^:RVHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH"U3)4DZB6HYI"-4UI MS="OFJ'#MVZ&#M%F**HYJ.:BFH=J/JH%J!:B6H1J,.HEJ):BFD"U#-4DJN6H MIE!-4UIS.JB:H>5#T]\
[6+1\KDI^E0*M1:,S4-QU9GS1KEWSI.:@VHNJGFH MYJ-:@&HAJD6H%J-:@FKI7FNV8,>CBU'S/2Z:CIJAFD2U'-44JFE*:R9X50T= MXM50L]@[N=%]**JYJ.:AFHJJ
:J%J!:A6HOJ":JE>ZU^4G^[2O0$3-4DZB6 MHYI"-4UIS=2N>J%#H8UV0U'-134/U7Q4"U M1+4(MU6)42U MW6N-)M:HW<02Z)@9JDE4RU%-H9JFM&9L5^70H;D
M;POK4U&4^3U?=^5H)U15'-0S44U#]5\5 M0+42U"-5B5$M0+1T>MVC'QJ&- M5DM13:):CFH*U32E-:.[JI8.S=72UADMWUE7B\^+JV)Y9:UW^7U?K"^+Y79^ MW;UB\F3;Y[6?
L_.S\Z.3SM':**]YJ.:AFH]J -J%]!:A6HOJ":JEI_W*"'30 M#-4DJN6HIE!-4UHSFZL^Z-!\Z]!T_N?B[N',^MMZNB]%9P2CC4Y4N8XV2%'-134/U7Q4"U M1+7HE9_&#*L/-;=%TL7QUC<9,]
YOM F*:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ M"53+4$VB6HYJ"M4TI34#O6J"CMZZ"3I"FZ"HYJ":BVH>JOFH%J!:B&H1JL6H
MEJ!:BFH"U3)4DZB6HYI"-4UIS>F@:H*6#ZDU&J/4.]=)S4$U%]4\5/-1+4"U M$-6B5WYRI9EUMUIN;[I7:]>]9\^65Y?VBK(_S M^\5V?KO?
3MUIN01NJJ.:@FHMJ'JKYJ!:@6HAJ$:K%J):@ M6HIJ M4R5).HEJ.:0C5-:.CFHUJ M:B&J1:@6HUJ":BFJB:W6N(S8Y'SWGV8"!L_T1[5GGE^9C>?)=$7EZ.:0C5- M:7#>K%=%)O'
M4JOFH%NPU>U!?9SB;39O+ M!R$Z:(1J,:HEXXX;%-MGP]9Z2HH.*KH&/=H)V6DO3:(O+4^<\]3FHYJ*:AVH^J@6H%J):A&HQJB6HEJ*:V&OULR&'72=#HJ-* M5,M13:&:IK1F@E?
%US%^&U2SV#NYT?HJJKFHYJ&:CVK!7JN_P34^&\$:[T6B MM5144BU$M0;44U<4)^RI#QY2HEJ.:0C5--8[V15$M1S6%:IK2FGE>]47'_?JB)YRI@M9$4:CFHUJ
M:B&J1:@6HUJ":BFJ"53+4$VB6HYJ"M4TI35G@*JT.7[KTN88+6VBFH-]+JJY MJ.:C6H!J(:I%]!:C6H)]*:H)5,M03:):CFH*U32E-:.#257:G/0K;?8XT\4L M]\UY5'-0S44U#]5\5
M0+42U"-5B5$M0+44UL=<:U_VZ&%Z!59W3R2F>TGM/6/Q;+W5DNF^7A^C\[0QOMBZ*:@VHNJGFHYJ-: M@&HAJD6H%J-:@FHIJHF]9MNUU#X_.Q\L'>PHW535'-1S4.U'l4"5
M1+4*U&-425$M13:.:AFH2 MU7)44ZBF*:T9_U7==/+6==,)6C=%-0?57%3S4,U"M0#50E2+4"U&M0354E03 MJ):AFD2U'-44JFE*:TX'5=VT?/BO6H0WRKUSGM0<5'-1S4,U']4"5
M1+4*U M&-425$M13>RU^B)\^Y3*UY\BT>=4HYI"-4UIS42NZJ.3[UOZH?/Q?*A.'UY M!BV7HIJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ"53+4$VB6HYJ"M4TI373ORJK
M3M[ZW]@3M,:*:@ZJN:CFH9J/:@&JA:@6H5],.@FJI:@F4"U#-8EJ.:HI5-.4 MUIP.JJ[KY%]V;U2SW#OGT=(K]KFHYJ&:CVH!JH6H%]%:C&H)]J6H)B;']T8=
MC,>3[OTRT$$EJN6HIE!-4UHSP*O6Z^1;6Z_/JSF_+M?%]6*S+=;E,7UY*%\> M[V\I+V=@'K)WLJ.E5U1S4)VCI%=4<5'-1S4,U']4"5 M1+4*U&-425$M13:!:AFH2
MU7)44ZBF*:TQ'4RKTNO47'JM+D9Y.,*WMBOK_F%]>5-&_WY5IROES6[?E$U8'L7+:.?BFHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ
M8GI\&]/AT14DT2$EJN6HIE!-4UHSHP=51IN;J_+A]]O%I:FRVIG<:#L5U1Q4 MU -5"5(M0+4:U!-525!.HEJ&:1+4%5)G9KOG_H5]H,V
MB]VS&^V8HIJ+:AZJ^:@6H9]XUZ:U[#X_&PRGP:]&RZ.HEJ!:BFH"U3)4DZB6 MHYI"-4UIS>"NRJ-3U -7"O=98[AY(]>ED.&'L:-.KW1+4$U5)4
M$ZB6H9I$M1S5%*II2FL&>-7WG!H+1-5!=WW%^]-J;5W.-S>=R8W6-U'-0347 MU3Q4\U$M0+5PKS7.:3XZJ3E"QXQ1+4&U%-4$JF6H)E$M1S6%:IK2&JD]JVJ9
M,W,M_53R\M'NOQ#JGTZ,[=/^ZSF MH'U35'-0S44U#]5\5 M0+7SE9VTPLNY6R^U-]WH.VD!%M0354E03]):AFD2U M'-44JFE*:Z9XU4"=F1NH/==S;M;%*^?GH/545'-0S44U#]5\5
M0+42U"-5B M5$M0+44U@6H9JDE4RU%-H9JFM&;X5RW6V?2M5W30YBNJ.:CFHJ':CZJ!:@6 MHEJ$:C&J):B6HII M0S5)*KEJ*9035-.E61GYI+L M20LZ\!#^*OR8-
ZXDH.69U'-0347U3Q4\U$M0+40U2)4BU$M0;44U02]9:@F M42U'-85JFM(;J7]1E6POSM]X)>=<'+=ZBFH-J+]IVJ.:C6H!J(:I%]!:C6H)J M*:H)5,M03:):CFH*U32E-
:>#]GA[\'-6._(1NNOJ.:BFH=J/JH%J!;NM=>N M"X\,&J-:@FHIJ@E4RU!-HEJ.:@K5-*4U,[OJM98/H=-><S%+OP"8U!]5<5/-0 MS4>U -7"5W[6#)>E05!C&H))]J6H)E M0S6):CFJ*533E-
;,*J,>F$N")YT MULO'U=U=&>Y/:RN'9W3&/-I7134'U5Q4\U#-1[4 U4)4BU M1K4$U5)4$ZB6 MH9I$M1S5%*II2FM&?]5@O9B\]:DO:*<5U1Q4;
[7Y%7F_GVZ=#>>/"#5I+134'U5Q4\U#-1[4 MU4)4BU M1K4$U5)4$ZB6H9I$M1S5%*H2FNF?-54O;AXZX4;M,**:@ZJN:CF MH9J/:@&JA:@6H5],.@FJI:@F4"U#-8EJ.:HI5-.4UI@.
[/.JPHI;#KL_W"W M>BBS??YYOKB=_WY;/-[;^]/#!F%=6)O&LD[GV92O\'WCGN4_3?=L,FC?ISMDAXU8+F:YA.52EA,';FS>91D[K&2YG.44RVF,;R6V74ML
M<\^T8Z%F<#X8=JS6[$Z_N2DN_[A?+9;;[O1&JZR_DL%[!QG,]R Q7,QR M"54L;TIRN>LB\>YHWM&0%NX+.>PG'O@ZB>\V./S_9?UQX[MKL]R Q7,QR"M?]=QV+A*-3NQL
MO:+W#W:T=\MR+LMY+.>S7,!R(S7,)R*)_M5HO_V9NO!]&]7!9S6,Y8.&_E?)8+6"YDN8CE8I9+6"YE.<%R&:G^5C8YSWO &VF>L?XR3GL)S+\1,N8[7VB MG,-
R+LMY+.>S7,!R(S7,)R*S7'#@&K<"LH?G7:?9L#U2E(M9+F&YE.?*$I96,Y8.&_E?)8+6"YDN8SE%M<B/=>SG&(YC7&MO*[U2,?'FG?ZA';#D4YA^5YX,#-&BOOH^/F M$=L-
1;F8Y1*62UE.G+;',G94R7(YRRF6TQC7C.=)K1DZ,3=#30OP\S\7=P_= M'22SVCNF48ZZ]^0P=.64ZP7,9RDN5REE,LIS&N%>]U/NO$W&=!?;FG?/3QIKC\XWZU
M6&Z[XYWMMJ*Y@.5"EHM8+F:YA.52EA,LE[&<9+F< MY13+:8QK31&U?NW$W*_]AK4?MF]+<@[+N2SGL9S/<@'+A2P7L5Q\X.IK/]/I M>#(8#H_6?
MBN+9=VPG9I4R7,1R,RG&"YC.4DR^4LIUA.8UPKR6LM %V\DK=VM]<6VG?*"+]:+86!^LYSN4'$![Z,]P_ M^=E6[YZKG[8O&)R/AI/V$A ZKL=R/LL%+!>R7,1R,RG&"YC.4DR^4L
MIUA.8UPKTP>U3#?W=4]9 OKEQ"4@\\U#]4YYM**R_DL%[!Y@.5"EHM8+F:YA.52EA,L ME[&<9+FNL?HSGDWMH\4? MMLR+TVZT M:-;ZYSC;Y-US]5O/V?;D;#
^"G*VRXMR/LL%+!>R7,1R,RG&"YC.4D MR^4LIUA.8UPKR&M=WNG7WC'7FE^OB^)JMW:S6'XN-MO5NCO;V08ORCD';MIX MA_9L/#K.=K:;BW(^RP4L%[)W#Z\?H)NEWB&.
<@[+N2SGL9S/RU GGSIB' MZ9_:;#\6Y5R6U#C.9[F Y4*6BU@N9KF$Y5*6$RR7L9QDN9SE%,MIC&O- X/: M/#!XZW-G9FRV%N48#^VY@.5"EHM8+F:YA.52EA,LE[&<9+FR
MG#AMCV7L]+EEMO=.M(+6/6NOBTRZY?_@P>/?^Z.:|_4-L=WP\L7]{NSXNI!^RQX^_KX;]^.M4'[^TVJU/?QC-\"7U?]/QR_SY_\/4$L#!!0 (-.##5GR,H79]P($8(M 9 >&PO=V]R:W-
H965TU[H%!1Q)O[9LRL9CT2E<\;A2A)5%065?\\A%ZNQTWC;\DKBSFU84E8 5TQP(B$;,V?]TTEDI^W!#P8KM;4F1LE,B#]F\SD=.YX) M"')(M&&@^%C"!/+<$&$8=VM.IW%I@-
OK#?M'JQVUS*B"B%+1*[L+UG5ME'DD*126A1K,$90,%X_Z?TZ#UL Y&D^<&N M_Q0P? 8P6 ,&5F@=F94UI9K&(RE61!HK9#,+FQN+1C6,FRK>:(EO&>)T/!%%
MP32614M">4HF@FO&Y\ 3!HKL?Z524I/H [(_!4U9K@[((;F]F9+]O0.R1Q@G MWQ>B4HA5(U=C1(;73=;>SVOO_C/>0W*)_A:*?. H(_Q+BIIY/@;.>=^)^&7 MBA^1@=.=Z9 HJD:RT-
_G7V4QIB??Y=UL":P?#=@?F&S]5)4U@L.!'K$ NP8G?ONF' MWOLVI?^)[%$NADTNAEWL\4.,,_:=-=DH24SK6@9IX^'_6#D M+K<%=;Il;"@$12\2)
T'>-09(<5;B@67O<(!]TFKB8.ML4-0S\(B[834%X M M]R3F3N>O+$C42(LZI=6"WBFLQYSF) .H>UHBE&Z]8!%N@H-=29U.7RK)W6K5
M!Z#>3UA+ZF<,V[49@CUCB*LC:RG5KW1HK2- M?R8TCA&[7."@!VD,\'TFA-YLC((/FKT[\#U!+ P04 " #3@PU92:B@[!(# M "."@ &0 'AL+W=OLXS*@96*N6J9]MBGD*.Q15;
55/%HSG6*HE7]HBQ0$G!2G/ M;,]Q(CO'A%IQO]B[Y7&?K65&*-QR)-9YCOGO(61L.[!<;[=Q1Y:IU!MVW%_A M)4Q!/]QNN5K9M4I"PG260ZL*XM ME, "KS-YQ[9?
H/(3:KTYRT3QB[85UK'0?"TDRRNR.D%.:'G%SU4>]@A*QTSP M*H+7) 0O$/R*X)\:(:@(P:D1PHI06+=+[T7BQECBN,_9%G&-5FKZIL&^P5;Y M(E3WR51R]90HGHQ'+,^)5(67
F&:H!&CDM ET#D!@D5\!T/R'.\P"">T>ETWV3G_Z)/ M7AW|(!E^W1]^H>>_]C[,Q2[E K,M/F),\"R#?Y0T.L5V.T'#]@'3;3IM M8_QNH^R3-
B9P'+/+3NVR<]3E/9,XJRQ"<5$QN>RT>LEK-N6HC8G\9N.V,>&U MWW#9QKC^7G.7-NV]#VP.?%E,-D)5:4UE^2ZM=^OAZ5,Q,S3VAVYOY!KVQVK8
M*F>CO_+EI':#^9)0H9*V4*&S5 @ O0< !D !X;"]W M;W)K&ULK55M3]LP$/XKIPQ-11HD3=N 6!N)EDUC M&AJ#,3Z[R;6Q2.S,=EKX]SL[:2A5J-BT+XE?[AX_SYU]-UY+]: S1 ./12[T
MQ,N,*<]!F]KB8.ML4-0S]\(B[834%X M-

MN5M_7#%6@]V"MP1/S 3_''XE$$1CS]'A#=+9ENWZ^C0#=,1W QW>(%WY1 0/ MS+86WHD9WK\18@E$Z%;O*?("U!&B^PLA';$LHC^G!'4*A@9@GK0P3\PP?P[$
M$HB@^\]ES2T]>_VHL&D%'L#[%=2^S$3.Q&C UZOY25=UDZH"X@G6,%=F]A0#]JZ?F-#.7^/+!0;,A_@R.KP8TJ8_MO*?R(2XV22Y0RNY54]8[3PU,<7CUXW
@^;YZM^$3EY)GU<L* 7J^WNN M +H^*!MH7L"9_PJ02P,$% @ TX,-64]HW7=L P LPT !D !X,"]W M;W)K&ULM5?;,MLX$/T50BT6"=!&]XNSMH!-C*(I MMH
1I^W#8A]H>6P1E4@M2=O-WR\]J8HD,TJ+NB\V*RH&)FV5)6U[8MLAO*+*Y8!52]V3!>8JFF?&N+B@->'UZ"RL#W'B>P2$VJE
MT_K9@J=3MI,%H;#@2.S*$O/'&RC886:YUO<'!V2;2_W 3J<5WL(2Y*=JP=7, M[EC6I 0J"*.(PV9F_>5>W]J!!M06GPD<1&^,M"LKQK[JR=UZ9CE:$12024V! MU=\>;J$H-
)/2\5]+:G5K:F! _)W]7>V\"U ,]' 7X+ M\&M'&V6U6W,L<3KE[("XME9L>E#'ID8K;PC5V[B47+TE"B?3)6S5IDAT1YN4 MT*&]>& 2%P@+ 5*@U:/:KHIQB5<%(-
'87Z*+.4A,"G&)WJ)/RSFZ>'V)7B-" MT4/,=@+3M9C:4@G4RlA9*:;F$>,](^;#CEXAWWF#/,<+#/#;#*/WSMS)'=O)*\:_)U88[,'/KZKP6%(,H2)/:+#4]4
M\^COQSYUDRA,IO:^[\NIE=JO).ZL!B*#3F0P*O)A*-&DKB$(^^]V/'B(WD& MLR#V_(E97]CI"\?U]4K*)"XTK!&27@DSF 6Q:$7F<5%G;AH5-P<=%*S@FT?
MT8*S]2Y3=;_$!1BECG+|;&*?B6S@=MRV'?_&^H|/&88SD0W"D'1A2,Y4W\EI M]AGJ^1]H+XGGW=_9W]WS]K@S\4V#,53BW?'>_P/E%?+T$_-Q DF MT7$&GYI-
G"A^IOS=I_[NOM#@7RJPX.18891W:F:29_=.U/HZ\Q'S+:$"%;!1 M..&PO=V]R:W-H965T=69!!F1B)H''.(R\3!EJ0RE_S]JZI*/DK(Q#]M3O9@P M'Q,6(,$:3O=KI_N=-
^WG3;90#PKE\/ZQ(-IL+2'] J)?G[93:VQNC[UZL8;W M8@W_Q1!9V>^<:;@&G1:/V3F$D&SI(FW-=9%0\:^ 3)B"":?,Q
M80$2K&'K;6WK[2OENEM,IS%A'B:,QX0%2+"&T\:Z2%&KNN$7&LK)LP:/LN/ MSDD&Q0P7/ IGU^$:!GRH#?C0:4#I72*;NJ_^(Q15-C^GA1?3&'I[D6M2@P9F@:GO&M9V#-
,G74YY(MB[V M)A9,JF="<;@"&@'7%=3U)6-R?Z(#U#MNT_\!4$L#!!0 (-.##5E&PO=V]R:W-H965T"E+"I^8ZV$6%_;-L]6I,3\BJY));]94%9B(6_9 MTN9K1O"\"2H+&SE.8)6?
W+/,\)!7/:0486=Q8M_ZA5$=T"#^RLF6 M[UV#6L3A#]8=JFY_G-Y93SX@4)!,U!98?SV1&B]FDO/XW)%;_9AUX/[U&_N/ MC7@IY@=ES,]/%W_E/,7;#NL8X%%PMNV
Y@S*OVD_\TB5B+T#RJ -0%X"&_=Z1 +<+<$\=P>L"O%-'\+N 1KK=:F\2 MEV"!IQ-&MX#5:,E67S39;Z)EOO*J-LJC8/+;7,:)Z0-Y)M6&<+!@M 0S6@DF M:\KBKDO/_1D__M\^@'R7!
[_[@-GW>$[_[0 N!!182]QBU+T+#4B!?S%']1T_LY_W,*5!!',!# M5#)&H3"*!ERI A5#%/2H |E>+!?3RI7K48&?*,.B72@;T2J]6HZI;_F;YR1 M&TLN[YRP9V)-
O_T&!LX/*B.U9/Y^6B)WD!23 Z;C =W 4V?.!S/G:S/WNU@1 MLIN8-OS8B5>53FWXN;XP29:8)$I- MD1W4(.IK$'VE!HW+Y(\VZZJO/E:-.:0!;_!>S<80=_CJ?9TE'4."(VMWW*N,
MM2K_>&+DY0M6J=(&GNLQDV2)2;+4$-E!]J&SVVDZ1K8*' .0B%1WRWVY1# _:[\MOQ"-MR&>E2&W@V:XSR98894M-L1V68-]LC;(E1ME24VR%=CU"U#?,)QLN?%&
MW@U&Z]P8Y(=H:+@Q*/#0T&]C4!0=VP5ORA^.MTMZ-MNK-=:+21,,]6FF([+,RNEX#Z9N)D%T:C YIPV'+.%"#H^N'0A@I4%(]\.$:Y M:,_2K5Y{[RRU)&S9'&)SD-%-)=ICL?YI?
U!^YQP/#Y[?P>L95#Q/ZH/UYNQV M1[^>RG_ :)7"1D(8=RKD+YRK#VH+N]$73=G.0^42%HV5RN")X35@/DIPM* MQ=M-/4#_[X;IOU!+ P04 " #3@PU9YW_O<.(" H"@ &0
'AL+W=O M3',1J8F>V ^S?[YR$##*HTL(TOQ"_W/.?G,.YNO!;R124 FFRRE*N) ME6B=CVQ;10ED5/5$#AQW%0)F5.-4+FV52Z!Q"V#+19L$.QCE=PB/HY_Q>XLQN6&*6 5=,
M<")A.;&N^Z.9;^Q+@^\,UFIG3(R2N1 O9G(;3RS'' A2B+1AH/A9P0VDJ2'"' M8_RL.:W&I0'NCK?LGTOMJ&5.%=R(] >+=3*QKBP2PX(6J7X0ZRJ0ZQD:ODBD
MJOPEZ\KV$HVC0FF1U6 \0<9X];6;.@X[.1!![@UP'T-&+P!\&J =ZR'00T8 M'.MA6 -*Z?:EO0Q<2#4-QE*LB336R&8&9?1+-.;+EHRF,UMC4>P-#8 M4>UL6CESWW#FD3O!=:+(C,
<0M^##;KS?@;=1>*/>W:J?NIV$7PO>(Y[S@;B. M.V@YS\WQ<*]-SO]YG_VS]U@>,U3\$H^[XBGT':W%7K0CC;Y,*1R&L'$PH2E M0*["MZ_Z_O.I[; GI(L/"79[$1D>U&7 M'*8.K
)G,*]VHWO0(CQH,>NRV!.W,,0-.\7-%@LHRP)FD48FHM6C155W^D0 M>=@D/&PRZS39T^DW.OU.G7>,LZS(B%ASD"IA,>K5@(]%F_2IBKEB,,.28<+%
M.D\BP95(68R!B/[_]H]X2K+0;PEF[^I5Q$_DL;H;>Z?T92"7 M9<^A,*@%UU7J:U:;MN:ZK.:OUJ?!T4V_93W$-JCJ6O[05SW4'95+QA5)88&N MG-
XE/B59]2751(N\++QSH;&,E\,$6SF0Q@#W%T+!H[<0X;)K#X#=02P,$% M @ TX,-6;?/|&K'-0 :E($!D !X;"]W;W)K&ULO=UKMT^1#<9]MZK^Y*?1Q?7,P^ MKM-\\^[3SP\?"\M//Q>
[!2K?9&&I5+OU.BU__):MBF^_O!N].WX@SF_OMOL/ M?/ST\WUZFXEL^_M]6-9_^OBD+/-UMJGR8].4V*SLOY8O1?"'_@_6\!=W%_NGE*VRQ79OI/5_OF:?L!5J3]5/Y)\']=W3 MH/L-
FX^/NO[PU==?S9>TRCX7J[_GR^W=+^^NWBG+[";=K;9Q\MGL,XWC_]-OQ]>B<8&EU?/;# ^;##N;#"9 M/+//!Y++#!Y+4;7!XVN.QL,'_N:Y@>-IAVOX;G-I@=-IB]=H/Y88/Y:S>X.FQPM
MU?VBKY_9X/JPP?5K1QA=<'YBU=0\O1FG[W,SVYR?+M'W?=[/'YND^,;/NJ^ MX\IQ_L'# M+N=A^WHGD6_VNT>Q+>N_S>OMMI_$DN5_7.7;,,"IK?^=Z7\AYIMTWQ5_5_E
M+\I'I;I+RZQ2\HWR^R;?5N_K#!;/D[MB5Z6;9?7SQVW])/;4Q\5A0.-OP/$S M-XX4K]AL[RI%VRRS9<_VKGS[F63[C_47__0*C(^OP&IC*6CO5A^4\?2l,KX8
M7RJ_"U7YC[^TOO;'__0\T\^O@$=====>)F7=3 4I:+VB.HKQ(OGGVJ/J,E%-5O4 M7_S\09P0^,57_%D]"?>'/,E>//TC(?!EASVTA]_[@G; MM_Y]?INOV\^MA@E<\F\./T*7\ MAS%\Q3OQ[
(2D4Q2:G\=1^Q62B[%<#!;;>F5O^WQXK]R7Q2++EI529HLL_]HI[?6;=)"A.4!B*HE]*8_8K-& M#HRF/3% CFF2F$5B-HYD):.2F$=B/HD%)::26$1B,8D)$DL@K!4#LZ<8F$EC
MX'.Q7A<;11QV^6FI?$U7NZS^W5\Z%_;;5!VZWRK_ZNSXR4'-1ZP[9F=(BQS2)C&'Q-Q7O1@>;.1/8@&)A206O>J5CD<0'GGG]+Y#)]\1@&)A206D5A,8H++$$@AK
M[<.OGO;A5])[^*]?L\TNZ]M52[<;NJLF,97$-!+3223FDUA 8B&)1206DY@@L03"6E$PNGC*@GU717(PX#[=4//M M<3*G4K;%M>6W2 M[.IZ=M69,"045U4\U#-1[4 U4)4BU
M1C6!:@FEM6.A44D;26/A.*.OW)?Y M(FO%PTNG6^7RX#P@-175-%334I7OY)E_OUKW[M'!..BJ::BFHYJ!:B;]6:AFHYJ#:BZ]>:CFHUJ :B&J1:@6HYI M832
MVO%PZN&.@"+N"&WBHJ[*:AJJZ:AFH)):A:JV:CFH)J+:AZJ^:@6H%J{:A&J MQ:@F4"VAM'8^G,JY^YM#20X?CM=_9M_O_*AG*5LL[+_*$(J#4X)4E-134,U M'=4,5#-1S4(U^X7OW-
&5LGZXAU5O)I#/Q$4U#B]5\5 M0+42U"-5B5!.HEE!: M.Q-.7=V1O*Q[FE)*OS\[H816<5%-134-U714,U#-1#4+U6Q4,]6$-HM1344U#=5T5#-0 MS40U"]7L%
[YSN]/+"WD)Y30.6X$]:CFHUJ :B&J1:@6HYI M832VHEP:BN/ M7E-75OZEB*S,LTKY]7G;B?Y#![3#C&HJJFFHUJ..@6HFJEFH9J..@VHNJGFH MYJ-:@&HAJD6H%J..0+6$TMH!
<:HUCX!>\P@M-J..BFH:JNFH9J":B6H6JMFH MYJ":BVH>JOFH%J!:B&H1JL6H)E MH;3V&F.GJO-87G7NKB7P6&V[S\K',MN+
MQ38Y/S0Z4$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"T\.V;CX[''Z:7 MG999A(X:HYI M832V]%P*CJ/Y47G[NS2;]+9)3DV. +0;C.J::BFHYJ!:B;J M6:AFHYJ#:BZ]>:CFHUJ
:B&J1:@6HYI M832VD$Q/@7%^.VS2V.T*XUJ*JH MJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J{:I%J!:CFD"UA-+:^7#J2H^E7;NW MSRZA-6I44U%-0S4=U0Q4,U'-0C4;U1Q4-
-5"5(M0+48U@6H)I;7SX51:GLA+RV\YNX"VE5%-134-U714,U#-1#4+U6Q4 M56YVT[; M/-W2XG#WBKR]=ME2>A,+^1"#8P'M+*.:AFHZJAFH9J*:A6HVJCD'K7E+C,GD MHO[?
M)L.:&\9U7Q4"U M1+4(U6)4$ZB64%H[&4Z]Y8F\MSSDO#-:448U%=4T M5--1S4 U$]4L5+-1S7GAY^#Y\ZJCFHUJ :B&J1:@6HYI M832VCEPJC9?RA=O[ER. M6D> EW!/U[O>:2.Y-
7C_CU:<44U#-1W5#%0S46+DM!A/53S42U M1#5(E2+44V@6D)I[5PX59_KA\/FES!? M98L [HN\/I+HN_5]?S9{!QF<#:2FHIJ&:CJ[&:AFHIJ%:C:J..CFHIJ':CZJ
M!:@6HEJ$:C&J"51+**T=(*=V|"70CKY$V\&HIJ*:AFHZJAFH9J*:A6HVJCFH MYJ*:AVH^]@6H%J}:A&HQJ@42RBMG0^G=O2EO!W]UM7:Y/S@Z$ KTJBFH9J. M:@:JF:AFH9J-
:LY!:Z[]-OIP=3[IA':D4JCF MHUJ :B&J1:@6HYI M832VM%P*DE?RLNAP\]'O')+-JD1C45U314TU'-0#43 MU2Q4LU'-0347U3Q4\U$M0+40U2)4BU%-H%I":>TH.;6K+Z^!,Q-
H=QK55%33 M4$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&-8%]":6U\F%CJEA/Y17K MMU\2*Q]@:'B@FHIJ&]KIJ&:@FHEJ%JK9J.8U\.%6TI_**]AO6 M$9++@U,#
]6:CFH9J.JH9J&:BFH5J-JHY!ZUYX[_1A]E5=Q8*+6:CFH]J -]% MJ!:A6HQJ M422FNGP:F873^4I<& U2+DTN"]/ZFIJ*:AFHYJ!]J9J&:AFHUJ
MS@L_!Y+5(M#GX;&;CVH!]H6H%]%;C&H"U1)*;R?"]6D]E3;U_MQYB;#,E)O= M9!DMGXXF>B,$+6BCFHIJ&]KIJ&:@FHEJ%JK9J.:@FHMJ"JKYJ!:@6HAJ$:K%
MJ"90++;&T=JR<'MK3&7!: FUAHYJ*:AJJZ:AFH)]):A:JV:CFH)J++:AZJ^:@6 MH%J{:A&JQ:@F4"VAM'8^G,K:4WE9^RVG)=""-JIIJ*:AFHYJ!]J9J&:AFHUJ
MSD$;-6_>RM>M/C7G#B6Y1;I:U4GPY4?SV$"2"FCI M&M545--034OE M=2<5T&$]5/-1+4"U$-4B5(M13:!:0FGM5#CUJ&?_AAYUN*J?T'I_,OK7V_V_ M9:L.R<7RX-1
N]2HIJ&:CFH&JIFH9J&:C6K.06M- M1HT_C*>S[BEK=%@/U7Q4"U M1+4(U6)4$ZB64%H[$$YUZOKA_]ADE'S)"?DS M&1P@I*:BFH9J.JH9J&:BFH5J-
JHYJ..BFH=J/JH%J!:B6H1J,:H)5$LHK9TR MIXKV#%@,>X9VK5%-134-U714,U#-1#4+U6Q4RW+SDA'V!P>*!%;%334$U'-0/53%2S4,U&->>>@-2^= MO9Q-)_/+[N046K%&-1_5
E0+42U"M1C5!*HEE-:.A5/%>B:O6)]/3GF[:IMN M;GL3 "U5HYJ*:AJJZ:AFH)]):A:JV:CFH)]+:AZJ^:@6H%J{:A&JQ:@F4"VA
MM'9.G)K7LRM@>@FM7*.:BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1 MJL6H)E MH;1V/IQZV;/7]K+_]/02VLQ&-175-%334>C"ZF%Q<7
M[5D7"QW61C4'U=S7OB0>,JR/:@&JA:@6H5J,:@+5$DIK[?+GI^KU7%ZJ?L% MKG)YZ+X>U514TU!-1S4#U?^%!8ZJ(UJ#]JYKWM!/'10']4"5 M1
M+4*U&-4$]B64UMI/G\K4/3/E];DGOS;97D_,#!/=1_1C4-U714,U#-/&M=FU)?7EQ?=_?W:+49 MU1Q4=BHYJ"_:^Z=?(P]!'CZJ!:@6HEJ$:C&J"51+ M**V]]S]5E.N'TE_WTJ7#!+
[_L.=/5XI9K);U+_Y_K91]?R2P/P H%EFVK)0R M6V3YUVS9FPS2408G ZFJ*:AFHYJ!]J9!VW6^ UW/#Z?XB"M%'-0347U3Q4 MU$M0+40U2)4BU%-H%I":>UD.-6*YT-?2C[T_^!'OV_*
[#:OZN.$%Y9XEH\Q M.!?0VC&]::BFHYJ!:B:J6:AFHYJ#:BZ]>:CFHUJ :B&J1:@6HYI M832VOEQ MJAW/@26>YVBS&-545--034U -5"5(M0+48U M@6H)I;7SX=0_GLO[QV_O#
<@'&!P>;"D9U314TU'-0#7SH+56OQO-+GHN+4+[MQ[CFH)K%[*0X?U42U M1#5(E2+44V@6D)I[5W^]4H\ER_B_);> %HP1C45
MU314TU'-0#7SH%VU+Z$YJPV@Q6%4_E0(GLL+P>'NRRI?*,&K;BPDMP;OU!'N+ZHJ*:CFH%J)JI9J&:CFH-J M+JIYJ..C6H!J{:I%J!:CFD"UA-):.7%U:A%?7;S!!,$5VA=&-175-
%334K<'=I&QW50S44U#]5\5 M0+42U M"-5B5!.HEE!:.QC&IV"05Y3?L>3
M>3<.T&XRJKFHYJ&:CVH!]H6H%]%;C&H"U1)*:\?!JM>:0PJC_WI"H<&QW60347U3Q4\U$M0+40U2)4BU%-MH%I":>UD.)6;ZX=#DF'HO8SD_:!4(#45U314TU'-0#43U:R#]N+1
CFH@VHN-MJGFHYJ-:@&HAJD6H%J..0+6$TMJ9<*HU7\EKS>'Q=A8W9;%6CC<_.DXI]<< M6F)&-175-%334.B- [2SC&HJJFFHIJ.:@6HF MJEFH9J.:@VHNJGFHYJ-
:@&HAJD6H%J..0+6$TMJQ<>HL7ST6Y-YVR2I:2T8U M%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M13:!:0FGM?#@5G*_D M!6?D5#3:=$8U%=4T5--1S4
U$l6I@l8Z%3VIFLIGDZONC/!:=D8U%]4\5/-1 M+4"U$-4B5(M13:!:0FGM:#BUHJ_^9"NZ?B3J#!4"L2;++C*8Q^;;$#;TJBF
MHIJ&:CJ[&:AFHJ%:C:J..CFHIJ':CZJ!:@6HEJ$:C&J"51+**V5']>GMO0U MT):^1MO2J*:BFH9J.JH9J&:BFH5J-JHYJ..BFH=J/JH%J!:B6H1J,:H)5$LH MK9TI/I[;TM;PM/6 9-
[DT."706C2]:.BFHYJ!:B:J62]\KSV_X)F-/@\'U5Q4 M\U#-1[4 U4)4BU M1C6!:@FEM1-A?H>4WZ53-.R;=".N,D'V-P5]"%.533 M4$U'-0/53%2S4,U&-0?
57%3S4,U"M0#50E2+4"U&-8%]":6U\F%T<:I= M[Q_+#B[>Q@KI"R,,S0^64UE.8S=Y0R6,UG..G+-&SN-IU=7X\FL3'V#2N3OD /3PFTELUR&LOI M+&>PG,ERUI%[:2W[MK8O2O>
/#P]TD\UR&LOI+&>PG,ERUI&[:@3%Z,.T>X]8=E2'Y5R6\UC.9[F MY4*6BU@N9CG!<@G&=7)BTL@)^;+6 RYT>H$;'@EH#9OE-),36^ MYR0W=F*?B<-
R+LHV+.>S7,!R(SG&"Y!.,Z,7'9B(E+^>'$WQTEJ7-! M<8MTTQ\.4F!X.)"R_DL%[!R_DL M%[!;.MY526TX[<:-2Z5.=B/I^>90-:N68YD^4LEK-9SF$YE^4\EO-9+F"YD.4BEHM9 M3K!
<@G&=;+AJ9(.\E:UF7I:*M:FVY6Z=;;;OE;\=P\':;+-ZS*T2VOQ7DE^ MW&?"/3OVVQ3Y?N_US;U%H^GO/^K/T30PC;+J2RGO?0RIZK_QsW3^Y]$MMB5
MV3+XFI6;_/9NJ^>;=+.HCl3V+[(H;LJGO[$VR^R[^);>[__&R_;UEOYI++3> MS7(FRUDL9[.QG,UR#LNY+.>QG,]R Q7,QR@N42C&MGPJA1\!
[)"]Y)L4U7RJ;89I5RG_[8'Z&\5V[+HNH_,2[7 M!D<"RJDL[&*SPO>U"V!'; MMD8YE>4TEM-9SF YD^4LEK-9SF$YE^4\EO-9+F"YD.4BEHM93K!<@G&=T&BT MLD?RAFSG#
()R4P^FI.MBM]GVQP?;S$8YE>4TEM-9SF YD^4LEK-9SF$YE^4\ MEO-9+F"YD.4BEHM93ARYYM38[!SZ,<&&[>1"HX9=/R;/(DBUX;%_>QC$[K&"YY.6O
MHK.';O2>1_*EJ5\YWRG,5R-LLV+.>R MG,=R/LL%+!>R7,1R,SG,%R)LM9+&>SG,-R+LMY+.>S7,!R M(SG&"Y!.,Z =*H3H_DG=ZSHP[E7XI89)NTC@OEVUVV4.9WF5+LMOM5
MKI?[NS'=E_EFD=^G*^5+NDHWBTS)*V65557]F>E&*4J[E]NJ_W1;*J(Z.?+7* MB_Z(QR_DL%[!PC@H4&VY-&.8WE=)8S6,YD.8OE;)9S6,YE.8_E?)8+
M6"YDN8CE8I83+)=@7#LTUHZQK5 M5%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&-8%]":6U\F%T<:I= M[Q_+#B[>Q@KI"R,,S0^64UE.8S=Y0R6,UG..G+-&SN-IU=7X\FL3'V#2N3OD /3PFTELUR&LOI M+&>PG,ERUI%[:2W[MK8O2O>
/#P]TD\UR&LOI+&>PG,ERUI&[:@3%Z,.T>X]8=E2'Y5R6\UC.9[F MY4*6BU@N9CG!<@G&=7)BTL@)^;+6 RYT>H$;'@EH#9OE-),36^ MYR0W=F*?B<-
R+LHV+.>S7,!R(SG&"Y!.,Z,7'9B(E+^>'$WQTEJ7-! M<8MTTQ\.4F!X.)"R_DL%[!R_DL M%[!;.MY526TX[<:-2Z5.=B/I^>90-:N68YD^4LEK-9SF$YE^4\EO-9+F"YD.4BEHM9 M3K!
<@G&=;+AJ9(.\E:UF7I:*M:FVY6Z=;;;OE;\=P\':;+-ZS*T2VOQ7DE^ MW&?"/3OVVQ3Y?N_US;U%H^GO/^K/T30PC;+J2RGO?0RIZK_QsW3^Y]$MMB5
MV3+XFI6;_/9NJ^>;=+.HCl3V+[(H;LJGO[$VR^R[^);>[__&R_;UEOYI++3> MS7(FRUDL9[.QG,UR#LNY+.>QG,]R Q7,QR@N42C&MGPJA1\!
[)"]Y)L4U7RJ;89I5RG_[8'Z&\5V[+HNH_,2[7 M!D<"RJDL[&*SPO>U"V!'; MMD8YE>4TEM-9SF YD^4LEK-9SF$YE^4\EO-9+F"YD.4BEHM93K!<@G&=T&BT MLD?RAFSG#
()R4P^FI.MBM]GVQP?;S$8YE>4TEM-9SF YD^4LEK-9SF$YE^4\ MEO-9+F"YD.4BEHM93ARYYM38[!SZ,<&&[>1"HX9=/R;/(DBUX;%_>QC$[K&"YY.6O
MHK.';O2>1_*EJ5\YWRG,5R-LLV+.>R MG,=R/LL%+!>R7,1R,SG,%R)LM9+&>SG,-R+LMY+.>S7,!R M(SG&"Y!.,Z =*H3H_DG=ZSHP[E7XI89)NTC@OEVUVV4.9WF5+LMOM5
MKI?[NS'=E_EFD=^G*^5+NDHWBTS)*V65557]F>E&*4J[E]NJ_W1;*J(Z.?+7* MB_Z(QR_DL%[!PC@H4&VY-&.8WE=)8S6,YD.8OE;)9S6,YE.8_E?)8+
M6"YDN8CE8I83+)=@7"=N&LWUL7S%IKZS M*=3/9_AD&%N"1SF-Y726,UC.9#F+Y6R6.2SGLUS \7;W^1DI4-1 MZ_Y,MLLJ_?[PQ-
%W*5E5C[,=U7[N?l2_J)\5*KlQ>Y)&:,3CG+]D=M?FOTT M(W?Q870IG=1'D>UL8T=6VY@.5"EHM8+F8Y MP7{OQG4RI-%8\'O7^#[+D.4A.QZ6^=Z?*5G4AR/;?\;@?)\>%2P3?8#-VI5
M)#|<7$_FYT'!MM11SF YD^4LEK-9SF$YE^4\EO-9+F"YD.4BEHM93K!<@G'M MH)@7N6NH3>4M=/>;$T\%%;R+(E<&)@'+]D6L&PQ[9C&#JJSG,%R)LM9+&>S MG,-
R+LHV+.>S7,!R(SG&"Y!.,Z8=#HI4_DO?2^T^6?RQ_5-EW!])3D M+BO3^VRWS1?5>\?;+.2GPN5C#8\,MMB.$<]RTJJ+@:R^DL9["R_DL%[!5TEC-8SF0YB^5LEG-
8SF4YC^5\E@M8+F2YB.5BEA,LEV!<)SP:9?3) ME)B28A=#1SF5Y326TUG.8#F3Y2R6LUG.83F7Y3R6\UDN8+F0Y2*6BUE.L%R"_M<9W0:%3*)_)*>?ATZ>S^3B2'Z:C'&Y?
<9:0^FUO)R>$1\LB-VEV)R?1L-HJM M>Z.KV/7)44YG.8/E3):S6,YF.8?E7);S6,YGN8#E0I.+6"YF.<%R"<:U,^&R MT?R^E#>_VR3;DJ@PVHL M#[.J/U!P9.I#UPS**
[/&GKHF!K+Z2QGL)S)R_DL M%[!6,(]><OQ>32>SZ75[EM!D![98SF8YA^5Y@.5"EHM8+F8YP7{OQG7"HM$,OY0WP[7O6;G(ZUBX+_-%U=]-%Q?GD]/#_M4X)=-OSE-);36-
E!A_N)B>101;$$AZ7\I7-C^>WWY=++"5;Y1364YC.9WEC"/7C(7+V;AWHHEM;[NL#B8=X>,5L M$UOQ1CF5Y326TUG..'(OSC:Q#6^4LUG.83F7Y3R6\UDN8+F0Y2*6BUE.L%R"
M<>V^21T6(OE;)9S6,YE.8_E?)8+6"YDN8CE8I83+)=@7"<0&F7NJ;S,?9A/ M4K+O]WGYN*3>-BO7_9G MKA13F4YC>5TEC->>E>GRH\L+?N2W62?B<5R-LLY
M+.>RG,=R/LL%+!>R7,1R,!"Q:X*CG,9R.LL9+&>RG,5R-LLY+.>RG,=R/LL%+!>R7,1R,R_DL M%[!^IO.[= M-_$E_NXH25:N%;=(^Q?,D*/#\X%M>*.4.EC-9SF(YF^4< MEG-
9SF,YG^4"E@M9+F*YF.4$RR48UPF-1C%*B^&>^GW?+U;*U^*LMYZ?R9] MD=8#YML?_>G!5L!13F4YC>5TEC-8SF0YB^5LEG-8SF4YC^5\ ME@M8+F2YB.5BEA,LEV!<)T$;E>^YO/*M?5]D554'1+/YG6Y^/-RPL%C?UP__M6BG5[DN5+_.TS+-**;9W6:EL[]+-/D46Q6:3+1Z6(?
^6;^^4159NTWVZ%)ML MF__WXP+EV?.W(O?E>G[CE3D7\;PG&&[Y"BGLYS!2SG MLUS E UL=1SF-Y726,UC.9#F+Y6R6&6#7#[Z\'A@&^OHH.< MP7(FRUDL9[.J#DYNBW-
[MSXJGF\UN7_S8+6^S_KL?'H9XJ=\A?R;# MHX*MDJ.1+!UT+-/]_J_;0KG?E8N[M,J4 MZBZMQU7^=7C0'Q579U='32]FD^OSK&!;XBBGL9S.<@;+F2QGL9S-<@[+N2SG
ML9S/<@'+A2P7L5S,SG,%R)LM9+&>SG,-R+LMY+.>S7,!R(SG&"Y M!.,>8^%C=9=E6S7=H]^7F?E;?8Y6ZTJ9,$_|?W+NWWCXNFC2IG=[%/CIU_'M[SZ>?=P8_>2,>C[NCGIR'C[^\
<1_^OD^O&POSKG\]@77ZKB06TX?5I1*:Y/PM)C8*RGS]XY3+%8T(<55EM-4 M(7FB)55RR=(A>41 60$NX,7#=P$L)2>SL\U\E=
(@MKD:U3:,&]ZSIFZK,LHA/[Z>+M]W4F;]]8^GKV[NS,?;]\/8Q?E,"E[1A%;SJ(7KDN M+@P@)AYT$S^FC4D/.TD?4<:$1_O"Y=WG2D?SSC%:,* I^PT3.@AYZ)K);IN,
M&1YZ1G*+BA$'2-,]M"C=1^A[0\;W*6:=V[PRD/=:;WKW^FC"0)L](@ZF#Q7H M5L%N%X]5$]=ZD4S'<98V[Q/?U@'E@B34>B9\8L\(9W/(@!63A&M#@\@L,AX
M)BRI7F3*E@>1XJ>&/=V#=UREDI T$V5NG4'_GE>W'P"[']AADG-<&!{8.3,PYDQ_7:CAIV8>*H?>"QFQ3]C=Q;0!3]W!UDN=\ M^X&S99I0/?C.";=CLN-
9JTRPGNH;.5,P MPK6JS_J3MWD31[/KT=

TX,-69>*NQS $P(L !? M3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T!!;X"O.DQQ0FE(2S,.\,W2 M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%H!%R=.B':5_',G0 & #M M- #P 'AL+W=OY:EVZ*W]A:Y;6V!AI#PQ>M{OS3\?!6W&JO;W2IZX>32?NZ M5!-1:,,K_5T5)Y/#B? ;>_>G=?]J[-;4LE[FS97DRF74'OBA7Z_Q9\S) 7LL; MWJ;4\N9* LC))#V$"ZZT\W5[1GM]"8RW"D[NWC6U_;#+6KDS6:L_G&VVVJS# M9>!73-'/:,,P^]L%\=C!GS#:U4KGZLSF3:5,W<71J3(&K_16S\11E;J9+({ M14A3B'-30Y#$PG27@G/#+X6O7A3=KZX!%\70'6LXX!9%"\X'^,>13:%K58CW MUA3*^.Z5MZ4N@ A!1@1DM$?(?R,$.2<@Y_N$G"/(F(",]PD9(\B$@$SV"9D@ MR)2 3'DA/[NU-/I[>Z!]PL^4SYW>MN_M"D%F!&3&"[ELJDJZ!^ 12[TV&CXF M84 ZS7/;P("${(\(R"->R%/OX&P'O#B[^$T,W;SSRAAS)B-<:9NN@P&{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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 94 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited{ color: black; text-decoration: none; } /* table */ .report{ background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /* Top labels */ .report th{ background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl{ text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a{ cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a{ width: 200px; } .report td.pl a:hover{ background-color: #ffc; } /* Header rows... */ .report tr.rh{ background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc{ background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu{ background-color: #def; } .report .reu td{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou{ background-color: white; } .report .rou td{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td{ border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn{ white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump{ text-align: right; white-space: nowrap; } .report .nump{ padding-left: 2em; } .report .nump{ padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text{ text-align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{ font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em; } XML 96 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html3884641false1190false11 falsefalseR1.htm995200090 - Document - Document and Entity InformationSheethttp://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm995200100 - Statement - Unaudited Condensed Consolidated Balance SheetsSheethttp://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance SheetsStatements2 falsefalseR3.htm995200105 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)Sheethttp://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParentheticalUnaudited Condensed Consolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm995200200 - Statement - Unaudited Condensed Consolidated Statements of OperationsSheethttp://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of OperationsStatements4 falsefalseR5.htm995200300 - Statement - Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit)Sheethttp://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficitUnaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit)Statements5 falsefalseR6.htm995200400 - Statement - Unaudited Condensed Consolidated Statements of Cash FlowsSheethttp://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash FlowsStatements6 falsefalseR7.htm995210101 - Disclosure - Organization and Description of BusinessSheethttp://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessOrganization and Description of BusinessNotes7 falsefalseR8.htm995210201 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes8 falsefalseR9.htm995210301 - Disclosure - Asset Purchase AgreementsSheethttp://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsAsset Purchase AgreementsNotes9 falsefalseR10.htm995210401 - Disclosure - InventorySheethttp://www.fortressbiotech.com/role/DisclosureInventoryInventoryNotes10 falsefalseR11.htm995210501 - Disclosure - Property and EquipmentSheethttp://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentProperty and EquipmentNotes11 falsefalseR12.htm995210601 - Disclosure - Fair Value MeasurementsSheethttp://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsFair Value MeasurementsNotes12 falsefalseR13.htm995210701 - Disclosure - Intangible, netSheethttp://www.fortressbiotech.com/role/DisclosureIntangibleNetIntangible, netNotes13 falsefalseR14.htm995210801 - Disclosure - License AgreementsSheethttp://www.fortressbiotech.com/role/DisclosureLicenseAgreementsLicense AgreementsNotes14 falsefalseR15.htm995210901 - Disclosure - Debt and InterestSheethttp://www.fortressbiotech.com/role/DisclosureDebtAndInterestDebt and InterestNotes15 falsefalseR16.htm995211001 - Disclosure - Accounts Payable and Accrued ExpensesSheethttp://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesAccounts Payable and Accrued ExpensesNotes16 falsefalseR17.htm995211101 - Disclosure - Non-Controlling InterestsSheethttp://www.fortressbiotech.com/role/DisclosureNonControllingInterestsNon-Controlling InterestsNotes17 falsefalseR18.htm995211201 - Disclosure - Net Loss per Common ShareSheethttp://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareNet Loss per Common ShareNotes18 falsefalseR19.htm995211301 - Disclosure - Stockholders' EquitySheethttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockholders' EquityNotes19 falsefalseR20.htm995211401 - Disclosure - Commitments and ContingenciesSheethttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes20 falsefalseR21.htm995211501 - Disclosure - Related Party TransactionsSheethttp://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsRelated Party TransactionsNotes21 falsefalseR22.htm995211601 - Disclosure - Segment InformationSheethttp://www.fortressbiotech.com/role/DisclosureSegmentInformationSegment InformationNotes22 falsefalseR23.htm995211701 - Disclosure - Revenues from Contracts and Significant CustomersSheethttp://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersRevenues from Contracts and Significant CustomersNotes23 falsefalseR24.htm995211801 - Disclosure - Income TaxesSheethttp://www.fortressbiotech.com/role/DisclosureIncomeTaxesIncome TaxesNotes24 falsefalseR25.htm995211901 - Disclosure - Subsequent EventsSheethttp://www.fortressbiotech.com/role/DisclosureSubsequentEventsSubsequent EventsNotes25 falsefalseR26.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes26 falsefalseR27.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes27 falsefalseR28.htm99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies28 falsefalseR29.htm99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies29 falsefalseR30.htm99930403 - Disclosure - Inventory (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureInventoryTablesInventory (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureInventory30 falsefalseR31.htm99930503 - Disclosure - Property and Equipment (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTablesProperty and Equipment (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosurePropertyAndEquipment31 falsefalseR32.htm99930603 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureFairValueMeasurements32 falsefalseR33.htm99930703 - Disclosure - Intangible Assets (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTablesIntangible Assets (Tables)Tables33 falsefalseR34.htm99930903 - Disclosure - Debt and Interest (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureDebtAndInterestTablesDebt and Interest (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureDebtAndInterest34 falsefalseR35.htm99931003 - Disclosure - Accounts Payable and Accrued Expenses (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesTablesAccounts Payable and Accrued Expenses (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpenses35 falsefalseR36.htm99931203 - Disclosure - Net Loss per Common Share (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareTablesNet Loss per Common Share (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShare36 falsefalseR37.htm99931303 - Disclosure - Stockholders' Equity (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityTablesStockholders' Equity (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureStockholdersEquity37 falsefalseR38.htm99931403 - Disclosure - Commitments and Contingencies (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTablesCommitments and Contingencies (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingencies38 falsefalseR39.htm99931503 - Disclosure - Related Party Transactions (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTablesRelated Party Transactions (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactions39 falsefalseR40.htm99931603 - Disclosure - Segment Information

(Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureSegmentInformationTablesSegment Information (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureSegmentInformation40 falsefalseR41.htm99931703 - Disclosure - Revenues from Contracts and Significant Customers (Tables)Sheethttp://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTablesRevenues from Contracts and Significant Customers (Tables)Tableshttp://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomers41 falsefalseR42.htm99940101 - Disclosure - Organization and Description of Business (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetailsOrganization and Description of Business (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusiness42 falsefalseR43.htm99940201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailsSummary of Significant Accounting Policies (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables43 falsefalseR44.htm99940202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetailsSummary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables44 falsefalseR45.htm99940301 - Disclosure - Asset Purchase Agreements (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetailsAsset Purchase Agreements (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreements45 falsefalseR46.htm99940401 - Disclosure - Inventory (Schedule of Inventory) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetailsInventory (Schedule of Inventory) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureInventoryTables46 falsefalseR47.htm99940501 - Disclosure - Property and Equipment (Schedule of Property, Plant and Equipment) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetailsProperty and Equipment (Schedule of Property, Plant and Equipment) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTables47 falsefalseR48.htm99940502 - Disclosure - Property and Equipment (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetailsProperty and Equipment (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTables48 falsefalseR49.htm99940601 - Disclosure - Fair Value Measurements (Common Stock Warrant Liabilities) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetailsFair Value Measurements (Common Stock Warrant Liabilities) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables49 falsefalseR50.htm99940602 - Disclosure - Fair Value Measurements (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetailsFair Value Measurements (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables50 falsefalseR51.htm99940603 - Disclosure - Fair Value Measurements (Weighted average Significant Unobservable Inputs) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetailsFair Value Measurements (Weighted average Significant Unobservable Inputs) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables51 falsefalseR52.htm99940701 - Disclosure - Intangible Assets (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetailsIntangible Assets (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTables52 falsefalseR53.htm99940702 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetailsIntangible Assets (Schedule of Intangible Assets) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTables53 falsefalseR54.htm99940703 - Disclosure - Intangible Assets (Schedule of Future Amortization of Intangible Assets) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetailsIntangible Assets (Schedule of Future Amortization of Intangible Assets) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTables54 falsefalseR55.htm99940901 - Disclosure - Debt and Interest (Schedule of Debt) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetailsDebt and Interest (Schedule of Debt) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables55 falsefalseR56.htm99940902 - Disclosure - Debt and Interest (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetailsDebt and Interest (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables56 falsefalseR57.htm99940903 - Disclosure - Debt and Interest (Interest Expense) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetailsDebt and Interest (Interest Expense) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables57 falsefalseR58.htm99941001 - Disclosure - Accounts Payable and Accrued Expenses (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailsAccounts Payable and Accrued Expenses (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesTables58 falsefalseR59.htm99941101 - Disclosure - Non-Controlling Interests (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetailsNon-Controlling Interests (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureNonControllingInterests59 falsefalseR60.htm99941201 - Disclosure - Net Income (Loss) per Common Share (Schedule of Diluted Weighted Average Shares Outstanding) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetailsNet Income (Loss) per Common Share (Schedule of Diluted Weighted Average Shares Outstanding) (Details)Details60 falsefalseR61.htm99941301 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetailsStockholders' Equity (Stock-Based Compensation Expense) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables61 falsefalseR62.htm99941302 - Disclosure - Stockholders' Equity (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetailsStockholders' Equity (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables62 falsefalseR63.htm99941303 - Disclosure - Stockholders' Equity (Stock Option Activities) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetailsStockholders' Equity (Stock Option Activities) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables63 falsefalseR64.htm99941305 - Disclosure - Stockholders' Equity (Restricted Stock Awards and Restricted Stock Units) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetailsStockholders' Equity (Restricted Stock Awards and Restricted Stock Units) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables64 falsefalseR65.htm99941306 - Disclosure - Stockholders' Equity (Schedule of Warrant activities) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetailsStockholders' Equity (Schedule of Warrant activities) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables65 falsefalseR66.htm99941307 - Disclosure - Stockholders' Equity (Capital Raises) (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetailsStockholders' Equity (Capital Raises) (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables66 falsefalseR67.htm99941401 - Disclosure - Commitments and Contingencies (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetailsCommitments and Contingencies (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables67 falsefalseR68.htm99941402 - Disclosure - Commitments and Contingencies (Lease Expense) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetailsCommitments and Contingencies (Lease Expense) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables68 falsefalseR69.htm99941403 - Disclosure - Commitments and Contingencies (Quantitative Information about Operating Leases) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetailsCommitments and Contingencies (Quantitative Information about Operating Leases) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables69 falsefalseR70.htm99941404 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCommitments and Contingencies (Future Minimum Lease Payments) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables70 falsefalseR71.htm99941501 - Disclosure - Related Party Transactions (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetailsRelated Party Transactions (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables71 falsefalseR72.htm99941502 - Disclosure - Related Party Transactions (PIK Dividend or Equity Fee Payable) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetailsRelated Party Transactions (PIK Dividend or Equity Fee Payable) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables72 falsefalseR73.htm99941503 - Disclosure - Related Party Transactions (Management Services Agreement) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetailsRelated Party Transactions (Management Services Agreement) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables73 falsefalseR74.htm99941601 - Disclosure - Segment Information (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureSegmentInformationNarrativeDetailsSegment Information (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureSegmentInformationTables74 falsefalseR75.htm99941602 - Disclosure - Segment Information (Schedule of Segment Information) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetailsSegment Information (Schedule of Segment Information) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureSegmentInformationTables75 falsefalseR76.htm99941603 - Disclosure - Segment Information (Total assets by reportable segment) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetailsSegment Information (Total assets by reportable segment) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureSegmentInformationTables76 falsefalseR77.htm99941701 - Disclosure - Revenues from Contracts and Significant Customers (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetailsRevenues from Contracts and Significant Customers (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTables77 falsefalseR78.htm99941702 - Disclosure - Revenues from Contracts and Significant Customers (Company's product revenue) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetailsRevenues from Contracts and Significant Customers (Company's product revenue) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTables78 falsefalseR79.htm99941801 - Disclosure - Income Taxes (Narrative) (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetailsIncome Taxes (Narrative) (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureIncomeTaxes79 falsefalseR80.htm99941901 - Disclosure - Subsequent Events (Details)Sheethttp://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetailsSubsequent Events (Details)Detailshttp://www.fortressbiotech.com/role/DisclosureSubsequentEvents80 falsefalseAll ReportsBookAll Reports fbio-20240630.xsdfbio-20240630_cal.xmlfbio-20240630_def.xmlfbio-20240630_lab.xmlfbio-20240630_pre.xmlfbio-20240630x10q.htm http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 99 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "fbio-20240630x10q.htm": { "nsprefix": "fbio", "nsuri": "http://www.fortressbiotech.com/20240630", "dts": { "schema": { "local": ["fbio-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["fbio-20240630_cal.xml"] }, "definitionLink": { "local": ["fbio-20240630_def.xml"] }, "labelLink": { "local": ["fbio-20240630_lab.xml"] }, "presentationLink": { "local": ["fbio-20240630_pre.xml"] }, "inline": { "local": ["fbio-20240630x10q.htm"] } }, "keyStandard": 292, "keyCustom": 172, "axisStandard": 30, "axisCustom": 0, "memberStandard": 31, "memberCustom": 80, "hidden": { "total": 21, "http://fasb.org/us-gaap/2024": 13, "http://xbrl.sec.gov/dei/2024": 7,

{"http://www.fortressbiotech.com/20240630": 1 }, "contextCount": 388, "entityCount": 1, "segmentCount": 119, "elementCount": 816, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 994, "http://xbrl.sec.gov/dei/2024": 34, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - Unaudited Condensed Consolidated Balance Sheets", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R3": { "role": "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_nemifiiyZUWW17lJmOXVfA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_nemifiiyZUWW17lJmOXVfA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - Unaudited Condensed Consolidated Statements of Operations", "shortName": "Unaudited Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R5": { "role": "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit", "longName": "995200300 - Statement - Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit)", "shortName": "Unaudited Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sHc1Ae783UWH3VgaDH7hag", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sHc1Ae783UWH3VgaDH7hag", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R7": { "role": "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusiness", "longName": "995210101 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreements", "longName": "995210301 - Disclosure - Asset Purchase Agreements", "shortName": "Asset Purchase Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.fortressbiotech.com/role/DisclosureInventory", "longName": "995210401 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipment", "longName": "995210501 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurements", "longName": "995210601 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleNet", "longName": "995210701 - Disclosure - Intangible, net", "shortName": "Intangible, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.fortressbiotech.com/role/DisclosureLicenseAgreements", "longName": "995210801 - Disclosure - License Agreements", "shortName": "License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:LicensesAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:LicensesAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterest", "longName": "995210901 - Disclosure - Debt and Interest", "shortName": "Debt and Interest", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpenses", "longName": "995211001 - Disclosure - Accounts Payable and Accrued Expenses", "shortName": "Accounts Payable and Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.fortressbiotech.com/role/DisclosureNonControllingInterests", "longName": "995211101 - Disclosure - Non-Controlling Interests", "shortName": "Non-Controlling Interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",

"decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShare", "longName": "995211201 - Disclosure - Net Loss per Common Share", "shortName": "Net Loss per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquity", "longName": "995211301 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211401 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactions", "longName": "995211501 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformation", "longName": "995211601 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomers", "longName": "995211701 - Disclosure - Revenues from Contracts and Significant Customers", "shortName": "Revenues from Contracts and Significant Customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxes", "longName": "995211801 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.fortressbiotech.com/role/DisclosureSubsequentEvents", "longName": "995211901 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJOjOPhR02d7TtWmsMinQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJOjOPhR02d7TtWmsMinQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJOjOPhR02d7TtWmsMinQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.fortressbiotech.com/role/DisclosureInventoryTables", "longName": "99930403 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTables", "longName": "99930503 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "longName": "99930603 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_lmbt-vWFV0mWHo5Lxc_OKQ", "name": "fbio:ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_lmbt-vWFV0mWHo5Lxc_OKQ", "name": "fbio:ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTables", "longName": "99930703 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables", "longName": "99930903 - Disclosure - Debt and Interest (Tables)", "shortName": "Debt and Interest (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesTables", "longName": "99931003 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "isDefault":

"false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareTables", "longName": "99931203 - Disclosure - Net Loss per Common Share (Tables)", "shortName": "Net Loss per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables", "longName": "99931303 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99931403 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables", "longName": "99931503 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTables", "longName": "99931603 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTables", "longName": "99931703 - Disclosure - Revenues from Contracts and Significant Customers (Tables)", "shortName": "Revenues from Contracts and Significant Customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails", "longName": "99940101 - Disclosure - Organization and Description of Business (Narrative) (Details)", "shortName": "Organization and Description of Business (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:NumberOfPartnerCompaniesThatArePubliclyTraded", "unitRef": "Unit_Standard_company__bI0hiT0FU2-skXFqt5HfQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:NumberOfPartnerCompaniesThatArePubliclyTraded", "unitRef": "Unit_Standard_company__bI0hiT0FU2-skXFqt5HfQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)", "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_CreditFacilityAxis_fbio_DebtObligationsAndLettersOfCreditMember_Fwq3p0cXXUCymlDy8DN_0w", "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R44": { "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails", "longName": "99940202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)", "shortName": "Summary of Significant Accounting Policies (Schedule of Cash and Cash Equivalents) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_mLX8JxsyLEaPHelC-oIzgg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R45": { "role": "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "longName": "99940301 - Disclosure - Asset Purchase Agreements (Narrative) (Details)", "shortName": "Asset Purchase Agreements (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:OtherAccruedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_13_2024_To_5_13_2024_rKBjYoB-lEWSACeRzLzP1w", "name": "fbio:NumberOfDaysToDisposeOfAssetsPurchased", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R46": { "role": "http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails", "longName": "99940401 - Disclosure - Inventory (Schedule of Inventory) (Details)", "shortName": "Inventory (Schedule of Inventory) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "longName": "99940501 - Disclosure - Property and Equipment (Schedule of Property, Plant and Equipment) (Details)", "shortName": "Property and Equipment (Schedule of Property, Plant and Equipment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "longName": "99940502 - Disclosure - Property and Equipment (Narrative) (Details)", "shortName": "Property and Equipment (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "longName": "99940601 - Disclosure - Fair Value Measurements (Common Stock Warrant Liabilities) (Details)", "shortName": "Fair Value Measurements (Common Stock Warrant Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_12_31_2023_sDyI-ntcIU-oEuGBmXCYfA", "name": "fbio:WarrantLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3",

```
"ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_ConsolidatedEntitiesAxis_fbio_CheckpointMember_us-gaap_FinancialInstrumentAxis_fbio_CommonStockWarrantsMember_OlqzsEZuBU2gyqh0TnBu8A", "name": "fbio:ExerciseOfCommonStockWarrants", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R50": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "longName": "99940602 - Disclosure - Fair Value Measurements (Narrative) (Details)", "shortName": "Fair Value Measurements (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_12_30_2022_To_12_30_2022_WzR1etXCCk-4btb9bCDyDA", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_27_2024_To_6_27_2024_srt_ConsolidatedEntitiesAxis_fbio_Ur1TherapeuticsIncMember_us-gaap_ClassOfWarrantOrRightAxis_fbio_CommonStockWarrantsMember_28pLyqKg8ky5wgGM1J4u0w", "name": "fbio:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExchanged", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R51": { "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "longName": "99940603 - Disclosure - Fair Value Measurements (Weighted average Significant Unobservable Inputs) (Details)", "shortName": "Fair Value Measurements (Weighted average Significant Unobservable Inputs) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_6_30_2024_srt_ConsolidatedEntitiesAxis_fbio_CheckpointMember_us-gaap_FinancialInstrumentAxis_fbio_SeriesWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_nrUEGiiA1U6RPJBhBaTcAA", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Divide_USD_shares_nemifiiyZUWW17IJmOXVfA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_ConsolidatedEntitiesAxis_fbio_CheckpointMember_us-gaap_FinancialInstrumentAxis_fbio_SeriesWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_nrUEGiiA1U6RPJBhBaTcAA", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Divide_USD_shares_nemifiiyZUWW17IJmOXVfA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "longName": "99940701 - Disclosure - Intangible Assets (Narrative) (Details)", "shortName": "Intangible Assets (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSiIA", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_ConsolidatedEntitiesAxis_fbio_JourneyMember_fVehrIU52kejwaPGZcaUXA", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R53": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "longName": "99940702 - Disclosure - Intangible Assets (Schedule of Intangible Assets) (Details)", "shortName": "Intangible Assets (Schedule of Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:AssetImpairmentCharges", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_fbio_JourneyMember_QQcUwy6IskuIJjOMKvTWNg", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R54": { "role": "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "longName": "99940703 - Disclosure - Intangible Assets (Schedule of Future Amortization of Intangible Assets) (Details)", "shortName": "Intangible Assets (Schedule of Future Amortization of Intangible Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_ConsolidatedEntitiesAxis_fbio_JourneyMember_GyLLO5onbUS8r6kSUWttnQ", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R55": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "longName": "99940901 - Disclosure - Debt and Interest (Schedule of Debt) (Details)", "shortName": "Debt and Interest (Schedule of Debt) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_DebtInstrumentAxis_fbio_OaktreeNoteMember_fi7uZDBaRU6uVzUl1ZzmJQ", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Unit_Standard_pure_ne0zVeQPBkidlJ2vnwzzvQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R56": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "longName": "99940902 - Disclosure - Debt and Interest (Narrative) (Details)", "shortName": "Debt and Interest (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_27_2020_To_8_27_2020_us-gaap_DebtInstrumentAxis_fbio_OaktreeNoteMember_Ff_U1sbS-kiIh5wCdr1K2g", "name": "us-gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R57": { "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "longName": "99940903 - Disclosure - Debt and Interest (Interest Expense) (Details)", "shortName": "Debt and Interest (Interest Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "longName": "99941001 - Disclosure - Accounts Payable and Accrued Expenses (Details)", "shortName": "Accounts Payable and Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "longName": "99941101 - Disclosure - Non-Controlling Interests (Details)", "shortName": "Non-Controlling Interests (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_6_30_2024_srt_OwnershipAxis_fbio_MustangTherapeuticsIncMember_xgOnvcegW0iQwh0O4nAETA", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "Unit_Standard_pure_ne0zVeQPBkidlJ2vnwzzvQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_OwnershipAxis_fbio_MustangTherapeuticsIncMember_xgOnvcegW0iQwh0O4nAETA", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "Unit_Standard_pure_ne0zVeQPBkidlJ2vnwzzvQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails", "longName": "99941201 - Disclosure - Net Income (Loss) per Common Share (Schedule of Diluted Weighted Average Shares Outstanding) (Details)", "shortName": "Net Income (Loss) per Common Share (Schedule of Diluted Weighted Average Shares Outstanding) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "fbio:EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "fbio:EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "longName": "99941301 - Disclosure - Stockholders' Equity (Stock-Based Compensation Expense) (Details)", "shortName": "Stockholders' Equity (Stock-Based Compensation Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_ConsolidatedEntitiesAxis_fbio_AvenueTherapeuticsIncMember_U85ADsccRUacO_dGKweNsQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
```

"p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R62": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "longName": "99941302 - Disclosure - Stockholders' Equity (Narrative) (Details)", "shortName": "Stockholders' Equity (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_PlanNameAxis_fbio_TwoThousandThirteenStockIncentivePlanMember_PYSWzBOww0ynz3mZiYvgTw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R63": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "longName": "99941303 - Disclosure - Stockholders' Equity (Stock Option Activities) (Details)", "shortName": "Stockholders' Equity (Stock Option Activities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_12_31_2023_sDyI-ntcIU-oEuGBmXCYfA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R64": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails", "longName": "99941305 - Disclosure - Stockholders' Equity (Restricted Stock Awards and Restricted Stock Units) (Details)", "shortName": "Stockholders' Equity (Restricted Stock Awards and Restricted Stock Units) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AwardTypeAxis_fbio_RestrictedStockAndRestrictedStockUnitsMember_g9qjPHCSOkq_7_6agOUeZg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AwardTypeAxis_fbio_RestrictedStockAndRestrictedStockUnitsMember_g9qjPHCSOkq_7_6agOUeZg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails", "longName": "99941306 - Disclosure - Stockholders' Equity (Schedule of Warrant activities) (Details)", "shortName": "Stockholders' Equity (Schedule of Warrant activities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "longName": "99941307 - Disclosure - Stockholders' Equity (Capital Raises) (Narrative) (Details)", "shortName": "Stockholders' Equity (Capital Raises) (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_12_30_2022_To_12_30_2022_WzR1etXCCk-4btb9bCDyDA", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_CounterpartyNameAxis_fbio_MlvCo.AndFbrCapitalMarketsCoMember_us-gaap_SubsidiarySaleOfStockAxis_fbio_MarketOfferingMember_APm-5WnfP0mrnNemo2Lixw", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R67": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "longName": "99941401 - Disclosure - Commitments and Contingencies (Narrative) (Details)", "shortName": "Commitments and Contingencies (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:ProceedsFromPreviousAcquisition", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R68": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails", "longName": "99941402 - Disclosure - Commitments and Contingencies (Lease Expense) (Details)", "shortName": "Commitments and Contingencies (Lease Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetails", "longName": "99941403 - Disclosure - Commitments and Contingencies (Quantitative Information about Operating Leases) (Details)", "shortName": "Commitments and Contingencies (Quantitative Information about Operating Leases) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "fbio:LesseeLeasePortfolioAndOtherSupplementalLeaseInformation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "fbio:LesseeLeasePortfolioAndOtherSupplementalLeaseInformation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails", "longName": "99941404 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)", "shortName": "Commitments and Contingencies (Future Minimum Lease Payments) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "longName": "99941501 - Disclosure - Related Party Transactions (Narrative) (Details)", "shortName": "Related Party Transactions (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_nemifiiyZUWW17IJmOXVfA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_ConsolidatedEntitiesAxis_fbio_JourneyMember_fVehrIU52keJwaPGZcaUXA", "name": "fbio:ProceedsFromRelatedPartyAgreement", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R72": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails", "longName": "99941502 - Disclosure - Related Party Transactions (PIK Dividend or Equity Fee Payable) (Details)", "shortName": "Related Party Transactions (PIK Dividend or Equity Fee Payable) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_ConsolidatedEntitiesAxis_fbio_AvenueTherapeuticsIncMember_A5es0duOz06g-cFYN935tA", "name": "fbio:PaymentInKindDividendsOrEquityFeePayableEffectiveDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "fbio:ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_ConsolidatedEntitiesAxis_fbio_AvenueTherapeuticsIncMember_A5es0duOz06g-cFYN935tA", "name": "fbio:PaymentInKindDividendsOrEquityFeePayableEffectiveDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "fbio:ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "longName": "99941503 - Disclosure - Related Party Transactions (Management Services Agreement) (Details)", "shortName": "Related Party Transactions (Management Services Agreement) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:AnnualManagementServicesAgreementFeeIncome", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "fbio:AnnualManagementServicesAgreementFeeIncome", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-

20240630x10q.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformationNarrativeDetails", "longName": "99941601 - Disclosure - Segment Information (Narrative) (Details)", "shortName": "Segment Information (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_nl3FwZPalUq-ojWpppq5zA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_YUMM9-IBPEK-YpwlkLSilA", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_nl3FwZPalUq-ojWpppq5zA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "longName": "99941602 - Disclosure - Segment Information (Schedule of Segment Information) (Details)", "shortName": "Segment Information (Schedule of Segment Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R76": { "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails", "longName": "99941603 - Disclosure - Segment Information (Total assets by reportable segment) (Details)", "shortName": "Segment Information (Total assets by reportable segment) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_CbtqKsRPQEeXF0kdBEfxrw", "name": "fbio:TangibleAssetsNet", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R77": { "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "longName": "99941701 - Disclosure - Revenues from Contracts and Significant Customers (Narrative) (Details)", "shortName": "Revenues from Contracts and Significant Customers (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_StatementBusinessSegmentsAxis_fbio_DermatologyProductsSalesMember_iSqB7oMOAEqE9yubr3llCg", "name": "fbio:NumberOfCustomers", "unitRef": "Unit_Standard_customer_2L6zA-8VakOPozjcZZAhcg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["fbio:NumberOfCustomers", "fbio:NumberOfCustomers", "fbio:NumberOfCustomers", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_StatementBusinessSegmentsAxis_fbio_DermatologyProductsSalesMember_iSqB7oMOAEqE9yubr3llCg", "name": "fbio:NumberOfCustomers", "unitRef": "Unit_Standard_customer_2L6zA-8VakOPozjcZZAhcg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["fbio:NumberOfCustomers", "fbio:NumberOfCustomers", "fbio:NumberOfCustomers", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanysProductRevenueDetails", "longName": "99941702 - Disclosure - Revenues from Contracts and Significant Customers (Company's product revenue) (Details)", "shortName": "Revenues from Contracts and Significant Customers (Company's product revenue) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_fbio_QbrexzaMember_tuOBvWj9Dkm65StWUzPymw", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R79": { "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "longName": "99941801 - Disclosure - Income Taxes (Narrative) (Details)", "shortName": "Income Taxes (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_yhBwMJQrukWu0c8PrZjeqw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_mOJQjOPhR02d7TtWmsMinQ", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Unit_Standard_pure_ne0zVeQPBkidlJ2vnwzzvQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["us-gaap:EffectiveIncomeTaxRateContinuingOperations", "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } }, "R80": { "role": "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "longName": "99941901 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "Duration_12_30_2022_To_12_30_2022_WzR1etXCCk-4btb9bCDyDA", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Unit_Standard_shares_irtcvh0MZU-yex5uqIBI8Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_1_31_2024_srt_ConsolidatedEntitiesAxis_fbio_CheckpointMember_us-gaap_ClassOfWarrantOrRightAxis_fbio_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_fbio_DirectOfferingMember_Op5nmaGvIkKKwsnEY09D8g", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "Unit_Divide_USD_shares_nemifiiyZUWW17lJmOXVfA", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "fbio-20240630x10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "fbio_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AccountingPoliciesLineItems", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "fbio_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AccountingPoliciesTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Table]", "label": "Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Other receivables - related party", "verboseLabel": "Receivable", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r58", "r59"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpenses"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accounts Payable and Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r56", "r59", "r65", "r1054"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r56", "r841"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r769"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r998"] }, "fbio_AccretionOfPartnerCompanyConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AccretionOfPartnerCompanyConvertiblePreferredShares", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Accretion of partner company convertible preferred shares.", "label": "Accretion of partner company convertible preferred shares", "terseLabel": "Accretion of partner company convertible preferred shares" } } }, "auth_ref": [] }, "fbio_AccruedCouponExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AccruedCouponExpenseCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of accrued coupon expense which is classified as current.", "label": "Accrued Coupon Expense Current", "verboseLabel": "Accrued coupon and rebates" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Total accounts payable and accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r59"] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"AccruedLiabilitiesCurrentAbstract", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses:" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } }, "auth_ref": ["r59"] }, "fbio_AccruedResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AccruedResearchAndDevelopmentExpense", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Research and Development Expense", "label": "Accrued Research And Development Expense", "verboseLabel": "Research and development" } } }, "auth_ref": [] }, "fbio_AccruedReturnReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AccruedReturnReserveCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued return reserve, current.", "label": "Accrued Return Reserve Current", "terseLabel": "Return reserve" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r59", "r790"] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Salaries, Current", "verboseLabel": "Salaries, bonus and related benefits", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r59", "r790"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r35", "r145", "r620"] }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "verboseLabel": "Accumulated Deficit", "documentation": "Cumulative distributions to shareholders (or partners) in excess of retained earnings (or accumulated earnings)." } } }, "auth_ref": [] }, "fbio_AccutaneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AccutaneMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Accutane [Member]", "label": "Accutane" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r907"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r70", "r841", "r1118"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital [Member]", "verboseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r671", "r985", "r986", "r987", "r989", "r1060", "r1119"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r920"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r920"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r920"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r920"] }, "fbio_AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Amount of decrease/increase in additional paid in capital (APIC) and non controlling interest in subsidiaries.", "label": "Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance", "negatedLabel": "Non-controlling interest in partner companies" } } }, "auth_ref": [] }, "fbio_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfCommonStock", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of common stock.", "label": "Adjustments To Additional Paid In Capital Dividends In Excess Of Common Stock", "negatedLabel": "Partner company's dividends declared and paid" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings", "negatedLabel": "Preferred A dividends declared and paid", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance." } } }, "auth_ref": ["r8", "r108"] }, "fbio_AdjustmentsToAdditionalPaidInCapitalExerciseOfPartnerCompanyOptionsAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfPartnerCompanyOptionsAndWarrants", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the exercise of partner company options and warrants.", "label": "Adjustments to Additional Paid in Capital, Exercise of Partner Company Options and Warrants", "terseLabel": "Exercise of partner company options and warrants for cash, net" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Employee Stock Purchase Program, Requisite Service Period Recognition", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement." } } }, "auth_ref": [] }, "fbio_AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital resulting from stock issuance for research and development expenses.", "label": "Adjustments To Additional Paid In Capital Stock Issued For research and development expenses", "verboseLabel": "Issuance of partner company's common shares for research and development expenses" } } }, "auth_ref": [] }, "fbio_AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from subsidiary's at market offering costs.", "label": "Adjustments To Additional Paid In Capital Subsidiary At Market Offering", "verboseLabel": "Partner company's at-the-market offering, net" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Reconciliation of net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r953"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r879", "r889", "r899", "r931"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r882", "r892", "r902", "r934"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r954"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r920"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r927"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r883", "r893", "r903", "r927", "r935", "r939", "r947"] },

"ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r945"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r433", "r435"] }, "fbio_AmendedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AmendedWarrantsMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to amended warrants.", "label": "Amended Warrants [Member]", "terseLabel": "Amended Warrants" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r5", "r84", "r372", "r1070"] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails",
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of fees", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": ["r84", "r372", "r981", "r1070"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of acquired intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r5", "r305", "r313", "r809"] }, "fbio_AmzeeqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AmzeeqMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanysProductRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Amzeeq product.", "label": "Amzeeq", "terseLabel": "Amzeeq" } } }, "auth_ref": [] }, "fbio_AnnualCashDividendPerSharePayable": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AnnualCashDividendPerSharePayable", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Annual cash dividend payable per share.", "label": "Annual Cash Dividend Per Share Payable", "terseLabel": "Annual cash dividend payable" } } }, "auth_ref": [] },
"fbio_AnnualConsultingFeePayableEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AnnualConsultingFeePayableEffectiveDate", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Effective Date the consulting fee to be paid.", "label": "Annual Consulting Fee Payable Effective Date", "verboseLabel": "Effective date" } } }, "auth_ref": [] },
"fbio_AnnualEquityFeeAsPercentageOfFullyDilutedOutstandingCapitalization": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AnnualEquityFeeAsPercentageOfFullyDilutedOutstandingCapitalization", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails"], "lang": { "en-us": { "role": { "documentation": "Annual equity fee as a percentage of fully diluted outstanding capitalization", "label": "Annual equity fee as a percentage of fully diluted outstanding capitalization", "terseLabel": "Annual equity fee as a percentage of fully diluted outstanding capitalization" } } }, "auth_ref": [] }, "fbio_AnnualManagementServicesAgreementFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AnnualManagementServicesAgreementFeeExpense", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Annual Management Services Agreement Fee expense.", "label": "Annual Management Services Agreement Fee expense", "terseLabel": "Partner companies, MSA fee expense" } } }, "auth_ref": [] }, "fbio_AnnualManagementServicesAgreementFeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AnnualManagementServicesAgreementFeeIncome", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Annual Management Services Agreement Fee Income", "label": "Annual Management Services Agreement Fee Income", "negatedLabel": "Fortress - MSA Income" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities excluded from the computations of diluted weighted average shares outstanding", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r206"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r24"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r24"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Arrangements and Non-arrangement Transactions [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r462"] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": ["r306", "r307", "r308", "r309", "r311", "r1056"] }, "fbio_AssetAcquisitionConsiderationInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionConsiderationInCash", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of cash consideration to be transferred in asset acquisition.", "label": "Asset Acquisition, Consideration in Cash", "terseLabel": "Consideration Transferred" } } }, "auth_ref": [] },
"fbio_AssetAcquisitionConsiderationSubsequentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionConsiderationSubsequentPayment", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of subsequent payment for asset acquisition consideration.", "label": "Asset Acquisition Consideration, Subsequent Payment", "terseLabel": "Subsequent amount" } } }, "auth_ref": [] },
"fbio_AssetAcquisitionConsiderationSubsequentPaymentDuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionConsiderationSubsequentPaymentDuePeriod", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Period when subsequent payment for asset acquisition becomes due.", "label": "Asset Acquisition Consideration, Subsequent Payment, Due Period", "terseLabel": "Subsequent payment due period" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionConsiderationSubsequentPaymentExtendedDuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionConsiderationSubsequentPaymentExtendedDuePeriod", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Extended Period for subsequent payment for asset acquisition due.", "label": "Asset Acquisition Consideration, Subsequent Payment, Extended Due Period", "terseLabel": "Subsequent payment extended due period" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionConsiderationThresholdNetAssetsConsideredForDelayInSubsequentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionConsiderationThresholdNetAssetsConsideredForDelayInSubsequentPayment", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold amount of net assets considered for delay in payment of deferred amount under the asset acquisition transaction.", "label": "Asset Acquisition Consideration, Threshold Net Assets Considered For Delay In Subsequent Payment", "terseLabel": "Asset acquisition consideration, threshold net assets considered for delay in subsequent payment" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": ["r825", "r1057", "r1058", "r1059"] }, "fbio_AssetAcquisitionConsiderationTransferredInExcessOfFairValueOfAssetsAllocatedToSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionConsiderationTransferredInExcessOfFairValueOfAssetsAllocatedToSupplies", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of consideration in excess of fair value of the asset allocated to supplies repurchased.", "label": "Asset Acquisition, Consideration Transferred, in Excess of Fair Value of Assets, Allocated to Supplies", "terseLabel": "Remaining purchase consideration allocated to the supplies repurchased" } } }, "auth_ref": [] },
"fbio_AssetAcquisitionConsiderationUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionConsiderationUpfrontPayment", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of upfront payment for asset acquisition consideration.", "label": "Asset Acquisition Consideration, Upfront Payment", "terseLabel": "Upfront payment" } } }, "auth_ref": [] },
"fbio_AssetAcquisitionConsiderationUpfrontPaymentDuePeriod": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionConsiderationUpfrontPaymentDuePeriod", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"],

"lang": { "en-us": { "role": { "documentation": "Number of business days within which the upfront payment for asset acquisition consideration is to be made.", "label": "Asset Acquisition Consideration, Upfront Payment, Due Period", "terseLabel": "Upfront payment due period" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]",
"documentation": "Asset acquisition." } } }, "auth_ref": ["r306", "r307", "r308", "r309", "r311", "r1056"] }, "fbio_AssetAcquisitionInterestRateOnOutstandingLiability": {
"xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionInterestRateOnOutstandingLiability", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents percentage of interest accrual on outstanding liability in asset acquisition transaction.", "label": "Asset Acquisition, Interest Rate on Outstanding Liability", "terseLabel": "Interest rate on outstanding liability" } } }, "auth_ref": [] }, "fbio_AssetAcquisitionPercentageOfCommonStockIssued": { "xbrltype": "percentItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "AssetAcquisitionPercentageOfCommonStockIssued", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of common stock issued to the company, pursuant to asset acquisition arrangement.", "label": "Asset Acquisition, Percentage Of Common Stock Issued", "terseLabel": "Percentage of equity to be held" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges",
"crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
"http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "negatedLabel": "Asset impairment", "terseLabel": "Asset impairment", "verboseLabel": "Impairment loss", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r5", "r33"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r114", "r124", "r148", "r173", "r210", "r218", "r237", "r241", "r280", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r464", "r468", "r499", "r610", "r708", "r801", "r802", "r841", "r870", "r1019", "r1020", "r1077"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [
"r141", "r154", "r173", "r280", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r464", "r468", "r499", "r841", "r1019", "r1020", "r1077"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]",
"terseLabel": "Current assets" } } }, "auth_ref": [] }, "fbio_AssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630",
"localname": "AssetsHeldForSale", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount representing assets held for sale.", "label": "Assets held for sale", "terseLabel": "Assets held for sale" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current", "terseLabel": "Aggregate value of assets and associated supplies met the criteria to be classified as held for sale at the date of acquisition", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": ["r100", "r841"] }, "fbio_AssetsHeldForSalePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"AssetsHeldForSalePolicyTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": {
"role": { "documentation": "Disclosure of accounting policy for assets held for sale.", "label": "Assets Held For Sale Policy Text Block", "terseLabel": "Assets Held for Sale" } }
}, "auth_ref": [] }, "fbio_AvenueTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"AvenueTherapeuticsIncMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Avenue Therapeutics, Inc.", "label": "Avenue Therapeutics, Inc [Member]", "terseLabel": "Avenue" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r942"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": {
"label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r943"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r938"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r938"] },
"ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } },
"auth_ref": ["r938"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r938"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r938"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": {
"role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r938"] }, "us-gaap_AwardTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": {
"en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } },
"auth_ref": ["r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r941"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": {
"role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r940"] }, "ecd_AwardsCloseToMnpiDiscTable": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r939"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [
"r939"] }, "fbio_BaergicMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "BaergicMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails"], "lang": { "en-us": { "role": { "documentation": "n/a",
"label": "Baergic [Member]", "terseLabel": "Baergic" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation and Principles of Consolidation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } },
"auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Buildings",
"documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": ["r101"] },
"fbio_CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., Jones Trading Institutional Services LLC. B. Riley And Dawson James Securities, Inc", "label": "Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., Jones Trading Institutional Services LLC. B. Riley and Dawson James Securities, Inc [Member]" } } }, "auth_ref": [] },
"us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash

and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r18", "r143", "r788"] }, "fbio_CashAndCashEquivalentsParentCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CashAndCashEquivalentsParentCompany", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits for the parent company. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents, Parent Company" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r19", "r113"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash and cash equivalents and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r18", "r90", "r170"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r90"] }, "fbio_CellvationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CellvationMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails"], "lang": { "en-us": { "role": { "label": "Cellvation [Member]", "terseLabel": "Cellvation" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r918"] }, "fbio_CheckpointMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CheckpointMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Checkpoint.", "label": "Checkpoint [Member]", "terseLabel": "Checkpoint Common Stock Warrants", "verboseLabel": "Checkpoint" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer (Dr. Rosenwald) [Member]", "terseLabel": "Chief Executive Officer (Dr. Rosenwald)" } } }, "auth_ref": ["r997"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r915"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r913"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r136", "r150", "r151", "r152", "r173", "r199", "r200", "r203", "r205", "r212", "r213", "r280", "r341", "r343", "r344", "r345", "r348", "r349", "r381", "r382", "r384", "r385", "r387", "r499", "r660", "r661", "r662", "r663", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r696", "r717", "r740", "r762", "r763", "r764", "r765", "r766", "r957", "r982", "r990"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r42"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightExercisable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right Exercisable.", "label": "Class Of Warrant Or Right Exercisable", "terseLabel": "Warrants exercisable, Number of shares" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right exercisable, Weighted Average Exercise Price", "label": "Class Of Warrant Or Right exercisable, Weighted Average Exercise Price", "terseLabel": "Warrants exercisable, Weighted average exercise price" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right exercisable, Weighted average intrinsic value", "label": "Class of Warrant or Right exercisable, Weighted average intrinsic value", "terseLabel": "Warrants exercisable, Weighted average intrinsic value" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right exercisable, Weighted Average remaining contractual life", "label": "Class Of Warrant Or Right exercisable, Weighted Average remaining contractual life", "terseLabel": "Warrants exercisable, Weighted average remaining contractual life" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r388"] }, "fbio_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAgreedByInvestor": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAgreedByInvestor", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights agreed by investor.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights Agreed by Investor", "verboseLabel": "Exercise price of warrants agreed by investor" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right Expired, Weighted Average Exercise Price", "label": "Class Of Warrant Or Right Expired, Weighted Average Exercise Price", "terseLabel": "Warrants expired, Weighted average exercise price" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right granted, Weighted average exercise price", "label": "Class of Warrant or Right granted, Weighted average exercise price", "terseLabel": "Warrants granted, Weighted

average exercise price" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right granted, Weighted average intrinsic value.", "label": "Class of Warrant or Right granted, Weighted average intrinsic value", "terseLabel": "Warrants granted, Weighted average intrinsic value" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares called by warrants", "verboseLabel": "Number of shares called by warrants", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued", "verboseLabel": "Number of warrants to purchase shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r388"] }, "fbio_ClassOfWarrantOrRightNumberOfSharesExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightNumberOfSharesExercised", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Number of shares Exercised.", "label": "Warrants exercised, Number of shares", "terseLabel": "Warrants exercised, Number of shares" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightNumberOfSharesGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightNumberOfSharesGranted", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Number of shares granted.", "label": "Class Of Warrant Or Right, Number of shares granted", "terseLabel": "Warrants granted, Number of shares" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExchanged": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsExchanged", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exchanged during the period.", "label": "Class Of Warrant Or Right, Number Of Warrants Or Rights Exchanged", "terseLabel": "Exchanged for warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Outstanding warrants", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "decimalItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Value of securities into which the class of warrant or right may be converted.", "label": "Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights", "verboseLabel": "Class of warrant or right value of securities called by warrants or rights" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Weighted average exercise price", "label": "Class of Warrant or Right, Weighted average exercise price", "verboseLabel": "Warrants outstanding, Weighted average exercise price" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightWeightedAverageIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightWeightedAverageIntrinsicValue", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Weighted average intrinsic value.", "label": "Class of Warrant or Right, Weighted average intrinsic value", "verboseLabel": "Warrants outstanding, Weighted average intrinsic value" } } }, "auth_ref": [] }, "fbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityScheduleOfWarrantActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Weighted Average Remaining Contractual Life", "label": "Class Of Warrant Or Right, Weighted Average Remaining Contractual Life", "terseLabel": "Warrants, Weighted average remaining contractual life" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r919"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r919"] }, "fbio_CollaborationAndStockPurchaseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CollaborationAndStockPurchaseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Asset Purchase Agreements" } } }, "auth_ref": [] }, "fbio_CollaborationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CollaborationRevenue", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Collaboration revenue.", "label": "Collaboration revenue", "verboseLabel": "Collaboration revenue" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 14)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r66", "r117", "r612", "r695"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r103", "r333", "r334", "r770", "r1008", "r1013"] }, "fbio_CommonSharesIssuableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CommonSharesIssuableMember", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Common shares that are issuable", "label": "Common Shares Issuable [Member]", "terseLabel": "Common Shares Issuable" } } }, "auth_ref": [] }, "fbio_CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during period for dividend on partner company's convertible preferred shares.", "label": "Common shares issued for dividend on partner company's convertible preferred shares", "terseLabel": "Common shares issued for dividend on partner company's convertible preferred shares" } } }, "auth_ref": [] }, "fbio_CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredSharesInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredSharesInShares", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "It represents the stock issued during period shares issued for partner company's convertible preferred shares.", "label": "Common shares issued for dividend on partner company's convertible preferred shares (in shares)" } } }, "auth_ref": [] }, "fbio_CommonSharesIssuedForExchangeOfPartnerCompanyConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CommonSharesIssuedForExchangeOfPartnerCompanyConvertiblePreferredShares", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Fair value of common shares issued for exchange of partner company's convertible preferred shares.", "label": "Common Shares Issued For Exchange Of Partner Company Convertible Preferred Shares", "terseLabel": "Common shares issued for dividend on partner company's convertible preferred shares" } } }, "auth_ref": [] }, "fbio_CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredShares", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during period for exchange of partner company's convertible preferred shares.", "label": "Common shares issued for exchange of partner company's convertible preferred shares" } } }, "auth_ref": [] }, "fbio_CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredSharesInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CommonSharesIssuedForExchangeOfPartnerCompanySConvertiblePreferredSharesInShares", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "It represents the stock issued during period shares issued for exchange of partner company's convertible preferred shares.", "label": "Common shares issued for exchange of partner company's convertible preferred shares (in shares)" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r860", "r861", "r862", "r864", "r865", "r866", "r867", "r985", "r986", "r989", "r1060", "r1117", "r1119"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r69"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares

Authorized", "terseLabel": "Common Stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r69", "r696"] }, "fbio_CommonStockSharesAvailableForFutureIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CommonStockSharesAvailableForFutureIssuanceValue", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents value of shares available for future issue.", "label": "Common Stock Shares Available For Future Issuance Value", "verboseLabel": "Amount available for future stock offerings" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r69"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r8", "r69", "r696", "r714", "r1119", "r1120"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized, 22,587,038 and 15,093,053 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r69", "r615", "r841"] }, "fbio_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CommonStockWarrantsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to common stock warrants.", "label": "Common Stock Warrants [Member]", "terseLabel": "Common Stock Warrant" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r924"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r923"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r925"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r922"] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r25", "r26", "r50", "r51", "r248", "r769"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r25", "r26", "r50", "r51", "r248", "r658", "r769"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r25", "r26", "r50", "r51", "r248", "r769", "r962"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r25", "r26", "r50", "r51", "r248"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r25", "r26", "r50", "r51", "r248", "r769"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r179", "r464", "r465", "r468", "r469", "r534", "r775", "r1018", "r1021", "r1022"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": ["r179", "r464", "r465", "r468", "r469", "r534", "r775", "r1018", "r1021", "r1022"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Construction in progress [Member]", "terseLabel": "Construction in progress", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "fbio_ContingentPaymentWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ContingentPaymentWarrantMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "documentation": "Contingent Payment Warrant [Member]", "label": "Contingent Payment Warrant [Member]", "terseLabel": "Contingent Payment Warrants" } } }, "auth_ref": [] }, "fbio_ConvertibleClassBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ConvertibleClassBPreferredStockMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Class B preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Class B Preferred Stock [Member]", "terseLabel": "8% Cumulative Convertible Class B Preferred Offering" } } }, "auth_ref": [] }, "fbio_ConvertiblePreferredSharesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ConvertiblePreferredSharesCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to convertible preferred shares. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Convertible Preferred Shares, Current", "terseLabel": "Partner company convertible preferred shares, short-term, net" } } }, "auth_ref": [] }, "fbio_ConvertiblePreferredStockConversionMinimumGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ConvertiblePreferredStockConversionMinimumGrossProceeds", "crdr": "credit", "presentation": [

"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of minimum gross proceeds from convertible preferred stock.", "label": "Convertible Preferred Stock, Conversion, Minimum Gross Proceeds", "terseLabel": "Aggregate gross proceeds from convertible preferred stock" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "negatedLabel": "Cost of goods - product revenue", "terseLabel": "Cost of goods sold - product revenue", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r79", "r80", "r571"] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total operating expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r86"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r177", "r178", "r354", "r383", "r532", "r554", "r609", "r791", "r793"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r340", "r1016"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r340", "r1016", "r1017"] }, "fbio_CrystalysTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CrystalysTherapeuticsIncMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Crystalys Therapeutics, Inc.", "label": "Crystalys Therapeutics, Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_CumulativePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CumulativePreferredStockMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "8% Cumulative Convertible Preferred Stock [Member]", "documentation": "Preferred stock upon which unpaid dividends accumulate until paid to shareholders. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r96", "r248"] }, "fbio_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CustomerOneMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Customer one [Member]", "label": "Customer One" } } }, "auth_ref": [] }, "fbio_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CustomerTwoMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Customer Two [Member]", "label": "Customer Two" } } }, "auth_ref": [] }, "fbio_CypriumMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "CypriumMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Cyprium Therapeutics, Inc.", "label": "Cyprium [Member]", "terseLabel": "Cyprium" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt and Interest" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterest"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt and Interest", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r104", "r172", "r324", "r325", "r326", "r327", "r328", "r339", "r340", "r350", "r356", "r357", "r358", "r359", "r360", "r361", "r366", "r373", "r374", "r376", "r508"] }, "fbio_DebtDiscountAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtDiscountAmortization", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of debt discount amortization attributable to debt issuance costs.", "label": "Debt Discount Amortization" } } }, "auth_ref": [] }, "fbio_DebtInstrumentAggregateCommonEquityOrCashDistributionsToBeReceivedAsPercentageOfAmountSetForthInAnnualBudget": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentAggregateCommonEquityOrCashDistributionsToBeReceivedAsPercentageOfAmountSetForthInAnnualBudget", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold amount of aggregate common equity or cash distributions to be received as per the debt agreement, as a percentage of amount set forth in annual budget delivered to the Lenders.", "label": "Debt Instrument, Aggregate Common Equity or Cash Distributions to be Received, As A Percentage of Amount Set Forth In Annual Budget", "terseLabel": "Percentage of amount set forth in annual budget" } } }, "auth_ref": [] }, "fbio_DebtInstrumentAggregateOfPrincipalPrepaymentAmountInMultiples": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentAggregateOfPrincipalPrepaymentAmountInMultiples", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Aggregate of prepayment of principal amount of loans to be paid in multiples at time of the happening of certain circumstances.", "label": "Debt Instrument, Aggregate of Principal Prepayment Amount in Multiples", "terseLabel": "Debt instrument, aggregate of principal prepayment amount in multiples" } } }, "auth_ref": [] }, "fbio_DebtInstrumentAggregateOfPrincipalPrepaymentAmountMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentAggregateOfPrincipalPrepaymentAmountMinimum", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Aggregate of minimum principal amount of loans to be prepaid at the happening of certain circumstances.", "label": "Debt Instrument, Aggregate of Principal Prepayment Amount, Minimum", "terseLabel": "Debt instrument, aggregate of principal prepayment amount, minimum" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r12", "r58", "r59", "r115", "r116", "r179", "r351", "r352", "r353", "r354", "r355", "r357", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r810", "r811", "r812", "r813", "r814", "r839", "r983", "r1009", "r1010", "r1011", "r1069", "r1071"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "verboseLabel": "Basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "fbio_DebtInstrumentCapRate": { "xbrltype": "pureItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentCapRate", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents variable interest cap rate of debt.", "label": "Debt Instrument, Cap Rate", "terseLabel": "Debt instrument, cap rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Gross", "verboseLabel": "Total notes payable, gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r12", "r116", "r377"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r351", "r508", "r509", "r811", "r812", "r839"] }, "fbio_DebtInstrumentFloorRate": { "xbrltype": "pureItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentFloorRate", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents variable interest floor rate of debt.", "label": "Debt Instrument, Floor Rate", "terseLabel": "Debt instrument, floor rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "verboseLabel": "Debt, effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r61", "r379", "r508", "r509", "r839"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r61", "r352"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]",

"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r179", "r351", "r352", "r353", "r354", "r355", "r357", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r810", "r811", "r812", "r813", "r814", "r839", "r983", "r1069", "r1071"] },
"fbio_DebtInstrumentMandatoryPrepaymentExcessProceedsFromAnyOfCompanySSubsidiariesOtherThanInConnectionWithCertainMonetizationEvents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentMandatoryPrepaymentExcessProceedsFromAnyOfCompanySSubsidiariesOtherThanInConnectionWithCertainMonetizationEvents", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of excess proceeds from receipt of any dividend or other distributions in cash from any of the company's subsidiaries other than in connection with certain monetization events, that should be used for mandatory prepayment of debt instrument.", "label": "Debt Instrument, Mandatory Prepayment, Excess Proceeds From Any Of Company's Subsidiaries Other Than In Connection With Certain Monetization Events", "terseLabel": "Excess proceeds from any of company's subsidiaries other than in connection with certain monetization events" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "verboseLabel": "Debt maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r149", "r810", "r1063", "r1064"] }, "us-gaap_DebtInstrumentMaturityDateDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDateDescription", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date, Description", "verboseLabel": "Maturity Date, description", "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities." } } }, "auth_ref": ["r62"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r12", "r179", "r351", "r352", "r353", "r354", "r355", "r357", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r810", "r811", "r812", "r813", "r814", "r839", "r983", "r1009", "r1010", "r1011", "r1069", "r1071"] },
"fbio_DebtInstrumentNumberOfInterestOnlyPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentNumberOfInterestOnlyPeriod", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of interest only period under the debt instrument.", "label": "Debt Instrument, Number Of Interest Only Period", "terseLabel": "Debt Instrument, number of interest only period" } } } }, "auth_ref": [] }, "fbio_DebtInstrumentPercentageOfExitFees": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentPercentageOfExitFees", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents percentage of original principal amount to be paid as exit fees upon repayment of debt instrument.", "label": "Debt Instrument, Percentage of Exit Fees" } } }, "auth_ref": [] },
"fbio_DebtInstrumentPercentageOfPrepaymentPremium": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentPercentageOfPrepaymentPremium", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of prepayment premium to be paid at the time of prepayment of debt instrument.", "label": "Debt Instrument, Percentage of Prepayment Premium" } } }, "auth_ref": [] }, "fbio_DebtInstrumentPercentageOfThenOutstandingPrincipalBalanceDueOnSpecifiedDate": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentPercentageOfThenOutstandingPrincipalBalanceDueOnSpecifiedDate", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of the then-outstanding principal balance of the loans due on specified date.", "label": "Debt Instrument, Percentage Of Then Outstanding Principal Balance Due On A Specified Date", "terseLabel": "Debt instrument, percentage of then outstanding principal balance due on a specified date" } } }, "auth_ref": [] },
"fbio_DebtInstrumentPeriodicPaymentPercentageOfPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentPeriodicPaymentPercentageOfPrincipalAmount", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of the required periodic payments including both interest and principal payments on principal amount.", "label": "Debt Instrument, Periodic Payment, Percentage of Principal Amount" } } }, "auth_ref": [] },
"fbio_DebtInstrumentRepaymentPeriodFromFebruary2026IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsLessThanThresholdRevenueAsOfDecember312025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentRepaymentPeriodFromFebruary2026IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsLessThanThresholdRevenueAsOfDecember312025Member", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to debt instrument repayment period from February 2026 if total revenue of measured on a trailing twelve-month basis, is less than threshold revenue as of December 31, 2025.", "label": "Debt Instrument, Repayment Period from February 2026 If Total Revenue Measured on Trailing Twelve Month Basis is Less than Threshold Revenue as of December 31, 2025 [Member]" } } }, "auth_ref": [] },
"fbio_DebtInstrumentRepaymentPeriodFromFebruary2027IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsGreaterThanThresholdRevenueAsOfDecember312025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentRepaymentPeriodFromFebruary2027IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsGreaterThanThresholdRevenueAsOfDecember312025Member", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to debt instrument repayment period from February 2027 if total revenue of measured on a trailing twelve-month basis, is less than threshold revenue as of December 31, 2025.", "label": "Debt Instrument, Repayment Period from February 2027 If Total Revenue Measured on Trailing Twelve Month Basis is Greater than Threshold Revenue as of December 31, 2025 [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r12", "r38", "r40", "r54", "r106", "r107", "r179", "r351", "r352", "r353", "r354", "r355", "r357", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r810", "r811", "r812", "r813", "r814", "r839", "r983", "r1069", "r1071"] },
"fbio_DebtInstrumentThresholdAmountOfAggregateCommonEquityOrCashDistributionsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentThresholdAmountOfAggregateCommonEquityOrCashDistributionsToBeReceived", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold amount of aggregate common equity or cash distributions to be received as per the debt agreement.", "label": "Debt Instrument, Threshold Amount of Aggregate Common Equity or Cash Distributions to be Received", "terseLabel": "Debt instrument, threshold amount of aggregate common equity or cash distributions to be received" } } }, "auth_ref": [] },
"fbio_DebtInstrumentThresholdAmountOfOutstandingPrincipalForApplicabilityOfCovenants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentThresholdAmountOfOutstandingPrincipalForApplicabilityOfCovenants", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold amount of outstanding principal, above which the capital raise and minimum stake covenants and financial covenants shall be applicable.", "label": "Debt Instrument, Threshold Amount Of Outstanding Principal For Applicability Of Covenants", "terseLabel": "Outstanding principal balance" } } }, "auth_ref": [] },
"fbio_DebtInstrumentThresholdRevenueConsideredForNoPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtInstrumentThresholdRevenueConsideredForNoPeriodicPayment", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the threshold revenue for no periodic repayment of debt during the specified period.", "label": "Debt Instrument, Threshold Revenue Considered for No Periodic Payment" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less: Discount of notes payable", "verboseLabel": "Unamortized debt discount fees", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r1024", "r1068", "r1069", "r1071"] }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Debt instrument, unused borrowing capacity, amount", "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date." } } }, "auth_ref": ["r63", "r339"] }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": ["r608"] },
"fbio_DebtObligationsAndLettersOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DebtObligationsAndLettersOfCreditMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to debt obligations and letters of credit.", "label": "Debt Obligations And Letters of Credit [Member]", "terseLabel": "Debt obligations and letters of credit" } } }, "auth_ref": [] }, "fbio_December2022OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "December2022OfferingMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the December 2022 offering.", "label": "December 2022 Offering [Member]", "terseLabel": "December 2022 Offering" } } }, "auth_ref": [] },
"fbio_DeconsolidationAndDissolutionGainLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DeconsolidationAndDissolutionGainLossAmount", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from deconsolidation and dissolution of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.", "label": "Deconsolidation and Dissolution, Gain (Loss), Amount", "negatedLabel": "Loss from deconsolidation/dissolution of subsidiaries" } } }, "auth_ref": [] }, "fbio_DeferredDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DeferredDividends", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of deferred dividend payments at the end of the reporting period.", "label": "Deferred Dividends" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r5", "r34"] }, "fbio_DermatologyProductsSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DermatologyProductsSalesMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails"], "lang": { "en-us": { "role": { "label": "Dermatology Products Sales" } } }, "auth_ref": [] }, "fbio_DeskShareAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":

"DeskShareAgreementsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Desk Share Agreements [Member]", "terseLabel": "Desk Share Agreements" } } }, "auth_ref": [] }, "fbio_DirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DirectOfferingMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to direct offering.", "label": "Direct Offering [Member]", "terseLabel": "Direct offering" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r399", "r816", "r817", "r818", "r819", "r820", "r821", "r822"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r399", "r816", "r817", "r818", "r819", "r820", "r821", "r822"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of total revenues", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r1026"] }, "fbio_DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreements"], "lang": { "en-us": { "role": { "documentation": "Disclosure of collaboration and stock purchase agreement text block.", "label": "Disclosure Of Collaboration And Stock Purchase Agreement [Text Block]", "verboseLabel": "Asset Purchase Agreements" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsDeclaredTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDeclaredTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables"], "lang": { "en-us": { "role": { "label": "Dividends Declared [Table Text Block]", "verboseLabel": "Schedule of PIK dividend or equity fee recorded", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r874"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r906"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r917"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Common Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share attributable to common stockholders - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r161", "r185", "r186", "r187", "r188", "r189", "r190", "r196", "r199", "r203", "r204", "r205", "r209", "r458", "r461", "r478", "r479", "r605", "r627", "r794"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share attributable to common stockholders - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r161", "r185", "r186", "r187", "r188", "r189", "r190", "r199", "r203", "r204", "r205", "r209", "r458", "r461", "r478", "r479", "r605", "r627", "r794"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Loss per Common Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r195", "r206", "r207", "r208"] }, "fbio_EffectOfPartnerCompanyDeemedDividendsOnNetLossPerShareCalculation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "EffectOfPartnerCompanyDeemedDividendsOnNetLossPerShareCalculation", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "The effect of partner company deemed dividends on net loss per share calculation.", "label": "Effect of Partner Company Deemed Dividends On Net Loss Per Share Calculation", "terseLabel": "Effect of partner company deemed dividends on net loss per share calculation" } } }, "auth_ref": [] }, "fbio_EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "EffectOfSeriesPreferredDividendsOnNetLossPerShareCalculation", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "The effect of series A preferred dividends on net loss per share calculation.", "label": "Effect of Series A Preferred Dividends On Net Loss Per Share Calculation", "terseLabel": "Effect of Series A preferred dividends on net loss per share calculation" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Effective income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r440", "r824"] }, "fbio_EmployeeAndNonemployeeAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "EmployeeAndNonemployeeAwardsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Information related to employee and non-employee awards.", "label": "Employee And Nonemployee Awards [Member]", "terseLabel": "Employee and non-employee awards" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Share-based compensation, period for recognition of expense", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r434"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "verboseLabel": "Unrecognized compensation expense for awards other than options", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r1053"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "verboseLabel": "Stock options, unrecognized compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r1053"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Stock Options", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1",

"presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r872"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r872"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r872"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r956"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r872"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r872"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r872"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r872"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r911"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r952"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r952"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [
"r952"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r8", "r137", "r157", "r158", "r159", "r180", "r181", "r182", "r184", "r189", "r191", "r193", "r211", "r281", "r282", "r321", "r389", "r448", "r449", "r455", "r456", "r457", "r459", "r460", "r461", "r470", "r471", "r472", "r473", "r474", "r475", "r477", "r500", "r501", "r502", "r503", "r504", "r505", "r510", "r512", "r525", "r625", "r652", "r653", "r654", "r671", "r740"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r921"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r879", "r889", "r899", "r931"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r876", "r886", "r896", "r928"] }, "fbio_ExchangeOfPartnerCompanyConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ExchangeOfPartnerCompanyConvertiblePreferredShares", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of exchange of partner company convertible preferred shares, classified as non-cash activities.", "label": "Exchange of Partner Company Convertible Preferred Shares", "terseLabel": "Exchange of partner company convertible preferred shares" } } }, "auth_ref": [] }, "fbio_ExchangeOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ExchangeOfWarrants", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exchange of warrants.", "label": "Exchange Of Warrants", "terseLabel": "Exchange of warrants" } } }, "auth_ref": [] }, "fbio_ExchangeTermOfPreferredStock": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ExchangeTermOfPreferredStock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Exchange term of preferred stock.", "label": "Exchange Term of Preferred Stock", "terseLabel": "Exchange term of preferred stock" } } }, "auth_ref": [] }, "fbio_ExecutiveAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ExecutiveAwardsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Executive Awards [Member]", "terseLabel": "Executive awards" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category." } } }, "auth_ref": ["r927"] }, "srt_ExecutiveVicePresidentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ExecutiveVicePresidentMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Executive Vice President (Mr. Weiss) [Member]", "terseLabel": "Executive Vice President (Mr. Weiss)" } } }, "auth_ref": ["r997"] }, "fbio_ExerciseOfCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ExerciseOfCommonStockWarrants", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exercise of common stock warrants.", "label": "Exercise Of Common Stock Warrants", "terseLabel": "Exercise of common stock warrants" } } }, "auth_ref": [] }, "fbio_ExpenseAssociatedWithPartnerCompanyWarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ExpenseAssociatedWithPartnerCompanyWarrantLiabilities", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with partner company warrant liabilities.", "label": "Expense Associated With Partner Company Warrant Liabilities", "terseLabel": "Expense associated with partner company warrant liabilities" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Gain (loss) on common stock warrant liabilities", "verboseLabel": "Change in fair value of Warrant liabilities", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r5"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [

```
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r480", "r481", "r491", "r828" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r480", "r481", "r491", "r828" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r482", "r483", "r484", "r832" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r482", "r483", "r484", "r832" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of the Weighted average Significant Unobservable Inputs", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r482", "r483", "r832" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r486", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497", "r604", "r828", "r833" ] }, "fbio_FairValueOfAssetsLessCostToSellInRepurchaseTransaction": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "FairValueOfAssetsLessCostToSellInRepurchaseTransaction", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value of assets after costs to sell under the repurchase transaction.", "label": "Fair Value of Assets less Cost to Sell in Repurchase Transaction", "terseLabel": "Fair value of assets less cost to sell in repurchase transaction" } } }, "auth_ref": [] }, "fbio_FairValueOfAssetsReceivedByPartnerCompanyInRepurchaseTransaction": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "FairValueOfAssetsReceivedByPartnerCompanyInRepurchaseTransaction", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of exchange fair value of assets received by partner company in repurchase transaction.", "label": "Fair value of assets received by partner company in repurchase transaction" }
} }, "auth_ref": [] }, "fbio_FairValueOfSuppliesReceivedByPartnerCompanyExpensedToResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "FairValueOfSuppliesReceivedByPartnerCompanyExpensedToResearchAndDevelopment", "crdr": "credit",
"presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation":
"Amount of exchange fair value of supplies received by partner company expensed to research and development", "label": "Fair value of supplies received by partner company expensed to research and development" } } }, "auth_ref": [] }, "fbio_FairValueOfSuppliesWithAlternativeFutureUseExpensedAsResearchAndDevelopmentExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"FairValueOfSuppliesWithAlternativeFutureUseExpensedAsResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of exchange fair value of supplies with alternative future use expensed as research and development expense.", "label": "Fair Value of Supplies With Alternative Future Use Expensed as Research and Development Expense" } } }, "auth_ref": [] }, "fbio_FairValueOfSuppliesWithNoAlternativeFutureUseExpensedAsResearchAndDevelopmentExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"FairValueOfSuppliesWithNoAlternativeFutureUseExpensedAsResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of exchange fair value of supplies with no alternative future use expensed as research and development expense.", "label": "Fair Value of Supplies With No Alternative Future Use Expensed as Research and Development Expense", "terseLabel": "Fair value of supplies with no alternative future use expensed as research and development expense" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "label":
"Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r375", "r386", "r476", "r498", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r626", "r807", "r828", "r830", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r842", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r999", "r1000", "r1001", "r1002", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066" ] }, "fbio_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation":
"Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible assets, estimated useful lives", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r146", "r293", "r312", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "December 31, 2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r314", "r784", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Remainder of 2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1121" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "December 31, 2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r314", "r784", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "December 31, 2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r314", "r784", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [
```

```
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "December 31, 2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r314", "r784", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Total Intangible assets - asset purchases", "verboseLabel": "Total intangible assets - asset purchases", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r293", "r312", "r573", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r304", "r312", "r316", "r317", "r319", "r572", "r784", "r809" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net intangible assets", "verboseLabel": "Intangible assets, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r572", "r1006" ] }, "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Assets Net, Excluding assets that has not been placed in service.", "label": "Finite-Lived Intangible Assets Net, Excluding assets that has not been placed in service", "totalLabel": "Sub-total" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r883", "r893", "r903", "r935" ] }, "fbio_FoundersAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "FoundersAgreementMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Founders Agreement [Member]", "terseLabel": "Founders Agreement" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r916" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "fbio_GainLossFromDeconsolidationOfSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "GainLossFromDeconsolidationOfSubsidiaries", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from deconsolidation of subsidiaries.", "label": "Gain (Loss) from Deconsolidation of Subsidiaries", "negatedLabel": "Loss from deconsolidation of subsidiaries" } } }, "auth_ref": [] }, "fbio_GainLossOnCommonStockWarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "GainLossOnCommonStockWarrantLiabilities", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on common stock warrant liabilities.", "label": "Gain/Loss on common stock warrant liabilities", "verboseLabel": "Gain (loss) on common stock warrant liabilities" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r5" ] }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "terseLabel": "Gain on sale of asset", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value." } } }, "auth_ref": [ "r981" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r36", "r37" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r82" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets, net" } } }, "auth_ref": [] }, "fbio_HelocyteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "HelocyteMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails" ], "lang": { "en-us": { "role": { "label": "Helocyte [Member]", "terseLabel": "Helocyte" } } }, "auth_ref": [] }, "fbio_IfDebtInstrumentPrepaidAfterSecondAnniversaryOfClosingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IfDebtInstrumentPrepaidAfterSecondAnniversaryOfClosingDateMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents if debt instrument prepaid after the second anniversary of closing date.", "label": "If Debt Instrument Prepaid After Second Anniversary Of Closing Date [Member]" } } }, "auth_ref": [] }, "fbio_IfDebtInstrumentPrepaidOnOrAfterFirstAnniversaryButPriorToSecondAnniversaryOfClosingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IfDebtInstrumentPrepaidOnOrAfterFirstAnniversaryButPriorToSecondAnniversaryOfClosingDateMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents if debt instrument are prepaid on or after the first anniversary of the closing date but prior to the second anniversary of closing date.", "label": "If Debt Instrument Prepaid On Or After First Anniversary But Prior To Second Anniversary Of Closing Date [Member]" } } }, "auth_ref": [] }, "fbio_IfDebtInstrumentsPrepaidPriorToFirstAnniversaryOfClosingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IfDebtInstrumentsPrepaidPriorToFirstAnniversaryOfClosingDateMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents if debt instrument are prepaid prior to the first anniversary of the closing date.", "label": "If Debt Instruments Prepaid Prior To First Anniversary of Closing Date [Member]" } } }, "auth_ref": [] }, "fbio_IfOutstandingPrincipalBalanceIsBetween10MillionAnd25MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IfOutstandingPrincipalBalanceIsBetween10MillionAnd25MillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the scenario when the outstanding principal balance is between 10 million and 25 million.", "label": "If the Outstanding Principal Balance is Between 10 Million and 25 Million [Member]", "terseLabel": "Scenario when the outstanding principal balance is between 10 million and 25 million" } } }, "auth_ref": [] }, "fbio_IfOutstandingPrincipalBalanceIsLessThanOrEqualTo10MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IfOutstandingPrincipalBalanceIsLessThanOrEqualTo10MillionMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the scenario when the outstanding principal balance is less than or equal to 10 million.", "label": "If the Outstanding Principal Balance is Less Than or Equal to 10 Million [Member]", "terseLabel": "Scenario when the outstanding principal balance is less than or equal to 10 million" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLeasehold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLeasehold", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Leasehold", "terseLabel": "Impairment loss allocated to leasehold improvements", "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced." } } }, "auth_ref": [ "r5", "r33" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Asset impairment loss", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r5", "r33", "r102", "r829" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r322", "r329", "r330", "r485", "r487", "r492", "r649", "r651", "r725", "r784", "r831", "r1088"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r329", "r330", "r485", "r487", "r492", "r649", "r651", "r725", "r784", "r831", "r1088"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r174", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r450", "r452", "r453", "r454", "r665", "r824"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "verboseLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r125", "r134", "r192", "r193", "r210", "r226", "r241", "r439", "r440", "r451", "r629", "r824"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "verboseLabel": "Cash paid (refunded) for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r20", "r169", "r446", "r447"] }, "us-gaap_IncreaseDecreaseDueFromOtherRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseDueFromOtherRelatedParties", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) Due from Other Related Parties", "negatedLabel": "Other receivables - related party", "documentation": "Amount of increase (decrease) in receivables due from related parties classified as other." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r785"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r4"] }, "fbio_IncreaseDecreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IncreaseDecreaseInLeaseLiabilities", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The increase decrease in lease liabilities.", "label": "Increase Decrease In Lease Liabilities", "verboseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other long-term liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r4"] }, "fbio_IncreaseInMinimumLiquidityToBeMaintainedInEachInstanceOfProductDisapproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IncreaseInMinimumLiquidityToBeMaintainedInEachInstanceOfProductDisapproval", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents increase in minimum liquidity to be maintained under each instance f product disapproval as per the debt agreement.", "label": "Increase in Minimum Liquidity to be Maintained in Each Instance of Product Disapproval", "terseLabel": "Increase in minimum liquidity to be maintained under each instance of product disapproval as per the debt agreement" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r883", "r893", "r903", "r927", "r935", "r939", "r947"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r945"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r875", "r951"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r875", "r951"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r875", "r951"] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIntangibleNet"], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "verboseLabel": "Intangible Assets, net", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r303", "r318", "r320", "r783", "r784"] }, "fbio_IntangibleAssetsNotYetPlacedInService": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IntangibleAssetsNotYetPlacedInService", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Intangible assets not yet placed in service", "label": "Intangible assets not yet placed in service", "terseLabel": "Asset not yet placed in service" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense", "terseLabel": "Interest expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r210", "r218", "r222", "r228", "r241", "r507", "r801", "r802"] }, "fbio_InterestExpenseAndFinanceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "InterestExpenseAndFinanceFees", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense and amount of debt issuance costs.", "label": "Interest Expense And Finance Fees", "negatedLabel": "Interest expense and financing fee" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "totalLabel": "Interest expense, Total", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r84", "r370", "r380", "r813", "r814"] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails"], "lang": { "en-us": { "role": { "label": "Debt instrument accrued interest", "verboseLabel": "Interest expense, interest", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": ["r84", "r371", "r813", "r814"] }, "fbio_InterestExpenseTotalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "InterestExpenseTotalNet", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Net Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expense, Total, Net" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r164", "r167", "r168"] }, "fbio_InvagenPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":

"InvagenPharmaceuticalsIncMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Information related to InvaGen Pharmaceuticals Inc.", "label": "InvaGen [Member]", "terseLabel": "InvaGen" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureInventory"], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventory", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r292"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "verboseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r971"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r153", "r789", "r841"] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials and Supplies, Gross", "verboseLabel": "Raw materials", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": ["r973"] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails"], "lang": { "en-us": { "role": { "label": "Inventory Valuation Reserves", "negatedLabel": "Inventory reserve", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": ["r98", "r973"] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureInventoryScheduleOfInventoryDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r972"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "verboseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r210", "r221", "r241", "r801", "r976"] }, "fbio_IssuanceOfCommonStockForAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IssuanceOfCommonStockForAtMarketOffering", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during period for cash at the market cost.", "label": "Issuance of Common Stock for At the Market Offering", "terseLabel": "Issuance of common stock for at-the-market offering, net" } } }, "auth_ref": [] }, "fbio_IssuanceOfCommonStockForAtMarketOfferingInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IssuanceOfCommonStockForAtMarketOfferingInShares", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "It represents the stock issued during period shares issued for cash at market cost.", "label": "Issuance of Common Stock for At the Market Offering in shares", "terseLabel": "Issuance of common stock for at-the-market offering, net (in shares)" } } }, "auth_ref": [] }, "fbio_IssuanceOfCommonStockForResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IssuanceOfCommonStockForResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of issuance of common stock for research and development expenses.", "label": "Issuance Of Common Stock For Research And Development Expenses", "terseLabel": "Issuance of partner company's common shares for research and development expenses" } } }, "auth_ref": [] }, "fbio_IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock under partner company's Employee stock purchase program", "label": "Issuance of common stock under partner company's Employee stock purchase program", "terseLabel": "Issuance of common stock under partner company's ESPP" } } }, "auth_ref": [] }, "fbio_January2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "January2023WarrantsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to January 2023 Warrants.", "label": "January 2023 Warrants [Member]", "terseLabel": "January 2023 Warrants" } } }, "auth_ref": [] }, "fbio_JourneyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "JourneyMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Journey", "terseLabel": "Journey" } } }, "auth_ref": [] }, "fbio_July2024RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "July2024RegisteredDirectOfferingMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to July 2024 Registered Direct Offering.", "label": "July 2024 Registered Direct Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total lease expense", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r516", "r840"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r1073"] }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdsAndLeaseholdImprovementsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement." } } }, "auth_ref": ["r101"] }, "fbio_LegalFeesAndCostsInDefendingLitigationIncurredByFormerSubsidiaryReimbursedByDistributionFromEscrowAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "LegalFeesAndCostsInDefendingLitigationIncurredByFormerSubsidiaryReimbursedByDistributionFromEscrowAccount", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of legal fees and costs incurred by a former subsidiary, in defending a litigation, reimbursed by the company by distribution from escrow account.", "label": "Legal Fees And Costs In Defending Litigation, Incurred By Former Subsidiary, Reimbursed By Distribution From Escrow Account", "terseLabel": "Caelum's legal fees and costs" } } }, "auth_ref": [] }, "fbio_LesseeLeasePortfolioAndOtherSupplementalLeaseInformation": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "LesseeLeasePortfolioAndOtherSupplementalLeaseInformation", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "documentation": "Lessee Lease Portfolio and Other Supplemental Lease Information", "label": "Lessee Lease Portfolio and Other Supplemental Lease Information", "terseLabel": "Summary of Quantitative Information about Operating Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescriptionAbstract", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1074"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total operating lease liabilities", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r523"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "verboseLabel": "Other", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r523"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year Ended December 31, 2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r523"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "verboseLabel": "Year Ended December 31, 2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r523"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "verboseLabel": "Year Ended December 31, 2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from

current statement of financial position date (rolling approach)." }] }, "auth_ref": ["r523"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "verboseLabel": "Year Ended December 31, 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r523"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Nine Months Ended December 31, 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1074"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: present value discount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r523"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r12", "r58", "r59", "r60", "r64", "r65", "r66", "r67", "r173", "r280", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r465", "r468", "r469", "r499", "r694", "r795", "r870", "r1019", "r1077", "r1078"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity (deficit)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r74", "r119", "r618", "r841", "r984", "r1003", "r1067"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r60", "r142", "r173", "r280", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r465", "r468", "r469", "r499", "r841", "r1019", "r1077", "r1078"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "fbio_LicensesAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "LicensesAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "na.", "label": "License Agreements" } } }, "auth_ref": [] }, "fbio_LicensesAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "LicensesAgreementsTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureLicenseAgreements"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research and development licenses agreements.", "label": "Licenses Agreements [Text Block]", "terseLabel": "License Agreements" } } }, "auth_ref": [] }, "fbio_LineOfCreditFacilityAdditionalBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Additional borrowing capital that can be drawn under the credit agreement.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of credit facility additional borrowing capacity" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r57", "r63"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Remaining Borrowing Capacity", "verboseLabel": "Remaining borrowing capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r57", "r63", "r340"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt", "totalLabel": "Total notes payable", "verboseLabel": "Total notes payable", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r12", "r116", "r363", "r378", "r811", "r812", "r839", "r1086"] }, "fbio_LongTermIncentivePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "LongTermIncentivePlansMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Long-term incentive plan [Member]", "label": "Long-term Incentive Plans [Member]" } } }, "auth_ref": [] }, "fbio_LongTermIncentiveProgramPercentageOfOutstandingShares": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "LongTermIncentiveProgramPercentageOfOutstandingShares", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Long term incentive program Percentage of outstanding shares", "label": "Long term incentive program Percentage of outstanding shares", "terseLabel": "LTIP, Percentage of outstanding shares" } } }, "auth_ref": [] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Notes Payable, Noncurrent", "verboseLabel": "Notes payable, long-term, net", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": ["r12"] }, "fbio_MaintainsVotingControlMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MaintainsVotingControlMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Maintains Voting Control [Member]", "label": "Maintains Voting Control [Member]", "terseLabel": "Maintains Voting Control" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": ["r248", "r818", "r852", "r857", "r1026", "r1087", "r1089", "r1090", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116"] }, "fbio_MarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MarketOfferingMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "At the Market Offering [Member]" } } }, "auth_ref": [] }, "fbio_MaximumAmountOfEquitySecuritiesToBeRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MaximumAmountOfEquitySecuritiesToBeRaised", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents maximum amount of equity securities to be raised by the company.", "label": "Maximum Amount Of Equity Securities to be Raised", "terseLabel": "Capitalization in equity securities" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } } }, "auth_ref": ["r335", "r336", "r337", "r338", "r403", "r436", "r484", "r570", "r648", "r650", "r657", "r686", "r687", "r746", "r749", "r753", "r754", "r756", "r781", "r782", "r806", "r815", "r823", "r832", "r833", "r837", "r838", "r853", "r1023", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r919"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r919"] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Expected Term [Member]", "terseLabel": "Expected life of the options to convert", "verboseLabel": "Expected term in years", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r1062", "r1063", "r1064"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Expected Volatility [Member]", "terseLabel": "Volatility", "verboseLabel": "Expected Volatility", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r832", "r1062", "r1063", "r1064"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate", "verboseLabel": "Risk Free Interest Rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r1062", "r1063", "r1064"] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "terseLabel": "Stock price", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": ["r1062", "r1063", "r1064"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r482", "r483", "r484", "r832"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"MeasurementInputTypeDomain", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r482", "r483", "r484", "r832"] }, "fbio_MinimumLiquidityToBeMaintained": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MinimumLiquidityToBeMaintained", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents minimum liquidity to be maintained as per the debt agreement.", "label": "Minimum Liquidity to be Maintained", "terseLabel": "Minimum liquidity to be maintained" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } } }, "auth_ref": ["r335", "r336", "r337", "r338", "r403", "r436", "r484", "r570", "r648", "r650", "r657", "r686", "r687", "r746", "r749", "r753", "r754", "r756", "r781", "r782", "r806", "r815", "r823", "r832", "r833", "r837", "r853", "r1023", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084"] }, "fbio_MinimumNetSaleTrailingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MinimumNetSaleTrailingPeriod", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Trailing period duration for maintaining minimum net sales.", "label": "Minimum Net Sale Trailing Period", "terseLabel": "Minimum net sale trailing period" } } }, "auth_ref": [] }, "fbio_MinimumNetSalesToBeMaintained": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MinimumNetSalesToBeMaintained", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents minimum net sales to be maintained, on a trailing 12-month basis, as per the debt agreement.", "label": "Minimum Net Sales to be Maintained", "terseLabel": "Minimum net sales to be maintained" } } }, "auth_ref": [] }, "fbio_MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Minimum ownership interest in subsidiaries for consolidated income tax return.", "label": "Minimum ownership interest in subsidiaries for consolidated income tax return", "terseLabel": "Minimum ownership interest in subsidiaries for consolidated income tax return" } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r73", "r118", "r173", "r280", "r341", "r343", "r344", "r345", "r348", "r349", "r499", "r617", "r698"] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureNonControllingInterests"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest Disclosure [Text Block]", "verboseLabel": "Non-Controlling Interests", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": ["r111"] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestLineItems", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Non-Controlling Interests", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "verboseLabel": "Non-controlling ownership", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": ["r46", "r47", "r73", "r78"] }, "fbio_MlvCo.AndFbrCapitalMarketsCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MlvCo.AndFbrCapitalMarketsCoMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "MLV & Co. and FBR Capital Markets & Co [Member]", "label": "MLV & Co. and FBR Capital Markets & Co [Member]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r938"] }, "fbio_MonthlyCashDividendPerSharePayable": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MonthlyCashDividendPerSharePayable", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Monthly cash dividend per share payable", "label": "Monthly Cash Dividend Per Share Payable", "terseLabel": "Monthly cash dividend" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r946"] }, "fbio_MustangTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "MustangTherapeuticsIncMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Mustang Therapeutics Inc.", "label": "Mustang", "terseLabel": "Mustang" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": ["r248", "r818", "r852", "r857", "r1026", "r1087", "r1089", "r1090", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r920"] }, "fbio_NetAssetsBelow20MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "NetAssetsBelow20MillionMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the scenario where Assets fall below 20 million.", "label": "Net Assets Below 20 Million [Member]", "terseLabel": "Net Assets Below 20 Million" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r166"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r166"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r90", "r91", "r92"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows from Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Fortress", "verboseLabel": "Net loss attributable to common stockholders", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r81", "r92", "r120", "r140", "r155", "r156", "r159", "r173", "r183", "r185", "r186", "r187", "r188", "r189", "r192", "r193", "r201", "r280", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r458", "r461", "r479", "r499", "r624", "r716", "r738", "r739", "r868", "r1019"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [

```
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to non-controlling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r49", "r112", "r155", "r156", "r189", "r192", "r193", "r623", "r975" ] }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "negatedLabel": "Net loss attributable to non-controlling interest", "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest." } } }, "auth_ref": [ "r78" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": [ "r163", "r185", "r186", "r187", "r188", "r196", "r197", "r202", "r205", "r461" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "fbio_NewYorkNyOfficeSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "NewYorkNyOfficeSpaceMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "New York, NY Office Space [Member]", "terseLabel": "New York, NY Office Space" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r919" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r883", "r893", "r903", "r927", "r935" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r910" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r909" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r927" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r946" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r946" ] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "Non-Controlling Interests" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Decrease from Deconsolidation", "terseLabel": "Deconsolidation/dissolution of subsidiary non-controlling interests", "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest." } } }, "auth_ref": [ "r7", "r41" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Non-Controlling Interests [Member]", "terseLabel": "Non-Controlling Interests", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r45", "r389", "r985", "r986", "r987", "r989", "r1119" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)", "verboseLabel": "Other expense", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r83" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense)" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "verboseLabel": "Schedule of Restricted Stock Awards and Restricted Stock Units", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r11" ] }, "fbio_November2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "November2023WarrantsMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to November 2023 Warrants.", "label": "November 2023 Warrants [Member]", "terseLabel": "November 2023 Warrants" } } }, "auth_ref": [] }, "fbio_NumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "NumberOfCustomers", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of customers.", "label": "Number of Customers", "verboseLabel": "Number of customers" } } }, "auth_ref": [] }, "fbio_NumberOfDaysToDisposeOfAssetsPurchased": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "NumberOfDaysToDisposeOfAssetsPurchased", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days within which the entity is obligated to sell, or otherwise dispose of, the assets purchased, pursuant to National Security Agreement.", "label": "Number Of Days To Dispose Of Assets Purchased", "terseLabel": "Number of days to dispose of assets purchased" } } }, "auth_ref": [] }, "fbio_NumberOfDaysToProvideTransitionSupport": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "NumberOfDaysToProvideTransitionSupport", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days over which the company has committed to provide transition support to the counterparty, pursuant to an agreement.", "label": "Number Of Days To Provide Transition Support", "terseLabel": "Number of days to provide transition support" } } }, "auth_ref": [] }, "fbio_NumberOfDirectorsThatCompanyHasRightToAppoint": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "NumberOfDirectorsThatCompanyHasRightToAppoint", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of directors of the board of directors of the counterparty, that the company has right to appoint, pursuant to an agreement.", "label": "Number Of Directors That Company Has Right TO Appoint", "terseLabel": "Number of directors" } } }, "auth_ref": [] }, "fbio_NumberOfPartnerCompaniesThatArePubliclyTraded": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "NumberOfPartnerCompaniesThatArePubliclyTraded", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of partner companies that are publicly traded.", "label": "Number Of Partner Companies That Are Publicly Traded", "terseLabel": "Number of partner companies that are publicly traded" } } }, "auth_ref": [] }, "fbio_NumberOfPartnerCompaniesThatHaveConsummatedStrategicPartnershipsWithIndustryLeaders": { "xbrltype": "integerItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "NumberOfPartnerCompaniesThatHaveConsummatedStrategicPartnershipsWithIndustryLeaders", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of partner companies that have consummated strategic partnerships with industry leaders.", "label": "Number Of Partner Companies That Have Consummated Strategic Partnerships With Industry Leaders", "terseLabel": "Number of partner companies that have consummated strategic partnerships with industry leaders" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "verboseLabel": "Number of reportable segment", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r797", "r805", "r992" ] }, "fbio_NumberOfSharesIssuableForAtMarketOffering": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "NumberOfSharesIssuableForAtMarketOffering", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Shares issuable for At-the-Market offering", "label": "Number of Shares issuable for At-the-Market offering", "terseLabel": "Number of Shares issuable for At-the-Market offering" } } }, "auth_ref": [] }, "fbio_OaktreeNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "OaktreeNoteMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Oaktree Notes.", "label": "Oaktree Note [Member]", "terseLabel": "Oaktree Note" } } }, "auth_ref": [] }, "fbio_OncogenuityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "OncogenuityMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Oncogenuity.", "label": "Oncogenuity [Member]", "terseLabel": "Oncogenuity" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r123", "r796", "r991", "r993", "r994", "r995", "r996" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r517", "r840" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri":
```

"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment loss allocated to right-of-use asset", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": ["r1072"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
"http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "verboseLabel": "Net operating lease liabilities, short-term and long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r514"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liabilities, short-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r514"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liabilities, long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r514"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "negatedTerseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r515", "r520"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use asset, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r513"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization Of Operating Lease Right Of Use Asset", "terseLabel": "Reduction in the carrying amount of operating lease right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r981"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r522", "r840"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesQuantitativeInformationAboutOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted-average remaining lease term - operating leases (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r521", "r840"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusiness"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "Organization and Description of Business", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": ["r93", "r94", "r95", "r111"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Purchase Price recorded in accrued expenses - other", "verboseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r59"] }, "us-gaap_OtherAffiliatesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAffiliatesMember", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Affiliates [Member]", "terseLabel": "Related Party", "documentation": "A category that identifies other affiliates." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r147"] }, "fbio_OtherDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "OtherDebtMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Other Debt [Member]", "label": "Other Debt [Member]", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncome", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other Income", "terseLabel": "Other revenue", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": ["r628", "r718", "r758", "r759", "r760"] }, "fbio_OtherLegacyProductRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "OtherLegacyProductRevenueMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Other Legacy Product Revenue Member.", "label": "Other Legacy Product Revenue" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other short-term liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r59", "r841"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r65"] }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other income (expense)", "terseLabel": "Other income (expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r85"] }, "fbio_OtherPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "OtherPartnersMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Other Partners [Member]", "label": "Other Partners [Member]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r919"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r881", "r891", "r901", "r933"] }, "fbio_OutstandingPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "OutstandingPayables", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of outstanding payables of the company.", "label": "Outstanding Payables", "terseLabel": "Outstanding payables of the company" } } }, "auth_ref": [] }, "fbio_OutstandingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "OutstandingReceivables", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of outstanding receivables of the company.", "label": "Outstanding Receivables", "terseLabel": "Outstanding receivable from uBriGene" } } }, "auth_ref": [] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r884", "r894", "r904", "r936"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r884", "r894", "r904", "r936"] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails"], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] },
"srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails"], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] },
"fbio_OwnershipPercentageOfSubsidiaryToConsolidateTheirAccounts": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "OwnershipPercentageOfSubsidiaryToConsolidateTheirAccounts", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Ownership percentage of the subsidiary to consolidate their accounts", "label": "Ownership percentage of the subsidiary to consolidate their accounts" } } }, "auth_ref": [] },
"fbio_PaidInKindDividendAsPercentageOfFullyDilutedOutstandingCapitalization": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PaidInKindDividendAsPercentageOfFullyDilutedOutstandingCapitalization", "presentation": [

```
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Paid in Kind dividend as a percentage of fully diluted outstanding capitalization.", "label": "Paid-in-Kind dividend as a percentage of fully diluted outstanding capitalization", "terseLabel": "PIK dividend as a percentage of fully diluted outstanding capitalization" } } }, "auth_ref": [] },
"fbio_PaidInKindDividendCommonStockSAverageTradingPriceDiscountPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PaidInKindDividendCommonStockSAverageTradingPriceDiscountPercentage", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Paid in Kind dividend, common stock's average trading price discount percentage.", "label": "Paid in Kind dividend, common stock's average trading price discount percentage", "terseLabel": "Common stock's average 10-day trading price discount percentage" } } }, "auth_ref": [] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaidInKindInterest", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non Cash Interest Expense", "terseLabel": "Non-cash interest", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "fbio_PartnerCompanyAccountsPayableWriteOffRelatedToRepurchaseTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanyAccountsPayableWriteOffRelatedToRepurchaseTransaction", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of Partner company accounts payable write-off related to repurchase transaction.", "label": "Partner company accounts payable write-off related to repurchase transaction" } } }, "auth_ref": [] }, "fbio_PartnerCompanyAccountsReceivableWriteOffRelatedToRepurchaseTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanyAccountsReceivableWriteOffRelatedToRepurchaseTransaction", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of exchange of partner company accounts receivable write-off related to repurchase transaction", "label": "Partner company accounts receivable write-off related to repurchase transaction" } } }, "auth_ref": [] }, "fbio_PartnerCompanyConvertiblePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanyConvertiblePreferredSharesMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Partner Company Convertible Preferred Shares [Member]", "label": "Partner Company Convertible Preferred Shares [Member]", "terseLabel": "Partner company convertible preferred shares" } } }, "auth_ref": [] }, "fbio_PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes", "crdr": "debit", "presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Partner company derivative warrant liability associated with partner company share-settled notes", "label": "Partner company derivative warrant liability associated with partner company share-settled notes", "terseLabel": "Partner company derivative warrant liability associated with partner company convertible preferred shares" } } }, "auth_ref": [] }, "fbio_PartnerCompanyEquityOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanyEquityOffering", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Partner company's equity offering, excluding at-the-market issuances.", "label": "Partner Company Equity Offering", "terseLabel": "Partner company's offering, net" } } }, "auth_ref": [] }, "fbio_PartnerCompanyExerciseOfOptionsForCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanyExerciseOfOptionsForCash", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Partner company's exercise of stock options for the purpose of cash.", "label": "Partner company exercise of options for cash", "terseLabel": "Partner companies' proceeds from options and warrants, net" } } }, "auth_ref": [] }, "fbio_PartnerCompanyInstallmentPaymentsLicensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanyInstallmentPaymentsLicensesCurrent", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Partner company installment payments - licenses, short-term, net of imputed interest.", "label": "Partner company installment payments - licenses, current", "verboseLabel": "Partner company installment payments - licenses, short-term, net" } } }, "auth_ref": [] }, "fbio_PartnerCompanyInstallmentPaymentsLicensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanyInstallmentPaymentsLicensesMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Partner company installment payments - licenses [Member]", "label": "Partner company installment payments - licenses [Member]", "terseLabel": "Partner company installment payments - licenses" } } }, "auth_ref": [] }, "fbio_PartnerCompanyNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanyNotesPayableMember", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestInterestExpenseDetails",
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to Partner Company notes payable.", "label": "Partner Company Notes Payable [Member]", "terseLabel": "Partner Company Promissory Note", "verboseLabel": "Partner company notes payable" } } }, "auth_ref": [] }, "fbio_PartnerCompanySExerciseOfOptionsForCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanySExerciseOfOptionsForCash", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Partner company's exercise of options for cash.", "label": "Partner Company's Exercise Of Options For Cash", "terseLabel": "Partner company's exercise of options for cash" } } }, "auth_ref": [] }, "fbio_PartnerCompanySNetPurchaseConsiderationOfAssetsRecordedToAccruedOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanySNetPurchaseConsiderationOfAssetsRecordedToAccruedOther", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of Partner company's net purchase consideration of assets recorded to accrued other.", "label": "Partner company's net purchase consideration of assets recorded to accrued other" } } }, "auth_ref": [] }, "fbio_PartnerCompanySWarrantsIssuedInConjunctionWithDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PartnerCompanySWarrantsIssuedInConjunctionWithDebt", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Amount of warrants issued in conjunction with debt.", "label": "Partner company's warrants issued in conjunction with debt" } } }, "auth_ref": [] },
"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r908" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Expenses" } } }, "auth_ref": [] }, "fbio_PaymentInKindDividendsOrEquityFeePayableEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PaymentInKindDividendsOrEquityFeePayableEffectiveDate", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment in Kind Dividends or Equity Fee Payable Effective Date.", "label": "Payment in Kind Dividends or Equity Fee Payable Effective Date", "terseLabel": "Effective date" } } }, "auth_ref": [] }, "fbio_PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Payment of debt issuance costs associated with partner company share-settled notes", "label": "Payment of debt issuance costs associated with partner company share-settled notes", "negatedLabel": "Payment of debt issuance costs associated with partner company convertible preferred shares" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r960", "r977" ] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Rent", "verboseLabel": "Total payment for rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Partner company's dividends declared and paid", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r88" ] }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "negatedLabel": "Payment of Series A perpetual preferred stock dividends", "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity." } } }, "auth_ref": [ "r88" ] }, "fbio_PaymentsOfMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PaymentsOfMilestone", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents payments of milestone.", "label": "Payments of Milestone", "verboseLabel": "Payments of milestones" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Stock offering, aggregate fees paid", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire in Process Research and Development", "negatedLabel": "Purchase of research and development licenses", "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination." } } }, "auth_ref": [ "r14" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire
```

Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r87"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r918"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r918"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r910"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r927"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r920"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r909"] }, "fbio_PerShareAmountReducedFromSharePriceToCalculateWarrantPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PerShareAmountReducedFromSharePriceToCalculateWarrantPrice", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Per share amount reduced from share price to calculate warrant price.", "label": "Per Share, Amount Reduced from Share Price to Calculate Warrant Price", "terseLabel": "Per share amount reduced from share price to calculate warrant price" } } }, "auth_ref": [] }, "fbio_PercentageOfRoyaltyOnFutureNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PercentageOfRoyaltyOnFutureNetSales", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty on future net sales granted to the company.", "label": "Percentage Of Royalty On Future Net Sales", "terseLabel": "Percentage of royalty on future net sales" } } }, "auth_ref": [] }, "fbio_PharmaceuticalAndBiotechnologyProductDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PharmaceuticalAndBiotechnologyProductDevelopmentMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails"], "lang": { "en-us": { "role": { "label": "Pharmaceutical and Biotechnology Product Development" } } }, "auth_ref": [] }, "fbio_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PlacementAgentWarrantsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Placement Agent Warrants [Member]", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r911"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r955"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r910"] }, "fbio_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PreFundedWarrantsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded warrants.", "label": "Pre-Funded Warrants [Member]", "terseLabel": "Pre funded warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePercentage", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Dividend Rate, Percentage", "verboseLabel": "Preferred Stock, dividend rate percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": ["r382", "r747", "r750", "r752", "r757"] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreference", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Preferred Stock, liquidation preference per share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": ["r38", "r39", "r68", "r982", "r1025"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r860", "r861", "r864", "r865", "r866", "r867", "r1117", "r1119"] }, "fbio_PreferredStockMonthlyDividendsPerSharePaused": { "xbrltype": "perShareItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PreferredStockMonthlyDividendsPerSharePaused", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Aggregate monthly dividends paused during the period for each share of preferred stock.", "label": "Preferred Stock, Monthly Dividends, Per Share, Paused" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r68", "r381"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r68", "r696"] }, "fbio_PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PreferredStockSharesDesignated", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "It represents number of preferred stock shares designated.", "label": "Preferred Stock shares designated" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r68", "r381"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r68", "r696", "r714", "r1119", "r1120"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively, liquidation value of $25.00 per share", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r68", "r614", "r841"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r974"] }, "fbio_PrepaidOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PrepaidOfferingCosts", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of future offering costs paid for in current reporting period.", "label": "Prepaid Offering Costs", "terseLabel": "Prepaid public offering cost" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "fbio_ProceedsFromExerciseOfEquityGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromExerciseOfEquityGrants", "crdr": "debit", "presentation": [

"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from exercise of equity grants.", "label": "Proceeds From Exercise Of Equity Grants", "terseLabel": "Proceeds from exercise of partner companies' equity grants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock for at-the-market offering, net", "verboseLabel": "Proceeds from issuance of Common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r2"] }, "fbio_ProceedsFromIssuanceOfCommonStockExcludingAtMarketOfferings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockExcludingAtMarketOfferings", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity excluding at-the-market offerings.", "label": "Proceeds From Issuance Of Common Stock, Excluding At-The-Market Offerings", "terseLabel": "Proceeds from issuance of common stock for public offering, net" } } }, "auth_ref": [] }, "fbio_ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity from under the Employee Stock Purchase Plan", "label": "Proceeds from issuance of common stock under ESPP", "terseLabel": "Proceeds from issuance of common stock under ESPP" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Aggregate Offering Price of Debt", "verboseLabel": "Proceeds from debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r979"] }, "fbio_ProceedsFromIssuanceOfPartnerCompanyConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromIssuanceOfPartnerCompanyConvertiblePreferredShares", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of partners company preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds From Issuance Of Partner Company Convertible Preferred Shares", "terseLabel": "Proceeds from partner company convertible preferred shares" } } }, "auth_ref": [] }, "fbio_ProceedsFromIssuanceOfSubsidiariesAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromIssuanceOfSubsidiariesAtMarketOffering", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of subsidiaries at the market offering capital contribution to the entity.", "label": "Proceeds From Issuance Of Subsidiaries At Market Offering", "verboseLabel": "Proceeds from partner companies' at-the-market offering, net" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Net proceeds", "verboseLabel": "Total gross proceeds", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r15", "r983"] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from partner company's line of credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r15"] }, "fbio_ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Proceeds from partner companies' sale of stock and warrants", "label": "Proceeds From Partner Companies Sale of Stock and Warrants, Net", "terseLabel": "Proceeds from partner companies' sale of stock, options and warrants, net" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromPreviousAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPreviousAcquisition", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Previous Acquisition", "terseLabel": "Amount of Caelum acquisition reveived", "documentation": "Cash inflow representing an adjustment to the purchase price of a previous acquisition." } } }, "auth_ref": ["r960"] }, "fbio_ProceedsFromRelatedPartyAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromRelatedPartyAgreement", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount received from desk share agreement related to design and build out of the new office.", "label": "Proceeds from Related Party Agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Proceeds from partner companies' long-term debt, net", "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts." } } }, "auth_ref": [] }, "fbio_ProceedsFromSalePaymentsForAcquisitionOfVyneProducts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromSalePaymentsForAcquisitionOfVyneProducts", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Cash proceeds from (payments for) sale or purchase of VYNE products.", "label": "Proceeds From Sale (Payments for Acquisition) Of VYNE Products", "terseLabel": "Acquisition of VYNE products" } } }, "auth_ref": [] }, "fbio_ProceedsFromStockAndWarrantsIssuedForExchangeOfPartnerCompanyPreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromStockAndWarrantsIssuedForExchangeOfPartnerCompanyPreferredShares", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from stock and warrants issued for exchange of partner company preferred shares.", "label": "Proceeds From Stock And Warrants Issued For Exchange Of Partner Company Preferred Shares", "terseLabel": "Stock and warrants issued for exchange of partner company preferred shares" } } }, "auth_ref": [] }, "fbio_ProceedsFromSubsidiarySEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ProceedsFromSubsidiarySEmployeeStockPurchasePlan", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow from subsidiary's employee stock purchase plan (ESPP).", "label": "Proceeds From Subsidiary's Employee Stock Purchase Plan", "terseLabel": "Proceeds from partner companies' ESPP" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Warrant Exercises", "terseLabel": "Exercise of warrants for cash", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r978"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails"], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r816"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r244", "r571", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r786", "r816", "r851", "r853", "r854", "r858", "r859", "r1014", "r1015", "r1026", "r1087", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r244", "r571", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r786", "r816", "r851", "r853", "r854", "r858", "r859", "r1014", "r1015", "r1026", "r1087", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r140", "r155", "r156", "r165", "r173", "r183", "r189", "r192", "r193", "r280", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r458", "r461", "r463", "r466", "r467", "r479", "r499", "r606", "r622", "r670", "r716", "r738", "r739", "r826", "r827", "r869", "r975", "r1019"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment" } } } }, "auth_ref": [] }, "fbio_PropertyPlantAndEquipmentAccumulatedImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PropertyPlantAndEquipmentAccumulatedImpairment", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for property plant and equipment.", "label": "Property, Plant and Equipment, Accumulated Impairment", "negatedLabel": "Impairment - leasehold improvements" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r6", "r524"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipment"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment", "documentation": "The entire disclosure for long-

lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r99", "r129", "r132", "r133"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r101", "r144", "r621"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r524"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r6", "r524", "r607", "r621", "r841"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r6"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r101", "r524"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful Life (Years)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Provision for Doubtful Accounts", "terseLabel": "Bad debt expense", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r162", "r285"] }, "fbio_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "PublicOfferingMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Public Offering [Member]", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r908"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r908"] }, "fbio_QbrezzaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "QbrezzaMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Qbrezza [Member]", "label": "Qbrezza", "terseLabel": "Qbrezza" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "auth_ref": ["r335", "r336", "r337", "r338", "r401", "r403", "r429", "r430", "r431", "r436", "r484", "r544", "r553", "r570", "r648", "r650", "r657", "r686", "r687", "r746", "r749", "r753", "r754", "r756", "r781", "r782", "r806", "r815", "r823", "r832", "r833", "r837", "r838", "r853", "r862", "r1012", "r1023", "r1063", "r1080", "r1081", "r1082", "r1083", "r1084"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "auth_ref": ["r335", "r336", "r337", "r338", "r401", "r403", "r429", "r430", "r431", "r436", "r484", "r544", "r553", "r570", "r648", "r650", "r657", "r686", "r687", "r746", "r749", "r753", "r754", "r756", "r781", "r782", "r806", "r815", "r823", "r832", "r833", "r837", "r838", "r853", "r862", "r1012", "r1023", "r1063", "r1080", "r1081", "r1082", "r1083", "r1084"] }, "fbio_ReceivablesNetOfPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ReceivablesNetOfPayables", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of receivables net of payables due by the company.", "label": "Receivables, Net Of Payables", "terseLabel": "Net Receivable from uBriGene" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r876", "r886", "r896", "r928"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r249", "r402", "r529", "r530", "r611", "r619", "r689", "r690", "r691", "r692", "r693", "r713", "r715", "r745"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r175", "r176", "r529", "r530", "r531", "r532", "r611", "r619", "r689", "r690", "r691", "r692", "r693", "r713", "r715", "r745"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r529", "r530", "r1076"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r249", "r721", "r722", "r725"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r249", "r402", "r529", "r530", "r611", "r619", "r689", "r690", "r691", "r692", "r693", "r713", "r715", "r745", "r1076"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r526", "r527", "r528", "r530", "r533", "r666", "r667", "r668", "r723", "r724", "r725", "r743", "r744"] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Debt", "negatedLabel": "Repayment of partner companies' long-term debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r980"] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Long-term Lines of Credit", "negatedLabel": "Repayment of partner company's line of credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r89"] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"
], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r177", "r178", "r354", "r383", "r532", "r554", "r609", "r792", "r793"] }, "us-
gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and Development
Asset Acquired Other than Through Business Combination, Written-off", "verboseLabel": "Research and development - licenses acquired", "documentation": "Amount of
writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } }, "auth_ref": ["r310",
"r784", "r1055"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Research and
Development Expense", "negatedLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost
for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business
combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in
research and development activity." } } }, "auth_ref": ["r437", "r784", "r801", "r1085"] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit",
"presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research
and Development Expense (Excluding Acquired in Process Cost)", "netLabel": "Research and development", "documentation": "Amount of expense for research and
development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction
other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or
both, used in research and development activity." } } }, "auth_ref": ["r1055"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]",
"documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] },
"fbio_ResearchAndDevelopmentLicensesAcquiredExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"ResearchAndDevelopmentLicensesAcquiredExpense", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Research and
development-licenses acquired, expense", "label": "Research and development-licenses acquired, expense", "terseLabel": "Research and development - licenses acquired,
expense" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis",
"presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement
Determination Date:" } } }, "auth_ref": ["r877", "r887", "r897", "r929"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": {
"label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r878", "r888", "r898", "r930"] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does
Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r885", "r895", "r905", "r937"] }, "us-
gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents",
"crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails"],
"lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash", "documentation": "Amount of cash and cash equivalents
restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with
general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known
amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r18", "r113",
"r143", "r170", "r613"] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash
Equivalents, Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as
noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of
demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r18", "r126", "r170"] },
"fbio_RestrictedStockAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"RestrictedStockAndRestrictedStockUnitsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation":
"Stock or stock units including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance
conditions are met.", "label": "Restricted Stock Awards and Restricted Stock Units [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Restricted
Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified
performance conditions are met." } } }, "auth_ref": ["r24"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Restricted
Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when
specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated
Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r71", "r108", "r616", "r655",
"r656", "r664", "r697", "r841"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenues from Contracts and Significant Customers" } } }, "auth_ref": [] }, "us-
gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue from Contract
with Customer, Including Assessed Tax", "terseLabel": "Product revenue, net", "verboseLabel": "Product revenue, net", "documentation": "Amount, including tax collected
from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by
governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
} } }, "auth_ref": ["r121", "r122", "r210", "r219", "r220", "r235", "r241", "r244", "r246", "r248", "r398", "r399", "r571"] }, "us-
gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerProductAndServiceBenchmarkMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Revenue
[Member]", "terseLabel": "Revenue", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for
specified product or service, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r961"] }, "us-
gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomers"],
"lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "Revenues from Contracts and Significant Customers",
"documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to,
disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized
from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r135", "r390", "r391", "r392", "r393", "r394",
"r395", "r396", "r397", "r400"] }, "us-gaap_RevenueNotFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueNotFromContractWithCustomer", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue Not from Contract
with Customer", "terseLabel": "Revenue - related party", "documentation": "Amount of revenue that is not accounted for under Topic 606." } } }, "auth_ref": ["r963"] }, "us-
gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails",
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues", "totalLabel":
"Net revenue", "verboseLabel": "Net Revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities
that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of
revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r121", "r122", "r160", "r173", "r210", "r219", "r220", "r235", "r241", "r244", "r246", "r248", "r280", "r341",
"r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r499", "r606", "r801", "r1019"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues from Contracts
and Significant Customers.", "terseLabel": "Revenue" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": {
"role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r946"] }, "ecd_Rule10b51ArrTrmntdFlag":
{ "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [

"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r946"] }, "fbio_SaleOfStockAggregateOfferingPricePermittedByAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SaleOfStockAggregateOfferingPricePermittedByAgreement", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Sale of Stock aggregate offering price permitted by agreement.", "label": "Sale of Stock aggregate offering price permitted by agreement", "terseLabel": "Stock offering, aggregate offering permitted by the agreement" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of National Holding's stock, proceeds received", "verboseLabel": "Sale of stock, net proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedPerTransaction", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received Per Transaction", "terseLabel": "Total gross proceeds", "verboseLabel": "Stock offering, gross proceeds", "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock, number of shares issued", "verboseLabel": "Stock offering, number of shares issued", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "fbio_SaleOfStockPercentageOfSharesIssuedInTransaction": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SaleOfStockPercentageOfSharesIssuedInTransaction", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of commission agreed to be paid to the company, percentage calculated over gross proceeds from the sales of stock.", "label": "Sale of Stock, Percentage of Shares Issued in Transaction", "terseLabel": "Shares issued (in percent)" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Stock offering, price per share", "verboseLabel": "Stock offering, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "auth_ref": ["r194", "r404", "r958", "r988"] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of accounts payable and accrued expenses", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "verboseLabel": "Schedule of Journey intangible assets", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": ["r1004", "r1005"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r24"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of Diluted Weighted Average Shares Outstanding", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r24"] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "verboseLabel": "Schedule of Cash and Cash Equivalents and restricted cash", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables"], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "verboseLabel": "Schedule of Debt", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "fbio_ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of effective date and equity fee payable.", "label": "Schedule Of Effective Date And Equity Fee Payable [Table Text Block]", "verboseLabel": "Schedule of effective date and PIK dividend or equity fee payable" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfFutureAmortizationOfIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r304", "r312", "r316", "r317", "r319", "r572", "r784", "r809"] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": ["r304", "r315", "r319", "r809"] }, "fbio_ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expenses for debt arrangements.", "label": "Schedule Of Interest Expenses For Debt Arrangements [Table Text Block]", "verboseLabel": "Interest Expense for all Debt Arrangements" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureInventoryTables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Schedule of Inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r13", "r75", "r76", "r77"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r6", "r524"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r52", "r53", "r721", "r722", "r725"] }, "fbio_ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ScheduleOfRevaluationOfWarrantLiabilityTableTextBloc", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revaluation of warrant liability.", "label": "Schedule of Revaluation of Warrant Liability [Table Text Bloc]", "terseLabel": "Schedule of revaluation of warrant liability" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Segment

Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": { "r30", "r31", "r32" } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSegmentInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "verboseLabel": "Schedule of Segment Information", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r30", "r31", "r32"] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Activity [Table Text Block]", "verboseLabel": "Schedule of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": ["r9", "r10", "r110"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "verboseLabel": "Schedule of Warrant activities", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r42"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "verboseLabel": "Schedule of future amortization of intangible assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r809", "r1007"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r871"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r873"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r121", "r122", "r123", "r124", "r210", "r215", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r248", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r319", "r331", "r332", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r798", "r801", "r802", "r808", "r856", "r1087", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } } }, "auth_ref": ["r246", "r247", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r683", "r684", "r685", "r748", "r751", "r755", "r761", "r768", "r771", "r772", "r773", "r774", "r776", "r777", "r778", "r779", "r780", "r787", "r817", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r855", "r862", "r1026", "r1087", "r1089", "r1090", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSegmentInformation"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r124", "r210", "r214", "r215", "r216", "r217", "r218", "r231", "r233", "r234", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r797", "r799", "r800", "r801", "r803", "r804", "r805"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "negatedLabel": "Selling, general and administrative", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r82"] }, "fbio_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SeriesBWarrantsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Series B Warrants", "label": "Series B Warrants [Member]", "terseLabel": "Series B Warrants" } } }, "auth_ref": [] }, "fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SeriesCumulativeRedeemablePerpetualPreferredStockMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails",
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "documentation": "Series A cumulative redeemable perpetual preferred stock.", "label": "9.375% Series A Cumulative Redeemable Perpetual Preferred Stock [Member]", "terseLabel": "9.375% Series A Cumulative Redeemable Perpetual Preferred Stock" } } }, "auth_ref": [] }, "fbio_SeriesOneWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SeriesOneWarrantsMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to series A one warrants.", "label": "Series A One Warrants [Member]", "terseLabel": "Series A One Warrants" } } }, "auth_ref": [] }, "fbio_SeriesThreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SeriesThreeWarrantsMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to series A three warrants.", "label": "Series A Three Warrants [Member]", "terseLabel": "Series A Three Warrants" } } }, "auth_ref": [] }, "fbio_SeriesTwoWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SeriesTwoWarrantsMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to series A two warrants.", "label": "Series A Two Warrants [Member]", "terseLabel": "Series A Two Warrants" } } }, "auth_ref": [] }, "fbio_SeriesWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SeriesWarrantsMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Series A Warrants", "label": "Series A Warrants [Member]", "terseLabel": "Series A Warrants" } } }, "auth_ref": [] }, "fbio_SettlementOfRestrictedSharesUnitsIntoCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SettlementOfRestrictedSharesUnitsIntoCommonStock", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The fair value of common stock issued for settlement of restricted stock unit.", "label": "Settlement Of Restricted Shares Units Into Common Stock", "verboseLabel": "Settlement of restricted stock units into common stock" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-

based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of shares, Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r423"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average exercise price, Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r423"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Number of shares Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r421"] }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue", "crdr": "credit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value.", "label": "Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value", "terseLabel": "Fair value of stock granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant price, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r421"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "verboseLabel": "Number of shares, Unvested balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r418", "r419"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant price, Unvested balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r418", "r419"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of shares, Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r422"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant price, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r422"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "verboseLabel": "Share based compensation, additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Stock based compensation, shares available for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r43"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Number of shares, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r414"] }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value", "terseLabel": "Total weighted average intrinsic value, Granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options vested and exercisable, Number of shares", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r427"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options vested and exercisable, Weighted average exercise price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r427"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Total weighted average intrinsic value, Options vested and expected to vest", "periodStartLabel": "Total weighted average intrinsic value, Options vested and expected to vest", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are

recognized when they occur." } } }, "auth_ref": ["r426"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]", "verboseLabel": "Schedule of Stock Option Activities", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r10"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Options vested and expected to vest, Number of shares", "periodStartLabel": "Options vested and expected to vest, Number of shares", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r426"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options vested and expected to vest, Weighted average exercise price", "periodStartLabel": "Options vested and expected to vest, Weighted average exercise price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r426"] }, "fbio_ShareBasedCompensationArrangementOptionsGrantedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ShareBasedCompensationArrangementOptionsGrantedWeightedAverageRemainingContractualTerm", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the weighted average remaining contractual life of option awards granted.", "label": "Share Based Compensation Arrangement, Options Granted, Weighted Average Remaining Contractual Term", "terseLabel": "Options Granted, weighted average remaining contractual life (years)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r414"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options vested and exercisable, Weighted average remaining contractual life (years)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r427"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Options vested and expected to vest, Weighted average contractual life", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r426"] }, "fbio_SharedServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SharedServicesAgreementMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Shared Services Agreement [Member]", "terseLabel": "Shared Services Agreement" } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shareholders' Equity and Share-based Payments [Text Block]", "verboseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": ["r105", "r109"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "fbio_ShelfRegistration2021StatementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ShelfRegistration2021StatementMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Shelf Registration 2021 Statement [Member]", "label": "Shelf Registration 2021 Statement [Member]" } } }, "auth_ref": [] }, "fbio_ShelfRegistration2023StatementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ShelfRegistration2023StatementMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Shelf Registration 2023 Statement [Member]", "label": "Shelf Registration 2023 Statement [Member]" } } }, "auth_ref": [] }, "fbio_ShelfRegistration2024StatementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ShelfRegistration2024StatementMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Shelf Registration 2024 Statement.", "label": "Shelf Registration 2024 Statement [Member]" } } }, "auth_ref": [] }, "fbio_ShelfRegistrationStatementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ShelfRegistrationStatementMember", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Shelf Registration Statement [Member]", "label": "Shelf Registration Statement [Member]" } } }, "auth_ref": [] }, "fbio_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for significant accounting policies.", "label": "Significant Accounting Policies [Policy Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r93", "r171"] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r121", "r122", "r123", "r124", "r139", "r210", "r215", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r248", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r319", "r323", "r331", "r332", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r798", "r801", "r802", "r808", "r856", "r1087", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r136", "r150", "r151", "r152", "r173", "r199", "r200", "r203", "r205", "r212", "r213", "r280", "r341", "r343", "r344", "r345", "r348", "r349", "r381", "r382", "r384", "r385", "r387", "r499", "r660", "r661", "r662", "r663", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r696", "r717", "r740", "r762", "r763", "r764", "r765", "r766", "r957", "r982", "r990"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r8", "r69", "r72", "r73", "r137", "r157", "r158", "r159", "r180", "r181", "r182", "r184", "r189", "r191", "r193", "r211", "r281", "r282", "r321", "r389", "r448", "r449", "r455", "r456", "r457", "r459", "r460", "r461", "r470", "r471", "r472", "r473", "r474", "r475", "r477", "r500", "r501", "r502", "r503", "r504", "r505", "r510", "r512", "r525", "r625", "r652", "r653", "r654", "r671", "r740"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [

```
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [
"r246", "r247", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593",
"r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r683", "r684", "r685", "r748", "r751", "r755", "r761", "r768", "r771", "r772", "r773", "r774",
"r776", "r777", "r778", "r779", "r780", "r787", "r817", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r855", "r862", "r1026", "r1087", "r1089", "r1090",
"r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110",
"r1111", "r1112", "r1113", "r1114", "r1115", "r1116" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementLineItems", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables",
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
"http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement",
"verboseLabel": "Commitments and Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r180", "r181", "r182", "r211", "r512", "r571", "r659",
"r682", "r688", "r689", "r690", "r691", "r692", "r693", "r696", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r709", "r710", "r711", "r712", "r713",
"r715", "r719", "r720", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r740", "r863" ] }, "us-
gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-
us": { "role": { "label": "Unaudited Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Unaudited Condensed
Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Statement of Changes in Stockholders'
Equity (Deficit)" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis",
"presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails",
"http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } },
"auth_ref": [ "r194", "r404", "r958", "r959", "r988" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementTable", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables",
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails",
"http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement [Table]",
"terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial
position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r180", "r181", "r182", "r211", "r249", "r512", "r571", "r659", "r682", "r688", "r689", "r690", "r691", "r692",
"r693", "r696", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r709", "r710", "r711", "r712", "r713", "r715", "r719", "r720", "r726", "r727", "r728",
"r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r740", "r863" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r880", "r890",
"r900", "r932" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation
Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number
of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "fbio_StockIssuedDuringPeriodSharesCommonSharesForDirectOfferingInShares": { "xbrltype":
"sharesItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "StockIssuedDuringPeriodSharesCommonSharesForDirectOfferingInShares",
"presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Total
number of shares issued during the period for direct offering.", "label": "Stock Issued During Period Shares Common Shares for Direct Offering (in Shares)", "terseLabel":
"Issuance of common shares - Registered direct offering" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": {
"definitionGuidance": "Shares purchased in connection with the ESPP offering", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel":
"Issuance of common stock under ESPP (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } },
"auth_ref": [ "r8", "r68", "r69", "r108" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label":
"Stock Issued During Period, Shares, New Issues", "positiveLabel": "Issuance of stock for public offerings, net (in shares)", "verboseLabel": "Shares issued", "documentation":
"Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r68", "r69", "r108", "r660", "r740", "r763" ] }, "us-
gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label":
"Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to equity plans (in shares)", "documentation":
"Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." }
} }, "auth_ref": [ "r8", "r68", "r69", "r108" ] }, "fbio_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": {
"documentation": "Number of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Exercise
of warrants for cash (in shares)" } } }, "auth_ref": [] }, "fbio_StockIssuedDuringPeriodValueCashLessExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "StockIssuedDuringPeriodValueCashLessExerciseOfWarrants", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Value of stock
issued during the period relating to cashless exercise of warrants.", "label": "Stock Issued During Period Value Cash Less Exercise Of Warrants", "terseLabel": "Warrants",
"verboseLabel": "Partner company's warrants issued in conjunction with debt" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit",
"presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": {
"role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under ESPP", "documentation": "Aggregate
change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r8", "r68", "r69", "r108" ] }, "us-
gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label":
"Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock for public offering, net", "verboseLabel": "Aggregate purchase price",
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } },
"auth_ref": [ "r8", "r68", "r69", "r108", "r671", "r740", "r763", "r869" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label":
"Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to equity plans", "documentation": "Value, after
forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r44", "r68", "r69", "r108" ] },
"fbio_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": {
"documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Exercise of
warrants for cash" } } }, "auth_ref": [] }, "fbio_StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.fortressbiotech.com/20240630", "localname": "StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsAmount", "crdr": "credit",
"presentation": [ "http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of
contingent fee payable on the proceeds of future financings.", "label": "Stock Repurchase Program, Contingent Fee Payable on Proceeds of Future Financings, Amount",
"terseLabel": "Contingent fee payable from proceeds of future financing" } } }, "auth_ref": [] },
"fbio_StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsPercent": { "xbrltype": "percentItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "StockRepurchaseProgramContingentFeePayableOnProceedsOfFutureFinancingsPercent", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of contingent fee
payable on the proceeds of future financings.", "label": "Stock Repurchase Program, Contingent Fee Payable on Proceeds of Future Financings, Percent", "terseLabel":
"Percentage of contingent fee payable" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ],
"lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity attributed to the Company", "documentation":
"Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r69", "r72", "r73", "r97",
"r698", "r714", "r741", "r742", "r841", "r870", "r984", "r1003", "r1067", "r1119" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to
Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit)" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr":
```

"credit", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity (deficit)", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r45", "r46", "r48", "r137", "r138", "r158", "r180", "r181", "r182", "r184", "r189", "r191", "r281", "r282", "r321", "r389", "r448", "r449", "r455", "r456", "r457", "r459", "r460", "r461", "r470", "r471", "r472", "r473", "r474", "r475", "r477", "r500", "r501", "r505", "r511", "r525", "r653", "r654", "r669", "r698", "r714", "r741", "r742", "r767", "r869", "r984", "r1003", "r1067", "r1119"] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Sublease Income", "negatedLabel": "Shared lease costs", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": ["r519", "r840"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r506", "r536"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Events", "terseLabel": "Subsequent events", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r506", "r536"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r506", "r536"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r506", "r536"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r506", "r536"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } },
"auth_ref": ["r535", "r537"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "fbio_SwkTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "SwkTermLoanMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfDebtDetails",
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Information related to the term loan facility with SWK.", "label": "SWK Term Loan [Member]", "terseLabel": "SWK Term Loan" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r926"] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Tangible Asset Impairment Charges", "terseLabel": "Tangible asset impairment charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": ["r55", "r102"] }, "fbio_TangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "TangibleAssetsNet", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSegmentInformationTotalAssetsByReportableSegmentDetails"], "lang": { "en-us": { "role": { "documentation": "Tangible assets.", "label": "Tangible Assets Net", "terseLabel": "Tangible assets" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Taxes Payable, Current", "verboseLabel": "Income taxes payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r58", "r59"] }, "fbio_TgtxAndOpusPointPartnersManagementLlcOppmMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "TgtxAndOpusPointPartnersManagementLlcOppmMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "TGTX and Opus Point Partners Management, LLC (\"OPPM\") [Member]", "label": "TGTX and OPPM [Member]", "terseLabel": "TGTX and OPPM" } } }, "auth_ref": [] }, "fbio_TgtxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "TgtxMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "TGTX [Member]", "label": "TGTX [Member]", "terseLabel": "TGTX" } } }, "auth_ref": [] }, "fbio_ThresholdPercentageOfFullyDilutedEquityCapitalizationPosition": { "xbrltype": "percentItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ThresholdPercentageOfFullyDilutedEquityCapitalizationPosition", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold percentage of fully diluted equity capitalization position in counterparty, to be held by company, until specified amount of equity securities is raised by such counterparty.", "label": "Threshold Percentage Of Fully Diluted Equity Capitalization Position", "terseLabel": "Urica's equity position" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": ["r997", "r1075"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r918"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r925"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r945"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r947"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "fbio_TransactionRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "TransactionRelatedExpenses", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Expenses related to transactions having to do with sale of assets.", "label": "Transaction Related Expenses" } } }, "auth_ref": [] }, "us-gaap_TransferToInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferToInvestments", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Transfer to Investments", "terseLabel": "Transfer of assets classified as held for sale", "documentation": "Value of investments transferred to the entity's investments in noncash transactions." } } }, "auth_ref": ["r21", "r22", "r23"] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r375", "r386", "r476", "r498", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r626", "r828", "r830", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r842", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r999", "r1000", "r1001", "r1002", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r948"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r949"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r949"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType",

```
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r947" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": {
"label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r947" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": {
"en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r950" ] },
"ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" }
} }, "auth_ref": [ "r948" ] }, "fbio_TwoThousandSevenAndTwoThousandThirteenPlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "TwoThousandSevenAndTwoThousandThirteenPlanMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand Seven and Two Thousand
Thirteen Plan [Member]", "label": "2007 and 2013 Stock Incentive Plan [Member]" } } }, "auth_ref": [] }, "fbio_TwoThousandThirteenStockIncentivePlanMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "TwoThousandThirteenStockIncentivePlanMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand Thirteen Stock Incentive
Plan [Member]", "label": "2013 Stock Incentive Plan [Member]" } } }, "auth_ref": [] }, "fbio_TwoThousandTwelveEmployeeStockPurchasePlanMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "TwoThousandTwelveEmployeeStockPurchasePlanMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twelve Employee Stock
Purchase Plan [Member]", "label": "2012 Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Type of Arrangement and Non-arrangement
Transactions [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or
operations." } } }, "auth_ref": [ "r462" ] }, "fbio_UbrigeneBostonBiosciencesInc.Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "UbrigeneBostonBiosciencesInc.Member", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
"http://www.fortressbiotech.com/role/DisclosureAssetPurchaseAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating
to uBriGene (Boston) Biosciences, Inc.", "label": "UBriGene (Boston) Biosciences, Inc. [Member]", "terseLabel": "UBriGene" } } }, "auth_ref": [] },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent",
"terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r944" ] }, "fbio_UnitPricePerShare": { "xbrltype": "perShareItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "UnitPricePerShare", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"
], "lang": { "en-us": { "role": { "documentation": "Per share price of combined unit.", "label": "Unit Price Per Share" } } }, "auth_ref": [] },
"fbio_UnpaidPartnerCompanyOfferingCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"UnpaidPartnerCompanyOfferingCost", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of
unpaid partner company's offering cost that were incurred during a noncash or partial noncash transaction.", "label": "Unpaid Partner Company Offering Cost", "terseLabel":
"Unpaid partner company's offering cost" } } }, "auth_ref": [] }, "fbio_UnregisteredWarrantsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "UnregisteredWarrantsMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"
], "lang": { "en-us": { "role": { "documentation": "Represents information relating to unregistered warrants.", "label": "Unregistered Warrants [Member]", "terseLabel":
"Unregistered warrants" } } }, "auth_ref": [] }, "fbio_UnvestedRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630",
"localname": "UnvestedRestrictedStockMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": {
"label": "Unvested Restricted Stock [Member]", "terseLabel": "Unvested Restricted Stock" } } }, "auth_ref": [] }, "fbio_UnvestedRestrictedStockUnitsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "UnvestedRestrictedStockUnitsMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": {
"label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Unvested Restricted Stock Units" } } }, "auth_ref": [] }, "fbio_Ur1TherapeuticsIncMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "Ur1TherapeuticsIncMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsManagementServicesAgreementDetails",
"http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsPikDividendOrEquityFeePayableDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"
], "lang": { "en-us": { "role": { "documentation": "UR-1 Therapeutics, Inc [Member]", "label": "UR-1 Therapeutics, Inc [Member]", "terseLabel": "Urica" } } }, "auth_ref": [] },
"us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text
Block]", "verboseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in
conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r27", "r28", "r29", "r127", "r128", "r130", "r131" ] }, "us-gaap_VariableLeaseCost": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost",
"verboseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for
finance and operating leases." } } }, "auth_ref": [ "r518", "r840" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity
Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r914" ] }, "fbio_WarrantLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "WarrantLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsCommonStockWarrantLiabilitiesDetails",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Represents information
pertaining to warrant liabilities current.", "label": "Warrant Liabilities Current", "periodEndLabel": "Common Stock Warrant liabilities at end of period", "periodStartLabel":
"Common Stock Warrant liabilities at beginning of period", "terseLabel": "Common stock warrant liabilities" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables",
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails",
"http://www.fortressbiotech.com/role/DisclosureNetIncomeLossPerCommonShareScheduleOfDilutedWeightedAverageSharesOutstandingDetails" ], "lang": { "en-us": { "role": {
"label": "Warrants to Purchase Common Stock [Member]", "terseLabel": "Warrants to purchase Common Stock", "verboseLabel": "Warrants to purchase Common Stock",
"documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified
amount." } } }, "auth_ref": [ "r860", "r861", "r864", "r865", "r866", "r867" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureDebtAndInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "verboseLabel":
"Warrants, fair value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a
specified price." } } }, "auth_ref": [ "r1062", "r1063", "r1064" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsWeightedAverageSignificantUnobservableInputsDetails",
"http://www.fortressbiotech.com/role/DisclosureIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement
Input", "verboseLabel": "Warrant liability, measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional
obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r1062", "r1063", "r1064" ] }, "us-
gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm",
"presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"
], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant expiration term", "documentation": "Period between issuance and
expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event
certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1062",
"r1063", "r1064" ] }, "fbio_WarrantsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname":
"WarrantsFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value portion of
warrants.", "label": "Warrants Fair Value Disclosure", "terseLabel": "Fair value of warrants" } } }, "auth_ref": [] },
"fbio_WarrantsIssuedInConjunctionWithExchangeOfPartnerCompanySConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "WarrantsIssuedInConjunctionWithExchangeOfPartnerCompanySConvertiblePreferredShares", "crdr": "credit",
"presentation": [ "http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": {
"role": { "documentation": "Amount charged from warrants in conjunction with exchange of partner company's convertible preferred shares.", "label": "Warrants issued in
conjunction with exchange of partner company's convertible preferred shares" } } }, "auth_ref": [] }, "fbio_WarrantsIssuedNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://www.fortressbiotech.com/20240630", "localname": "WarrantsIssuedNumber", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureStockholdersEquityCapitalRaisesNarrativeDetails", "http://www.fortressbiotech.com/role/DisclosureSubsequentEventsDetails"
], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued during the period.", "label": "Warrants Issued, Number", "terseLabel": "Warrants issued" } } },
"auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number
of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding - diluted", "documentation": "The average number of shares or units issued and
outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref":
[ "r198", "r205" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.fortressbiotech.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r196", "r205"] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r912"] }, "fbio_ZilxiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.fortressbiotech.com/20240630", "localname": "ZilxiMember", "presentation": [
"http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanysProductRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Zilxi product.", "label": "Zilxi", "terseLabel": "Zilxi" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic":

"210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"

}, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r453": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",

"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef",

"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r957": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r958": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r959": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1048": { "role":

{"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1109": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 100 0001558370-24-012063-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-012063-xbrl.zip M4$L#!!0 (`-.##5D&01Q?C20`&FJ 0`1;RTR,#(T,#8S,"YX MIN,TR33;>]+#R/1-CNR MY*6D)-Y??P%2DBF)$B79R=*M'G;'$4&0(@ 0!$'PAS_+WSGD?*(A<"O>.,# MHSV'!F[HL6#V<2^)L_M_VOOSC__SNQ_^=W__'V>W5XX7NLF"!K'C')'TA"U-MLA+17 ;N)IP#\U-1UY4])#$OG'0H53IR(R0I;8? M6%# Z@,%##11B\0/,D[S7S-4S! J*Y,5+7@,,))961J!FYO*A0@0;)XD3'O9.C M0_H'HC3O0,Q+XUGH-!0?8C&B/]D_.MT_/5X3 M.FLSMU.PG!W/[EQ/!I84J"!QS-E#$M.*(DN"BBH#QFNEH3@FT!9K$%X61#$) M7+K6C\RL`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`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{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`&Q[XFOAH C>Q\7U5MVL.@0^P)W_0G#87GGZ0/7+RM7R4K>6B4X[2]T%=]#ZH%E_$Z]_ M"0S7$$0UIYOOB<4D,RUOE(*4X-?TR7*UO2$!_<;B8/39FFN8V5RJ9*!E\V - M;&EZ3\2AQ\B%L6SKY'2L;>9SRY@5Z;21S3CK=@:N]^;Z+5A@G+DB&<+%E,_%O"HA;'N1VKF]G_?3OVI\TXLIT_M#(;#5B,B36SO4M7$\]YI2@96;Y75?TL(/L\@QE,)CAL]As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{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`]BFF&L] P:#P?*Y^; M9#N,U@=L#0ALV[EUVIMNWW>P$WLTD[-JD\':Z8'I?(/\)O29N])%]YM!RUK$ MDA!_=$C[&#^ !W:8+6,<7 "_4OT>IU=VQX&+27:\LQ60MZ!_0;?+66+AX1' M6':!&RSV(/HO;B=%+@^?TC?YU*L0K]>F-;)FF(17++*#99>A+XLKG[?(=_5G(M@2CY:#@4%E;KSC5M.7CM%E:8K4V9,3(0_%7%DFM?Q3Z3K=AW8%=C)'A>KA)B M7QQX'J5T/Z>]Y9@'<9]):0!C>A+<+:G+I@Q,ZR;*\.1]8Y!4D<#1;,9!0<9] MK/LZG%)&O:?)O6H'J1..7=&1W4D)'[.EWQ!+UQG/;@[7-4P1$H=\M:8-`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`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`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

Q+A"^!)%3^$T\GB@-G'O+,PR<.ZUH9LW}\R^6LV>;(8!0W"' MP1Q&(:QF+E@WS)@X05K3V4Z&8@=+>]#K,.[8W|'^ M)UP_9R[|F',)!TJX)F#S(CA1OR2@C@D@KLF7-PH^@L$L/@Y/^RN)4R?-E\$_ M(7\..SUOO U_3A]_PO_$(%2RI9SBQ -G7@.TYW?[%W:#(*+7 M4&^GJ?N.9 XJ/>=;?).W4DD#I;QIC7!V'H(]$12-N.@\@/Z?!7?3;@W!6RH MZ"%;S#95Q$UHZ\=![^!7W($!T!1NX|!!15G2UV^65"LIB'Q'L79[H:=@\FE,(M-X;FE@\%QE#L6OG>NW%>H%/;.C*;&4K@!F13-(P^/H5CK2\|@BC*_.P-15@(W MB ;#%V[!1WY0|"KM@4Q9?>E/.] M.ZM0P<\-P* 3CH7F38TYOB.6?GI/I])KAY;'TQ,R|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|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k+R=+B:-M@WN7UZFKW=/=)ZOSBJJT"R-,4" MA:KJ;NK7OT!=R+K@6A<@.6*$PYIF)8!\,A.W1"+QM__]NHEFSX@D(8[__LV' MM^^_F;'8QT$8K_[^398NW_SEF__]7__C/_]V_[UY\W_/[F]F ?:S#8K3F4^0 MEZ)@]A*FZ]DCWFZ]>/8)$1)&T>R,A,$*S68?WK_]\]OW;S_,WKSYK[R*,R^A M17 \R^OZ[NV'ZL-Y61N._SK[R[L/']]]]_Z[/\[^]-_LO]|HNW-*, (X^>MK$OH]FW6;=G_Z]MW+R\0;EXIO,5G1XN_MO/N_GVX>_#7:>&"_*$F!V$??S"Cl7Y\QQOL>VDNGEKQUR<2515\!+=02TC! M_GI3D;UA/[WY\-V;CQ_>OB;!-R6+[!+-& (07Y;X>^Q/3AAQ|^>)=_W9/2BH)T M3UNO|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}8D(RSC;E'$?7 M-V&BPSJK/:D"ESIM,$S0$&61_<(:3'*8.436=(-SC_@5\^4_V_I R<9[BS*' MM^P_>9OO4(*6[TKZ=R]T 4/>Q'3?/A MPYOO\M"P_]EN2QO)QJ4P3M%%K2;?FA=%_5BN!8NQ +;O<_[RVH8S1?_-C /' M;X+"W$9DD5/WJ SGO60:?LNJ1V WK^G-!FV>^EHLG]=FO<,975.>B)\]H3=[M,8S(+K?V&M/40$*Z>\\'IOA+HUW$A]\ !57+C- N1AKTP954="&7G;53E5M5$54<' Q>T/2CHQ-O?VKE(+UL?7V*SRJV56+JG.];[^SZYB'7*TGY3%E4%;.IYE21BC)}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}J1 M!"!\4<\P**0I A#]15^ON* <86GU(V6#9F;0:@M2A,D.)%=^4@Q*.VGJ$!"P_M"^<:@Q[|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|/@G9YOW>2WEK&M'G4B;= MSXXA<.U:3,"!X=YVA3+'&E#J5MJNB%@GKP) (]OBPQB1]E"^TI315I@ ^#01$ M_$0(:,Y5; Z0<66]K.K*=L"8R.A$Y,77*I MM&"X)VW8##:66+WW3\AA'D^@Y S48/+BD4 P#7*_52;8 .9DVF/*\|(4,'51 MDRRRH=:B.>"5G$|5_'#CDT.V^2'0,GW#L7JN?+&" 4,)D1@?K>FR/M8ZET#Q,/9TR(|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|QYM,^*OO031GKPBWH;36^3$0J.1%W*$*DMM! M5.2&0(=W#VVY8SWFK7<,&?/UGJ%BW'K78&%4Y1FZH#^T*#JV(:"QS[_0U#LT M*@SC&+18<%C2HC73Y;+ (;%7(FM,%SR4AF)QC0E#Q#9^62WY [1_P_FP2]9 M^29QC?6S7>V/DC .Z,HOXUK[E$T)AI2I&G/AS#@P>X5)"YCV2;@0) M2I*G$*?(7[_U>9=+]_+]&?%"%C\E[W1EJ? WK#VZ_DW#>M!KRC(@!BUA_O## M||^]?__^A_>S-[.JLOH_O3B8%3?/FE5OHCA!\+K7)ZWO8X[!B2XCOJELV[B; M)\A_N\+/[P(4%CV<_N/0L>D? _ZZ8K#'VR!+KM7JRG/1=;P8'1826^Q#1S34- M^HKQ<4^WUK0D\;,G]&;?#>M671]^=%10'SPD6%H#AEV=U-G1V;0W"*?10FT(M+-OAJT#;K#@[!P8,MPK FPV.]V'P:0N_R/D3F M2SHCY()_Z>/[W-ALE_^_4"G,92<9YN,)7Y^IMNY *$-ZY!T@MNB-/,B.U)> M\A7+>UA5-E?R71^5#(.W9>1*.AWF[C!.M^DUV=&5 [JF_;X]>;C0)H&1%T6& M%|A!,4_/V;E&2#YGQ] M/;$;]1*|%)\=]H6^&BD8=]T+_D_FD121B*[AMW2-+!%TAI*FS#^.(,..!M?B M+[9+EW%P0=<<=$N&WZ&R*_H_CB+Z%P+7@\ZL3N>24AM\EM2G^[T<;;3H@7&F@ MV 1?A1&ZS3AK)CZ)38G_:9C$N\R[E?0]6H5)R@[I6!"C4-IM,IL2__,8$F\# M<"MU%D)*:$?+.<]WE>?,'T9VYS@0*T%1RJ9._C*&3A1XW*KHT7N]#BB<>C91ZJ]AS&OGC*$)%;U<3 +;$<"0AUL/2K M7O3_PJUT_N836U7%P)VR#(U>B+A]IV7WX]BE_9Y(CZBZ)55$/W/QVN7,P:Z;LIXYU=R_: N!6Y@\)+XJ]'&U"F;>HK,I\E%UJ M"X!;F5]N$%G10?!'@E_2-Q=06]7!*-M3 1#'|K|&4:1209/(]N0'M]E5Y_#M> ATBP?(K-\DB2Y/4B]G;6+P0DA:RJ"!NUH=/(X5A-BC&-%U'*#7 M_T:B3M&ALZJ&48Y[.Q"<^]"_D$?%LB9C4JOP';H;%*%R'F!Q8 MNJ*_R& (+,Y16%3!P=RP$ 4/^1=R1G@8:M^9U,'!K+('A2@MSRD^0\Q1YO.FX M]=UJ,.' G6^+=:6$__9N_'M+^XL*GV,O"T+V1 *FDT^KH:Z/ .1Q&"5\B*K-=AO/K)BS+16E&S+!A%"P*E-$D@ M/:V2#B\R&NM."!|HFA/DA2B:^P>*@BM,V /7+>F+B!5>7]06M(AW.+U!Q^X= M6OB?AXY.$!GR&-FO\\S)=Y%79,BB]\(MVWB)WY$3#K*_F (X, 1SL+RJ7' M0B%OD)=(_O8OF9+IS,HK%JY-N\ NPXH%050C,$DRF+Q4(.#]J+0J5W4I M"V:M)AW\^+S#443!FW21!FAUIEZ609+M3>@]A5'(KGN@8V<>_+?&$469L#$T MW2E\R?K% :P#|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`L99SF#T)QQE(YJ?V!5.4YZ@RD<@ @Q,X=!U7$ M;D M%F5IZ"=TX2Z6IY3<82XE0!%*84P@Y<_D@[:(O;0.LQX9RE>,X90O[FO~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|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|/HD>>C7P8W\R6; MU@!YJ2'V.INB!.7GK!B\0%N"_#_/Z7_CE N_3B8;S!)P]_RWX5 Q:[0D:[' MO*)1.4|'$@8M$EB O GF5U&^SF=@<8^)VB913?A4N2XU2H)(.G" MR/JKHP-XL-'_@9GOWW^G>WQQ>EWF=-0PZDLTIP.%TX'"R3,*XLCA2#RCH]R= MD+TU]0V-0^]-$@">&#W=-- D^O:@Y)#LFZ+CC,4VOV<1KW+N#NS>B'WT\B(_ >:,>"PR?UMHLL@3TTI.L21FL23|E'2*#G^QX.N2? M."'QXB^[>2)$Q?28MSUB;JH"RH7P%!W2UB#9 U;D@:#E"'M[2<;^A*(_PM M7R4QE$U8 FVK"D%8/O;4N H:G".3KWI3(#I4Z:G5D1?V0X]|]S'UG\()2F. MN5=(N&0 O$:F2A"# ;:#JH_VS2\]ME2==T8Y6ZJJP1E>=C\?PS:K2H JW4:U

**MB'[^J=A5>61/^=1/^=1/^=1/;B2#N&GYZ'ER$YW<1"9<'|Z4<'"%AOZE66TN_R-MDY4>'M9.)A:%A[5@8U;GXV@=KP?9#HUM45=P8 M%LLQ+>KAZ6MR?R3UB9]=.(D3=(^80UF M%/Q'L9?@P+FE]O[X@]}G]{D;_[K'D*%5*0!/C1WSZ$(_5LM@=OWX@DI*VH#X#;R: (%YF,V@BNZZ!W-!HK* 'BF[)E 7GJ MT$LQ7]45Y#I[\V6*B$"YPZN#\/97GU#.0;#=*9@Y22]?_2AC0;_E+F?MI?_P MDEN$4&;US+PX MF%5-,]ZV.(9C3&8G(Z_V+A\'I"-AD MZ-;;R-.HB*8RCD-JTR[{ M$TARX7V4$2#E\+Y]1$0#ON+8D.>P#&A]49UM":F?'60K^Q:("T1Y5-6&< M>X3LV+YI@!/.P]1Z1X5S P5L/;]M*VXY ,<|O17& M!01':S>X>%R>,2U04),$P)&+@2Z:O.,1>Q-"/0MG'N,8*%^[-*D P!%)[^XC M1P95H9^\E+W,O+N@#%^@Q"?A5A+9KED6P#%';S4*04'58)X7[V%+D!ZON)U' M7E*|)BXY0Y+0@\D\HGF4)('B5"5U=]1G23Q"&*=(2]NJZX$'PZT"\&:#XYP? MZ8,2'#H 9TYB\VD(O-;6A #+-LWO/ MB*0L/"7G\4Q#[B8%(?0$+9NJO\JG PS"W%#F35V0/&NJ9+]6T-N?KK6..H33 MM00*/)7HS-O\$C F<*6=*34SX?ZV-G>]WV;5$$,8HM3&4QN?A$@ .,+!OY|I M':*=XL\.\62'%##U-/YLY*@I88)UDL:(T(%LZ\4[UEARY^U85Y,\K;TL V"5 MKRUG-9K?:0"EUMK07@#E<+],]I2@7S/*].4SFT|VTG>SA=3VIT>M@ JQ3TT$ M!)HRD).DA![&+*FP+H5&0#C96GO)_3P"6@ 3K-*R)*IPEF=\[YU|\%'LD1 + MCKX%=/;')*WH(.ZYMP"""?9&7S7^.DRWRPV6(N&9MX36_9&WU';V4A[0MGK2Y0Y2#X(IR?H6>2..1'2WZI^OE(TZ]Z'|1'!BAPWNEC\0+.5.K M6O*3//;H.KE!":LN&[-<", D:1T%9=IZP6W-^WHD_?]!U?R]>7(%CT?&1O[({] M[-=UX"3GV(#_;([Q1X)HGR4V;=@6EX[C*Z8Q8UO"F^)>_[()-+DC%&H8W+%0 MS4=\%9(DG<=Q^(Q(0L$NEN<13B@B%J8KMKPQ:G4<**)O*6. M:#9DJM%O"!'Y M)I$V7V=96G+\@'PV!X,Z'=Y+&4'7C!E ! M'4GODX'SQ!MJKXX!Z3.6S32K%8E5G4|/+[%%X<|+[U:<CTVZ.V'#4XWO"/81RA(MF(.$P4@]'((^)Z$_KDNP$B!PM,,SK"]#6G(<.DK!{ V3D'#I0R=%,/E:T% M;X0QN>^N).6D -)KZ@Y]0@QP.M%7F05 E%3331[4?M,X;$/,;N] [],#K)8 MWI$PIL.M%W$7^P/KLJJ^_GZ1@2CMZK)!5,)N\M&0&H]3Y:,[']61M!FS#;,':5+67&K6NOO1#$'YDY)EZ]T>80Z+[AJE[*J MDOY.6$T\<)8G90[.B@31UTF2>;%/NWN2BMSYTA)6%37''B@X^GOPV",(,;-T4^(S+A_6'A$^TRPD MMZJG_NX1-1"0NKG-F #H'XS\A$W(()F-1^+%B>=+,EZ:56'U$'NX]\0]_1SYB[Z=06S32K%8E5G4|/+[$%|X<|+[U6SCGW9EL'7A&KFAL>6R(' M T=/52]!.9

CW];ZYP("6+_-EA M-WMN,RD.]=DCN!4O'PAO}3@5MH0=2[OF6^ MV/%K@?(!-! C^U"+E$#?EP!RW!^LCJW(8!5+@&Y9A?V,(ZMD>Q(< +ULN]L# ME+.(?TS3F;W3=F;1 M3K!/(Y-,T9Q,3JMF%8FNMZ,8W&:86@6@4L*O@D<AT1UY'& M%I//.(_Q%EYMJHS17-3Y-'6HE\MWAK:(8ZX-FD'7]P"8M59_]271@PV;B=4*

M>S=O3W;>X#/KA#DUCS0V.7Q9QT\M8]"D.89R'\YSJ-QS%E)&. M88%I=D=3UP%Y6'?JVK,27$0@=!ML<;V)X?+FE,]6@>E*ERQ[UX,H _#!FTI MZTN\@=8DI(45I>N%I*45I.-P45YIA8(WZANM&A.T[\ =3@;:UMZ0TS?\&VXF M0H]>.^2VS0>5'GR#:GNKY'G;R:I52W#^P|.+FCVQP*\X$O9 ;YA+_'B)81W MC5727Q4'7<^S+&'/^TRD|&OQ/'RJX-IE;%:@T#IO KIF/LNAE[%72CAA2K<">G8TV=%LSZ?!2OJ6-,3_^NZ;[[Y[^V\ZR6S&%7G[^]5W MWWT'_T^\?;:)$_9W&JQ(]6E 4_82B73$1PKOP)'S,AGLA]4_?/\/][<__"'_ MA#!A8?GA4RCY+,_Z'?P#4F^;,1]+\L-W*P)A*]I<4I]NG_E"]X>WXM,?5ER/ M=$=]4"D)K/@\GH-*(&_^"(&!SO_Z_O=<"U!3LG4UPX^C3I1I:(8;8G1Z'4 @-MU39XP44KJ8WK.3/ BM$\?*

0H%M7#QO40%@0QYS*NP\?WWJ]__X9)6WW%$@(&-M%&A2^#!0I*N@0(SQ;1G+2;4@W3JPD/K)VQZ.OO5'.FXNMP9@&5UX"5R+3 M<]+7DR(:7.J%B,8\1AUO!ZFY[O4BZUV|\(9N#]F'WSN7+$C(#[Q1N)#+YM7M-M/"$]@_JJKOE*L=.G/'V!OJPU>O6ON.&-RQ;9)UAA|W)F=4$*LNC]I14\W+ M%9>W_>!^7GYKP45LOF<1G^]QXV)2HO&0@W-<,>E3B\U*H_;X(U)K:231B2D M0,11QJ4+85U7,'K@W;1^\AE/&BBV7];&+2BI2BD%P6ES#56E)F3G?R8(&#LHJ M_78,,6!FZ<0$+,-1IT>\?27$-58UZ(9[K#++5NT_Q?+SCB['D%G(>E6+YKM,? MI]'U)"=2.(POM.M'Y'QQ?Y?P 8,O>L79UCU-1.$3H_/UELZXP[R?#?11'[}> M>$.^I_S6DD/N9>TCR4N>Z1+.39;^\[H-?EC@Z+X^6C2S5T&E) MP:[361_DQSV6$MQ;N:VLN1 *A8(GEZK4\R.BR6YV10*)#,3O2WZP'SMCL MH6U5:*NU.?;R6F;"#ZXBGY&D*N4=[44Z#Q0NKNJI MMEB&7G,U(@//R@XXP|EU\A!

I)+/MX=5AYN.RPO9![V[XE;ILJS@;1+'<=@0K/-"$\:1ZY[$<;_5Y$-"WU2T'^06-?+-M M+EW/)05VJ_;ZX&[LMI0 ;Q?>FK,K;$C%|!7NUDR64"\2I2I+8+E#U'.OVZPG*

M;A#HH;WF\M'RMKC["&_GBA*^S>WY,>!T6UM1UW!/N[W'8H+:9#>[I?DB@MCZ MCF[=<7%L8L^GKXWM;_L!V[HCIF^]L$#5[X5IFBXH0"WM"S4%)Y;;OQ.JZGSW MZT3-[[VOCBX+B\V.3:^\V@N*4IO;/LVAZGJS:T:5<6QSR1>DQ0P^CB [BFGI M6>.:.UPXMU5#5>,4;I5T"#_76CY&W#QBL22_B*(#G;L1?:1S"+HW8M\E9BLH0 M>?EBWL#-'7-Q'Q;>[SF\%_4H--9J;(C;>?6ZU>^,'[?"ZI(ML@Z_$RXO1 N: MY!=)U4TYMZFUAO,<:61=+C?28($K":[

MG@)9F9S^R%XBMF8^O/U]L4\S/@@ECFJA3J6WPTB[Y@8OI/TSRS:%AYW:K]*2TB'@=8IV&D.Y#!GW4#U)F9(#4<4$\3EQB@7K)LV!-.&^7 M"#&KC>Z3.-C[D%LI>#>]T6-%>0/*EDG5'_6.?,A)07>D:MWI'Q.,YPHUZF9 M\D#\;2/D29|K-.=GZ$&67N@G2B:RCYT7<1YM3CV)8NX>%K,JC/MA4/?RD?(U!B@YUJ-I%P]O M?)Q(.';7SDFI#&M:?

*"9HXGO)*HXW%(L7Q:]^KR#<[RN7?RV]K@!H%/3QL=X MCQOCA8AND0>/0>7KLP5IUZ\BS:$KS4F[R9E*L[OUCW$I:41?8/76

MGBDUN<(O0N$5LJOO)#M*#)M)W923[-1YIE5!2GF,;]B^EUR*,-[!_FZ.QE>? MBR,#_V|[EM#@)K1/8FZ2%-313]C&4,0-<1:L55^N#":%R1M*#5|421YYX\6 ME=R+^0YY4PI "@G@?9A+UYMBV#V<8*3)1I7.AGB6(Q M!>62.7F'@(]ZTS_2B*]!0VZV\V#++(@:K-7BD+Q!+--8V!HP;YOK9H/9.@%%/-MO)#44_ZA09"S69&&<>]_CQO@L!+P<+/=-M>2P!;+

*[8>,F+!L!+VQ@WQK7K6'1OM+$E7@SKD'>HK\HY4$67Y(0= =2D6K*2 M%KING3I>KF\&4=*+M%\,X]39*07L>!:',"W;HT?-<&.E3]_C Y3&D3".ZY1'>=11:;XD[P%]T:SR$KYKA M#;,V8<;QXJYPFT(_(")386.G-\0_Q%%<5R\'E8YD&)-^N"/1 M6',U+CL[X8U2<|$'YW.I',JPS9E\/7'>C,%L='H#R-UBEFN>#Z),'J2ZB5YI MFL$466K;\6IJ2W/<0=RE9IV$27-;O"";*?'@%51)(_3U:0O0B1H$YX2J2D)Y M-J[:EDO+D @T^3M.}:!+!YR19JYK>0NSM37RZYAFL@->E!G&^TAD M-2&1@OAYAM-SG"3O)OJ0!3Z"5#;?

AU;P[S@A7EJ^UETLR^3><4DJH,^9*'(' M8@JBT]2,:;$*J&6Q6!G"1D<+IDYP! 0XS;TO.J;+Z@Z\% YA:K:F3LX)KCR6B MVO%Y\%[IB=5WZY^])/&B3+=$[^]#$_-Z:.Q.,5H[X)UGF(D]U\N!>E[NZ(/ MP%5P<'2N,*W6%QO>CT*JW!KT%Y6\|0>E/DH'ZI*V3DX=IM?,1XX]_@=WYKTD< M\4%)E'B4[Z7-9 ;<;#_BY4_\)1LU(P/.PMW45*SNAUT

%.QP>6H'E;&++5?M\UJB.]SK4.Y)SWCFF<)BT%3MX?T?4\ZT8=IKPA=8'!.YZVMA^].TF:FTS5/ M5YL-B<8D%UB"(=IX1V2F)W_C-/A1*'E,.D7+IW7LI\(T SH;*@L#6WBGY [R2QE.'<M7!&+@WG!%,)&25(TY[LB-@K,,G1 'UL&,)U=>$O%Y1'\'$_&<;!MJZ-KBQH96 M+&5,&R(-\[;Q1WJK255PLG*X^GC-;N8X5I=*QC&;M!HDUF' MN)*ZC>[<)SE?

TW@OJ,,>WMV[6Y\|XMXV O>E@3O0!UE$#?]>!/""PC UAH90 MP8WD[(CD))Y*'\$>BL'0Y^>#LRBY>;1467E,05/Y>-&W0"Y^MN>98>.XB.F M??$#2"\+U$JOFG3$"Q;IQ!\:!Q\C;Q\P"(2+. H@=T;\E6?B\G^48@!JR+M: M<-6ZMFGX%9%2D3>7=,U\=E+]?MY0D<)?F>X$K*O/0D*C3>/& MD&CJL(!0:!5[\/I<^FY%E?P"=(_K[\RSBU17\#+>>NSX#D=76]P^VZIA,?^H MJ2%>'VT7UY9ODE\D82?.:<^G1E'VGL+43&.%HR.X7,%)GU]>H_(7[-KE"%H MOTEBY!=)SHV7<3(T2?bD!98B[=[6W!2YU[7H5\]^RC%Y-O.I!WLC051.=O4 MN>4*I0Y-+1WTS<_,O>KV1LH>O0IFC2<;GK+#W426)Y!LCV<;+'")SIL%R46>_I3FB+(A=&MJED0=P.Y;G1U\K|&$##P.2^\]UAP$UUX.Y9Y8>NHW]4')U[UTKCVVD9;!P3 M

C.0!Q<6**D3('IV$Y&N?0C[A)?P/@^<\4.%[IOH MZC,\(WFW+E/ZVB-Z !WD43]4,K7([TL$,1H,5F5PI%0<2,XK[1P:,;C!T<7]

MAHLXK9#0T05W]OO>W1#7]L>;TP;23WBGO[91<,ML]3M)H ;G9VE3K%D5%1<': G7#1*Q0;4U7R7Q@=*Q9;H/;?[MAK>X3^*7Q-L^T+_M6V'E!^K'+Q%KV$)S+PUN,'3|*]4W.IR(

M@A?871MD^"9%*3=L(;_M64#R4"[\2FY!GD&W@*@*K$BA0GI T4RA[^W33TIK"\5O) Y0I=QDV4BF:ID"PYU8+OW#B*!\APJ.[^(1+85\=9\ M<0?U&=:49?

O$T:ON\YOKIGB!)UI?"U\G5.Y3\1&#RJRG'6?A9NW;,!,Y2)L M60Y*BT0=^L8PX,F<7ACI$REH"G6+0O&GDF-5A?Z'&]@FY#YP_TD_A&G]AN MUG>14--L

=,Y3=EQ<7"B$7_4=#_'#R+YY&NH0^2RK-4W$+;F(NGK)\ M@1H;&,^ PEH".OFG@,%B4C4M#N]BE&7L=?B$:1HLU()@*E!PZ@.4X8AHW4/D M3)L)1)MAD4"|_\Y8AUW3 *-

)&:Y$H:68ATYFCEM#B,-10G0EGEMK]?M&BW/C&,Q[VU : MU9; Y-8R .J1^X6:FWP%X[NU4@?W.D]L_=>\BO-[G*W/,)?W[XD7:0!SBAKY:L5L88IS:07)DMQ-

(2TWQ9T8HV3S5(O.^/6,,M]HFW/= 9 O,DO M3XXQET+C"P#(8XOT!LJ"P|<"F"?]# Z*C^3576H A!8$3=7=!I}>HL=2>P;K MCZFDG%SA1==)[-,'9:>9@AY?1:Q!%

*275D"1L;MO,B/#X#C8%FGD-8Y!76S E)=?YMT'G-91M9GV(/9HI9.U8fVB)'01-,2]HH:(T'&7%U!T M\TCP&RVY"^BR7 XK)LYQ<76V$%]>G5W*<1!"GY?;$/GV

MC5WS3K:0SW<2[M9W,_%VS76<7'CIQF#-H. ^)&/CZ:.];YFNZ(0>HGDI87/HK MVU5RBS.6+,6>%6QL[O,)+I8-8 O+ZZ MV*|Q+ MQ)O>!A>E#P3QWGL#&1%?L^J69

&F]Y4]L*VC@G MZGCRK!0'/I4"0; 7(I%"}]OH]T=IRD@4=F!],Q.+17KQ,X7@S[.!# M6_ #H>:\R0$-BBL#Q=!3N$Z],/'+LM5Z)0]TDT0^X;6HH..$@2HP0XXL87BH M O2-

N':.@}^!"BUA3IW/X,LDF-KJQMD$U2!Q4PX2=_5263./#UAL>+HW@F9T M4+)ZK^/D@::4H^CF/ HNZ2L-XQWTO(O:39F%4S 8^$CQO"+]DLXZ\'@"QA5

M!]DIVQASG(U6WFX0BV'8[QMOB4B46 !Y7,Q0.U&)/39C6Y>;}:>E/BVL2T:'/8 MYC2PNC73E)&A7O(U*$0J- M'PL^&>0!9RETO/..AQR.I$=U-08,E*I2>I\B,HXP8-1,5U!D4TS2[SY>4U

MAV!^=QRE< \&AZLRN"Q#C2,I6*Y(P53N:ARQ M=?*&UO$&..+W;<#!)0!W E%@-*\NST5Q=*;:D>7265PIF^PJ5%!;7QKDF7[G M4= V&[,. 2?X3&C-7KNXYN21SZHG4G;\JU\%

(TX)CTO1'&V<->;PX]O(G=/N MYMDD:FF7XZH1=XI=WML[??RVWR &(, GHZ1I,BK>(BLD9QB/'1T9 MW?C\D%E%@37]R8_(-FO00N6A_?V*#3QO%I-C2[X5;9

MTMLX3<<&'/^\Q[#NE3S&5;,}+.IY<1@02DEZ6]'K,?1&B1H&%@&P/P,*&R.! QT64B,"E9(WH: MWH&%4(6NP_A3?F&TR2Q.KF_<>P=8I*=/<5X7 =)48I^E:7,5.8U)\Y#(C2-O4T# M[5)__ZD?

#:RX,EB3P5E,.4.2Q21G*5.]!-.J *M7+\#]*)MC?O-P)3:PN(O7 M^I*J1?41%+|2>^2;6^/DU?M\XI1HWXN80.:RCB!LI[YQ7E?G1"ZFB MC@#$E,DGPGXZ1 "-\|)/X\GO0#HX46"T9;-3

M<.)KDG)1H#C83AEE?_K+AROH)628]VC9B95*K 2N!-AR_%315&'J-13G%08J MV,]?(=*)D13*)SZ">VMY[#X:6L =;HMA6\AX)UL#=)AQRQC3^=-4)]F=/[*2

M"'"C/GZY9Y&6^A?.G=B3:]+ T#VQB 1PN5Q8&(B2X3@4G)>K[S)X-T?0=V.CZ! M:C*,TQ.HN_5E_N1-6CUR *^B4>1 ,{#RB!2?=*R(^U"'G3$CK-.T)]2##%24

M&:/,Z/+TA/G,_2P(>/,F!E.Q7ZHLBXIE V%ZM9) ?.MXH17FMVMN4S\WYV[3/W) MX8086W9JW'/J26M!6T]#-1MSAT$L#5BTVL.W'+WA-7(O",1F @\H/R^L*JK2

MLV=9>#R+13.N%\L.2AE\+SOCGY]MA9P\0G-!W6U3S6W1^FZ5[]77%2E%(.?9 M&?\9SJ0@1)3$[<:5,L.)#VQ|0WBW'PZ97_K6BD34S1ECE[ET0Z9!/YR@WEOS MVBRQJO/B..&QZ';

<7WWX6$4-PF.WA6:?U>;OAU||HHG/4GV:7'L7 MG.#=1U_=-/:X_3)FL%JI[?AU3IZ4]W/6]TK7%"""T,T?NI>9*#"Z3)3%5KYH M^#AXZF5(V>\CK)(<-:: 8$%3:AZJ3-

F"N653W.>3*;J=S>_2@DM)D9R6"M3 MV'<-WD#X]O7#K/7YK#64>:::IRY9XT]4M9FM8QPF_H3\(RF7[F;_IR>9QGL MZ'5UP@FI_73N,/%=QD:>F=Q3G>-.MI"Z0?:^&+Y4$(X

WR\;1HG3L94%C1[ZJ_3 M9$.?S/E?Y],F")9BC>%LMN3 .F+*5,!)R5BF_I/B1VF<@ON*?)CF$,|\ZH35 MB58DWD$01#5O&GIPVNO8X%%YG?SXU-A\BZZ#RD+0MY]5.HX$VD@L"'=

[*F'1] MZU_=A4T5"8B7B>^/3AH-S@=(<^7&RZ;GUY'-JW4]^\P9DJ[G\!U%/+VFS[2R+TBP1-EH1;F?F M>V%X4&:S7Z6UY 0.DIO92AW11+>^+W$@BA#J91TA!8TE_G-UC#_/=1\4W'FM)E/9.CH_VG\!D]#@.DZN/OL;KN*),7J.'Q;H+V0TL67)YN/XD<07--)84W5P MM9"6(_R376J=^M+^IP5H^U%G&:I>9K&?(Z5T>;GEFWJEA$&

M>:19%M+@0YOI!AEKI#&/+W;M5PTM=NAB'U4L:VGA2G;):G6,#|(_H]$Y*0 M3UR:D_ 407F62HE(\"+-.WC\MQGMD)E\2=:TO%*QFIG_0'=E(L\##4$)L.8! M+*\+_#'OCG.X&&H'7?

9^6U_$*6QI-;"SC'!3)+>1+4IMO?\4>$H@&P?:*&R.! QT64B,"E9(WH: MWH&%4(6NP_A3?F&TR2Q.KF_<>P=8I*=/<5X7 =)48I^E:7,5.8U)\Y#(C2-O4T# M[5)__ZD?

FB0MSRR+*+7#!9PS,9$#6]<,=E,::ZX;@QDYXP]9<=#O# MS&WIVX*+N/(O^#@?:^?0_F@^_E5*>$MY7;,)"+,/KVWDM:0?[E@WUEVPM(B\L MULU%MS-FSQ/KPP;RB?

5OV+!%$>SFA50U-NQ% '2X|?%L#+$> %A@ X5EAW& M5,-*L.(I\HW^\(,.\4XZ(D;BN:@SG@_R$%|]4+ 3X?.)HES.=P"U^<1T'] M

Z7E/4U8')P^6IX7W2M.V1XX=%^MUU1;#7UV(7!#EYO?1(6_>27 "Z&.[#"F MJOE* K$BQXI4(LHOX4#Z^+-:RDZ*60G;PKIOUZ14Hj0!4(%(')[""L))\ MA@96FC8H3 L/7?

C%5R/^N)64XL.D^LI&%FYQ.UY,\?-IV6AN'9R_4*S% !U3 MP-|. -15U+KZ=6\]8]B"FXJ4?PR+.*:'=$9[S/@J_0LRVS-]85$$8^^DQIMV MP!U_"2$6%UJQ#Y6/^]TNI"(,*@03P',S-

Q'<:!#941TO1)GWQCW\];2"-M 9 M=L4I/|558'":]<*'E$\;$875Q(\|=1[%,+%$P%(_C--]0LO$<9$VSBK&3MYX MNHFXO3@^W7LL."WKHV^%.] U6]D!?=0$;^#!!'WJE@4]

@35IS0N9'4&]G<* MJVW9;$7N^-#NS?#FHT&U>-N6D"\(% "22)HYH$Y44$FHSBSKE\5:F]XQ$"1[N#K/]$XADP M2G[QPS[4^%\#_ M0'W*7B&[K6Z%F^B!%F]:B.$"?

+@Y5BW01(S.MBQ68O58@LB1VYIZ%G%S64B MK8"4,N-):%,~ YO+9FN$D@3"PZ^;BJ,\O5YQV- M4AH\Q0\I3SBX:CYDK[2,-Z!$W 9H+Y90"+,\3H9\;2YA

M:PC37$Q8_B:YH&+#)]A$=86"SD\U/8L]1Q5L4NUQ[OO@$KF]/#ZW_#EA&3=D M44(-#&4XS;-&&3$FVK6>4JW)!EGD2&A9R6F7\5XN7AZY(|_Y!.*>Q>LU_U"6 M_Q

1:S";F1;_D!CV?E(36H>|>^\P!=[U);LXL!MDMPZDZT5SD3 W3,/Q&*<- MRIT4J$|$SES1%($=;5IO*CQ[_$"SXG'2BSA*62#2O>)(V1.(DP",Q(V8[&D@ M3GZ[33Z<|&(P;.3M-

*@VD,]B<&VLCM:1|:L4:HV5SRS[IE#US2DA%P2)R4C MXG4 E^CFRI]V;6@&XV0E3%E'L[K[(8]9/D8L2V^B+-8 33R4!F+L!8]3Z M$0^.1X/5&?-

.27V!3'T.1"W%G9:B02OE\!'LN>?2S8LVLJNJ8@AUW94KCI(G M$4PA1SV>[E5HPR?R7-I&YQVI?+=&\2||T/HQ@C3>^@!4O/X'98J;C&30!S%T

MFFI<0F57!^30.'S^&<CTRIG87K!KJ&%/5/1O*F9)LXV?D$TW@429_+(?@KWX MVH-,&)$(P\$3R,#33,5'SA:@DUM1,CC)@BEX$& R?]K+7&IWN,M4R^5+SN*5

M1\XKS=_ QN&7>,PM9=K#P8,4TC' CZZ2V2U2R0+7%!CN'3ZFQK0RPHY2K>1"%A M(9GS|QKZK<'_V\23;+TY=MYKF?]* R=ZFBL>9ZOL1WE<:1%,^6YO--&V%&\ M3>3Q>Z#K?

2;O4"D3IU2]$$W$1)LWYG+$B;A,)0N]S/TZW01FR(G6Y\M.WHB; M4+G=_CED_NB|\?A;MLF+%[&_"T>''>HX9(§LMA$%]Y"UE ?!W?]Z>%SWD7\B

MMCDZ+|]:HHT3WR:Q8.VJK@W">,_PV55O\,5>10]1G'=)4S|AN^>)DY-T^A>K@ M.FI ZRSTSDM9>K=6K53(J8C/I9B?KG. N>>=?4,3)_HY>Q>>'JS,Q7.AL6S3 MXD8Q;H/A F/?

JMHV,&%%:O*MB)!0G%,K,]V*G*CA!^!))2@I)"6_@*Q$"#M) MYX'1:U:,&Q4S+12,1A$I.3 P5U8:>-C3Q=G2?,3^]B7P|\+4W1XR!!GI6 MF:#ZMLB14IRRR)6^Y\ ,YA4@1-5

E6A,LP@03;=7UQ[>?$5>_M&H--2UO$2-.E80DSNH,(,:93[,&75Q_.WLX<5UH$^9*4,->/Z31-F,I9O-M7 M)HT\I'%[\#2"""*A&J334 MZ5FU?>@E)*C=EDDJ >"?

GZ0()"QDF/G:GPO#]}D:#W5SY(Q)R?DD@<4!+CHW M4I?/,,EH!5CR$Y>*RLM YU%0&(+1]#WUP-^#N^B!^OLD@:<@HN!#"'"7%/T69-MF)*K9ZHOXG8W'_;4+++]^+MXXD=

f)+U#+W9F#,,Y-;3?]#\Y2X%(2(2,)9<@!,SC:4_&59RP..)+Q7/HM^H;4BW1^C M^#FER:LPK_P5W-Y#.^/?_MF:^2*R!EM;S5.OQ MCU$!Y=WZDC[WO7W:V&490-.F_-\[+01?]!IE=]&.P-

Y? @PB]I3G&!PM*)P M/3W'I/0Z3H#5.>SPO<@R&*TA:H$&8XW>M!9SNC%<,[N''''R7@!!< M$%$F"@##H\!197)UUS&^F$DKNX/HY;IR"O2@>)G!5E<]R#]WVK&E9&&Y,#PU

MENNM-%'!+WW#F" \RC@GR1[JFY:!QH#2*)$\EMVDNW<=:7WA(FF\PG0[Q71>;KIB2'0,65'& A;N,[YD?H1C$V&3 M]\|^N]H(-\VW>[V67]6?>4ED-*

*>9WM/D<>,9O'<_!:/%P)MEVVI SQ*714"A M;5VM *0B%*FD(H58Q;.]I6#B/8Y<-,)E(T(XE/B)T=Z7(! W:WG,>EXW=BKF*!Z@1WFHU1+8[? M':HF?$(L*A=]lI+(@;@<-TY_X*

*IL&4),+ZP U;]JB^$A!4_$=37R6"LL;X9=K MH9#CH&OSG,*I4XD0X5(.N|C&=W?S#-)=U':Y%D2HL2*Y(BLB59&U!')EX)X? M?+Q2)\|YBU(E1"/(PG_,XY$H_VV*L7K8,S&C!Z/ M@:1PQ@_T8^]1>9!A /R^PCM)E\,L/5/UL3X92ODB$M^TUXFAZE=TCDPE(%'F MD)}\|S%BKD|CA"",. QHDD+1U^SP(^&HI&6TJS# M-Q^0*BTSC5;(VP.>\OR*2.P'VJ[*2"8D3(D7 @U8XC%=<(_2<3HQN*1?L(D[- MDNSTK7'#28>6*EAHFN*%@BZ!A_JJH+LB0!G+C:NI5%7#,@0>Q0&HO6RZ6YJF ME H%[N,D6\XWU&[G8TD14-*

A1",YD=@IE(2(4A93>&]E\&QL]F^T3!, ';M@G7]9##/QX8K,PY]5L<1LZJ[E*O(P1K/9&Y^,]5NE\G[3^]9Q+;],8'< M%LL,UI7D&8)\|%+UIX<01*Q9]N#W1CQ#R*

MB=|HM>S>Z7E"%$ 1J6XL9#I4[/VL^ V5Q90_IX+7 1%W/ RURB)+Z/!YH8#3?Z^Z% M$Y-[;JW.XS]ZX\VSF0H^U.U+^]1@XIX(YM*|%]n:A/KX3Z:>0 :/YW+TI<;,B M:IJ#6_'1B(/H? 7?(O^OQ*M>3&FY &&DES8E<'U)X 62L0E9.XR1Q4K)6MU16 M(H,J;X$&>S"93;\;-,I,D(_5>7A+ZDM]7>"R3+K95,.L+VY\Z66!^K3#H"-> M[.@G_O IB,HE+VLKW@9 4-JA1TCQG4R 1,3)+%L#N?2,X6-X$^[*%&^=WZWDNR MB":0V>E%<+|SXV7G";W?/X?,#P|/B<=G0$T+MKX$<$;Z<%N4>SR]>B/?V!FF MR^"\0L$-O'PG^1&_8$@RSI`/;]=SI-D@NF|VSA.*

['"5R6Y/4J&!#@2SI(4 M/(ED.O\Q'7X?F0H_5>++XW7#!^&>E9"0M1"MZ"-G()RX< M8;ETD!,%XN$9#1S;5S]F@&!$D8R4HA%5-@+"D4(ZDHN':W3Y,GW8R?:B5^8:

M@T%9(GZ\8Z,3Z$:Z%W$A\HA43@$Z@2@/G<#3(%(A2T,pW%2RW95R MTQT\^7GN^\F>!K?,>X9JOURO=C#]U;2/ZV0IP8Y8/@@=?*

_\Y#N&>)Y%ON_L@GS/WT6"HVYYOH:X9."X\M$(C_P"0MA'ES?BD@(8A_#>@6_@D MH+LX95D^67CVHE_%C:4UB[S(9QP+6)1F+-N+]J7?P-N'4%V(MQ$YO:\R.-)5

*MBZE5$Q1X;.6%\LD()^)OO(0')4U8"H\6BKW'(_Y0-1*Z{(0M\BG/X1MR'J8Q M%R)GFV[B)#OCA+8KLF$O&[X(#QDW9,";,P 5,692S7*D_N"FMY!!_T,I-Q&_$ M>P8LY4,C9GU)XOU.-*

*(4,I3C*6 3>?2=+#HLS/WT^@V]?Z&RS(I)1OAX9\M: M|L5MZ=I\/+R/0^8710F;+V#'ER90 M=.?PP=0I+BMJFN$$FBZ]BI3TIC;X!NQ.20OD_;V0'E]TK0C3G?N+*

[Y%'I>>VG<3O7HO-+K?>'P@]L5X MX(7M\[?N+CB=MH^^Y2RNHISWRB9RI}$,]I.9X D<#F+\|VQH1(IXSC^%FUY_ MJ:B[#?&9-'2Q/2-VXL_]O^U9RL##6O;^-4UQXI")?NK>3%,[?

$.CD;2#I\|V M*%&H.MSK/E:P=:-;VWA9KJG?XFYNN1SWM#15:W!0ZU.UC\\)@X)N[^(TBZ-W M+$Y1IOE/"6C_C7ZZ9M8-IS_VU;N2GZ FZ]U;YEG!&^P7',B>XD<:

*MAC=1M;FFKT@_CA+.H+=@G7+N,XP,\NG02*6QL3AU(U9YU?$H9*RS(_T%MG MXF&(%+)$8Y)"5>=]Q*-'Y(PFI3#P1E$AS;PS)4<6 ;DI\;>39ER%D3X VV M*

*NY0@+GB[ZS>OW-#';N5,)2?&RK-#=7L31:OMQJ.,#?1U6<^STSOUBZCSL)&^2CPL1*6W@!H#:GXK%,A1SP57U8 M@5%## #Q"H$$!.0B*1@P\YN(6$W<8]J^ L-?*

E89O&]%6Y%PU>R'F_(.14G,_ MT&U>@Z,5_SU',G64@4.L)38!_B\Y#;.-^(RO=+K?;9/Z,>47GW> MT8BS/T\?;$HY;L,5MDOZ2L-X_"2?!\Q-[#)!_%P-:5EFY8HUI@@'ZHF57G\ M0,7')?

$TRM&P5$:Q>)XFBGF?$R;9T3[MK8UG,XQFO[FQ;$$CV9^ MS-]\^Q&>?+L0[_IE;0H[8X5@3XG:WCY PX MKOCT,!,O>4/,%6R)X+LB.6=WQY0S&N?

E);$O4/[L+I8+,9QC2Z3(,W,7N+2E MXO5(XB<,'L+T8*BF\SY(WE,P8V2RW95R MTQT\^7GN^\F>!K?,>X9JOURO=C#]U;0?,QT5L&FO0=><<##&4>W!I-?%>;$Z? M

*S1,O[GKZ&7M.7[^F4X, M;R(H#]9[<[OLAA.1^NIM=C G^R!?[O71P,*1&52\|Q\NR)$ZJTX_1 #+TD)* M+$3G8K,.TG7(QG],ZD 1."!ICCUH1]A[] M\2[L!FDQN,P3;%O*

,BRP6Q')4'P@6!+)$^-8-KE(NG9HEE6:)2K.DTBQ,\'2T M])O7$L"&:\YG4BQZ,37%W/ IENOW-!%VZ#;,3WC/7,^)?^I0&D&$1#C"O6>1%/F^7YN]B-$UP;3/ B633V;)<

*MG5]EGCQ=.XVN@!=3M:=7_%*LJ84%L@@IX%-N0W_9RZ&>7Q_SK4]!Y\U\VX MC"@13;GAE,LC-O *@"W*1R\UET'0%F'G-1.*7*88N2BS, 7A\NN@)<,'0F!O3*

MV;:D_\4/%W5+6AXM)/'?Q&!OI[5BTZ_I7'"DOTFE":D9$L=)2S9]:+9&P&. M6GW1Q;:'CQZ+,N,TO8M@?966M[BB0/QOL]UY+!%51OE:Z.7D7NT(,CA'B[%V M4;=/^M+*

*NZTR6).A(00,R1M@^36@3K'[N(,_P':5V_:&75#/L'KJ<10 M_ZV.A@+.2-R*X][:,)(I:?!"*>R%YI/X^_19E&>V9G\^;U8.?MQQQXZR/*FG2?]^W1&'[0 [F"45U_LB#^PAFHS?*

*KMI+PD7"G[CR M;:L\}6K:]QG).=-'(#(7EI+5,L'6T1.KG1BS M+[2N"=-)'/4,&O\C|A/OFF[B,/C VXASP.)K"B70+FGH'6XL,"X, MYI-4?!H6<,G.88Q6?)(%;EP74-J^<[*I?*

*IP/T%#^.))5LA M'A'3D)L*_ >/6 MS-IM.TB,*QLX/FGB%D7I>5!"0L1&BL#(=G M3)C!A@U%XPJNY$%4LHV(PKBL!7IP# ^4S6*X7;1RD? MDN[6^1VHQOS3EK:(H;-*

*+PQ(@=0V1PV"GV.//,I,*A9@>\(_R*VMBRYH\'V3E MZGB\]Z+#O @VF?H*X968>]ZMBVN.#M=+FTQ-I*PB+]\@IH<_KZZ\&04K%4V:. M-9%-W01-POJ=J5 -/<###F\= @!*ES4*

*4X%FOS122>@,I'2ZK1&H3L_FLR@7S(G MIK3-6IJ;+0--M'.5AC;+P9$)9B@JB)13$R0(8DU=-;S?C]K10S:>^ M66 H]^!3A9P\KCH$);8,*J)/- !3?*

%H2=QO+/+DM7L^V]1A(<&HU;4Q($]:+R H]3*/#DQ2TB8%<:M!^4>19B3> MOOV,@G)*;1-)TLE3(3Z'ACV\1L!'_1U-LL,]5R?C, ,&KO^V9>$;\"3:Y-,;I

MT1UWW;U0^U!>.<>&,ZMP:#[YSEY%=$,! +TI(%^A4P^4W+Y[<@-L$L4#5 M^]WAB:,]_\QTX[593]P T$<I-?0-NN$-^SI"3^+N*P)\R"_ %9A-U(*""5+F -G/2GPN[*+?MSDBb(9@M.4?*

822DGY3,0;_SND M\ <\!|R-DXSJ77RN-9IF^+%('BY9EU#0<#O)/JB0K4LHB M7_)6I%F1(;Q;U4'/448S&IO>TC3]4PWX.T4>5$N\CRE=[\-MM;E09OUQ U5 M;/0W6OE5W?

"3!_A)YKY2X6.%:"5HT@:(C>?,7ZB7!UTXN(I5SK;MU>=JH M,8NN++X8;M6P=O.HJ2'>.&T7U\+>U<;= M3I1WCEZ$YI70M_H=UHXNN,/41%\U6MO:XPU:

*(ZD%V(QB,NX7;EE:VI=[:I. MJG%K+"?L99.=Q>NS?9J7M<&2T,H%A(N2%%2+7Q_SK4]!Y\U\VX MC"@13;GAE,LC-O *@"W*1R\UET'0%F'G-1.*7*88N2BS, 7A\NN@)<,'0F!O3*

{X\4> ^RH.3F;EDHC[S)3D M?,4PNR(E;[$B4+F/N 6H.2FYB+?;.'K,8O_7G{TD\72)]YV-<4:-F8[E48>V M?))3C6ZY+3P7P*)UG&SEY?N$AG,Y2,,+YB3%+B33SG[>8\LIM-?4B;"-"EH*

MN\FHJ=M'CBA;U+VEZBW.+/+YU&S?%+E57Q?ATL M3121BB5,0$1I)NT"1@@V-G53,\>X^DP3GZ7T;MTP2VK"N.X..$/-7-=RFM': M&OD\PTQVR^L,./CR6)2O<&@N AP&*

(%CM3&N1@CH\%M2X^IE,/C^3PKI?UR9" M^1LN)%>D'98:6[\6U[U6"@ =-T&/.E]!>X8:R1>\(F0XA)%IE-, M^,6<%&O/2@4IT R):Z,&WM<0-L:-U>HNZQGCG_=TB# 55H =^*

M@=S=Y75%+T^>%O^YU/U73-),V M2^]+G2_^S?=WZS5=-4@NEOC[$Y#+"33N[@+;!"!@)"<+>5 M4LP[O9O0#G7U"N(.[])GU[5)M9#02]-R7GN7/$#23\O\KZT[3HPRUK16)$37*

M&.]XV2WRX/-=H SC9$Z;Q D1U!W.!1NU;9T$MO=8H._]IWTMS1?FOY8F>BT> M;'W2=Y_0ZWT4T, @54';%<[FNBG7/YN;(=\HM4>ZK=_^-^DXD NXNB5)IEXW[ED5^P<-*

@]FHY+K2VPKB, MP'[[=<3IP_UU5Q+P#?HAGWSVTV'<8N@=5#=S+Y9)"[GR&I'C6.Y\G6AXF[WRV MJB3];SRH$<\?3W&V1H0D!4AZDQ=<,5<&O&X M.0W2:QZR-

*VFZ]W@X;_/TC#OA!*1^.A\5]6GI@7>582CWB%(^@CP[^Y*"@;)7 MI;R8ZY1.?Z 9U*T4+!RIC3ZQAK)<[0N4OM5I.@LX%0J=1X$X\4CO]EF:>1&\ M3_%$DZW&.@;=<*

.4J=XJ1'7UP0M2QI/GEG O1S)@B@\5@2X.$&JN53G:^(= M2^2Q37;JK+M3[P|I6,O=K1_+1?B%%X8T>'>X\OQ-O6V?LI>>=''#@37+=9ZS M|R&*%U#LJ6;]S'Y%!:PB<[/:>)*BD.<#*

*6%.>KEYPL:Y%2M3Y9MW?5VF%$>2+\2]QV"MQKQ?5+PK@=58; >_')+\8<-;U;%K M Y9F8'SA2B>1+FH?P.U;H?*5]V%&A77=;. ST'=XIELF|K'RA7W^XYK 8^C*

*MA!."+5BG.18=1 ;YT<9(I2S&\X?-1"[>]Q/>8"\N6L"I[8XF+ YF/]UU8QPY M!E77BIG=\1BD7#DNOTQ)*8&#,UTWEBHIB=>&T,V,BR(.]PE3-W +,]SM,W@9 MT,*

*()P58LU#GWI2*TL!FOL3H3S'/+TB&"N7K<, ^W4=NBT:G);E0;9%09Q>Z2K M9LM%6$I4R M$@SL2+>RTLB'E@D:TI3LO/8\<;"8LH90W\!ZT_4WT3L,WLZ M^<,K+2QQ8*

<<]K9<'UC'#R!V$+:+U^_K(ZB,NY";:[?,TJY(UJ7C;?\?ED2,1 M3;N+%6C:X8RS3LW^<7%3(^13Y%:1!P],@B@YGS3M6#KLGDQOG/OFXRZ@ M0ET

*JH;Y='AGT7KSM+T*8]0PTU:.[:JK2'#EZ& H_XEIDJI[D,O=;R_G2CLY.]>F7V)"9/3YQ72P6[EN8X$*?'@\B//DVL" MI!V6KFO2M+5R76N'Y?LFOFZ=OO6R_-92U3J=YPXO66?*

*==\5FL|AJ;BVI8|!M M67ZLT[O-FX_[+,>GM9);\^R5/+;(CS&RPEU QT&E\#DI G0)@5OD?& *]HGUO|L M#?]S0G_(=7"4Y>'^A\< ?E>?=]3/: 7A7N!7F/'98&=?O-*

JB)"GNO^.'LBFU#=E:)-(4F^BQ%LJ'W07%<'00-J4!H * !S'R8%Z"8I= M+S%# 2F&4FPARPZ]P$S7=UEXUFJ!-DAK[+@<5&L72[2G5Y1QP=LT:E<$D8#8*

M;+_N%Y1V=#O#P^H=;'%#9IUQVGRS%Z?:W\2[D>9SIR+=CGJ+?31ZM%'5.,H91 MS4_3DP3NJ!YB#|/R9\?|H4;,("TF*XMV$D^.IA4NK,)?B1++F#BNR5>S &NPP*

*MSP.R_H8&>WA6[*8*Z)I%'+*.W)4&-Q$WQ0L4KI80W9:WW)L(M 89I/:(:[.]M*. %CH%Z##X&RMG!-DK%\$QP)!5+((GG:S_O]-VZ\B#9O%##0VP.G'>EW*=+W:*

MM_C\KT7&H;Z54YL_!VP.->99F>K#OW-U:=859S@-T;^VRC/HAR\$!TD_>+75 M ?2.5U5Z&WQ,Z7H?

*WK*U]D7G=>E>OZI_F;>7_5;HN6B#D(C@Y5&K\OQ^ADGU_V"RZ+37FZWH;CG2B MSQ)C_4CR<6\?G'@Z.9-_E"4:754XFLD K+_+Y[QH<+Z%AY+ ^WG2-*

M:!2AQ0)!AVT.H4%#99%@T:7+-!/D"%5'X$I6Q533YHS1-)(HS! /19"H+J1;P M]!:8>5.UQ1!F&ZH&!'##1W1;-&^D=O7&"Q<#=+*"Q@=]UIAZ\>3KI:*M$+B1D

*M1"E|H'''U)X'''KM/M'PE;Z/HVPS8,O C.B7A%LZ MFPV'K&.*7PI,:?6:%ZA #"+E(%*0!4"4===M=4E^<\Y$?WJX G7Z/'YT E9\^ MQ5,L6='ZDK#HR$+#(2@G]*4@S[$Z\P(.<.> $R*

9FP9ZAA=_G$AZ,(Y]S=

*M@5'JF(${"QA*5)5=X6$BN0 #!BED(*OQ1RPX3T.$NB5^>~<+IOH%S/'9N!|]H"C M7D73,L+[&@./9B71=5V4O^4^KT8HS(6P=G$6I)U6:*=GN_L0@G+Z&/FZ ME/LE$<|9\;LR3TGN1?7?Z<6^+TG^=YP_8#]YBRJ/IERG!"S\U+_"I6RBBMMJ^8M7"(F.N(<58*N4-\#KD8^ MP)CG;4%_!W&9DU-;H2).2SY@Z@O,9\F2$N_$:DD] ;S8%;X/R_-1,5_Q2IG) M P/"?,3P/ ;9Z8^YO\ M,)0L^/U]?@\|877Z9IMWE4KN666"FR05?Z+MOK/]Q;N$^*!)H_>;6,D4 MK1)\P/30;P?WS#.U* MD>L,,UM6;7F!- %^3TCDV6W.S=SQ<2VRAYT.,'\'{ 5B1_*&FP*L6\]9U50R M0^=U!FIHRHTTU2MW(-1$N. ICD0T;>?M?C#X^%M1R4=8*.M,+;K@)<6\R+6+EL7^2Y):= (T_9F4.+Y3Z%:WMA&T'F;W#@%ZA-(.,;D"CTI. MWCY#E:1+@V!;MD=MHVVO,J0 9*_+D,O 9&&[5R^,Z MI9-[",LQ<'ZV;W3M' MXP$[&X7B#E[O&(>'- 8!PA)Y191LSL[D7"H$SV9VMI';AK\2=!LV#+.LH$5] MS9U0LS4_N/""]$6#XFE"F.R),O0/W@O>;#=%3NO?T\,)?#BB=FA7C1#@=#C)-CUGSA6H M $]+TW2:;N]78ZT!>YE) M9*$? ^2YZ'-#JD;2F^U-"_U0S(J?FIZHCF;_#92!=`SA< MMBIW;+G0K&.%N6'I]_)5?T5*UQQ@S<^X7,?!+*M9MK.'.G(&\%L^:.OS.9l;'W$OS? QAV2>FT.:G(/DTRXZ]=)W)ZWTFRQ[HF\V$+F_>;^OJ4 MA9#E3L\ET;\0&9>V,3.CM4JQ<{7(HTC]*>GZ*YE[A1G=6'(Q'VEC_[ZA=NQW ML# ?.>/]?D%YM 4@('7O?*0F^ISSD<$'S!?S95[!'S&7C^\1,.7W:T M#B?[LR#$>1#)H:1W\SN\E6?1!\NB8RU"_C4TEC]DBHAH9-,_M/+2(>'4V$.D]K8'-^C&5%G!*VWO"IEC;_C"OJ0$LE"W-^C#&!]FHZ?(<@P&C M$BP||YO_&]/2O#GV"\J[,QAAS@2>Z2_C."JY??E+\XN7X M-L[3,,Y"O^TB$01Y/F0Z4O]2=A]6"Y!% MR;F^("OXA=Y.TTM8&I9=@"D_4]_*V;M>EER>_5W<#6Z=NO=F;QO\8&9G:Y.> M?KE7@1GP"U-65-?&@!WF%PL,!32IG<0^NR(CHE]+L_#@LOW14WZ@.G#MN3O0EPDQ@^?GA1?1 M6WQ=M:-!"@OS#X.T5?NT&81TP.?1L&P$(>]_/-3*HAJ&B*MHIM=Q??OB??. MHOBUIQ"%6YL%H>IHY'Y]NR';926O4HAK4U91//HJN7'5+(*$VXD]V$UN M$R=B;DQ]9L0Q3OS-$7MI]OMW-"_KW@T&.B_3$Q!FV@=1U*EOS,@WI/MR\;(}- MP_,+^@_< $E=[_#CSZ(S@!ZBSL#E9,+!^,FN?ZN ;_!.0OFU_"S@-%)\R! M)Q^K)H#_1%$I^9PWR)V^463ZVYR7!OE!OA#X[$6:E=D!HSS/R,[>H#MC_U$Q MOOT[V('X)N^/B/ =%H /\&)[,<\;=/_*/TG,CL/- R@^QGICPGPW4: C_&E[.\8YLU_GW.dN7W]+[O9T G M2V=L*<>*?-*NAYF B?91T\X[V=YX6=0KH^84#2L-S_3U):+5GBBF&*(;C;S MZT(PE!/F_ZQG&PSLZ(/ELO'P?-9]? DD7&S7_R&<&300_GYUN M]7S8?&;[$_?GLW>|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|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|=054>@%&%W6MJ#0V X)X(!73=}//=C^B_ M>OO#_T"$$_+B -U+\8,4TI($8Q(TILP_^T%IUX4$#$V MAP..=SC1$9S+R&/L!N(O_;BV\?P@@?B0VOO+HTJX&AOQW MIB<2B[*&IDBJBN[N"}&+,;O'3%A%U$=<7,851I3'C.K>ZUS^^L/DO[U\X2EY M;Y5)OUUS [<1"U'C"3SPAMZS"IK#O8ZA(K3^ M9)S11HPXJE%'/U/ZD#SX*]'5ZL;9J.RS2"]N:JS@Q[S#XCSY1.P9?)ES,#AO MN4F*,,!IMGY)\<#%]^ZF,)U21,]RG- W1#IX+*DFKZWF2+BH).US7LZ>DP4W) M//%_NH_3_D>=QZOSFWRRF;T5/14N)B@"CA(MS5FMV@^-=3!+XE->@@KJ!!)30Q.6K8.<4DRW*&%D4,J%0P*1B6R.')AK;DHF/ MTTOX &S&1$!D;6/ M:)?)S=V.Z'/+LS-HFVYTCSOP!!X6/ M@QL2<>ROI'GNI^32B_R"SOF$&.S/;:I/H@88=Z9;J2H@KDT*.(894$R[% B! M.99AD<>8HY1S1_03BE_8F^_TM(LO19"PR^R"X&.C<6XK!#GCA[JUF(_H7MI MK5*&|KD0]I.#8NC+=B^#-S-91MEL^6"5C36?(TQ&L^N\^;)$FQ7'= :,QZ-M M4%WC5.T)'&W'ZS%|&/E8S9\I,S;W6^>?R##RDWAWI&,N,R^6?CQ3#-SZ7)(I MIJOE>A$F6M+Y_OKE)<4O!'2E:@SX'6[OPSS'P<6Q7$IM73+0) 08('79IE]D MU*$"'#BGZ:2]K$:XLCAARVN>9%Q&A1@_'"1O!'PDK01WRXN0RS.0@U5&-T9B MQI$F6;J6X@NL#39:0I9TGY*BH5AN/^^M4+(Y%D;Hf\2+%< FV\8M\X+S6> M!F"XU;5(=8QR) '@(*NMCH&[+NRY]-IVCR=9LT)EC'GRVAV<=6Z3>1@,-M,4 K>;(>LJ/&Z/ESTO>>IVW;B)6/5M_(&BAK\D9PE3I(M>O!I +W@^C@=![=Q[3C-0.)1I0$8-W4MTC9"52('#>UU9FPM"6XR,U^@HS"M)<;-@1T0>N9C+]\D/TG'4^0-@\1204$+RQTS\RH\RD2'[;R*LQ[C1JXR0QN6>ZMW'=1;PCMAKBBOKM=2IJA!%_W,*#NY MHW.FY%T8X]L<[!LNF? 5V6)BKGNG:ZZVEZP6Y[+G,)MV64D>,O)N7?ZRJZR0Z M<99AO"'C*E9@_0X3V:YPYJ?A@=TP./VW%6: 2Q6E? $3U2 M 6U_9WSH%6S!"3%6*U1CAGZ6(}RDJJ81[D+O.8S"_-AAN. [6L)U]0,NZO,0P+K.N^9TY;DG:2E^=6,*&$4"#D^2?R M)?:LB$.4Q" L7'V[>R.3KT/2PZ'V*?\.DR-;^KT68A2TK.>J]8..4HM;-Y5-[MN\#%+57!M7=)&CL9D@.JL7#TL.:\;HM-TF2++CT<%224*^^(./A]\FK*:?X MQ8MN.,I6<7"99'EV&U_A+8YIO9@IPO2%+;S>QGZ1HG2=ZB9)ISA1+)ZS. B] MI/B P_US06&Q>2 KNB+WR'SZR^##7/-1DD)6]KWZ<:M2V8V60.$SC(BHSVF)ZVH9D>Y^*C4(A(CNI1\]7T*I162GGBNYZ!E(STB{J ME5L1<)%*R&-L8MN9_C.H: <41&3.]"#PQQ>QN6BSG>S%)$165E4YCP]+;&)7B MHKO:)Y 2HXLCXC*CQ]K']\2F#>]"(RHIYX]{C(;O]+>WE?!:>6W^7M4:1^WD\ M-9[2[$(TA)G,35_]<.RMQ1L"&"4! M*- EW[3J>-8(=7^TZU6.KV0)N7'7(]7WB29!#G)[1:/I7KDW.K@($?=%D6BEZ ML"2HA9&3?/6CEX9T?W8H7;6U@QU-G9K5 ^]L$=R8ZA95UP,E10"9:D;EW..I MH;A:3CSUQM$"XL> <:\T<+CFMO-9[L^8K5(&X\0_/6 XTRGUH+A2=.]=Z2+ M\0$U6=#H;PPZ??AVD\U"R)=S &1#7Y5Y1*4IYQ^/^E9\5'W0',59FS-^(s M;AHI6/K=C(+!HI>NR@#30N-A0)-GR:S 8WDBBC; M%KHB@/-9%JQS!C2!-$9*BVN<(XQ[9+FK3EO)(=Q5@0<.'(\DL21$4;/"\.G, MIOY+01)%+8P?0BY/%I93G!4BC\T?2&X[FUU**NW#!RX[+9AV0Z+>B_Y.Q@Z= MJQ83",*.INFV&CK6KT8-;J09T&G.N..5&NZ],%BA4@IZ.(?+@:@@;BX!N;/; M%WK_Z7.2Y[L,7;/?DJ^PSQY107_Z;H4H8(#%)0*:?7_#7_.D-1Z^8ZS#%P.WD MW@$F]=AI- "*U7%HX'O5I9 N-:'&[#BBJ6(*$0VV'GSY!!A\K|]9),@=% MY7U S(E5>)!%D%@^H)PJ9F4?!(LIPMK1 JAM_5 R'\##R$9V.)LMF3$R2O4X!Z;T6D@' M6![$EH\N[>K8@QBAA= 0R0 #C1FK;7)=VC?@,04OE@\1]E'! MT=EM2^;@1[M[ZLR @X0?8GER! ?77WW2E%^2U[%D#ZT%@\60A921HXO00F%D M4)TY,.7.'"NXFU01_<4W9GJWY!X2$:\(R-9.;D@[.]P4-#2__^8O:YP[Z7Y ML5:'/[LX-G[IJ5ZL2PLVU$RR4.-6L@XAN% S31WMZ\"""$UU{J@C1K[^N@49 MN#P? 3W6KZ_<44KJZ27_NHZ#S:'(L[PBK$<$'299

MBJOA@-_O7VY@_!-P!U^!=XO@"A80'8LR3=+7$W:EJ{(.D:*.A\>+%B*:WOTK_MNA'.9.1-$XUE1X&\N&2*C@RFKY*89X110,H09?#'@3OHO$"?9*;'^05K>=LY_M-X2BU6WC0>LKXDX"#_[84))>[_:97L$V1G0"ELD3$<$'?\M<&,GSE-E(A>@O_M48KZ75,$YUY!H_6+N2,"-OV*H;WL@ZN:2\^F24/)T=%!5$9%ZXDJZP/E

M_N!WG*X7K[2!*U!;B&FAOMF@S<,52M;H8)WJk!G5QH-,3}(_MJ\B6I'DRN_P#}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

MD%.9TEER++:^/E(=.N@Q]A'R8G7EST9LNYYO*#1QP.;DL"XJH:]JX#Q,:T]DS M Z/BP'G14="1157$T1@R4PB%#Z4257W@?!2G0P2>)]&X\N\52N+L"&W#MO-. MD 5M9V9I WH:?6GXT>,M)./@']D=AG,SFOX:A1QX=@.@5NB!^_M"GWZ?2JM@FT4D$,RZ9I-2E(-IT&#P2P?$5Q(U3B9U!6: ?V09*++-7G|5AQJ MW#J2&\.'1D@)038YU15X;6+8Z-6:I5T749.LNH%X"D1KS/=A"/)+\I%$(V M7,]+)WA>1F&Z6%ZD,9KDL7Y6+S @1/@=]3X!P6P^EV)C^_L:T45ZT=SU+Z3 MW@WC@#SN_!4$2/D^SI_AK6 L>(3^IR*&C&>5;,KQGK/0&V,K7BY6U.%11Y&[QJP,#O >:!:4W'_6L?4WSA6#5L3&BL^R:$]@I)@9V M-;@"[N:!"NKK;/Z4OL30@T[$H0:W\JC)T4[ZKH8&Q?.&&H<-JEY9/AS42A6]M30_046\Z:-9TD%K#^WN#7]ED&ER=XQ!4YAFO#>(C".4M?8]MM =L0;VV5X(@T M^_#*]R#9FMXZ1(V5;F=»5P!:C;$4K(IP9)Q_Z6@A,[AJ_'IUH)^1 MOW04R\/:7C@Q=(7F#VXKXV1+2[DUQ 0VR*I2&D M/!#.@RI89U@AKZ9'\#B=F8Y?Q\= _!6(,8,:^8 M=6P!7 (_!NC"$C(X4$SS1[W;O(ERF!&.RD6L14X8A 83.$\^2T)258-FLR%K M*#I*Z$3E-)TE1&7(6";RM7)CA%U,2--OF:DA9TCG-T&.\9+3""FG]\B ;2/J MX'.%4!(I,X8$57UB8]YLN9G/'307SCBF-OW@:7;_CA]&R^N59A

MLT6VG5$R2(D2%'D^F615\VT]DT"L*E4U'4]/#P\'SQ5I>0>?>F1'6CQ,2BH276L(I=YC%E*4 MDJT*IC%.LD^;BEAB##U!4SKGB9+'7?@^_D%_HA4Z!N58>?D0Z/QC=UL.4= M5YOYCAJ29F=RE4MGB MFD[*TA9ZR6F(K0%59TJ2JO/57BH1O39O07VGS:;*_MVI9]1-,P.&P 6S>]+%TH4;=A"C>X(MV0+4Q%;)Q!EFP5?H@<";!3@I9P B?"IU

M@O>GRS!X!5$"7WRP]8FDLDE5V[:PK-L$I%4;]MXN#X%]K E,]3=LH9Y^!FEB M:Q\3I-\G8:_?7/((;#97/S>V:-L6@FJ8&U5I0]&K?MM9)CTM=OB&+:S33QY- M1!WRM,@ZOQ?!8Z_?0.3"N!9M0KZ!BH;0_S=_0=1F@NLNLMZ8%'JID7&I"S>+\6P^(_V,T>G@THF7 LL8I>8XR-)!UH(=N2!%V+!4WL: M4*N.D0=RPA9$L_/2>82[FN >EX5G7(7G;DX"]_.R39OA\)SA-

***NBH-A(MO$]$MH:%2;_T3OD1) ["PRLB9G9X'B'0^N YV8<^"F*V=D#I)^]22Q64AG'; M4QZI\<%S3*<>"FZUOCNVALUE@QG:23PVYF*G) ?6\HW]X5UGK10L['I+]GF**

ML+.!Y1R"K\#+]E/HEJV,@TF*Y"Y>NW:I"C%Q08:/-W=H7MX>?2B)*3NT5%7: MT?!>D*]6O2","->9Q31%VKH ; 73 :4C01]G!2[&*IE;R@E9Y0W#WNFI;#

MJ#I#U98M@(RS)BFU7Q@\Q_K22<$^E8$GC; /"=H\'O$XW%Y=Y1%2@IZMK;;VY;RE9V@#HH9P K_4V&^/UZC5<5CU$^&Q4N-:BCX-YJ4 MP\U2 8Z&'4RPU<;--

/UP=$!AV(9,+XWJ*'C9]>%@%ICK.BBFH2%&81LT180D M*]#N^@]K$6U;,C+A&P4G7M[XX??-*B20>>E3A\Q+,4F]A#XZ*;YJ>VZEC8;X M*94:BO:^K\!}>

(A"?'7D7;Q_C;$Q=E9D9#]W$_B*S@])DS[A]JCZ).O9R0B MR.UL2%1{JL@YVV10NK;Y[V"K1C$.CLX(H\ ]8HE 8=>#%R(#F?E;?ISJ&92 MT?&IO6%B;\H;?-

ZC*X!ZZD+6;4FYB&T,Z@WH.L>X:AG!?/>K P.LPUGPY/C8 M7A^%2&_).XX=1!($A&"F_$*G\P2H7"NLY#MMG\B')€) ,.OA"F+\D\]<]= M-TSK5W$B5:HZ^VS_U? M,/

XEQ[U@A_$DE7.N(*SXGUFC+4*F%;S^@TK,(7Q,K,#-KCN"M?[(%9'77A- MMVG;-KZZ$'I* S D6>+H^1WJA;N39E3XXUD515H5+[$RXOK0L/?(UPLT>!" MVB4&LG?X%!**

(9QL,Q\45*LZ17']+"&E7.(8?OZ3_2:8A()T! K3&9]:_IE> MNY:JRC*?;,'4.5*A]@81=BJ7 $W%(;ZF !Y^6U8]0>=^]G?0>8$^46@3[5HU M],$ZU8.M6I*GB55]HVS_MWT"7S_KG[1P1M/YN/#O(-?-!.E=(&$1AKYQDEEA:B)RU3^(I49EG<-L MV69\NT4S-XPRB^-=B([H\!5XF6WH;\#'L_U7]DE$J.X'\Q3H:V2AMY"JR5/R MXDEY2;G%2TNVWZ-X [;13YLW8T>5C"

%>%T#AUC4D=_M 1=AD* 2NOHP-JZ)IKESB\XR ?I0W=PA5*>JJ"%.DJ+.QLX4GO1;W0L TN4I) M.J19L@3I(_!QO_"16)PSI ;VCD"2JNBZ8%G(IMO@(0)HBXC.O)$A5DP\(A6 MF!?B[1K;.Y9U4$M7WT,K&4>$WNX^Y1C65'D/&26LAJ[.A58RJ-@/CCO>(>(M!A+VQ4Q1_Z@71MT;VT.&M5:+5I_$(_/D*V;Q1X#VG]GX\6ZGWAY22D0#BA)[MT^+&R&9YUS-

Y122Z*K;]/3MOH!AB,C-6,OFG= M44HE @92""_DB'@#^TLT.95H#BS2NYVI4,=-&)'Q!KQX M7-TTH37RI*(]9*YD^(?KU=H/WT$V+3^DD;MT8H#M+ZTF*V;+HZ>4+AV-ZY18 M5E>7]#(NLB(GTNM4M78X?3TD]DLS+U,5$)*L"]HI(BM.I/GUK"32QN@9 MHTXK6ATY>_>+:3BH",R4F)5&SZ4:.M <,5+#+]D26 3I*(MU7?YQAB\R_2,>\ M:4BXH='S1[%]K**

H2*;7OWLS!6'<[)U7QO3:KE?WC4@>]:/YE+T\%J#2-C5Y MEA#S5VKR=WZMJDJ.IFGM#HW::*&@TFMQ+XOKM[,RY-]3JJ)*"8YTMZ\8\A;'T

M^/]C^]ZKXP,201*I$+]{_@'=$*N_]%4\@&@T>#5GWKGKF7%0?H1C9_K^1Q0 MO8S[I405R4_3TR,SR7AD/90MT-+@'U!WTJ$.]NXE&5GOWE*[7/E&DXQ>*O

WF8;3*4&2_Z!&L7=7?9Z0__M,Q&T94G313Q%(=3,Q7@H4A{C),AU?QM5N05H%@G0\BPG9]0F//!FZU*&@+(+3R2 M73$42*$C'QZ3A'CGCZ'F096C,UH8]FJ6DZFIY_-**

&HP4@%IGBKCDBE84 MS=E$5>1P[)9?<'144:D3K6\N%;E:WC@P^LWQ4R1K%DL]2S^#+:E5V6^#1[#. M'TZ0<81T6<^BK:3-\1-,BX84/<[T-

4U7)9G)#A$"]M1YF@@/YXP3"&VGNOFJ M=D\1@M/Q\D^+LA29F751L2IA/?'6[^AK2#6%*PT677#J4]/R^ FH44^*S-#] M%+-[BOKNBM)D56Z\'H]W8.D> &+-

K0Q]$CL91RX;,,7P0)Y.#XE M23% @."3KF7#58U.1'\IE6I29/#61;S,R3DSY6PO>K(3T!<)O%MD(3TM\BM MVA@_G91H'\;*$$4$^AK@[*5\5.\;\1^]DV$X=49/T%;.4#1RU#-[UI*

(ETA M@5X14]\@?P%4I*1X5_.*1L.'QD^_M0VD,>])/EE>>A6'6RU6E/C.> %L# M642E'L134;+29B\0KU(L3^:O1XPL^!;K#L3Q[C%\\62Q<$A"@T\7FKS#![GSI[^WQT>(#^

M9_+39-L\^D?Y"Q,G\":E;TS"^:3TE94?Q R5X<^]H$//#_U>I)?ZCX],H0^] M0ETJ)2!F\YR:CK^Y@*;=KRMJLV>/ EJG+YP8QK-YN>,%]"6LLS2HV&""AQZJ M[$(0/R,V7?

CT*%):OUD9VH<'4_0?1J8\I0RK.#;TKCU|CE3ZI*G=+5R(G30 M>8*+ ,ZABY.IU.27F R/ZI-A_@T\[Y6^,ME^9E+ZCI7385TCE#F.5;!G=UD6

MGKP92*RR+5,)'YV*JVQ[V88\T(F5M+"@GB\B "K>3@(C^[@^LDFCDZ+52:59 M'0.9G^K#N1R,E=ORIH.E>;YYD#-+]NVT7NL*;SUF5;%E M_ I@4?50EQ1IR..QR%78E/I18&A^K@_-HD5B7"BW:>4XI>9JI(O6@?*!T5I M(I#X&)9IHCH #J>G!V:BLPKCMA/^DN@&MS(>QKG&P_!+\#!_Y;=8I_4!SIN M>.&&.UIO43/! M

K]++*#T<%!BEITT[Y:*I_ST)@+7K*]AZ'V'OH]FY6V/,_\I[@Y:LF[O3X I M/>)OK;DU;1G+K=#;>17<2M8A;]WOH(L]\5M9O*;U@9XW9\S4E7_YEJUN*55 M6+'J[3.M5(SB5=X=H2.?

F9MX025OK$ZR(@UWM<01,+.9AT06D!A&9_5AA!LC M1]=2_"1OGXS, _N3TB>L*5YG^-"*8Y/&Q:9)?L=KU1 "X|/ M"'3VL2U;LV6\"R!8'O0J1WRI'!/?%P2]%P?FBZG,5-

#@O(8: ;G4ZJ3< MK)7#'WM,UK5 F0%XA?N=!+[@+@_%OT0'_"-6T9W&+XE,=W6^$&/99!$DAF6#VU2Y MO?^8;%]TX9Q=(S,I*;[K$/[C!5*C5V2IY3I#2C9CRU@6

M0Z[B&JE"TB$/=+Q$PBS &9(<[X'1! <",1?HPP9/JE++#Y&"]V[250Y^A#:Y) M3+)NS\&J13K'FQ;D&K%E4FB%:24\=7>QASQ#E/.$E0*.L3TNQD MIUTKYP:.'BC3

.]XWIF)FOLC/OPE6]@.@D_3TX-/1L.^*&;5)$3=Q!SR6\"_M"SS/E:(P2XSK!E>NO+U)M4$KAW?>U4>P1FK";Y I^WUJL9W^COJ$!_& C5M M&;X4J^3"HJ^99B#7FX/HD7$*2 I-

TCYFND&[Q'*3WXNDSC)%RAFWX$0&[P]BJ^ M-,' 3#;?(CO[\@O'\N>L'..Y(&6-X=@B1;^IB[E@&K;[7=&:W^ NZ6'5;I@-) M[*J+>@=1ASQ%E-(B2,P

#6Y@64.3HB4K!_=&6(''48R2AC)ZR'APTJM4&?S9 MX.,H+A:-Z3M$11KRH'Q*7V+P1XI:NWZ5<[\;/ LV[8VV31GY?#<%9NVQ:86 MZSO]5K4?

W{TUK;PM0Y*G_VIZ+1EAACT81>*!2,8,%4-L.CAJ'Q9D\F/Q7W^R M=30/,$)(\@!GIT/OV?_F#6^QRK:,=;D((1UD&T%,M:\X$-QUG,"54X_SV5RH

MJHH3=$XPDWI$#F8!&;3D1^L_,2N^J.%D%-W-FTRX3KOYZM#D,*FB7&)%6600W M!:>3'H:Z; ^T6>T:)D9V6K#*T%&V[CL9@=+(# M^Z0^L"D1Z;P?

V0,-3;?)>D#42UN;*X6J1,;;3#./#62#SPE(H6@X^B;L+)M$ M%K4.;BQC&\S: M@:IS@Z\/G>#&45("%OUK"RKZQS^W"8B =QTD)"Y-PYS/*FH;Q%(3OK1@C!OW M(D_X

&@.2FY=DG-@5M@;S3.590+$4X*QRTV\N.1_#] M^&F>:G,WY7CY2J+1W:M%.]8BSP9Q9Z KDUS#8MT^3[6XKV,,V, M/^K1\Z&:34'V:N6TR0&B:#)++K6G_IP FX Z^@EIW

M+]Z_.Λ*HTO?B?D/XSHW;,L4U#D?B295C. 13J&9<,[0R$V:8 6O<(B/+-]Y M'J==RIU'Q2=&QTAM2M'WHJCW#""RZ]U9?;VKI0&Q?KT;4#Z0[>R*^R/IXE>O M4J7S%-

'93!8L\7#4D7\7[W\HL_=<@T5AT89!/3@Y.A)-E0)Z_X\VIW*C7K8'LJ MNWBO)2 Y_^Y$WHP(&_^&CG3 P\]YT.$"AV)Y#O&?9FD2)^CLD=U;7,^!R(4Q

M4:@0)8UV:L#4MD!OXC@=!\&KT0QVVMA#!!JBREAJKFW3U'#J$&U;\k:5"[9 MC7K,_5;B6?0(%FN!\)YMVOLNG=2*K"\0E*$T:L'#88H$,Q<6=9OZT>;-.L.

M(%U>AK'831*EM"VCOW,;+!GY+'7'OT.#' BR ,:_/0AR%2QBQ9@N@I7:!] MLF5S?%*B(0E.^4:I;5N#YX-ZZ35XQ_4]4!MS-8@KX]Z_<79A/OT%K! MJ555UN$@V-

%%M"$[JM3S+LI.^0U1BQJ2+UH_UP\M"^/60++3HY+2+][S'R4L M3#*MV3+0I;(U*A1UR)?#,AD<9:>$AMOH<)D ZD_\BC6& JM|C M6SS928/$@;

[P//'IX+">4J[\03(YE#Z)HY,7'YW\N/GLGR8_YE^V=]XH2[6- M>9#I]*&$5BE$T^:M*>VTJ:A-%4?2^Q2'79C-\4X[(Z,;]0U$#\OG>0\ @_I MBP]=''^_!2T0HGT.E&K!E*E$*ZN:$VET5EIK68+|S7D%6(4X*P&Y.48C&RR@ MFY>-EW =XVGZ-0#01'V]WP"'V66%]52R_L+^%4*FSPMG:D@I(?,UIFIH&/:5HE>?' MTJ-CL]%O9#*[24AD791Q3K321^Q@2XDKN-

%NRDT=@"R9=GD,@U!DS<^=46 M]/@0-,#%$,%@<.8OSAMJ"/#%,(C!9OOUY(+ B6!(F<4: MR|F"2<<935PV@!%?VZ&;"_0UB-?`11L[X%&#:%/+VH*R%0[$$L)IS5^]A?T

M5;1O#N+?0DQ6*=S:&TD*8-FMW]U%$787+CN,2AD)&' MIE[0%M0[3+N2PAD,X*L8:&8"FJ:BMH MB1@/:E.S+XXY-'OQ879A2Z*N@@3/ M K-

YUD'Z1"Q8M2K3I^GID1E;G+3>=Z;D+N*;GIV%[2]WE+CIO.*V@-QA"FXE MH@:3;D=,9]_S2<$+E8ZPM\?9"-Q*3O3^;)R 3PO 8R*N$)-B++NS'(^

ML$'=X81;)2B:"KS0);FI\A=0!B.L;Q\S-]+W(>!F^4MIJSRX@V,A%6*!-<: MMER61K05A@2H_1OPO9LPPE>9C>O*;J&1X"PAG(9740:G!"+S[6KMP C/49=+ M)UH VGFNN?!(*-

!"2$5,"C85,+FWW7J;-T^!+;YSC[!G:!1@*<)Y=.%+VC_I'<(#1#@4A=6Z84L3OB]J*-X.D=;X?4 MGI= !,;"75X#T*L9 [@M844?T#GO^=VAPF>=2+K&K+&N) %/T& M'L>;L8*?

O9!!JOD3:[&]"2+!D=V6P771V ?$-S4%+HH&$.80E\ MI%TSAHJK>M<,<_C*0=7*-8,'LY+G2"#)6'0#P#.BXT#.$M'.ZYVS M2K?8WG60D 0AE+TUK:AUB,MNKZ4$L\X)KP7 U"TVO;

M($OCQ8>ZS4RNY)8\ M"Y*R!)&S!FD"W?@V<.F[;$9QV\$1FG!;"6EZSJ5YMZ:QQ6\=Y9T=Y"-A6S!>4.BZB@4 :=)]N|C03K7?OKKJS4]52X MKBWP2R%9)4 W6;6NM+?!J[,

PQV?/R)PJ51E.I]//!^;>8792 M_,X/%,:0@$8W8 M =/.9-Y6V,%/Z)L9\([RLHE>T#;TVUU7B(F5XWPRAJF\$B:-!$?+)!"?:EAX[]D/&#BOWH1:U5Q_0KU/++V_LP

MP4&Y9_,K&*_#V/%_C<)T?=I+ M- #9Y&%7&@U96HB9P^/4"G*T.1'.0[*9IC/[49^P?GG3RO MF%\U<'!G=A',"O!#$FPN>P),*,";S.#)!E3P@E-=[<%;Y[+B

MS"EO,?/86:BW%P(%D$SF%5V34'3XFNLA8LL,..2V%!:3/X"'SR,B6[YVB\ MAJ>7KFC@TP'2@"510J30EI2O0+BK25;73IEI;?RZ1AH+DMQ]6V5K58?!_Q= M!2[X8+695D+

(JO0;'6#8N JT:6?O:,*6O.!+5U.P.;YLW_>WG4=]++>P!1\1D M+CP]3#O*F%'^PF%WM0^\D5H6CFRPQ:LA#C7>21)A02J-5G5Y>'T%,_+(R>2 MF![*0@W8&1E5C9>A[VWBD!4_

^RM4NF&*=9?"E.QJ#MNP M8S0X9O/![X1L!:I66TU+\K & M:T.QJLO'QE=Q=L:3*5@!IAT^]YTOUYZ=8 &1L%)?:>Q*@^=#!S$++=MAA+E65 M/PC?%1+0[NIBQGDR(5)W-

%QI+VU!&=W.L_H3:MP&."!J&+UOTWEM_B2=3.-3 M/9G&IK%[@[I-GP>0D&NKCVT:DN;T&D(U^IT--EUY=+Y_0>,D@HZ/"4]YY2Q: MK3HJS*?

R%L"H//);B3>"I%P;N7\/HV^WF:=2S.5 I?!8D.<+-?C\6QM9,V M8S3Y_AJ&'A?M2N&QH,T72E%, 2M&-WYJG'M;QR!ZY<_RM0ICP5U,L*X/^,\R M[

.PP+XZ9K%'.U<>VJC(6/"EB:+H);R!#'=H15J#*'E'NQ&Y-& <1/T)#*;N , _]^820=ZA?$R0E+FP5N%[@#:=&,/*&SPW/SC M=K6.PM",AI7=H<<+X\RO:QIF^SIML!0Q^

M1T*5^]MPY<37Z-14]+\ MZ/C8BX*ZGI\N*]E"DR_NF55&2V/I(56%8=_]+7/#.^QF">^G=P3KO6$ZA9 M5=EGI++/(^<)1W8-QRZ#/@+0+W3A213 (M/ &.1#T!-A_YN.GOX:;_DC2.=H/

MSROG<(RWN[7GB\(XRA3;S2-K)FWU-^SF)VT!C!37["*ABY$+.8M)PH%9U(:>6.<-/DVL!)5JM+H)B4:U<_:)5MHA0<"H7]8IR M8MS-

2E#9=92X0FEY7;7=%AXKC*923J[59)>N%1H\BA)B*;J-ZAR+U/Y7]@/D M004(^/A#CV0-"!*BA 8;-*NHM830 O"64-(Z&0,W&FW1[,)579P: M"W4MC1P*ETO@?EN'D/)@5! M"IZ7:->

[!FD"W?@V<.D>@,HJ//T]9(4UL%.@_1H=N-SL>4*4DU&#MZ7GW MGB7M<_Q;\IB#^"!0;_(I6T!O^^-5!NUJ+4;]VPJOFZ4"=)"#D0O4*<[7$V M;Q _QI>;O6C-Z-**

7\U"U$;SRYL&Z+:,=G=0$HI MQM*=Y(/ON,I\=XXSRO+9P"J_]X20UHWI+:@5YL8[C@>)YF_81M'>-T?:E:EH M&]Y!F2T69XNJ7(;WQR-F%Q\@<-

I{[LYN<9A0M=VN2F.LI<:+$_.WK5N7>O}(X MR:Z?BVF>.WLUU*EJ;FK<%:Y/3K57D*)5DQ<&O^.L<_T&(A?B?-D-^\2FF8=9 M89^9TE({5OG^4$GB+IU@

:C3"*74!QW5&*5]T^/VY,]9(2<9A3Y_V3;D^N M'H# D]0^X>9)-6'F51_GR&]S)1P[/EPZ.E\ 4W 5GBW%.=9^QQUC!]&S6.

M=8D.=\O;*#Y9S#U(&/(MT]GT]-.Q_;=,5/)HUXS66R9]5POE<=6.3.NK!1ZR M1J\6^G8C-4^4OM8;.9TPK&AMGR_;XQY]#G=I'/@0FIJ_N[N'V@>#^(PK))GI M6;8W'

(A(RDEX>"OY)_2EQAZT(G>\6OIV9P8RAGG-FIY6PA@ZN0FIQB#U[!= M*,.5[]Y9H?\DNUN'Q!)GGMSX%6TCD1RH#.1H)[%!,Q!EB;@"+ID$T2|'LSGJ M RVA]>T=0"W

VAGR9"4U_0VH'N:!=^>)X\U=VBQZA(LER]A'+6\;"I>-.04 M_^C,'$V2,E<+1HV*<Ex?(.U\,DH;.1@%:< 0U;[U08.+N*VX,G#9/1-*R6EZ M5:"U0 W*;|[%;#I-

(-A<=&:HR4MIY/.28V!ZQIPS%CKEYS390^S2"I:1GK,S<3(K5<4]1.*:32$D"$@#DO)BVGC> M#UY!E.#XJD01%P(XBU>T#FMYR&JF@+9BFS8+6.&2?&?!T:\%[.O=!U6[,G-.

MGPYQ3U*Z,<)^!M CH61#K Z)@BDF-(5$O\BE-_&&.G(@?S'K6EPC2'IE?! MN"MN>)70M)@RBN\S:UKI1H.IUFR"H$+OW5]%BE?694!PU9

M!:Y8Y>KW$$$7/(#H:>49FB=>\0\N2>I&T=6_]N5+]0]9BL\^Z!!8^!B/*N#= =MRFVBN5+4?IDW!IDF&_M]*7H$;0U'"RF;:1<<@4

MM0^NM=21(DMU\TJJ*+>6AN@++>T:1%H19"ZP90N%9^!LSKU*L?H>LJ!59"Z^ M+]_)3_1+,9'*^\PO!9K*^38=RT+7Z/"TV0-@+6=#T/%]X%V\7SONLEI6QD-3

MIMT/GNI28D[ALW%,F9(Z*G8?>4$IKW3Q5C_(JT>%A:7VP KNTNX_68+OBEE$ M*]M-OMBAI:KFCO>*?*K55A!.Y16K,9-E$0^16)KJ"CJ4F2)Y;>TS-]4KKF"G M+?%+%5Q-E#T?KN

K]$#@/3H)MH"ZF!L+FCE9I.H'^SKHJ2!;U|L*S=>D7P.8 MI*X?F@OM,S,D-%)P0-$S0Y,SC?-.XB;E5N_BPNXRC.E7H(PJ^\R?UOHIV*0W M=?

^^>/_L)^FZ*ZQ@H9Z[W\>/LO\.TZJ*%_0DN CB+MI:?@W"EQA$ MK|CY[S98ITF,?-[*PO%|BXY,G*PGDU?)N6^3++.?(0!MMGG%M^!;NF-IJR)*3"D+,MV$ Z"<3K?-&N&4O>\N?

7E,RG^Y4R MML&L':@Z-_CZT+IK1U*B:9,?L*VIG&WH\56YLOL0%LKTR_J^\Z ,$4QIX2S= ML*,-;H)F'21#?H/&FE4%;@P>V!;B#7[G7KHM(1<@>+5A;-UIQ6W#WH*]NY2J

MJ#PRSP;F5IQ>P39&2,$AAJ;]^^3=7A,/&^)NP]PZ\ZI513Y!(D^MPU9J;]Q* M8--[->7L>(3QMYL(@-L]0G$"7;.D^()O8'1,T92=--;0N7L71:0?X4? MMGZO7[3/=8(%CAV;

(7*/-8.CT4I[\YX>',YZ\VX;GV2M3W[&OM#7VRX1YP!;K:P@4M,VUG15CB M7'>^0CMS^&^" U9,500*^NQ*MN'>&](ZVBT$US1+6!I-5+O18#H|/1D-E3JK

M0=&%C^8@%MNG]%^@#^(D#!K#6#04&R'V4D]IN:RQP;!37H=WSKWREIXC 4M/ M\<%),*___&'],6C]*=+%,:T|E4*VS K=K3=\L89FG6F14MG\M"Z 0_5PSI;$ M%H-

***R[S(YO#@J[8!!H8(P\R+;('^&=VJ(L 7PTX+B;Z,RH-"CRN&G1YE?=\0 M#'"%DA),$J+S&J@,OY,#-/S.!GJ/V4UD@]C>O.PA0 PM"AL'A88.\,P#_?I2#ZF6;:S$BQQ(F?9 M*$K[71RE(HC!**

(\!#Q\,I+& -0%L/Q_P$<6L@&!2WI;O|H68,O9AKIH1ZNI^I/= M+|Q'Q[FQLa[|2H)&>5GB2DVEF%K\:N MWUP_Q>\P\Y\TDG^YL3W87(!0$!BM:-;68Z%QL>,ZEK?AXIT5!.P5,%UYC*

M'\;6Y Z3?X!$@%U"%<=*G/;"YYR8CN,=OFZ_AW%0IH/@.5W.M$PA_;V]O@(O M27:U2V);RW7^ =IKX>S>F]W,[$";O)\8F]UP/^>0 >#40;/-<%6]%^1S[N MQ39A$\L9H:%DE>I'T].3

R-CG*W0M 5%<*2] C5(C+2GM0+VH*-K.9YF%%E MZ\UEH#5^]Z*G:R$5MQN+*F(*#D"'C5?F'$,+'4 ;ON9G[-4NWS1-

$[ML6LPC2@G2Q95>S&DHT(#T\!237'9^_]=J>@*^!DQF'M@8?W\\(4::@W9IZ(BMMU|N>\TNK=U^$N#!9XT,'D/(''(Q?@LQ>P6K@7'QI*/<(\C25-7 %R=),8>OD/!7('8C

MN&8\#1:J6U7[A"TO \H=X[WBSX58D@WIKCH7,H1!=Z M]3$S1E)]11?ZY@/1[ER&M$\P=%8/.]MP#S*D!$/[>0%B;E@KO "ICE+C@4>5 MOZJT;>ZE0[%3UHZ ?

34^!B8>#Y!#D%I'/@0,@2T|OFD?0 PM+AC-N>+I57M M7U'@'\ALXNI<-^DXA^8WAL4,O;0H#VVY5V(C+&M#&_R'+'F9X;

M]8*VP2@'1AU,00DM<9RZ#%>K,"'"=;9R"]>5L@TU0[0UX"4EFVKVC.]!9R$+X M"AZ*@N@SJPT'@K(BVDP?#ME3X7V(*\@2K"+-5'$A0#.XA6MPUB>LIU=5WNQ MAS\79

.E3X4WBT@B/,86C%K>-E:TWX+)B3CD@,,-DHKLV9IJV$8 .1@%;=!F M%V=P&=AL9XI4EZRIGU)X$+@*K?$MY!S_*IL-81YX-O/Z(*R,=PXC 79UO(; MXC.2=VH1EA*SLI2 UK^&L

T(CCYWIE(OX4Q/H=2LR%$2@ @M!VLG>,8CHUR!>_Q?.(?"H M_FS4LE4)3XRZ>(A#L .=E'!:#Z]5[CV"M?:,_^,!H.YY-TC2&_ 2I4[TC]J> MW,Z7\?NF1X!FDQ1M_QWL,.O-@N?

(@>A3BU+T8.+7?AO?@1C'# MPO,UX&?I> M7O<\QF%O7#(A'1^BMX_2^=.6==$J DH1:><@, 2/]W!=R'-X Z,X.0\"^ JB&*EO-K_T

MPQCI"#^FHS.]>ZNC8:8F51@T!0DR*9=S%LPB$A-W5]*+-,EU\ 3<,/"ZLTSM M%T?+P![4I.C)M7YV%@4HYI]PFV-G6#=%#-GJ]2'&T^GT].1H8!:1-@(R0E-; MH_;0XTL(,>)<8.B?

DE,'<$UO+8S^$H+:P_MDU"O(9Y9 MH8^Z\<5Y@ZMT55,*A4DR38R+2ITEUQ(P:LNF4S4GFB8QSSWT#|)9'DW:-#$. MFBB37&MVJ-ZGG(=3.3$5!0)RC?.

MAJ;QD:7'1.,BRQ)$;V1>S0GHE,;$>4N:! M]V'CD9+]H'R(8N'#M^(TFP4YM515WAA1G4X3(#GNJCBHHJ',P\ L^AKA MZ&40"0"\FS"Z#W=?>>/?'NCY9

"-10\&LP<5!HE&^>X"*Q@NA*:=NC51\L2 M>:D+4BAR[^N1%-=O,+D!8-=!0;#67E"-*6R!O")W/)-FX(SF<98 |S:.4R=P MT0P9)S3O%4:-<1"CK: %*11YP1DDQ7F6FXE -9O?P

)C]V7#%:PJE2T=7J MM&73>4>6%M*2%KQ0Y-EFC2&F?[GL^!2X*^M4!]U-#&N)C37?2"2KI2C_1N MF*F&]KN"KVA?'GA8)5PBB50=%W]:2US0QI:KI>Z/S!T?Y/%$'R+H8OF?EDC[M%*K0BH^+'E)2%I3H>AUEB3=#2?;[%+N8HW]@V6.\;0/>+7[K%<2.R[#HRC0Q M6N*TD[P@DZ[[I-T*HQ%!,Y'X *T2N,,A%*$$FBDJMA#I-CC<5"JK>R%LW!7 MTZTUI-J>)XE>Y,[:]2KC(HRTI 4]]#PQZ)T<1?33<[2APR%4XUF:X)0R'CI: M4LC!]C(NCE0U.P[^:-5&P;&1/$$HS!"7;VL0Q+23U$ZIJF*.!KX/%A&N0+VKD=<2 MU,ONSL6;F!Ef!=S JQ7&OQ03.0M:]$TD;8VHQ(MP.IH?I1XRU:M,BYR2$M: MT$.7W5;1A7%G,/_?'# .%=$,27CN\#[^=!V)7EY1HOD[NU. [6Z%)$ M02I+5MUC1:3:IO.I&K"$'Y4XP\PP*_U? HW".'XFWD8VM6MJ3#12J(&"/R,Q M =OKXWMZ/-#SDRY%%,SK:B^FWHC_Y9>RCI&XW\A?=_^8BUK3\CR,$E0T1B,N M >[R9S=<91_<9JC'*CD/O$('.T>'*Y XT-_,81FT .O' QN$$IC@[YZ=G7TZ M.#LXGOPTV3:/_X&^,'$";U*T/?EQ\U_Y9_XT^3' TH0HRL_B!D:P]]\<=#) MKO=1N17K_ 61R'%W=Y"T0B8G$!+O1FABJ$?&,3C@V?]F#V]Z$);D0U65.NGT M$Q+KLT63,5WS/,RHLC$>3%BR/*M)GD60=EE1$>%!R!+0l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l\'O/V@AOTT'O& M5Q*S^<6W@X9>E*>I^LQ=F8SG;4.QKI993B,X\M+++H_@Z3)3&PHR[@>*W/(?%B M>*X\#[BE8BRV&Y^LP4N$PLL6PE4 M\\>>D*..OM*OMJ#'UV:#YNV<"K\X;W"5KJC:K_QNG?X9W:HBP!?#DH-B<5W! ML/25B]B"B"G3'E<7EGC^"OD#L*Z[/AD/>,.5-1T=AD!:G_P\?P^?EV$:.X'W M!%Y!?OP'\%%:^.AS1REVCQ$ =;I U;$%ER=WNS/F61 #@6&Z,YZ"[A>P&0FXF M%!,Y%6"ZB@MGZ>GIP=[,75*ZR2'^=2:YR4F0KN8XX1W7X-YP;\"X-F#>9LG0Z1K7FZ7'SLSQ+.GJ?)$AT<_KU] M0;U#0T8-Z_BE!^\ZL61U,K)PQGT'@-@C9G50C];L$}.^2,:Q4(+H%;J@61WW M89YN*XO@^1PFCE_^3]P1T>_?X#D$;CA(L #M/3\C[;R]O+M*H8GQD_9O5'< MG'85A=ZIONFL!TD9P1C9M)15(D&UGI=.8&K<]8--#A<^D[<3R;YSFO9I$C7"R3^Q1; M@7 "P")CU;7C^\"[>,_+Q7E!VB+3L=6]);@.O3%N(IL?.7J_QVS4T/4;B%P8 M@X<(S0J.'S=]H&I=ZM]NU5G46)G-[!5\|#?Q*E'@;9'L=U?<9 MDI_?6X8;57 ^6,[V?K 46ZISSX.9#@0O6C1^\6-(!*33XJ+G0-,P.![<,,C5 M]NI '|_|#N&S-,')B3P8++*)0>QMAD!# M5;U-QW_CKUA5!<54YA4QN?TF+\[B. 7>51HAT;-AEBF ^G}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| KZ57;QJ@+R(|)N_XQ135B[M>K*J%$Z0%P\FA>O7@%M0'8P_=J_?V M(UBGD;M$\IXOT/1$/!5V9* ZTFJ]|(,_]K9?CS>>#=O$1Y M7+HL|$\&3(\5[F!U;$*MF_IWYNZ6HNMU&D>K2!C=P.3?"Q Y/IJ@?IZMT12U-M!' %@2OV\#}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~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|L"\2./ A-#7= MGK^"(7/2X F)I FT(UO Y<^WS**VPZ.^(PK*Z3I*9<"[=_#-.I_FD7F \ M\/"%HMJ<^LY;E>_8\EPE)-L2PU!$+6\+=GW8A>24H.@-@SJ'++)D8$R4!F>;B M>D'K""$%6AUT00GUWOR "$U#E^DJ!8E3ZR/P %AAYCZ : V2U/&K6=49=T+M MFJK*?1D-IO(21"5W0LAA<*;7GEU71{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|K_G@2-_5 MIG66T2, "RQ)C2!%2$[!|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{6-L85TFM,%Y*WWW>BET X.%@/X?D.Y=-\E!M MZY(N.F%VZZ:S>13Z$"YC>MG;71RG-[@K:B#..\0!#*5D\V9>]=0E6458M9/7 M32,2F#TD.!?SS>0(*Y C.(% 0*6'OX31(@N&>D55Z=* N$W=UHPFK -Y6Y9 M^G9B^-D,COJ!7L!P0Z]VBA'YY 83P_R:-"55:?5HF] Z*44FO.Z>,1LY[7DQ M=1N$840QRM=.!U/;|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|-,HN^IE!H(+]_VK-)3 M8:A5\EZ]UZKC/X]5DGUZ@\G0EF,!_0CQYI6\+E ,R=-*5V%US_ 2KUKU]2N(MKI4/F-2Z[B+T? *E5E8FQ,DFV%^C%[2$>$GG'8L-\?DJ3GM'M&(& M-]."H4ML!QR#RMO@8KW9$X]]|RDP#R55;,Y/FVSM=$5>__F!BM"-$ M;_*5E4WJV/M;_GJJF#LF'2V83!%VA/$-')0LS^?81(IFS+[%WKA\)N5-'5-* M:\A,-5TC!3U/5JZ+WW*8T#<'%&M&5<3G!/&G,9*L 8[1::BVE'$>IW$,DZG_ M/45Q5A6@'$Z3)L%TZM E 9EW!!.4U8G>19$:MG>2@WR;=F?;>@!Q M@FG*C:O^N1CK=,(:"8*JV.URX_ 8[@'0;+W\&V:I!%DZ7F-L55Y,Y>$T!8N MDX#5NX3"F.!$UESXZGM_4(0?7'S@=1>;R5XP2T39+LU%$% M|P7]?[P':-3 ,3(CZ:.O-9M#B(ORB|-6?X)@E2VU:;0LNJ[4^:+P40JC*V)6 MD=*.^&I/E4K96Y:[)29JY)A06H!E&G$FW[7L@P(YR\Y4T4B]2=5IGP:_1=*@ M0I2@,GT8NBS0FHJ!,P)^3R;B&I5(]TT<$X8V5":,KC%5V<#QVX>R,PFL,|F__MUO^Q@%1O9_9M,?3_L0Y?/D!_F7_A73Z-)O-FNA";TF=@G5W7=Q@>X M?-N&25!"^[Z\/#\[.S_Y^UBOT@C-,(DK\4G9X4O9[4NMT&.!8X@O;_#&*8 M0?[M0R[%XM_^^3]02P,$% @ TX,-6:8I^LSYW00 1TH\ !4 !F8FEO M+3(P,C0P-C,P>#$P<2VH=&WLO6F3HLSV+_B^$P<U*V1M04US/^"_N-_NL)F)(EJ;HO__*\E2Y*_ __]9_&T&>U&Z,J$W)EN0;

9'$7Q!$XD,]AZ<&,OI%5(+]/|Z[O(2!3M__X:>Y[|\\?172'ORUG M|&?]PVK,O|87ZZJH;:^_%T-'7UT=OB+Q)_IY&!)D<_G"55[=/4|LKL7^
M=.LU7AH#0T14T_5$4WJY*WRF[&UOW'T%\>?YQ\VEZL)#7"""]>DGX^??(FOU1 MS7 X("+4'\\135>Q'$/T0K*&#\((!$TC"6SS'-?QWA(@_/+5Y-7%L:F'G'U¥
MV^9R!RA'247^"7_=G;]Z@JK[!)&!^HXFQF'/[P>L&LE<2QUZM'/5ZOO,,0K M+)/)_%E$>-D\%4CRX=>'/[QZ_>(-6EX],_U(F,/F> \N.(*3KQ"]'D0H^8Q0I=<__QD#4?!G/P;P
MQ"?),KU0T_SWEP<6WHG:D8WL(#"_EK_CGB!#7[^>‹_GNKI\,,,-G\ M__E10TL_OF/K,Z>7"_0P7!_&-(S4DW$L^R_"=3V_AV'|$_X\ZMK9-6U=3'X
M:UHFB"Y0%W^CIP'G^4|5EH&Y^C.\H."(4C3E)]]4/2["KQ#^,>!#"LJB(P\$ M/C\(QKEYO=)T?*WCHU*:=?H3,)V'E"_FJH>SM#Q0V*O)K1X?D;6'3#*@!PD
MT$'$P@$UJ*95EV,;.@64$W.T2V='=3S[,JE&:+@< M57HUI+SOK/ ZP ;8,Z%;U@[5>T*]GD'*.9:N(CU[KFLU7M6W PQ5QU\Z'(T7 M4.'@'%$OFS)85$'P/*R6-&":)M?
N-,"2N/&E,8L OLP-\@/WZ!PUE+HEG M"G?<<+!%E17$O4>$!W:E/.AO=T.V2-QJDI+BB44F>2@,1V. M]9HY&B2B(2,(AH<&X"0'FU_[&R\#+H3?N-OAULE>,LGD%BV4L5#?
K9<*=M?* M#I+1<*-7W&^L;/@"2WX]6E+#58=PYS..L<=:(ZGZ1L=H#HAHM$W*\>:#0RO_Y))/$4EDAO9KR9XLVF M?(9>O-JY* 5F7%&"76J M.E-
E7]2S"!5=_4(O@.1[Z@RT0T<^G+:KAG/RZL 8 F>P)L> U46S$1)H=5?D M*@UJECEJ <7>*N;TL;X*PG!R2-$G:6JV&$U8?O >S%9%7P4QH
MHVQ@NJLI99W0%1J!2+ARP$RWA@XK;%H M,G;T"+<8/L)SR^:S$GG%NP3688Q"'; :,LK4*G-<E@*Z>A))U^7F&U2?H2*"G-*D:=I,9N\'H/=;= MT&_AP$AU(_=B^C]:JQ\R25,W"HJ*
(G94\O6L9&2",=;6 <93[GK*,-_GD*F M_(Z)78A<2\9DWTB$ MI&*:-&>>FB=HXD-Y^,&,0+-)% B><45T;N0\#X;>BR"]2#LC:B'$0"$UUK$ M.ZGN'7-4.JX@6VQ-JT"KP2@Y]$_V\?
EY=!'PGQ'CDW>:!*SGJ2CY?31IMNQ12 M'=>*M(B49D-%DROT,-2E67_DN!Y3 ON?IW#$Q/4FSL^U2,_5+-%<3!UR MSK3 37=1KSG.&^-0OO- 6KUX M,_G419/!'WCJQ:R_?/KX_!?
=,=V:M)09S;-%OX!.Q&%-'9V>?UMT5'&H@W(X MM!#R'A?2H178@%YXH:97PU]H,QJ^^!80LM<[:D>2$@3N7Y M_AWE*<[2^K)&?BW;TR_,$?Q1YI<5X MQ(BYHED82-O2$QB*
|LO'SZNMC9W\/[0!5,_Q)>A?^):+6Z M[9$@DZX5O967')K*.&D[%O6 M1\/]6U=-U?"-!0!X40=NR\|!NJB:7O@O>..UNVDu\G,)3:04M>EV)*G?&)385 M*C/T2SW-
YF&ANB$*X5!,Z860T:Z99$7B.KCM*=*\LS_'F==UW%NB#DC_O/ M?Z*<^%]WE;D.1_RTRI'_C9+"__WEADZV'J6Q5]^-5ZL+$1&135K\|*5HPSA MG[UGKCZZEN^L/[T6&_ZNJ,*:P;-
S1JQ|LV>(4.'S;^FJ*U>K=QK%;@O**O[M$<1&K3!8$&T0QD!2&"-(>Q"B=-%U&:4C1G&(QSA<)%0[ZCND1(H,$H*[?OY7;6^_JJQ"CA-$.DK^^MZX1*#<6B39/ YOCT>#Y3M) -
MZTF#59RP^;2*U2!%!#=V#%<'!P44DJEQ6I=[,(F \)?Y3#ERWL<(#4]J M6C2>9-6(E)9EAHOTO+_'Z!M"9B47)PC\GS\'WWW[&R+H32'N-OAULE>,LGD%BV4L5#?
PXQV5X%KEN6K]:"O%4R%4&>)5?KW]2^;SYO[_KP2%^BD M)]0"X(KRPV?,,,N4W[:1L>4C/<>E);IW8|Z4G&WKL/C@L/-'=7)0V
MWF:YUR[Z)L36@#LMSMPYVB%T=Z9[Y&)4BR/"3Q#A/F3I M%K*T4E9M2Q<|50_)M7Y<9F9,)9M-YX1J3L+D/)5A6O.'&,5'C ZR]2%!MY @ M>F$#*1Q=M#Z\?E9#-4NC1-
LT&!$$N2X5.387AP#U\]/F]Y^OUDYU0T?988 M;3<4>.LROS7?KAX6!75B7G9(3!;PAH6)FE/R.]XC=O^09)UFUB-6^E$2=B* MPHJL@O?
99DW#"U(W4;R6KX6QQ3$0]9^.:%0%K=0=#K4Z?I+%>E.Y3%-2H+-6 M)9EBY(=QB[G _9#X"UI9.Q24%=D)U.M- 2\G]\+/:^,-YDX!F4/0?L&D=KN
MJH1WQ4QPL$_(&*N+THI@V=$+QVZ9A)_-S5Z[O*SJ*-5?2HU<2]#,>AQ-VC&Z MWUK,3G'L1[B/BPG7 =%0'X;(F36'2:MKS2M*%,^HF'G,57SK[2:WR(MV+L>8VY0KN1;J<0"-?
#A+*AVZF*^&L=5L(=\2;>&S>$_A@F%-[$T*GU+T@E;$3@11@PF?HQL]&0AB-9-KRT M#D=Q-%X/8?NI MD16T8GUHX+G@#'JK M(5' V-+EZ"'"+
[8>R83O6;$6J3:)CV2H6!J5$I4RK8P0L GG!LR/HK,V&UV>0 MX 48Y]+@FO ((>!X43/<=04<%OZS?<[VMRUQY9U+=XOE-K]\OB1UVS!ITY7R MN:MXU(K<,B,:O()-
PS*CASF6KH="O?$,UU#AN;G-Y9UN02BF9+,?PGWHM: + M!;;=A$Y-^ 4DIV82"!J^-4 MH?V4+&,3^8YZFL6\H+)#:6S2PWF+6PV", 'GU_&U3H7,BLDMN8:$66*Y9F
MG93A!#=WRN\Z^9U\U!6M72$[)_KUE-S7\"01) U*:XX%Z))!\%N[VR4?KVGN M\I7RT.0#L:3QE-RLL\W>W)O'7MG=P=Q!P^X/VSO&9Q.%F0A4H6/Z6!&W&W8S MB+O
PV+OK@R+3=1[58V_Y/)5N)(Y#3@&$N#,A$MRS[R61?P^B89CNLJ?,;J M"+-&+;.DIUP_9?52@[G^4/@QYO:'!3VW*,ANJ.47&C5K=7IS?EZH/?3|T#%
M>N5X=0#EZNS)LNOZT>ED:]Y7QFP*SU=;4ZT*M$FY0V#3&GP;$_D_7K=]=AD MX\'AQ"UBN)ZL%#/LR*"UCFYFJG4%&TRDAT6_A-
>WR%9MQZAWLIA/U<3W31@V[UD2GG50WI<8]-/E:B86ABN:MQ *]."\D MY!S0IHV17YGT/7_6CCMCOU!BH2@$.2BRI2';Z#B)>4^89K0:EIP,Y;D9=UW\ MA2(+2R7
6YFM!6J=8%@$(LKK(^O/U-!YBOW&A;^264A6@^:^,%K&6U+@9FE4 M3$U4-3.-.-=HW .B+Q59*-9RWTILGY(LKC5,.+2?!H6)2K(*$(#>)++Y.8]%8 M3LHL;3+ZRJ>5-
(T4RSJ@K3LE%.Q+S/_6HF%8:WFK<1*U8Y,\!K!:WZ(IY* M"J.103UL;+R6&PZ*K%N2L"Q(I1-"IY1HC\1*346'R(;NWSS6YFE*UPB, :C MEA:TLFZT[QA1MW]^FK9/;F^>)HCWM#-
,!+@5-K;K7&EN^*ILR#&3"SIKSS M56NL.AX 9G3?1G1EH>*5%<6G*7GFS?)L5BK"NZ=A=\+K*J>/SACV3..YG1Y. ML;XU!_H,T(:M6P$ *Z"SOB.-11?LL#[?+(%\LE)LT-
5LR2S!NIJ'5VJ=9 M?],K\EZ]I}Y='*Z"D[5TK.A5-]5PHKI MEWH:-B+)OK/,,?,Y&K<IC+A-%7>[-1*Z;: MX;W)?BMT'$V09>>B(V]!P:P 8%H337]AL,B3:A |[X13'7;,#% 9VSV-I M-#[H-
+EQ=S0KE*%U"%[-=@V)CTP7]H39F4K@-=,WW^Y->\-@JMP8YG6!H8NM MNLREB/:8*B)K%?88O/GZX-2^E8 ?Y/SVIZ@)6TOU=, H95-69ZKLB_J*^=$O M\ )(?
J3\VJH$PC#'77%B4TAPU'#4+',4=L&M,B/59'(4BG!,SDDI MH*LGH,,44:.T@W3Y14_TTRG"'$7/9\S3*9)" M?=2^\#5VJL F7+&D910N8X MGT-
K4A+K.IZOUC2U8AJHHJ;2\PET]:AWT']"+@^P7A.LB1VP)NZ@6|/&N# L M)X'H2U112?@Q4B)EL.G10*!.%OF7K9?AV2IS1UOD523ZOF8[2O#9M5/@2RRFHWG($'%&7*>LW8]O
'(.06D[X*=30OTN_I=\=437GCCH: M>^LO*Y8)W)8CRJM-26XX2?]YWPH/G%MH:+OW._>94'0392&KFKF56PI>[M?&AFG!5GWS9"OP3=$E_K#+-5-$ ZU(:51V(>,!6RI0-
71+Z+L>EO8>V0_2\ M'=JP:U8U##+G@NV<$R8H78QVCJW/(F_<+M(@+X\X>.0?5Z9S":*D$4(PL5R@ MVXKG:%T&VYZ&L11REYR9M\5((AFX@S!W!X&YR
U+'A!24!Y9 M$@EN0IAI'MW031I=EO9OD#V'J/2% 2YZ@!2A?OP9+_0D[UR 3L- MP-/G'E\E.-AIM;ZM0EPKH3V@AT^? <=3AS178J_6%((!)8*A9T990U)SS.B MD)F3H
!I#'=2S1\CUQ7@>(S.+^=.O4_HV^$31_#T%2L\B)U*?&!P*ON1Z\> M70K9XZ7!9^IUUA^&=-W/O^5F?K;354FTF"CEL#Q1Y+/=.#HQIZA[4X1_O);Y
M:FK^$$=OF9DFSL],$SOQYLW6**XD4@A="ADX M;G;D@!4*KN!0S<6I@/93:413$7&48BE5+TVA7)RI[^"=X,WZ_4>8$W\GZ^[K M0I^6OG-"[IL('YU>MG*E3@?7C 1
JX,YW;>JAL^@RN M1-ZEK"OH_RQK($3'5%C4<,P&,"R\IL)ZF/31;-;[-'KHX=N4].TG?N,9@2!& MG9_JC]!8W7*9HA M>'5,IB'-G#UL"$PH_I G!,F:U:=$)6"Y61(U.KHV!6ZU-M?TQ1Q
:FD>BX|L%^)DU9(U:D/&)EL: MA> S"E50UV!)YZ1@YP1=N7U/GRMCO$5%EX^=98!-0]#ZK$)K;R9I2-1LYL+=G_9VU\I/>TZ+=68R2C4H$1ZMQ[8@] M<+75R7K;Z'M;
(SS)+EF/EB>"VB&3BDQTBU4R;B5K+XRYW-!$KSC*T?5[CK/T M9AF4 UC8W7VW#X;/C^,@BC.J1B.,JE?DW?S?#^I([YLD3?^V7X6%&V) M17VJHBT:
(&T3H0(#J(6X^;/7D/0X2=Q)EOXDJ;NN,!5QLY&>(I*.%I=]KCQB M'-]/06?UO@BHL4;+)=G"[^C'E8MD4NL6"Y0V=;416ZE,>CWX$/WPXZ"P*G?Q MX^Z>P?PF?
ARMR,6*5DPFQ(_[5993\N"_RXV"3NNL*$[,9 M;EWH:.2CD_/P8,7,:=#%-?/RX^Z$E><$]TI?TXW+<@,HJJ2E-RIUB$N&< %=^ MHG9_^'$P^G&)\V.]ZZ]\?5)'0.;'M8;%TD@S4R3-
)VC"EVU&*<-WU-O#CX/ MCX-0Z]XK3#VSZ4B*F/6%8K>#)[IXI3>:0F?U8N+'W14MEU0+?4<_S]LP>&Y& M.S6!88(Y.9=YB@'763R\..@L"IW\>/N7L'T3?PXBB<*66(\6@BJ-"\#<3GH
M=FO0V.Z''P>"P>;U%U7F)KI0=OJ>T!!22=1D)6LPA9-Z*Q>?/RX^Z'E>.T+ MZUBR+WF,LY:>%SW95_6%NLEC(8-A#1.1LF D9SI-=T.+!@)E='MH/FLML3.A M[!EZ?
@F7FT,'+);BQSL,R+L,GD-8,D>*\C+-G @-+ZG>#S]RD],+WA--.M@5,#(U$*UA=Q8-5*8\U[8HH,9=\?!X+.;YX29I-,(_B!NO'IGD@<\T;/O4&$L MIFO6SR;)9#6CJH+F-
\9S3T/T'#^>)FWK?G=&#SUL^2Y+OB>9&R+7JW*&KY8 4 M^(EE23/&;J,2="[=>YQ^-:?OR>OC52[G>6P)#A5*PLPRA4Z#9]DJ7ZP-L;AI
M\R_RV&"KJOB(QU:WNS6MW.!_C*/+5Z*'AE<=6*Q/U-#NJ*@1!/5B>3 LIK,/C^U; M\/FUQ]8;#8IXNBQ@-,B49"6MEA37BYLA_SJ/#<::M_,\MJ"Z\)A!2"5:S!!=
MPN66(.C&S9)_A<<<&8?W$1SRVN>F1@S'!SFB2X,&AKD#V/?A.BH3*8XL=I]_S MV%P&.3F\U2HMZJ3COUN3N&K\(94H\M=FAXY,%1XRG.+16Y1:M"D6@7&G4- M8V-GQ[_"8XL?
GU]|;(QJ=F=L,+>$8E5IZ1AH5N>MN"GX+_+8(*UN:\]C2]*! MXM?S\ARE*G.E2!52Y1J<[1#OI[!'5BGQ$8^MLZ39/*71&LI4\6Q=!8O<7(V;
MZOXRCRU>G'XWQU8'K6)NC.#"M,%82DDNE#-,W&3\CAY;O-#PRF,#9!.QDWQ6 M0@VT0R(EW*-3Z=C9\2_RV&+&Y]<>VQ(%2\'Q9ZM:$5B8BFB\/^3B%I9]GZ5?+?
DC7.QI7V)'PF934\[QT"GW]6EK;V:[+3@_:K7A,0-SW7'UUTP$U=C M^:DK8N4:$%TPMG3YF0KK#V7#=]S9]XT[%I5,F]F.2&M4-TBE M9QI!%'K0O?-#*_6\@P4OM\KDTB(?8?
PX/!=\Q5<]W0-367UU$?VT0@'5SWT.:O9QH/WAYP MUF_BQC'=@NY85K6@=:9)35ZJO5K_FZCS.[MQ5W;K/PF($W[<4D@2RV1:MFC1 M[_:43#F;]>$[@S,>?
AQ<3#_JR+&U6:O,EIF)0&9<7"#G,CO!OX?DW\&1@XWQ MASTYTU%)SDDT3@8O>>*[<@IP,IF\HY*)G(VUYV MU!KVEM!FY>!SY;[&W)V5%&+G+"+BFD?>'S_(Z 5)ZBQ\?
DA?:;!SJS=&\]'Z;M^:7$"WQ++Q/G;"HGK'@NVN^DWN=?N_Y8 M[H#PTWJE7_8%!3G"L&O39CL#G?%^8/D0EC^PJ3GY=:W[IX?ESQPKRDVS=&?D
M%KIHM5\NDUI24&3SX9[<7@ZNX1K[C*-_]I/P[YSU&]B.ZAM[HG'=YGS;!D\K M7.P)&A].#;B4;_CA$]09X(,@"$.=<"&0P:>+^]L T)'13W?HELW_M4T#2H& M7A2%8G;
(46[93A5AE<7C1_SNTO_SZ(>E>]}1EF\Z^%W&<|A72;:6CQS@J1W3 MM_GPOND3'.R=R/]T,(5/GP"4T-*KB[('1$=!L<6\]9(*'8:O$29(>>9.(8F MQ\AU>P2?!>A;&A82P5-
G&Y:72^]_LN9UND1?U->9-]OUDD@"'U6+M2#*7K;3I M+HB;R?@.?9WAZJ<,:>$XJS6"!"]D5%XZ H>'M+TD\YL@N(\D(ND*<@8:4STK(465.N% M_F#,M#HRI!'.0YJ^]-A'4GAS!T
MU!$P0$;=5'SG=5$[@N_SSN'<2RH10;H=:(Z!^]%E,. MZ>$!:6Q:NC7:,$+//QG0K=W*+UUQTYJ:6@[V<75)\A&+@W5-\D@HO*S\?)\-/RL#=&E$539;E<@-HJ"!0U4'*:,F,#5V\
M'V=$P9:%NC6BFDRBH8Q2G:S&5!I9HVHS/5^!+N:-+:+BX$M=&5'F='!I49[-@5O14? *=YP$1^ZZ_]>9T M$!-U_BFO-@N^3G>O^OI%/VX"73<_D)\C,X,;#)'0AY,!D=6A2^>M].
];6>VV M*WR9UO<,,DZ[A,>; K,(O%H=Y%*F"VV8>A01'YSV]W3Y+D/,OHY :;;*NAK, M%Q,4.7O!:(=T:]V5/(&U>;RR[I2'=CZ,2 MNR%>=@D6#[SL)>D_ IAF4Q+F 5EV-5^O3)AZ==;J-
+ZO H$M.7^S4+6@F](I M]:*^E[C,_+]NA;!992LM6U0FZ.A"L8,WZ2+G^/'L'W0[W^8(05_6>$1]'L& MGY>BE1H#2;,M=8NWRU#:1!I9+-E9, ,+PYIU*]2.5\EWH\LMGH'2?'@]T0IWV
M.X;2YV6S3=>[[["C\SU[_GP+5*Y*6,R %#%082I71G*!@W1H$FUY]7IT[0=UO MA>)C#>VS<]&1M_U.5XCC0%1))'GKJ#EKRGO?"%;Z1> H,YVP)8IGM.D@-2#%
M4:@\^]#Y=]MZJ=W9KB'PD>G&PUU_N\+Z62ZGI";=2 X[30&9:R[&*X6! &_)-M.*1<3EQJK]/I:N_73-I\2QNV;@4 K";-V-%S-L8$U_IH T%K B*EO9*E3:M9 M*RY,WGQ]='K?2IM?
A(^/B|V6XB2FH]$(W0&YO-,5H+%?%P0<5>OAPXA1TIO M/JHC-%+H-@IN,H6* \2=R890'$|C@HC|Z0@(3YF]EH|()4A=;;$:+DS3RBC3
M$12[#6]1%K0ZXJX(2:^[^]$11%X^O%N?)VJ> T##\C:;+ K*0,#<(8]H:GE, MS"G9P:HXM-'\0]]_8G=C.TH@J;/;'ZW=^EG0\'T.J5_"9OMLC40,1*I:T%/
MD;M!MRYV4]#*_'W8O./XK5AWR_-GS^>"CO671N7!N?N= M.7>,=?Q<:P"]%GBQO52.SR1:??0!LV/4"$]%ICK14_W?IF8K"OI?V8=6^E MSLCUS%H)(0G4^8(NC0M-
%)W9=9]QJ$4L+RR\V#IC7"/%A:^YMPI?=CY]7($NNF.Z-6DLYIGBWX!G8C#FAH_7MY4 M@>[%)*$<|EWZ=;U1CG?
M6+FOBQ/+H7S7LPS@[%:4K+]JS:V]Q7K*,J5PUL]/YE17RP4Y8$IC0W1>GPJ8 ME:2H';,+ 0FHL^@\B/>?]/:XWN\ UQNN9'[@:/HWNW/>VT1ZIEB=W!EQIF#E50=(^X*5SV V7^1;
M-MJ9\GBNVTP1 ISARI?M]IX'^O5Y/2BG1I7D)1#.+F=I&+77+C^"DF]1,HL M0K40ITZ5-03G:[-V"]ODJU#Z[=](RGX*SF\%VH!W,N@P/VK3))DV98)%P%2' M$K0/"%V*
(^(+0X/GP\,_[+MLKF"=,&+WP-8V;]H6=([JE[$%;T_ 94!!"%3R. M>$0&'_0X#O'FI*SN>0P5V\1/B@19_)75U^K&[&GA-97_/GI:%<4GOE\O A M/Q3?^XA0!2H-1G_/5S(V<'%'Q3/HF-
E,_) = LA[DIS?^_UC?E7%UX-H M?MPV[7+0T\HD)YGNN)0F4*;#T8,E32)-$4I/ZN\;<;P;*A]F[W5$[P N7@3O M(#!NIVV>!ZG;R7_JBO[G5>0?!@&>"!D>317[$X'W"' M'-U>CJY^2/'-
%WD.2E%_+(.Y05MEVAAY,.?(4K5\.8ZYZ-L>;@SS*L_7RM!U M&\D\[[;X2I>K=^2'L@S#,E>TVQ,?,F_W!,WMU 5Q3GL.AB:,63&.(G"]D?O MP?\H<6^)PVOL WK&(?
$!G^@:NCP;SOET='1"C;/^,*3D?MZ820;DW*W1=#$; M&((RRV0SL6SN?5\U?I QM]?@AUAZ.\DAKN@%75UR+@&_.C&HO-7)R9K?SK<'`MJ:[B)OIQC 1N"_JOB\(D-
/56@9WMJDO5*0A(OZ!Q_MB1&?Z1V,V]_-U[/":O MZ.-=>"X^91]J2]I?:@#88-5V;C4]5X>'GH DJCGZJRN6*6?./AO>!Z:6K![5V4R-F$:8G%6UBV)N6O2/3233\=1
MV=Y!5![ZUD]#*R_&\UV>$I:BSXY*0(')"()428\T>(UCP$);;Y,H>DC+ T &&M/>\G^IO+/1XW%PT]WV]@4W.!S61!PY=B'(']2XUCF H@EV_XQD^*(Y#KB*C
M])#NN"F2[U!N<3R]>?;RP[._9M.PET:Y1JV;KBS3 #NF7OE-Y-Z\QRO"#[M*@WPJ>!56\F1VX,N(/K(WM++'"%-'?&-VC5=B*JFY,QE>C3+"QVD,5LJ@T8N M*%;0HPWJF
[L_IZ'09I/V,@DYG7$ZHC2N$SV8S?XF*MD^ZWWQV.T_<:!E MA4TNM:+;8NDJFIPY,X\4>2,.#NK-#K2\>XN#,T\^^+QB\,C.IG%2[B&I&V9
M*4TSFK6,M5F)0R,,+SY#)YR#K.JAG9T!'DB^LY(C>B'IO@S@E,9E&78OK=Z M%]/0HF.&L;O+ H(W+"MB>,&G4JB I'-0FMN M;DB?Q^F27XK"XZ?^F++A4LK4T]J49.6]7X%-
!!H]=R7(/)QSM@7H7-=T3$# M;NC&G#B':&BK06[<)PIT-:A7%STL:?32/U-KKFLTWB/9 ZE?A]0U2.L!.<;) M@EBA.\DF@E>)P,C!5S!R=Y#^ 'P>.XWMR[W-
GFEQU<:DW:"9H>'H+%.89IF? M"NBS:+-/QL1#Y.K/P$=)[K;3;* M_3S#+E1'HYC4I&MG2-4H//+S-'W=+R)IQ(78.T]NBY:8MKAR'1M%5K]!EJ5B(> M(/UB; ,.N^#R|C' L["PV'*
(9M60V:-$,HE/#7%8,=CJ! UMM+4M)OBMTJFZ[M4B&(9M*%%EE'C]):Y[?K?/Q\'6' M_4)<>G'^*7J6@^NH7Z]2=-%1,+:45^1Z"[J=K.]R_>M.T8,AVW!M_8\L)\5A
MAQ(X0>Q*&I4HU.W.*'ZB?T_]'V],1%>(NAY=$E)LM8I<4Z60\"IG_CAN&:UZ MI3'-F I@"XLBEH3O/+$/0N3=:3\0L^,Q>&/@1#|N]MYFTR@U=XL42@*ZZ/9R M/2.8Q0\1>]-
Z>]8UA%M-8-(-6@5=R:/P,Q9?ZB+ 64E[L+=2) M&:Z,O?Q0H%Q6HXQ2:C$+XB?X=_,6[EHV>0U,4)8Y XZGAJ1B': QP'R*FFS M<1;F6JZKB*3#"-,J7BEK"],J6=*F_,]$R'NS?
N#E9'9AADPS2\$:"$6K6.UD M[&XC!]\.1H@L!S3%U5>T'#0WMP>S\IC1C'2*:UF301J,X^<+W--RP+HV8650#VNKFN^I>PKF*73]JC;C@ M$1QIG-MP\&\;
(JE%W9D4]>8(#H@/Q8'GH.2^'A9,)9C-JE FZ8X,>N7NK$SIOT]5SL_MCY@B"*WK:F=U5C944W571U//P&O,=))4I.6U^CV!U!I*5R.XHMF%5H^F=&Z"XU+!-
L/NT"@$DYLWZ5;R%:4>B@BLU9&L0MK0X"X-U)_B0T M7- -+M.H)%)<:+.,HT+W4|!5;5TL4R=!"X9CO.\GW4XTMA321S;N2Q FBQ SD M8G4.&BYT#@
\C2WA0XW8#T"23TMRD8%H>+/0<<@^P5H] M=[WLDT9VID5,3$VT3JHC(>P\VR-[C^S3MT+-9=FG>5IL%Y=C6]?\U+S;9<7D
M5)M!ITW@RS[!QOT/1YL"5]ER;]&;U,CN0G;0!95TA$>T^5UX_GZT"0*1M?VY MFZ6I$6*TFLU"5=&AM0GP19NP5E]?R\|$<\NB46QQ2PW1%$;LAZ@:P]N"""H_M$^);V^OYF0PF-
"VZWFX*5;=>ZU6GG#?&XXV9^_J9$*+F,C]3HYJ"8/-H._RC M20\[9*T"0!P36U_I9\:2^R=7.579P91VH]U#C:QG5>;SI3(I0.=UPKK*"2$> M+ESE;#+5A-UM^E.ATU+P>@?UDG@5NK
3ME5.B/E_=MS)FKV9D00C1A#U'H>5 M,,?P,.@'T:]KKM@%QX,G[+6>"SW+#HL:RS# #K>A#%G=^B(8+5CF[MT^,0\GDE)P1;JY
<)!&'U^+H#'[9*FL^R"%D<8W"OI!!L>+LP^U5*^8/,+ M<2F(!%P5;,,PJ,)7[!A]@E6_I^=?:(+]8K(5:2^4&2PB;EP]98J0!=V0)5] MBA//W\\^S;CLDK3'%*-5*P IR4VRG
R@%7WXLD^PH>&"[--<$WA>3142&J : MLCOD@+H4H=,!D&6?XL?W4]DG8"HSC^.9N5!$YQQI"_/E>!%'1_!.V:T2"4S2C8Z_6D$7K<06373D7G@S%0I9-7(:L+U@\HICFE.^?3G!:Z
M'X6V9&#D8,N1?$,O+?478/NA;Q',7:VA3N?+[N)M'W&?'XB MPR(&D&+Q$]A:)<*RBJ+]:GC!QKO/U>FZ[53Z'EW4RIF;T6_B)*P+BY]A^L%Y
MQX/O&#Y(8*]CN^LQOHEXTY23HK(T&.+TD)T8%&~&];!SO@$@N%(KNVP"=B MZ[;Q=K&Z5+O5KF"4@2]IB81E3]#*3*P^W[>YN6^):*G,_J9VMOZDU@KTHM8"
M&R'@_:$+IGZT!|P&C]XV@W;D]P-WJ[(J.@$OZB'I5P?C[?B.OAY$ ^3 2'5# M' (YKSI \AA%":=NCM9/PYO38&*E14GH5,A6EV@4RO,.I/)TG13,V8@^PIX7 M,3K(G^N\|R!C-
P[O69R|6=(A)52YV^X2NU8KRMOO\.N(8.4+KHNUZS/CV8< M3AV-=QL5.Z#@FS*0UQ>X'Q/"@R(W-;,%3K^NCVG0|K)88+F 1G'E-2U1>XH M-S8=E
^SX_8R]]42]H$MC=A5).SCR8E36=TSI:MAS5;71^;ZPP*V77%VU%DX M0E87I5U'T<^4G.3,3FLH:=4$>4G64DHWCH;MDL3RU03N.(=N^G/;!?>#O(U'
MD/W%LE0133\DY2Us]>DY\Z;,CG/:-#EE%K5AD!>,.*8*[RI*1QGTD*0K2M)1 M1Z^@FJ(I:)^\#R*#5FRH__%_IZ0-JH2GS/XYO4+%TD_"3,CA0L,JQ/ MB_F^.U.KV121>7AB'Q*$H]2-
!Q)W%AQBJL)G09;*=>U@]%&8V\>]O4ZR"%^U MVD.%WUN%7WG!YD."(O'[Q&52^95U]"L'39];E[E[ZV01V M:H 1YX8\@,=AO#IV@C*':,*3/@/W-/XO6]S%R5E%JACY-
BK2$E!$,HW8LHL,FPKF($/$(W"]1AZ$]//!V9^]&[M-V"WBBI730C"D(4TTQ,M6,AL_3 MT-GVCR#@(3CP>D#-:&W4P{J-8H[SDTKV)>2O0+;WST *0% A_=LG@M M=-
F=B&)N\EIF=NXE,N4#D MZKT4]6-%4Z$+(VUB0X>->V6;WG&$WR$N[-;H=]5^EZ2K!FY{@H^G7D'PTUF\ MVL?G50*^;;2QW*X_]T25S9YX)\<&.*%Z6&)43Q86"]HW4P&X(M-
)L0NL:P=(1 M!88S059U .^T@!MUN&C%V]9\>N?Z,K7MQ>F,[AXBV%-MBPR=Z;.%Z^72.YJPLZI7KB$[^*P6C%+9J87R4XYP"C.ON(QER>AM:UA@1WC\ MG+1;(1S;1WA D9VA[A-
#=%IK6&6UH2;4WL,Z7 /A^[3^G@@G!L0V<[;]^X(H MY(8N46(?],#*"9/1,(6CQ7IB"9J%0I;EXZC6KQ=TP.D&[7/NEKE'(OSGO-SC M1PNO6AUF#K&M[VPX(W8:*\)'ZLK7?53V/N<4
&P!"_F"!8P//%W76 0IP MHD;3T:T"-F/:\>II IC&P>CHA PK;GIR++>*T&G3]X4]>Z3<.:!7D;#Z[BV M]|T]|A5JB<8'"$;S>[HH]=*"&/A[[MVKV_-
RRNA;/FNYID,2LKIQW4D)-4D:ZE6S4LCL[Z-Z_YAB=DP/!G$.,1B/$/ M[%_NO'W3%\D?/H,,)X:&L[5!;F#GL=R8:MO MY3W783F+T#*<#-QI5B9[M*^-7V<5^AH(^M5-,+_W7;EA=Z&:%
>(ZEK[D]3G/-@E'2 MJRB5+AFU2@*S13@++# [.<%L:=GR*/PT)\)NPD;ZN;G@+O1NA0*T :$(0] M46?B&)<^2"%G1>GBSF%7N\F:>'=5X<0Q+N.^$VC3V@#!VM.R6QY":18?757N
MGQG"SL\,8=:;74;[#YRO&T%!TIH"]A."A$YXC M1VV^]*TY8=`57E)GL5*[.87/(7KHA&^I$V +O#^L$[*2%'G,+@#[R#LQ|CPD.+O+<6'2\4>EOVY8]6D%[4T;0A"
M53,XCJ13^;KP\/8?.N'F.@&:8L(#+7B^JVGG_+1M9W/#+DKQ=+'B[/=9SW'/#F)A;=S-KRCAQ3?<]**,B91:F2:T3 M.*4NLB [7AXZ>'[2?7^?BM\1S==SX"_?L%_.;C6&L,RAP*
<=4N.%CN>94,+K M7JT:,GF.'YZZZL;SSQWOVT_E9EA'+MV_)3C?7>1B:=N M%(I=1!G]A8?<,_]TZ=+)]/R?@N/ZI=MFSD_'$977;R.XEW>@ MFRB8HM9>6Y3F+[7.-
%|SAZD9!'DM",]]^8DH3C^C&(U0G%Y7S*#O964#WU'? M=-4|[6K_/N2LN?7|1XZK/RHX*H.DSY79U*12'C;W,]>1"T[/P2EQS M,D%,(9@8[7XW<*H5!E+!NE.?DX?

=>H,51.)5S3'Q7!+W=5:= [881'^PJ_='-7 %,'1\T0G"AY%E M165YHKZND*L#T?5#)C%F:*Q5735'K3G09Z >CFZ<$UW5?:E..(T=X(XM75[? MFPV!D0?2BI0)+!KHGJ2%E!:FWZ;2O::&MIYKVJ,IL>)73L@JJXWI9TPP# M"<<-F<\HE&ZY(8>CT5TL,0;9LER IL*G;;2I_%2EJG"V9#N=.G!9TD75Y#? MHP31]"2/QZ]_96?RZ W#5$1,$:]31[5>9O\!'_Z@P._=[=J9/:*/
M834]SEV9F3=\H(G,"F/$+?N#!RYW*FJY2AY *5UR MB%,!:GAZA;DHR%"L00>&6Q3201(2?YR71W>@O',H#S\&NL*!D>JN&TE%|<~V M9J5^5KU3GLY+Q91/&^/D4.!$O4JF'$<|7'|
/RGOGJ@W^^/QG/EVUP 3&P? MF)WYLE4F?%T6R+&38?E1(;/0.?EW'NSR248W2=UW#IZ*UK^F%,QY++Q !+?8[+TC}ZQ%%!#2=-^<\ MB#]0?
2);X)$AK\+H)$"+B?@V>KE*(9=?U=XYE")93 MF4RXLX$VK8L5N60*+;$([9KS.[C8W0UZ8+(/??%1=,P&[C WHODL2E;FMML1 M!^80OH9F*/C?KKCV+DN>$X=U,?
+%EUL2DRCQY$IT+TY8V]*N6MOAWOI^+42 MK//;?[W;)V"]S7B]5YUQ.'4T/]M3)ZV:\&T.DIK 3$?%>M8)>FCT!GQNW8*
M.$K>_8*V&WW]6YX\7+I54!\6;^+LUK8O9.^RJL.D#O&4<)AFZ/UO5:?#Z@\ M.Q3ISMC-#N?S43,/7XW;W1O7O9=DDZRJ"'()U3>8[M5IYC9TO6N\\M927H/E71<_AR MQ@D&2Z-
S(I?FQK4X&I?;1;8PUJ)CY]>B8U?;8W6U./:=_<$-X*WZA[LYH%MS M_,A!;Y_KXVY) F'W"037D+Y&+"F#L[%$'$W!;8*)]W8BGV31YT4.WO;Q5]W M>G&F$W;IXK0*'> 9G=> 6""\-
%!36B^.^=*'=-U4NF#*U!Y"%*\C32/::!47 M LH)%)?I 7&H4?]AS0!8'V'EMO%,F<2DTK.%8IXD6GQPV5"L./H-WW%5A]X MJMTNQ0%C2E8H.-&J_AH I3EJ-2K:0!
(8(ETAZ<&R,EC&41F]F=J#\V?;M>*" M0.9+25"U*9] V+14:[/+'[,4\R/Q4 I=42G8-CZP<0=3B(#LT#A-E3,]U,'H M>AP1\'I>#YZ_VB3ZZM 9[^X#4AL'JU7:]3S.+
M)BKE1!E>^O;)TH\JK;MNH+K&-OV&94;/=BPl.JNC'(D>:#'!"R=@W\Z7%,2B M 5L?H+CM%PD?Z.S9![_=>GIKQ+8W;_3;O7P,G65E>+0J%ND94Y;))B:,JB?H: M*(X@T?E"OHMKI-
!VFKF!6M+@;>5l)E!.3OE{N4:,1Y:.8Z]QF1IM(,A>)5O M%'OE9G8ZT:#S0V*B46 +GJZI4UA#626ARZ4CHM&B7>;
MD),.Q27SBQ2;5NI:-5/0!J7YD,S7X@Z4NV@4&'S93^'DM$:9S6:+9&*<+FE, MJ<:K9%>9,>6XFY[[:)38MHTX2Z.8*6LVH:PI*1C)_+)/EIE%/AMW9_9>&@6.
M!A*WT2B^0$Y8H9GBM&JO)RI+A1O6X=L.%1>-\N5(V=^4OO1;=7EV"8-N@54 MDW.TLG!N[DE\+/MVY.XU5W'Q01DQ/*&=@H,^,;]@W.NFGL\
MK"2X))L6.=0KTT6L"&K&4!M-;W^&51QDYIV>,*18WBS_G.J9F-.*]EJ"452*!IVHB_V;D_T3YNAMZL=/ZR#Y]5(^-1" M8-FM-[O$A/2U(NG.6ID!4^T!^*,@>)?&[HZGS1IVYO.:9$%(
WQ90,L:WFXM MIXJKIX48=,V[DR9Y[9:E$31S+;?L \S\E#)8N,7\HKE<=M%J<89TZ[/.I#F" M/X"!5QG< A+OV(N>4*]GD'*.I:M(SY[K6HU7=1C\]KLH1M]4GZDFA'!$8F/*
MHB,/UCR:WS>?H3>^\ MM3?H9_,XPR-CDU.#'*+(-FG8.SL/7[VO]XDWN:NVH /5\:39&*WW!20 "*? MEG/E=//-Z]8\6-WSB9<*?'X0C'/S>]Y7'\%'1Z4TZ_0G8/IV@IK)7$L]3>\
MY>,OS*NS$'JKUZWG:0(CQ*$:](5.!TOI%8/IMG=B57EUP^[#&KX!0BFRG L' M]N;^Z,L\,"U#-0\]]EP*OWK$G]>C/Y\1=OC8D";HL@V:;$Y39;V"S\SYM2FTG($XH3R]-RMU!'_:--
'YHH]3TENR MKMZ[N>DS\WT^2&\P&);1L=I""P*.N%JW,/6(DG+DM>M|/J,^MFV#!DUG2*.5 M!+T4<+Z47ZI\MC?/'*'SRVVGW_U'7?P-|<'R'0FXSQ_'0)17=B1$^S__"?_S
MY'J!'IHC0UP@7^)U.OWSE1&V5-M]9SUN6 MP|<\V_Y__H[JC-23<2S[+!8\G?2]OX=2ATR!JM'X-AO,OQFYZWAS?;F5B4T M,(@B&JH>_/U7*_1*W*<&F#]QEB&;__]?
YV_"_[NA65+^]>_5U:ZZ!.&#HK>L MWOLW_/,I^I=_G_T?/%I'/HB__WUOUH,%7Y!0PZ^>N/]H[^FY1BB_OS4^?-H MUU_]^J<5>39/EO)$12;0!$)%$STEI*D8_FL?H*VD]'Y.
[2\\;_WR7R(?N(* M*0,)#)-*)149*)DD/DA*"AB(!)8"BAX*@R)!)$YM?S6Z]#M,B>(Z*NCLR_M$H@6*G;(&(UK^)I0J_NP*==*@TM70ZO%1KE%IU_XEO9%LW_Y_PF3#0#9.G
M*8$KM\HT_Y1MY)_H+E7*-HKT$\74ZV6>+-S.-ZXT!\\0!X'Z>AJOQ]T4W3P+H MBIYE_L]3_C?U^pe?T.G.KP=88+CZ__Y?&(G^>S6H4/$8EKDRYJKT
MM'8=N4@,+W.RGTPQ5=\JI.A>8JO3D%"-A$;V+X:' M7\U45QVJ>A@*_!VK[VA)@TXI-ZEQB"JAQ8;8R#/S"'^(V8A7ZRN] ME39<#WAH..%U021+UT7;!7\W?^Q2(5+Y:P,0*4/I68F^-
C@1+5Z;&_2-H2"< MS5O73\.>"> C)F^]71^)*HKZF=VB$UH] ?V.AI=JA^_I=&O[LJ.Z=9UOA\Q3= MFF](O?F,S)TP2!XZ0-20>4B =XWB]G=QZ%JZ[X%_1_;Q[0R?
[!Z!6C^N0H&KNUB1<]\K>&5R%?R_OM+#96="Z10 MOUKZ4-1URQM:BU^W,0!-7W1"(Z4'+ MQ_NUT6 ,.E'[O2!OH$$&]YOS$54Y9 MQ:0Y5HT5^L]<33+
<*TG5N!X(=MH/;68I"+.:H6NTK.]OQ)/#/>$$?^O_/\] M"3\$4GEHE^FG'U=]Z65FJ]13^C&42R:WO\B(Q?U:F)=:&]_8.[VFO<),M#_>?XC&MSM/,#W M0H#WD)#A;A=*?;TWFB"2:8+
!PDI=$F3:8 /1)!(A'ZI0B:D-"""':6G?&]4< MNNB/1GU? U1-Z,Z!;EOTZ.&-PNJR/;Q1^.;V\$;_PAM=[6M>,6C/';6KCIQT MFBV21H+VH"5/-;=(_?_LO>ERXDJV-OS_O0I%=??Y:D>
CP80HO;I'<$@YAED M#'\40DI (''30P."K_S)3 F.#9V;GCNXJ%TZD'-:S31D\JCAS1BK@50=P.5M03:MZT)Y9_6:W]2KG5"L_+7I6P4'"*,[*)Z" MRNA0-(&(1%$6Q[:*BC@^ +W1?
^&6X*Q;_5KTL<8^C$%=`6<21ML,B\3G&F. M"7-1CN>/;."R-?D!6WH8(XNQA?!GVR?]/#@\E-W-.U&2M;)_FF>G,FAK,H,\- M=H_PJS-\VV7T9 QO-<1FDTKFJRTQE0MTC7PE=>=OX
D!"J?S6UPJHHN)!7FQ M;##0'81!EU(\]?MZV#@L/Y3'6 M3.1]MML;M[/Q=]TX6"8+3AT>"O.I0V'I<)2)QCCA=37VTK#U$>T.TS)EV93E M#H%-C3Q;=S0=5UA$ZIZ^3?
=XF#U03/T1__NO2R+&CRPV?]>X:]Y1XF1J6"NX MVN=T0U6LN[^(%>]"89[0-!LX3O!723?$+"?5EN7,4,^G M!Y\". /_HXJ*"5"DKFIYM@.HIJ=#=!
H(^94<7YGW=T4_+%JMZR%N;6WT5;D MT9H71VEI%NOK9@UEF=J)/YXE-[FU165$ZQ>Y"!Y!U#,35G[X9^_(&A$]E$@WW! M7+))UZ"0
3GB=F"!74\]1/@$FY)63%LI&\N.VF,^1WB9TCF3Z(-WHFG5[M6)T';IU"S#5!]*!>Z^^#DRX3@F>L: BI=V^VUNO!A"3A"& MGZC@S]0&6(% 6_\
[V!5T4QH>NM&H1WT*MU_#YM*1#3_7IXI!@250/.19P(_A MC0.(*";L MY]8?'\)?1P=4R8(24FUHF,L.EXP]= VWT7H04]D47[;B24==)CZU WR4#4>B M-'UE2&IL7 M(BF%B?
SN4"PPP1=M$F7B?0ELP@PJ2@G%V6"#%7^K?38A;&U?> M#YP?P 8:-87R@8>\(*Y%P1%8?F38W!V_$.J1GS*ANG\.".V3N3P8A>D+<4V0 MA9Z@R!&V%Y5[',O(?
9KM1=0(0T?!VCVQ<61P3FN6R@TS$RGE1L.6R-9J31%% M*>RX/!P6, _):BY"IYK=SJ0]M3*KPF(K)&LS,QZEX!53JMZ+U;0B+5,%H]V8 MH52"R,N1=C+A>_.RNBC#ZR-
O=5UW>S";G5=5QF6^1ES5H2;BEJ0;; MSXIA>YAU;MPJ,*G1[O?C+]#;*U#-U8Q(K;580*F;?I,*_1A']"SA:1PB /D' M0'0"OVF #PF&%VZ//BZQ!OS>9_<;2IV,'I)6JA9C)M>OGJ_.KJ%2'T
95] MAU(SR7R54.@7/1-2?20@8 0"B^$"UP&E;[OL70);9E&"Q5YD*T%VJ98O7Q MWLLD:VK;PE4 WR+ABN)HRNPU(G|KFU1049PJ*_88N#ND\),O4=(G=L0
MU2C3ZPIU:59OU)8)ZFCKU-'=]J,WEJ M,WMR5Y.[^APXV'^=UR6O41_F\T-QXC%%D1M-JJ,$ L%'KO.:H6)RGU\.A;]S MY7>F^=X@-EW)XYEFN8!M#U*YYN"\5_YA(Z*N,/QI-
W+K+6_GRSW.FQH*-P-4 M;T6I0Z".*?B<,;48 AQ_ASR'3RE6?ZC?3)"'.E078W!A.$]J+C*.HIY72X&_ - 1XZ MM8$*L"F-8?UGX&H>#O4;/AF"D7(\=4@Y0PLE?
ZWS,MVAXKY8$+50GD\:S=C_M+]*XU)QVG^'' MIJR<.VI-$D>/DDEYD V8KI_'C6XOR%L\9SMB:-0=E*>Y[*.TRI:\3KDP[|"C M]T#=_;>[':7V M=E!.(1]'Y#W171>B AB0S&W+1+>QL:(
O)E7%.X$AAJ?0V$!K;B*GQ[\ OY/ MS]B.3FAX1E"M?\%

<[-1:U(N)^EZI)>7]N7A@QP6V&G-]]%$"O<5@G0·M34#BYOHG/GK2(?YH5H@?'HUTLH#$-WGN#VNP.E)4[T>]J;P*#>ME%E'G !)·M.R$A?L55,] CWVKSZ D3'^@'1USNT0#(RlO"],S20/T4$Y!XF*#M% MHVL4YBUTTF5'F4C1>4@\0";H%R+E::CS[6.#-\@LSH0,PCUN+IGC#-SC)-&7 M^ZKW2/0B:20+RS';GL>32>LU 2S#YS=@6RY^_2IWI>U.[{)(!8]Z&%NV6MOQ4K 0\!S3O!<63?7;!"%^Y>Q;TTOU*:!FJ#H MKE]C" 5Y15(2G TP52B[4+]1^ O%1/ZZ%N7EB(;)GQGO?=8HC[5=;!^T3ZG Z_<2U]G"]=$@R)$>O%$2C2H MP!ARIMXAN+];\" >M=3C.UN.^C."%'_?MNSF=;GN@:P?]-O MSR.;8*+W=7W5E=M#)F84)M6'>^2[_%YP1+Z2^81!{VFO 5I$3;&K=%E-ET Z<5*7*#= M*X8'·L#\@\GD_:]WQ6%-N6&V;!I%/E_H/8M)+R?7;Y4!N+"7@61]N&3WEY M3[8/PCUP<_>%]3%>Q09LN-9JE1_FBU__T'/! MQNFV]\Z'=+DKA5=@&?5F^61>J)^3?OSN& G/'5HV!)6V=[_LAC2:68EEBL[V MPXM(HS"/../OTLW7%W\RJOG0ZB/EL-KK2>9";/-JHEC+9^-)A!HFB@I=OU+L M^B7)*)MW7!/-
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f%^0 &VU6;;F='T1K-BG*]D&"T'AU?(RB,@71P]HPSFQV3<#GHT6@S"U% MU*Z&5:5]>XJ!C$LS\,R<0N=0"IX@F -(C!OIGS\ ]2NZK[5MMA!M"&/^LL(\G67P/V6Q1E:5*+)H93QY'394Q M.# ;862C7EWQ2$B(]7I"_]IFJX9?L-K9RD[^_]9YR8KKVGK/0[*):U'N$% I M:P)I?T7T)*(G$7O'"<24[:(!(@;E'IYEYY.,K.?%B=A\'07.2.;;'C_B$'|$; M:\0@R[J9)]$$P<32<67RR(<@;'+%]M"PBE-ILA{8=<1H]@CB#,^\% D;<: M|UV6C>,"]?IBRN&?N/K1SUKRT0,NOE<^EI Z(?6K"6PX5:E?G\963F MIV*[T>9+2F^P;-0&"/[(`Z=#\>BN2>U[7H +,?EOE2*]?%V$."M)%,)5BR2[-MML&\]1H>VK6:9:,%) (7'"H1V;)0U]TGQ>,CC*SRV"T/QUP)T#-OV2LUY_7, MHK>0(S'L&XB$HO'=U$*"?8+]*PM4N#D?P1?YP$OX9SG;EQ'N=[4M -"[)?L'-Q9[O.VZ+A../A(*/1 M+ \523X1I_DX4?W[Z+TDS[T7%]V=]Q2]O1.F]B$?;D83YF"14?BQ$I/&="6:M7=4XR&L%7]2*AGA7SX<83"$P9R(P7S$RD08S.G;?W^4PY2747K *.I"*DK3 MEB%6T_UA#G,8W!,\%HJR^U\A>B!EN0_%8N01+H&TSA@Z@_R<1.0T I MJNI'M"(_GFFY2"STK6/JZJ9BJCNUK\/<-/7N=(MZMMO^;S;Z&OL)=5'3Y_\'_QC_2C5 (J- MF,SP[^=/Y=!|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{QE,N$F7$15*0'[G$U M&F30/'<7GY#Z>;K66>;&LXK4Y,1[$+6]@1S=79)J/-+S1-^H2HH+J8-^8"RU-MMH CN9LIG3RT/UOIA$(^,O1^8-D*53]Q5/9!NE:"3LZH6V M79?YW;=WZD4]'DDE$^(L&U5B6KOK\'#K8KLC-6;4R36%54ULU^+1JC6QA2Z; MD&.[\!3M!-MCB]GHN!HUH&I.);[P@*.W)EGK3N+LEZCS(ZK527#Y%]!S2XN M9&'WI4NAK;H!?+U8J<%)+LNEMLSB"1ZS]!J'F)GQ=6D;#.=CQ0SM7!/&L S MVAVZZK$/87,&DN.LV>M,VW:+Y^,#I-GL#*T*%:,P6?0>Q=<=:=G " M>\BYW}3L;K;KH[!PWPRZCV,DA4+#]T]U

[.C:M>A.7|%T4J|/MDYA0U066,-I:[")ZOUNB6E" M)8+Y@P*G9.SDE-74>.9),#PU2 YU3\?-FR,E4/AFZI7;E>94/E;^!.#^5))>5>P&,_?D^#H$G\46-J8+M*[TM#LCHSX%$JRO D$I'@_]:X'*=[WI(0@Q1OH_M81[T\&:5$*1XGRS%^U3VR{"K[&28KW=$SG%Z4;D\Q_9RG!J W4.>4,)5HLARFP@+E85GX\-P"2TEQB M)X[N72N45WX.WZ6>N8*9QD33,)YJKLU8YI5"_+=+*V0|=S4\?_)?=W?\+$H&F M*YK96F'YFA#|>91;R-$$%34Y%$K^T!E4U.12#T%%#0ASSW.[1U.O?+AT!/*? O|YO9<3[_EWWPYL31Z\DVS0:!SSZ,'0$HN1LH 64OCZ>|H.T{4.;5N!TEY0=7+9,-=IS*|N MKQDJT%3X%\=?^OM2-XKO=*>Y)7.[SY^W M<05FHY5.(GVOZ>VE^):,'H(4.&@L Q EEV4QMW%P/MIM\.P%-/E;\MD+;X"F MYU'LCP,HH+3G5#&/B]AUYGZ[Y.$RO[>$ZHIDH'Y76*.I79=&/]ZUZVZ[RN<; M;PK,MX>Y@D10MIS\8:P7A65LN=]HTAXHW &%.Z!P!Q3N@,*=&Q8=P)Z[RA"Z M@3H1H+U >V^F4B%1V\|? S@I0$KHRZB($SF% R\-[!\|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lVFEU_'!X/JRT!E^I;XUZ#|U.A*,+J-J%<_A814+(9[*D5/+7R&A M'JV[@"Z70@$1TDHH-$!%L7'<"->NTH1 M 8GH0'MO5WOSGXA^.N4%R=%WIKP@.?KQM!/ U?4S7-2?[S^)R.N*9E!Q[BKC-7Q%%/W]@UFB>F/5Y"Z(-K MNOA$G>GI*X >5SG{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|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|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|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{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{B26/YS'#^);RN'N/CW>0.O\K">LP:R61FA__+5EZR M0T#L(V_VD)1]+UGMUZ%XU\-JL4#ZK.W>0-$OOPXB*2@?3ED6&QB#OPTN>'; MW\NSP+<&^IP60] MFE6G"&S"/8&URGA7[P2NT,?QJPR;P^ :GS^L\TA5K+//RULL/1R^U M,'L!4N/A&M21NI7^<@+7T@3;S'394KLOA+&IRFK5WK T$C82C*6D&4\CV2TB MK< EAF(T1ZFH9M99+3(2THQPM>YH[0Q&TI"-K;&ZTVY-"%H\5"MD)LNV3-Q3 M95FSG- *XW:V&2[+=/Z34960&>TH0-4O5A07YTE0W9*9-PND4LNY6DEP1IFM5 M*79DI;P_7PI/M+9L(A MSTKQ;%M>!MJ7EQ]>A[

[^!W=$=AS@8A=3$K0,1=@DV#S! MO3E\>>PD@18@!SL$(@'YNA'Q@1!'RJ80K-N0W1T1S@H'N]+|=NVT7E5N|+>?/) M=9P%F($8@|;0P;

(63HWF/!6#RLXB#F03)'ST5L;=_'[FX1P;%VGP==*AE\) MH/G/WH[F[85[)*.PCRCL(PK[B,(^+AOVX0E!UX%V,1#"""Y!PF37\M8N'C_1V MSH6/Q(&TUAE+H^+#"E'3)*Z9DT?*

5N7DD#N3X=9\;!|)'E9G N)?1%+9_Q/$G M;T\BZC'60QL+KM#7P%OLH<@DK,+;)MK0GR-%{)+X+IC!J_8_#B*D=]'/ M>%=(UGXF"CKD;_'L''0;__!3P'O;V#$H^>Y-3\$C0V0WY^:

[7H+?!2(7T#68 M>'7T7@&2V_4@:^ZB0!+Q M#KZ,1F<(5.!^FD7/|(@92.M-+CQXQ6R$0!4U.S8QP< &B|O_!K +.(@SV&^$ M:!BV&Y9)N(LO3=!4_>AO\%FA85+#;T]Z/.(15W-

*[Q0W_@,^#TX%R[T[6 ?F\P MH5I!,1'X!3@!S27\^8,O_+WW,W0XD*Y&016JH)&%;=/=%Z"-BO8:$=/XIJ+(MR>;N47[W3#D531+?9+$6+ M(@R\%L*F>NT6_-GUVDSD=!WI;*

*({UR:E9C8=M!X!=3R._#3M<)/[^(C!QT/2#LNMQ1T4LA)Y [FY'+SO6= MPW%QL/GJ]O&%HWI.D]$OG;[P)HSK\ \/^A$^PF/E>F5AAVFN'Q3O[SH6VL?P MYN*OM0,_#Y!*>-*

#Q+QS>9_?]$_X!CWXYF.D010#[0MSAPLY5US/!0=P%>[3A M7=?=)B3f"F_;\!"$

*@"3] M&^Q"!'[]^UG_^Z&)}]=-OD7-O\]7,\GIN_AH0_%4/O:://N!YEO'[WD8Q@N^> MPVQIN,Y0^%:FH<;F#IQ,!G"=G\9*_VA?\9);M=HI: M6:T13++:LU:L)^-_'$T'!M!#3.P MOR'@_B4\HMBUNSJA@CW^U0R88(!X(BBT% +Q3R!>!V$6OB 46_;BUK#F: M-X",.LF6^8I29^-UUIZDJ5*=+]^N80"9QM(HCNO/<7I)TCJN3*>Q6GG0$. MQRT(@7)D 3]U7D-O?4G)KJ[J%6-%F"21UVY3AM_WM!?BDN/=-%>]3>$%SV$!! MNP1J4R'$&+!1K_9L/0EKG;@G#HQ ^M_0/8&,W?'>X0./8H+9>;0!>\L4G*RT MJK[W\T[%0")#8?A> N2BRB6 O*AYHI-@/8C|&!>0W6U\9;]G=6*;#4WS@6+ M&Q7:YT'@&^(\("7;[?WZJ-P/CPH)OX!W;V&TM|/4/G"VXT]^A<,9\" J9]>2*

M=G/@\;A+_|^C(8%IST+ER4&*N0[%MSEJ#E>$CCAY%;76^WF';9WE;(?$935,.4@=91YQ M-_\LWV+P0T)%$>_>83& -"YR96B8ST(5$=%7_6R\OH[=62GNEAOV?>!@TC>^ MXSX%O=[OF2B^\^-8>ST6L&*^N[.[NPX[9ESK,'9,3(5CN'9]YHDEEX5]"Q;O M<[L;]_@X@14$ L"%8(YW**'$-R6]JFPM\& "R=<&J -!- >M@4M6QD?H?(B M:S>X_,%;/'B#B$(Z\"[[U-T.WYW2@H:NCJ.CT=D#M,$.#1H_8/DCT(#6GX#DLVWT5?%Y,O59"_ 1AW1*^VV+6.W(WI 9Q MSY?Y#_ 7BMU"X8<&;/A_B[N4B!@<=#1/7XKW=6F@0.7Y]<#RI_2 YM/7O50P/*

M!AD'OO@3C\>2IN $6^D./GJ&9![_B_9D:T@8AY$8S^D.,;HM/S?A:V V&0R%P MP<:R%8+1EY#Q\>B872F4-Z)GL-\YH.Y&H?U,$[5)6#;&B<.AV4!EAZJLZNN?

E31#>]B;V&KA'\;%WCWOL[N?M[M8E|$$CCAXC%;76^WF;9WE;(?$935,.4@=91YQ M-_\LWV+P0T)%$>_>83& -"YR96B8ST(5$=%7_6R\OH[=62GNEAOV?>!@TC>^ MXSX%O=[OF2B^\^-8>ST6L&^N[.[NPX[9ESK,'9,3(5CN'9]YHDEEX5]"Q;O M<[L;]_@X@14$ L"%8(YW**'$-R6]JFPM\& "R=<&J -!- >M@4M6QD?H?(B M:S>X_,%;/'B#B$(Z\"[[U-T.WYW2@H:NCJ.CT=D#M,$.#1H_8/DCT(#6GX#DLVWT5?%Y,O59"_ 1AW1*^VV+6.W(WI 9Q MSY?Y#_ 7BMU"X8<&;/A_B[N4B!@<=#1/7XKW=6F@0.7Y]<#RI_2 YM/7O50P/*

M!AD'OO@3C\>2IN $6^D./GJ&9![_B_9D:T@8AY$8S^D.,;HM/S?A:V V&0R%P MP<:R%8+1EY#Q\>B872F4-Z)GL-\YH.Y&H?U,$[5)6#;&B<.AV4!EAZJLZNN?

*E31#>]B;V&KA'\;%WCWOL[N?M[M8E|$$CCAY

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|C'IV7^F*]2U0_ZR(5^\[MT%ZDX$9@B]f@00*,B;?I>_>]O]OZ8R[>X(#KU]9X_HJ=CCZKQO'*

4N2(?EZ6/>8LT1X:HJY(BN(-V&X73VA%O=;K2/1UTNA:8/&B_4I6UE:S M@@+,H]EK&?ER0 LNL Y%-7R28;%,3E%HG"6;]6)JG.+:/+U3O4A\H#!\/4W: M$)]0)G;M.7WRY50V*5O8)E%=KCHKVRN.,#:G:5AO=TDD\-&@&P6C\0.96V=*

M*)1P:;F[O+X)KI>NO>Z/ZYO@&N:GZIL+I(.>6>&D):V0RFM8D4WW\0S.XYW& MTFA<2>%4R5*B/5O%EFI)7E&M? +Q5H]M0X9!G5#C7E[IKA;;N=MWW$_:7V[' MA#=D<(7?P/EZH!'^31;YOHRK&SL<-V42AZ"ZP<&(K3IBHYY2%4KG-CL5K- M&]_!$/>/Q&- ")IVLM1<[A^-'8)H^=3BBQ.9TY$U[MQ(J#@8IULSTRGAZZ;'W5"%$Q,;S#L^=?)S.EOI3G>2GCZ)IKC[DS] MPZJ#) 3-D9O6F)TE%T*GJO'SZ)2^ENJ(]MKVH#P=%]@TM\Q-2;0HKK*P42*

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|4*I4\OB? %512M6JA//+PY1$XUV\56M[@B'XK^^52G,?JS(MD6_>';+]PG+9H6:T8256]!\ M!@.JIF&M?TUQMF)WUE4T;9$?

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{G#A@:9S+ M_[FVKO[KU K:=WBNO:JK^4 W?3#=0A.[>U1>PTDKQ505TF.Y4C+5$40E-Y*O MIKQ& ;PW%X6>QI++2;[4D@B.

])Y3U&W'Q)C>Z\KTQ\,Z Q1 M:Z%C@U&\%"H)4U*?#FX! .T\;LR:R=N Q\-G5;,=F-4M%:LL46U,F"<8CH3XW+#/(8N&O(XLVIPM44#Z*4@JO)] M@RJ/,K]15/F)BQK#7H[/2(-^?,/JX'7QW@9QYU-JP;/[fKQNIXWRP4F#3O M;?6S&$O4A,N> EO!]3K,+;-

Y#V=5M)_+>76M%7>_4>#L<9WW467CN?;R6DL6HI@K]J(P%]],3*MQ+65#-173[>6(#%OS*KJ7 M3PB=J 91*F'&8^R,-N>=*YL["Y2>%QO^0[B(P7? ASZ]VE;T11/F/M\1EP=9R MR)5GZ@\&2L,,8$1133'$W\ E$BWXT[\O_QRLR=>RM[7][5U\?%-"_.WU+VP2 M_]H(OU'>FH)I3#

<@L5'P(|_^TZ2P(0^[@&X88G%80CO_%R3%LAV$ MU\R@0;$"OC.U1$FT+.#TF!+X 4+^@\=L&K]"8XKPT?KU$-P4<6TXAD,J\&!# MTIREF8BMZ*X60,/.U^BFX!O.V!1,S92]"'*-U@6[:[],$X,S8MZR%GY*P-ME M?M5.)[VNQN:Z1(/)-2TWE;PRX*U2+QC#>10C6;>!-=*A]H8A>"=8M%B ?DY"T0@L C2?Q:B1N@!/F MZCXI(=X?IO_L:&[U6YGT\MWA'$%]@#8)O!#/U9S>#_>[-9(1;#S\L"I(,"0 M*/ZTB_KR$(':%8"+E?

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}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

{"7R_F.HS*62OL=<-F(_^OB&&Z2 >^._4WS&8-68'>_;P M*1\VY<.F_);*=4^;FDY?=-[6F7A5FM12?::#M936*J-H#D'W%A!R(# ?8\2W M-A_;#]/Q(;CU;'K6=;7GWI#QWY!6 VHS%I%NH.%33F9SI90<3M,S($#PE N^XQAUDMBO4V.Z6"V^XG8/O>T%8LS9:J/!LZTO+?S)_|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

*M1!7KMB=2Q1@6V4D:5MN2WU_63]9_)(SZ?@?&G[J6.#1$;-41&_64J@A:D9@;_MB]5]WKC\(?=YOE^'L9N<({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{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i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|<8 MWR[>>7CYE:IES10!;!70.>(L#":\!PB,2 M.##@WN_,.OQZ-OS;QE8+/1I3N.OS.KD,3K>:%.S4>],JW!+&^O;.XX,ZNIBDQIUV>]S% MQ$6ADR]IL?`/YSZ>S"B!*'\ZEP%(\H9@^,']6-CR&YAL7_^M&K9_\?>E_8FSF1M?W]_M!>IG1]I0L8IN=Y6@)C]AW,]@494P:C%2\8^/5OE8T) 3I;0T,2W]+=2DAA M5]4YYZI39VU#Q?+0-AA\)&LF/*3@47*=N@!7EB#L#0*$'GYLOT&+;@?&WYV8 M8 =B,A.G'J'P%57@ZH--FLPL:%N&M[93L/KGOW>Z^>N,(JWGLX:8+;4$ID!L M03?E\]MDYA:,8FF>\YQ!=HNX, />/" 6VGOD:$Y?7Q6/]>XM(33#94T#+?E8<\|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|<8 MWR[>>7CYE:IES10!;!70.>(L#":\!PB,2 M.##@WN_,.OQZ-OS;QE8+/1I3N.OS.KD,3K>:%.S4>],JW!+&^O;.XX,ZNIBDQIUV>]S% MQ$6ADR]IL?`/YSZ>S"B!*'\ZEP%(\H9@^,']6-CR&YAL7_^M&K9_\?>E_8FSF1M?W]_M!>IG1]I0L8IN=Y6@)C]AW,]@494P:C%2\8^/5OE8T) 3I;0T,2W]+=2DAA M5]4YYZI39VU#Q?+0-AA\)&LF/*3@47*=N@!7EB#L#0*$'GYLOT&+;@?&WYV8 M8 =B,A.G'J'P%57@ZH--FLPL:%N&M[93L/KGOW>Z^>N,(JWGLX:8+;4$ID!L M03?E\]MDYA:,8FF>\YQ!=HNX, />/" 6VGOD:$Y?7Q6/]>XM(33#94T#+?E8<\|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|<8 MWR[>>7CYE:IES10!;!70.>(L#":\!PB,2 M.##@WN_,.OQZ-OS;QE8+/1I3N.OS.KD,3K>:%.S4>]J,JW!+&^O;.XX,ZNIBDQIUV>]S% MQ$6ADR]IL?`/YSZ>S"B!*'\ZEP%(\H9@^,']6-CR&YAL7_^M&K9_\?>E_8FSF1M?W]_M!>IG1]I0L8IN=Y6@)C]AW,]@494P:C%2\8^/5OE8T) 3I;0T,2W]+=2DAA M5]4YYZI39VU#Q?+0-AA\)&LF/*3@47*=N@!7EB#L#0*$'GYLOT&+;@?&WYV8 M8 =B,A.G'J'P%57@ZH--FLPL:%N&M[93L/KGOW>Z^>N,(JWGLX:8+;4$ID!L M03?E\]MDYA:,8FF>\YQ!=HNX, />/" 6VGOD:$Y?7Q6/]>XM(33#94T#+?E8<\|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|<8 MWR[>>7CYE:IES10!;!70.>(L#":\!PB,2 M.##@WN_,.OQZ-OS;QE8+/1I3N.OS.KD,3K>:%.S4>],JW!+&^O;.XX,ZNIBDQIUV>]S% MQ$6ADR]IL?`/YSZ>S"B!*'\ZEP%(\H9@^,']6-CR&YAL7_^M&K9_\?>E_8FSF1M?W]_M!>IG1]I0L8IN=Y6@)C]AW,]@494P:C%2\8^/5OE8T) 3I;0T,2W]+=2DAA M5]4YYZI39VU#Q?+0-AA\)&LF/*3@47*=N@!7EB#L#0*$'GYLOT&+;@?&WYV8 M8 =B,A.G'J'P%57@ZH--FLPL:%N&M[93L/KGOW>Z^>N,(JWGLX:8+;4$ID!L M03?E\]MDYA:,8FF>\YQ!=HNX, />/" 6VGOD:$Y?7Q6/]>XM(33#94T#+?E8<\|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|<8 MWR[>>7CYE:IES10!;!70.>(L#":\!PB,2 M.##@WN_,.OQZ-OS;QE8+/1I3N.OS.KD,3K>:%.S4>]J,JW!+&^O;.XX,ZNIBDQIUV>]S% MQ$6ADR]IL?`/YSZ>S"B!*'\ZEP%(\H9@^,']6-CR&YAL7_^M&K9_\?>E_8FSF1M?W]_M!>IG1]I0L8IN=Y6@)C]AW,]@494P:C%2\8^/5OE8T) 3I;0T,2W]+=2DAA M5]4YYZI39VU#Q?+0-AA\)&LF/*3@47*=N@!7EB#L#0*$'GYLOT&+;@?&WYV8 M8 =B,A.G'J'P%57@ZH--FLPL:%N&M[93L/KGOW>Z^>N,(JWGLX:8+;4$ID!L M03?E\]MDYA:,8FF>\YQ!=HNX, />/" 6VGOD:$Y?7Q6/]>XM(33#94T#+?E8<\|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|<8 MWR[>>7CYE:IES10!;!70.>(L#":\!PB,2 M.##@WN_,.OQZ-OS;QE8+/1I3N.OS.KD,3K>:%.S4>],

QOONP??,_M+')P-[BRZ>/*1-F)1_#B$_I\;[]\7#$CILMMZ/):N<"8+C&._MQ72)<>S>Z?)*Y;*8+#&,Q72)8>S>Z1*K8_=)EQC'[I4N,8[=(UUB=>PNR1+#MV+W2)8:Q>Z1+#&-W2988QNZ5+C&,W2-=7BO='=/EC^CR>]F)B$!W4VWB_":P M[]B$KQ2@_D<{()D:^O#_?N"I'Q_<#CKUB)]$=?_5:C5HW:_&_+V]8$E'62=J M\..YD^"-*9@FRIX!P@!'$GN(BOA-CD.@8QGZ{C+$?E2$"/:19+^2"*$$Y:]9 MS^?6G,*$M>6^$]>0=PZF[/OY_W\4W'A=*73%(?O_[UCX1B)-RYZ3FB,77^_M_8EP];7-"(_'TW_/RP'Q43E@'ZE/)P;O9I,H>2MFC_=[(E/4EV>// !.S!K? M3E>+:_X672M.^&!;P$/\>D1LT=\>ER<-1CZL['&.T^/+] U451=&X $RDR. MR[E?N$;)=]^&W_9R^AY52_"/]6H*)1()Y*X@>S\U\!5;-PM8H;?@QMU\1\YBM_BW*FBD#E6@4FAN>+Q"$,+?F;$LIM\84*E1,/*38*Y8N_?;"%&/*BPU48Dy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{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{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{(AM;SL"[Q5=O#/E<7]^;D'91WX>]H$FXD? >0)68;KPV9:X$2?:Y$MB.))4C\S6K/[O)#7"53)GI6@LWL(H\\\M=U5?T;6:<0@ZS-'O% MXCK?2V:^(TY\OQ#',X>)]^97Z1372^:XBJKW%_UME>8U;CZ#T(_*]Q%7M U]-M+S'YCM0JQ#WA@UONRRI_#]7SQ2 C0&K,A1@LLC;J1:$A'10\ :/4R)B4(CU_MA;]C3SF#"7S;M\:KTKRAZFRJW3478Q;,,W*M6(RX93U9SV;4#E->,]DEU:1XM!!3(L40]L-AW0(IG;^'@$B:V I]:!-H*H&6A-XB&DSQ]S7OZ%G\"G+E[XVX,

MGZ)E+NNVH&2CM,TK1DC%@GW7@OT|CNSSX8Y_)M@9&CC8U&ML,6:6E/+#>]ID MW1O$/@Y$^/6TFN?
4OHVU!=DWL";&!#O]XQ?)7C$/(I;LNY;L[W%DGP]A_#/) M!H:\0$"7Q5Z'245)Y4 5>?.I,V4+;B M#32";J;;UJM65U.3;:NQV91E90H0$B#+!_Y
*D\PGSN4\LG34/ <2?A:;9;^' M6?;F:3^)?]V;B6(G >>-L4.'7';K*5WFD_4V-R,R1;VP_0N0!'FMJ+M.4[&]G"#"8'[_8N'Y^#!>Q?G$3N\ISN%!;(#W%*
*MVC[/YYE>)\U4*X *EF3Q@+|ZQ8L"(-M 2/6+ZYEHGD,&:|G23*\G^K+'>R596^4Z8YY/W^!"TG12 D/D;Q@&&UJERPVQO M=5S+(,#8Q7"*
<|91^VAB.ACL'=FPP?A>XF?84V,EP|$_<6B<"%D_|#Q;\]XD- MRLSM%W<':/91\TH@2KOBEE&# ;<|JM,593GC00U>E]IR?HA7;X!IUM:I5J6,
*MD<'$"=G9)/.9MIYJ04!#1A;ZI82\&!&^,R*D;K^X^T&$=^LWYQ!!Y5]"8'6P M'ORAQ4_Z3+4,P T"5<=2/U_>FEI9 -BR/4W5,*M1#!*
!E=6XHLTU1H1/C0BQ MCO G)I)SB."S8]^PG5N:ZJ7\P; I4DMU=0-#2:/E#X84H]-\P<"DCM9N9LJM M !%0%@L>AY#%D!
K"987K5E2OK2:BP"2$"F$/]+1:? 9W9-5]3@8TU)34[0/D%;/VU4 H0[%=N' M+V\??HX@)$20J>E--' ;?/S'57U(-
U_K'<#E>2N+WBBW%HWFO(T1TU37[>M. M33%NH L5%K+#K+KT5B72_1E1RLBL:D'@(Y&]A'I(IZ]H,HE!X7X$Y2]@<-Y/
*M=/.UW@\H'.E02EUO:I5>:L0WUBU,RLVR0];Z@39$-658!I_LU\G*M#MV M1\49 @648O- O-BG-0:%&:1B3>%RMI:A4*NEDZ5LDZ\DAY:OJ=6.HMT %!B]*
M!$H9FR-5K[40JV-B6JE TTA_>-7^H&E7TKXCT$A:!H584[B(?? >. MN^.N< T9:&.: RN@F18:NE.\G;&0 M[H/<7!R[-
*L80\VU>W\Z;E/S\)*2OQ_1,R/1UT;;'?I[)%&LD*PA+PBTQX[*G M,]3LQR_L\50S3D >T=!F(ZI'8+ M"I!*K^7PY+PC5(],/4DN*7&+^X@"I^Z;B (/"1LX%H ?*
*PN5M'A*F_*H!'.&+ M3D(Q),U#\J88Z G!+@74G#[M4_0%-!1R A?7W%G2? TH/ DIC9HN$Z"5V< M0FDV$T"W-',#X%?0L^!W'$]S@Q'H]T\CN05@ %O4(-*
MDIKIB(Z+'KT"SSFG M3W'EKMH=#05&KYMLAA;5O8\)NF(A>PGNE.ZBUXKWT\3:CX M+++[-AHT<*%E\K5>2Z@XM>]PLFR[<^(F-*
**#$I)=TEVM";>06I)=L-]-;"THO M^0)^'DOOL63.PCT(A>?9+KPHF[\3RH>$'NR:@V "G;\3$Q(7_3)5;/@ TSZ1*
M\V=;JPB.LKY3!>\'U?;2QY,W65L^8=4!SS12]D,)ALG66[=@\+:TU'J#9FF] M$FT#,(C=I M ;;'D
*):R)750IQO1^49HD"L(/Q=R7W;X:0R_64!%U,+M9_J2\FFGQDRPYMP M3DH8 !_O-:=8GS: T-(*FU8'<@[!>%K=]K/([MMHD"LNW6[&(QT>C!R[8FRD*
M%.#^/WO?V9RXE]W]_?X]N^=]CY5AE% A)YYNXH@4V.%VDAO;PXP$&(GZ&] MW]M!<'^U>9B5^C/29.Z$>_!?<3?G 7_^(YK NV!W;J-*
"QLK@"Q0T>]'Z#!+! M /2^6>X# J8 2HXU(#FV] HA-S<4,BP%7 -N882]V,"-AN>80YI[CN&H"0L MW'8CP$K(8Y!IY1@6?_G$7O9.4 MND3:?
E=%#FM&2@GZGS1\6[C9Y)9(%C,S.# _!#]L MOQL\)S;Q-$%AEF&7UV]000S+ -C\PUBF%GS@)H2]3_SZ M$>1?
<(6F'KR8_T#46_G[6LBB>"1Z]I>4$Q<';]^!6XZ!6@6$"WX/PU3\GY', M,U+8!F3ZSTPS1"A;QU3U]7K@/#BYE1H8F6R;_:IW7.=,708B-;3N< MTD7?+R?
_!DM;__O)F@V1?/+E ?F"1= G8QZ1,6_@$C[YD#&1DQC]3[;<+7PY"9SSY,NG^'+F M^;VWDB]WH\$976S7=78NGB5D>=7D]3-I$CPW ^XQTD7PG
(O+WBX4/A,1C7" M>P^^'0G?RD@\;?@@0PV^.0E/Q_E/$GX^)'_2\+FAW("$3_I=-R9]TO"SX>.3 M@I^,]#Y-PL3Y%!SM/',
*[X>37WZ[[&\]YG:4,6"TC\/_]]^CCZ"C/Z.IK;(9K MFNQ)Q3-^>APJ?8D(Z>Y$>L9 SQCH_C3\66:?U63XX?_[A?WZ^!:0O*Z_>6%G MR45K?*
6_#_L6<:9U7&%$%+_ATH)^C0]4.E /P25?I8#_0,WY7=D,)Z& MZ"D[J4Z3'OJKT/%V\[^;BP2-%-2BQR.CB^)DO?7 K>V$9\B__^^ES%(G MV-
*T1IO["]*I9\)"M1R-M[/W7@$?<2H(MMR-]'F'CO)*R/B3+3 M1?;+.'M/*7H8VIE@%Q=50V1#"T:VOHK#]^7V,>P[R%Q]TGA(]-$%(]XX 0NN@+OPQ- #*
*;X<8@Q0UF>Y3=[.XYN *KPBQGD!Z/_ MY;81^6[> TYAWE[O>U%Q/8=N*.HFNY@@U0$==O@E8#,IQ<:$U..S11.;V4-B"(:E% M'\B';\# Y8*
*%X:E\5:.S8]/#L'\[284!VT**/WK;HHTM9]%;0])'9E ;:O*Z@ M:YO.Q7(14^XEEPCE:(/Q;#RKXHP ;#]* +E'(_'8WN2$B|>7]Y']F/N((1? MY+FOD*)*
[Q%WI[N6 AP@:/SUBZ98AI"OQ1E%M %)]7%[7#... K]?#-6.&UYNT MA"WKTLJ6QBC%-\&BX+S:/("V']]B=F'_I1@42SNP5GK-]M"UL>5HJ,A)W032EK'F*
*M0,MG;+ "T!+ JL1?L6G[,#=KK'DR+[EU2O6HFX)WZ\$8BX'T*L"WH_,M=]%A(MOQ;XV;P7=>K"H(;4+3K*.[/A2K@N@'=W(_I8)(Y>*
(J+_\N7A([.+OFO&^@:#E MX2^E^EL',ME/;/ 9G1>LNRJTI=_MU6IN",.XFPL@GJ7C.Y6.[ZUO]RLWWOE]T\+G&]KOG;E>34;U 2+*2#A6C]M M-*
Y2.GEM""P0KSQ$<>Q:>;UQXOK<&WJ\P?>^5WS5+\-5=G)0@Z+S F/R;:0,' M1W%3FX-5Y:OU87(0RQC&T@86Y_I(@P%XLC\4F4!
(_U4!@%TXU/%Q>83WY[A8IA8=Q/':><@[>$7H.DOKE M.Q-P8%HXS8+L>DC;\DQ*>#9I:Z+DT:3$J)4=$ PE]&B1J,VH$=^T1:TY3-RB MG?
*UA%/%N_0EWT*1;I1ONO2H3CS6X*.M6)+KM[7 _,$/R -IUJ\3!O==YU_[V[Q2N?BE&?K?@]+A1?SLX14=1\96GZ#5W\99@XPZ4AE9FL.3Q^?H"*
M^!B'/9R:IGJI U?N#1>O=?OO&!#[JP\KU]%]..8)]B)R'1V&EF M&<%+U[>%,_A"Y@1^YAO'4 A% ,1X]SL%?S#S.V>@ZKY\3W#9\]0)7?;F?&I
*MI6BL/UVS;$/AJ@O(,QAT@"IA9$*6839D&3YN649K]|K[F:+'@=A< 0^1_! MZ] M46(=K]J'(C*-/7K+Q[9VTI"+AZ'JVGG'C?;Z-!'Z2O%*
*MZ%XM9T3C"#,,&PM.H?.C^1>@[\),*IA6R@S)3'F63TJKI-&2FK_^$1'X8?KN MZEG$V[_!A9#&HFHQ?K#F#F[/<&CG)RN#+T/^;O-I*
<;AE76/FY%&D%RP:^+#K M#1/Z);N#)/]G9U[FNGX29C59T_\$CNC6JOPYG9CKDP!V!O'R8S!@_\PLLTX MAK_*1""K7,[?];.+*1#B(@D$O*;7Z$U-*
@CI<(LPUL$\SW@L,R/S3_>MX/ M7.<"OP?31:"1Z)3:I\F+P#5/^RX0F.E39_VW7 M,P>=,_@SD%"@8?(.7*7_T:^_;=,_PN]%CA68JU8\9W3_PO:O#*?*
*4I9DM5N(29N*U#*#\<589Y>XC#U/SN ME0299C*QSDI$YK7^LKCL\@2^$L"5>_>DECF9&3&E-))9Y9RZ((L9NV,/HT/D M]97U]BJ*RBIP+9#?*
*AY'M])=8$5^[=LU/!6K-V/S&0G%DLRN3Z%EXG4D-B M_YYZMJI.2ER5D[K3;#C-QNO$) V/)NU=*839-IJET '"%/EJ?\(O2@@/^P;V*
MKBS%.LTX8H5CM#.>)<8&&A&.X9.A#2+> S=5:;TT:2@88'R4:*R%E6K KQTCT[M M I=:-BO$7"IW6;4TGN2Z5AG*2'SOILC4BN+V%'AVEA*
.S\RY(U,"=&_VGI^B M8J.4.IT!9TJ/A:ETM43&!FF;&.MVE5NBBPPW2"F *_=O*K,3 MMI90[#]=F<=;*
[5]*2P[U"")ZW;2]#F<+BE$61IB3UA(S6ZA>4CR:K=%IBL.B?4BY5 M>HQ8C,\'#?N0CC!YP\#?XQ0*

M2P'V$NXW'9_4/M]=M=9E"G9=IF"WRQ1&4)R F]+-~>(^\QB6+]WO5AN/YZHP7 M.(5;C&B 9]RF|~)T@\B!2A 0-
31$37AY?/D6D0^U6OC]!.BNU1R+,FQ5 "$; M>%,@'H)HF'[\O.'Z[QRX*E33(B$ 4Y2(1?;A5M>~,@R ~1"%BZ;(^^E<)GBXNUD;X$%;>80- T\?_WF!3293
M/W>1YU5@1N20%Q)X;"U&TI%8!-XAD*M("$@O;(9!XUY1ZO/"&T\2:.Q.X85O MX,MN]+7L1O=D5Y:O)+'$$(U_3F+AEU]+K805B23#M[I2?
I3.2K&>V6^A|Y3: M=G2T0(I-G2?G#<0NX]TZ]T^!,T$@D7T,J<](;71/;M=<_HBLWLO G[\WI4R7 M!%4O$5D'HJZ+JG#G?0IX;6[N^LU(X(A$-
VA!ZXS";P6[I4W?_/S:6[=4K-@ MM\6,T4UGU\NLRHN,%DFI7&ZD^[Z,QPDCH[TJ;+ZAW][7 OX%]9.&$B:ZZKB! M*+I:XQ4-
JXC+|_5Y7=S;E!K^P;NVOS',PM;#X;M M;T Y/2]!;)8'+A8'1.4M*V(NE&*\5R479&Q5(,/33#,IIX[$O($5B83.VE/P MQ]I37F4M[K]G9(B.5*9[7CV,=P/
M;2KU1#G>%LRZB%#+57G%CSMHJ0HW%32"'Q"+^^PE9ZGU=Q"(.3&C"KU5IDQV M^Y9=5:51UA3NNI?
D9YD=QGX,!V)G$YA2(\3*FN&FRVO!RWO=_8P@@&O\ M1HV;M;KBZ%F)%X_NKQ1AU5 JH_HLUI8R86R10<:(8;7ON8EFF6E'*CC9&AE&
M6W,TW"A9]4H*SEK#$?C__5K>5LN::!]PQJ:XN398<(..DNT='C5@UF3=)V3-
MX*]7&U:^Y@TTI2W8B+#N':XRP%^SE/,,V$'>.92>1$99H4/&8@F5(QIA?OX1
MQ)F3*1K+]XM<(:199Y+,_YUAG^A<9"=N38RE]OFS$'F2C+;=C@MX\P_SD[@ M)?G=>T
7U\R\A;MT&74;3.)X5]'Q!NE8H_RBE#$+3>IC&)1P16^['UHCK&%" M+RV097QHZC3!+##8@H!'\/TJZ%9,"XBYITBP14BW9-YO$5VKX@1XNF[;IH]2\N-
8>%+G=K!;UG]<*QIZD-,\ MN43RR4R[2RLT+=7R85VE2FZY&SO@9ZXY_>*EI45%X0$AW#"2WYRO]UOBW=$+_MH1,0 +<@\ &_%O3.8-
77Q,U(!CP(3V*;753PU+Z%M4$LUA1RJEP1ZJ/$HT2 M.8[**1GHQQA662 <@?'Z]#]X#UG6["'$#]HSW<@\ IP4<^.Y@QTF<"8 (>%Q MTN!DL?
EFF681\]\CCN-()SLSX5EIIHE TMQ>0Z_& MM%V%VQSV? "',1L[,1/?VV]^H=*JT@BBN^45G>*I7N$">-!U?2-$BRLOQ)> MCBX2HMZ!,< 3CBD$^_?
X7!/GKG[T8?]-/0ZJEZ]UM MQ?GKEPZ.&E[&ESU4 ,9?%X!Y+4U/A5$<0)5?,4W<[E4@]U/+%W-PAOO440 MJ &*?"@W).CP*E-@;^[IW'03,SIU9PJ8
M5J. ^2NC\#;VWW;8KJJR/]VVF\\+!8#>N-R13)E)?%6E7H]^@, M##%<"'?DP!#DM^H?7XFK!],AF^\U=#X'<\MH@G ZH/) M>9T/C]W5K_/HD1
)SWGO_\6#3]B:@0'U_C;5KJ_#^0*3S#'1#K(DY^49TZKI M0XQLGS0';MX9ZU!T6EHG66/);59U)>R+0'10=GAAW[UU]-_MY8_8
M>3W=J&MBR"5X)7ZLKK2)9_08(%AHT-2$7V58ZE^@.!+?5^5!)_G1=^-%Y\Y!; M2_1;K&TG]'J_:%DR@L53P^$DG]-:4]MC;?1 7S+D[;Z]]_:)H_N _V& S,-
X MLB7!9Y1$!Q!?X,)J9KB8D#=]C,1+A1^ M372E1YMN M6S.(1@ZT%KBM(D!&MMU/;#-XE74[YKSSW8&\N/5SMTT+HC!!D#"(S,6'[FO
M>IA'AX1PZ_X;,=SS;4YY&WNON-T!X2(_[83([MN=WP=Q/0G<*GI<4 ;S,'CT5,!RVZ8ZZ9;OZ&9N9ITU&>$]C#Y15$] MEVU#)?M(,IL0[N_%OW/YGS*9)
(RD[+1JS.L-FI5.NM29PO\%.G0=_MW=$)3038<" *T5;SIKD%$[J?%"7K'SI;#_-O@ M88L<<)K0Y#^1NPU<:E@Z=.#,5\BGZS;8G.8VDANA=5>69WDW9-
@IMP6; .;;K M]KT[^>? I2_25-7R4. :\+S=EKANOAD08TV+"OR#*R?21H8+)QT$DRKE>8EN MR,NE<&X&ZG63W3:.]=N'?
W;PK&T&6P+E6SI2W5F59@N,+H09UQSO9Z7^%:C, MYO25:GFHS^-C&[T> MX(.P9(_6#>PMO0T\&F;&6Z;(GG\2^U!C,/]Z,;AKK]I%PI(Y.C;1DPU*R"57
MR7LB?XU9=MC'I_9$ZH[L-]]A2@Z'(Q: +I_P#?<;@!]&_WHE7=\<[FN!V&B0-MDPT%$9SG/H,X;@$W]75,>F-#LS.%RC_J$5U;%[>5T'4E '=^B_]X0Q9
*!!@-MDH(=,"3S)@P1F+7[NFU,MCQX'/#5;] J;NY1<;_]NK^+Y763$=5-2]>;]US?
M0801B*KZTRN]ZKU_M^T1("B^9,75@Q7R31QGB2Q&Y$A1ZXJE*F/&Q@D0_6+$ M2R)^H,"S5<7WG"'**]T'(U]D9RL4@\)Y6-
*UC7+AWG@W_+@L[S6)0 OQ6_R(MWM6 3Q]X"Z<4;Q-U^@^%SWQYU?UR?'E[]_.0G/87M[%_FZ_L*OUKE3?>L1[C M(R^]\XH%;\;QTW]\83T"^E_#?
(RT?%$0^U645(;=B=@>-2@+_T3D= WS$1\N M+++Y1+[1()9>VBGQII2MIV+&:C+[$8@<.3YUM/XY(.+0@FS\=L""[WWME0MZE M&,%W=A2#!
(QS$WZ09)7@#YX@]"$X>Y0,?@QN^A]ZI2];K=0M3>E'0F66'" M-X9=H0!];=!8!#O5I_6R;K4\+*, 0%SN:S;/Z;R[G+PL9K'\O+[B]U0O1S= MG"ZH-
,P[85B$B)Z2E]OEZ#\X1OXV;_:Z8/"&%_7B!F;'7337/W1WF;6>P1,4 MAPTX#-A9QIAX':HZK/K +,_W5="[VO-WUQT^HIRN8P_&>UF:)C--
MB;2TF)UM.G[]"L?'O*FKF]#DE.]R0/; Y:)^:$/8%C]WF&#@A'QC"7S\+>*Z M(MA4QV$ZK+/;Q0L,T=S!CZP_Z9/=+H>[(N1Q95UAW43(
MIM\LY0Y(AK+DYMXV35._E__N:4PDYG:2.4M>Z=N*7G>2B\MV@ MSK.%SEITTC]%=-(7EQVMEYS91,J2++LPX@IBOU@-
^VN@?'@+&S%A9!8MVRXS54OH9'E=0EIX+|"<'6@ MB^268H.@X;7$[.]\ '[!FNW=^2-T.-FE;B'CM?VYU!*20W!7@X.)A*$1;]IP M]/C1'-
U;*147AL$K0L+;,89H^../+OV*M_7[!6]/4[2;7F*2E>71>7U@&3I96 M/CB[.7BW]6SEK&C DT&6?K@8CY$#/]W%C9XDFF;"FDG -Q;=>:=FG^C37,G2H
M'K4C/NMYK>!*&;+PNTV;^P><0[+(N%H&1=:W".?-J=QD +^A]%TS<+.2!3VZ MF"4D)*95:&X5]\3'O0\VB)PK?@-KV9=KVX8RUC3@NX9'!3.] J?E3\
MCM@G#D9B]D4C(!0AS@W3(3H+/ 1G3D#<+WJX#]+*RI9__!*Z1ZZ@,J:IBV#O MF'A/3+R'PL0CSL+$B]T2$V]#VY1[1E4-16:Z*)_H+^3XL0B\ M/]A,O,
]8;CK.UR?7=T+;=6^.!PNVKA<<[-795!=NU*(3O9!#F]SU2T5K)0U) MI2XF*@NA4!H-'RPM9K96W&32K8RE6"D_E9QH]T]#:.%8(OD22QP =-MAR^L<
MV3IWOS\9Y2Y%R=MQ\CX]'G$>6>E4*4_22CS/3T=3AUW8$!DM@AU@W<:'WFY$ M@ECQ;W3Z>=G.S1&]':@+,'=%=S\&O#S88'?
D@,I^2]7(^2P,N*C.FII[*L'K MO\1>O/+1A''39C?O/T&&]'O<"?ND*$TFS65-SK9KR%Q=H@N.EK 5\P"BE&E4 MJ;*X2H;)N-U(=V=1&";O7>T##F0:)PH2
M03M3S>#EV=C4I;-[%#X$X205Y1]IS?&YQ%28/)=4Y97,OJ?UX.7XP+,/2460
M*4L&IQ]^FE"\KN/9?'R4,YT"C5#ZR&K0AA)3K=M@MC67]882'_=7)%^*FIE& M1>+2[+N;Q^YX-&^
^&XQ[I3OEM[I'XNZL06NO:9@ZYA6PNI8$66NG7 U_!L MYK']N)*U'-T>)"36M9$Y^K4@[G.--W/;**Q MR-+=H=!JK5)"?6G!'?,%CR=?\-A)-&1?*G;LG8=+-
V.<(_Y!3SC6[#*_M0+'ZQ4MR?&D#Q>2*-9(D^E>OYQ;'BEI96E7&G2;%@5+;_-$ C@)O;21]D3S<@?_Y, M'$T?8Z?IL&GNUQ]_BC, 7X?
353GB8\0$N&R.T3EQ]"V(1=\SZ*X]9UC6ZT'903&XRUCF;\C^RYT.&5:8)/D;;.8 M2975=*/;?%LVO [4X-!S&'U]#.CM\PX79\N[CHO65?YC'70'N=K)LY;8T?
0% M6295P:CJ:#Q#7.LP2L%*DZ6B7AY*0-L*MC.TZ_VPX)VE",.S%'M'*>#IG9<= M1,C*5K'7HIFQ6SJCK%,,G0PSR2 M6]6ZPQ2PMZ8-S*43'FN6[]5#CS
L:+1>,PW_,DR#7OP%V48E5;M!Q=$F7>]2 M?(Y2HZ093UV);5,1+[)2 8V25-:4D)RRX+VT%G!<3O#KU2E(R](ZL,"HFH* M/)H//A;#G"A;[K[&
<#!3XN$#O<:[=7?#%Q\^$&ZPFH-YYKL>V3[$+[QH ^L;',$)OOW] MQ,[FL,[:Q3MT:F>GP^8VA;DO&/Y?%P!;5K5N1Q[;=;(K+0FBWJ&H9MH]EG*J
M^=JKU]1D.9" +QNI?_F,#2M:\]HP![:8>3+3C2;43@9:QY.9FT-9./?XY ;8 MB-FOGD>^!Q(FCCR1,)(F$\DS"<2YD,A8=X)VS+PP1B(<0FV)7=3"$ IUVB4
M-ZW5W"=V27EKOV# MX81@LHXA,AT]_$(G$"X8?P.L_U@ND\PM1LXP-1)FX02YT(=2_1]]O <7H'$B9
MLW+&LWJ7G$51G:8S6I%']&X_QK9@&2=`"/(]UTGB#1;^>[#,MR]OTQ=WP4'] M"?)PIR1RH3]B**2;E?(37$669B(Y[-IO)Y&]5-
>CIK1NQ[^KI+.2XW8]51G6 M1Y*8GYN4W)*_,?YFNMA#$^%\<&F72]YP"B]-LV#D+WCZKK5!&\AN'*=48]EI?RD62(S. M8&&LVNDQXH?1\ X+
M!SCGMMTK7MN]=SJLQA@<,P_IELP;=^U\^U+LOW] -*P0RZR1$7'$R6#(V!0; MD@F/CN(O*'6/K]X8/^>3POE:5\ H"PQ\CO0N'Z XD>OI?
CR2.JHT5@.E:B. M.HVK:&$2+7F*CR3WH;>]2OF&;YX5V:.M#.$*GEQ(-ZY)P**4HED]6*@;^<$B ME?NIR\6VEO$GG@7%8_?C@E*C0N5711JK5[)LU+S3[?
* FJU769BB#[YCRH5[5= MSNZ;X;M@UGXC#E\^EBP3V12N272'S$MR6+.JHWIT;!_C[W8L.>)9\$X!*]V2 M@#6#"5@?B\]?'ZEXZ-*PYC)2#TU2]?,:.M-
UN_PFA<4?_/,Q&N8QY?I)$Y_C+C71B0_NZ!((*^H"7//O9^P>>J.[2M(M&T8RS?)44VDQ&QIP!F$R MCB.?\%TT%G=4UL/SFQ/1&GQ+]XQ]4/IH.V
MVZE:4S.Q$):M&)VO35OAS$!;E6#%!(M@1]NI@F;[5UUT:]S&5_C7^RUU0%R> M G 1 6AX$T>"(UL!@&E&,XY@E^(#7D[4G&6?["*Y9'TR)]/AO/
6=NEM&N>^ M(+-NV3@7"SOR,A%=84B=GN?X9H /2",FT*"?D&I MO3&Z]J)M+DI1MD!(L6B^0JIJ.$EFFM="=QU[W5VPL?PXK.LW06SYB'@4AGAQ
MUDN8,\1)1J 937]P-RMX#;D!F.LW!/H.QD[%P@]I&S_BH05A_J[4D M[.M!NF&^M<&@Z=GZK;MJH;S9RV2D<'1DCI*C3-,)?GRTR.=C$ =ENV;R.+"_*?
J21#Z04)TQ>FC!R!9_U3FX&WIJ1%5BEDYWBC!Q MLM%O5I<&E?T,P,,&/;3!Z'7=W:>X#ES1R5KHI#DK%ZDFUT9B%(4KS6$#ZW4% MKZSR1EUE;
fY4!.X@[P)'#D3<=PY=^=['27Y G]%_\4N][<&+6.*]C((C]3J M2X*3\6K](GF]^O3]A;!])8U!;0',TC6A;+JWRL2]PQ MB(^(8"?IL*';+N@:<. ?
>CC25]"S@[X88-I;FI98L W+E!(ZV2TR1MZ@,S8] ML=T6^N.:M@$8/^${@!#?Z*S2/U.<&7]/- M<)PC4^#*O:%[HNCK2W5DH!/IN%RFRXTQW1/Z
M.CU5["&^OR056>AL8WHDIA)U!O=;F+8EP1PY=Z2,JQ"%/!'1"B'#;]$OJ_,Z MKN;A/?>6U&28PGR>E6-DN:)W2%67='$"K]Q24GO.2W9Z;2+U**-
(2YJE\V@* M7+F_I DU*ZFCN&'0E%@11SB.I;ARG-(M[%]9T\466^.!@CB%$K6T)E%ED!* |=B[,HTY\A)MY@P)*YE\7!XLTZM5$URY
M1R9Z@!;SV+A4)1V-5>;#=#K6KMG@RCTR8:9(*WJEI2'==I/3A;&%$$P*7+E'-M)KZ?
GLR:K1Y/BG.^3:BY,EMIP_=2YDGKG,/G:*_0CPP;S/P,J9N\1<[@KIG@W8.KL>Q M(,LEP@/%YI^P^\EQ6-X#Y[UW@05@%O"]1WL?8H5>[G)S_AV-1D);8N
&23N" M<+>DZ]F#*XA6>,?@KGO5^^_5\%^@TC#SD @M8 5+^%P7!KYXO//0=>$11ATW] MNAN;AD1EQHBZER7U2R>&P9O0C[9F4+
<,_TRTEUGPDTP>"D]8&XAL-50MF 8[;I:UNNXI[$(EQ@W M<^%;U\O0\7>Q=61@-]QW\%-FAU_%:XV<6X?AC@KF@A:CX)1]8 B.D OLQ[@]
MO<8.N8S0;X.'6643O.0_]YMXLYX_(%EW6[C23G -^'73=9P#O!876P5BMK,?7@J0%6BK<&DUNO@-=-$<0+_I*]][C6 ;,]Z!G8L_8FZHN_5[H/
M#BYE1B!TLTS^RG OAZMS[H7OW[BW$'O^^V^3>P?9)Z+)A\$-6(@< \GE+Q.+ M$-$G(QZ $>B3$0_"""02?=JF1^ LWXDQ$/P CTR8@'800\$_'DQ -
PXFF; M'H013]OT*(QXV]8'X<33-CT((YZVZ5$8\;1-#\()+!)-/!EQ.4;\V]1A,O9B MB=?;K3IQQJ]OFN+\])
(3>RL^52GT"BO[_ZYKA\%]64V&)/A_OXA?'UUY+!*_M!9CKZP+Q;!ERFY1" 9S[E4GS&?QM=X!*J.I5J@A+]TH)" MBPAQ>3A]HG]19[=R_?
[_]R3F9IE,"IG_/.%MHRS=LD/(_>_M@_8 M1^T#BD:2]2]M'V#3P%?9)MXUM>+1Q87XZN*'?
REQ>0K'TY8\;7X\OB$UUM/38N[]ZS/W#)0J;#4\7LSWO.M"/]B, M>(D&J'NO^_\NL1*O@^@.2]DR4V[CYK;PXCNC_]Y[/N[LDX_1@^VZ2KW4G-8; MDQ;"
<=DKJF[V("S\Q,N)=.4DETF)@85Y1BX[R9__45?,/RY\SZU]ZF]![7W MU<[;BC823 LQBV0>S?,5920)<\Z^KO8R3*VM((J=H)VPO: D/ ;5 M-
QG;'Q1SL<3&O<7XP^K[<-6UTYD+%^F#VSZG^0U]9C=,4MQTD4$U]U)IB3M: M4VA!?W_IQ -EC5RM*;JLIO 'S.$>>3^/1?KG43=O@Y6#2 =VW
MG2]\F2+"_37O!RSXB3[5;Z&BU\TOO*FBQ!-M-%^E";Y5IPT>TJW:E#@)_8 M4T6_FHI>=']QIIWD^S FYJGS^7V8C3D.)*I9?4&WARLA*@ -,_-
#"#1_<$P M3]U[7-U[;H]?,0GPII)F,NG$:&F4$8GI"--F3!T29BP%]VXW 8#@T2MIZ7U; M&WY6[T*'T447.NC9NG#-UH4[=BU=/Y'P@.M]@$SN3=(0@?
J>2N1.R*AJ#/1! M3YIK;;F=KHQ)I2D,"9B)0./[1OQ9A+E\$>;>^G!ONAPMZ=R;,(]C**Z;#'F/ MH2##\[$S"YN(Q!A]_V^2
MDGF/_G/B6)6Z,QE!,'Y%R,7>K*['H?XG?_W%D\]>JQ^G_T]'X1$-Q7730N\Q M%/BDWB='*6Y!=LEY69ECLDI'H;&
F:'H@,;MXMW8%@_F=OH.WZ7#&UV1\,C<#.(P7\&N#Z1B/1*['I5=L3OF'*?YG01(?& MZG_;]94S3<@B'+U5KM%
M4E0H7;RWR4S:QI[PLUC*14*]6#5%TFBIFBZE6D;2N,X+P;& D.!+1\%[3U$*T MREB<'$IQW*B2JCLB(CA\#69'J#&]\W<'-O-7OC0/=DYR-0
M2"=MVJY.'E*V]>3>94%NE,,MM(S4PY5QKXPYHTK-/C2ONDD 0^1Y6SO*26%N8 MJ#W3PZERZM 4;E+CQ*0:RY)TQI2;L;9$K1*4<&@*-3M-
5*4E(Z<146@I?!QK M)CG\X!3J5DQ@^W0'S9!\]M!=/MQVJ3]+-0P.CX]%,(==8#"R)B6M$"^',U6S8 M/#0PNNY,3#-GS2>(Y833\I(=A[-4ZM#
:'2,+8O9669$B['JK#Y14;-AI0[_M=B;DDC*7->Q6A]W%FN1B;B(,TP.F/HVLP]119[M?24?KJ4[+#\5$-&0A@V5;0BE6>K0#.I!FY'-

BH.*I#.0!ZHHA>,;B6',F+P9+V#]&M5C5DU5L(A^9R&^QF2 MJ*H$V17*T3K2;Y<&IGU(/HENV]DT%LD*4NZG.AU.I*P25ROXW-N12KM=C>>
M]3HYK"P)3)LD2'2-$F](((@<>7\(LN6'I&3,%+ ^(#C] ?Z>U&&]?''?P=CO<\8 HY= MPU¦\..RUO3,TUW7$C9!A*> B<(_0W&+ 2YO>>&%1];
(BN&)FI%GF]AQ>?^JR M$=)VX>B,%Q#/ 6_0&T3,:3/WZ\!M25&94%N;B6PH$<7^*Q[P?GS$Y5]_7T+! M6&OQ[U7G]8Y'H@8B.L/@O0)T0]-
-0!U12ZE<'2Q IZS93':W?$;N>,<7UC19 M3_--S6O[%2VV4DBY52S$%G93I@;-*TWSW?)DD&?S3?C'[SW9-Q:+H#]T
MYHT7^T40XH2+>,]91(GXDR^/R)FR^ #OV M-&2/R)>G(7M0QKS1(?GDR]T<9>+)EZOQY?T=T<<8]&:(>:-:P'LH=;,AAV^% M=Q>>UW6
(\RRBX1(1(//2 3-K=<++=U=$-+TR:"R_^M-W_"AITYG&3ZUO2 M-]=\I ¦_CZ%_5S>A'JUN'V00$QY!'GM&Z)DJ==$Q7]J9X4R_V*VW9NU)VDK/I
M9\YF,OO>Z4F2T,E,A;?[3]S[C6]=OI;[.%R7F]U2#F_#WN.Z1%\IA1XNS(VO M*;]J:N[L4M"G!&:NGN+^DZ\I?_P"%/68NOZ%[0O>\LFYD-
T&]XXO[_VMFZ>! M1$=NZ\|GYIJ@,.-\!ED@@]D06 0= M?2#\2[G?H<#L?>R#Q.YOU^]"AQY?*!C[)4.R;[U5\OZ-DG?65#D3WMK>*O'W M]R'2UD?
+`JNL/S'D.Z6 M0HTFX1F>!3E:HD&.%KA@L>_`!3X1QK[+QM%YOSU$J8N@5-8%-=B?M@?T)?#I MQ@F,RKILT=$L?B)D9M76-"
[5R[4%Z]=NH!]BS/%UN&_&QMX$6_&0D'UK0G9I M< M9V4WP#NERVS-/P%Q\HB^B#!M+:_52*PTUE8I;(\¦_@T<]I*AS M-7G_'+*6#,G:MR9K-X._D-
7=#!%SIGL]PI8;I9R\/C,J6CXI-88E22256E-, M!(83WPK6H?K@(6L[7>0[`8;9)_O@]YXK"%TN8!%A:HQ?JG+4X1N02XC?7,V
M4LCZRF161B*ZT254F1+B5_(A2IT[O_TM"%W;=''3]R@F'0BYWOUPN#+Q]"YP[M
6W#C+Y9]P1ER5%RG^F+.MV(>4TQA:D9]1!GDM^*FZ&9^DG,+6##*2&6DNX^ M77 -*5M(V;X\93L: ,43AMX2RP1CJZQ X58R;,K.T&\G@,V3,
[%*J:.LM6ZL MD2F56R6BY$Z6BH8" M9H8Z@FJ$IO."O3A[C1;_F9!D&2]>9,B \%1G0JB.3:F M?__X@1BN=:(_A78/G/5E0+R(X)?T.9C5&7)-4@P!(]G8"?
F++L6A: '4> M$+(,$,0R*S"/1G@#X]8FT!,00 (,PX*MT29WAWBMP]AYPMY\/>SL_,=@@/#I MMFOA.8??A5@&'0\[>!]^)'I;
[C%XIAW48&BKBBI9T$KC#^>2Y1CP<3)NB#_5 M;1/Z,>925<#QC(\PY""M=26=|
F3A1Z"OOJW;')UU4!H3]@0W]&\H]F$PPA>&2R=#C\R;+ATCY\HRP>:[_]EQ\6ISU;_ M5SM[]OH$&,,9;E@F-(S(S-F[:Q3A3)Z",*1R$,-4
XN]Z5HVA]VA:ZL&5*O# M*']',LVD-53U?6R!LS#QE1_(?+LP]DCP;OH#>CO 4($3O]"Q@/7 M&<(D!"C[(@]A(R'!_400OCV7RN]_C'H%_X>?
^!...),5,OO+=9;",ZZBZ0$ M]L]RMB]$D E-OFT:4))48^I:"/W@NL%VN-S13I$=2X6@@>;K%!Q"O59<.'89 MOEQ%(!?,E84<"&<-
<6\FC<$_$'=T,$8/5P"$&QO6B,NH89I M=QR]:U1!5R-PK1]#"+`)6T(]:W\E'1/6MM;,SGY2.T*-/[<\7TT#T3L,9G\ MBWCZ$)=+'>YC*%X%A0L99Y)-
A:EN"%-%_,%ME6D>.O@P:G M>G766-=,"(1^-Z&!$ P)@K$#00M.+(0%V_\)!P(E]'$.6BD(CA!XH8OH^%SY M>N;]]$7.EU+G?/@F[%E,.]3)4\KV#"2W"8?
D"CNC$BKIHVM(^+.14,&)DW]-++T?(O]8GX&ZTQ1?[K-\"_1/_]!QI'&^ M%&G'G?#@L^R;'L@ MM%NYW>NAIX/^B.B=37R:"#P0-
?.1B*8B\(C)"DC$RB=U6^ @X^#D<-F)#]D]T M47@)]@ZCATUD53C%*B1H&4A[*4S[4"-.L]'>&T]_/NC@WZC)WN")RHZ[;N?A MT4_?
$\H'<^O#)3*D(A2.=4R1\L8JJZ2*""/\P MB+][UG M2U*0CRY;_+]?JBW-$=6$%!43Z[U.P<^@9$,E"5AB('W!)+L0AJ$+:T'%4& 3 M%\&P81J1N82,W<%;
(/7UT)*-(#!99 4N@FW.$S]A,]E0!"W$T&HGF2_\\183]Z!08C9"'#WFX$APB M0I^,,#(BN(L Y2]2AC*XB\PVBN5=8%9T10$3=(;&((@#TA*#40;\8=F2- ^X?] MA*=)58\/-
J$_HU.L]IG>G)S4IW,]^S/Y_ ^V?DK*/CDG]Q*)U)9C"+B\?>!'U M$;>=["SL"G2 .3P]T!MN^)/S0D&'V9)LQ32J1I,N'X_%RDM *>3X&+!.M[LJ
M8'V9\@_!YC#&4\!/%P+F\9X**=Y@!N*/B1O7OKKU#$ 9B'\/(2C] A>?819_M]K% M]KT9^(RAI<+W%%!"4#1,]$[H=45.)G/_8R'UKB?
LD\QP*'2AT'VBV;]P\0CL M]*-MLVS@\?N_2?91%9OO0P+N78 ^@S-\!=1ZY_WO.W6)+U'UYON]XVGY(MP M@E!P[FU*OII=EWP['A1E-T?^?
T>NKJ^_L66_O9"$MCNTW2$$A[8(%)S[F9*O M9KL5%=5%5D{'=KIT$[?N2B%RN-%S/CW$4=9FN.+#9L@7^C7L/1W+B'Q;R4B1=MVGP=L M7K?
P"'7VS/MJI>EFE\!PP<6P\,Y&=X,DY(&5OK-Y^/"=&=MRQ/U<;YSAX(3V M[$]U171E1O0E"'"7RE>; A7-E%PVBB ?BVP,V*3BUC=D?!R1<_U;BHXY[&'^
M"?38&>S01)'6;R!9P#BXD1-<8RH:Z!+3]O227;>>W\)R-3I\"O!- M"@S-70N(!B W'=!LI#55T4O4TO VFV7S72E8KJ,R3PE>LA3@7.GE?
I(3Y.I&2>]283[D;^#X] M%/D*,8TWV-V+B3CEB_AA],,+[&;6AC#N+[U?Y*B M+0%8F)5\W1W/.2GC:)5$OUF>6EKIIB$@4N MMJF\Z2AF
/$P;A'&+3XE;O%F-;FG8(4BMG.S#;>@-,GH<[-(*:*BO&?)/RY8 M<1V.$P8NKL]Q)D#6YJ9ZH;+9?Z G]KUC%T_R$<#RH+BABSECM!+43:+O-'H%
MH^I]GM9>')YV*IR/1(DW*[;M1VJ9Z%\JY"]5'$9CZOON7PCHG)?K"0,(3P+ M(=!A".%KAQ#6AP/R2^9*>*1>*G)!93^5<2EJR
MD^EGFM_>]%Q:FI]05)]QF06]53"0)G!R3W]2V/[FPAC!V'LX'-B!V]2D7L* M"'3<7GE0=+*D0.7CGC!=KF0YC;4HC!R$D,0$3DH -V4U\[ESG?
^D43FN[*6 MK70$F#RGK.@HMHYW.8K+%%-]THIRU<^D+4QMVIL4C5Z$G+&VMLX7V]%TFD6E M1W:TA2++#L,'7#!O<'2%YH_3?
$R.IN1N;ZHB9J.:]5%.95>A6N!|$"G)M1O(-_MZ<=WY!IW1ARK+1+M\?7U*QB+>1!55;\'2DD90KG<;F M,QE+K-
)K5&N39)_C&T*+Y[.6$"=Q6;/G@9;POQ[1%"X &,9=PKC+EXB[U W9' ,#F9!OX9F&H9<+TYH] 0F0 MN>"19]VDB;)0CR5+<4[5";,^EU2\>Z)$S8PI3P?
C8D%;>!6EWY=3^>D<%SK^UH&? M,-CSA8(]C0&TG?U:L-0S_4YD6!%7W!:BRTC-BVE;2%/Y>MM?KBAA?FG91'! MU*@RX,;S=
<69:NM29L+9I]^R/7S5SZ=_&39P^3G/'Y.C.)"N,&]V8&;U; M_>Z)(*V;[1K-2%2,]_>T:;8\;Q?)^5B,,F',Z(^/&?T'UR7_E"KJSYF"_Y== MZCMJ_N:L[6^KI>
[_X2>)WGN>.:)>8_KXTD+3\>N*ZW82]C[9FKL34XHLZS8= M:/3G*3F^HZZVP-P"-I11FW F@ !;#D$@I"7,$0$D>4+8NVRX:+FCB7]M(H<4
M"E@VP8XM !!!>20XU+91+!-*@) Q "8)Y"C @5)N8^V2%@ */7B@9ABOI MZ# PI9;-4IK!EY[N"OK4A.9)->_WCM\/_T9,))NP54,&Q! @X#H#1LIA&,2
M)"E M[QUXBX;M $E!0B8=2,$#\70G$HF_4S"MI"Y#ZM0VB?0;[31TYZ^O<-JV2<8 M-B(8Z'OPVU ,[X[%O_DNZ ?8.XLG;>;]R*IB.A%"]RL6VC2O<*R
M/9V\3_/V7:7#4VN$ZQX205T68]]N W&8W/DE\W1T:_/Y[U"'^?OT7_K.5>5F'-MQ@YQZ,DS":;1S 8,&GGVUV2%%+.EQ3M.3-/^.'&O\;__L]_Y)U1' &=:/[<)
MF?=&%40G* Q18Q 96D#2(M((OOBGI'M0LX)1)I./%//7$RX&O4+S0,0>D\F_ MB*5,6D7V)BQ F8@.1LY/_UO;C[!SO?W,M%6THC\MH$N(Z*!G'SQU
MAR)4]!$A[0S^NHVY,(_,E9;IF;M"/RW*?R5B8B%5_]]V/7.R$?Z&8H=U$C] M(-5]\-&/7VV?_(VP546T62P6[EZ]WB>)Y(%^MM M+E-
X\%6U6,L\$FPM2_!"FB]FBVRKR/$?[.8KO3J;T!O9N]"(!P1SP0!<1470 M 2<6FA';_VF'MD0.LF9#5B'T0V1W,(5Y*J#^25XO)P&"85BI)3\PY=0:1NT<3L<
M[_;DHL8!?:V.!:N?!AHKXM/,ARWGU+#>K0Y)FYL-NK%Y)%ZDC:(G4B+YO*7< M9AD65$L5C1_%F3'/UI@ZPXKX0-YAR[ZTGD\F0VG)U?EV*I-
<6YEY$K4\>KMC MFL,5FZY'H F=I 9ZHY_SG+%('[^]SA2ELEAK=C6]Z?8[S6I>28E-D3EN.00Y M@1^V4@T-K&=NJ1)9+'(,:AE]WE(JZDO'2C=S7%[-
ESS;KM.IA2?&CI\)LHEI MIQO-S%8F^;A;BH\LIEH8>V+RN&6J5Z>$7C61Y2+MK#?M-V/5G(LID[TTQ!FK-?< M #+?9U;;&"2K\T@37:PI;AK99
9B*F^W._R_3%OJOFYB4^\' >TV(T-R5R/ MT:C!@"<;NCN2^OC8V%%3@OPRNIL<-[5RG$R,'"[&,QN\G7K4=)++M@TGE]X43$M ,Z-
);>9V0P9Y"W\U.V:0C]!R)X*:11F MB_B+0]&(Z(K9Y4H;#E#>:#F9="(EMRFBIE&?'L)O (5U7FM-_7CQ',EV8II M5(TF73X>BY67@%+
(YE9NSYO[^BS@U(;, RJ;[1G]8 _MP=$>9R(Y^+:;3FP/8H;>06:Y*| TU-(BABIENT0D@S)/6SZ0'@3 +]]{;]9 M5V5D"U%HR$2?>;H-7V-
Z\$GV1)T3F(_9R(&2B+EE*JLG"/8^])Y4:KB$R=,_M\^4S5K,J&9#)XO ##ZPE'-Q>_,O&'?_P)F=?]%93D6*ZP94C ;FG:Q5>U=FM M$^7:D;$DS7_N]A^S0-
:ARZE@0M>&[TCKT+O\L=79>GR3+-L:I9,9LK*L:*8[ME!GHN@'H1,WA\QS+!==P+$[&M=M[#C2*$&)R CD1]+],XOR<$G\C*43<@R+_ MK?
*LC7^,_OL/X;G.A) A=D@J#A6ISG,AA<[MDYC"7PCX:@5.@*4.\D.>M*S MJ!)]=$:O@@C9=N9@AQ#.(K,F^0[% M$>P\2:YC;C_P72?
\R8&#M;>)$[0Y]E\=:]NQK?OD(^';*MO%J,?HV1-Y>PQT M[_DF?.8(+N&6PFY_CR!3\M/W1CTX3Z\Z@GN1I5U3:0BIO>N S_ WU)],?KV
MJ:$!G_ZW#P.DSA[S"M?E-NL233PFJ7!A[F]A0H6YUW5AXN&ZW^-Z1),/8Q2X M,/>W,!#(0D9VO75Y>^GGEQ:H5]=D
MV)&3A3D_Y1CU:],Z%]UUQ/V*N\,A2X4NI(7F[7=PW@C#$.!_^%UP\'*B\@?7&/?-U?>L,;Z[@>1/$]K3">7D*A;F^\C,WT5#-F?@
MG_]P]SG:]@MMT%5LT"UGPC\)_150X!]OTGZ.3W.KB[,?*2?^CKNS/K_-['9 M7TN*MEH-5DS4R#G"VEW&ZXNI.1>ZZ+@4]>-7#@PM=(7DNO5?_CP)?
RWX_97N M[]X6+[[CV]H"GQ77D[17+34M5^NZ]QL6(,I6'@7/N;_$95_.O$?>>>>1_Z?C M'=O3';O#'1 , M*Q.]M//Q6Q!-T8B(]8@Y0HQ"]8-
J#U/W=U[X9&;]W>;@B/PID M4.IW!.G.IN'2G.GNDY[@FWK4)4;LV_D[6\]/-OVW'.I3*>C08PMC$K]1*OR* M9K=@>GE!"AXQ2&"ZZ>0N6*U&4-
M8]GT=,W$-& ,>M'BS);9) N'\517YMH;*/>VXF'(X(\,&<=P=XWE_@]7/8CSC MKEM4-5P(*I;"C_P[19SYWIR)\4AO&K:H?>:AB#^6C)\2NRF+$]
M#XRQW"8YL*X9*'L9?O&GO9EM,,_<\P\G+EDNQ79"R->F8Z%Y9E@8P, M-^V(':MWH\NQF'QB+!09QEW^P+C+#=0_#-!<$T0^GQ3%5I,HW:GF*
('7Y$TI MJW'E9H^%V!*&9[YK>":HQ1UZLV%XYD*%V]_(?9)DJU!3^\L"R7NKGMC46XOQ MU!-31]&:\-),&*T)HS6?I/"?SU-;198A%YSG:?
E$CY9SA<)Z.$8X$ 9OOFOP M9J\J=NC'AO&;ZQ=7OR*-Z2=!ME(SZPT-5+1E6S6$^FSIH>H"!_>/R?#&31C& M"
<,X=TN6WHXEG\^0>JE!@AG/K96FJJ5UL=%+T;4VAI@PE/-=0SD"M-Y2Z.B& M@9P+5$Z_(OM)M?/=> <,_MA3>C/3>>E*_-@=X-+)]/A3@N+W?
B,T[C\6]74XPPF!,LPAQPFC1=XT6;>N) MA;[RUP\5G0/(\Q,3U P>C3'0?V)>[7N6EIM,R@MQEEO;W@],VM.NU/5#,+>>
MHG=I'_'WY_*3EXH97HMD^$EL3VU(B5'%& ['.;),@1F5TI2%*#=195?(,9@'-M\@3+^">,N'SYB,M!Z>WC%,>A]W]_D9B/LXH_L3['S8(4-#1XBNFBEJ/W0
K^ M[UIQAQN,\[9YT;ZD:!]4BOZ]QG3 M"/_O7[^\,A'\]29P!M#L.3\,U;%4($>4CA%V3(C F)F$E3TX+"A>LV6U!.(-%! M7T:UU>&T/%61-D>
[!SZ]1;=-0K)MV'/8&';4;Q%4?,?OW2O"3.#$[''X)3XU][6PD:%CE2;@ *YJX.]>_OK@O!X7N^?[TA< M1@H.BEUCY3FQ[/@C%<>4-
2)O2:A,>PO(0%U"81]NB8,8W^>_,>Z4!60$D[BT.]0*_B> M+BX4O^U3()"$]%1A'O\=58_K!4/1WA43IY J@QT=:8:V+/P7Q1X&O!=N'*\ M#>>#GLNXJ
"KIKK:]O:UM/X)=?8!*@$!"QH7CX>-GL)\V @H;?7#\WA,C'JZ892.0V-:PAQV8!V7M MCW" ?
OS$%;V0>468@!!2A;,2["'@,IM[Q41E'4@6(D>39XA/HYYU@E,GD(\7\]40V@EZA>2!BC\GD7\33CV@VCJ9R)]TB>Q-V)W^M[8?86*[M_>R5:J]
[5I>*/F)PA:]N\L\ SC\R5END9!M)/B_)?B9A8* SVO^UZYIFL[F&I M@>);^D&YH>"C'|_:V/A!E4/, "G73FJEBR/!?]FCHX2)!;0Y@-
\10L]40%+H)MS_"TPF^OF&M(53&NV+]I1>FX%9!=3A0Y< M#"(SD5389>,!ZI4%%0MY*]FGIR'*X_L=3]_;?@6_,3-1P6COC_71"#[60CU%
MXWV$FHW<(30"_ 9)DKHEYT,!/-B 74VA#X87,3]Z1F9_G=M24>$\[UQ" PP M4AT\(39RATP("P@B GZ%F-QN#HBAA*#&G4/UD&0'<;R)"5]#>*;EP3_
CX/7 MZ_@9<\N<0B8%YZYXBKL!?T&4)UXH/8TCZ&N :=#20":)CGG9<)$1ORVY1O!' MFGS8"@;%X$'!^B#@:O&TH0O4/SN;5'C-
:G[OVOM%S%GSK.X2(0QHZU!)_?I M+$M[[*R'TRNN'1E+TEQL^=,,"J2NVU#0;;^;=G]]_Q?\B%-?>?:T]GH.ZB/V
M26.>WNU#SM&>TS9M3EO*ZPN5;',@TC$BF'24,J+GQP3Y7[W[7$$_?K8]H2A M17P!QI3M8Y4'0>]GQ*??WO$PZKJV-0@QP;

*MG2[=A|({@Z]SQ_&^G@QR(R6?ED:K.->!]M@P*W C$F<2P*;B" MF'4VU68ELVDB&4Q\6 :)NT*NZ+="K@P?R[&QR7@EJ+)7!-)&*
[/4]GRXUZ06=K,D32N35'?M(:FA?EMJ#D$+>K[.2YSK@9#FD.JMX, AZ?;&GUZ#37D6?R4&I]G%"QLHPFP68-I0ZMCN6']5'HQ:X! M)^-:%GSU2?
*%*SJTX7\EFRB05I:(&+5'5#?F;AG$'2M 54EQ C*"\'WH->,\(M.4I/,_=X^7#_&6]4/='_P*U]U?TN07_(&LX/5<*IKSN3=<-8G=1)4IA+A%] MV';L>]$3]-*
TQ",SMCYT:HQ_FQ'>MN1Y[XT?+>NF]ZV1VA]1 <8/?WA]'!('JB MV-[<'4*9A9^/H%#!]NJ>8""AP&XYBD4[&.Z?WOAB\& I66@/%.U;HNW6R+9S MP;--*
Y,I#[3;&#\08SH<%.X'W8Y09[).-0B)H@TX$Y&77 Q"H,4H#)4]JY >R)/0.SJ&2;SV&VK!,&0#%1B3EP"1N07!G M1L@],U)1TC.J/O1.D&*5MOAUFVV-*
*>"YWL++ WG/6/WD*3ES{Y]3EC93[^%LT>'4786"%Q?S+B_DF%'0$G/,F^^]==H/> 6X7]8;*[+S5 MJ%?4AB!E\H--/-%C&?1&SDQO!*.NLJ2\W0MD2HQ-*
G$2_2&^PKT\>:L_.!\1$8 M"_;$@L0]6$>,9UN6A)<1^(?J7R U<$F'8"+IHP,Z<]7MM^T1@_W3(@>[R5E@ M:\&QO*,-Q';ONJ[+B7-=+WLSR$4XWUFX2)!
*[SK]0^JY<%5TA@C[E'"A(%?U M3S;A[VY_Q*2TS'8GA1"0H.YIXF]"@(?&<-5\&8ZS#SGY U'K/P2L?7MT"/-V M7]_GP$*;W.B)P0L,'F3*LCM7?:G*
*W4*T/X@0(^L;&:XC^ ?T!M6^'-6%]AB! MCG]!0O718#!]N#N#D ?FV)+F$W26]ZDU7 ,T!+6U[_+Q:$K?'FI!LH-%Y^D(M5_!EWNA4"U(MRUO6,+.,*
MTKFJ6"F2]1Q;G%F]23V7QVN8?&4-\3D#%&38IQ"^B3EYMO&8:+\&A!/)?K99 M=!B9_=XH\&GAVY?EL35E-PV'4Z:"VHTS(R76RY?C[?*
OA3==HYOGLVG-S2VM MR+0PUV8TCMO&-GB8N0,A;9;88=)19<7.GFWL2+6E.C3J\]\TFFN-G%JKL8M MU&1EHO.9C9![JOD%(M9Q"&*
*(/"&6!=\&PJ[. =W"_ JQITN%'CZ!V/SF+O<-_MC;*DCELT8R9SW*S0\$I*,U<%Z>L2FQ7I1')JOL20KD2[#3F;T*H;%)EX9&Z)*
*M.+^YYWS#-5RG9LFHY)@K;5VNY@;BI-[N*A\W)&]90YX=9A*"),,).C^-V-(W9\&,W<@)$ZI3J67G%41ZO6U%_>4L3%.?_)tT%:ID1[4 M-*
*O,HV:TVH@EAW4PY7>|-0O){Q.:52+#E!WNO&NO]NL>I^'F^O%%[Y9XP*P)5 ML6G:-*;G*''$!C*2'L^T%/LIY^?OAXDWR^',J2;*!=*=DL4-3WLF@_98#/,X*
M2CR4='Q_\3WG6&YS)N3\F9:@#"]'!3ZV<;?E&\9V[%A_0&XZH-E(:ZJBEZBE MX6TVR^8+$)KT(91$$)H4Z>"7|^)\6+WU.A]P^6,+MEV?80O_.Y)-4*
793/N MS/4O$K6 N4:R5D#=AF@"'"# B.](@3Y5X/'>VN^ZTAF)H78C)^A"-9;+6YZC MVD]B(%-H"6Z(#S7H>G%]!126]8=P|<@]Y1|*
(+9:9)NZLG>1&1J/("%;J#O? M3'?L9)&UL1:S3X[2V^?]'N%]I7/,\] M$&=YHP#ZHBNJEB,O)V1U($368!5S%\5T,=G\G1.W7UCF8HLD*,VHO"3DV6$K
M8Q?GB;S1O)3,86YDUUT'U;="^[8G3RI4Z1'GRL)\S2TV$R\-,K-!985.*I#D M0_S4\8\G#-J3&\)\>LW-Z,CS_# 'YS'W.OO@CV$"$15E80AV7OT<%WZ^!IR,
*M AUHT'W&Y9^MP,EA4'!17Q.R9$_VDD",7G,#?0# ##S0! /,U)&JK@=*MQM- MZ*59O=<9L:K"=V-E"'+TG]2#V2+5&/6--*
LJEG#Z;6,E<)S;&&W#15(P^/IF^VZ/(7#<_MF=!:!;IBXO//_AF 4$3N4$2"\@WOE9!Q=C%]-6H>UQU)Y4ZWGU[.)"AU"/-
MG++,SR0D.)>^AYF>]NN$Y#H0"7&B,9P$"F(-FH_M.6Z$3"/5@G3P;YR#RH"- M=I_]0PQ-0X(_^ !8M9L& B,Z, 8.Q-TD!S'%"1H^E6.LN*
M%BN;+))!J(BOAH>,T?U.K?PYNF.C @>]#4[RA MU&<1\C$1F^]7YL371F W7_E6\OA+(09<%P.H#].EBKIP@V13_A^_(9\&@MRD*
M%6'X8BQ#+JJ=8KM!\KU)K0F'(/9X@C#YRZ_/1TE?0L>'U#JN>[:Y!W?K0RI MOR19!JJ. V1QIO^>%ECH66]R;
MGYBABC4($W<5:NE.A:&ZJLX^[ER>YRX-"HPM)57'G@_.PT2\I<90Z.MB7_=Y M)%1QK6>14&P^N6!)VI!?UT>';]A3$YJBNMG.?
*&.)F0+;*XLUW]TLH1]+,<$6 M_?.T@GZT$PGK+H<;9N.V2>@F.ML/%W=GT[9& NWA&::#3T.B7CP2;'#W"%F#*
*M!T+%YB^P)D>MD7GCP=SQKR_M]L@[IRPU4)'3>VQPMA*J8"OSNHS'1MA[D!S\ M'D6U96MWUVK[]6.V $5[Y*+W^5H/Y?*
AIF,38E5"V0'!X1OCQA41M7SE]XP>R M--U?YKE8F'DNS#P79IX+,\]=,?.F)U+'+?OE@@.ISF!#QIV"4YD+:R$S9D4:54 \;+E)<$MF
MFC,L(6]:&LMJ#3(V'L.61\\L BK?]LTD48NTFGQ>5!M)KSL6F>-G>F,WV^C8 M/9Y$5]R:D95-@LVPL.71,SVK4LO5)\LB)XT\5];S-=IGM-
*B6TB]F"=U=CO]JP8/\%/TXEDN*J5 M(2.S]EQ3DI1CQE'+XYF7DXWZ=)HJ"9ER)T/2?{U7-QYL>=1/U:R(B;E;6&A@ M:(MVJ=QBQ6H3MCSJI].?*
*3NVQI3MT.M)W^SS I_* MM",IICUK1YNP9?QYRTRBE1T,,Y'5>N3*E=A.NED9; MF#2T8(MXVX*OATWIYTWGZ\2T9!6+I@!*8C8UBZ0ZJM@+?QX]-*
*;U:. ^QLI6?(MNA)Q%WRRWZ+[8U1/YZAIGE=;GCY]&V2WE$X.-2?5+TQQZ9VC)>4+LU*ZR2Q6 MPIJJB$*U:;;*@$5-MROUX1*L+U4B.G2R>3!&<-*
*P")^9 S*A'"RMFHFUR9T1\$@"[[M';L5QPV5R:^RA^P(,2U-9":*EN@CHF&WL6(AI_)(*9(8J&[W?AC>E/A['W MDF1 9QM8^ ;B:KQY._OO&CH=,X;-*
"1=6$3,.:7<^GR]B&_;"%:V>[X]"<.YUB[9Q+! M%-@/1!:@KD&J/EY#;I\/:B)WTT]>T9A(\,\RSIP:I*Y(JY#?R!/C\'M[.3U]*
*M]T_RSQNA>^USR'5D%3QM9P5+A*B*%&Z:B/"B;S#^5Q7_5TKZ!GN.ND_<"_+ M!SZU1-CN#%U"W8!=:DP"RH)J*D@6%-A?!]U^],4#?*
0UZE:Z.TH4@3WVGEML& ML! (_3R>(^+O_T.RY4Q,UX;CM_ YB27!VM C3X#BZJ ^>@Y">RJ77@=_? 9' M>>B S46WSM?
3E5+3Y5RRV)GP49Z,)9K/$.E>N6/WIU#/UAO;%86NPQECQ7=6>/6^\]WX3/'$$MV4]) MJO<(JO3RT_>S$?"\ZN+N53?9-96&T&EQ'? 9ONW+]7_VOO?
*>&$OP[V]60Z+. M5CL+U^4VZQ)]I,\68 O7Y4;K$GV,AD!VAPL3 ME]KDL(9'>Z+A#(4N'"W-_" M0""CPW6YOW6)/C*AX;_'=0F!*
*[*H+\]ZRZ*]Y^C>;A.0{)N&J5/2F,_#A+=*"K MLL!;3,GV+1DXA*&EPJ<6@+X$:%CH#9)A1XY>|VDR]*]?^4D[Z5]Y#K^U'LJF*
MCC[$IVP_*&+48^PLT_SM^4F^7\+.'40YW+59Z9FFY+MW^_N;]-6)[3X-P'^ MV:+C?R\$HV?)X7W Z(<6/"1FH4'XEL3LUE/R-;C7C6?
I6^O2'TBN)$,)&=57 M853W/P,A[_H:O.OX@F-H3N[4G%QW?BYL3O:.85],K(02\HT(Q\&YVY!ZA-0C MI!XA]0BIQUT:EB]%/8(K';
(.T+>\;)XA(PC9!PAX[@2XP@N)FWO-\U7!,X/ M0&R39]QPL_$L-K1Q-3Z+QCCN;AO^[W"&-&XQL3^7Q7?G]H=+/AWKI M:D"OE&,]RE69=FW5
*+:]3;JQ7^-IMT&S#9A@RA*DI8R2H-U?5B<14I)4SQR# M6#-5.ZP&1K^_T--3T@_ZQS8K3K939IA2.E+6U$F.2XS6RUI:08F.Z!^_HLQ#*
*M,G:]:^#&)E^8)1?*5.(@;E@V/XX6&PQ*>Q;_\8LYKA%P,6I]9\IR"\Q@ M[H]>AIAQ+D/NFMDRF#C&=K4FKE M)3K<^T'[1 MRRN?>Q#]"'R.!D?*
\?;>,Y7.[&]2]!5$>Z2XD1]NJ[HRI*R>0+5-2=3F?++*" M3&@8 -C%6$WPQ 3R<>(/L1-TV9]0_4/U_^QMQ3=P#UQ#B+K$\.YLY_P/V2O_M3MY\<^-
T86K)+I-B#ZU&/M8O.UJ7B>5+PZ+&.@X+34KJ#2;E6^PHM(-)$N> MX"R^ROY&6A@=_,;1P4O3ZSMS]V\..G?+N+?Z#K%Q+ ^[(K>:H",D)A 11 '2R
*M31E;?:9H3],8T+@N KU"8'CRV\NO]0QB/%F:8C M'"G4$YU),D>/5_,6!P$E_N-7-/J0B"6OA2GAML.=;CN$F/*E/*SW:GPM(>9[*
MBW+"$Z1!V]$3'MUBTTCCT8X$]1!/?,'+NJ4X\T#7<97:,3" %11(D929:JBV M8^'LEV%<\HO&)6\PYG#_XGZ]J4#5\[ZB0T!D#]3\94S,V+P]]\R:)IFGF\G4
MJER8]R FIO!Y+?!JJ[&@D+0^!/&';,5OYXG]6$PT2<#,1DICJT\AF'P#%^K#JLZN544&RW*<[*Z&N4&F M9A>;$:3]T)>BR(+NC\9(XW,$^3MV9 (L*
OB\6!E]_AU+=+K_$/%+N&O;N=L>G9AKF M'*"^&^.B(9NSO6_-G$KXM!-@.IBF2G+'5-,/ M93VU.T:7V!EM(0Q]F@_W(9"8+UIT-*
$*NXL(BKZ>$=K%MB5H3@00ZA?= TL=I M ;[;QE$ ^H1NVG88-+]ZT/P0$F@("8KI#G5P%T!YW>QI-Q_Z7#B'I!1Z@EI:YC/+S-!D$6BA+;[8 Q._VE7.
*<(_O MS!['?S97Q=NG@;C[TN\:A" N,;T.)K,60::8GV&1>KZPB4L4M-N-CA!)HTR_Y MD*3.A]JQE_@?1X*+>*
(4UFK]VHX[6^V+Q3)7]O^R"$-3\S54Z+]U+SWNVU_#M MG0IFNN;,X-OD$[\KZO+7?^$_V[?(.1 LI)&3?P^G@D9="O21)/^ZB@H=9FZG
*MF*T2[30(11CFVU[C?_]GO_-/"!&1H0&U?FYA8&]4$S_?.84180PB0PM(6D0: MP1?_E'1/6MO!*)/)1VJW$?!S!R5H'HC88S+Y%_'T(YJ-HZF<2:O(WH0%^!/1*
MP;1 MN=(R/0,V^FE1_BL1$PO!T?^VZYF30HM^AF(*<48_*)05?/3C5QOI.TK!F$'H M9]"288$,2Y=4KOUWXX3WYZH&P&[EZ]UVB^_Y(EVLM[E,
{2@[4ZQE'@FVEB5X M(3X"W;SE5Z=3^ /Z;/M=],Q"<&07 5:505-K(+B>_BG77D#(J<:
*MDB&KDD[LR.I3K91/JI:$0/84]SH:W5LQ[RRF'>KD*663L"F#)I1A2%JA1#))*
*MID0F.9)%B;*3HI($5%0:22,FQOSP)53:&C^Z5>XO(_&$S644+Y_9U"6J;7C0 M.,>>MS1$MY3NQ9PUJ*

*%SJ#SW22S=0RZ-GIN*9=MJ-YU9",3T6O7)Y5$-)8V,B M>?1,]YK6!B7$/^HG5Y=2_79GLB'7XT;%XM7Z*A='+8_Z MV=**2;(:226X12Z=ZK26"R^FH-*
*2Z1_T$K9*HLOQ1RT')0ETR[.XS:F#HIU8%&5ZSC7%U"'+ M^7P*IJ-N/Z_EHW*T*:P+"0/1./*X:?-2=IV-7EIQ$;;852>SC5M,X&->]/.F M\9Y(+;16:DK.!B0=+WO.).-X. ?AZ*FC9;6H4Q-*
*U1+J,_KS));QHD\4\\JBI MO%F-H][&R GEX3K;B/2X5"&+HVE'"R451TR/"K47W(P9J/UABV6L)'[JT4J5 MN2E/3L?4F*N+]WJU].72T0A^ZN%2B=3E##]-4*YW0.#>IEB35:*
I=TL7D%S0^6AR5WGLB*R7Y7B!+;,' M0_844)C6U\WO7O5)9ZWH-VVPNE$YVZ9T"BIJPIC:E*5G@5(TF9ZK=%7,.YBF@ MH+A^LPO7K,@MI/ZJ_]3>]+:/ 44!2?;CI'-*
DL!E5H+'#DNMJ-PZ"130@8@[MJ7(\PEC\]9B(2$_-. 879<8LI2LX7-6K&,SFO&SRK:OGF;#0R*P9U]TFRTD.W_9FDI8(5LU30##&)M?E8LC:H"G&J&U\8CGFFW*
MTB>!PB(39FFMU7(:\,1BFW'^>R:/0443*FKM$B!MS0^5VP.0=UCO85W"BAZ MEFK$Z0YK:.K2C4K29IS/-5&]POC1NFO9 H3,V>PI2^OEB M-6>.J#R77Y>\,ET8RK,)>PI22M4-Y-?*
2K,F5#2I'U;N\8.U.0T!JR'KE29KC M2=>J-/7H@.M7Y7%PFORP:<.KE^T6TV4$:5T8%'46+E\4E(L4EV%>7AI2\)JA>@:$ES16$'-^8N4:SR92$E.@POIG8"NLn=.=Q=SD3
MR^PPW3P):T)FUX;0V%#YC4COB@U5OJ\XIV %"K&#..T1(L)2DF3&)$BLE4 M4A(E*1FCXHH2I9-'#^<,,Z\NI6B2DJ;\O%"/2CW-/ TIB;:Q)2&ORO MUZ0V?*
4VHEYEAP9FO^[1R$E+]DJ\8\D^G"E:?7&;'62\GKQ?@DJTA;"L_+1?,< M*0TCRQ[@6_-)VCL%*1F>3RCY25\5I.G83!.-BLEZ2897<_6>?84 MI"BUMEX=LW%%FI%2VI6R&C_->:*
*<@I3YOQ",RW5YH\8(+V(4DRV>>0I2S"Q9 MFGLQ%W'HU5T6.($4F%HV+$D@H(DDE MZ:&2))/R,'6$5]!9"W9=

(I,5UX&?\&4;X7V>TW5Y@C&KH[+JJC- M/'8+^:5FX$8P'XGQ(7'-9}//B77L41]DT7@0"1'T@$#X2 8RLSY^70@Y=R $ M0X:O0[+/X$&),(^V-7.]41;Z8GB5GV>1]N1%= 6)

>G(@E$PQQ&"(P1#C"BK/ MA_:S;%G:0l;7&.7#>CB]T)I9C#5@/V,U9)80)J(_GDN#!N0.44S#..^.+_¦ M9G>71_ NES1KJ*#K0-A%RRM%G:NN@[\PZ47&$9[@C M%$5;8,;DR (8G&'-\$7XA@#0B3/Q-5A5EJ&@E:Q-M>$.92 IPIF9"M@VX#@UNN.%T--=T\@3.L'7&O_Z#:\#W:Y:!F9QM[R M$AH6\8:,#ZQ:JY:IW#:LO,67'R;M4(N/)1]#,&5 ?_2TN9K%P_@VM#Y4$96 M@Q-.8YB _4W&]9WPXQN);I\8?8'-(R*FB# WT$_G-W=0T S81TD6U-U MH26HH)'IQ9]@3L>.Of%1CN?_"R,W=>>M]M-"=$9OMTXD3QD97)EYY/D:?N8(*

M[^TL9B\V+E4&&+@M4RT-M-]'/Z_ 1>CO9_\%SU5^5H_B3\C(?>N4R5_7:%%Z_3:MSF.S>,Q@7<:/*2%EB6 >\$A!-8)'6Y-] M5G#U:8WN2AU,?;UH?]:6.D\KO\OV-OVM[L\{3MJOTM'5?X?*:Q+E^=M5OMR1 M\BS8¦PEI4!_OWGSA9LU,(OK*L/V%):.)KKX%/99XK+\N?M3V^@U0C]!{397PK-MROAPRDS@\0N]Z5_PRT_9Q,,5&>C[!O0ONR" "_I>C(7S@3_C@2]U\. ^$F#,1

M@(D 3 1@(@"#_^\B OSNBS]_Z;GO\T [.1G)S\[^=[^\E>OJ[+]7^OD_KZU-M5$3=7]$^0#^5^7#TJ^#[^R;IlE=O>&C_A_M+1RN4\3X^G4&?%!?X4S D+7X=!W5%D_<]Y_VAC41FZB?_2,Y8OD2'04Y5-] MH[.8CF:IN\0TO$I^O'Q10<;S0Q5YB:3M%]:P=(_,8V7=^'GZME;J-_.U^V)5 ME-O9RF+0@*F20D;QV&&/3(8"# 4<7=7?*'#67@O?*

*M'1?U ?2R+=AV L?6]FA MN;@5FO5&'O4*_%3*Y$=K_>/U:=Y]V-3#>E@:&D520E7[_RA30>8.H- MA\T7<"6U=V7FKV ¦?(D%/13^6,K])#(71= ZC/P,IW,C:\ZF?[#3 7RD;5*

*MPK/6C'3D[*W:?JA/D\A:#1(@4T?C@5@D=#F9^D_?)0PJMJ(,@XKW0\4':X$^ MY&K=e++Z3%?+Q63W?TY3,[6#V?LGIS1"RRH[,WF(Z[D^[:3YM]1*]=":,P! 2 M__$KR0>BJ<.2?*

E_!P.R+W4-5&@8A#$+,KQJ]>8-K77TI-B9FJ%-,2K=M-%'4 MW#WU".*A1,!/GO8Y_>.K,Q6HHD\0ID'EF'2=5ES2:,WT0N1:R1W<??,,X MH\\$A3YV18>2.7C5QLV#]>~N"S^%3.!X?*

^Q0'GY(//POGNH=+++O$=G5]@U MV\U;]\5ERK5V/EL*_'__$XKS_Y;OLS=<^C[*M3]95CE73C?+^=89A_G*J\YW MN/,6[WQ^_+K73&3089HU:UU$%2\)'@ 0+BX'"H)\PT,J2*

*%\79%5015E0N).) MOYC1M1^>><]%/S8.P4BB\9.4#WO'.[EW@_!*Fl>]!8YM-X&3l_WX,1)0*#\61 M,! Bl=$@&@F%!L.A) Q2\80P2HKA* 1+/RB'TCO.XN!Y.C[HB=Q,X+NW;_-A*

*M,)XE8M75(#2{5\9B1D+K5_?S/F]?PF'RJ[ZI*2VA,0@?7EG*W@FAA%YZXKO5 MY>,LFKM5^,%XS!F$IZ_4[YMEIC(7PYVB41:[#=1%3D0TOO+@F8,2&65T<VY'*

*MO%R*Z8:7;$CAAN#Z.$S"X9J5E)Z;9(O)A+/W4GD-MOIK_"5!\^,-]#$[\K MG?O">1+DVTIS.=ZL!K$!OW]E)UY0"I.@D>6+F\IT/:C%)+1.XRL/WM[*:N)L M9=QIT^"@V G-1\]CO0Y7'KQ=GL8V9GPFRU-KN3+&SZ/$NCD;XRN3!U3#._]#07,W0)#LMUFX7B;R0U<(:O#V^:?V5W M77A>&:EN+Q_7A64X9H[S]R:_6!&"S48+D]Z=5-^-D3B_#'9C*P*Z4'B<$99*

*MZ7G3?TH:T4Y7E#>Q8PJ4U4D;2$4]W!*UM%8QA[7DXA64M MOOPP:85:?"P!FPRN#X'_@YP]K=*)SU(#HHP-I/\YX,7T."\M<]:@!*1'E>[M9[M'G+9/ID/1Z2*

*<=,DR\H,>Q8R>/B$$,WKZA1*AFQ##)C]0@F&33PC!L,DO MA,#8E&*4\ $E,#9%&"%\0 CFD?$++(1@V723P\6PZ]>?-.OF.65]40OS<*7_8 MWGM1X>Q3UL!Y;!:/>:C+^#$EI"P1S*

,>:A&\,"YG\8EKVITG^/U^%]+]F=M M+5%3X,O_^Q'^\5$F"M_$3D!\OJT@R=_TG-4G@C[#X],(M%PGV&7EW#_P4'E-_MHCP+H7=F3-V=A_\^$_:=E,]NA'T?*

*(BF3B+X9;']AB>C:..:3F>?*R>G;8 O M(-4{JL1$*=-^.CZ<-A-X_$)O3 7+AB@ST?0/ZEUV0WP7[*:K*BIVGAS M/O\G//"'E#OZ,K)6*AGY@(F OS4V8B@%_HS40 _|*_OT6*

NJY)ENA)YF , M\+W.?YL!V,G/3GYV\K_]Y+>30.QHF-!\S9%D.<[))/U,O]8K.IZ(9D.D4U=7 M)&3G)H,Y<.2K8/[)ORREV]XH>/]RKSP. ^C?$A3T9>WH=]>IS!LW_M>?

*_G?/]Y*TS%LT%)1T #$O(%E!,>"_!^XI1LREB&KR#!:_M.;$PJ..37LC$8#65MX/$(.)8!(B)4B0PYJ,R?9&V<,_5\:QJ*CNN=?%OI-GYP M$A+EF: 8__0VY:!BN5.4,M:Q!1^AE>^D;'C5S_8;*

*<.YV M%6RW[FY3O6E1ZXZ-YB@;?0_&@P1(U:%X(!8/7TZJ_M.W"<.*K3##L.(#6+&;_M;I96I9V_+1L^/.9;&T.:M5PG+Z7+&B_"S%57|<'5FA\.0QIKA?/):W;T?C6 MT_/#*

j5/C>3.IKC"&Q' \2O&!>.)2FOE5W0<%N17AXR(21FI[%V-+ M3 P3^0Q4L<6Z4B(>2$9/@2 ## 88[!X?GVN7D=BR/QEUARG> M0M5Z/IN;&/D% ,DG*$S?$4A>\ Q=?*

*7,Q(G*VM.KV[P5S/1E(Z<6^'B^OPS& M'PK)H0BU[$%KBB<'L7#|\-.WIL]H%>2ZA Z;$"1%,1*4;N;@OPFIZ/88I+(/[8:^,J#1AD- M1>EU]-!TU@G/BLE5RHK>):KI0?CPF>7;6%-*

M11NM3E@U9Z'T0#4=H/&Q]BQF M(K)5*S\>AJ45BIZ#C8&]R%XYL';(]G:G=EX*O;XECEZJL8EO1T6H1M%*+1-*

*MZ5Q:WFJYX%3E%W(VE'16"HD0%B(BAWTZM'7&>.)#=TJ~5HS)PW'L64^JZ4'T M2->5=;L<38P?"M/@>AQ/ZVU5W4EKH!FTDDWY(IV05GY+Y6385>IXO6TFCVRGTT^J^.M4BI9--RA"\,'SO94+.3?>!K]7)G=:Q%2KL> M#I:"_2[*AJO\XZ+0?1X[W*4'J2/-5)9*%[%FIXZA\,-2]>RPE^B4@9PJ4R[VY M9QJ=4N41GWEWN>13MV@-4! O?*

0J.E=TK@XGH9CI]JG6GQ4,M:3IX> XO2ICK M^*DXS0YC[72GD^PJ# ^32@[&V[]>9U&,PE^>#C=20CZ=DOA]> MP;%],("5& U%1H6@V>FF'I//BP3/5Z4T7'K IK'-8_ZVF4@_3K-

RM#",S0KK M0F\,EQ[P:0\[_31:#L?3;K1KS.JANJ#$R .&'72$1%02+?ZJBWK&TR M9QB;]T}]W]5L.8+ _(EFG.R(8S'.AK3WD;;B.V:WL)L%1VSL/<(\@_*

MX;631YL3Y[M7$QF1_^$K;C5+5]&&FP@&9TX0EK0515MA:G,@!&.E?,/A)TX1-M-)^;V_:^-<8ZFC]+ 2XM"A:6 =^-/L&:%%@'N4E;4L

(7Q(GLFJQOUE81%5X5IH;A+%GP.UX,\;+]THL'KV^$A, M9N)?POD#ISLL)>@(_R&"2B5QLDHFT;EIW3@Y)^>6G]ZUY*]E0QXER<5$O]>& MWL9+1SML#1%F LZP9OAW?

*#MEC:PVPP/:DL{F 2AGY/>3]\&R.4ETA/6#,HD,5N-L MXE+/(ZNG\R=^\51CGWRZ,?]7V:/Q-I)N6T]>FEAL^=]*EYC6;3:02C"Y^1,MW M[13E;*

[HDOVV;1W_3!>,8HXLOZ<)PS(]T2=ZD0HPN_J,+PS&_TH7AF|_IDK{) MQ!E=_$<7AF-^1OO#,3_2)763_*8-B3^%+N_-B7C-7'FU1?C$6ING#8.7KSMY MR35Q:Y/%/EJ,+(P7R-

\%"@^LW\E291,=(6Z&?Y@8'%+!UW9KJ<@N9LD'7BCI M=QGQX-M55^0F_D=Q5TM>'\/$W(7]7BGT_5YRKCO2WY@H?U!1G6.$SK@C=\/$_C"LB7UV<\QY]>\ MNG_BG!EO?

*X\YO^:I_&@OI2UE$VTI]N:R"_R85BVS M\#ZE&(4S"9E>=9!D7!0X#-161\@4XHA8*)&,1AA4.*SYF*_CN M6/$;8D7W.5_/9:?Y*5^\"Z>K.EIG5O*U-9!4[_G9")O#-.+U29Z[_3XDW*

MBE 8@T4X$$]<_HNOY,BE%A>G@@SSY#(CZ9?QV(K;SN)L*1OFIG)L51^##]-6^/(6 TO176Q2@!BI-=5(\&ZH/;TO3,+ M]P2(S_[^^PH@WB4&[0%$359]R_IFI76=T);":&W:I],?-*

HR"EIPU+CG:Z MM=1(+Y0?^\/T& -$' B=DGSRO?:+-\1(#XGA, ?'/$1F\]H>0/3'@V(X6>Z$ M\BA5DD9)N30RS&LK2CTM&VG'[GLZ+|^#Y7KN.?:T'(($08TJL4B2(01#"'\'-M8O@

*(7Y'A'CF4?!QO:K?38M("\G\:'\XHWR/'CW M)#8P0A!3"A\(A_9.-R7\2RT*B\+9_FCC66,)Q@'7(DDH@Q7&*Y\AKWGV^+*ATQ 7ERIE&/59'U\ MV^)GFTVU6!X,B\GTM>45X[G_9*

*Q68C$?1/5F9695ZI?\"D\0#$"\;I=5SXNKZ!X(SB/MM(B/^.[\6 I..83R6M!GN3*4RE??A;&TW#0?#)S MK4AP50!Y\LJL?"L'\!-*2 B6 M.!/H4LGKN^/U??#:,(CF-R.KFI-*

*6?/9Y M-2IF"XER)7EMG;)?E,M%?B9-IIMF.I@66NGJH@?8 #:39/)4V80_(LZF9DZ0 MSOW#*6@LB)O[+M4L_H,9G5G\S77-,F2'5LCVM"^RD<^&U=@B.)0L;!+IR(_-*

*MSE*4*_"P;5%KJK2,]6BN*EU-O=6LB,,XVJH.QXDP523"+-B- QH6$".WVP\ MKP&-40NV]9;8[^4%I7VWZ%97QF1Z,;M/V4JH2K^964V%YB23?*Y&K?1S&@,-*

*MC=&)G0J49E##H(;%Z%$#9/0:UGRM2&F\;(SYCOPD/M1R#YF;KEW;O:Z-GOC$ MW6TZR<^R8246OK<>1,V!H8:$[213%$OD??L]QI"&A>\U\S +U*V4144;N8F03#*

MG<5]31N5I$(Y5;NV5:]8:\HCV5H'.U9)2PL-M5]#08 :L$I% N&3#]VO%\F3 MU11%&&J4RF>W/7TOB/B.5G@ 1O;`)$/A?YDOB7$QBT%YHWU"OI_5E;N'Q&.^ MMF[P8FZS"(?WZ9?-

.#TI-'FSG"^&BJ@R&T['""G] M#K;WG$K9:FI3+[6&8QH45UMM?U@9'&IQ+1_^*G$D__B@$>V4H7(7^Q2JA M(IA(N.";FY84,(?;54[T@J7Q1J<+=; ME,-FG1'U6%##M75!-*

>C;C%\.0CQ&$L0>3&C/(,/%@%P+@=W!O/#15QNZ.!+25]?0Z$8CO?3!M M?[SX[=*E!\%'.3ZZ#0LK,YVWYL-)12-HUZ#P$<F#P0?S!)_3$G->^&@D!P .:HXE&?

*%R/%*11>E0QJI\'T\KU)+JH^KM=+', M#%XQN9WW;SJ8!/L#2$S]_^LGUY^9H#|DR-%T">E!>O'/T'S-&9HB2|S_ M\.1_/@-&YFAA7/XA>\.7XO(O&1[@'-CD."JK(CZ:CW5IJ$=*

*[X=+=>IX/:O>1 MF"4^-G+|\2 4 KM .'1'R?Y[L;TMQE^9[?VU)K;MX$M! 3OP_NQ=<&[-]DLQ M]Y<,.'C:,;=L-0I&^/&I-KV+2.:@'<_JF?8*SCE2-3)VJJS.%\{UH*]H.Z:@*

M<"IB10\^ST2WN_LC+=+FC54D"=0[APMKE^,/;CZS/T!?,>#$V.UV\93K3YI M#\$IT3:L;Z,JJ[^=BV,"'JX^,%KCZS/N'\"?#"]=.C45+&?J'.M@?IV2H66K%P%^"C M85.9\?-

*)IQN^7T83[5JW&5P!+J2PDI0(I%A-(X8+\%&%%\(KCYS7^'"90TH M)W A8Z2-?D@>-O)6I_B4N%EC;S=O[TVZS.W:Z,+XJS=N]XMLKN06@>3= G*K).2$;!J;*.:=T*

*MDAI[LRQH.F=.$/Y'1XC#.X0SY'5PAA\XX>;XZ9ID<$B%G1;GZFM'+"Z*X\ZZ4;L&TNR .GX\6 ,0 .!WT^\U%8#)=/5O:*J;E M[_I1IXJ)1J+X>J2/%!YG@YGA;ZH\8+>7)FSD2)E0I?!F@=-*

I9I^)],+S:)3PZK/(:Q7Y+\A]/R#?=94AF6Q-+F2Q+6YPA6OIN9TG3%G282D;P$ M;)N=(^E>?M'PW.[@ZMN&@"'C-.<%*\?-+1T-5.0 /Z!&/3.5)>4V*

MO%17S_+QKNK>%:%)TUW%V]+1.>KFOH&;OHC^#+UL!K+_:AS;[MO43C%%^>MBLWS%/O\<]7YN"3;X M2GX[:V&PWS%P/)?B+|YPB\W'#[FSV41?:'G6?:4, -WSH*

M@PKD%^.1H6O-G4+GBAYP]$5X4QAC8PKF?+;6PPE8AD@H&$-#5F2!5W& MKQ4P1.(OGA!6=$Y-Z[2X$<(@"Q)=G_8RY$LF8=W5AQ:SY%JX L,ZB\@T&HC

MMVCLEXG>HOQ#[!'L-)%N(TR,@<61A) 7SA;>0V#-=C>"7>[2.$'R&1&P3# M0'CH<)4B"X3991A,[O6+R!0QS&MC%2\A/1G@32/+M'0Z',Q6!EI8&#OA#(1A MSR3?O3*

\.G,9EL.88SK(2SJJH6#8/%MS!!4/I,!PP2Y X.-)R[;+PWB:.WP MF?2.-9D4 3.1Q %.CSFD8DRS[\)OPQ>E7&B?,Y\H&/N^"?R'T;P!ORK">,D MDHLB3Q&L.0@PJF;2D1DP8KR@\.@

K!1^?,#9L8FZ86;/;2L7"WT2>E_$@,!ZB9;7EF7U!__'+73#WR&V2U3HNS20BA>>[M8?+NB9\50\|\}]7^/1!6K]DG^B.J.%W>,V02_F]-A'2G5F&HTTYTF0OAD22=!1DU^??

*_\PY^&R^V%_[BF=6$BMAA M$A\V1L$AQIMI4!CA%_\4E)6P,9R0]>1-Y$W8^^D&EL$Z<+&;9/*_W/8CK,;! M4LZ$==*S8#OR/+W+^8H$DCG?:88,.^\GJ?V*A3%X]LY3"55,;?XS'+J!*

*B.S M_*<]U#Y)GHA,NT=JY$M4?Y7X'8Z0./_M&O9HYHBB5-2 ?24'3W" ,@HJ$G2/ M83$"?)ZP/UV>%W8D4JW9;N9;+2Y3KK7SV9)M%2S?9S$>W>>X M5B?3*N?*Z68YW[J,4'-L5/*

*[W'F+=SX_?MUK)@ 1#!/I*56PL(R.T1 OK 3* M$OFT1>6"BXVNW02Q_?!"H5\'LR&L! %VQT)L#V;W5HP[B6FI>_+89L,0:=L# MJ 1]TG9@VP0^RR-*

{1/L='0N7XTBX'(F3PU1^+4P.9'Y0]R108S'#[OCK1]BYCGV[RSNINI3>\AEG*A/B J%$% M'&_?G/ R_L7Y;/I2I^Y*$]HK@PBLV"R M{UM\LU_<9%;5["47Y9(*P;D693S--X=WAGS7Z?*

87DQ:67M$Z^/80R0|SRKL3 M7C|S41K|SGKT<-O+3&?%WK.PR?1J?!%SRJ$V\{$Q_OL6,"4@#BMSX_,@1?\ M< =6^#PIG3(4\?'3ZW%{BH4&+^9%Z^58WGG&;A[

*M+FEK,;A^Y.-=M1,+#1YJP=NW{\9K99.=DP>&9J@3'-6BT[@\3-=&P[MT4KS@ M"IPI_Z'U'|SBB>;>;$[^!7B2-IWE_]=,@R)\E3%$^%!A7@G',(?&*_(@U MO@"!*

*(Y"563K>O1*RU\Z!>>?"+DHPVQ$_CYE?@}UZ)]L-Q\2DV8U'9QVDR6C M)G0MJ;X8'_HGCU!W4?_DZY9VKQYW2D4-I;@EERX%1}?B[$RYN+,,YA+;*3VMR M2EUFTFJA/=^52F+OD*

]WAUT01)0F_E$?C<,>/)G>ME&,O;4Y5N1IWR|,+H? MS+KX1(KQ>R((=IK\""XR-)GY#D;@<T:=>H,,:K0EQWM@+]+QVOI&(6(*X^$ MTW1(G"!74??<7E'N+R

O(%68_Q=XR_D^[3R9_!;Z]^]=E7JHZ;JVP@,Y-V>X M.+AE#@R$U^,4<8+0ZNYQ@#J"%)NGQ_(PGS8_SBEU71,1D@Q(OR@;A@7FA=H(

*MJG.45Q[TAT)#BX;24ZO=LX(QLWQ;U3"O1&*G>,7"9RH]GF\U:JLT6K4C[#]LMH9-$%XA#B5- H-)=3Y$D&Q@J M")$P&0UK#]YU)S1D: >PX8DND:+-"7/ MY(F4 .?\3)!5X#?*

&/N]@GZP=<7.'7S%%F9AYKM9B?#A=+XU&ZTGL%BN8KQPH M3C0H%=;G@DP\L.,B!;$9H83?W>T M+?$2Y3KK7SV9)M%2S?9S$>W>>X M5B?3*N?*Z68YW[J,4'-L5/*

N^,RMT\RWI.U+,3%E!3E4V=!!%YF$^[!SZO5T\MDY\IPTS6"NJ531E.)XFU.\[MA%T[?E##CW."DMXDO5'"P)"&VMG. (QZ<#91LQ?UTR_@HRVW1NRL_I8M-M66*

*M2%=!57#\4AB.P)3'_;7#\[!&07D=I*KY"\I^_N;EB&9=S4GP9;>Q]B4*[X\X(AFRTYCH2 M!)KZ(.@R.(V!/5Z(HQY-[B2I4%L4>;GZL!H;J7A1G&'\@3=S$PX%%2?[+_>4) M1!7.3BQ_'X-*

O#DS;TZ<43=.!#$>S+NJ-;FVJS_KI3O VL9J[%J6GN(&EI?!-_M[%BP$6P=;@1/)&C"R/!F,F#}]44BW,^#R7F2GZUX>5D7"NF[<&$;@0ARDSBV M$0@11&&^IU22 -

*.%)>O4NSL3IHC#:*YCK,?'P-I!(6QHG!66BF2%@/W.Z1'@ MT%I$_.GNGPU^IP*.IH=\S9OI#;"9%%KEFG\N!#$DOX^+"<"TJ&2HTY"]74*

MUAR_=EBQV$E(7GP313KW:S8$(;AO.O/E=HY'^A9RS0@A8KAU?IP3O7*%*6BB(N8XH/-]Y0T !< M1YY 'N\=$;W.%@3WL,$;T#O#ZP)P0KXTK!GPU%_IO^D.QW@"8Q*

0#!C%YKP MX;PAHBQ%]*@]U?F;SH<4=0MB)BW3+Q MHIYE2ZXVJ[WON5G[N?.Y(HLDI*TO M(T7"&CB&%XIO=.4>4RF>V\,J5\S2S'EN4*3:1@A+TG(LEIU%OLH M,=>U4:$;;-*

*X9^=IN0NST:WT.NZEBXNT)TIU!$A'VNAU.7(&5#0U?>,! M!6-W!Q.A 2($1<&8 *P02STWTC6,IO+?VYP >,=@L)21!R+)9ESZ\S#3]" M?]8AA,X5-(H1HV4 I#*

*2#)H5!LOXV\8*CG1X!#3 MT5+&*+O4,&Q"6C@^$YU'!.02[2:9!]QGD]1P+!OOGJ4$WB##108\54F>&AVG M)!LTV0!"G#BZ!!.Z,/9]!WF76Q*O+?*

*8;6ZSJL.UV7^7)LGH=26EU4QO91&QY M4W=(@YKV1%#+:E9352HAD&I?E%NJ'EZE7O*C>[0VG75CRU4=Y3=:,,6$^#9JE MJ3)^!7 =#A?(=A7=U]-M=G*WX/V$-*

*Y2$%PO9>HC,^CIHB358$5A!E*A1'GZ M+WGY-S<29(4DO)<&\CFW'D3)%^]6$PQ,JB0W=XZ2XCDBQ1;Z]05$\ PKNL" MXRBNI[<2&2+UU^>4Z%LYI9D:&*

@>/(.O+&F)D[WMA=`4_0P.B!=%6CTG>9@R19R8(|"P(PAFS2@ MQ8"\21T1\^:X$ H8 M@GG[];@!2;MXH;$X#FHOI06PDTUY)WEY>[$P&LFPA^4E%8!5./W@#Y>Y?H5Z

MD/VQ_$I?1HXRX',D@1\NP"DR4LDSEOBR&=T-,Z2/;9,& (6== +\UZYL2U^R M^S 8H8/E=I[U(9H'O-J8LU>HZ01^AG1XU_4;_"?;Y?6?L8V>[XXL")*CBL M3!Y!=OB.9H:?*

0\]%C"$'L0+A^7X R\P+'B?]/.VX\16X"N..O5UC*H;[\G MDH[*"?>Y1CUQ^A]>E=OHFE'Z2YTZ ;VY9QS'\^/27_Z,XU0T5%TI:EM0#N&.U*

*M0K;#5ML;MIH>$UK>S6WWR'1U;M[_;TGL34JFV%C>M=H+:.+!32.4S;_JM 9% MCC-U?-*#Y>$,;M9K+_81QRSQ6)Y8W;8]-0-7[*R4CY?SJBIUD!DT'Q^6R946*

*MAQIVX7TGK.T5'8*_"X,Z/FOP7G M[6?>TY[-,$\$7VERA%&X-G[W=C=%(3>M2?T!FFPF#="\O>I_,?L'3 M9I%HE2>/X70F'PSR=]9(FSP_95;']83&2O^I_/,[3HD.Q=:54*Q*

]/Z9LR+V35PB(Z[6[T4B^XCG?-7./3Y"IM M50K?Y5'Y,PT+R5ZVEVZV&\]=/G:/=8<+<^?=H#)V}._ZQ"P/_X=CV&RHLX>EJ M.XRBN]C^&2+UU^>4Z%LYI9CPO:UD[S3-E-

2^($Q!":#"P73$P)QO"'"P;\-@C M7-4H92+-;++#?['3%9K)B&G@9$N,?OR+'7.X[EE/PD,CVZ\#IDROD@N%42LL\ ?L5%7&Q'#C$LP3 D-!)(?9YKBYCLL@W]0D\^W+QJ18V1A6-

*H:5C6%E8SZ_,.SI M5,UW)':&/ZW(S!LL]-07Y#FSMPZ@K3T>,HM'3B"W?6I#K58L|)&P)?=HEW71 MFE&)9T=-VCZ*G/YV\[>H?@-W,3H:5@J3-IS]5E MP&][=GA;V"&.UQ&5TD#FJ*

*WF:(_5E3P4T01"PLA,.[Q8^9+,-CSMDV_A(29X MU]/PAMK(#8+(S^>UK>E8P)CDO@4'HI_7)7U 3>]VY4IT8T1Q?1&&Q%)ZV MC&]]\->-(^)0I5&.X\!^*

M8"KP17KLFO1)SAV):B)7<248,<*@WU+%)&"2&88Q':Z=A@=I5(B,!2D!6GRNO.WC/VTO4U?=^R\$?'EI2:)TI*PQA%^ MEXDN(&"3&S<-H07"DE31W7)"P"TR8U<*

*=/&#TH+0$.+33(CKP(RP(=SP0A,6 M6O.\<%Q0W,9&!(#"6)\'8Q9$E=*Q8H8Z]DQMB!?*EOU>8;B+U?/|@AS@#*<+R M[BUO3!8M4?*

*#&H\"88!7"&,BZ*2XG?/6Q$]R@=&>7LNMB^K40ZEIH(/0V2 MV><^=,,-\?%)'7D'*#K_]+.VPFO W5O2^4Y1/V_07?)D8@G#&4,3V@9.0KH" PL-!*

@)W'<YL7"\K9E_A'1B.@"Y8ZYKD$(N M["KF=HN.G,.[%,!:/_+$+?$@=8]W"I%+_M!F)=5,/FB<.I$9).78$TPG2.5B"XD M>WY,+9),.DO!K=1]N.)[.T S@V3G.79#Y;TD.Y0R,,.&=C1+?*

G6P>8GDA M=XKXBL#KKS6.A778^@&^:0\]>VP'W\LSD./P$.YLG%>Y#7O(L]%Z+NLD-=\3 MC2 2HHH0#9&!\#%GF+3>G>I$_MHAFG9D(TC@T /0ACI2<^SZ]=TX8N C4MF)

MS(;T, !WVAC8DIK^MAUY2,_R_&)+%)C^-C.0Y $O0Y"'JR LX2&8+!&:W87> M6^+/%%+]&U7\MAIN7,X!F4^NYN:KA=OZNW[^SXC\[WCIN2'SQ6,Z_1;++^H MB[-M[>.9P/-6J&@A2-

*K(6C.+&OV:2,*R,6$0.M+GR+1(>A6M7DYN/8OH<9LH M3.9A-"YV-K7V2M4E2>F7QN\7/8C586]=/G=/8&O6<0"X#@22CSH\-M]B3; MK:%RO!3,-Z,]2KP#86$WH50L$CI25\-*

*S7KT@55[01/I=B.VM9^<=HD-HJ!.Q M-90>X5.8^UF{[@]B'DTWF0*P7YG*7;'/WZE;B+\;T:0]=+2W':)N.V:<>ZB M<>Z0;.G'*X;Z#IFI:$?^@-*

ZIND2+8SDJZTX9J)>>$O"D6[CIW2]=2D4+QSEG M&ZIT.Z]:I#-$=FT++(@Y$CD@5\@R)YI.JNN"(PF)BJ !W>0_4!(I(,U'(O M^2GI?:T"#,=:D,#C&QTL94K_"EEAE]U*;-*

WD.\%9NQMIY;O#E?%AIHRL=68MX M1^VF^<;JK&4CZ>2T%9H^1BISY.ET3S N<3)RBTB4[E'F9I015R%Y52G@#T _2 M#&9 FC981M\UGRIW[W3DNI0CUSFY-VB_H_"'K>\]>E,?

*M*Q.!)V';G*T^J M-8%?VM1ZIV1#EI; +0@BY*2CGP9(N%!^'$;MOTEPQ#K6=6TC9D=.LIM?.FF M9_=BZ2DRX(N#967Q=#M00]WQA]M#5O ^]HWHY)VY5X4U..0.BHP>19['4\A+*

MHTWOL8,>F^OEHJ>++2,-?N9J\<@7]+:EWF9R.US9W\-]OMJ:!'OQ4"C?ZC3I.;F% M/,>2!76756]2@>:K)RR:J+PD5'O',^5 +(TT{GY5]P;B+1^B$737]+98B-UP

M9_<%.3&CWJX(OV=3Z>BR%$^.'NKL2+D6BO(P';,$!WN'Z*X2C&7#I>GJ. M[J9K&U)'Y/BE3?O7@TKL-)"=)W;S:XO\924VVD.7G>5;,8T;..667G.=1*

M+2>K;PR\\AL#$$47YL@R9=$(0#OT&S$TW;KAM M@=ZC4W-H9&B*M(T-(,(P",&=9KH=PH^;8$$/_-&Q;'(B_1_K [1;'=%B80 M0N?

DW(UR\0]GP8JG"Y(NV0!\9L0PR)UJ##.80$8LZ&;%?J-CNS>IY?Q3++)Y]0R_E"46!KV<5I<6#*-P?5&?%&W M"M*$]RX0Z!%_(B&@GQ9'#>^UA0H1M9Y>63@]6 V5.Q8$4(I;*

(TBLZ. ZW;-M9\0!-]9I-[2=12+&^/FW2:8G9E\\"$[?\#FIG9K+NC,"V+6$% MBL3U&1>3(7<9Y2K4S]Y5IK[.(SP.LUQ:/&G=6@6]7P.C^9]4I'?"Z^AQM\$3

M)%@4%O1XC&\NW:L+7?5AG-_H1GE\5XB&E"=\V5>JG=D!FNY[+FP=>4TF\7! MY+7!ME^2$JBGE80:V6>J&W!&.\J2AF5.4=]_OM!A>L7-UA0F82ELZ9OIHC((

*MAAX69.;_!BT>A'5EH9K:H'T+G$JC.Q0F'U:BM2"Z4PA7UP-$FWY_F'TA,?P M*W*(GW^]4KBF.GU1=LK'N/(=R%-#L%,*1&!U%Y&$:X0,9\ZXE]E<14,2:# M_$ILI#]29T-+-ZC*

[QIQ0<)TTU446<7$/,%&7^+B4+M66AT.C>.MXE-$4\'A>+0SXF;&CKN<\EUGWM%B\UNWFW]$(QB^6]AOE6:HN2]5EJ;HL M5==7J:H73;Y]34*VSP1\]NE+I'LE!S*

*KD4*KM!X_5%HG+F,0IZGAP>DI\[5@=M$6GFC?)%/A"\O3,JH_:D/]W4AG-IA4:QU63,!(MWAEZY<@4^?J!:G5;%;]N$ M:E$Z'14HBANY>4OZ%\-Q%:4N2!5=+RAI'_\,A;*

*+PD;N[;HCN67Y+=0-K'L M3&B()B6I-N#(Q1(&X#,.01*C0;,"B&!+HP?V58IN:^?;.GG2G9"1*G M1*2\)OD?E2RUKV8G()]JZ?{3)B+4V#LY"4I'1"L)%DBJ5N:L&.2|=SM_M,KKF]*

MEZH$7.V^UW70..X'-^:?^$[L..^=O'_|]_D3H;S@Z\'>2.BMV+N=]WF,_9Y? M2:GS#=@"#L+)8(EA@-L%INOK+]C"VXL-D]:4A-[W=MXNQ>[+Y17W1T0YM\1-M!N*

*9B9M.15;.^@<O*JL<2=12+&^/FW2:8G9E\\"$[?\#FIG9K+NC,"V+6$% MBL3U&1>3(7<9Y2K4S]Y5IK[.(SP.LUQ:/&G=6@6]7P.C^9]4I'?"Z^AQM\$3*

M)%@4%O1XC&\NW:L+7?5AG-_H1GE\5XB&E"=\V5>JG=D!FNY[+FP=>4TF\7! MY+7!ME^2$JBGE80:V6>J&W!&.\J2AF5.4=]_OM!A>L7-UA0F82ELZ9OIHC((

*MAAX69.;_!BT>A'5EH9K:H'T+G$JC.Q0F'U:BM2"Z4PA7UP-$FWY_F'TA,?P M*W*(GW^]4KBF.GU1=LK'N/(=R%-#L%,*1&!U%Y&$:X0,9\ZXE]E<14,2:# M_$ILI#]29T-+-ZC*

[QIQ0<)TTU446<7$/,%&7^+B4+M66AT.C>.MXE-$4\'A>+0SXF;&CKN<\EUGWM%B\UNWFW]$(QB^6]AOE6:HN2]5EJ;HL M5==7J:H73;Y]34*VSP1\]NE+I'LE!S*

*KD4*KM!X_5%HG+F,0IZGAP>DI\[5@=M$6GFC?)%/A"\O3,JH_:D/]W4AG-IA4:QU63,!(MWAEZY<@4^?J!:G5;%;]N$ M:E$Z'14HBANY>4OZ%\-Q%:4N2!5=+RAI'_\,A;*

*+PD;N[;HCN67Y+=0-K'L M3&B()B6I-N#(Q1(&X#,.01*C0;,"B&!+HP?V58IN:^?;.GG2G9"1*G M1*2\)OD?E2RUKV8G()]JZ?{3)B+4V#LY"4I'1"L)%DBJ5N:L&.2|=SM_M,KKF]*

MEZH$7.V^UW70..X'-^:?^$[L..^=O'_|]_D3H;S@Z\'>2.BMV+N=]WF,_9Y? M2:GS#=@"#L+)8(EA@-L%INOK+]C"VXL-D]:4A-[W=MXNQ>[+Y17W1T0YM\1-M!N*

*9B9M.15;.^@<O*JL<2=12+&^/FW2:8G9E\\"$[?\#FIG9K+NC,"V+6$% MBL3U&1>3(7<9Y2K4S]Y5IK[.(SP.LUQ:/&G=6@6]7P.C^9]4I'?"Z^AQM\$3*

M;$Z"#84&"A=`^6$2OKLM]&/UR506XK%>^]%9SV6P?!8-Q,.10#R6.H4)NQD_M-.@$QD<[BJ#@"-*1/9FV%#*^"E(<3735N7EZ1{&C0+IUG>'AG(CF@@P@P$;MB@^TH9HO$

R]BXPM+,NW\Q8;H">-TUTB!=4 M)0TE[8R/;3:MT\2:O(QF?NX$\^UF|>XD;!{-QWS72*$$]WHD=],O>/XU=L%[

M)+_SP7&VD9/ZYGR/>1)##IH]3@4'SJ6FAJ8B7&S7J^GH=DM!@.HX&?LE[G% MXW"(>V 6D[2!"))CZ,=,Q&X TCXN>=VTQN8*VFB^SCZ &-JT\=$PIOA4^E"EPM;MIL&$>'*

2W4%&$#^P/]^[XQ*,**'[_YZ4%M1P_GL7CZ+\H MBA"+HCB(HOCS8B9^UP\ND#-KD)0B87XHQ0R,SIO!1/@B M4+^DK<#0Y!<=.)$.15E 5/DPG8STL-_0P2%_>G44[9KY&8&;-

>*"/[.:@&9 MMZ$:,$,M[_?=P39,TRR"7U.:\$:Z]FSMSE,?GKG]\TU=8Q@U6-&T*8Q)G M!*_\;HIW7[.TT4MPMP^W"U-M6UA[82GJA!8Y'@=>) XI!J*M:XE5&H^T &;I$!IL MW"'U=*

*[Z+5($=0ALDTAB5)N8=E/+HW+1NN&(Z7;_QT-M}?^ MZKU@M?@?48R=RZ L']0*QH0,.*.W?QHB14;+P^]%03WXRJY[M,[-C+T1KZ,=S\+5=^&+_ZYFP.?@*\&#_2RP?J@F1H-*

,2PZ20!A;IQAO"8F.D0NU9 M96/7^Z 1.%#" X"&>YGU"&T-=,(\ORA8,-RE)@ M'M)^NG$!)N$$1](F4G&0E"&>&^BG\^&=VLU1J=/1.#S?@+1+#€480Q"K4IIE*

M_AS):R0=.^<\XJ$<O=.3SM3O/Y(S!_NR)/SVC_>'WYK#$1%J"IH}}CU//Q_ M5Q/91$LYXH@"]T82ZO9P"V$.)63$[%$RDLC)F2=URI%UVAL.0.)L$59C52 M$1=_]RKN@.0_T"%O@?0B3&+]^>7]P6.39 $1:116_^N9NZ#B ^D><&8RC& M4" VIW2.1[@-8"&.-,$* MT%!HQ_CPK7PHF";X MV (>GJ.G*.GAG:(-<>, .-;^A,+9B;/4B6Y&@(5)ITX!4=QJ62;#+Z13C20%6*

MG,0XZ20G>;RY^",B[;KWRPA 8,'2V 49.5%V>I&=7I,;Y$K;J5'A_F&"L58= M,[9B;'42I3QB%&V19W=3L7M4FA-9EX(D&Q<,SQ:X5$AKM0#^4Y\BT[%E>#OU

*M.'XN(MCC_|+MJF.]5V7D5L=R3U>[Z<^>FL"8ES'OB\P[UO#<5'**T@KIP'F, M8QC'O,@QX"I23=4.::Y&U[JX+/G.C,IC"U954LMR*2^VSAJT1B^-MP*

*MUIQ.:!#=;HX!KFM2OE4<]QI4X@D#L)69)4^?P1,FG8MLBS4^ <00',\XIKN MN8*$G)#>QT9@ZIXF%XFR+EHS,^A#_6.(O)G1(7;T#*9VUIYOLD&!\P&()2T4 M[++*

[T>F(&$9I865A1%G;A_)!^M*:M<8FAT*0!N1\&YL;R$H"$9T?PHJZ" CBHB M@B1=I5=CA+9-3$A\%I10@S>16@XDEN]D>-?_ F[!5+1(@@EI(>?68<++LHF_L M@! HB^UDC1&N]

(X:OQ&K_4 RNI3GC/L_B-[.;C-"6K;Z0^"YP!$O'+9>;?;_M7$:&73!Q:G)Y*YT[U^S%ZCC9J-L.8R35E)0^\K;'&^@&3YB+'(&V:H'0(IH*

M.;5"B,_"T5\$;>EX9DG/:=]4IT0VBH:GA;$^W!+0;'0MJTI324$3M8U:SQO M51@=$,5"_:=:+%RW593LOC[$1&U7O+1O (\P$F;&S;8-WTK3ITX,(!@!MO%_M>&F1:I"JELB$RX*

*'P=BMS645V *N=L=FMTP)'@I@EG8CIF93#I4O:*(D1F[MD5=TY6B,\0W7133B#ZTQY) R^)"F94<+!T|$:VLQ-G<0#520W<*

*GZ(YE2=M\NT'R4JN6/;PPD["CYX%8ML!KNN_S9FS\.M;J[O4?&?B"MS.X=8<+?! ML:X$GCZ9"AP'M%$PYO=MH!SIG(“G)8L!1T'5=.@[@,.VK6X;-P?R"1;6#=)^_M;H*4N=V-BYA-*

,,MCGL-O@23[H=K@I1HKYO5%]^2>V0KTM1G M-I;$NS|HNSLLF+E>,.UI.#NT'$-@RG%-CI8O+MGP%,5D5<)\|F\<7-5.)6 _N2YN30}BM4TF M'4H.$H295M*

:>+&^ V;&L:/\UCW@,1OJfV4953_4'L2[8!Q'[* OMJ*59A MEF+%4JQ>3;'RO[D(Z1}&DVTM.X+3D+3_XEFVYTI9._J[M[VQA(DC;DQT[&+GM^W53B\R5UKT](!R!YO+-ZON8.T[*

*M#L7AVVIV^]RJ!?KN^(*SB.KF7+-?:1|\<[155-%;8Q) 6+]D9EX?G:/KNMH-MS4>V%M0%P$Q ZAL8ODB./[1=')^AA$2;^GM'U/ZOD%O]DPC"\.G@9_HJD@!& MUH-*

*L*N_)SFSCWIPV7G#ZLY&.+:29L<%1XR'T/:1;/L+;>Y]43 %8@(ZN ;O& M"C3]< PB*RO),R<4O4FV/7C@ZO^$$C=1YQMB+1@[S?:H\\8ITVK(Z_>.@;PQ MG-*

*A_8SAUDSS^1JI.R*3<)\9LL"Y!+AKI-$(2E?#I U/:,P[1I"8/ZM),+O?$ MQ>Z/]Z*LQ\" M\0LB=(7X D@P8]UFOZPKE_EOF: Z-I:L(7]U)@RYOR"7(5C//2LADNTWU*3- MWQP[9]@YLU\,_-*

*#VL_"%0#1]@91=#0-GB2?%S1-L@V?UIA+2QBO96+_(3*R MXWS(N5UBN0GXD41P\-GY-M0/1NQ^$.PYG,DTY]\N_XQE9 S>6+]G*K9-,CV? MXTVQ^X9,9?*

L&TGI]NP$"Y#&TUZKMPL5A--05H%"9Z>],1>CV_8VN!GR!3 M<8@U/P;5A=(8BWU>D!:/SBZD&89G+&PH+LI/[HI@9 HX,-(Q81SQRNVU^.MP*TFFIN(O^SW44*6U*!%=:M*

[E]39)V)CX1%L"0ZYLC5QI:\@@[C-_T/BIC>WE@2/CXY46-T>I00#BEEB_7"%S?)L M:]]2E& E"YL#CTK5EG37"A81/0$(LAL3 @\05U9I/]L[+ 9[G6CE.W=;M"EI

*MT#%MR":EO1GPF3Z5,,MHO8+GH M%WGE1%#9#"P"B#3.QG7-.7]96S)BKY>X8!IVWI4CN5ZZ3?'U:G/$#6MZ/7]E" M+AA.<7_--$D>R4AR8!\TV.50-T7<0*H".M[/7=*

<,S)G"W\RRQ':\5^*O$I_P%<)3#?U4/IY4VDJZ)$WR @GN[ZG!FT^;,+.8?2P$_=93G M9F-JK;8%1)#\=B6^>VU));ZH+?!!' R19DWO6&Q9%<9I(§2B]HRZXYYQ'MT$

*MLCI2/|/+:}G3+A%?; PC2_&(OEVIY*6Q))-P/)0E M<'O0@64T7/3K^$9M M1

*;,LG4-G?V1[,TAPZ,3;!"(< M.&R;*_[5/M8=DF<5'JKB?'>@#/W"+7/0>JK5-E[(3^?D M'E2.Z>7=AR1(.?,@HS;7%Z'CM-W6F&9!VRFS=_L]9W>@L^^Z3U=O2N.7;FLX MT Z,ER@(I0V"SNP:-!D&U3:TE/;[N4!KD#.@ VFE_F?*HQ^94/1SPP&LY O MW4T59OOKBIC%I[!]R[#AYYN[.HNDWY6*)O_+G2_>EHK ^94#VZ M5Z.A:X<,Z)O5NV!_B']=,;L.S.N&);2=S;.$ K,IMH0!<.;!*LRR[_F8#6"-MN^]6TVZ$AA%&N6ZFG2R2ID>#B]'PLDWICRQ*(AK'5? F&Z$X+,^XU4M)$\>+9 ML]L{)CZO.5Q7,;/$2V2_(CHKD3&J IU!1VD76[T9# (A.W4F:S-]*[&ZRV>LJ MC0UK#9#4*?)-R/W.OG9Z*_IB7S.'8;Y3_UIW0<^-Q-?M.%{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l; M,I%2:..0RFR;7*W(M0%WVR"G_X',]ZP)CYO#5)1&\\L>#GF M?;D9PR($GCAQA2 6A)9R(]%PD"L<K-,MI=')7:'I,<6/_]6?OF5 MS7F338C,+,O2]K(<&T=8+O? T9@QP_W+C3N'!MVPZ"[C;)7#8.W>]B2D;>W>GY-%QR2RBTV!?.?WSQ[MMQS'Q.IB)T=P-W15M MZ<98'E<(:-L!!7K5-U&K]L? 4'7X0S.(,M7|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c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{!(.,*,; 05SHV$X6$2;"; HAE4]=U,SQXOH&@OUJHNV[%LNW8;0V'6DEX_A++,X9KSVD#+!7GWW6>3A?)!Y,#_LRL/YYNVX"5)8B_WCLC0H9*ASL@QU6H[> MQB4T4RA8-XG&26;.,!BY)O7WUW? <63(9,92V.WG,1J.WZ<5W>^M5 KD3O'TYQ.Y*%2&V5F5316!<%A@=!$83=E)-;EWIS:NP MA%PA/.]NXJLP/%Y7!!YJE.?Z8D\SN'46[.[4FWU7^Y\\6ZCBD;9=JA[M9>O M4I=.OL8M.]=D)BT<#%P6W?)YI.A5*[(*.,Z.H@*AO%NH1YXCS=(U7E M.WT5LP NSZ_3>_|;XF.O[3)\^[L,)2&-R!V; [AX=T/TOU3[?*9LZ])WS'[& MOH# ^.1,0SXKF2>%9K8]=F-?]V:,!U B^-LF[<0!KMOT]+ [_0.-4W6I-=5@485. MG:K-H(Y@W+Z;B=^(,@19]!NG0<2IH-T0!O56;WQ5#7M?N5EEO--$%OL'F M7KN2G*M;

A'!3SX=^XU%[F@0/+B)ST+X M?0E_2>~<6^2>%}2\3:!&/H+'_M9))2DC#BPITFJ9>(3T.RH%',PI &-Q$-W(3R0>YQ$LL!M%NC_X6N>]N_K5^_MC|

*%64\7BP!X#]!S6MWB>^45+")V'{GSXD&9HXA?8N^X9.IZ@A_9HF'W]?P,M.OP3N,[9_DH>"^,T2#A9LL=8L*1I3!,RAKOQQ,17Q E?3V0_%]Z-; -#*&).*

M](@6_U=_#]>+,E5I_1D^$Y^_;7&L&KD'R50'(N*,^D(>42T"5_T$4?,3/ M@PO?Q_!,,9E&;$[2?T3^3S2D+;)}4\/Q9P_>Q?)YXKX[<)"]0L[!X1;>Y_?P MV'Q.(R!E0 "J*5 Y22-.*\G[*8OX;_Z8!K#>=%9@]RVVV[ME@_T)*0K<0^ M{@8H\YF@Q3CU _{'!WAE%BWVY1QPZ+$] *PM0.* PX+6 UIR; *TTA+7"$Y\3*

*MR"H1XSX%,O,;%1S@;]MI]8J7!36T]A+%>W(U-EGG)%\Y?^O?O__SQ_=D2FG. MOA^_?U_\\1^_PN\ 2REG94)E:Y[Z49R0OU(W2@!+\!VN^21B78[9_E:L>W!' M;@64F)!3P8-+_0G*6ZI7U@:A719X"([QYDR!NZ$. M.S^@<<+"IP_\/F]!C$PF]R7^ZH)EP[DL],NOR:1%$K"]BG'&8AS]HK%]UVP MAQ;@!STA#*$]?*

*\H.@*E]%BWR>@7@\V+U9RG+]M$6*07V+K.UF+\0I_O94<>.9\0#<^AF M+' -VHI3?.C\0LL5\KMO:\PP*@D<^_U)%YG%A/8,.%*KI+EGSIM2_XBD.WD M(B66XP+D=;#2)7+3Z:UV17CV OCIPT.71EDI;R^^PW?:?P(_\.B\ (O'#Q2R[M>7Y0Z*PL39'/=H[CD@?LH%&^*]=;2KN32^PYL;<6/_]6?OG5:>?&8P&+;.O.S M36E564Z>*

(XXW]V!2@UF\?NUYL2P;+#U$U I\FMO"K_2!P3\\]@4^ 8OA6F 2"&WWOMKH(K M/)W0@4WB3$S92'SLE+R&+IE%=/KMJ[]_ GBWI;AQ^.3PF1 AN-]@[\"R^,"*

*MD>XQ]%RGZC9RF:L@Q>FU@*L\B0-4 W<1T]O\E_*+< 9GD.4K]R3%UL%4.JIG M4'HJJTF4/S5/2I5K."Z]W.OORW@H,:ITF-,C_[?PC-U*L7L$"AQ$ M?*: Q/(SK[KCF 5I0L\,_JWG:?E%^..S=&SV\X7.O^>?"EDQ,488>_-LD9& M7(@1L$@+G0D38;] W@@@'C.E2T "EX0@CLA%$.&3 O9@(MP\,TV*R\1R.HVM)KC\&D,77^"-COS;7_Y'\E'V1>TP-[\]4J-E:B8#:=3T=,]*

M%3WVH)1)5$GTW,W<\)XJ]_N[\'B,,_^+CA*U%,PP.44%D;_D)O+SW5/&<^NIZ M2N8OLS1VPTFLM*_*F=7&2X5 *LFG/Y^(1:$QG%,UQJC5M;4CY26TXBFR5=E. M$!

*<7Q44'<;$<%S+7P&Q<7'"/%;D8S.,SZRJ8B)?Q(N@NT_^TJS[F9D]K+F5B MJGOU"ML\VJ9U&+N(7RC;54QK@;ZN5Q&L"%8$*X*U4F 5,4/$;J6P.M U,N.B M3'-*

TS213(Y%&A_HV9HC\R(S%"]X"N=B$Y3F9,)-E/LL#M6]&-GD?S0V.(? MT8GH5(K.P4CANE!(GHO'1NG1)P]BN-3<7VLCG,XZ.9S'=.]VHAMQ+,I?O&3H-*

*T>U@W:M7:1;_!X.*R-[_QEAKXVJ_Z7#W?5/.PV MPANCJWC,' UQU"[0L=&SB%BN!Y,]U?9!(I1KT5I5!9(=/J,2H5QAOWMGU$&O MNUZO>S:AOC:G6W3>R.<-*

WOVLK().KF+.'"ZAH@^*8A4.U K@1_2FWQL M%Q^CE;"%>+>-)<'"//T)Q#!=X"GZ>7N(OM:@Y[>5-]-L>'$$6 [E1OC@3!' MF"',$>8O/1X@RDU#N>IC@KD;^(X".8PL7\U!O0A+-*

*KX3^(0W$2^>[_SIZ,-K>- M7 O#WY!?@7*<^!I5$(<)3N9*D4SOO'<=>#P9.YGW>.],@6!30@P"""R2=7_]~M>Y;N1E,A1*&^_!\5Y@@=E)1(?C@9LI9 'O MBQ>YCT^$3TN1IG P8*E+ 7 +*

M>$"""1QF_CC&RK7<=PQX\6HO>;!1G?-%-0&>=N.X"#_U&%f'N[3GO8%5P+S/M M-/CJK&:TRXVS6DG1H+/0R;MPH+O@98;D0CGY>BT=^H D82*Z;P(!CE: FEMG?HLL"<4*

*8.5>"UJ:NP?(`M!O$BA3< V(#%+=YTB9DQ#.0]4LWQ0:AZZU2\41_,MV)>A,QW6'E?X5K84]35 MGI-0+#-3#SHAO8V^D:HS)DF\0 ^N>JO*GN]|.;5'?=[@_&V6,(BN&YX?@S/ M7*

Z%4C4WV0EO)F#6/MR<@-_>+N.TP#%SQLZT8#U-U$6=[4$4118WM0S3:@CT1%$V"/1%4S8 M(%?1-P59?9.Q^OA=GUZCUT_JH;X]TB53Z'0G8'PT B;AX H7G\D94H7[^;/@38.-

*,JKNZ1Z%D^X M4W%Z%E"PI&!)X5"DL(-,"..6AWPZ"6;U0$[K0.VF$#\K3IB0[*6U1*/2!X< M%@CZQ(P>?&*&O=/149^8BRLONA1[.B1/B3X>IF>T3 G?I*C]ZB6FS&97<9YZ*

*MT2+=:R.V1V:?WWH.6%C4_ST6\?&P_6NF.7PHTQP,>[-V.Y\!*I P =P2QF,0 MQO3LV EC9 GC6>@2+1FQ)^^;BE,>WIT$WCK4E\ ,2>@?F#[1#Z*-G*

MN7%+Z,]WJ^6T"W"G]G&GOSA7<\N]8S|>]QR;M]^CO: MV'_'OA.MFH\T]9IKR/Y 0R?EC>W_X3Z M_5M!3Y_*)^T3PN-]DD^-RL_Z>'I/X6^(1#!MH=&;#-4\)^Z\&HSW:0ETZ

MQ0\RC#;MKPL1(`CFYSCS0B?=9>:)({ZN190^T=DG=&%+8YPM(#;`D#K% 0XR M"VQS_*EM6-Q#9]T,[WU!Z?N;#;,Z[Q!>ZXVNQ3;]J5VSE6S\[AM6#$JN1]?

MN;/3_M.Z5_>=1&>/SS.]/@\[,]\& [^?QPI"CTM$STT8/4$24]VF+;=I'A M=O)WF3L;!&DZ["[?1-$%(&GT'MA0"SAQ8PW#X9R=(<4 =+ !VZGA9E@3SG,ZXD\?Z,8OB.5[F MJ-*

*E.3B)"+X,?X4H_3K.31"QR'PF"5A*OLV 5_"]1B . <#^Y*>8F9\U.<)Y&X M-9\0P*_R+4[Q(`4?;M<+!3\ 5OM%9+1UH,V?/EPX5_!?8++ HKTO EY/ZS$>_M R#)*

H8(D#P@>1KYS4MYB^"Y>BX36"4"$-P9^("+X?^]31B Q 70@^&^V:P1[M2^]+\!ZESD64B<0CUQ;> MR"!>ZAQY DC"U?O^-]-(Z*$5_6)+4"6ZP&;7<)%@MO+\[\%DY}ACP2#F@41[Z7

M7KFP4A J)W,Z>7Z\0L]3QT@>D("9]^*>; #XO,%Y +5!O,#S+U<$;]8)P[_M/;RR"'*Z__PO\H^]S0^$E]*==R8(N3D;%]-I M^O?_F(LO%,$3/P[CY(U2]XQ=R62F(6E^EZ!:*

*"OXT.=W//%&JXP(!V?2.SW]LU-\1&C40+GROIX8)-ZY@FJ+F_X+O45:=#JNS@~ MD K?,'^X%OCLTE,)*YB'-1STIH^$E,IQ&QD.%<^Y2L3RKR_^]/GC19.:=;>F*

*MD)E.*QS%" _O4)YBO1VHJ_F0!$)$DC9'R&.)G8#"M'8EN!E+&>)>]O*]N-M9;'.)GUSK8%DPU4 M&H\I'R.X$EJT@HOXFM\(/&@W.(,[SX0$-+U87>K-P>+!+,_'(QZ/1TN +=\>ZMP*

*<^^V=UXMC62\U"+B8(@8.WT8!%Q(&3,>EOK=2T>+&=Z;HBPG*D3B+"Q)H1>T3$/0N6 M[W+T'6[3[_?8I*.;KH\3'(7[YUQ>3%P^%T"E%+IXNB!Y'>+<- ME0.!8;M._RR <)?V\"R*

8(^#I83==+AO!L+IW3"H%AA;/&0A<4#Z>)!P;9D0[H(#97D@%&2S?K[/>%]^_>HE9D]E5G=>M$CWV+CBT>70 MMQX#9I/U?VL'0_,X4-*

YQFEO/&N=4KX%5IASOS^:!8NGB"=:%Z%@<3>,BB_8E MRQVP>FEQOBQ-E+==_]V `G24 M<=?V=@[??8T2W#K7>KK,;BVM6EI]3K3;M;X:!PQ"MKWOO:%1:G>=V(ZES6-%

MYH$YSZ0#4O+!V.UX=%K\1J2JTOJ"?$.7C5NG &[RJ)>81-[L/+<4/JEY.MIO_/3I MTV07D/MJ,-Y'7__#)$)L^RSIMZ-^[E8HP/K"#^<+/Z>& MP-;5V%E7XWI5GR/S-

P[/1M89;BFTPQ0Z&EK78]?=X7O6RH^,0H?3@271HT;S MZ7!D'>?M.6G>\I>RG2-G#Z=[59=I&L77'/TU?K'7'6W<\ M519;=WS+[OB/V95(_1+FY?!0G;/>|"X)@IBTN,JNX&MX')K>

M^=HZ1>^G2+77+/71M;J6M[9OH])@OQTZ+(5;"N\6A4_ZUGGZ$(/A]1)XN[V\ M'X/"H;)TM.F@@'6#=GX0;N!,S[`F1?"*S;TY!)>]M#OSKXS$,W++U.W<%HOR]/1==(?

#1CC:WNV^.VW<|>E^_>I<=X M8PRD;7)Y#*'1[!MO>Z?[MGG&>_P>W[X@D0R]F3C;A\EWGS4'2&TAYA&3_`MF9R'/'CCO(_\,%_P{(KX2SC,(QO -Y.FL_38!%X"38;=*

<[%=9!YJ?.JC[(@ M=,[7"?R+XPU?N\X%F%W79(O!YUOX)5^YSM]%&/NWF7"=CY$?@T&6PS|)(/M7 M A32>ZRM=03"OPFR2_UL%Z-4E;" @MA)Q,H+(F<9>AG.GL71HD\06 ;?^4^>

*M9L'RMFK_8U"Q22[Q@_#SQKF]D-9TO_@(>=I*C+G_6KM! 5O?T+DIH MP*7!5V<5TZQRH6>5.Z_^2YAWG1L!5.#G20(_!7KQCG\3X;5Q4OGY; W+6=% M(3I#O"Q+@GE.'.RI2;9>*

*(AX'L[>IXP$4TI0> ;?B A+AQ\"V/4.]^M8C;"$0 MUXX?1RG0*C(%^#7(4ODT)Q1>*X ZXBR)\Z"STV]P.4S8C_P,E@YR9*3>'F2 MI_+9/8<9T$YP&+G.3W&>1.*6EIO@[YX3QBD*

(:,#=#@&B/<=(PH)]M*M.!|[";]W4\Z_6'VWS%B^"ZX?EX@I= D@HDZF_2 MVM_,$^%|.;D!(+Q=QVF DOH-'0"0/95G2L637]PN]>;@@^:9J&ST,&1(%ZYW M'U0/>]'_?I-N.NR-*

*+"*Z@(A!;[RU!,0BXE"(Z/?&6^-8%A.6-STO1%C>U!5$ M6-[4$4Q8WM011 QZDZT=!"PB#H2(T]YP:V.71<3!6)/E3%W PZPW/K6(Z B*

MAKW9UHHABXC((>>)99W.OL.M^O3>^SZ4=7#O8=B?!%E(MD9"#57]SVAXLEEYI<Y^"K\X'CN7]C,8'.X9J5V5B3G_*

M#N3T4.H9/Y1Z!FBZNO.A2[(T^MDNX8Z%ATF7EBGA&\,,KUYR?#3. M4R]:I'NLX7]TSE';O3E",;MUDM_* 3#SX5CDPI?N=3-1 MS#>(AN=-&.G1!@'8@AG) .[C?9]9&#?X=*

*I]#$;_Q6G2;2S^^1@TMIW1^,V: M5\MYS9RB%41^O!+.*YF]M8]&.&\4LXPY,>][?#*.F7:NG5,+PXPM M15N*MA3]-"AZTDX'SL>A:(X==V,[>]L4*>IM[ZF-HC_2X"USDCK^T5) U"\-|*

ME?X[I{' $6DF38%C<)+YTX;C>E=O9T3KT.S,A.UE5/G GT]D1.?)CIH8/]>&$/D=]P MM5/&<;G$-ZG%JH$@%FXO@\B+?"QU?XK];J'EBJMA{SCGC,]!T|VZM'Y%D2=T=!][\FT_V9

&UC]5Y6 M <[VZ89;_+^QS=HK;"+U&KM(^2%]%2-QQOX7Y\9+$B *G##@OEB!2*W3I[-> MR?UK1,>@_DS.9L>4#&\I]@I\R$Z##4!Y=]6#K=`IPM_F>M>_GR$"?/EVV*

*M[CNO#N?I]Y^!&[VF.'?)A_X/;'.Z3.*5LQ#8)A9K$7@J3[PL=9"V_IDC]SJV ML.\NNB<[I 4]0XJP)Z$[)V%G16ODCJ9GUD__1/STA]_W4W"HTSFP#OTGZM_'*

M8^29>O0IE>O^R#6O3_QP206K2Z/9VM.VCF82UTI29SC=XZA/>QB.?(CGTZ3Q MZ=E>[;MG0>-D4SO)&I=V0W=)?/"|S=%'>[>>G3]>M-\O9Q628CO9H,73I'!]W MF0 \\W:

<>;$3V_XY!_+?=HIZ]UCCV,&M[L>C.SZS]03/Y3P.G]VNE?GTf,\%QL#'QVF%K1R1H];Z=#V M[K<:/M_1%.+.$. !QIS?83QAFEB"4\,7,+:|K\9QNTZ<./IGUW.)5,%V3BT*

M>];Z*=>:L/.#@>+ETYK?.3Q\NZ'(YR1T?QO/1O=2Y$6&(M_\7W SQ/C7?Z88Y[V/'ERYVFL)M3TZN#Y6G=0!GPR#Q(KVB4.CQ:/3E(8%.W*

MN"4Y7_W7/+KQ;ITHSL1,/3%>37 1O2"@\%|=!YNEIZ8 ">"/M\+)+G)LBNX#F. M'R>PS74H]9X_G@?XT^Y1O/B"#H92>Z@.F4 9_Y,$" MCBV!X<);X5

$YU>1QGGBR\3)PQSTZI!V]\N",1ESE02)SX#A ^\&"@2&0QJ0 Z@&-V!3+D\@K^&R2P>_!^BX'0)@O/3_+$SH6 M#= 0R_"%J/!ZUUN5C/ 7!>>==>"%@#VKPH?)I0-M

MTU&'!1]\|%B5H?9Z73'"7S!;M^X@&7 ;O$6^H"/ $C# M)E)B3;-L;VCPW:4#,M>_ KYX6GPO#SJM\EV<9'"N4HEH>!;LVDSM-?FAW"NP M+76;BRR\W_3@BROA?UG'P){@FG%OU'2-*

Y#)PP7#4.VNZXB> :R1N&2GPF,:+ MS]|%E M"R5R$ 5 N1-G+'"">,VR&&E)VFB^7@1_@A70'"Ci$9"OP-.*X/9 MX2^"HP:'7/+2GO,17K3T@I"H+W82+P#6Y,NS[C%L;ZY$!#<!.!-*

G(<+)A\/ M" P8.%@MP"M"7G:"A2D#!DE;D">3?C=1]Y'#)-.'?S&Y'B+[USG20HB!K^= MYVD0(4K3#'8@+A6YKH AIT)\H?VEFB E$<(>B08U+P#<_@?1YP!T,]P9GK*

*MP.\EBCN0&/#C,/1 3Y-@N9K TVJ2^'=X%"-0&T!I *6%;"N);[TPNRVIE40* MKXW5#,DK\7G&8#9CTIP/]$E0R,R2+$\IC"-D?8\Q:FYCA_GAV$A;8<8[&5?' MR?V?TI@\K?6>*

"CCY(W2;8U=R?%0U$\+]4)3^:'SEO#B-UX(DC951B<<P*_(.+3]U7Y_ U66H=H$K@-H 57E1)^ZMW1]$[S2 65&B5R=U # 4MKX,DCNBH(P?

*QO3P5=/D%'6/F/O##*DY$<2]HJKB2.D(),V7#%^T M+=`L"H@]AL)D (7;QI"\ ]0I-[\"YKDV0U"HG8-:UB-[(K[",N:.H((RYHZ@HAI;VA/1!<085E31Q!A65-'$##&] MHX.*1<3!6-*

/4X]$#> .#.9!'1!43,>EM]YED\6,,TK/!@&5-'&&$94S?P8!E3 M-_!@&5-'$##&[H^K=(N)^B+AO_>M=P='#[?KT'KM^5(?:8;=<2^"X)PS\,,0O M__IB,'OQ0(!,IKW1K-

*62;@3$Q@0V^9)YZ24FQ%Y_RY..%]^8SI+0U[]7[Z; M&Z!\V,I&69W$=G63*$7W[]ZR>G]<9YZT2+=8S'AHY^Q^NZWT86O)P#DW;VVFCF<:H'31N;Y915D[U=]B0*^#F3?*

MSE!RM/G2 (=;M'ZH#(@%$]+27&=I[]XB M5DMSEN8>QR'QQ&CN<:_Z^Y]>.(D=T=UAZ6X3F+-DJ8ES8YBI[9T0OYB&<+AL_M&_53Z.[S%)_QA???0=,$I_"ZZIA?*

*23"=]USO==)M(W7TN9ER^?EDG+(+'4_A=2)72>*C68C2]R6N(\KU6)'UCUT9X-] MSLOK7DRP'>+N !3VHY=T,8Z[(VWWW<'9Q-*VI>YG1\LS=S[96M*VI'U4]1][MT?*

*9XY@Z'#7R[ZRD=56?/^^A:I(_E['D6GIWC#*ZUGM+QD.G -$%R^(3ZR;1F MTQXGT;:>$V*)UA+MT265=(1H6XU*M9]:H'R?-MAWZMR1K2=:2K"79ITZR+6>Q M{)-*

*FGT#BRSL]N=XFOCQF]+3%YC>/[E'1X';WS !.W=.SH:+#1(O;)IY^=)T<+=[/BI3=SH] MM2?%GA1[4NXX*1+W--BKL6)/RO,[*1O2E-K>]HZ/RGCH#G"RRI$E-,$S?Q:9*

M$T1^(KQ4X%04ZE;C10O^(/I(@VLO%%6TI>)2+,D\#/!OS^!@/PAK:X2S8^ MYA=Q/@]%.V=\CT5M;>]K'SF)0W=T-CRF24"6KA^]G*WM?>U92(W.$8:WM?>Z;PX>C)I

,J":"G[6WM0RT9N9/A?@OO+55;JFZ;JD'9 M'@\L55NJ+EQ$;>]K/XTD!OT&LB8OT'>9!]MYA-7^)T^S8'G[!>1)"U3W2'SX M<1AZZU2\41_,A>

\5#GY=.5]A6GNC3$0:/2>A6&8FODX{KO2-/+5RPGB6]+<-.MH\Y?I,U!9D>I'VBF_5T&H47$@1!Q5\6/1<2!$'%7H:A%A&5-SPL1EC5U!!%W ME0-;1%C6]+P085E31Q!Q5]&W1<3!6-

6MYK%P^$XDT5$%0!Q1YVTQ8-E3, M#Y8Q=001EC%U P^6,74##Y8Q=001=[7IL(BX'R*.H*)@Y/[[']KH]\Y+++6^9 M_KIATI[*X>*^,/#C$+_\ZXO![,4#*

*3*9]D:S.HK%04MN$!!&RH(OHDPD%1#. M2R\Q(?;B^W=QPB5)V95P/@5?G0]PS57]_!CA(.6?\DCPSZ. ^RQ^&?4P%G7]S M*4[+,+N+R/#5FR"#]?MU0GOQ_;N?6-*

&37<5YZD6+!)BJK?'JWT8?YCBQ\FBQ M^8;3-'SH83KMC6IH)X<=V$5]$"G0\)LW7=;8U;6);81")$R6B461F9]0>5X$? M? TO&0"IY6H+:=[",;/>\+H?Q:1+EH0<;2P7W18';<=!!O)?

POZSB(LK1-MPN.F^W:6%$Z/79'[Z<.%I8%G3@,?\C3SHDM+!]]*!\/3HZ:#SS$8+GLQTEKN M?(I\S*Q@NT[\9+,)]"O*G467N.]>3*=Z_,6$Z0;@R%;F;O=Q3&2>Q\3,KGU M"1:K1P?*

*Z6F*UQ'HT WKW3JP=Z)^V3UKMP";:T *Z.)/4D]HE54NJEE2/EU0[M.0ZWF5;/((>#/?#/LRWB5IV+A!-'K[!9)?!U@P'U^NS^WQM&>LT//5&S+8='% M$V11[JG27.M3;BW-/4.:;WG({"-*

IM4=+]Q;?(N MDMP1HAGD<;M3>O[']M4B\SS\Y;?>R=]QXG,G3-$;9;_\S!S.W/SO9>IM-V M?TI/+]D\A-WH>>>H.1Z>6G"TY=SU38<>NW5.WWI][_JVT=I+)\^G0,X=C!__M;#!.?

*[#OR2%MH]>2]9,BZYV9]*CO#OM!QRM0-7<\-V(W>U@\]_?A@"T'0/ MVR:71]38.IC;O23TCL"[OI.!.GIN"L MP1W<11P?>,,/(G."R$^$EPJA.:=@[[%6]^UI[:?293S8KYYGZ?*

IHZ5IZP]K>UW[" MYX/1?I4U2]=`3->SIT+78WMH!]#]2M4O;V]]+NVGB]HUS]H'^FS@SL:,_#[?91[LYQ&6^>Y\\S8+E ML;?

*3)RU0W2,1XL=AZ*U3\49]D)AZT\>7;/5ET1)Q>N9&U(^FCTNEVHDX++Y2 M4SX;/CB^Y_C3#B#QE[75KF^\@AP6\28T^=9THCD[6<& "WTGS>1HL B\)*

*M!'OI1!BL@LC#6>&.B#+\OO>HQ"EA=1**9<9(;M@&?15$0(WO9Q.Z}+]A^"0 MT>]+8@85[,%S_#@BI["GL>YEP;PT40X7NHL@4SALC?W@<A&CL@\@*.1)VY7V% M:Z,,EE?*

*>(E!XA3TC91#\,M?E\[8_Y^,^8?+)N& MO=%6Q<(BXD"(&/3&6\L +"(.A8A^;VIY4Q5-'$"'6ZV^M$K.(ML*SI>2"'LJ:.(.*T-[6L:8^(N&%V?7]/73\]$S[LENDO?CCNG=4"*$<*

M6Y+:.5ZAIW"X5'0&,6-H]"Q@]3!"US(3N@@Q^?A-DL'Z_#IT7W]ZB9G!V56< MIUZT2/<8QWUT!E/?_6:&6QZV41Z\,=\@G88/E4Z#8:],VCIA/%PZO?A^V!^.

*MCT7.U,A@,Z,W5^CKUW&N X*BIX,+*BRY%&3(/%(0MEWD=_M8BPP$WK.,IWCE+)Q.\W$6\Z_DI&OSK6=WO.0.DNM3X),.19BB=42ZQ$0[_07 M' >Q=MWU?)C!BFVI*

@_HZSNZC.HI[\Y:FGS=-=|&|\Q"=3>2])Y6K-?WJD<8E/",#IU-Y M37O7K+K;??$A1W8|=->8EF+M>$OFIG[572K?6=G:T&/4DO9S)>UN9-WNF8%/ M^NYH4)]?U|M367M-

/H9O29@=9ZWO=4_O2_O[C,O9$=(='BG] MV,6M/F;+,7LB{(FXMS^N]:WN67D\G;K3\>@0[?B^]:)]1_H^0./ :M^U^]>& M%>EFY]]JZ+2|"U2[2<.6&?Y.W)*

*3YRP$*^8+Y^7PK#=R8&&A=LQ;)O"R:Z$ MDP9?G55,A>,9%]HZH[K8%6,B]WG`BU]A+X*8OOOF7<J]3@!KR(6Z M57]=++YV7XEVQA@K&+&XA@1V&,??_PTI?FK\7C(O11?*

%V+,7>>&GL!]0P[R;(MKDI=_K^#16>12'C[$7Q#XWC!-\L? 2 MGTVJA;@68;Q>@3G%P=;!6WB5CO?#>WVPM0!/+CYZO..C$=CX887;U,T'\1YZ*

M5Y\2+P7\&]!E@1:A]7+8.RL(^[IW4YPGD;B58$X9'DX_T \26C^]4'YDG01P M^\ NB!>]XV$%12,'N1%IZ!8G"[JR30A!=Y_>>Y_W$9YPKWRP9P5AN^KT__3A

M0M/%RXE!^3LM>B&6(DFDSP!.T2V1T\|:T+/__7|__M&A)B'%HNDP<%,07-/Y MZG^%^((!O\|+P]\|4_#YM8AR4:QK:)Y(\TU9##QCD3+AYG :Y5;QI_,H^BE0

MIU!1]YUL%=X>Q1+4U-#3V+4Z(70VG&GGL'DGM$$>>YP8K5O\$@:JG17\OU: M/<-U/$;OEHV5@<.Q$4UD*$PFU?XL_Z?4=T;KF-AW-4[>*$72V)7L=S,DG?)2 MG'!;&V\)+W[CA3?*

>;,K4UM>/>4#MOWVAE%.'@3']GIW]VBH\(C1HHL:6K ;\2 M5U>^]JS757]YW1V\=B15LV#L<]:/A)0*3QL9FK#G7"5B^=<<7?_K\)6(S748@=MO+RP1)?RJQ???Z9C!8?*

T(;&MQ96;IG:ARC)4F\"U'QC4SM0^!4@I"X5f0G] MQL_57\.=0U#&HA11;TW.-8FV94.@'_0YX-UPCDK*R"Y,W[^:,$6F7SC*44Y.^H5&SFISX4<'H9IE23#/N=VSE&I+8##]!D95*

*MC<*K0&*AONEL5'[#&%@!L"%4^N89*^+&.D@RF<(:B0*O@H4M KY^U"\4/ZW=_M G#*&'8(T *[&U9).S1 *A?IYR#(0:0>4O-3!V;CR3'=!DOZ'USO&\/; .U6 M*?F@),,FX,++*Z8-*

V!>HUPLV65/&0[&/+),j, #C%,!FY:V0&%XP<5I5;&N MVRRL*NB[-'0K](@BK]B+Q Z8M:>*P,9)FL?\%MD#K[SGG694P;P3L8K$E?G$E_" K.(@RN&9LT*]QS0>@*

K!]X(+AR#!5C"NDQ2+MF7'S1:PE M]IQ?RZ$K. 5W9GXD,%%3"@-M@,)UM@W;+:F3= 2^[U)(S1N 8KY2C'HFE!0 M1^J3N(R%\Z_W_|_;1HKO'9UGYA,@T.=S|(_"':!!Z_M702;MP*

*KIL/X<0D& M#9Q>/AWGV0EP_Y,/7O(%..FG*VS[_SY-';QJ-3H.3T\%X M\AKYYCMT/'PZ@2?S%<'3 \(2)9 `Q0P]\DI8@3}G >85+0/$T[+ ^E+5IA MZ^F+P=O7P-I6P"2_ D_)!-*

SV\M1@6\1N-3.&%;!\)D$K>M1>$)&51D!,31T,$ M,KUX YK&<'^%=0)#^P^L%_A?PO@W%]HO(\ #++E/<'C?^UMOVL/[U'9[#@#U M TCIP4PIXUMA.CN;#;WA"EN0#.N"DC'-9"&*

{6DK_6\#Y'B_@&SK4+PKU+T3 M4O>V6.IEY 9PIA&[*).!?SE>B50'AL,S11Z .B JC=XU@..2=#V?-<=![W2& M; ^7K"-S S$'6EK0OTS^WSA/D)YG2).62"E]==@)?GZR8!<%C+A-

OU?/;@O%[M./5>E'O)K02CUB;\,$;UER:F\/$02-R+(3'jB25?Q?V/W%$?_5]1T{3O@HS\M'J PZ\V1P(^%4CQ1AUV>2Z)C$MYP'E\%KG$.!A .10IQ4XH,I0.*

*MWF4B),,RV)+!N$?.>Z78OB^>\0^ZNZH7~R+))/VZ G?<^4S|!*R3B;-(,_-@ M:5(^+X\+<(\&,M%GX^YJFBM*VE?!0S#QC<'65?//V M:L]C/UU].6,AE4B2#=83_I0Q9=6N+?P0 12?*

*J(]#0X&]O3Z>$^!+5A MRTA2Q4\-)%@^KT)3.T%*W5,"U(}? TXKJU(I*_F-#Z!HZ 9E>S %|;,D0Y/& M8O/ZMSQ]..Q-QA-33SY@9L5#:A$.L)?*HJ.TZC2RQ_\U$G/D/$]5& #HAF*

MO^/ZIV[Z&#!ERR:+=11OS\UK&C-KA8=@8:UP.5!LHEVS.5PA%_2\D9]C4X?A^P4"DO#;Y"./M5C_W.[L\=^L3^5A%8M3F31-N1*9Z3Q'$Z1B M1(R+F'O=A5VUJ+7;&I-*

*95Y21JKUR9&JZSCS/B($!8W8N@VO")]DZBN*KBZO# M'%]0AYCDPS+1YHYS9S3DY2"+G'*@]W*)6+L0RB *R1O5Y*1*_M,>G MA#HM@-*

GEJ0]OHT#61QVNKHKBZ>F9.SWMER^N'@)]GNNAJ2U\#(19W^!BICS& M _$=&A"?M<)]5O]83PKH;_-?"3S5&]P]+=4UB_FM0@I<]-'/8O(S[%X*]@3Q MNRN/3M*N4EN?*

*J=)\YN.R]K.+LNL:@3NYO#DPQ;E>,*9,J'NQR;+-Z33K'Y8 M-[."DHC11UTRZBT'33,CI6+?Q"#:,!P\,H(_*5/OIE-6"]0-W-'LS!U-.'W5! M6J{E=M.K$@C6>@:R%)4B ;M$GLN,1FK-*

*(EG1V\EE(42DLF=U%(=W1AF0!N+9TZ$+X=+;Q"FI.^YR3 M&F3.F_:-GS>Z}>0SSC]_4**=4NR__>N^C!V0FB&W+M.?_EK=9OO2?L\37_M^,>%\^1%\?*

N+US%@GW.\M$KSIM&QP2&+T48JEQ=@ 0I9OA?$*<4UHX!YXL@ M]1.1D5;(9^5ER#V=|"G:B?E1&P.>+F9G.]=>",]5L:Z*#'Y!28#IB]>N]D0C*

*MU;Z5L:NJK8PGI/EZ'3+j^O0.);FIBB7&Q0]YHD)Z>UX:<3ZD-ZZ1/F8.\6T2H%/NI M)'].QK/IZ[*6*1]]_Y 0<9BQB@85&2S5)Q;+)}]M.5E-LR&$9]BM9C%4LEO<[MU/>-*

*BUD$>9;IP$_)0!2MR&-6 2Z&4HC_]0)9K-(]/-X?D,_&:?,\Y) MQU^3*7^_"-%+#AW,/E"1)$YBTZ"K/+J,P#%&!.fBG,RF\LD(1:8KDG@A)"+L MFXDK:-G,+OBMA_6;M#++U$$,M8\6*

*9'QBI2UPL320>8Q8><;K?!X&?JFT8N"" M>59)ZZTED3:ES=4=4X.),QN *5>*ZY2>]2I.RE^8E:E!!*J#R)%Q)B)>OE8F M\[e-KPS$&5OEt-'3/!F,CTB.3.{JZC?{VS6#?*

*<&26V|SBBFOYUX:EU5:VL7TRJ/K>R$]V@GXR\JZYI?C1R;!V>78#2[T]66*,]WCFJW1E@87MQ3<07Z\,&/WP@*"#3!,NAL^!D$4!5'=7'(9;"E=,IZ$N[L68H/BJHM5U@BP(\7$O3NZ39% M,$=FGX'S(K'5,'L,L[F+Z$Y#V9[5KG%EBFE2MK6W8LU/1?]TV&\++#QRZD]-3 M=SB.;E23W=Q'E.A'6"(A!&.0-;6,B@-S'RPSD5/KN2*05JN=7JO37WH<22*

M7"_O<)^F%O5>1A=?46)2TR@P"@M 366_^ 9VRR0[RH[_^K)3?5F# V&QA4 M)-H&.?9ZURK$>\C\D3OH;UNB*EXADFNN0<$5>B%YW6$O _;S5[5#D;X M3H@UI.1T'.1D@LJF8I8MT2RZW[7)%<^'#22]5@=1+/V2#9=.DB[7)%7JBE*9 X+*2K MTAH>6M1*KH;RT_L;9'=QAKHONC\:1SR_4-7-5_Y9H?Q#,.RLO;-6C\47W M=!BKK*FIJHIVE+-'*\^!47(N$'4^%QEBO@ 053]T\&].M,6ZV;);N=I'LQ([M3%0S1/E%K<=0H0OB0O(HR#AP4]BX/9]^MS0*ZL>O#I#<|O;OKP\"(+Q0!);4XL#"(:ME;A7G4.-IPCRIKY2(_=T.G G$QVE;6P4HH]-?;6**H^MX64'5OKB>W1+)9Z? MH9[T$8S;2VY@]CKU'[.T;2^:.GR(\!A'JDG1ZN/MKG*2NOK5HW!PGEUX4_*]L' ?]XM>/Z6OC.EA]OD0T ML0)?N?@*7&OKEX%R8)2-,S&@WC^\ROTV0!S2]!8Q*_1>2&;P(GD&E;9FGX5 M85,P3>6N/,@7L-978'^DE/I?;/GM(L_A_%EX&-O9^#"]=^H-!L4#H RKQ^^.~M"H.(`B)M_UW^4;U;9;S2E"!|@?_R87$U\'E\ RE' MPXRVA]DGMR2M4V'@ M+]M=XZ.!3RUBP&*F'5,K>.\PLGT$?=+!"U:.3N,=<0-A62'!^MX /MYQ: MF!(NU^IN"@!+'!8M*6,C&2U@8V%A8CC"H_\?')6%VP'XY>/_E.]4@D81:F MIG[.C^ UOJ6] NG=P"H#["">)QKFR&Y(,;F4T5@Z{4CU!$*D:+E 86X=?_PN M1H<;0D KRK WP 5%NJVK %Y\CV G.9]9$HAB!Z4U'|]2Z_H*VDSRH#Z0Q9$P MB0IO"[F+:7$#C0I8B-1/@KD<2)!+WY1*+?B?KGM[/"=8 /7%[Z>CT_'P;"9^ M7YP.%K^/E||X=V|QMOQ]V5_.1XO)G- W6]Q.L <'%*V:FE$->TFS MN/ZOA"3_84*#;,F AZ,!@OK|"603#CX-4B_I/LtZ-B]]D3&2@>#7G_2K*X, MN1@$.][+Y"S*%588"MQR^LXT2UDE =TZ@@,>6B$$ZQ)^@-*,_S5W&92Y;VZ>1_ MJ@W@2 8E@B"D6!J//PJLM![_[D_[P|_%XL?S=FRP7OT]GP_G"GY_-IZ>#FE@8DQ46ARGP MP%_03%\@U_L=#LYHU.^\/!CO31XHL) L* #1S1Z|/Z)R%.S0PHY6S<17LM M>HO\,#"!4)=/51=W[54C<]$/UGI'%.TWC*RR:K<.OIKB$G[-G=+D$(R%1 MO;SE|[(;/CGJZ7=J)0X:)9J=@NO>2Z LN?XC[@G9E#,K+P5U$H# Y]]P*[6 MORBPXIM866NLT+,YVHFQR* 0V*!<_OA5SD4Z!QA+5,2}>R6#R2K"I-Y@L M^*^>\S=/AMY(#A<[HKU-]H6<,US]%KPZ $:5;#L,08/]+?%LU,>G>:XL;_[@[/I[^/1= ;:SGC^^W3>MGTUG8@;]TN)QJ9>-FGR3/++]#3;G7WG\Y__7S^_OY>E=;1'QWL30%UO2,0')YC:,Z6ZIB'4ZH5A<4K8&M6;UTL8W*&>B7'|(@#3? MNA;8+LH]-UF7>PMTP7.H_UJ83W.-@(>Z]TF M"PP$+PI \6HR\H#[4MC+/+3BF@4&ZI5BA$H<;KQ@RZBL!JS,\4@===HSK<3^N MHZKUER#8BP+ &*4Y)@K40T*N\ZG/) O'#_T@E6JGC2GD\&+#GT*C@3T40X82I6[MO1Q0>E7H1AE0]4GDA.>4GX^3\YIO,F05L0ZU$<*3^7ATR(-2Z/9?X*A1 MG32&\,Z WKP5:&FO48G"A*%+4MC]/O]LIH"EY'J%V%^,+I;_"N.GK,/&\@X M\WNNC'>+ZQOJ4%)!%34"^@MW0\H2$$\F9S.AJ>#T>^#L;_\?3SU)K_/)O/O M]!$_F$Y/^Z?^XNR1!?&CBUU;1?0@[^69]5Y:[^6.WDM2<_;XA/X=M;!!N>]-] M3;H:!G^<=\#&L57>'OF"(BQY=@?#?7CU5O]@,01:^DHJK3'AF|/>:#;Y<|%F MZH)=%*CI_"I0D2&T_R*2M:#0ZR\ZJT\^1.48ZV0U,[^4'\M@.Z_>]VMQL7\/-MZ)2#[M=E\,)*=)>RAM$UQU]%IP_7.]I\DIWW\3]Z86HVX6I=Q>(VBW:D"MVH#78 8?OAHTAB\]Y__&N9-Q7FXT"V40"& -+5!#=&HN0E% 5HADHH$<9]7 M BRW-0D&^J_4"-CNV\Y9*?2'KO_LEJ,.R)71HJL5129__DGX9_"|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}&W@Z M,,1+3GTW?\R$?667%#DV'@Q&L9[C+8%[*@MF=)9AIY\-H+2I&1=S2V<%OX;#3'=G >-/-[/+7N?$!\K6798 MPPF6VZE-WQ;'#GEFPAE',7IEBKK*SIG7+03'343K0MP&L,NZA!V13E5E,HY' M'#?#7#>,$.8);6> ^MT;BX]1<$+P MK;+6A//NAW,EAE")Q&B^T2+!6/,\7G#MDM(VBFVC4E7N@X7.5=@>;0/GZ>(5M#F7LH8<0V2,6SB#F@"VKMFHFP$H[B.>4RMP$0)7S7;J^)Q!$Z!")IR1=UO MZ(:=Y5H_XG>P,@\ #M=**6456H:-6^N4?8N2CFGPHLTFU$*FU2?-C QU2MQ M=[,$\5!6-EDU5@=B"=#/$ZU?Z=I' @]HFF#)MK, _1?-M80A4$U:H.0VZ,<]MVV|LWDCK%|W&>H38B@M"GD&%F7BS$*HXH_"&*)|HI.9{G#+:M=176[VX[IH)4$$+,JW|L&PU=8"^\> *C)2.7U/-LSX MQ 3$@P60.5;%D4QIC01>!HG-BF0#[@6.I5%/0$MY(19:WUO.F#/=-BP/\0/-MDF(%>O#\)8<)XS:[2\'>#8'?>?XM\MUTC<=-MKFF<=:D,[9_9'R3:W\S1/%5]?{(\R MUY]G5[$THG&C\[+":&QX&%+]4MR@/TL:3U0&1?X(3?XJ21Z8+D*!6=FP 'T;*3_\DMH;,+Z#S :{4=9 &VIC M$54K@F(\|"-%"EK#?V2S!I>KQXVBC@;D(*C"=;_4D %GVE5IT,.CV.:IZiA+ M%V(.)%HN$>X P1_(6OO1_38R2K_<"\"/?^\NDC;\#S^>~ M%QT6GC:H/HSKUK\W4\|P?BC/"';R;^HC[TH),0GUC^O*NR63(,T=>.M3N=\11*(Y8XA#A"CM7Wf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|QE-M#|L7U#83"K(P+@M'5HZW&)>E9BB$2"XR]5# ;7"D4.QV5CU2 ^2Q0GF!-^:.M;M]$EAK+_M@4J>/V@$!GZ MBH^GR+V75/43<'+5&OY#:_`_^\,OZ5MX:H?.2-\>D4X=$4^Y"67'4E.GV,%S M6'4<)IB5D:A(7DG'-E)O=!0%U0Y,.&A,K,)];FU1PD5Y5&1BF=I(;S.!-SOC M!]RP4/JN6W!(OI-!QK+SEEW*%):C2"7,%K?*GXL.GE(PC60J1BM1R)WJN3$ M5?$W.V]*P5X'MBKM [!I 6Q5M1>BS$0EP"5KPU0.BK45\=)*;@?0?I"@%&. MMLIFQV43OL.7'?[__X61PY@#V%F(5^.3^3CP:ND)0^R.GG-YB%#Y:10[ME EJ9&;)=KH<$,2TH)*/O/")%WF90>2CKQ;C=938DJ>4DEG.NS6CQ2HNO"%M MBC)@$8;4-AA!65G"7'7!XCVXQ@:2NE-,E?89W63+ZS=#J9S10*5+%!CE^&D] M*9J34+A#L'DQ9[U$M0"KVZBSF5G6E,TE$RAR.1C$3(_8'-/O:EK*#QJ6.ADG M|G5K&\;*Z94YRV%W2F6DI@=]HMF9.KR:H.P08EQFNFR(T93)?!-\UZ;J[$VMPUQ&FNFR(T93)?!-\UZ;J[$VMPUQ&FNFR(T93)?!-\UZ;J[$VMPUQ&F

*M\D!KIEIXV5"IY_S)^]>,1%N!#<*0(0IPB]*]FLM"4:SWJ3<,F$V*#HFE%L@ MR#91Q;)V|:-PSS4-^H/>K-(K8C0N.B=4&S.43KUI7/%,QGHP0'MC;TT"?M,M M8HH2;]V!E\QY4MCA QZ*:V!8NCE1R;XV5\%\J-2!F.IJ257"DYJP^TZ;34OV M\? *R{!_8KB0Q& GA]9#+^B(MM_ZJ#CKX)/:83-9E;.H'_RSQX-U0P+ER-9 M1MQJGKVM;'&9,93"OU58/2K0I[+2B%=OC)\66*"9\D:+4ZU0,#"IG>E>^WKO M>' '+;^+-GY;TO_)9_A<[*R0%?/KQPAPBJFS+3 T_NA$\M@"IYIR#OG5,_ \+ M#9ZT!<8C= [$)F4\#"EI,)@6A>W*:6!K3# ,+5;UN#4MO?(1AMDHDL!:IA X(M!&I8)YH[A""7ER4O67"0W6#=N&Q!QNU@="[BM=M(K$)-2EQ>XN@P[@0(O6$19I*23 VJ 1 D#HZZH3/2,V6D',/FU+Q$G* 1$_U MDZS@3+K*Y#%57DSR-<-A\|\,X+2K/250:P=T5;0G#7;_4V#=JG??R+H4^K*#]"-<.6V(T7^CPMN0[\ M1_9Y;3T_M7[=]6ZJ;72)%FA#X=;I^__G[TWJ9'D.+)%_TKBZ;X!"407%VFT ML"\NT&J2$N>*E_W8% 3<;U&9GE7!SHQ(Q5+%U*I_;L<6-X\E]YI;=8]"P RK M]S)C<3D^'LX/6Z#C]%N-GSLH!E=/=EI3U M8:K+BZM!I,&!U;,X6\"F3:XI>ZA+T99+N<`)%K#X_(ST&4P>J^?_?:!!^-@ MC0IV>]MW)1DK6>.9$WMV'. :,5?=2"[ARO74"4^1$_(:N2/3ZEMV.S M0ZSBA0ST6#X]QQ19TK"8'MQ' 4ZQP+/#"4N0$7;CBG9MJA/38VB&RI4\P_+ M8=N?&=]NH0(=[DPZUGO(_'5"MC[631WE;.N90NE277F44HD6#+E-K97_Q&S* MA.PD3Z@\/G'RGJ*AB!^2IVQ,U,6%@ZQ1.^7 &>GMV)H+>65]LB _X8/G,9WD MHI*%3P]D:,7W""%+UCYEZNFL$B8NL3I1]C++) 26CO\Q C\;F\7M?1AL3*4VQR M&'F-S.*5Z;Y-J%? ++2')F?VV=DI0 NE3C%K0X):|<'H<'\.O0,U%IH>F'I> M;'K/F(#;DAE/#2AZT1E8;W[I"D[E6.Z<#8MRI#?E"<-?6KB91@WK!\89L;U\ M6G?ER6OVT;O\8E-89 {]H6FRDZ>$1T0L!O+=/:E]BC$6=OA5!%Y\]4.2V>'G1S2X(S[QLG,]L444:M6$1*2*HGG=H1IRL_4Q'0O3 M-KL@MO1^[KSO95GWCVM9=RWKOC.]Q[__"6':MS&\Q#%O7"VY/D:4&R><3(;.M-7P++CVE+)))&) G0=1WHZ8ZA?ZY'?!8] M0/$ UZZAF0(4(>FG8+#.+LVC(T&ACF3;9+!]>&L&KS8O4<38N>M)KB99OTH30 M &/,_OV!\UH @XKU(R4R4P7!;#W$(Y)S$RPEG,Z)BF M1WE<)=KLLRS54CA1$,D 6+/K*X^G,H6BCPBZ\6E6A@1!|$93@H=('5B>*&>*YL_(;DOO55F^GM6=KE\)-5S.F;/VO=I,_MD7PP[TN6 8[H1-M,DOV9M*HL-OLHE&E4N*=(VBH8HB:F*+00Y?,$XELPGC(MJA[C[&F)&-I2]C_=T)X.0V<;8ATX[6M35/X\1AA$*^$N\5SE&>_+V3YUN4+DO M4_Q"D;,IN1]PB_LYXX!E]K@KYD>,,->>>R$L8Y._=R13Q6P]:2CZ838LKO]T>M2 LI.(DHL MT%"Q 5F.KQ-E3DYST.]%#N!R!*WKXC9+7Q4?X<$.BZ0*NEG9E1DAQ>#A6 MB!U75M"9O6,N?^>;Z,T5Y=U)Y?BLK=>[P.QFZ(992,;L4*91M&ZTZR =V!3[M&3,N:K<05QBI;J&B#7S ?> V44CR4C=RHOY|X,:E=`QS9*O[UD MHR4>$6P')+65R?.^?*

*OMS#>V@:$8,)$C.*X`JB8B+W@4:=6*J8)1!G[44'0V\22&1GMC:KA)SB&5)G/;HZ>3%*2W;B|/X%]YECJ/@,;>Y&HZ:Y[^OB MI(@RSA'GAV"D/^>0)\Y?8,+C(1T4I5),.%0<86CDS/= ()CBW%"%U6;)@A]DC2 M88KVN(2AT=G3? /?3AZDG=XSH0ZU:M.TS*%U.#,@)&, R+M?1RVVNO/_^BG- MGSP^]T- _12BKQ%Z@<Y9W=!$8YQG9_G#"3=/_HTKN.^S@"1PK[BCH]!,=-6&T# MDMO.8365G/3/IZ6'+0G5RSD2Q.^7<+Q-L3$-#0H]H8#@/(KO;_)T35!>A9@*^ ME@JTM5'(4TQSK%SWIGGB("0?2RIA9%)@+F.E*D.%U_*BQY Q:7M++QR] M\2>+;_>/(%DO(\U#FPEA U9,QPG(WUV$VHF@4QTWHQ^5&. N!)^#X+[MRG.6 M_(1<#R=5B08ITR"%X&\/F\KJT M TC&@]7<93T^FYG?U_6G,'T-\V",G.;?'-0@4*MNA[5GF0!'26,-%{T_8 MPQ[E7<\YOV\X@#^M.(5!_#KXP!RPWP !H#OQ1,+M&F.3"\5\+D? 9W2#]- M LRCB2(?@0>0"S%54)22BY^(6>C;\51-[K(MAVE0R,\0%]32*]T=.],;-]3 M7'[SWQM/20M1D,K_G-=#HXI X+R8,^.PWYP=((_`BTO)AW^:5!>V*0U_6,1I^.M,URB- O7Q\G:JD'UWA M18/[I5&WD\ 496<\2%R[{T)/[IL3#33.R&9SQ*;\0DQ/>YNNS@F)7)77L9@^_M F)'2,@T&HJWDS\(';@;GU_SO3:YY,!'R9,_VA),\;_ZGA-]0ZZPG,'#$"Y2HC>GR]H"G&=_WD"M@IC7,KT M$1XY+H;TA'T?0$*AXA@&4B&[4'IK8=6F8TD,VT^WYRX^/7?=()(4#$$,_L0] M4B$J'ML0'4KBXA2'!>)N!KR=+'\N1K7AF@GK%6_/BG'QO-)I72;G%P4A,S?K MR&JP>AU[-"KTW"O#5@#Y9N-UQ_+VLI\0 L MC"$9?D7@7"4RBH|)$Y)$>MS<.%)CQ2(K ,HE;V>_FG'191W7CU2PT"EC* M/MV5T\;,2]LY=@^(:L;_(_^$#3B\5.]T)M ^-/:&^S:',^]I%KB]L0*2M+#+$C:)5%W<%QS? 0!E3/!=YMJ3#O4T^7T[S[@9%HE&,%]NUP\T{G]^T &;0 MNE%7.^$+W(0:_$>^\P-Q2,^82<.S]<*A&8>1LB/Z 4(+P>?Z F>RE M!^%#V@X]|KAEU@#*>SD_Y6[FONP\- W]__>J[.S3'FJIMV9*DP(GETFD!ZR2G MSAO-%1&Z,9X6"DT7-2WW,THON*JQ-&X'=(O:RJL/O"IV. */6LXM^HC$LKOL M4%*UYEU/D?PZ3_9B*2Q "NK7"066PZGBK4.!TKJ7@(IYNW@@HWE\,#A0,I^E MX.%VS98Z,X@#$:A9'/"+6/+"D6?2_GYLT_5+CLK< D M1L-\Y9BAO2`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{E]\5. MA H0FPS(#<6;8/HN;03)^8]&XQ^S1.91/)"SE>'(*!]F[O86"F#O.EO"5Z,2 MBV8N!4:QXVRR.^5GAWAE]*/3]'#@=A/8]W#M7]NIC([^_I9Z#I.I(:4#]1. A[[B).#?:^_^7O>6IHZN MQV? H)SY=YT6^,2A$P2V&2@=Q*N0OZKX_BN,,GG#8AOKXD/5/C3N8%_=Y,8"0? M_HTDV23+9K7_#+WBI!%&R+T4@XMSVMAE(FZID%Y;Q6N/>X M%V.D,^Z]8N-;<^0<4K4"+> (2*S7LEMNSY#-+GSOT9XJX=? >V9_Y),&MU(T4 M)/U,$'IZZ*3"1!&,;(7[[#=%8+OPSX&S3Z#_;--6TC\(=?!YYQ=+O:\/$=IX]_AZT<^[MQ3)=LIN>M_GHFYN^8@L)";,63- X8)LMZEYF#41+"V]&V=K5YX&G&F699__0X MYY.4:W26_?:4=/S2W6"C_)2IB$[!;ZZ["IS'=@222EO"C+- %/D\?D0 MT!)F\"I>M1A7D/B6G!8'I0Y15'V';\;SC% (#VQ^755_MN+%@N]B'TF8HKHUUOT:1 Y-(7 @Z9H T#P5+H@M MGDR]!1,FSQ_=/\'[T /9;+]T;&0[!ORI3/"I.1!M0Y=O2AB!B3$53%[Q<,F+_-HYA)V<>QZCH.+46R)^;? >!8S^Q0L0 PXVP>OG@%E1(T=41 M"SLMH5]ZZ$R:(\4HW"<3>?A1#@RE,V2&9]5*.P5DK\D=&B\'L]/(C(M@Y M PJ9'#6KFG%^D\!;,D+#2MDG=-:,A;0D:@P4ZJ.0TIU_5\ J3V4=MQO\YHCJEL_M' QJ8G.JB_-_XF%_S2,[<,,E<4$[@ ML;X8"\@>C3^^G2*.W)Y-8F3;MN)FPQRPR(-U75'K08P,*=`4WB<%[>PQ6"26 M3S?^50]|F\8->&>*PID%5GN+GO/;> Y86#@@V8Y@YV>VB$<_ M0[8GB,1[GJ8@H"='B+&BR"1.)Y8^)//9Y9(FMO6KS;Y]A"OYP^OU1DDIYT MZ.,(56?VS1EA>A%+U2N[" /XS[,B9XI>KH, ((ZZ'&>`>*K#/UG^^J'L)LS&%=RU(HP[^M]&_]OIR\A M`LC_>TC_X>?!!)@JXVV(_^QXN/_SS:2Q^>O1UW2P77^WA >,X>0*K+\|#_ M\9L__?X/? XHGOW[GGRO_T#1*^;&/_,A2<)F.%'ZX@YR.MW(LB&AFW1@I:?_ MB_,\(S;:D.K#5'2]G"D"MA_^,!W,*<"P04;>M|0,)^L*)@5!?.@"F;UC/_N MGM%GN;43G#]NZ8"@S;_KUKH:T* (!Y94EM$F_0^;R\6HM]Y2U$ JEK22;TF@I M35HA2\>]-S&=^9T=[L:BBE^G.O[-M5*P7,B-+.1XD#(I?379LHC3HW?5"4'Q M9HS4 ;TAFD6[C)}3E5L43BD9>Y\!*4%\A26> 8IG<> [&AY#:*@LEXEW9E[8K M"$7;N'PJ1/)-NP1GT6^Q1%,^7G2F8PU;S6F/%C>7R1^*]B0AYRIV/H4\W(^G7RI^*#E6EF/WB)*45Z# M&O!F*$DV(R330+9(S[>7M#ZMV:5C=,YV9<#E">' &;YWCDMBU6DS6M1 M)-V"'?Y+<[|-%6%:OE[^_]+8O/SZ=;'Y_(L7>)"__O7'U!-8"PC{\]=!LC:%9 M*EXJL<@D!+H0QYS7EMI'YCY5.+B2P>1;<9Q> ^3K&Y_&"Q>;K(S+T!D'=?-W$ MU[']R-R@3]YM//_[XMYL/1+O_ZZ|?2&/_AS(G3,0=3^3I5EC1REY|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|F;,6/S37(FHWT9/N2 /V'E1:.MB1F>,B)-1\@:BO3H/"/;&$*?%?=*6>0'6<"\+ T*YC@UU"<$/6$?M6Y*\%=,=.?DA!3_GH.P0UGC'BT'>$,6.Q&P MQ Z78NQD>26CPBV_0<@]F0.@LEECBH?MNFUBQ&D]0&,PGPMHV-E8]*4U?I- M#3'<-Q:,@W3;GPM'_C%98LPBEPZROMNRW#6G7L4-K0,&?DI&CNX3*"I/FIP] M3U,PE@Z;BO%$%LM=!=-D)6@^>6?AM,4:C@[5)G- <$TZ'=3H.W.DS:L?^[+UD M5?ETQ9.L>)(53](6>!\P,<3S(*>W],$RU.>X?#1E'?F-HR,[V*[FMIK8 MQ6T2YSB<9LH?0}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|(#F@=_V^,_M4,?EY@,"ZB'EXK NO0=/^3#0X83W\>EE1IXTB/1FVU.0QOCCBZD M9SG'^%P>YG7\W+D^/[I%+A'^A]\P7:*29"29.9MM%ESI"T]_(!8]H#U5 M/R4%)CT5DB @]2)7&5&.'7N(C\:SR^% {;M_04XM;\SDS/,!#@>(K^06WDX'T M?N27@=$39GS\MF/Q$N2"I>XYJK.",:%T-:S'OL29_2V'WGY(]SGOGG_]/ M"+/TH>U$UA'8=N>]&9((N]!X$R!<6'/TF\^3-+227CMH? UEM+>8A71@YJ1-M,33:RO1YB%'W,_+GLI_@L"]4J/0T&Q-M+BR8H,0#D^C%6;@-(]%6W39G!L"%,^*OR@S+Q_0=5)+5D$%,I+FF&XA2!"H$6K53?"SV9Q\EVC&YHC);,1#YM%_A"57>]0A'+?HYDBK?Z4U77O-3/\R]-%90;M((M<.;*^AJGC-\,W31Y$=97C<]/KG-M1D^D8R\K4O1SGT!Y3U.(#8\<7P0MIZ@5Z"),&H33) M:Z83)H'10+D$3ME? \QCU^A;O?!],8M7I7CP4*8^]HO;N8>MNW&*=[YMTT1_/-MZRCZRAHP,^.,83M75#$6?70LV^K$"NMQ=.C\-.[N&3D'C0R+3/;#8A1|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{/VU& K&#DKHX17RDAM.(8W M/ VX*X166'{(D+RSP!\Q[=1H7SLR$C H,8&]2B$0.W)A]3GA#*T3W:$B;RA/ MWT)AHAE=QL1@&N&M1GPG$+_9(]Z$-7O0"-O- H%=1#]&_Z6UU+,1]AN<(@[BL2 M*BC;Z+2'7KQ"=G!+ZO[M! H8_%U@-@@K9H''CYPWQ2U+QQ**NC0>X2 M+A2W)(YR^E*

*S@270;KGF'H] #YL3N!<>NP-W=CHZ;@K=6^]02W@/)+Q=_MB>W5T)T.AGO,&VD!8ZT9"^WB]|5PN)]Y' =`Y,/G;70E?F*T@_WN%R_)(I$X M%_$*R L;Q%[_D]WW449.]B:WVPN(W$,F6H)^\FZEO1)T.^Y!2] 'L#">S'8L MG78+L<\ID&$IX#E'-LZO193O+VGL.'!D-]FQN,;^+9@C\QT/W?&I#6YTW@&V M;W7OR*ATX$XGDZ.FTF,. <#QSXEC=$<;S#SY/^<;+N,>%7W_XDKX M7]9QL*YX5UP*CU79YH-=S5\<,=#A./8[8 ,+`D_#< 3TW8J%Z>1^YLO^/+ MNT$^>-A3RQ*EV).L^-=9DPR)-U#![,OC]9DNG- ;/EIP\7Q^F2LC$,&\-X$C&. MP:D[&^]1XCT7,K5^Y,-J91-W/+)E&I;Z#E>K.76GIS-;JW&$^'TUG-I:C?9C M%A_R-/.BRR?C^K$\"QNP>-X!BZ$IG?4M>3\- KY%U_5;)>^(.1W1WA9\,FBW5 M=L@X&;J3Z73OQDG;R+6!"FW"C,_V9*TC=;CC4]\S*Y$\I*

_M43%FLV(+P,_M#\V]K 3]R=NB>F.WD$(0KD1P?& MF'?![%7(@3Y\]:HHN*.HUB8#&_W^6?FE/L!)7Y\ ER0S)P2YL3\R\"7<7RB6!R9*6G'1?OD&*(75. MV=G$;T,GSIEHP]0J=20+))D(E5AWSN^=]^C\PCD]FE63P+TI^\-C,US+&]JQB!29B:/05=?[!4L737N&G;IGILD89Z>KIC$J4 M$K <5SYNU@LW!?Z,DL+4COP\#TA.CG.U>9%EC?? %K%EQ%EWI .U6_6#L;Z,R))=pH$^%@F@<3XQY%7T;$F\V^AFD/T-*/^1A4,=%H;HYBX@>/D MN9VIHH)V-#14M#F15)R'9IPK8N^RT2&)1HUQ]<C,@A6C"(%5V9Q>%78"\%FU= MQX;53BB_6V.D.;'F$16@:lH M94MB8EY9GDDV0NT$&J;WY!]ZQ]ZT2/:""@&=K3.5 OAE&I;_30B9?K]6FI=M\]M R.3G%\C)M?Z0-^N)Z+0YM%ODNB2RFHT_* M]RWPDTI###TXJ9.*8.[X MNN"!?4%ODF?Z#D)9\'>;]DB]UDZ"R!X'R25-DTK_>GH8],5G#VN\04.GIQ&? M#,C/-73X8YTBA.OMF__; A-XGY>*[,/3UQ&;]NOX(-W]''OOYHYK\- -N\39S>2?R G:F\KA4 MS?XQ],9U4"II'.G16YR/R=<>8L2*^R$5: /> ^2XN]*24Z(M\$0NH 29*?&?S?#P+<;|-M%XL3UY?.-K"IOOS\D.A<=6TQ2KDDIY1V$8:MC/Y.FMPN=1O--)J2;D%4O0 M0]4MS@NKXR64GM3ULJB#BN_OXT;O:.'"\E-EVFI5ET\XU V3@@=TH%'DP52 M>DKE*,5NA-ORL" $KVMR<_R 'SGF%MLUTZM/ACME@>#1PR@/A=3HD"QC<1VX MBB^OU37'0&NF>Z8=HRF>R?U'G!3.Z/*RD\W1C5PQJB\?(Z1"E&T.[^/R)A0 @V@F6CVI:JCJN+8^:.1 MP.G5Y@L92'W!N;V#0%KY+*H6+Q=)2Q*V2SN6S"2}9!3+U-RV? ='"9"JHA3A MA1&A"BXR>YIN3'TA%"RT;KZ3[#)G%_G(F%?9/P@.P(UH#E;RK1\FI7.1 M*LHI(^O0]U0T'Tj8IH]\NA27] AGR_QKJ$(_\1? 7'U^2)P#RS13_A37_3&DG#+O_T$U_]MVU_[]W_Z MW=6?]-J6+E3813M;;F6I)1OQ;2O R=0]--H(O0W+ =0[W1Y6I8 6Y\A)>;9G- M>>KUUN:TU9(6+LOH72A>ILN6<'!>]NE7 M9+7$2Y8HZ1W!MZ&63=Q!= AZM@A#I /,36TFR^RND\SB>TC7I9$6,B 4$,0S M1(S\>H[@<-Q.IP-WIG=)EI31U_C9G>=]ALC81<%8RN=0-]!Q[NBT,I=\"Z6ZY MZLW? \K Y:UP7TO* (%! "8AHK4,.--#SZ#A+/WUF&?W5^D2D6W*#C802Y"A MDK2('I2 @7P:W,D7& X#.,@=$;,SZM#"/1OUE79J=7QOZ?C*'24MM&:14/#8 M>N=*%WIN6$.[U:XNV!6YK4$$-*

*M\D!KIEIXV5"IY_S)^]>,1%N!#<*0(0IPB]*]FLM"4:SWJ3<,F$V*#HFE%L@ MR#91Q;)V|:-PSS4-^H/>K-(K8C0N.B=4&S.43KUI7/%,QGHP0'MC;TT"?M,M M8HH2;]V!E\QY4MCA QZ*:V!8NCE1R;XV5\%\J-2!F.IJ257"DYJP^TZ;34OV M\? *R{!_8KB0Q& GA]9#+^B(MM_ZJ#CKX)/:83-9E;.H'_RSQX-U0P+ER-9 M1MQJGKVM;'&9,93"OU58/2K0I[+2B%=OC)\66*"9\D:+4ZU0,#"IG>E>^WKO M>' '+;^+-GY;TO_)9_A<[*R0%?/KQPAPBJFS+3 T_NA$\M@"IYIR#OG5,_ \+ M#9ZT!<8C= [$)F4\#"EI,)@6A>W*:6!K3# ,+5;UN#4MO?(1AMDHDL!:IA X(M!&I8)YH[A""7ER4O67"0W6#=N&Q!QNU@="[BM=M(K$)-2EQ>XN@P[@0(O6$19I*23 VJ 1 D#HZZH3/2,V6D',/FU+Q$G* 1$_U MDZS@3+K*Y#%57DSR-<-A\|\,X+2K/250:P=T5;0G#7;_4V#=JG??R+H4^K*#]"-<.6V(T7^CPMN0[\ M1_9Y;3T_M7[=]6ZJ;72)%FA#X=;I^__G[TWJ9'D.+)%_TKBZ;X!"407%VFT ML"\NT&J2$N>*E_W8% 3<;U&9GE7!SHQ(Q5+%U*I_;L<6-X\E]YI;=8]"P RK M]S)C<3D^'LX/6Z#C]%N-GSLH!E=/=EI3U M8:K+BZM!I,&!U;,X6\"F3:XI>ZA+T99+N<`)%K#X_(ST&4P>J^?_?:!!^-@ MC0IV>]MW)1DK6>.9$WMV'. :,5?=2"[ARO74"4^1$_(:N2/3ZEMV.S M0ZSBA0ST6#X]QQ19TK"8'MQ' 4ZQP+/#"4N0$7;CBG9MJA/38VB&RI4\P_+ M8=N?&=]NH0(=[DPZUGO(_'5"MC[631WE;.N90NE277F44HD6#+E-K97_Q&S* MA.PD3Z@\/G'RGJ*AB!^2IVQ,U,6%@ZQ1.^7 &>GMV)H+>65]LB _X8/G,9WD MHI*%3P]D:,7W""%+UCYEZNFL$B8NL3I1]C++) 26CO\Q C\;F\7M?1AL3*4VQR M&'F-S.*5Z;Y-J%? ++2')F?VV=DI0 NE3C%K0X):|<'H<'\.O0,U%IH>F'I> M;'K/F(#;DAE/#2AZT1E8;W[I"D[E6.Z<#8MRI#?E"<-?6KB91@WK!\89L;U\ M6G?ER6OVT;O\8E-89 {]H6FRDZ>$1T0L!O+=/:E]BC$6=OA5!%Y\]4.2V>'G1S2X(S[QLG,]L444:M6$1*2*HGG=H1IRL_4Q'0O3 M-KL@MO1^[KSO95GWCVM9=RWKOC.]Q[__"6':MS&\Q#%O7"VY/D:4&R><3(;.M-7P++CVE+)))&) G0=1WHZ8ZA?ZY'?!8] M0/$ UZZAF0(4(>FG8+#.+LVC(T&ACF3;9+!]>&L&KS8O4<38N>M)KB99OTH30 M &/,_OV!\UH @XKU(R4R4P7!;#W$(Y)S$RPEG,Z)BF M1WE<)=KLLRS54CA1$,D 6+/K*X^G,H6BCPBZ\6E6A@1!|$93@H=('5B>*&>*YL_(;DOO55F^GM6=KE\)-5S.F;/VO=I,_MD7PP[TN6 8[H1-M,DOV9M*HL-OLHE&E4N*=(VBH8HB:F*+00Y?,$XELPGC(MJA[C[&F)&-I2]C_=T)X.0V<;8ATX[6M35/X\1AA$*^$N\5SE&>_+V3YUN4+DO M4_Q"D;,IN1]PB_LYXX!E]K@KYD>,,->>>R$L8Y._=R13Q6P]:2CZ838LKO]T>M2 LI.(DHL MT%"Q 5F.KQ-E3DYST.]%#N!R!*WKXC9+7Q4?X<$.BZ0*NEG9E1DAQ>#A6 MB!U75M"9O6,N?^>;Z,T5Y=U)Y?BLK=>[P.QFZ(992,;L4*91M&ZTZR =V!3[M&3,N:K<05QBI;J&B#7S ?> V44CR4C=RHOY|X,:E=`QS9*O[UD MHR4>$6P')+65R?.^?*

*OMS#>V@:$8,)$C.*X`JB8B+W@4:=6*J8)1!G[44'0V\22&1GMC:KA)SB&5)G/;HZ>3%*2W;B|/X%]YECJ/@,;>Y&HZ:Y[^OB MI(@RSA'GAV"D/^>0)\Y?8,+C(1T4I5),.%0<86CDS/= ()CBW%"%U6;)@A]DC2 M88KVN(2AT=G3? /?3AZDG=XSH0ZU:M.TS*%U.#,@)&, R+M?1RVVNO/_^BG- MGSP^]T- _12BKQ%Z@<Y9W=!$8YQG9_G#"3=/_HTKN.^S@"1PK[BCH]!,=-6&T# MDMO.8365G/3/IZ6'+0G5RSD2Q.^7<+Q-L3$-#0H]H8#@/(KO;_)T35!>A9@*^ ME@JTM5'(4TQSK%SWIGGB("0?2RIA9%)@+F.E*D.%U_*BQY Q:7M++QR] M\2>+;_>/(%DO(\U#FPEA U9,QPG(WUV$VHF@4QTWHQ^5&. N!)^#X+[MRG.6 M_(1<#R=5B08ITR"%X&\/F\KJT M TC&@]7<93T^FYG?U_6G,'T-\V",G.;?'-0@4*MNA[5GF0!'26,-%{T_8 MPQ[E7<\YOV\X@#^M.(5!_#KXP!RPWP !H#OQ1,+M&F.3"\5\+D? 9W2#]- M LRCB2(?@0>0"S%54)22BY^(6>C;\51-[K(MAVE0R,\0%]32*]T=.],;-]3 M7'[SWQM/20M1D,K_G-=#HXI X+R8,^.PWYP=((_`BTO)AW^:5!>V*0U_6,1I^.M,URB- O7Q\G:JD'UWA M18/[I5&WD\ 496<\2%R[{T)/[IL3#33.R&9SQ*;\0DQ/>YNNS@F)7)77L9@^_M F)'2,@T&HJWDS\(';@;GU_SO3:YY;!'R9,_VA),\;_ZGA-]0ZZPG,'#$"Y2HC>GR]H"G&=_WD"M@IC7,KT M$1XY+H;TA'T?0$*AXA@&4B&[4'IK8=6F8TD,VT^WYRX^/7?=()(4#$$,_L0] M4B$J'ML0'4KBXA2'!>)N!KR=+'\N1K7AF@GK%6_/BG'QO-)I72;G%P4A,S?K MR&JP>AU[-"KTW"O#5@#Y9N-UQ_+VLI\0 L MC"$9?D7@7"4RBH|)$Y)$>MS<.%)CQ2(K ,HE;V>_FG'191W7CU2PT"EC* M/MV5T\;,2]LY=@^(:L;_(_^$#3B\5.]T)M ^-/:&^S:',^]I%KB]L0*2M+#+$C:)5%W<%QS? 0!E3/!=YMJ3#O4T^7T[S[@9%HE&,%]NUP\T{G]^T &;0 MNE%7.^$+W(0:_$>^\P-Q2,^82<.S]<*A&8>1LB/Z 4(+P>?Z F>RE M!^%#V@X]|KAEU@#*>SD_Y6[FONP\- W]__>J[.S3'FJIMV9*DP(GETFD!ZR2G MSAO-%1&Z,9X6"DT7-2WW,THON*JQ-&X'=(O:RJL/O"IV. */6LXM^HC$LKOL M4%*UYEU/D?PZ3_9B*2Q "NK7"066PZGBK4.!TKJ7@(IYNW@@HWE\,#A0,I^E MX.%VS98Z,X@#$:A9'/"+6/+"D6?2_GYLT_5+CLK< D M1L-\Y9BAO2`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

;;9$G.5BS#_^(F;MC3"GP36*0|A#>96VWL@-MF$/=FC@VK7/#U6=F^D+?E\CLFUQ"%&'.-?7-19U=>L>%5QLKRDIA("H5\E"& MY@;TE &F@]7(62T-@'FM7@B!QV!B8M<+7);H"=P\$T;3WZHV@=G(7M+#'3V[$LE?O):;M#RNF;<6TO0N8 MMI^O3#2'VUCH%W9B*/E7!/H".#9*>KMG[^OO0KFCCKPN1]BU[UIULV5GS3%% M7KF=C:$F]6\4Y=.A-N_TS-M]!-XP=Q* @VV70?K^/"U-&VH!^_#|!>7Q|$"D M.9"C02.HV%RVA/AV* C1ZHE;C6? R#_AS.)0E(S78)='T_]VG645&'&6^HR MB@15H@OM@V-;%3&NLGOH_8K++U!9/|(T:_A4! Z4(XM/6#>;rW<'&$P 4Q*!U'T9,,I8"'AK89)HF*$Y0Y.)"@LIHzL;S?$2P+R(*FBYBP.+-GNT MGM4CA5BA!.%@aU!)HWN8'X#K4?3(BRE*(sU^]tZ>#-L^8 \MVNX2%FQD*0>?%":7,X]|P+CTU\(W>:IZ#P3Z> MD(#4A*,T2/%&U^D4_W8X-/=QA\[@: 1X47[&4)/> A-\ )DYB[E4-A!0]]M MJ2UM $_KE:+5@8Z)U(4L,N6E7#!, ^\RZOI*NG.YF:HGG1M35CN-9M)M*Y0W MB8V(XG/IMR%@\'#H@1YB2 PO7#)'"K-[SYKZGF' MP'*_O&MR%<@=B1,8 SX+#7 A=7*[:H <_TC)>FNN;D5*=+"N3F&V832WRG7: MX=(/ 6LQ2$GXH";&>&&;;<.003BXB-"A$FR/9@#B]H:0HX)/V.UXXM(C%=?/]MC[.;#V"I.9N,@8W(KT5N&2.TLA{'Q3UJ]:C7YN"9YUQ\OH>>Y2]_>\7MM:DI MV=?);>)NV; R=J{#ZMMF_O^E$A4M+.(&;*MY&,RQM(-RNIE@<&=IXZ'#@3P/TC M\;VPW-(%PLZ^B_+6R[B%+/OJGN$:I289>&PM MTZ_]&C0)V-JN-M_.0H?C-' 'IS]EU#=L6"V2H6ABQ\)k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|\ M847Y:7]8"BU X6HOZ/%C.)E*8N\1AL&I&S4/B[Q,MC%,+41]"6TE;VLADC+)-MMKB)D6HF$*N\P?]G"7;000G%C6+D^ +'7S\6'PY738D$3@S!0C*2/4R(?NM=6 MQ2-A3]U[DB]QH2>SAYT]97QB,VQEV&L$})]S#6{IY4S%<23;."?(M+3VBO#VUPTVV1TDR3O!>3WGDO@_^B*LS-WKO74+=%!1+)[348"N+F>A=KXNNR+0]<4,R-P&MN"$YN5TOJB[TP M'$2Z#@]7:(/=Q!TW'FAQ?FVDTGH=Z.)R34YVY\\/SS!DO(^9B \B4\O[Q35& MZ$FF36R;) #(CR4Y[%[?) M_+L6L_5V[L*_LW-LHAV;I:<9X>&L0\5]HI]!"Z;'[O*""ZS1'"/WM)0 M.[?99@&A3[;!3.8ZPD+AQ$>V-V%[8I/Q/&7]7%67.I2VAW!D%)@^-M%I2YB?_NJ5;4ZV%V:T&Q0FG=,G^Y,"7>BX);6A)\5;TSKO2,*,NT1;+IH#"O M$ *J[,%R02P$A&7/C8!P9R7;%SE5<<8&SUDZU3^9%_O:¥5(7ZP[YG -B 1O(MVH2X-NQ --Z=1]T.PGDHDEP'F[M3EQM(Y)M)L[+&$$WV\Q&LQ/OD>H:?)R8TI$CZ-M/6A7_%$Y$>]N4_5?XGDATM/6:;\QB1X_E RO*QG-V3%#9%)2(0QZ60IUZQJM\1)_^[#]^\+FGOWO^+/(HRRJW%74*"Nl0T-KD)"2Q)4&8IP[T M=*ME/_< C6#9EKQ[VMA|. 1C)<B2AL-IW.CEK+Q*<3P'43W+C/A2%)'FEELKB#/? M="8(@8FKN5__QFT]^__&OS13\JG(8^]:(DHZF!"9P[.)LB-J-VC(C)X$)/$&* MFNO&)]434PIM9O9>]&>_(@/SKJUDFX'9.UZB4 3] M1)/G A#T@A]I#>]8C!G0"B,=4AYQ.T H?W"\8BPJV MCI_*)1+% + ;B2=A6;1QE5NXTZE*YBK;/S].LX@%TM(1-U=/04NT!5'?L53TN M" 4)=;;3I@'OIRQ]A63Z?U7Z)#97<-]!CU^W\=$$7NPXE"F\VX(Y1=7GD',V^ M#%X?B'&3?DT;AF6)XQ6&A!2-'#7X>V B?(5?XWU8;YTP|@6 $,OSZ X9W6 MH/W*EP'|>&5%Q|%FI)O%YU9T&0]3#2R2E(-$'-?LWSNUVKDJO$HM@N)&-#)= MH9/0#UR\[*650[L@7:'?$59WTE5!^V%?(6.[E;;$)1:4A0M9XISJ->A!$FKB M>'WMP<[QP5FE9LHJ[\0?/=UF^ G>$;/A?M.Q;/B]\(4LP7N0/W M[C*-R].U@##A[=S8MA0@.'1"E:-7]-&82@\1RC,%W?&X$.(NPA@?N4HMT5AO M@L6/Q$A?9P4R"N>N=>WR [%BGG:O(=!D$DB6V|SI)X#D2MD7/VBA-!;C5@3=/&&TQ632N>!!@SA'#%E1E6PX5H3M-ET9M#IM4MS"KUUDY&P7BI(/+':YDA)!8!VD/=::1?6U^V]=%>7UARA],>R#0X[&1T MG_%L3+DJGZJFDC7WZ3K!7*(Y*I3Z<7S)8[D+&0:5&X$UD:2/1)&>*|<7@G@, M;PJ&'%)U/S[.3J!VE10V%]5.ZVAN<OU.0O>R|U=|+_E M31@)$Z+MF76I$<=D_1J):OI7A\KP'D9-UH1^*_MM0SPZKMO\%3784N5+>6S M9]J2D^8RVA+-ZJ[DG|M E$ "ARDV_+:3CK|/_\+6P*'N-#|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|*.IJY3XG"KC.W"\08D)_AU9Q@CS?*|(DT:\#1!W M=4PI.G-PXW3&4E;)?758RA TYJ.WA{(Z=C)1F!_O=#\;M5+B3;B?!/0!=^11 MF3W&@%P]U\=O/<3.CS,)[R6G0];"@ ?,-ABX:[CRA43HKP,F^_-)/*/CCQRLB M8$4$O(N4!O\{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f]^(#[JC=._;29B=# A:-1 M?W]*^GN.9 G.:'1 5.F[D/AXOFPIJ;FU!D)CM-@-K_;LE.573KP\{1MW?1>D1#"-6B^(A'!*%8IG\4U=6<93*\U:83,/L_EZ'?) 65#H]9"3QM-K+UA8X:SD*7W]|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|R+@V"V)[\B/E@?":)IQ;O.+W^CPDV-C^(YAH)(WR)+| MU(?B)<@5P8Y-RZ\V_0 ?QR2XN8&N7I MN)[@L7)*Q*O+7LY\BXQ=S&OE6 V2IY;$.S4\[414=D0;I4 N0&S(DU5S#2]5 M3TY_\]GDDDU;'KE:>R51 F5!R0^X:HSR%E|9AVH[VRDWE+[CAYD:'4HW)D(+ MY&,,%V^H 4T\1G34M-/1:8N2@"E@<(ZI6]*Z%4#*%)-{6<\V"_' S 3Y;\1= ME!3U5"?!O4[H9\Y>6=UT22-9S+]6AM05@)A#M1!>/UNKC M^N'!$}>T7E2G!>4D0=7=4CUKKK+UY*65'TME,@8]R(*1%>'\QD7H,28M0UM5 MO=%0T+XI/)"@%A[!!$I*#:0F+@/2U#0Q[KKWB_D=L@.\2%PD).$?Y9V,)P6'=/RAD*7Z#-9&M&TG>3KHV0E9,7)OU]|W^4P 1N M*"&'E)+&43X%QH3]9H?I[G]HT MW0CP,F%'C2N-SA&#M,|<2D]PWE:Z&'GFLOSH8HO/3!G@^R%NSY2]E)QSW+O.MJV%Y1X5@VGV<-A\\L?,.3J;6X+VTO25H-,D3,14O!AOS5=-5J^2RV@NQ O MI8!8E++ WJ!2\//EV!E\DX/UN W6M0+IX=3<_FTP!TP\\?7\0H:,"!B_4I^ID M>Q^&,=3!K_,,S6(Q2!2S>HM258;X8;ANMGC]3LW:,&[XA8F\"@SXRR%>NE_A MT=RU9QUI@*U?1:GZ+YE=>1T_;"K$3G93[#$;_PE_?U.G-$I"6'.Q(1[6 MJ]TL6!AHEW#$=/M(_LI')RF+)0)WK]ONB-)34*]#?;4 Q-Y6D^_/8ITV>IS MK@M@70 7."?/F4D*![[O5D-HCHC5X$]]&\APE#]^:HXOVT=SA;6[=$.2&Z8 M\5<4=]/V;%E9769+A^7M;?"BX@11N[FKFH-DL^?CXY5M-23?_1H\|R ML3A8DNV]&V5FH6T;5X R.W7+Y]WG]K5EPWO?,%.?KIBI%3/U(&9])2S\|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|'XH+]:G%0;\&.^(OYK03B>W;B;.ZM5LRY%9,2XK,OOF'UB/J]62MMQE ,:Q?MU^].12T^?8;32BKK9/N!3A9QWIHZU M2..3]I.0GM*DK+(UU$:U_E48Q,Q6U@&)+0TR^-.#NT^S-^^2WT&%;00IK;DL$ M;1+Y\@/@.E 64+0%.[L$+RHE#0T!VN-*%Z.1 %NQZM=?57A_A+;F;=HXHI@VD!::-IH)W M*5ORJ0R9WP7&YZN2AM>V0'9_')VL-$LDAQFJO[@'BJD1@D[5HT@F)L;9F8E M%H5R*QD_5>8+KEI?X5(HM:Z<=>5<7#F281'>T8R#>'*\GEDS'Z0BD)* 6(-Q MNK2EJ;H/I2I-Y1G*0TAO8JMGS1I6NXQYI->S5L!<->^1-RLOZMK8S7QU<27NW\4N)-P5E*Z$)VU3%.-!%C"5IESG7+SW'[OMK]A)*;2^:=PM1$%]=<*KA2;Z ,:4J>9,RDWT<+H|?8"T# N6[@AIKF1;A7GVZQ]IF5L!K]:U)[S(W:C|HN\D'T:]#-QI:O|OE/EGM_&H9GYA5F3/XPSO1'EVT&3?;X5$=8[:.*8RML3$$'D9*MIDRDQS+1QM4$YI M(1/L2<%A=L-'71CA+SW2"[H= @CR$S'RIL)A1C^^UO.1*6^1-OEF18X,Y+'"(_FD#NJU:1@*1TM"S'?D3]V339:[BZD"U7H/K&I*PMUNZ";C]RZ P3VMYD+L"!WXS=\;+ 3]]>OX9Y]%|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|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|00RQ\%/D)U3&K!2@(Y+756 M=3>TP$INE5836<++#05?E<(K#-PL=^FMS'T',3!^,N9#"]ZR-GHJ*@JT1V)6#-M5,9YRCZHR4J5N0J).XSQ)S*UZ8OAS;C;YX^1-4Q\A(J3,QD'?\|G!,X!U"*M0NNO;.1%CMPT>)A1,,_W.1 M(//X;.A*WR9$S;2Ds];@2V0VU.$I*?+;DF2+*}]FHA^M M+!](^"4GJ>J<5S+QTP$MQ=T#?;-Z"CP%#N:<&R&>_= M"X8?MB$L4S5*"]C:$L&@"XR$S":.]9[1FRVW M'>:KW+"8N$[*3]Z3CQ98GC"?QX<]8E;?%13;VT]2W!X/Q-R-ET5@)5A9H&$]M1C7^)+B;@NY!GD]@<#2^LAD-6)P,0&*N,3*PE"?!;N?ONI(<.4(%5]X M@$NNDAO)[fY'Q@",(*RDR)F9,P:(*KFI"S;,8GSOB?!!@ ZVQMCL3M'G_M_^7K5_G-O=O[YU#RWM00<6^<>_U%W!-E^^"W;,,R/1$^.GX/05&HEMCJV[11.N -V7]:^XYJ-L1KOPGAQ%:"7\U>%Q,!-M8X^C7:NF#/?F)'H&MFK?#-0V^X-90(BKC1-I@=LI]36[&2]'>B*FY^UZ-7+-(9U8CP+ M"X6WX24#A8](8,;_H!\F?@A?.C.B-K[*&)G$X1WJ|-_$472]N&\F)"]!R@OQG M3X]Y=$C21VQF18YBW*C5LXY2MZ(:UW0)9^-1\R%4[CY-#F[-5 &7 -=&[FM6CMS8H\Z3QQ#.U8:G6K2:TF=<&DW!8M40]Y]H5V11RO5PF3U;H>B>YG'K?-(?0] M>EZ&>.KO#P2OT-[$B_HR?GSNS_^=%K6@>'1,A;1P01OGM5:[M6NWJ@EVMAZY$-E-RBI3MW$W:K)$=B+]{>Z652++/*=@?J:?5]%;36S:]/=5^ M_AN!K7^_@JU7L/4*ME[]WENU:-9Q7$8L,%,;6 \)JV4]*I@[41>>B;\:CU,5GY/U8Y$MPA=^[!BE<0'&5NZ;DZ[?,@[,A8^>&HJ:P+Q*\[IYDTZA%("YB,\X$,/3;A,_M3GC]H)9R:#I&"_W"B6>PPX_!T!6";& (U"17&2LO-$LXL@WM;#1>&,$)S=% MZLV9G9$>]J9*R5NQ$0VGV<-M5(68&+,FBP<;$,EC>XJ,8I.8/#]UV$[B#^;?C[GT9I"$ > M(=<=Y-N+@#@R.V*G2TF\URT-4ET>;9.:,3$_P+PAM=B6 :4V<.(/<$8$VN+1M5PG)K!HF.9+Y.?&8F]-M&1WE-@R|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|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|OQ185$/W5"]:H _^1/?.H]1O.O7[UZ\2*?[FYNOG,-K/!#V Y\^H+6WS%PM]4T/MF%8XGNHA6AL[K)13I:)P MOCNQO#4J13!EASSPJ43QIYZ"3*)S&AT.YM'D[SFZ0")7KJM^QRBB7BSVV8 M X+C7^&'LZ2-U8$E+T#.B Y[?) *1:)NHX,+Y4FHM) |-7!N!AJ38:W-I%M1 MFB(2M+CD;|O#GDN>^G9<|"B4CP%C!L:)<5[?]<;EBY>]6=V8T*2O?&D@?N.=GHZO\;S$"9:?TB*F_RB/1^?I25YS]H+[?E]^_M ;K(_(%RK\<+TC-^^O'SDPZMP3.PK/4JSM\$"_2Z/UVAGN9QUP@$#2ZCH]14ZK.ZFP|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}F=!K(97;GZ#F/VB-*JE7T?G0 G\2EW2D),VXJ[L1"0MOD)3%(=_&T]/__:N["PV+'QT3D\>RL>W(;JE9SD068W#G,*.MB!%C'0YH?.EB&"P7MJHJ-3-RR1()'O$[Q#:&R+T2\>K&ZPOI%?< M\V2 O0E5-N960PD-E/=E?&X8Z?)44L2^K\?8MG8C\(2QDB59+QK%HZ>\=#@=2VTL@5OH16@?9LO,2P]-B).AM-2C"6YLY":;2[2.M?W+J122B[GW>&6SP]$E'GLXE\,G+[3PZ7 O3Z%5HX#VZ?!IDCXX-,AWQ#/G MFU_F>/ C<;._\EI59M>M-"-GD DUY!:]5;[\{X)["%[H]\-6RHEJZ MRNS"S]*

<[|_K8#4=^4E.U#2_OF=ZY/"_5N-:.EGLWN1^?\Q;Q\W?#@;8B:0[E-MA-0?2>W6=U4[|"K04#LI(38_?>+9ETL+UEXI?U_O}PRSU[2G!GYN7Q'L_7"@-M;.8MPC&<1|?L^WM4HN$A>7_/1(WBVO121AQ0QJ6]57@;:[G0LX6>NOFVW'E+-M:P(>E.+*6F!6()"!JF1=Vj'4VI%EXI!]A=Z>-[E8MRT'RP;${)A-P4!<266-M'5-5TY?BX'94'R};<=\136RYMKA-IP+Z)>76;G4O=-!,7(>/#?91-MZ=X;60P%IN7W>+KAD0(,J,+E]OM!CI*,.VE\|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a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

*MZU28A(QD4="DVVF_;G=[!^V.YQT?P5AG52>9!^30[_;] M7[>W3$JO@NZOP<$^>?>6[\X8G>U9Z?/KL]&?]X9NVG[9"=Q)@B\/W1=-J>]MM2C?W1C9^8+-WW M4RDU;S/#=HZ/L 4^.67'1QDWE$0)59J;USL?1A?>(4@885)^?.37WTXVE&QV M?,3$A&@S2_GKG8RJL<@](XN@WRG,_'KZ<'M%YLZ;"F:2H-OI_'-04,9$/O92 M'IO@H'UXN&A28IS,VZ1,6]!X2HV8PJV;W7,W M7P/#]XQ'4S&&V;!UX P25+8(EV:=NHZA3!G<'-XE(A2&]+OMW1$?@N&*IU S M A1SM: (G]O^HJA.A0=%4F%F0",9X#CU^>7'8Z 0'1SY*/ZOJGS+QV?!F='EQ M>78RNKR^ F>Z>?_4Y&I$1M?/;>]/*?U^>&;5[7=ZY/[*C'X;DO$CC_+;41\>P3R-D8H*Q5};)%SNE$,/*]R%LDX@I% MB$FH";ZG6DOAKO*1-8H:IM$#B8S@6>%-M7*C[&[>+R^ZKSJ#K_N\) F= M<*+X1/ I9%63"$W^**D"/TMGY(874AG(M>1"]@R2L?<'D3%>&,6U)J="&AXE M+7*91VVR:Q).T'R]SN"&CX4VD%2-;>@.]@:,;LJ_&S)ZWX2,4ZHMRR+9C-5F M^#:TYBD0-R${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|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sE9),?.@Z7L=IN^U=?AR/(0MRW%^[PP=9Q2,RH%=V_4@4"3)N.8R(<)QQF=;L!5KG?J.LUPN[67' MEFKN!!=.K!=BUQ%29LRFFFX=]*

(T$/QFA!_T%TP3"F*B,Z;=;E\&1U<49FFO! M#OI_;><.Y-T==^G_HRO1+L[=:"J#E/+"U3O^.FNH>:#@[?FG-M+3G5L>^Y M[L^]E%#*D[DE6*3]/;O;O1$I/H_7,EF:YBLFB.97S*S=6#44C"A_)G7]8G;&_V*X-)HG-M>,*LF!4P/=M[T]/L6EM$\#GN9J2]TB%^Y8O9Q][+4G$F!<7!\77,9UQ#IVU[M?6>&CDL? V: (+&;J%DZC_Zl0KWB&0 77*S_FE+($-7YYU6V[G5[?,..?%/I] M+AZ.+X+CH^/A(#B>G.%ANIA>#LX"'";@=>'2GMI#&Z;C83'J=?;OMP.15,7:-MG]9KlVB#I, 2BO7LMSQAT"%,8.I9"T@&$1=U<31Z4Q;F"I,Q.H0D%,;76&<-2 M+)&XSX)GF<&/OV8FQ00(),5,,@381E;,4@!!R"TYX0C.R@H&-'LY8LB2"MN#4 M'MDM&,:$*_1Z"\ ]15(ZATZUBZV',680 $) I"3")(AXR9?QB=JL,;Q409BO M(>/X%]2YRG*"U-"RF30]YYND4=A-J$Q-A6].KR<9_E?,3(F:D81EUN1:,+0@ MU&;$\+^%XP2QHMYB!1\3N41'SIG_D$3;J,2=? 9QR! 4*$7HE;Q:3G>FZ^ MASG;WLXOK[Q]M_=UGP'&N#]]42]PN(3(*V'HOSX2BGW*N6+F.IF9X-]0:9OL M)XW;V^,[]PG8HWWIK/,.]Q^[C[]OU&D_,'!>DQ?VW MR'LX*QX8"3DLG9L_=U:*I+Z,VR3/UI+],)_=G\EDG+C>BJ995+DFFT8_03\:6CB MX&>R]>R:J7]-/SL(+S%X\ACLO@3A(8/@:&52U?=)2X_A@Y%YUN?#()_CA0+O M=65[5!KWG4[V8YAQN/*_%+,Y"541K'CH=> 9.047KG%SQ,;Y63./?WCC;T_ M'.F^Y@;S(!'Q@>'UK,-<\RWYNM'VA[MEO^S:\1@&WO&P!;YG;2]4?:']4QFX M?:YX$O*4B'_R0PAE5_7K\;K MTLV!"E3[%LBZXC5?TVX\D]@0K=__IF3.K+)](9%FRB=7DM.*!MVNW=Y=U]E2 MYA:OC,OWRL6+ZH,__5!+ P04 " #3@PU9XW;1TG8% ^'P & &9B M:6\M,C R-# V,S!X97@S,F0R+FAT;>U9^W/:.!#^5 ,H7)O,X!>0'#4T,P3(M-#=I2(,S=_U1V +K*B17ED.XO_Y6?A"3Z_N:1V_(9$A8:.5O=5_M:NW^ +Y8U M%C$1(8W@=?#F#" (99DLJ-(2*$HW2%=,O!#))B(W5"G&.1PK%BTH@.?:AI;7 M.K!=RSKJXUK#4DD*'[J.UW9:;JL#[']O _>8?=.#B#>Q=!78R+ M;2^NCLJ.A]"P':>/]M!Q1L&H&.C8K@>!

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end XML 101 fbio-20240630x10q_htm.xml IDEA: XBRL DOCUMENT 0001429260*

fbio:MustangTherapeuticsIncMemberfbio:SeriesTwoWarrantsMemberfbio:PublicOfferingMember 2024-05-31 0001429260

fbio:MustangTherapeuticsIncMemberfbio:SeriesThreeWarrantsMemberfbio:PublicOfferingMember 2024-05-31 0001429260

fbio:MustangTherapeuticsIncMemberfbio:SeriesOneWarrantsMemberfbio:PublicOfferingMember 2024-05-31 0001429260

fbio:AvenueTherapeuticsIncMembersrt:MinimumMember 2024-04-30 0001429260 fbio:AvenueTherapeuticsIncMembersrt:MaximumMember 2024-04-30 0001429260

fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputSharePriceMember 2024-06-30 0001429260

fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001429260

fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001429260

fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001429260

fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputSharePriceMember 2024-06-30 0001429260

fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001429260

fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001429260

fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001429260

fbio:Ur1TherapeuticsIncMemberfbio:PlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001429260

fbio:Ur1TherapeuticsIncMemberfbio:PlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001429260

fbio:Ur1TherapeuticsIncMemberfbio:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001429260

fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputSharePriceMember 2023-12-31 0001429260

fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001429260

fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001429260

fbio:CheckpointMemberfbio:SeriesWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001429260

fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputSharePriceMember 2023-12-31 0001429260

fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001429260

fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001429260

fbio:AvenueTherapeuticsIncMemberfbio:ContingentPaymentWarrantMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001429260 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2024-01-012024-06-30 0001429260 us-gaap:NoncontrollingInterestMember 2024-06-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-06-30 0001429260 us-gaap:NoncontrollingInterestMember 2024-03-31 0001429260 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-03-31 0001429260 2024-03-31 0001429260 us-gaap:NoncontrollingInterestMember 2023-12-31 0001429260 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-12-31 0001429260 us-gaap:NoncontrollingInterestMember 2023-06-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-06-30 0001429260 fbio:CommonSharesIssuableMember 2023-06-30 0001429260 us-gaap:NoncontrollingInterestMember 2023-03-31 0001429260 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-03-31 0001429260 2023-03-31 0001429260 us-gaap:NoncontrollingInterestMember 2022-12-31 0001429260 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-12-31 0001429260 us-gaap:PreferredStockMember 2024-06-30 0001429260 us-gaap:CommonStockMember 2024-06-30 0001429260 us-gaap:PreferredStockMember 2024-03-31 0001429260 us-gaap:CommonStockMember 2024-03-31 0001429260 us-gaap:PreferredStockMember 2023-12-31 0001429260 us-gaap:CommonStockMember 2023-12-31 0001429260 us-gaap:PreferredStockMember 2023-06-30 0001429260 us-gaap:CommonStockMember 2023-06-30 0001429260 us-gaap:PreferredStockMember 2023-03-31 0001429260 us-gaap:CommonStockMember 2023-03-31 0001429260 us-gaap:PreferredStockMember 2022-12-31 0001429260 us-gaap:CommonStockMember 2022-12-31 0001429260 fbio:TwoThousandSevenAndTwoThousandThirteenPlanMember 2024-06-30 0001429260 fbio:TwoThousandTwelveEmployeeStockPurchasePlanMember 2024-01-012024-06-30 0001429260 fbio:TwoThousandThirteenStockIncentivePlanMember 2024-01-012024-06-30 0001429260 fbio:RestrictedStockAndRestrictedStockUnitsMember 2023-12-31 0001429260 us-gaap:RestrictedStockMember 2024-01-012024-06-30 0001429260 srt:ExecutiveVicePresidentMemberfbio:LongTermIncentivePlansMember 2024-01-012024-01-01 0001429260 srt:ChiefExecutiveOfficerMemberfbio:LongTermIncentivePlansMember 2024-01-012024-01-01 0001429260 srt:ExecutiveVicePresidentMemberfbio:LongTermIncentivePlansMember 2023-01-012023-01-01 0001429260 srt:ChiefExecutiveOfficerMemberfbio:LongTermIncentivePlansMember 2023-01-012023-01-01 0001429260 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30 0001429260 fbio:JourneyMemberfbio:MarketOfferingMember 2024-06-30 0001429260

fbio:CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMemberfbio:MarketOfferingMen 2024-06-30 0001429260 fbio:CheckpointMemberfbio:DirectOfferingMember 2024-01-31 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:SeriesWarrantsMember 2024-01-09 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:SeriesBWarrantsMember 2024-01-09 0001429260

fbio:CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMemberfbio:MarketOfferingMen 2023-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember 2023-02-28 0001429260 fbio:MustangTherapeuticsIncMemberus-gaap:CommonStockMemberfbio:PublicOfferingMember 2024-05-012024-05-31 0001429260

fbio:MustangTherapeuticsIncMemberfbio:FoundersAgreementMemberfbio:MarketOfferingMember 2024-01-012024-06-30 0001429260

fbio:AvenueTherapeuticsIncMemberfbio:FoundersAgreementMemberfbio:MarketOfferingMember 2024-01-012024-06-30 0001429260

fbio:MustangTherapeuticsIncMemberfbio:DirectOfferingMember 2024-01-012024-06-30 0001429260

fbio:MlvCo.AndFbrCapitalMarketsCoMemberfbio:MarketOfferingMember 2024-01-012024-06-30 0001429260

fbio:MustangTherapeuticsIncMemberfbio:FoundersAgreementMemberfbio:MarketOfferingMember 2023-01-012023-06-30 0001429260

fbio:MlvCo.AndFbrCapitalMarketsCoMemberfbio:MarketOfferingMember 2023-01-012023-06-30 0001429260

fbio:CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMemberfbio:MarketOfferingMen 2024-01-012024-06-30 0001429260

fbio:CantorFitzgeraldCo.OppenheimerCo.Inc.H.c.WainwrightCo.Inc.JonesTradingInstitutionalServicesLlc.B.RileyAndDawsonJamesSecuritiesIncMemberfbio:MarketOfferingMen 2023-01-012023-06-30 0001429260 fbio:DirectOfferingMember 2024-01-012024-01-31 0001429260 2022-12-302022-12-30 0001429260

fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberus-gaap:RelatedPartyMemberfbio:DeskShareAgreementsMember 2024-04-012024-06-30 0001429260

fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember 2024-04-012024-06-30 0001429260 us-gaap:RelatedPartyMember 2024-04-012024-06-30 0001429260 fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberus-gaap:RelatedPartyMemberfbio:DeskShareAgreementsMember 2024-01-012024-06-30 0001429260

fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember 2024-01-012024-06-30 0001429260 us-gaap:RelatedPartyMember 2024-01-012024-06-30 0001429260 fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberus-gaap:RelatedPartyMemberfbio:DeskShareAgreementsMember 2023-04-012023-06-30 0001429260

fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember 2023-04-012023-06-30 0001429260 us-gaap:RelatedPartyMember 2023-04-012023-06-30 0001429260 fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberus-gaap:RelatedPartyMemberfbio:DeskShareAgreementsMember 2023-01-012023-06-30 0001429260

fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember 2023-01-012023-06-30 0001429260 us-gaap:RelatedPartyMember 2023-01-012023-06-30 0001429260 fbio:ZilxiMember 2024-04-012024-06-30 0001429260 fbio:QbrexzaMember 2024-04-012024-06-30 0001429260 fbio:OtherLegacyProductRevenueMember 2024-04-012024-06-30 0001429260 fbio:AmzeeqMember 2024-04-012024-06-30 0001429260 fbio:AccutaneMember 2024-04-012024-06-30 0001429260 fbio:ZilxiMember 2024-01-012024-06-30 0001429260 fbio:QbrexzaMember 2024-01-012024-06-30 0001429260 fbio:OtherLegacyProductRevenueMember 2024-01-012024-06-30 0001429260 fbio:AmzeeqMember 2024-01-012024-06-30 0001429260 fbio:AccutaneMember 2024-01-012024-06-30 0001429260 fbio:ZilxiMember 2023-04-012023-06-30 0001429260 fbio:QbrexzaMember 2023-04-012023-06-30 0001429260 fbio:OtherLegacyProductRevenueMember 2023-04-012023-06-30 0001429260 fbio:AmzeeqMember 2023-04-012023-

06-30 0001429260 fbio:AccutaneMember 2023-04-012023-06-30 0001429260 fbio:ZilxiMember 2023-01-012023-06-30 0001429260 fbio:QbrexzaMember 2023-01-012023-06-30 0001429260 fbio:OtherLegacyProductRevenueMember 2023-01-012023-06-30 0001429260 fbio:AmzeeqMember 2023-01-012023-06-30 0001429260 fbio:AccutaneMember 2023-01-012023-06-30 0001429260 fbio:DebtObligationsAndLettersOfCreditMember 2024-06-30 0001429260 fbio:DebtObligationsAndLettersOfCreditMember 2023-12-31 0001429260 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2024-06-30 0001429260 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001429260 us-gaap:ConstructionInProgressMember 2024-06-30 0001429260 us-gaap:ComputerEquipmentMember 2024-06-30 0001429260 us-gaap:BuildingMember 2024-06-30 0001429260 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2023-12-31 0001429260 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001429260 us-gaap:ConstructionInProgressMember 2023-12-31 0001429260 us-gaap:ComputerEquipmentMember 2023-12-31 0001429260 us-gaap:BuildingMember 2023-12-31 0001429260 fbio:AvenueTherapeuticsIncMemberus-gaap:PrivatePlacementMember 2024-01-052024-01-05 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMember 2024-05-012024-05-31 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMember 2024-04-012024-04-30 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMemberfbio:MarketOfferingMember 2024-01-012024-06-30 0001429260 fbio:CypriumMemberus-gaap:RelatedPartyMemberfbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2024-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember 2024-06-272024-06-27 0001429260 fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberfbio:DeskShareAgreementsMember 2024-04-012024-06-30 0001429260 fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberfbio:DeskShareAgreementsMember 2024-01-012024-06-30 0001429260 fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberfbio:DeskShareAgreementsMember 2023-04-012023-06-30 0001429260 fbio:TgtxMemberfbio:NewYorkNyOfficeSpaceMemberfbio:DeskShareAgreementsMember 2023-01-012023-06-30 0001429260 fbio:MustangTherapeuticsIncMemberfbio:UbrigeneBostonBiosciencesInc.Member 2024-06-30 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2023-04-012023-06-30 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2023-01-012023-06-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-04-012024-06-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2024-01-012024-06-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-04-012023-06-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2023-01-012023-06-30 0001429260 fbio:MustangTherapeuticsIncMember 2024-06-30 0001429260 fbio:MustangTherapeuticsIncMember 2023-12-31 0001429260 fbio:OtherDebtMember 2024-04-012024-06-30 0001429260 fbio:PartnerCompanyInstallmentPaymentsLicensesMember 2023-04-012023-06-30 0001429260 fbio:OtherDebtMember 2023-04-012023-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember 2024-04-012024-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember 2024-01-012024-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember 2023-04-012023-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember 2023-01-012023-06-30 0001429260 fbio:JourneyMembersrt:MinimumMember 2024-06-30 0001429260 fbio:JourneyMembersrt:MaximumMember 2024-06-30 0001429260 fbio:JourneyMember 2023-12-31 0001429260 fbio:Ur1TherapeuticsIncMemberus-gaap:WarrantMember 2024-01-012024-06-30 0001429260 fbio:CheckpointMemberus-gaap:WarrantMember 2024-01-012024-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:PlacementAgentWarrantsMember 2024-01-012024-06-30 0001429260 fbio:RestrictedStockAndRestrictedStockUnitsMember 2024-06-30 0001429260 fbio:RestrictedStockAndRestrictedStockUnitsMember 2023-06-30 0001429260 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0001429260 fbio:RestrictedStockAndRestrictedStockUnitsMember 2024-01-012024-06-30 0001429260 us-gaap:EmployeeStockOptionMember 2023-01-012023-06-30 0001429260 fbio:RestrictedStockAndRestrictedStockUnitsMember 2023-01-012023-06-30 0001429260 fbio:OaktreeNoteMember 2020-08-272020-08-27 0001429260 fbio:OaktreeNoteMember 2020-08-31 0001429260 fbio:OaktreeNoteMember 2024-06-30 0001429260 fbio:SwkTermLoanMember 2023-12-31 0001429260 fbio:OaktreeNoteMember 2023-12-31 0001429260 fbio:OaktreeNoteMember 2020-08-27 0001429260 fbio:SwkTermLoanMember 2023-12-272023-12-27 0001429260 fbio:DermatologyProductsSalesMember 2024-04-012024-06-30 0001429260 fbio:DermatologyProductsSalesMember 2024-01-012024-06-30 0001429260 fbio:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember 2024-01-012024-06-30 0001429260 fbio:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember 2024-01-012024-06-30 0001429260 fbio:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember 2023-01-012023-12-31 0001429260 2022-12-30 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMemberfbio:MarketOfferingMember 2024-06-30 0001429260 fbio:CheckpointMembersrt:MaximumMemberfbio:PlacementAgentWarrantsMemberfbio:DirectOfferingMember 2024-01-31 0001429260 fbio:CheckpointMembersrt:MaximumMemberfbio:DirectOfferingMember 2024-01-31 0001429260 srt:MaximumMemberfbio:DirectOfferingMember 2024-01-31 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:SeriesWarrantsMemberus-gaap:PrivatePlacementMember 2024-01-05 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:SeriesBWarrantsMemberus-gaap:PrivatePlacementMember 2024-01-05 0001429260 fbio:CheckpointMemberfbio:PreFundedWarrantsMemberus-gaap:SubsequentEventMemberfbio:July2024RegisteredDirectOfferingMember 2024-07-31 0001429260 fbio:CheckpointMemberus-gaap:SubsequentEventMemberfbio:July2024RegisteredDirectOfferingMember 2024-07-31 0001429260 fbio:MustangTherapeuticsIncMemberfbio:UnregisteredWarrantsMemberfbio:DirectOfferingMember 2024-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:CommonStockWarrantsMember 2024-06-27 0001429260 fbio:MustangTherapeuticsIncMemberfbio:AmendedWarrantsMemberfbio:PublicOfferingMember 2024-05-31 0001429260 fbio:MustangTherapeuticsIncMemberfbio:PublicOfferingMember 2024-05-31 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:UnregisteredWarrantsMember 2024-04-30 0001429260 fbio:AvenueTherapeuticsIncMember 2024-04-30 0001429260 fbio:CheckpointMemberfbio:PreFundedWarrantsMemberfbio:DirectOfferingMember 2024-01-31 0001429260 fbio:CheckpointMemberfbio:PlacementAgentWarrantsMemberfbio:DirectOfferingMember 2024-01-31 0001429260 fbio:CheckpointMemberfbio:CommonStockWarrantsMemberfbio:DirectOfferingMember 2024-01-31 0001429260 fbio:AvenueTherapeuticsIncMember 2022-10-11 0001429260 2022-12-31 0001429260 2023-06-30 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2024-04-012024-06-30 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2024-01-012024-06-30 0001429260 fbio:DermatologyProductsSalesMember 2023-04-012023-06-30 0001429260 fbio:JourneyMember 2023-01-012023-12-31 0001429260 fbio:DermatologyProductsSalesMember 2023-01-012023-06-30 0001429260 us-gaap:WarrantMember 2024-01-012024-06-30 0001429260 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0001429260 fbio:UnvestedRestrictedStockUnitsMember 2024-01-012024-06-30 0001429260 fbio:UnvestedRestrictedStockMember 2024-01-012024-06-30 0001429260 us-gaap:WarrantMember 2023-01-012023-06-30 0001429260 us-gaap:EmployeeStockOptionMember 2023-01-012023-06-30 0001429260 fbio:UnvestedRestrictedStockUnitsMember 2023-01-012023-06-30 0001429260 fbio:UnvestedRestrictedStockMember 2023-01-012023-06-30 0001429260 fbio:PartnerCompanyNotesPayableMember 2024-04-012024-06-30 0001429260 fbio:OaktreeNoteMember 2024-04-012024-06-30 0001429260 fbio:SwkTermLoanMember 2024-01-012024-06-30 0001429260 fbio:PartnerCompanyNotesPayableMember 2024-01-012024-06-30 0001429260 fbio:PartnerCompanyInstallmentPaymentsLicensesMember 2024-01-012024-06-30 0001429260 fbio:OtherDebtMember 2024-01-012024-06-30 0001429260 fbio:OaktreeNoteMember 2024-01-012024-06-30 0001429260 fbio:PartnerCompanyNotesPayableMember 2023-04-012023-06-30 0001429260 fbio:PartnerCompanyConvertiblePreferredSharesMember 2023-04-012023-06-30 0001429260 fbio:OaktreeNoteMember 2023-04-012023-06-30 0001429260 fbio:PartnerCompanyNotesPayableMember 2023-01-012023-06-30 0001429260 fbio:PartnerCompanyInstallmentPaymentsLicensesMember 2023-01-012023-06-30 0001429260 fbio:PartnerCompanyConvertiblePreferredSharesMember 2023-01-012023-06-30 0001429260 fbio:OtherDebtMember 2023-01-012023-06-30 0001429260 fbio:OaktreeNoteMember 2023-01-012023-06-30 0001429260 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0001429260 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0001429260 fbio:OtherPartnersMember 2024-04-012024-06-30 0001429260 fbio:MustangTherapeuticsIncMember 2024-04-012024-06-30 0001429260 fbio:LongTermIncentivePlansMember 2024-04-012024-06-30 0001429260 fbio:ExecutiveAwardsMember 2024-04-012024-06-30 0001429260 fbio:EmployeeAndNonemployeeAwardsMember 2024-04-012024-06-30 0001429260 fbio:CheckpointMember 2024-04-012024-06-30 0001429260 fbio:AvenueTherapeuticsIncMember 2024-04-012024-06-30 0001429260 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-06-30 0001429260 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-06-30 0001429260 fbio:OtherPartnersMember 2024-01-012024-06-30 0001429260 fbio:ExecutiveAwardsMember 2024-01-012024-06-30 0001429260 fbio:EmployeeAndNonemployeeAwardsMember 2024-01-012024-06-30 0001429260 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-012023-06-30 0001429260 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0001429260 fbio:OtherPartnersMember 2023-04-012023-06-30 0001429260 fbio:MustangTherapeuticsIncMember 2023-04-012023-06-30 0001429260 fbio:LongTermIncentivePlansMember 2023-04-012023-06-30 0001429260 fbio:ExecutiveAwardsMember 2023-04-012023-06-30 0001429260 fbio:EmployeeAndNonemployeeAwardsMember 2023-04-012023-06-30 0001429260 fbio:CheckpointMember 2023-04-012023-06-30 0001429260 fbio:AvenueTherapeuticsIncMember 2023-04-012023-06-30 0001429260 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-06-30 0001429260 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-06-30 0001429260 fbio:OtherPartnersMember 2023-01-012023-06-30 0001429260 fbio:MustangTherapeuticsIncMember 2023-01-012023-06-30 0001429260 fbio:LongTermIncentivePlansMember 2023-01-012023-06-30 0001429260 fbio:ExecutiveAwardsMember 2023-01-012023-06-30 0001429260 fbio:EmployeeAndNonemployeeAwardsMember 2023-01-012023-06-30 0001429260 fbio:CheckpointMember 2023-01-012023-06-30 0001429260 fbio:AvenueTherapeuticsIncMember 2023-01-012023-06-30 0001429260 fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember 2024-06-30 0001429260 fbio:JourneyMemberus-gaap:RelatedPartyMember 2024-06-30 0001429260 us-gaap:OtherAffiliatesMember 2024-06-30 0001429260 us-gaap:OtherAffiliatesMember 2023-12-31 0001429260 fbio:TgtxMemberus-gaap:RelatedPartyMemberfbio:SharedServicesAgreementMember 2023-06-30 0001429260 fbio:CheckpointMemberus-gaap:SubsequentEventMemberfbio:July2024RegisteredDirectOfferingMember 2024-07-012024-07-31 0001429260 fbio:CheckpointMemberfbio:PreFundedWarrantsMemberfbio:DirectOfferingMember 2024-01-012024-01-31 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:November2023WarrantsMemberus-gaap:PrivatePlacementMember 2024-06-30 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:January2023WarrantsMemberus-gaap:PrivatePlacementMember 2024-06-30 0001429260 fbio:CheckpointMemberfbio:PlacementAgentWarrantsMemberfbio:December2022OfferingMember 2024-06-30 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:CommonStockWarrantsMember 2024-06-30 0001429260 fbio:CheckpointMemberfbio:PlacementAgentWarrantsMemberfbio:December2022OfferingMember 2023-12-31 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:CommonStockWarrantsMember 2023-12-31 0001429260 fbio:DirectOfferingMember 2024-01-31 0001429260 fbio:MustangTherapeuticsIncMemberfbio:UbrigeneBostonBiosciencesInc.Member 2023-07-282023-07-28 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:CrystalysTherapeuticsIncMemberus-gaap:SubsequentEventMember 2024-07-15 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2024-06-30 0001429260 fbio:DermatologyProductsSalesMember 2024-06-30 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2023-12-31 0001429260 fbio:DermatologyProductsSalesMember 2023-12-31 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:InvagenPharmaceuticalsIncMember 2024-06-30 0001429260 fbio:CheckpointMemberfbio:DirectOfferingMember 2024-01-012024-01-31 0001429260 fbio:LongTermIncentivePlansMember 2024-01-012024-06-30 0001429260 fbio:LongTermIncentivePlansMember 2023-01-012023-12-31 0001429260 fbio:AvenueTherapeuticsIncMemberus-gaap:WarrantMember 2024-01-012024-06-30 0001429260 us-gaap:WarrantMember 2024-01-012024-06-30 0001429260 fbio:CheckpointMemberfbio:FoundersAgreementMemberfbio:MarketOfferingMember 2024-01-012024-06-30 0001429260 fbio:MustangTherapeuticsIncMembersrt:MaximumMemberfbio:ShelfRegistration2024StatementMember 2024-06-122024-06-12 0001429260 fbio:MustangTherapeuticsIncMemberfbio:ShelfRegistration2024StatementMember 2024-01-012024-06-30 0001429260 fbio:MustangTherapeuticsIncMemberfbio:ShelfRegistration2021StatementMember 2024-01-012024-06-30 0001429260 fbio:CheckpointMembersrt:MaximumMemberfbio:ShelfRegistration2023StatementMember 2023-05-052023-05-05 0001429260 fbio:MustangTherapeuticsIncMemberfbio:ShelfRegistration2021StatementMember 2021-04-232021-04-23 0001429260 fbio:JourneyMember 2024-04-012024-06-30 0001429260 fbio:JourneyMember 2024-01-012024-06-30 0001429260 fbio:JourneyMember 2023-04-012023-06-30 0001429260 fbio:JourneyMember 2023-01-012023-06-30 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:SubsequentEventMember 2024-07-052024-07-05 0001429260 fbio:MustangTherapeuticsIncMemberfbio:DirectOfferingMember 2024-06-30 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:InvagenPharmaceuticalsIncMember 2024-01-012024-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:ConvertibleClassBPreferredStockMember 2022-12-012023-02-28 0001429260 srt:MaximumMember 2024-01-012024-06-30 0001429260 fbio:MaintainsVotingControlMember 2024-01-012024-06-30 0001429260 fbio:JourneyMemberfbio:MarketOfferingMember 2024-01-012024-06-30 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:CrystalysTherapeuticsIncMemberus-gaap:SubsequentEventMember 2024-07-152024-07-15 0001429260 2024-05-132024-05-13 0001429260 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-

gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember 2024-04-012024-06-30 0001429260 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember 2024-01-012024-06-30 0001429260 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember 2024-01-012024-06-30 0001429260 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember 2023-04-012023-06-30 0001429260 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember 2023-01-012023-12-31 0001429260 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:CustomerConcentrationRiskMemberfbio:DermatologyProductsSalesMember 2023-01-012023-06-30 0001429260 fbio:IfOutstandingPrincipalBalanceIsLessThanOrEqualTo10MillionMemberus-gaap:SubsequentEventMember 2024-07-252024-07-25 0001429260 fbio:IfOutstandingPrincipalBalanceIsLessThanOrEqualTo10MillionMemberus-gaap:SubsequentEventMember 2024-07-25 0001429260 fbio:CrystalysTherapeuticsIncMemberus-gaap:SubsequentEventMember 2024-07-15 0001429260 fbio:LongTermIncentivePlansMember 2024-01-012024-01-01 0001429260 fbio:LongTermIncentivePlansMember 2023-01-012023-01-01 0001429260 fbio:SwkTermLoanMemberus-gaap:SubsequentEventMember 2024-07-09 0001429260 fbio:IfOutstandingPrincipalBalanceIsBetween10MillionAnd25MillionMemberus-gaap:SubsequentEventMember 2024-07-25 0001429260 fbio:JourneyMember 2024-06-30 0001429260 fbio:MustangTherapeuticsIncMemberfbio:UbrigeneBostonBiosciencesInc.Member 2024-06-27 0001429260 fbio:CheckpointMemberfbio:CommonStockWarrantsMember 2024-01-012024-06-30 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:CommonStockWarrantsMember 2024-01-012024-06-30 0001429260 fbio:CypriumMemberus-gaap:RelatedPartyMemberfbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2020-08-012020-08-31 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:CommonStockWarrantsMember 2024-01-012024-06-30 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:SubsequentEventMember 2024-07-05 0001429260 fbio:DebtInstrumentRepaymentPeriodFromFebruary2026IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsLessThanThresholdRevenueAsOfDecember312025Memberfbio 2025-01-012025-12-31 0001429260 fbio:DebtInstrumentRepaymentPeriodFromFebruary2027IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsGreaterThanThresholdRevenueAsOfDecember312025Memberfbio 2026-02-012026-02-28 0001429260 fbio:DebtInstrumentRepaymentPeriodFromFebruary2026IfTotalRevenueMeasuredOnTrailingTwelveMonthBasisIsLessThanThresholdRevenueAsOfDecember312025Memberfbio 2026-02-012026-02-28 0001429260 fbio:IfDebtInstrumentsPrepaidPriorToFirstAnniversaryOfClosingDateMemberfbio:SwkTermLoanMember 2024-06-30 0001429260 fbio:IfDebtInstrumentPrepaidOnOrAfterFirstAnniversaryButPriorToSecondAnniversaryOfClosingDateMemberfbio:SwkTermLoanMember 2024-06-30 0001429260 fbio:IfDebtInstrumentPrepaidAfterSecondAnniversaryOfClosingDateMemberfbio:SwkTermLoanMember 2024-06-30 0001429260 fbio:SwkTermLoanMember 2024-06-30 0001429260 us-gaap:SubsequentEventMember 2024-07-252024-07-25 0001429260 fbio:SwkTermLoanMember 2023-12-27 0001429260 fbio:OaktreeNoteMemberus-gaap:SubsequentEventMember 2024-07-25 0001429260 fbio:OaktreeNoteMemberus-gaap:SubsequentEventMember 2024-07-252024-07-25 0001429260 fbio:PartnerCompanyConvertiblePreferredSharesMember 2024-04-012024-06-30 0001429260 fbio:PartnerCompanyConvertiblePreferredSharesMember 2024-01-012024-06-30 0001429260 fbio:Ur1TherapeuticsIncMember 2024-06-30 0001429260 fbio:CheckpointMemberfbio:ShelfRegistration2023StatementMember 2024-06-30 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:ShelfRegistration2021StatementMember 2024-06-30 0001429260 fbio:ShelfRegistrationStatementMember 2024-06-30 0001429260 fbio:ShelfRegistration2024StatementMember 2024-05-17 0001429260 us-gaap:CommonStockMember 2024-04-012024-06-30 0001429260 us-gaap:CommonStockMember 2024-01-012024-06-30 0001429260 us-gaap:CommonStockMember 2023-04-012023-06-30 0001429260 us-gaap:CommonStockMember 2023-01-012023-06-30 0001429260 fbio:CommonSharesIssuableMember 2023-04-012023-06-30 0001429260 fbio:CommonSharesIssuableMember 2023-01-012023-06-30 0001429260 2023-01-012023-12-31 0001429260 fbio:Ur1TherapeuticsIncMemberfbio:CommonStockWarrantsMember 2024-06-272024-06-27 0001429260 fbio:MustangTherapeuticsIncMemberfbio:DirectOfferingMember 2024-06-012024-06-30 0001429260 fbio:MustangTherapeuticsIncMemberfbio:PublicOfferingMember 2024-05-012024-05-31 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:November2023WarrantsMemberus-gaap:PrivatePlacementMember 2024-01-05 0001429260 fbio:AvenueTherapeuticsIncMemberfbio:January2023WarrantsMemberus-gaap:PrivatePlacementMember 2024-01-05 0001429260 fbio:Ur1TherapeuticsIncMemberus-gaap:SubsequentEventMember 2024-07-152024-07-15 0001429260 fbio:MustangTherapeuticsIncMemberfbio:NetAssetsBelow20MillionMemberfbio:UbrigeneBostonBiosciencesInc.Member 2024-06-30 0001429260 fbio:MustangTherapeuticsIncMemberfbio:NetAssetsBelow20MillionMemberfbio:UbrigeneBostonBiosciencesInc.Member 2024-06-272024-06-27 0001429260 fbio:MustangTherapeuticsIncMemberfbio:UbrigeneBostonBiosciencesInc.Member 2024-06-272024-06-27 0001429260 fbio:Ur1TherapeuticsIncMember 2024-01-012024-06-30 0001429260 fbio:OncogenuityMember 2024-01-012024-06-30 0001429260 fbio:MustangTherapeuticsIncMember 2024-01-012024-06-30 0001429260 fbio:HelocyteMember 2024-01-012024-06-30 0001429260 fbio:CypriumMember 2024-01-012024-06-30 0001429260 fbio:CheckpointMember 2024-01-012024-06-30 0001429260 fbio:CellvationMember 2024-01-012024-06-30 0001429260 fbio:BaergicMember 2024-01-012024-06-30 0001429260 fbio:AvenueTherapeuticsIncMember 2024-01-012024-06-30 0001429260 fbio:CypriumMemberus-gaap:RelatedPartyMemberfbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2020-08-31 0001429260 2023-04-012023-06-30 0001429260 us-gaap:NoncontrollingInterestMember 2024-04-012024-06-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001429260 us-gaap:NoncontrollingInterestMember 2024-01-012024-06-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-06-30 0001429260 us-gaap:NoncontrollingInterestMember 2023-04-012023-06-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001429260 us-gaap:NoncontrollingInterestMember 2023-01-012023-06-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-06-30 0001429260 2024-06-30 0001429260 2023-12-31 0001429260 2023-01-012023-06-30 0001429260 2024-04-012024-06-30 0001429260 us-gaap:CommonStockMember 2024-01-012024-06-30 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2024-01-012024-06-30 0001429260 us-gaap:CommonStockMember 2024-08-09 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2024-08-09 0001429260 2024-01-012024-06-30 fbio:segment fbio:Y shares iso4217:USD iso4217:USD shares pure fbio:D fbio:customer fbio:director fbio:company fbio:subsidiary 0001429260--12-312024Q2false342713834271382164652164651Fortress Biotech, Inc.2258703815093053August 31, 2025December 31, 2027http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberhttp://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember0false10-Qtrue2024-06-30false001-35366DE20-51573861111 Kane Concourse Suite 301Bay Harbor IslandsFL33154781652-4500Common StockFBIONASDAQ9.375% Series A Cumulative Redeemable Perpetual Preferred StockFBIOPNASDAQYesYesNon-accelerated Filertruefalsefalse22813954342713876201000809270001046500015222000968700010206000224000167000464900010500000220900010343500011702200035460006505000672123500069487000017877000225440003247500020957000145980001587000145685000167526000148550001696100027885000291260001830003640004100031000410006600021100025900014896000173860002792600029815000655778800050105000643520001089720007340007150001567000175100021220006425000472400010721000512000616600070000597000336900033690002820003950002600006990001036000911960003494000547400028824000593010006784600011444600017876000345250004148100068133000109480002477600026365000463130001333900026917000311990005059500000.73-0.73-3.65-3.65-1.76-1.76-7.14-7.14183168741831687473773327377332177362991773629970864827086482342713830001937534319000733290000-710287000-269620003937000499800049980003429329844510005100010922831000193000019310002693046000460002028345300034060003409000341000341000200800020080005265000526500012363000178760001787600010948000-10948000342713830002258703823000739086000-721235000-32475000-14598000342713830008694477900069355400065577000-17990000198060004217000421700055154100041000660987210007210001106623000108000131000200800020080001446000014460000880008800018500018500030003000300030002720002720005891000589100012172121720003452500034525000-24776000-24776000342713830008777156900023000699020000-680546000-34452000-15943000342713830001509305315000717396000-694870000-209570001587000985600098560004957612984451000510003303305300010115000101180001554483200028240002826000647471140001140002028345300034060003409000299630004148100041481000-26365000-26365000342713830002258703823000739086000-721235000-32475000-14598000342713830007366283700067594400063423300083040005002500089480008948000183856110952620001315200013154000106425116800011680001106623000108000131000401600040160002197700021977000194860006813300068133000-46313000-463130003427138300087771569000230006990200000-680546000-34452000-15943000-67846000-11444600075300014760002900001520005740001365000186700-737000521000017600002796000162900021380001893000105200098560008948000012330004450006166000114000131000030000000-336900026490002923000-4605000-10897000-519000-199300057000135000-1837000-2243000-92700097000-283700043300003640003700010002390000-980000-94000-94000-47225000-765110000200000003400005000050000070390000401600040160001011800013248000282600011680005100003000001330008800035200037100026214000244550001779000003000085400034100000210000500000090000040375000028000000030948000421240008194000-5101000-917440008336500018095400078264000892100003536000513100011500052000340800002209000025090000-6967000036440000-13950000043480000300002460000330000940000 1. Organization and Description of Business Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holding and dividend and royalty revenue streams. Fortress works in concert with its extensive network of key opinion leaders to identify and evaluate promising products and product candidates for potential acquisition. The Company has executed such arrangements in partnership with some of the world’s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center (“COH” or “City of Hope”), Fred Hutchinson Cancer Center, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Cincinnati Children’s Hospital Medical Center, Columbia University, the University of Pennsylvania, AstraZeneca plc and Dr. Reddy’s Laboratories, Ltd. Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business, scientific, regulatory, legal and finance expertise to help the partners achieve their goals. Partner and subsidiary companies then assess a broad range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint ventures, partnerships, out-licensings, sales transactions, and public and private financings. To date, four partner companies are publicly-traded, and three have consummated strategic partnerships with industry leaders, including AstraZeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”) and Sentynl Therapeutics, Inc. (“Sentynl”). Our subsidiaries and partner companies that are pursuing development and/or commercialization of biopharmaceutical products and product candidates are: Avenue Therapeutics, Inc. (Nasdaq: ATXI, “Avenue”), Baergic Bio, Inc. (“Baergic”, a subsidiary of Avenue), Cellvation, Inc. (“Cellvation”), Checkpoint Therapeutics, Inc. (Nasdaq: CKPT, “Checkpoint”), Cyprium Therapeutics, Inc. (“Cyprium”), Helocyte, Inc. (“Helocyte”), Journey Medical Corporation (Nasdaq: DERM, “Journey” or “JMC”), Mustang Bio, Inc. (Nasdaq: MBIO, “Mustang”) and Oncogenuity, Inc. (“Oncogenuity”). As used throughout this filing, the words “we”, “us” and “our” may refer to Fortress individually, to one or more of its subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context. Generally, “subsidiary” refers to a private Fortress subsidiary, “partner company” refers to a public Fortress subsidiary, and “partner” refers to an entity with whom one of the foregoing parties has a significant business relationship, such as an exclusive license or an ongoing product-related payment obligation. The context in which any such term is used throughout this document, however, may dictate a different construal from the foregoing. Liquidity and Capital Resources Since inception, the Company’s operations have been financed primarily through the sale of equity and debt securities, from the sale of subsidiaries/partner companies, and the proceeds from the exercise of warrants. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and prepare regulatory filings and obtain regulatory approvals for its existing and new product candidates. The parent Company’s current cash and cash equivalents of $38.2 million are sufficient to fund the parent entity and private subsidiary operations for at least the next 12 months. However, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, sale of partner companies, grants or other arrangements to develop and prepare regulatory filings and obtain regulatory approvals for the existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for the potential products, sales and marketing capabilities. If such funding is not available or not available on terms acceptable to the Company, the Company’s current development plans and plans for expansion of its general and administrative infrastructure may be curtailed. Fortress also has the ability, subject to limitations imposed by Rule 144 of the Securities Act of 1933 and other applicable laws and regulations, to raise money from the sale of common stock of the public

companies in which it has ownership positions. 4338200000 2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company's annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of Avenue, Checkpoint, Mustang and Journey. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company's Annual Report on Form 10-K, which was filed with the United States Securities and Exchange Commission ("SEC") on March 28, 2024 (the "2023 Form 10-K"), from which the Company derived the balance sheet data at December 31, 2023, as well as Checkpoint's Form 10-K, filed with the SEC on March 22, 2024, Mustang's Form 10-K, filed with the SEC on March 11, 2024, Avenue's Form 10-K, filed with the SEC on March 18, 2024, and Journey's Form 10-K, filed with the SEC on March 29, 2024. The Company's unaudited condensed consolidated financial statements include the results of the Company's subsidiaries for which it has voting control but does not own 100% of the outstanding equity of the subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, but retains voting control, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations and presents non-controlling interests as a component of stockholders' equity on its consolidated balance sheets. All intercompany income and/or expense items are eliminated entirely in consolidation prior to the allocation of net gain/loss attributable to non-controlling interest, which is based on ownership interests as calculated quarterly for each subsidiary. Use of Estimates The preparation of the Company's unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates include, but are not limited to provisions for coupons, chargebacks, wholesaler fees, specialty pharmacy discounts, managed care rebates, product returns, inventory realization, valuation of intangible assets, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Restricted Cash The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of June 30, 2024 and December 31, 2023, the Company had $2.1 million and $2.4 million, respectively, of restricted cash representing pledges to secure debt obligations and letters of credit in connection with certain office leases, and an undertaking posted by Cyprium to secure potential damages in an injunctive proceeding. </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the unaudited condensed consolidated balance sheets to the unaudited condensed consolidated statements of cash flows as of the dates presented:</p><p style="font-family:'Times New Roman',Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 76,201 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,022</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,188</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash and cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 78,264 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 89,210 </td></tr></table> Significant Accounting Policies There have been no material changes in the Company's significant accounting policies to those previously disclosed in the 2023 Form 10-K other than the following: Assets Held for Sale Assets held for sale represent assets that have met the criteria of "held for sale" accounting, as specified by Accounting Standards Codification ("ASC") 360, "Long-lived Assets." As of June 30, 2024, there are $2.2 million of lab and cell processing equipment, furniture and fixtures and computer equipment that are recorded as assets held for sale. The effect of suspending depreciation on the assets held for sale is immaterial to the results of operations. The assets held for sale are part of Mustang's repurchase of assets from uBriGene (Boston) Biosciences, Inc. ("uBriGene") (see Note 3). Recently Issued Accounting Pronouncements Accounting Standards Not Yet Adopted In

November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires that an entity report segment information in accordance with Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on its financial statement disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity's income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on its financial statement disclosures. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company's annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of Avenue, Checkpoint, Mustang and Journey. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company's Annual Report on Form 10-K, which was filed with the United States Securities and Exchange Commission ("SEC") on March 28, 2024 (the "2023 Form 10-K"), from which the Company derived the balance sheet data at December 31, 2023, as well as Checkpoint's Form 10-K, filed with the SEC on March 22, 2024, Mustang's Form 10-K, filed with the SEC on March 11, 2024, Avenue's Form 10-K, filed with the SEC on March 18, 2024, and Journey's Form 10-K, filed with the SEC on March 29, 2024. The Company's unaudited condensed consolidated financial statements include the results of the Company's subsidiaries for which it has voting control but does not own 100% of the outstanding equity of the subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, but retains voting control, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations and presents non-controlling interests as a component of stockholders' equity on its consolidated balance sheets. All intercompany income and/or expense items are eliminated entirely in consolidation prior to the allocation of net gain/loss attributable to non-controlling interest, which is based on ownership interests as calculated quarterly for each subsidiary. 11 Use of Estimates The preparation of the Company's unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates include, but are not limited to provisions for coupons, chargebacks, wholesaler fees, specialty pharmacy discounts, managed care rebates, product returns, inventory realization, valuation of intangible assets, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Restricted Cash The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of June 30, 2024 and December 31, 2023, the Company had $2.1 million and $2.4 million, respectively, of restricted cash representing pledges to secure debt obligations and letters of credit in connection with certain office leases, and an undertaking posted by Cyprium to secure potential damages in an injunctive proceeding. </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash from the unaudited condensed consolidated balance sheets to the unaudited condensed consolidated statements of cash flows as of the dates presented:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 76,201 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,022</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,188</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash and cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 78,264 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 89,210 </td></tr></table>21000002400000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman', 'Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"> 78,022 </td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,063 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,188 </td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash and cash equivalents and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78,264</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 89,210 </td></tr></table>76201000780220002063000111880007826400089210000 Significant Accounting Policies There have been no material changes in the Company's significant accounting policies to those previously disclosed in the 2023 Form 10-K other than the following: Assets Held for Sale Assets held for sale represent assets that have met the criteria of "held for sale" accounting, as specified by Accounting Standards Codification ("ASC") 360, "Long-lived Assets." As of June 30, 2024, there are $2.2 million of lab and cell processing equipment, furniture and fixtures and computer equipment that are recorded as assets held for sale. The effect of suspending depreciation on the assets held for sale is immaterial to the results of operations. The assets held for sale are part of Mustang's repurchase of assets from uBriGene (Boston) Biosciences, Inc. ("uBriGene") (see Note 3). 2200000 Recently Issued Accounting Pronouncements Accounting Standards Not Yet Adopted In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires that an entity report segment information in accordance with Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on its financial statement disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity's income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on its financial statement disclosures. 3. Asset Purchase Agreements Mustang Agreements with uBriGene On May 18, 2023, Mustang entered into an Asset Purchase Agreement (the "Original Asset Purchase Agreement") with uBriGene, pursuant to which Mustang agreed to sell its leasehold interest in its cell processing facility located in Worcester, Massachusetts (the "Facility"), and associated assets relating to the manufacturing and production of cell and gene therapies at the Facility to uBriGene (the "Transaction"). Mustang and uBriGene subsequently entered into Amendment No. 1 to the Original Asset Purchase Agreement, dated as of June 29, 2023 ("Amendment No. 1"), and Amendment No. 2 to the Original Asset Purchase Agreement, dated as of July 28, 2023 ("Amendment No. 2," and together with the Original Asset Purchase Agreement and Amendment No. 1, the "Prior Asset Purchase Agreement"). On July 28, 2023, pursuant to the Prior Asset Purchase Agreement, Mustang completed the sale of all of its assets that primarily relate to the manufacturing and production of cell and gene therapies at the Facility (such operations, the "Transferred Operations" and such assets, the "Transferred Assets") to uBriGene for upfront consideration of $6 million cash (the "Base Amount"). The Transferred Assets included all of Mustang's assets, except for Mustang's lease and related leasehold improvements of the Facility and contracts that are primarily used in the Transferred Operations. Mustang recorded a gain of $1.4 million in connection with the sale of the Transferred Assets and recorded approximately $0.3 million of the base consideration as deferred income, that was to be recognized upon the transfer of the lease. In connection with the Prior Asset Purchase Agreement, Mustang and uBriGene submitted a voluntary joint notice to the U.S. Committee on Foreign Investment in the United States ("CFIUS"). Following CFIUS's review and subsequent investigation of the transactions related to the Prior Asset Purchase Agreement, on May 13, 2024, Mustang, together with uBriGene and CFIUS, executed a National Security Agreement (the "NSA"), pursuant to which Mustang and uBriGene agreed to abandon the transactions related to the Prior Asset Purchase Agreement and the agreements entered into in connection therewith. The NSA obligated uBriGene and Mustang to terminate agreements between the two parties, including the Manufacturing Services Agreement, Quality Services Agreement, and Subcontracting CDMO Agreement. In addition, uBriGene must sell, or otherwise dispose of, the equipment assets purchased within 180 days after the execution of the NSA. June 2024 Repurchase of Assets On June 27, 2024 (the "Effective Date"), Mustang entered into an Asset Purchase Agreement (the "Repurchase Agreement") with uBriGene, pursuant to which Mustang agreed, subject to the terms and conditions set forth therein, to repurchase the Transferred Assets, primarily lab equipment and supplies (collectively, the "Repurchased Assets"). Pursuant to the terms of the Repurchase Agreement, Mustang and uBriGene also terminated existing manufacturing and services agreements.   As consideration for the Repurchase Agreement, Mustang has agreed to pay to uBriGene a total purchase price (the "Purchase Price") of $1.4 million, consisting of (i) an upfront payment of $0.1 million due within five (5) business days of the Effective Date and a (ii) subsequent amount of $1.3 million due on the date that is twelve (12) months after the closing date

(the "Deferred Amount"). In the event that as of the original (or any extended) date on which the Deferred Amount is payable, Mustang has, as of the date of the public reporting of its then-most recent quarterly audited or unaudited financial statements, net assets below $20 million, then Mustang may, upon written notice to uBriGene, elect to delay its payment obligation of the Deferred Amount by an additional six (6) months, with no limit on the number of such extensions available to Mustang. Notwithstanding the foregoing, if Mustang has not paid the Deferred Amount in full as of the date that is twelve (12) months after closing of the Repurchase Agreement, any amounts that remain outstanding will accrue interest at a rate of 5% per annum beginning on the date that is twelve (12) months after closing and until the Deferred Amount is paid in full. Additionally, in connection with the termination of the agreements described above under the Repurchase Agreement, Mustang agreed to forgive a net receivable from uBriGene of approximately $3.3 million, comprised of outstanding receivables of $6.9 million and payables of $3.6 million, resulting in total purchase consideration in the Repurchase Transactions of approximately $4.7 million. As of June 30, 2024, the $1.4 million Purchase Price was recorded in Accrued Expenses - Other (see Note 10). Mustang allocated the total purchase consideration of $4.7 million to the Repurchased Assets on a relative fair value basis. Mustang used a third-party to perform a valuation of the repurchased equipment, which resulted in a fair value less costs to sell of approximately $2.2 million. The remaining purchase consideration of $2.5 million was allocated to the supplies repurchased. The supplies repurchased with no alternative future use were recognized as research and development expense in an amount of $2.2 million. Repurchased supplies with an alternative future use of $0.3 million were also recognized in research and development expense, as Mustang does not have plans to resume operations in the facility, and it intends to dispose of the supplies in a single transaction with the equipment. Mustang concluded that the disposal group, which includes the repurchased equipment assets and associated supplies with an aggregate value of approximately $2.2 million, met the criteria to be classified as held for sale at the date of acquisition. Avenue InvaGen Pharmaceuticals Inc. ("InvaGen") Share Repurchase Under the Share Repurchase Agreement between Avenue and InvaGen Pharmaceuticals, Inc. ("InvaGen") under which Avenue repurchased all of InvaGen's shares in Avenue, Avenue agreed to pay InvaGen an additional amount as a contingent fee, payable in the form of seven and a half percent (7.5%) of the net proceeds of future financings, until $4.0 million in the aggregate is paid to InvaGen. In connection with equity financings in the first half of 2024, Avenue made payments totaling $0.6 million to InvaGen.

* 600000014000003000000P180D14000001000005130000P12M20000000P6MP12M0.05P12M33000006900000360000047000001400000047000002200000250000022000002*

* 4. Inventory <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:77.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:77.4%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:77.4%;background:#cceeff;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"> 4,640 </td></tr><tr><td style="vertical-align:top;width:77.4%;margin:0pt;padding:0pt;"> Work-in-process </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> 296 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"> 884 </td></tr><tr><td style="vertical-align:top;width:77.4%;background:#cceeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"> 6,213 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"> 4,987 </td></tr><tr><td style="vertical-align:top;width:77.4%;margin:0pt;padding:0pt;"> Inventory reserve </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (405) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (305) </td></tr><tr><td style="vertical-align:top;width:77.4%;background:#cceeff;margin:0pt;padding:0pt;"> Total inventories </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,206 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:77.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div*

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:77.4%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:77.4%;background:#cceeff;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"> 4,640 </td></tr><tr><td style="vertical-align:top;width:77.4%;margin:0pt;padding:0pt;"> Work-in-process </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> 296 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"> 884 </td></tr><tr><td style="vertical-align:top;width:77.4%;background:#cceeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"> 6,213 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"> 4,987 </td></tr><tr><td style="vertical-align:top;width:77.4%;margin:0pt;padding:0pt;"> Inventory reserve </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (405) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (305) </td></tr><tr><td style="vertical-align:top;width:77.4%;background:#cceeff;margin:0pt;padding:0pt;"> Total inventories </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,206 </td></tr></table> 3583000464000029600088400062130004987000405000305000968700010206000 5. Property and Equipment <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"> Useful Life </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:65.62%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-

bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Computer equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"> 595 </td></tr><tr><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"> Furniture and fixtures </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 1,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"> 1,017 </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 13,175 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"> 13,175 </td></tr><tr><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"> Buildings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"> 40 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 581 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"> 581 </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29 </td></tr><tr><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"> Total property and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 15,368 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"> 15,397 </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Impairment - leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> (2,177) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"> Less: Accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;">

 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,645) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,892) </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,505 </td></tr></table> Fortress' depreciation expense for the three months ended June 30, 2024 and 2023 was approximately $0.4 million and $0.8 million, respectively, and for the six months ended June 30, 2024 and 2023 was approximately $0.8 million and $1.5 million, respectively. Fortress' depreciation expense is recorded in both research and development expense and general and administrative expense in the condensed consolidated statement of operations. Impairment of Long-Lived Assets During the three months ended June 30, 2024, Mustang concluded it had a triggering event requiring assessment of impairment for certain leasehold improvements and the related right of use asset. Mustang assessed the carrying value of the asset group consisting of the leasehold improvements and right-of-use asset in accordance with ASC 360, given the significant changes to Mustang's operations, operating cash and the repurchase of equipment. The assessment of the recoverability of the asset group concluded that there was impairment on the carrying value of the asset group of approximately $2.6 million, which was allocated on a pro rata basis using the relative carrying amounts of the assets. Approximately $2.2 million of the impairment loss was allocated to leasehold improvements, with the remaining $0.4 million allocated to the right-of-use asset. </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful Life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</p></td></tr><tr><td style="vertical-align:bottom;width:65.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:32.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Computer equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt

3pt 0.05pt 0pt;"> 595 </td></tr><tr><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"> Furniture and fixtures </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 1,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"> 1,017 </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 13,175 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"> 13,175 </td></tr><tr><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"> Buildings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"> 40 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 581 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"> 581 </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> N/A </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29 </td></tr><tr><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"> Total property and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 15,368 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"> 15,397 </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Impairment - leasehold improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> (2,177) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:top;width:65.62%;margin:0pt;padding:0pt;"> Less: Accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,645) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,892) </td></tr><tr><td style="vertical-align:top;width:65.62%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,505 </td></tr>
</table>P3Y595000595000P5Y10170001017000P15Y13175000131750000P40Y5810005810000290001536800015397000217000964500088920003546000650500040000080000
style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt;">6. Fair Value Measurements . Common Stock Warrant Liabilities . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"> Warrants </td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> liabilities </td></tr><tr><td style="vertical-align:bottom;width:83.66%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 886</p></td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Change in fair value of common stock warrants - Avenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (139)</p></td></tr><tr><td style="vertical-align:bottom;width:83.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Change in fair value of common stock warrants - Checkpoint</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Change in fair value of placement agent warrants - Urica</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td></tr><tr><td style="vertical-align:bottom;width:83.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercise of common stock warrants - Avenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> (400)</p></td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exchange of common stock warrants - Urica</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (151)</p></td></tr><tr><td style="vertical-align:top;width:83.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Balance at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 172 </td></tr></table> . Checkpoint . Checkpoint deemed the placement agent warrants it issued in connection with its registered direct offering (the "December 2022 Placement Agent Warrants") to be classified as liabilities on the balance sheet as they contain terms for redemption of the underlying security that are outside its control. The December 2022 Placement Agent Warrants were recorded at the time of closing at a fair value determined by using the Black-Scholes model. Checkpoint will revalue the December 2022 Placement Agent Warrants at each reporting period thereafter for as long as they remain outstanding. At June 30, 2024 and December 31, 2023, the liability associated with the December 2022 Placement Agent Warrants was $0.1 million. . A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the warrant liability that are categorized within Level 3 of the fair value hierarchy was as follows: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:16.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:15.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"> Checkpoint Warrants </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.4%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.51%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:middle;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"> Exercise price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"> 5.41 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"> Volatility </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.94%;margin:0pt;padding:0pt;"> 106.9 </td><td style="vertical-align:middle;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:middle;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:15.34%;margin:0pt;padding:0pt;"> 96.4 </td><td style="vertical-align:middle;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"> Expected life in years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"> 3.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"> 4.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"> Risk-free rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.94%;margin:0pt;padding:0pt;"> 4.5 </td><td style="vertical-align:middle;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:15.34%;margin:0pt;padding:0pt;"> 3.8 </td><td style="vertical-align:middle;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td></tr></table> Avenue Certain of Avenue's outstanding warrants to purchase shares of its common stock are classified as liabilities on the balance sheet as they contain terms for redemption of the underlying security that are outside of its control. The Black-Scholes model was used to value these Avenue warrants, at the time of issuance and when re-measured at each financial reporting date, up to exercise or expiration of the warrants, with any changes in fair value being recognized in change in fair value of warrant liabilities, a component of other income (expense) in the unaudited condensed consolidated statements of operations. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"> Avenue </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"> Warrant </td></tr><tr><td style="vertical-align:bottom;width:81.62%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Liability </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:81.62%;background:#cceeff;margin:0pt;padding:0pt;"> Avenue common stock warrant liabilities at December 31, 2023 </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"> 586 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"> Exercise of Avenue common warrants </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"> (400) </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:81.62%;background:#cceeff;margin:0pt;padding:0pt;"> Change in fair value of common stock warrant liabilities </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (139) </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"> Avenue common stock warrant liabilities at June 30, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">47</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the warrant liability that are categorized within Level 3 of the fair value hierarchy was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">Stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">$ 3.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"> $ 12.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;margin:0pt;padding:0pt;"> 4.52 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;"> 3.84 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;">Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term in years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;margin:0pt;padding:0pt;"> 3.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;"> 3.8 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt

3pt 0pt 0pt;"> 160 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"> 148 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td></tr></table> . Urica . . The fair value of Urica's contingently issuable placement agent warrants in connection with Urica's first close of its preferred offering in December 2022 was measured using a Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Urica's warrant liability that are categorized within Level 3 of the fair value hierarchy was as follows: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.07%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;background:#cceeff;margin:0pt;padding:0pt;"> 3.93 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term in years </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;background:#cceeff;margin:0pt;padding:0pt;"> 0.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;margin:0pt;padding:0pt;"> 153.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> % </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"> Warrants </td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> liabilities </td></tr><tr><td style="vertical-align:bottom;width:83.66%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"> 886 </td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"> Change in fair value of common stock warrants - Avenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"> (139) </td></tr><tr><td style="vertical-align:bottom;width:83.66%;background:#cceeff;margin:0pt;padding:0pt;"> Change in fair value of common stock warrants - Checkpoint </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"> Change in fair value of placement agent warrants - Urica </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"> (24) </td></tr><tr><td style="vertical-align:bottom;width:83.66%;background:#cceeff;margin:0pt;padding:0pt;"> Exercise of common stock warrants - Avenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"> (400) </td></tr><tr><td style="vertical-align:bottom;width:83.66%;margin:0pt;padding:0pt;"> Exchange of common stock warrants - Urica </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (151) </td></tr><tr><td style="vertical-align:top;width:83.66%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 172</p></td></tr></table>886000-139000-24000-400000-151000172000100000100000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;width:16.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Checkpoint Warrants</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.4%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">2024</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.51%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold,">2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"> 5.41 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"> 5.41 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"> Volatility </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.94%;margin:0pt;padding:0pt;"> 106.9 </td><td style="vertical-align:middle;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:middle;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:15.34%;margin:0pt;padding:0pt;"> 96.4 </td><td style="vertical-align:middle;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:middle;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"> Expected life in years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"> 3.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"> 4.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:53.44%;margin:0pt;padding:0pt;"> Risk-free rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.94%;margin:0pt;padding:0pt;"> 4.5 </td><td style="vertical-align:middle;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:15.34%;margin:0pt;padding:0pt;"> 3.8 </td><td style="vertical-align:middle;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td></tr></table>5.415.411.0690.9643.54.00.0450.038 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> <span

style="font-size:1pt;visibility:hidden;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"> Avenue </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"> Warrant </td></tr><tr><td style="vertical-align:bottom;width:81.62%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Liability </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:81.62%;background:#cceeff;margin:0pt;padding:0pt;"> Avenue common stock warrant liabilities at December 31, 2023 </td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">586</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercise of Avenue common warrants</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(400)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:81.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of common stock warrant liabilities</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(139)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:81.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Avenue common stock warrant liabilities at June 30, 2024</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:12.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 47 </td></tr></table>586000-400000-13900047000 <table="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"> December 31 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;">Stock price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> $ 3.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"> $ 12.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;margin:0pt;padding:0pt;"> 4.52 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;"> 3.84 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;"> Expected dividend yield </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term in years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;background:#cceeff;margin:0pt;padding:0pt;"> 3.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;"> 3.8 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.15%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.48%;margin:0pt;padding:0pt;"> 160 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"> 148 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td></tr></table>3.5012.000.04520.04520.03843.33.81.601.48 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.07%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;background:#cceeff;margin:0pt;padding:0pt;"> 3.93 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term in years </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;background:#cceeff;margin:0pt;padding:0pt;"> 0.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.7%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:21.91%;margin:0pt;padding:0pt;"> 153.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"> % </td></tr></table> 0.03930.51.5360.082028341.68P5Y 7. Intangible Assets, net The Company's finite-lived intangible assets consist of intangible assets acquired by Journey. The table below provides a summary of the Journey intangible assets for the periods presented: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> Estimated Useful </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:12.92%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Lives (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:55.97%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible assets - product licenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 3 to 9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"> 37,925 </td></tr><tr><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"> Accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> (16,124) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> (14,495) </td></tr><tr><td style="vertical-align:top;width:55.97%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated Impairment loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,143) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,143) </td></tr><tr><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"> Net intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,287 </td></tr></table> For the three months ended June 30, 2024 and 2023, Journey's amortization expense related to its product licenses was $0.8 million and $1.1 million, respectively. For the six months ended June 30, 2024 and 2023, Journey's amortization expense related to its product licenses was $1.6 million and $2.1 million, respectively. Journey records amortization expense related to its product licenses as a component of cost of goods sold on the unaudited condensed consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The future amortization of these intangible assets is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:84.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td></tr><tr><td style="vertical-align:top;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"> Remainder of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> 1,628 </td></tr><tr><td style="vertical-align:top;width:84.53%;margin:0pt;padding:0pt;"> December 31, 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> 3,257 </td></tr><tr><td style="vertical-align:top;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"> December 31, 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> 2,471 </td></tr><tr><td style="vertical-align:top;width:84.53%;margin:0pt;padding:0pt;"> December 31, 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> 1,775 </td></tr><tr><td style="vertical-align:top;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"> December 31, 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> 1,595 </td></tr><tr><td style="vertical-align:top;width:84.53%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,990 </td></tr><tr><td style="vertical-align:top;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"> Sub-total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,716</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asset not yet placed in service</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,942</p></td></tr><tr><td style="vertical-align:top;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,658 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> Estimated Useful </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Lives (Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:55.97%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible assets - product licenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"> 3 to 9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td

style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"> 37,925 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,925</p></td></tr><tr><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,124)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,495)</p></td></tr><tr><td style="vertical-align:top;width:55.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated Impairment loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,143)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,143)</p></td></tr><tr><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,658 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,287</p></td></tr></table>P3YP9Y3792500037925000161240001449500031430001865800020287000800000110000160000021000000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:84.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td></tr><tr><td style="vertical-align:bottom;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"> Remainder of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,628</p></td></tr><tr><td style="vertical-align:top;width:84.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,257</p></td></tr><tr><td style="vertical-align:top;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 31, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,471</p></td></tr><tr><td style="vertical-align:top;width:84.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 31, 2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,775</p></td></tr><tr><td style="vertical-align:top;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 31, 2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,595</p></td></tr><tr><td style="vertical-align:top;width:84.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,990</p></td></tr><tr><td style="vertical-align:top;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"> 14,716 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.53%;margin:0pt;padding:0pt;"> Asset not yet placed in service </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-

align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,942 </td></tr><tr><td style="vertical-align:top;width:84.53%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,658</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p>162800032570002471000177500015950003990000147160003942000018658000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:12pt 0pt 12pt 0pt;">8. License Agreements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 730-10-25-1, Research and Development, costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use. The licenses purchased by Fortress and its subsidiaries and partner companies require substantial completion of research and development, and regulatory and marketing approval efforts, in order to reach technological feasibility. As such, the purchase price of any licenses acquired is classified as research and development licenses acquired in the unaudited condensed consolidated statement of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">9. Debt and Interest</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total debt consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:46.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Maturity </td></tr><tr><td style="vertical-align:top;width:46.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:46.92%;background:#cceeff;margin:0pt;padding:0pt;"> Oaktree Note </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> 50,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;margin:0pt;padding:0pt;"> 11.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"> August - 2025 </td></tr><tr><td style="vertical-align:top;width:46.92%;margin:0pt;padding:0pt;"> SWK Term Loan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 15,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"> 14.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> December - 2027 </td></tr><tr><td style="vertical-align:top;width:46.92%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Discount on notes payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,993) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,144) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:46.92%;margin:0pt;padding:0pt;"> Total notes payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 67,007 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 60,856 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;">
  </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> </td></tr></table> Oaktree Note In August 2020, Fortress, as borrower, entered into a $60.0 million senior secured credit agreement with Oaktree Fund Administration, LLC and the lenders from time-to-time thereto (collectively, “Oaktree”) (the “Prior Oaktree Agreement” and the debt thereunder, the “Oaktree Note”). The Prior Oaktree Agreement contained customary representations and warranties and customary affirmative and negative covenants as well as certain financial covenants, including, among other things, (i) maintenance of minimum liquidity and (ii) a minimum revenue test that required Journey’s annual revenue to be equal to or to exceed annual revenue projections set forth in the Prior Oaktree Agreement. Failure by the Company or Journey, as applicable, to comply with the Prior Oaktree Agreement covenants would result in an event of default, subject to certain cure rights of the Company. The Company was in compliance with all applicable covenants under the Prior Oaktree Agreement as of June 30, 2024. The Company was required to make quarterly interest-only payments until the fifth anniversary of the closing date of the Oaktree Note, August 27, 2025, at which point the outstanding principal amount would have been due. The Company could have voluntarily prepaid the Oaktree Note at any time subject to a prepayment fee. The Company was required to make mandatory prepayments of the Oaktree Note under various circumstances as defined in the Prior Oaktree Agreement. No mandatory prepayments were required in the six months ended June 30, 2024. On July 25, 2024, Fortress entered into a $50.0 million senior secured credit agreement with a maturity date of July 25, 2027 (the “Agreement”) with Oaktree. The Company borrowed $35.0 million under the Agreement on the Closing Date and is eligible to draw up to an additional $15.0 million at the lenders’ discretion to support future business development activities. The Agreement replaces the Prior Oaktree Agreement in which the remaining $50.0 million balance was repaid in full (see Note 19). <p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> SWK Term Loan On December 27, 2023 (the “SWK Closing Date”), Journey entered into a Credit Agreement with SWK Funding LLC (“SWK”). The Credit Agreement provides for a term loan facility (the “Credit Facility”) in the original principal amount of up to $20.0 million. On the SWK Closing Date, Journey drew $15 million. On June 26, 2024, Journey drew the remaining $5.0 million under the Credit Facility. Loans under the Credit Facility (the “Term Loans”) mature on December 27, 2027. The Term Loans accrue interest which is payable quarterly in arrears. The Term Loans bear interest at a rate per annum equal to the three-month term SOFR (subject to a SOFR floor of 5%) plus 7.75%. The interest rate resets quarterly. Interest payments began in February 2024 and are paid quarterly. On July 9, 2024, Journey entered into an amendment (the “SWK Amendment”) to the Credit Facility. The SWK Amendment increased the total amount available under the Credit Facility from $20.0 million to $25.0 million. The $5.0 million available under the SWK Amendment is contractually required to be drawn upon FDA approval of Journey’s DFD-29 product candidate, subject to Journey receiving such approval on or before June 30, 2025 (See Note 19). Beginning in February 2026, Journey is required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans, with any remaining principal balance due on the maturity date. If the total revenue of Journey, measured on a trailing twelve-month basis, is greater than $70.0 million as of December 31, 2025, the principal repayment start date is extended from February 2026 to February 2027, at which point Journey is required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 15% of the principal amount of funded Term Loans, with any remaining principal balance due on the maturity date. Journey may at any time prepay the outstanding principal balance of the Term Loans in whole or in part. Prepayment of the Term Loans is subject to payment of a prepayment premium equal to (i) 2% of the Term Loans prepaid plus the amount of interest that would have been due through the first anniversary of the SWK Closing Date if the Term Loans are prepaid prior to the first anniversary of the SWK Closing Date, (ii) 1%
 of the Term Loans prepaid if the Term Loans are prepaid on or after the first anniversary of the SWK Closing Date but prior to the second anniversary of the SWK Closing Date, or (iii) 0% if prepaid thereafter.
Upon repayment in full of the Term Loans, Journey will pay an exit fee equal to 5% of the original principal amount of the Term Loans. Additionally, Journey paid an origination fee of $0.2 million on the SWK Closing Date and incurred issuance costs of $0.2 million, both of which have been recorded as a debt discount. Journey is accreting the carrying value of the SWK Term Loan to the original principal balance plus the exit fee over the term of the loan using the effective interest method. The amortization of the discount is accounted for as interest expense in the Consolidated Statement of Operations. The effective interest rate on the SWK Term Loan as of June 30, 2024 was 14.9%.
The SWK Credit Facility also includes both revenue and liquidity covenants, restrictions as to payment of dividends, and is secured by substantially all assets of Journey. As of June 30, 2024, Journey was in compliance with the financial covenants under the SWK Credit Facility. Urica 8% Cumulative Convertible Class B Preferred Offering In December 2022 and February 2023 Urica closed private offerings of its 8% Cumulative Convertible Class B Preferred Stock (the “Urica Preferred Stock”), at a price of $25.00 per share (“Subscription Price”) pursuant to which it sold a total of 135,494 shares of Urica Preferred Stock for gross proceeds of $3.4 million, before deducting underwriting discounts and commissions and offering expenses of approximately $0.5 million (the “Urica Offering”). A non-cash contingent warrant value of $0.1 million was also recorded in debt discount (see Note 6).
Dividends on the Urica Preferred Stock were payable monthly by Fortress in shares of Fortress Common Stock based upon a 7.5% discount to the average closing price over the 10-day period preceding the dividend payment date. Dividends were recorded as interest expense. For the three month periods ended June 30, 2024 and 2023, the Company recorded expense of $0.1 million and $0.1 million associated with the Urica dividends and for the six month periods ended June 30, 2024 and 2023, the Company recorded expense of $0.1 million and $0.1 million associated with the Urica dividends. The shares mandatorily converted into Urica common stock upon either: (i) a qualified financing pursuant to which Urica raises at least $20 million in aggregate gross proceeds; or (ii) a sale of Urica. Additionally, in the event that neither such a qualified financing nor a sale of Urica had occurred prior to June 27, 2024, then each holder of Urica Preferred Stock was eligible to receive, at Fortress’ election, one of: (x) a cash payment equal to the product of the Subscription Price and the number of shares of Urica Preferred Stock held by such holder; (y) a number of shares of Fortress common stock equal to the Fortress Share Exchange Amount; or (z) a combination of the foregoing. On June 27, 2024, as neither a qualified financing nor a sale of Urica occurred, Fortress elected to exchange the outstanding shares of Urica Preferred Stock, which was recorded as a liability, into 2,028,345 shares

of Fortress common stock. Interest Expense Interest expense includes contractual interest, and fees include amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan. The following table shows the components of interest expense for all debt arrangements during the periods presented: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:57.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Oaktree Note </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 1,390 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 1,912 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 1,391 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 712 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"> 2,103 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Partner company convertible preferred shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> (403) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> (358) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 391 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 239 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> 630 </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Partner company installment payments - licenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"> 85 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Partner company notes payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 499 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 64 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 563 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 3,301 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 272 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> 3,573 </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Total Interest Expense and Financing Fee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 631 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,202 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,425 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:57.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Oaktree Note </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 2,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 1,024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 3,805 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 1,136 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,917 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Partner company convertible preferred shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> (290) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 90 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> (200) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 651 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 299 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> 950 </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Partner company installment payments - licenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 176 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"> 176 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Partner company notes payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 985 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 126 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 1,111 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 4,801 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 432 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> 5,233 </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 113 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 332 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 445 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Total Interest Expense and Financing Fee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,240 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,721 </td></tr></table> Total debt consists of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.92%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Maturity </td></tr><tr><td style="vertical-align:top;width:46.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:46.92%;background:#cceeff;margin:0pt;padding:0pt;"> Oaktree Note </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> 50,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;margin:0pt;padding:0pt;"> 11.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"> August - 2025 </td></tr><tr><td style="vertical-align:top;width:46.92%;margin:0pt;padding:0pt;"> SWK Term Loan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"> 20,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 15,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"> 14.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> December - 2027 </td></tr><tr><td style="vertical-align:top;width:46.92%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Discount on notes payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,993) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,144) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:46.92%;margin:0pt;padding:0pt;"> Total notes payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 60,856 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> </td></tr></table>500000005000000000.1102000000015000000.1492993000414400067007000608560060000000.02025-08-2750000000.035000000.015000000.050000000.020000000.0150000005000000.050.077520000000.025000000.05000000.00.07570000000.00.150.020.0100.052000002000000.style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:57.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Oaktree Note </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 1,390 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 1,912 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 1,391 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 712 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"> 2,103 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Partner company convertible preferred shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> (403) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> (358) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 391 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 239 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> 630 </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Partner company installment payments - licenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 85 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Partner company notes payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 499 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 64 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 563 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 3,301 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 272 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> 3,573 </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Total Interest Expense and Financing Fee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-

align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 631 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,202 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,425 </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:57.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:41.02%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Oaktree Note </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 2,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-

align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 1,024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 3,805 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 1,136 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,917 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Partner company convertible preferred shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> (290) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 90 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> (200) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 651 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 299 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> 950 </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Partner company installment payments - licenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> 176 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"> 176 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Partner company notes payable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 985 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 126 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 1,111 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 4,801 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> 432 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> 5,233 </td></tr><tr><td style="vertical-align:top;width:41.02%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
— </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
8 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
113 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
332 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
445 </td></tr><tr><td style="vertical-align:top;width:41.02%;margin:0pt;padding:0pt;"> Total Interest Expense and Financing Fee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">
3,484 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">
1,240 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">
4,724 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">
8,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">
2,199 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">
10,721 </td></tr></table> 139000052200019120001391000712000210300040300045000-358000391000239000630000850008500049900064000563000330100027200035730005000500034000340001491000631000212200052020001223000642500027810001024000290000900000-2000006510002990009500000001760000176000985000126000111100048010004320005233000800008000811300033200044500034840001240000472400085220002190000100style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">10. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.95832825%;padding-left:0pt;padding-right:0pt;width:101.91%;">
<tr style="height:1pt;"><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"> Accounts payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;">
37,957 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,810</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,681</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Salaries, bonus and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,531</p></td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,644</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,015</p></td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued coupon and rebates </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,987</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Return reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,077</p></td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other¹</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 817</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 68,921 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,562 </td></tr></table> . Note 1: Includes approximately $1.4 million of accrued consideration related to Mustang's Asset Purchase Agreement with uBriGene (see Note 3) as of June 30, 2024. . Accounts payable and accrued expenses consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.95832825%;padding-left:0pt;padding-right:0pt;width:101.91%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman', 'Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"> Accounts payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 34,810 </td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> Accrued expenses: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"> Professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 2,260 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 1,681 </td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> Salaries, bonus and related benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 4,903 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 8,531 </td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 8,547 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 11,644 </td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> Accrued royalties payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 1,656 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 2,015 </td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued coupon and rebates </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 6,596 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 9,987 </td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> Return reserve </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 3,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 4,077 </td></tr><tr><td style="vertical-align:top;width:74.38%;background:#cceeff;margin:0pt;padding:0pt;"> Other¹ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,788 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 817 </td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"> Total accounts payable and accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,562 </td></tr></table> Note 1: Includes approximately $1.4 million of accrued consideration related to Mustang's Asset Purchase Agreement with uBriGene (see Note 3) as of June 30, 2024.
3795700034810000226000016810004903000853100085470001164400016560002015000659600099870003214000407700037880008170006892100073562000014000004 11. Non-Controlling Interests The Company's ownership interests in its consolidated subsidiaries at June 30, 2024 was similar to December 31, 2023, except for Mustang which decreased from 19% to 7.2%. 0.190.072 12. Net Loss per Common Share Basic and diluted net loss per share attributed to common stockholders is calculated by dividing the net loss attributed to Fortress, less the Series A Preferred dividends and adjusted for subsidiary deemed dividends, by the weighted-average number of shares of Common Stock outstanding during the period, not including unvested restricted stock, and without consideration for Common Stock equivalents. Diluted net loss per share is the same as the basic loss per share due to net losses in all periods. For the three and six months ended June 30, 2024, the effect on the net loss per share calculation from Series A Preferred dividends was $2.0 million and $4.0 million, respectively, and partner company deemed dividends were $0.4 million and $0.8 million, respectively. For the three and six months ended June 30, 2023, the effect on the net loss per share calculation from Series A Preferred dividends was $2.0 million and $4.0 million, respectively, and partner company deemed dividends were $0.1 million and $0.3 million, respectively. The following shares of potentially dilutive securities, weighted during the six months ended June 30, 2024 and 2023, have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.92%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants to purchase Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"> 5,769,787 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"> 1,127,296 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> Options to purchase Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> 18,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> 36,423 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested Restricted Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"> 1,693,684 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"> 1,374,116 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> Unvested Restricted Stock Units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 273 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 73 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,482,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,537,908 </td></tr></table>

2000000.04000000.040000008000002000000.04000000.0100000300000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.92%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants to purchase Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"> 5,769,787 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"> 127,296 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> Options to purchase Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> 18,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> 36,423 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested Restricted Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"> 1,693,684 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"> 1,374,116 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"> Unvested Restricted Stock Units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 273 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 73 </td></tr><tr><td style="vertical-align:bottom;width:73.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,482,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,537,908 </td></tr></table> 576978712729618896364231693684137411627373748264015379 13. Stockholders' Equity Stock-based Compensation As of June 30, 2024, the Company had the following equity compensation plans: the Fortress Biotech, Inc. 2013 Stock Incentive Plan, as amended (the "2013 Plan"), the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan (the "ESPP") and the Fortress Biotech, Inc. Long Term Incentive Plan ("LTIP"). In May 2024, the Company's Board of Directors and stockholders approved an amendment to the 2013 Plan to increase the number of authorized shares issuable by 10.0 million shares, and approved an amendment to the ESPP to increase the number of shares issuable by 1.0 million. As of June 30, 2024, approximately 10.0 million shares were available for issuance under the 2013 Plan. The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the periods presented: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Fortress: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> Employee and non-employee awards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 2,271 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 4,708 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Executive awards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 273 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 410 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 497 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 817 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Partner Companies: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> Avenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> 192 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 27 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> 383 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 38 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Checkpoint </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 1,171 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 567 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 1,881 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 1,536 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> Mustang </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> (619) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> (542) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 280 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Journey </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 1,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 873 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 3,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 1,519 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 58 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 115 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 50 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,217 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,948 </td></tr></table> For the three months ended June 30, 2024 and 2023, approximately $0.7 million and $0.5 million, respectively, of stock-based compensation expense was included in research and development expenses in connection with equity grants made to employees and consultants and approximately $4.3 million and $3.7 million, respectively, was included in general and administrative expenses in connection with grants made to employees, members of the board of directors and consultants. For the six months ended June 30, 2024 and 2023, approximately $1.7 million and $1.5 million, respectively, of stock-based compensation expense was included in research and development expenses in connection with equity grants made to employees and consultants and approximately $8.1 million and $7.5 million, respectively, was included in general and administrative expenses in connection with grants made to employees, members of the board of directors and consultants. Stock Options The following table summarizes Fortress stock option activities excluding activity related to Fortress subsidiaries and partner companies: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> Weighted average </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> remaining </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> Weighted average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> weighted average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> contractual life </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;">exercise price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> intrinsic value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"> Options vested and expected to vest at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"> 18,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"> 1.76 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.4%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 540,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6.71 </td></tr><tr><td style="vertical-align:bottom;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"> Options vested and expected to vest at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 558,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6.52 </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> Options vested and exercisable at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.26 </td></tr></table> As of June 30, 2024 and 2023, Fortress had $0.6 million and $0.6 million, respectively, in unrecognized stock-based compensation expense related to options which is expected to be recognized over the remaining weighted-average vesting period of 3.6 years and 5.7 years, respectively. Restricted Stock and Restricted Stock Units The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress subsidiaries and partner companies: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:13.89%;margin:0pt;padding:0pt;"> average grant </td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> price </td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"> 1,458,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.05</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 443,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.01</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,303)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.76</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.84</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,582)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.43</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,684)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39.61</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,861,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21.27 </td></tr></table> As of June 30, 2024 and 2023, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of approximately $11.5 million and $16.0 million, respectively, which is expected to be recognized over the remaining weighted-average vesting period of 1.3 years and 2.0 years, respectively. Warrants The following table summarizes Fortress warrant activities, excluding activities related to Fortress subsidiaries and partner companies: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"> Total weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> Weighted average </td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"> average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> remaining </td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"> Weighted average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"> intrinsic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> contractual life </td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> exercise price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:top;width:37.57%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"> 5,787,289 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"> 7,794,450 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> 4.91 </td></tr><tr><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"> Issued </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> 3,506,140 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> 3.12 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> 8,113 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:top;width:37.57%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (17,500) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1.70 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,275,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 64,538 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4.46 </td></tr><tr><td style="vertical-align:top;width:37.57%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,275,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 64,538 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4.46 </td></tr></table> . Long-Term Incentive Program (“LTIP”) On July 15, 2015, the Company’s stockholders approved the LTIP for the Company’s Chairman, President and Chief Executive Officer, Dr. Rosenwald, and Executive Vice Chairman, Strategic Development, Mr. Weiss (amended and restated with stockholder approval on June 7, 2017 and May 23, 2024). The LTIP consists of a program to grant equity interests in the Company and in the Company’s subsidiaries, and a performance-based bonus program that is designed to result in performance-based compensation that is deductible without limit under Section 162(m) of the Internal Revenue Code of 1986, as amended. . On January 1, 2024 and 2023, the Compensation Committee granted 216,465 shares each to Dr. Rosenwald and Mr. Weiss. These equity grants were made in accordance with the LTIP, and each award represents 1% of total outstanding shares of the Company as of the dates of such grants. The shares’ original vesting terms includes vesting in full if the employee was either in the service of the Company as an employee, Board member or consultant (or any combination of the foregoing) on the tenth anniversary of the LTIP, or the eligible employee has an involuntary Separation from Service (as defined in the LTIP). The only other vesting condition – one based on the achievement of an increase in the Company’s market capitalization – has already been achieved, with respect to each annual award under the LTIP. The shares awarded under the LTIP will also vest in full (and the Company’s repurchase option on each tranche of shares granted thereunder will accordingly lapse) upon the occurrence of a Corporate Transaction (as defined in the LTIP), if the eligible employee is in service to the Company on the date of such Corporate Transaction. The fair value of each grant on the grant date was approximately $0.7 million for the 2024 grant and $0.8 million for the 2023 grant. For the three months ended June 30, 2024 and 2023, the Company recorded stock compensation expense related to LTIP grants of approximately $1.7 million and $1.5 million, respectively, and for the six months ended June 30, 2024 and 2023, the Company recorded stock compensation expense related to LTIP grants of approximately $3.3 million and $2.9 million, respectively, on the unaudited condensed consolidated statement of operations. Capital Raises 2021 Shelf On July 23, 2021, the Company filed a shelf registration statement (File No. 333-258145) on Form S-3, which was declared effective on July 30, 2021 (the “2021 Shelf”). Approximately $86.2 million of securities were available for sale under the 2021 Shelf as of June 30, 2024, subject to General Instruction I.B.6. of Form S-3. On May 17, 2024, the Company filed a shelf registration statement (File No. 333-279516) on Form S-3, which was declared effective on May 30, 2024 (the “2024 Shelf”). All $50.0 million of securities were available for sale under the 2024 Shelf as of June 30, 2024, subject to General Instruction I.B.6. of Form S-3. At the Market Offering During the six months ended June 30, 2024, the Company issued and sold approximately 1.6 million shares at an average price of $1.87 per share for gross proceeds of $2.9 million. During the six months ended June 30, 2023, the Company issued and sold approximately 0.1 million shares at an average price of $11.31 for gross proceeds of $1.2 million. Registered Direct Offering In January 2024, Fortress closed a registered direct offering of an aggregate of 3,303,305 shares of its common stock and warrants to purchase up to 3,303,305 shares of its common stock at a combined purchase price of $3.33 per share of common stock and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $3.21 per share, were immediately exercisable, and expire five years following the date of issue. Net proceeds to Fortress, after deducting the placement agent’s fees and other offering expenses, were approximately $10.2 million. Checkpoint 2023 Shelf Registration Statement In March 2023, Checkpoint filed a shelf registration statement (File No. 333-270843) on Form S-3 (the “Checkpoint 2023 S-3”), which was declared effective May 5, 2023. Under the Checkpoint 2023 S-3, Checkpoint may sell up to a total of $150 million of its securities. As of June 30, 2024, approximately $77.7 million of the securities remains available for sale through the Checkpoint 2023 S-3, subject to General Instruction I.B.6 of Form S-3. . Checkpoint Registered Direct Offering In January 2024, Checkpoint closed on a registered direct offering (the “Checkpoint January 2024 Registered Direct Offering”) with a single institutional investor for the issuance and sale of 1,275,000 shares of its common stock and 6,481,233 pre-funded warrants. Each pre-funded warrant was exercisable for one share of Checkpoint common stock. The Checkpoint common stock and the pre-funded warrants were sold together with common stock warrants (the “Checkpoint January 2024 Common Warrants”) to purchase up to 7,756,233 shares of Checkpoint common stock, at a purchase price of $1.805 per share of common stock and $1.8049 per pre-funded warrant. The pre-funded warrants were funded in full at closing except for a nominal exercise price of $0.0001 and are exercisable commencing on the closing date and will terminate when such pre-funded warrants are exercised in full. The Checkpoint January 2024 Common Warrants are exercisable immediately upon issuance and will expire five years following the issuance date and have an exercise price of $1.68 per share. Checkpoint also issued the placement agent warrants to purchase up to 465,374 shares of common stock with an exercise price of $2.2563 per share. Net proceeds to Checkpoint from the Checkpoint January 2024 Registered Direct Offering were $12.6 million after deducting commissions and other transaction costs. As of July 2024, all of the pre-funded warrants from the Checkpoint January 2024 Registered Direct Offering were fully exercised (see Note 19). Pursuant to the Company’s Founders Agreement with Checkpoint, Checkpoint issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the registered direct offering noted above. Accordingly, Checkpoint issued 193,905 shares of common stock to Fortress for the six months ended June 30, 2024. Avenue 2021 Shelf Registration Statement In December 2021, Avenue filed a shelf registration statement (File No. 333-261520) on Form S-3 (the “Avenue 2021 S-3”), which was declared effective on December 10, 2021. As of June 30, 2024, approximately $24.6 million of the securities were available for sale under the Avenue 2021 S-3, subject to General Instruction I.B.6. of Form S-3. Avenue 2024 Warrant Exercises and Private Placement On January 5, 2024, Avenue entered into (i) an inducement offer letter agreement (the “January 2023 Investor Inducement Letter”) with a certain investor (the “January 2023 Investor”) in connection with certain outstanding warrants to purchase up to an aggregate of 25,871 shares of Common Stock, originally issued to the January 2023 Investor on January 31, 2023 (the “January 2023 Warrants”) and (ii) an inducement offer letter agreement (the “November 2023 Investor Inducement Letter Agreement” and, together with the January 2023 Investor Inducement Letter, the “January 2024 Warrant Inducement”) with certain investors (the “November 2023 Investors” and, together with the January 2023 Investor, the “Holders”) in connection with certain outstanding warrants to purchase up to an aggregate of 194,667 shares of Common Stock, originally issued to the November 2023 Investors on November 2, 2023 (the “November 2023 Warrants” and, together with the January 2023 Warrants, the “Existing Warrants”). The January 2023 Warrants had an exercise price of $116.25 per share, and the November 2023 Warrants had an exercise price of $22.545 per share. . Pursuant to the January 2024 Warrant Inducement, (i) the January 2023 Investor agreed to exercise its January 2023 Warrants for cash at a reduced exercise price of $22.545 per share and (ii) the November 2023 Investors agreed to exercise their November 2023 Warrants for cash at the existing exercise price of $22.545, in each case in consideration for Avenue’s agreement to issue in a private placement (x) Series A Warrants to purchase up to 220,538 shares of Avenue Common Stock and (y) Series B Warrants to purchase up to 220,538 shares of Avenue Common Stock. The net proceeds to Avenue from the exercise of the warrants was approximately $4.5 million, after deducting placement agent fees and estimated offering costs, but without giving effect to the exercise of the Series A Warrants and Series B Warrants issued in the January 2024 Warrant Inducement. . The fair value of the Series A Warrants and Series B Warrants was allocated between the January 2023 Warrants and the November 2023 Warrants on a weighted basis, with approximately $0.6 million allocated to the January 2023 Warrants and recorded to loss on common stock warrant liabilities in the condensed consolidated statement of operations, and the approximately $4.3 million allocated to the November 2023 Warrants deemed to be a dividend such that it was included in net loss attributable to common stockholders in the calculation of net loss per share in the condensed consolidated statement of operations (see Note 12). . . Also in April 2024, Avenue entered into definitive agreements for the immediate exercise of certain of its existing outstanding warrants for cash an aggregate of 689,680 warrants for shares of Avenue’s common stock at a reduced exercise price of $6.20 per share (the “May 2024 Warrant Inducement”). The exercised warrants are comprised of warrants to purchase shares of common stock originally issued by Avenue on October 11, 2022, each having an exercise price of $116.25 per share, Series A and Series B warrants to purchase shares of common stock originally issued by Avenue on November 2, 2023, each having an exercise price of $22.545 per share, and warrants to purchase shares of common stock originally issued by Avenue on January 9, 2024, each having an exercise price of $22.545 per share. In consideration for the immediate exercise of the warrants for cash in the May 2024 Warrant Inducement, Avenue issued two new unregistered series of warrants to purchase up to a total of 1,379,360 shares of Avenue common stock for a payment of $0.125 per warrant. The warrants have an exercise price of $6.20 per share, and terms of eighteen months for one

series and five years for the other series. Total net proceeds to Avenue were approximately $3.7 million after deducting placement agent fees and other expenses payable by Avenue. In May 2024, Avenue entered into an At-the-Market Offering Agreement (the "Avenue ATM") under which Avenue may offer and sell, from time to time at its sole discretion, up to $3.9 million of shares of its common stock. The offer and sale of the shares will be made pursuant to a base prospectus forming a part of the 2021 Avenue S-3, and the related prospectus supplement dated May 10, 2024. During the six months ended June 30, 2024, Avenue issued 87,683 shares through the Avenue ATM for net proceeds of $0.3 million. Pursuant to the Company's Founders Agreement with Avenue, Avenue issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the warrant exercises noted above. Accordingly, Avenue issued 25,567 shares of common stock to Fortress for the six-month period ended June 30, 2024. Mustang 2021 Shelf Registration Statement and At-the-Market Offering (the "Mustang ATM") On April 23, 2021, Mustang filed a shelf registration statement on Form S-3 (File No. 333-255476) (the "Mustang 2021 S-3"), which was declared effective on May 24, 2021. Under the Mustang 2021 S-3, Mustang was able to sell up to a total of $200.0 million of its securities. In the six months ended June 30, 2024, Mustang sold approximately $4.4 million of securities under the Mustang 2021 S-3 until its expiration on May 24, 2024. On May 31, 2024, Mustang filed a shelf registration statement on Form S-3 (File No. 333-279891) (the "Mustang 2024 S-3"), which was declared effective on June 12, 2024. Under the Mustang 2024 S-3, Mustang may sell up to a total of $40.0 million of its securities. As of June 30, 2024, approximately $37.5 million of the Mustang 2024 S-3 remains available for sales of securities, subject to General Instruction I.B.6. of Form S-3. On May 31, 2024, Mustang entered into an At-the-Market Offering Agreement (the "Mustang ATM") relating to the sale of shares of common stock pursuant to the Mustang 2024 S-3. During the six months ended June 30, 2024, Mustang issued no shares through the Mustang ATM. Mustang Public Offering In May 2024, Mustang closed on a public offering of 1,160,000 shares of common stock and pre-funded warrants to purchase up to 15,717,638 shares of common stock (or common stock equivalents in lieu thereof), and three series of 16,877,638 warrants each for a total of 50,632,914 warrants with a combined public offering price of $0.237 per share (or per share common stock equivalent in lieu thereof) and accompanying warrants with an exercise price of $0.237 per share. The Series A-1 warrants have a five-year term, the Series A-2 warrants have a twenty-four month term, and the Series A-3 warrants have a nine month term. The warrants contain customary anti-dilution adjustments to the exercise price, including share splits, share dividends, rights offerings and pro rata distributions. The net proceeds of the public offering, after deducting the fees and expenses of the placement agent and other offering expenses payable by Mustang was approximately $3.3 million. All of the 15,717,638 pre-funded warrants were exercised as of June 30, 2024. Mustang also amended certain existing warrants to purchase up to 2,588,236 shares of common stock previously issued in October 2023 with an exercise price of $1.58 per share such that the amended warrants have a reduced exercise price of $0.237 per share, and have a five-year term from date of shareholder approval. Mustang Registered Direct Offering In June 2024, Mustang closed on a registered direct offering of 3,025,000 shares of common stock at $0.41 per share (or common stock equivalent) priced at-the-market under Nasdaq rules and pre-funded warrants to purchase up to 3,105,000 shares of common stock, at a price per pre-funded warrant equal to $0.4099, the price per share of common stock, less $0.001. The pre-funded warrants have an exercise price of $0.001 per share, became exercisable upon issuance and remain exercisable until exercised in full. In a concurrent private placement, Mustang also agreed to issue and sell unregistered warrants to purchase up to 6,130,000 shares of its common stock, with an exercise price of $0.41 per share, exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants and will expire five years from the date of stockholder approval. Net proceeds were approximately $2.2 million, after placement agent's fees and other offering expenses of approximately $0.3 million. All of the 3,105,000 pre-funded warrants were exercised as of June 30, 2024. Pursuant to the Company's Founders Agreement with Mustang, Mustang issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the financings noted above. Accordingly, Mustang issued 575,191 shares of common stock to Fortress for the six-month period ended June 30, 2024. Journey 2022 Shelf Registration Statement and At-the-Market Offering On December 30, 2022, Journey filed a shelf registration statement on Form S-3 (File No. 333-269079) (the "Journey 2022 S-3"), which was declared effective on January 26, 2023. The Journey 2022 S-3 covers the offering, issuance and sale by Journey of up to an aggregate of $150.0 million of Journey's common stock, preferred stock, debt securities, warrants, and units. In connection with the Journey 2022 S-3, Journey entered into a sales agreement relating to the sale of shares of Journey's common stock in an at-the-market offering (the "Journey ATM Sales Agreement"). In accordance with the terms of the Journey ATM Sales Agreement, Journey may offer and sell up to 4,900,000 shares of its common stock, par value $0.0001 per share, from time to time. For the six months ended June 30, 2024, Journey issued and sold approximately 0.3 million shares of common stock at an average price of $5.28 per share for gross proceeds of $1.5 million under the Journey ATM Sales Agreement. At June 30, 2024, 3,861,553 shares remain available for issuance under the Journey ATM Sales Agreement.</p>10000000.01000000.010000000.0<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Fortress: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;">Employee and non-employee awards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 2,271 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 4,708 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Executive awards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 273 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 410 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 497 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 817 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Partner Companies: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> Avenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> 192 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 27 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> 383 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 38 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Checkpoint </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 1,171 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 567 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 1,881 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 1,536 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> Mustang </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> (619) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 45 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> (542) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 280 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Journey </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 1,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 873 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 3,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 1,519 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 58 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 115 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 50 </td></tr><tr><td style="vertical-align:bottom;width:36.92%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,217 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,948 </td></tr>
</table>22490002271000444200047080002730004100004970008170001920002700038300038000117100056700018810001536000-61900045000-542000280000167400087300030800001519000580002400011500050000499800042170009856000894800070000050000043000003700000170000015000008100000750000-style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> Weighted average </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> remaining </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> Weighted average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> weighted average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> contractual life </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> exercise price </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> intrinsic value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"> Options vested and expected to vest at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"> 18,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"> 1.76 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.4%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 540,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6.71 </td></tr><tr><td style="vertical-align:bottom;width:43.4%;background:#cceeff;margin:0pt;padding:0pt;"> Options vested and expected to vest at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 558,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6.52 </td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"> Options vested and exercisable at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.26 </td></tr>
</table>1889620.55P1Y9M3D5400001.6816200P6Y8M15D5588962.3216200P6Y6M7D1889620.55P1Y3M3D600000600000P3Y7M6DP5Y8M12D <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"> average grant </td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> price </td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"> 1,458,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"> 28.05 </td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> Restricted stock granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> 443,024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> 3.01 </td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"> (17,303) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"> 35.76 </td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> Restricted stock units granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"> 37,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;">

1.84 </td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"> (10,582) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"> 11.43 </td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"> Restricted stock units vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (49,684) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39.61 </td></tr><tr><td style="vertical-align:bottom;width:69.31%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested balance at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,861,655 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21.27 </td></tr>
</table>145870028.054430243.011730335.76375001.841058211.434968439.61186165521.271150000016000000.0P1Y3M18DP2Y <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"> Total weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> Weighted average </td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"> average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> remaining </td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"> Weighted average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"> intrinsic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> contractual life </td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> exercise price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:top;width:37.57%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"> 5,787,289 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"> 7,794,450 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> 4.91 </td></tr><tr><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"> Issued </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> 3,506,140 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> 3.12 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"> 8,113 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:top;width:37.57%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (17,500) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1.70 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,275,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 64,538 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4.46 </td></tr><tr><td style="vertical-align:top;width:37.57%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,275,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 64,538 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4.46 </td></tr></table>57872891.887794450P4Y10M28D35061403.128113175001.7092759292.3564538P4Y5M15D92759292.3564538P4Y5M15D2164652164650.010.017000008000001700000

14. Commitments and Contingencies

Leases

At June 30, 2024, Mustang identified triggering events that required an impairment of the asset group consisting of its' right-of-use asset and associated leasehold improvements. The assessment concluded that impairment existed as of June 30, 2024, and the impairment loss was allocated to the leasehold improvements and right-of-use assets based on the relative carrying amounts of the assets (see Note 3).

During three and six months ended June 30, 2024 and 2023, the Company recorded the following as lease costs for the periods presented:

<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> 950 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> 1,969 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> Shared lease costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> (519) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> (519) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> (1,042) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> (1,034) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 174 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 199 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 390 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 400 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> Total lease expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 630 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,335 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr></table> The following tables summarize quantitative information about the Company's operating leases, under the adoption of ASC Topic 842, Leases: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"> Operating cash flows from operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,850)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> (1,762) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"> Right-of-use assets exchanged for new operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease term – operating leases (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 4.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 4.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"> Weighted-average discount rate – operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> 6.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> 6.5 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> 0 </td></tr></table> 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"> 0 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.49%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"> Future Lease </td></tr><tr><td style="vertical-align:bottom;width:84.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> 0 </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Liability </td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"> Nine Months Ended December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,819</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,542</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,272</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,923</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,967</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,125</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,648</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,233)</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating lease liabilities, short-term and long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,415 </td></tr></table> 0 Indemnification In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company's request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. The Company and its subsidiaries and partner companies also provide indemnification of contractual counterparties (sometimes without monetary caps) to clinical sites, service providers and licensors. 0 Legal Proceedings 0 In the ordinary course of business, the Company and its subsidiaries and partner companies may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company's product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeing resulting alleged damages. 0 University of Tennessee Research Foundation v. Caelum Biosciences, Inc. Caelum Biosciences, Inc. ("Caelum"), a former subsidiary of Fortress that was sold to AstraZeneca's Alexion ("Alexion") in October 2021, is the defendant in a lawsuit brought by The University of Tennessee Research Foundation ("UTRF") captioned as University of Tennessee Research Foundation v. Caelum Biosciences, Inc., No. 19-cv-00508, which is pending in the United States District Court for the Eastern District of Tennessee (the "UTRF Litigation"). UTRF brought claims against Caelum, for, inter alia, tortious interference and trade secret misappropriation. UTRF primarily alleges that Caelum unauthorizedly used non-patent trade secrets owned by UTRF in the development of Caelum's 11-1F4 monoclonal antibody, known as CAEL-101. Under the agreement pursuant to which Alexion acquired Caelum (as amended, the "DOSPA"), Fortress has indemnification obligations of Caelum under certain circumstances, including for certain of Caelum's legal expenses and potential damages arising out of the UTRF Litigation (with such indemnification capped in the aggregate as to Fortress at the amount of Caelum acquisition proceeds received by Fortress – approximately $57 million to date - and which, at Caelum's election, may be satisfiable in the form of offsets against future amounts that Caelum may owe Fortress under the DOSPA). Caelum is defending the UTRF Litigation, with Fortress participating in such defense and maintaining a consent right over any potential settlements. Caelum's legal fees and costs in defending the UTRF Litigation are being reimbursed by Fortress by distribution from a $15 million escrow account established concurrently with the acquisition of Caelum; Fortress considers the amount remaining in escrow to be in excess of the amount of its anticipated out-of-pocket indemnifiable costs and damages in the UTRF Litigation and therefore has not accrued any liability pertaining to this indemnity. Caelum and Fortress both believe the UTRF Litigation is without merit and intend to continue defending it vigorously (including exhausting all appeals if applicable). A jury trial is scheduled for September 2024 in Knoxville, TN. 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> 950 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> 1,969 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> Shared lease costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> (519) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> (519) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> (1,042) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> (1,034) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 174 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 199 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 390 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.53%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 400 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"> Total lease expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 630 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,335 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td></tr></table>595000950000123500019690005190005190001042000103400017400019900039000040000025000063000058300013350000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#ccceff;margin:0pt;padding:0pt;"> Operating cash flows from operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,850)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ccceff;margin:0pt;padding:0pt;"> (1,762) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"> Right-of-use assets exchanged for new operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#ccceff;margin:0pt;padding:0pt;"> Weighted-average remaining lease term – operating leases (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ccceff;margin:0pt;padding:0pt;"> 4.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ccceff;margin:0pt;padding:0pt;"> 4.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"> Weighted-average discount rate – operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> 6.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> 6.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td></tr></table>18500001762000P4YP4Y4M24D0.0600.065 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"> Future Lease </td></tr><tr><td style="vertical-align:bottom;width:84.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> ($ in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Liability </td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"> Nine Months Ended December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,819</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,542</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,272</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,923</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,967</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,125</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,648</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,233)</p></td></tr><tr><td style="vertical-align:bottom;width:84.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating lease liabilities, short-term and long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,415 </td></tr></table>18190003542000327200029230002967000812500022648000423300018415000057000000150000000 15. Related Party Transactions Founders Agreement The Company has entered into Founders Agreements and, in some cases, exchange agreements with certain of its subsidiaries as described in the 2023 Form 10-K. The following table summarizes, by partner company/subsidiary, the effective date of the Founders Agreements and Payment-in-Kind ("PIK") dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, exchange agreements, and the subsidiaries' certificates of incorporation: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> PIK Dividend as </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> a % of fully </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> Class of Stock </td></tr><tr><td style="vertical-align:bottom;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Partner Company/Subsidiary </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Effective Date ¹ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> capitalization </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Issued </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Avenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> February 17, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"> Baergic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> December 17, 2019 ⁴ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> %² </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Cellvation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> October 31, 2016 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"> Checkpoint </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> March 17, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> %³ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Cyprium </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> March 13, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Helocyte </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> March 20, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman', 'Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> March 13, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"> Oncogenuity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> April 22, 2020 ⁴ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Urica </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> November 7, 2017 ⁴ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr></table> . <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 1: </td><td style="padding:0pt;"> Represents the effective date of each subsidiary's Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement or has since been amended to January 1 of each calendar year. </td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 2: </td><td style="padding:0pt;"> Due to the November 2022 consummation of the Contribution Agreement between the Company and Avenue, Avenue is now eligible to receive the PIK dividend and equity fee payable by Baergic. </td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 3: </td><td style="padding:0pt;"> Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint's common stock equal to 2.5% of Checkpoint's fully diluted outstanding capitalization. </td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 4: </td><td style="padding:0pt;"> Represents the Trigger Date, the date that the Fortress partner company/subsidiary first acquires, whether by license or otherwise, ownership rights in a product. </td></tr></table> Management Services Agreements The Company has entered into Management Services Agreements (the "MSAs") with certain of its partner companies/subsidiaries as described in the 2023 Form 10-K. The following table summarizes the effective date of each MSA and the annual consulting fee payable by the partner company/subsidiary to the Company in quarterly installments: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.25%;margin:0pt;padding:0pt;"> Annual MSA Fee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:52.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Partner Company/Subsidiary </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Effective Date </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Income)/Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Avenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> February 17, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Baergic¹ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> March 9, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Cellvation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt

0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> October 31, 2016 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Checkpoint </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> March 17, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Cyprium </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> March 13, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Helocyte </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> March 20, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Mustang </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> March 13, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Oncogenuity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> February 10, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Urica </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> November 7, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Fortress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,000) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Consolidated (Income)/Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 1: </td><td style="padding:0pt;"> Pursuant to the Share Contribution Agreement between Fortress and Avenue, under which Baergic became a majority-controlled and owned subsidiary of Avenue, Fortress also assigned to Avenue the Founders Agreement previously between Fortress and Baergic, such that Baergic's annual MSA is now payable to Avenue . </td></tr></table> Fees and Stock Grants Received by Fortress Fees recorded in connection with Fortress' agreements with its subsidiaries and partner companies are eliminated in consolidation. These include management services fees, issuance of common shares of partner companies in connection with third party raises and annual stock dividend or issuances on the anniversary date of respective Founders Agreements. Shared Services Agreement with TG Therapeutics, Inc. ("TGTX") In July 2015, TGTX and the Company entered into an arrangement to share the cost of certain research and development employees. The Company's Executive Vice Chairman, Strategic Development, is also Executive Chairman and Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX reimburses the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. In connection with the shared services agreement, for the three months ended June 30, 2024 and 2023 the Company invoiced TGTX $0.1 million and $0.1 million, respectively; for the six months ended June 30, 2024 and 2023 invoiced TGTX $0.7 million and $0.2 million, respectively. At June 30, 2024, approximately $0.1 million is due from TGTX related to this arrangement. Shared Services Agreement with Journey <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 12, 2021, Journey and the Company entered into an arrangement to share the cost of certain legal, finance, regulatory, and research and development employees. The Company's Executive Chairman and Chief Executive Officer is also the Executive Chairman of Journey. Under the terms of the arrangement, Journey began reimbursing the Company for the salary and benefit costs associated with these employees based upon actual hours worked on Journey related projects following the completion of their initial public offering in November 2021. In addition, Journey reimburses the Company for various payroll-related costs and selling, general and administrative costs incurred by Fortress for the benefit of Journey. For the three months ended June 30, 2024 and 2023, the Company's employees have provided services to Journey totaling approximately $8,000 and $21,000, respectively. For the six months ended June 30, 2024 and 2023, the Company's employees have provided services to Journey totaling approximately $18,000 and $36,000, respectively. At June 30, 2024, the total related party receivable was $0.3 million, and primarily relates to reimbursable expenses incurred by Fortress on behalf of Journey. Desk Share Agreement with TGTX The Desk Share Agreement with TGTX, as amended, requires TGTX to pay its share of the average annual rent for office space in New York, NY, based on the actual percentage of the office space occupied by TGTX on a month-by-month basis. For the three months ended June 30, 2024 and 2023, the Company had paid $0.7 million and $0.8 million in rent, respectively, and in connection with the Company's Desk Share Agreement with TGTX, has invoiced TGTX approximately $0.5 million and $0.5 million, respectively, for its prorated share of the rent base. For the six months ended June 30, 2024 and 2023, the Company had paid $1.4 million and $1.4 million in rent, respectively, and in connection with the Company's Desk Share Agreement with TGTX, has invoiced TGTX approximately $1.0 million and $1.0 million, respectively, for its prorated share of the rent base. At June 30, 2024, there was no balance due from TGTX related to this arrangement. Cyprium 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Dividend Obligation Pursuant to a private placement in August 2020, Cyprium sold shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock ("Cyprium PPS"), as of June 30, 2024, there are 300,600 shares of Cyprium PPS outstanding. Pursuant to the terms of the Cyprium PPS, shareholders on the record date are entitled to receive a monthly cash dividend of $0.19531 per share which yields an annual dividend of $2.34375 per share. The Cyprium PPS will automatically be redeemed upon the first (and only the first) bona fide, arm's-length sale of a Priority Review Voucher (a "PRV Sale") issued by the FDA in connection with the approval of CUTX-101, Cyprium's copper histidinate product candidate. Upon the PRV Sale, each share of Cyprium PPS will be automatically redeemed in exchange for a payment equal to twice (2x) the $25.00 liquidation preference, plus accumulated and unpaid dividends to, but excluding, the redemption date. An optional exchange to Fortress Series A Preferred Stock is available after 24 months from the issuance date so long as a sale of the PRV has not occurred. Additionally, if a PRV Sale has not occurred by September 30, 2024 the Cyprium PPS will either be automatically exchanged for Fortress Series A Preferred Stock or cash at the discretion of Fortress. The Cyprium PPS is fully and unconditionally guaranteed by Fortress. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> PIK Dividend as </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> a % of fully </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> Class of Stock </td></tr><tr><td style="vertical-align:bottom;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Partner Company/Subsidiary </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Effective Date ¹ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> capitalization </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Issued </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Avenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> February 17, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"> Baergic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> December 17, 2019 ⁴ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> %² </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Cellvation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> October 31, 2016 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"> Checkpoint </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> March 17, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> %³ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Cyprium </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> March 13, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"> Helocyte </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> March 20, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Mustang </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> March 13, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"> Oncogenuity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> April 22, 2020 ⁴ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"> Common Stock </td></tr><tr><td style="vertical-align:top;width:43%;background:#cceeff;margin:0pt;padding:0pt;"> Urica </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"> November 7, 2017 ⁴ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td></tr></table> <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 1: </td><td style="padding:0pt;"> Represents the effective date of each subsidiary's Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement or has since been amended to January 1 of each calendar year. </td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 2: </td><td style="padding:0pt;"> Due to the November 2022 consummation of the Contribution Agreement between the Company and Avenue, Avenue is now eligible to receive the PIK dividend and equity fee payable by Baergic. </td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 3: </td><td style="padding:0pt;"> Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint's common stock equal to 2.5% of Checkpoint's fully diluted outstanding capitalization. </td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 4: </td><td style="padding:0pt;"> Represents the Trigger Date, the date that the Fortress partner company/subsidiary first acquires, whether by license or otherwise, ownership rights in a product. </td></tr></table>2015-02-170.0252019-12-172016-10-310.0252015-03-172017-03-130.0252015-03-200.0252015-03-130.0252020-04-220.0252017-11-070.0250.025 The Company has entered into Management Services Agreements (the "MSAs") with certain of its partner companies/subsidiaries as described in the 2023 Form 10-K. The following table summarizes the effective date of each MSA and the annual consulting fee payable by the partner company/subsidiary to the Company in quarterly installments: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-

align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.25%;margin:0pt;padding:0pt;"> Annual MSA Fee </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Partner Company/Subsidiary </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Effective Date </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Income)/Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Avenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> February 17, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Baergic¹ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> March 9, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Cellvation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> October 31, 2016 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Checkpoint </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> March 17, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Cyprium </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> March 13, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Mustang </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> March 13, 2015 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Oncogenuity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> February 10, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Urica </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> November 7, 2017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 500 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;background:#cceeff;margin:0pt;padding:0pt;"> Fortress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,000) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.11%;margin:0pt;padding:0pt;"> Consolidated (Income)/Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> Note 1: </td><td style="padding:0pt;"> Pursuant to the Share Contribution Agreement between Fortress and Avenue, under which Baergic became a majority-controlled and owned subsidiary of Avenue, Fortress also assigned to Avenue the Founders Agreement previously between Fortress and Baergic, such that Baergic's annual MSA is now payable to Avenue. </td></tr></table>2015-02-175000002017-03-092016-10-315000002015-03-175000002017-03-135000002015-03-205000002015-03-135000002017-02-105000002017-11-075000004000000100000100000700000200000100000800002100018000360003000007000008000005000005000001400000140000001000000.01000000.000.093750.093753000
style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">16. Segment Information The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company are consistently applied to all segments. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment ($ in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Pharmaceutical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Consolidated </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,896</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods - product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,541)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,541)</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (913)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,758)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,671)</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,495)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,823)</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asset impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,649)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,649)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (434)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,036)</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> (3,361) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (25,463) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,824)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pharmaceutical</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dermatology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Biotechnology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"> 27,885 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ceeeff;margin:0pt;padding:0pt;"> 27,926 </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> Cost of goods - product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> (13,357) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (0) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (13,357) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#ceeeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#ceeeff;margin:0pt;padding:0pt;"> (8,797) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ceeeff;margin:0pt;padding:0pt;"> (28,698) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ceeeff;margin:0pt;padding:0pt;"> (37,495) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> (18,748) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (20,029) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (38,777) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#ceeeff;margin:0pt;padding:0pt;"> Asset impairment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#ceeeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ceeeff;margin:0pt;padding:0pt;"> (2,649) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ceeeff;margin:0pt;padding:0pt;"> (2,649) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> Other expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (786) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,708) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,494) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#ceeeff;margin:0pt;padding:0pt;"> Segment loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,803)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (54,043) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (67,846) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Pharmaceutical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Consolidated </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> 214 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> 17,386 </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> Cost of goods - product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (7,767) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (7,767) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (1,774) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (30,368) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (32,142) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(12,141)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (12,298) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (24,439) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Asset impairment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (3,143) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (3,143) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> Other expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (710) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,486) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,196) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Segment loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,363)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (50,938) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (59,301) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Pharmaceutical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td

style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Consolidated </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> 430 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> 29,815 </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> Cost of goods - product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (14,216) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (14,216) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (3,807) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (67,841) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (71,648) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (25,433) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (24,347) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (49,780) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Asset impairment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (3,143) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (3,143) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> Other expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,285) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,189) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,474) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Segment loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (95,947) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (114,446)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following tables summarize, for the periods indicated, total assets by reportable segment ($ in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Pharmaceutical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total Assets </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,658</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 127,027</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 65,189 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 145,685 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> . </td>

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Pharmaceutical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> <span

style="font-size:8pt;visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total Assets </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt,"> Intangible assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,287</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,239</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 76,849 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 167,526 </td></tr></table> 2 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Pharmaceutical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> <span style="font-

size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Consolidated </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> 14,896 </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> Cost of goods - product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> (6,541) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (6,541) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"> (913) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> (11,758) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> (12,671) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> (10,328) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (10,495) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (20,823) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Asset impairment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> (2,649) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> (2,649) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.58%;margin:0pt;padding:0pt;"> Other expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (434) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (602) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1,036) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Segment loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,361)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,463)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (28,824) </td></tr></table> - - - - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Pharmaceutical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> <span style="font-

size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Consolidated </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> 27,926 </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> Cost of goods - product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> (13,357) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (0) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (13,357) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"> (8,797) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> (28,698) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> (37,495) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> (18,748) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (20,029) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> (38,777) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Asset impairment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> (2,649) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> (2,649) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> Other expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (786) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,708) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,494) </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Segment loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,803)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (54,043) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (67,846)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#ccceff;margin:0pt;padding:0pt;"> 17,172 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ccceff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt

3pt 0pt 0pt;"> 214 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,386</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods - product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,767)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,767)</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,368)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,142)</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,141)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,298)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,439)</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Asset impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,143)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,143)</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,486)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,196)</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (8,363) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,938)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (59,301) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Pharmaceutical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Consolidated </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> 430 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> 29,815 </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> Cost of goods - product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (14,216) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (14,216) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (3,807) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (67,841) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (71,648) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (25,433) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (24,347) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> (49,780) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Asset impairment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (3,143) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> (3,143) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"> Other expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,285) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,189) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,474) </td></tr><tr><td style="vertical-align:bottom;width:55.59%;background:#cceeff;margin:0pt;padding:0pt;"> Segment loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (95,947) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> (114,446) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Pharmaceutical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> <span

style="font-size:8pt;font-weight:bold;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total Assets </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,658</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 127,027</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 65,189 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 145,685 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;">

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> <span style="font-

align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Dermatology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Biotechnology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Products </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Product </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total Assets </td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,287</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,239</p></td></tr><tr><td style="vertical-align:bottom;width:55.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 76,849 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 167,526 </td></tr></table>
1485500041000148960006541000654100091300011758000126710001032800010495000208230002649000026490000-434000-602000-1036000-3361000-25463000-28824000278850004100027926000133570000133570008797000286980003749500018748000200290003877700026490000264900002649000-786000-2708000-3494000-13803000-54043000-67846000171720002140001738600077670007767000177400030368000321420001211410001229800024439000314300031430003143000-710000-8486000-9196000-8363000-50938000-59301000293850004300002981500014216000142160003807000678410007164800025433000243470004978000031430003143000-1285000-4189000-5474000-18499000-95947000-114446000186580001865800046531000804960001270270006518900080496000145685000202870002028700056562000906770001472390007684900090677000167526000
style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 8pt 0pt;">17. Revenues from Contracts and Significant Customers Disaggregation of Total Revenue Journey has the following actively marketed products, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Luxamend, Targadox, and Ximino (until September 2023). All of Journey's product revenues are recorded in the U.S. <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> The table below summarizes the Company's revenue for the periods presented ($ in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> Qbrexza </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"> 8,079 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 12,173 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Accutane </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> 5,719 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> 5,579 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> 11,538 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> 10,227 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;background:#cceeff;margin:0pt;padding:0pt;"> Amzeeq </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"> 1,205 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"> 1,374 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,960 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 2,568 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Zilxi </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> 369 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> 572 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> 642 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> 886 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;background:#cceeff;margin:0pt;padding:0pt;"> Other / legacy product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"> 726 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"> 1,357 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,892 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 3,272 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Collaboration revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> 183 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> 364 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue – related party </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"> 31 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 66 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Other revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 211 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 259 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">14,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 17,386 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">27,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,815 </td></tr></table> . Significant Customers For the three and six-month periods ending June 30, 2024 and 2023, none of Journey's dermatology products customers accounted for more than 10% of its total gross product revenue. At June 30, 2024, two of Journey's dermatology products customers accounted for more than 10% of its total accounts receivable balance at 18% and 10.8%. At December 31, 2023, one of the Company's dermatology products customers accounted for more than 10% of its total accounts receivable balance at 13%. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.49%;background:#cceeff;margin:0pt;padding:0pt;"> Qbrexza </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"> 8,079 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 12,173 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Accutane </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> 5,719 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> 5,579 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> 11,538 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> 10,227 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;background:#cceeff;margin:0pt;padding:0pt;"> Amzeeq </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"> 1,205 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"> 1,374 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,960 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 2,568 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Zilxi </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> 369 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> 572 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> 642 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> 886 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;background:#cceeff;margin:0pt;padding:0pt;"> Other / legacy product revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"> 726 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"> 1,357 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,892 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 3,272 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Collaboration revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"> 183 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"> 364 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue – related party </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"> 31 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 41 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"> 66 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;margin:0pt;padding:0pt;"> Other revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 211 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 259 </td></tr><tr><td style="vertical-align:bottom;width:50.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total net revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 17,386 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,815 </td></tr></table>6836000807900011853000121730005719000557900011538000102270001205000137400019600002568000369000572000642000886000726000135700018920003273

18. Income taxes

The Company and its subsidiaries are subject to US federal and state income taxes. Income tax expense is the total of the current year income tax due or refundable and the change in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all, of the deferred tax asset will not be realized.

The Company files a consolidated income tax return with subsidiaries for which the Company has an 80% or greater ownership interest. Subsidiaries for which the Company does not have an 80% or more ownership are not included in the Company's consolidated income tax group and file their own separate income tax return. As a result, certain corporate entities included in these financial statements are not able to combine or offset their taxable income or losses with other entities' tax attributes.

Income tax expense for the three and six months ended June 30, 2024 and 2023 is based on the estimated annual effective tax rate, and includes interest related to unrecognized tax benefits. The Company expects a net deferred tax asset with a full valuation allowance and 0% estimated annual effective tax rate for 2024. No income tax expense was recognized for the three and six months ended June 30, 2024 or 2023.

19. Subsequent Events

Fortress

On July 25, 2024, Fortress entered into the $50.0 million senior secured credit agreement with a maturity date of July 25, 2027 with Oaktree (the "New Oaktree Agreement"). The Company borrowed $35.0 million under the New Oaktree Agreement on the Closing Date and is eligible to draw up to an additional $15.0 million at the lenders' discretion to support future business development activities. The New Oaktree Agreement replaces the Prior Oaktree Agreement in which the remaining $50.0 million balance was repaid in full.

Under the terms of the New Oaktree Agreement, the loans have a 30-month interest-only period with a maturity date of July 25, 2027, and bear interest at an annual rate equal to the 3-month Secured Overnight Financing Rate (SOFR) plus 7.625% (subject to a 2.50% SOFR floor and a 5.75% SOFR cap). The Company is required to make quarterly interest-only payments until the maturity date, except fifty percent of the then-outstanding principal balance of the loans is due on March 31, 2027, with the remaining principal amount due on the maturity date.

The Company may voluntarily prepay, in whole or in part, the amounts due under the New Oaktree Agreement at any time subject to a prepayment fee. Subject to prior written notice by the Company, to repay any amounts due prior to the maturity date, the Company must pay the sum of (A) the aggregate principal amount of the Loans being prepaid, (B) any accrued but unpaid interest on the principal amount of the Loans being prepaid, (C) any applicable Yield Protection Premium (as defined in the New Oaktree Agreement) and (D) if applicable, other unpaid amounts then due and owing pursuant to the New Oaktree Agreement and the other loan documents (such aggregate amount, the "Prepayment Price"); provided that each partial prepayment of the principal amount of the Loans shall be in an aggregate amount of at least $5.0 million and integral multiples of $1.0 million in excess thereof. The Company is required to make mandatory prepayments of the Loans with net cash proceeds from (i) certain casualty events, (ii) certain monetization events, including, among other things, certain asset sales and the sale(s) of priority review vouchers by certain subsidiaries of the Company, and the receipt by the Company of any dividend or other distributions in cash from any of its subsidiaries in excess of $5.0 million other than in connection with certain monetization events, (iii) debt issuances that are not permitted, and (iv) failure to comply with certain covenants. The lenders may elect to receive warrants to purchase common stock of the Company as an alternative to cash prepayments in some situations where a mandatory prepayment would otherwise be required.

The New Oaktree Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions. In addition, the New Oaktree Agreement contains certain financial covenants, including, (i) a requirement that the Company maintain a minimum liquidity of $7.0 million, which may be reduced or increased as described in the New Oaktree Agreement ("the "Liquidity Requirement"), and (ii) that product net sales of Journey meet a consolidated minimum net sales amount of $50.0 million on a trailing 12-month basis, tested quarterly, which may be reduced or increased as described in the New Oaktree Agreement (the "Minimum Net Sales Test"), subject to certain exclusions. Both the Minimum Net Sales Test and the Liquidity Requirement will be reduced to $0 while the <span

*style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-style:normal;font-weight:normal;">outstanding principal balance is less than or equal to $10.0 million. The Liquidity Requirement is subject to a decrease to $5.0 million while the outstanding principal balance is between $10.0 million and $25.0 million, and also subject to an increase of $3.75 million in each instance if DFD-29 is not approved by the FDA by either March 31, 2025 or December 31, 2025 with a reversion of the approval-related increases upon approval. Failure by the Company to comply with the financial covenants will result in an event of default, subject to certain cure rights of the Company with respect to the Minimum Net Sales Test. The New Oaktree Agreement contains events of default that are customary for financings of this type, in certain circumstances subject to customary cure periods. In addition, the Company is also required to (i) raise common equity, or receive in monetizations or distributions, by the end of each calendar year prior to the maturity date, in an aggregate amount equal to the greater of $20 million or 50% of an amount set forth in an annual budget delivered to the lenders and (ii) maintain a specified minimum equity stake in Journey. The capital raise and minimum stake covenants and financial covenants will not apply if the outstanding principal balance of the loan is less than or equal to $10 million. Following an event of default and any cure period, if applicable, the Agent will have the right upon notice to accelerate all amounts outstanding under the New Oaktree Agreement, in addition to other remedies available to the lenders as secured creditors of the Company. In connection with the New Oaktree Agreement, the Company granted a security interest in favor of the Agent, for the benefit of the lenders, in substantially all of the Company's assets, subject to customary exceptions, as collateral securing the Company's obligations under the New Oaktree Agreement. In connection with the New Oaktree Agreement, the Company granted warrants to the lenders to purchase up to 506,390 shares of the Company's common stock at a purchase price of $2.0735 per share (the "Warrants"). The Warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offerings and pro rata distributions. The exercise price of the Warrants will also be adjusted if, while the Warrants are outstanding, the Company engages in any transaction involving the issuance or sale of shares of Common Stock or equivalent securities at an effective price per share less than the exercise price of the Warrant then in effect (such lower price, the "Base Share Price"). In such case, the exercise price of the Warrants will be reduced to equal the Base Share Price. The Warrants are immediately exercisable and will expire on July 25, 2031 and may be net exercised for no cash payment at the holder's election. The Company also agreed to file a registration statement to register the resale of the shares of Company common stock issuable upon exercise of the Warrants. Fortress Dividends On July 5, 2024, Fortress announced that the Company's Board of Directors had decided to pause the monthly dividend of $0.1953125 per share of the Company's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the "Series A Preferred Stock"). In accordance with the terms of the Series A Preferred Stock, dividends on the Series A Preferred Stock will continue to accrue and cumulate until such dividends are authorized or declared. The pausing of these dividends will defer approximately $0.7 million in cash dividend payments each month. The Board intends to revisit its decision regarding the monthly dividend regularly and will assess the profitability and cash flow of the Company to determine whether and when the pause should be lifted. Journey On July 9, 2024, Journey entered into the SWK Amendment. The SWK Amendment increased the total amount of the Credit Facility from $20.0 million to $25.0 million. The $5.0 million of additional availability added in the Amendment will be drawn upon FDA approval of DFD-29, subject to Journey receiving approval on or before June 30, 2025. Urica On July 15, 2024, Urica entered into an asset purchase agreement (the "APA"), royalty agreement (the "Royalty Agreement"), and related agreements (collectively, the "Transaction Documents") with Crystalys Therapeutics, Inc. ("Crystalys"). Crystalys is a Delaware corporation incorporated in 2022 and seeded by leading life sciences institutional investors. Under the Transaction Documents, Urica sold the rights to its URAT1 inhibitor product candidate in development for the treatment of gout, dotinurad, and related intellectual property, licenses and agreements to Crystalys. In return, Crystalys issued to Urica shares of its common stock equal to 35% of Crystalys' outstanding equity. Urica's equity position cannot be reduced below 15% of Crystalys' fully-diluted equity capitalization until it raises $150 million in equity securities. The Transaction Documents also grant Urica a securitized three percent (3%) royalty on future net sales of dotinurad to be paid by Crystalys, as well as the right to receive nominal cash reimbursement payments for certain clinical and development costs incurred by Urica related to dotinurad. Urica has the right to appoint one director to the board of directors of Crystalys, as well as an additional board observer. Urica has committed to providing transition support to Crystalys for 90 days, and Crystalys is obliged to use commercially reasonable efforts to develop and commercialize dotinurad. Checkpoint In July 2024, Checkpoint closed on a registered direct offering (the "Checkpoint July 2024 Registered Direct Offering") for the issuance and sale of an aggregate of 1,230,000 shares of its common stock at a purchase price of $2.05 per share of common stock. In addition, the offering includes 4,623,659 shares of common stock in the form of pre-funded warrants at a price of $2.0499. In a concurrent private placement, Checkpoint issued and sold common warrants (the "Checkpoint July 2024 Common Stock Warrants") to purchase up to 5,853,659 shares of common stock. The Checkpoint July 2024 Common Stock Warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Checkpoint July 2024 Common Stock Warrants with an exercise price of $2.05 per share and will expire five years following the issuance date. The total gross proceeds from the July 2024 Registered Direct Offering were approximately $12.0 million. *

* 50000000.035000000.015000000.050000000.0P30M0.076252.505.750.505000000.01000000.05000000.07000000.050000000.0P12M05000000.037500002000000000.50106*

"

=